data_2lfu_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2lfu _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo . . . . . 0 N--CA 1.444 -1.414 0 N-CA-C 111.575 -0.202 . . . . 0.0 111.575 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 308' ' ' ALA . . . . . 0.662 ' HB3' ' O ' ' A' ' 394' ' ' TYR . . . -59.47 163.54 4.01 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.15 -0.62 . . . . 0.0 109.974 168.828 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 309' ' ' LYS . . . . . 0.526 ' HB3' ' HB2' ' A' ' 312' ' ' MET . 10.8 tptp -123.96 93.45 3.93 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 174.1 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 310' ' ' GLY . . . . . 0.633 ' HA2' HD11 ' A' ' 313' ' ' LEU . . . -57.24 -34.02 66.47 Favored Glycine 0 C--N 1.332 0.315 0 C-N-CA 121.147 -0.549 . . . . 0.0 113.013 -173.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . 0.417 ' HA ' ' HE3' ' A' ' 349' ' ' LYS . 11.2 pt-20 -62.82 -26.9 68.97 Favored 'General case' 0 C--N 1.319 -0.755 0 C-N-CA 122.483 0.313 . . . . 0.0 111.581 174.807 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 312' ' ' MET . . . . . 0.526 ' HB2' ' HB3' ' A' ' 309' ' ' LYS . 90.0 mtp -102.37 -6.37 23.1 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.921 0.391 . . . . 0.0 110.567 -179.77 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 313' ' ' LEU . . . . . 0.633 HD11 ' HA2' ' A' ' 310' ' ' GLY . 92.4 mt -75.26 133.2 41.4 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.729 176.876 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -143.68 137.09 27.97 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.017 -173.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.53 -159.53 15.28 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 121.001 -0.618 . . . . 0.0 111.665 178.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 12.7 p -123.89 156.17 36.76 Favored 'General case' 0 C--N 1.317 -0.806 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 173.462 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -146.51 160.41 42.15 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 120.918 0.39 . . . . 0.0 110.694 176.657 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . 0.567 ' HA ' ' O ' ' A' ' 342' ' ' ALA . 8.7 p -138.78 113.75 8.5 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.691 172.849 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . 0.567 ' HE2' HG11 ' A' ' 344' ' ' VAL . 55.4 m-85 -98.08 127.46 44.04 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.331 -177.256 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -115.79 132.4 56.65 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.478 174.459 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . 0.478 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -166.27 -143.17 3.65 Favored Glycine 0 N--CA 1.438 -1.197 0 C-N-CA 120.697 -0.763 . . . . 0.0 111.948 -179.143 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -136.94 164.67 27.78 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 120.927 0.394 . . . . 0.0 111.236 -173.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 323' ' ' VAL . . . . . 0.578 HG23 ' HB2' ' A' ' 340' ' ' PHE . 75.2 t -126.34 116.42 45.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.53 178.792 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 324' ' ' LEU . . . . . 0.416 ' HB2' HG23 ' A' ' 419' ' ' VAL . 93.7 mt -89.4 101.76 14.43 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 175.486 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 325' ' ' HIS . . . . . 0.49 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 1.9 p80 -102.24 114.76 29.19 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.493 0.663 . . . . 0.0 110.066 -179.123 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 326' ' ' PHE . . . . . 0.506 ' HB2' ' HB3' ' A' ' 417' ' ' PHE . 49.0 m-85 . . . . . 0 C--N 1.323 -0.552 0 CA-C-N 114.734 -1.121 . . . . 0.0 110.897 -170.011 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 337' ' ' ARG . . . . . . . . . . . . . 54.6 mtp180 . . . . . 0 N--CA 1.454 -0.23 0 CA-C-O 120.957 0.408 . . . . 0.0 110.707 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -96.82 -176.81 35.22 Favored Glycine 0 N--CA 1.447 -0.591 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 173.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 339' ' ' ARG . . . . . . . . . . . . . 29.0 mtm180 -112.41 163.31 14.58 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 118.055 0.928 . . . . 0.0 110.213 179.393 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 340' ' ' PHE . . . . . 0.578 ' HB2' HG23 ' A' ' 323' ' ' VAL . 30.7 t80 -151.67 140.13 20.55 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.83 0.347 . . . . 0.0 111.137 -179.243 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 341' ' ' ALA . . . . . 0.555 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -137.25 152.55 49.94 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.12 175.364 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . 0.926 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -143.83 118.3 9.71 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.044 0.45 . . . . 0.0 111.513 -178.375 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 343' ' ' LYS . . . . . 0.512 ' HB3' ' HB2' ' A' ' 352' ' ' ASP . 55.7 tptt -96.52 103.61 15.54 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.109 177.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 344' ' ' VAL . . . . . 0.567 HG11 ' HE2' ' A' ' 319' ' ' TYR . 0.7 OUTLIER -122.86 140.33 46.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -170.691 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -114.4 121.31 43.19 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.839 -1.073 . . . . 0.0 108.46 171.164 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 346' ' ' PHE . . . . . . . . . . . . . 51.8 m-85 -76.7 -17.04 59.34 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 111.734 0.272 . . . . 0.0 111.734 -175.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -75.29 -42.12 29.14 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.461 -0.876 . . . . 0.0 111.269 178.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 55.9 m -88.37 -10.93 47.7 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-O 120.811 0.339 . . . . 0.0 110.108 177.33 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 349' ' ' LYS . . . . . 0.626 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 48.4 mttm 51.24 58.81 5.12 Favored 'General case' 0 CA--C 1.52 -0.198 0 CA-C-O 121.863 0.84 . . . . 0.0 109.896 -179.723 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 50.7 m -147.77 146.02 29.02 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 114.777 -1.101 . . . . 0.0 109.607 176.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 351' ' ' VAL . . . . . 0.635 HG21 ' HB1' ' A' ' 370' ' ' ALA . 1.3 m -129.69 156.35 41.97 Favored 'Isoleucine or valine' 0 C--O 1.237 0.427 0 CA-C-O 121.181 0.515 . . . . 0.0 110.461 -176.451 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 352' ' ' ASP . . . . . 0.926 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 0.9 OUTLIER -109.48 117.37 33.81 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 170.481 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -114.7 117.08 3.95 Favored Glycine 0 N--CA 1.444 -0.792 0 C-N-CA 120.218 -0.991 . . . . 0.0 112.136 -177.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 354' ' ' ILE . . . . . 0.504 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -117.65 133.14 65.39 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.127 0 CA-C-N 115.321 -0.439 . . . . 0.0 109.916 -176.995 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 355' ' ' ILE . . . . . 0.524 ' HB ' ' HB3' ' A' ' 366' ' ' GLN . 3.4 mp . . . . . 0 C--N 1.32 -0.71 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.797 -178.016 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 366' ' ' GLN . . . . . 0.524 ' HB3' ' HB ' ' A' ' 355' ' ' ILE . 17.5 tp60 . . . . . 0 N--CA 1.45 -0.471 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 37.5 ttpt -156.54 136.98 13.04 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.427 -176.344 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 368' ' ' PHE . . . . . 0.415 ' HB3' ' CE3' ' A' ' 381' ' ' TRP . 46.9 p90 -129.51 156.42 44.17 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.095 0.474 . . . . 0.0 109.978 178.876 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 4.0 tptp -116.62 131.59 56.91 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 175.149 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 370' ' ' ALA . . . . . 0.635 ' HB1' HG21 ' A' ' 351' ' ' VAL . . . -128.87 140.77 51.53 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 112.193 0.442 . . . . 0.0 112.193 -170.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -101.31 130.83 47.54 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.603 175.311 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 372' ' ' ILE . . . . . 0.626 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 84.2 mt -80.8 105.17 10.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.842 0.829 . . . . 0.0 110.08 -179.24 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -113.63 83.93 1.93 Allowed 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 114.337 -1.301 . . . . 0.0 108.944 -177.16 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 374' ' ' GLY . . . . . 0.555 ' O ' ' HA3' ' A' ' 310' ' ' GLY . . . 101.34 -141.79 15.46 Favored Glycine 0 N--CA 1.444 -0.811 0 CA-C-N 115.159 -0.928 . . . . 0.0 111.117 -174.15 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 375' ' ' ASN . . . . . . . . . . . . . 30.9 p-10 -97.57 59.56 1.52 Allowed 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 122.582 1.182 . . . . 0.0 109.545 179.034 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 162.1 178.43 35.98 Favored Glycine 0 N--CA 1.443 -0.893 0 CA-C-N 113.993 -1.458 . . . . 0.0 109.959 -174.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 377' ' ' PHE . . . . . 0.474 ' CZ ' HG23 ' A' ' 401' ' ' VAL . 4.8 p90 -139.45 150.99 45.86 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 117.655 0.728 . . . . 0.0 112.155 -178.412 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 378' ' ' LYS . . . . . 0.434 ' HD2' ' N ' ' A' ' 378' ' ' LYS . 0.0 OUTLIER -115.06 129.5 56.71 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 172.818 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 379' ' ' GLY . . . . . 0.511 ' HA2' ' HA ' ' A' ' 370' ' ' ALA . . . -126.33 169.3 18.28 Favored Glycine 0 N--CA 1.444 -0.777 0 C-N-CA 119.997 -1.097 . . . . 0.0 113.411 -171.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 11.3 p -131.19 140.17 49.86 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.118 -0.541 . . . . 0.0 109.872 178.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 381' ' ' TRP . . . . . 0.479 ' CZ3' ' HG3' ' A' ' 366' ' ' GLN . 73.7 m95 . . . . . 0 C--N 1.327 -0.401 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.701 179.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.737 0 N-CA-C 112.27 -0.332 . . . . 0.0 112.27 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -99.66 138.94 36.04 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.817 0.342 . . . . 0.0 110.594 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 389' ' ' VAL . . . . . 0.464 HG22 ' HB3' ' A' ' 405' ' ' TYR . 22.1 t -109.53 144.81 17.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 177.641 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 14.7 m -147.44 139.64 24.43 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.52 0.2 . . . . 0.0 110.557 175.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -145.08 150.14 22.31 Favored Glycine 0 C--N 1.32 -0.326 0 N-CA-C 111.692 -0.563 . . . . 0.0 111.692 179.38 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 392' ' ' ARG . . . . . 0.626 ' HD3' ' O ' ' A' ' 393' ' ' PHE . 4.5 tmt_? -118.67 136.55 53.85 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -175.501 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 393' ' ' PHE . . . . . 0.626 ' O ' ' HD3' ' A' ' 392' ' ' ARG . 8.1 m-85 -82.24 159.76 23.13 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.263 -177.693 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 394' ' ' TYR . . . . . 0.662 ' O ' ' HB3' ' A' ' 308' ' ' ALA . 2.4 m-85 -100.81 -174.67 2.68 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.861 -177.164 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 395' ' ' GLY . . . . . . . . . . . . . . . -38.42 170.45 0.01 OUTLIER Glycine 0 C--N 1.335 0.487 0 O-C-N 124.277 0.985 . . . . 0.0 114.985 -177.718 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -51.52 -15.11 2.35 Favored 'Trans proline' 0 N--CA 1.477 0.502 0 C-N-CA 124.384 3.389 . . . . 0.0 115.526 -163.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 397' ' ' ALA . . . . . . . . . . . . . . . -80.22 -20.49 44.54 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 111.735 0.272 . . . . 0.0 111.735 177.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 56.23 18.62 21.46 Favored Glycine 0 C--N 1.34 0.763 0 CA-C-N 116.09 -0.505 . . . . 0.0 114.081 175.046 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 399' ' ' GLU . . . . . 0.887 ' HG3' ' HB3' ' A' ' 424' ' ' LYS . 17.7 tt0 -73.15 -19.15 61.19 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.193 0.52 . . . . 0.0 110.838 -177.751 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -116.7 137.47 52.17 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-O 121.18 0.514 . . . . 0.0 110.362 177.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 401' ' ' VAL . . . . . 0.474 HG23 ' CZ ' ' A' ' 377' ' ' PHE . 9.0 p -139.46 134.55 39.67 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.546 173.423 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -131.14 135.18 47.24 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.172 -179.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -151.05 -176.64 24.12 Favored Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.177 -1.011 . . . . 0.0 112.152 -177.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 404' ' ' LYS . . . . . 0.707 ' HG2' HG12 ' A' ' 419' ' ' VAL . 27.0 mttm -147.69 162.47 39.1 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 -179.352 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 405' ' ' TYR . . . . . 0.464 ' HB3' HG22 ' A' ' 389' ' ' VAL . 6.9 p90 . . . . . 0 C--N 1.318 -0.77 0 CA-C-O 121.251 0.548 . . . . 0.0 111.593 175.644 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 417' ' ' PHE . . . . . 0.506 ' HB3' ' HB2' ' A' ' 326' ' ' PHE . 64.1 m-85 . . . . . 0 N--CA 1.447 -0.605 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 418' ' ' GLY . . . . . 0.49 ' HA2' ' HA ' ' A' ' 325' ' ' HIS . . . 82.4 77.32 1.07 Allowed Glycine 0 N--CA 1.442 -0.935 0 C-N-CA 119.78 -1.2 . . . . 0.0 111.447 -175.454 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 419' ' ' VAL . . . . . 0.707 HG12 ' HG2' ' A' ' 404' ' ' LYS . 19.7 m -105.08 146.96 11.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 -178.109 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 420' ' ' PHE . . . . . 0.444 ' HB3' HG22 ' A' ' 323' ' ' VAL . 47.0 p90 -130.29 161.07 32.06 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 121.023 0.44 . . . . 0.0 110.696 -179.299 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 421' ' ' ALA . . . . . 0.478 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -153.92 136.54 15.17 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.025 179.821 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -132.54 141.67 13.06 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.187 -1.006 . . . . 0.0 113.052 -177.336 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 72.3 mmtt -102.46 125.56 49.22 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 175.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 424' ' ' LYS . . . . . 0.887 ' HB3' ' HG3' ' A' ' 399' ' ' GLU . 80.0 tttt -63.16 105.72 0.75 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.272 0.558 . . . . 0.0 110.626 178.16 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 . . . . . 0 C--N 1.321 -0.673 0 CA-C-N 115.53 -0.759 . . . . 0.0 109.984 -179.708 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo . . . . . 0 CA--C 1.533 0.441 0 N-CA-C 112.672 0.22 . . . . 0.0 112.672 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 308' ' ' ALA . . . . . 0.621 ' HB3' ' O ' ' A' ' 394' ' ' TYR . . . -47.51 153.88 0.5 Allowed 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 121.137 0.494 . . . . 0.0 111.965 170.091 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 309' ' ' LYS . . . . . 0.661 ' O ' ' HG ' ' A' ' 313' ' ' LEU . 65.9 mmtt -91.76 88.28 6.62 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 178.157 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 310' ' ' GLY . . . . . 0.599 ' HA3' ' HA2' ' A' ' 374' ' ' GLY . . . -58.31 -40.22 93.73 Favored Glycine 0 C--N 1.333 0.41 0 C-N-CA 121.616 -0.326 . . . . 0.0 113.818 -171.213 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . 0.406 ' HG2' ' HG2' ' A' ' 312' ' ' MET . 0.2 OUTLIER -72.61 -19.97 61.37 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.818 0.342 . . . . 0.0 110.95 -178.4 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 312' ' ' MET . . . . . 0.406 ' HG2' ' HG2' ' A' ' 311' ' ' GLU . 78.3 mmm -108.43 6.48 26.3 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.812 0.339 . . . . 0.0 111.192 -178.687 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 313' ' ' LEU . . . . . 0.661 ' HG ' ' O ' ' A' ' 309' ' ' LYS . 91.9 mt -75.47 133.8 40.99 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 175.224 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -151.61 139.4 19.85 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.773 -172.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.23 161.81 11.63 Favored Glycine 0 N--CA 1.448 -0.556 0 N-CA-C 111.306 -0.718 . . . . 0.0 111.306 178.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 21.7 p -97.82 135.01 40.19 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 173.044 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -133.47 151.51 51.79 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.78 -172.166 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -120.75 110.4 28.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.439 -0.8 . . . . 0.0 109.384 175.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . 0.749 ' HH ' ' HZ ' ' A' ' 346' ' ' PHE . 90.9 m-85 -99.18 127.49 45.16 Favored 'General case' 0 C--N 1.312 -1.04 0 C-N-CA 120.327 -0.549 . . . . 0.0 110.424 178.327 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 48.0 m-80 -120.85 132.74 55.17 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.377 178.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . 0.566 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -166.53 -154.18 8.2 Favored Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.54 -179.598 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 3.7 mp0 -116.12 153.95 30.87 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.056 0.455 . . . . 0.0 111.122 -174.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 323' ' ' VAL . . . . . 0.524 HG22 ' HB2' ' A' ' 340' ' ' PHE . 72.5 t -112.06 117.44 55.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.355 -0.839 . . . . 0.0 109.208 172.397 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 324' ' ' LEU . . . . . 0.458 ' HB2' HG23 ' A' ' 419' ' ' VAL . 93.7 mt -95.69 104.31 16.22 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.129 0.49 . . . . 0.0 110.298 -177.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 325' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -98.52 113.98 26.21 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 179.512 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 326' ' ' PHE . . . . . 0.524 ' HD2' ' H ' ' A' ' 418' ' ' GLY . 57.9 m-85 . . . . . 0 C--N 1.321 -0.636 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.377 -174.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 337' ' ' ARG . . . . . . . . . . . . . 51.9 mtm180 . . . . . 0 N--CA 1.45 -0.438 0 CA-C-O 120.911 0.386 . . . . 0.0 110.268 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -90.52 -177.13 44.36 Favored Glycine 0 N--CA 1.44 -1.08 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 172.827 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 339' ' ' ARG . . . . . . . . . . . . . 65.1 mtt180 -104.49 154.92 19.28 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 176.237 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 340' ' ' PHE . . . . . 0.524 ' HB2' HG22 ' A' ' 323' ' ' VAL . 27.0 t80 -148.74 139.02 22.42 Favored 'General case' 0 C--N 1.309 -1.16 0 CA-C-O 121.165 0.507 . . . . 0.0 110.494 179.161 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 341' ' ' ALA . . . . . 0.69 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -136.84 164.2 28.87 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 114.967 -1.015 . . . . 0.0 108.908 175.809 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . 0.846 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -151.76 120.11 6.39 Favored 'General case' 0 C--N 1.314 -0.943 0 N-CA-C 109.654 -0.499 . . . . 0.0 109.654 -179.758 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 13.0 tptm -100.81 98.43 8.95 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 344' ' ' VAL . . . . . 0.485 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.2 OUTLIER -118.45 136.93 54.05 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 CA-C-N 115.833 -0.621 . . . . 0.0 112.176 -169.576 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 10.4 t0 -107.23 113.0 26.13 Favored 'General case' 0 C--N 1.321 -0.63 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 171.194 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 346' ' ' PHE . . . . . 0.749 ' HZ ' ' HH ' ' A' ' 319' ' ' TYR . 48.4 m-85 -74.77 -27.64 60.42 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 111.701 0.26 . . . . 0.0 111.701 -176.091 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -61.87 -33.36 85.13 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.695 -0.764 . . . . 0.0 111.654 177.198 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 6.8 t -101.59 -4.48 26.57 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-O 120.688 0.28 . . . . 0.0 111.083 178.162 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 349' ' ' LYS . . . . . 0.479 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 10.0 mtmp? 51.28 59.05 4.88 Favored 'General case' 0 N--CA 1.466 0.362 0 C-N-CA 123.148 0.579 . . . . 0.0 111.543 -178.265 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 40.2 m -149.6 140.51 22.83 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.14 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 351' ' ' VAL . . . . . 0.485 ' HB ' ' HB ' ' A' ' 344' ' ' VAL . 0.8 OUTLIER -129.08 156.43 41.68 Favored 'Isoleucine or valine' 0 C--O 1.236 0.369 0 CA-C-O 121.289 0.566 . . . . 0.0 111.147 -175.665 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 352' ' ' ASP . . . . . 0.846 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 17.9 t70 -111.72 119.19 37.79 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.981 -1.009 . . . . 0.0 108.414 166.493 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -111.31 120.81 5.57 Favored Glycine 0 C--N 1.306 -1.11 0 C-N-CA 120.621 -0.8 . . . . 0.0 111.369 -178.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 354' ' ' ILE . . . . . 0.518 HG12 ' N ' ' A' ' 355' ' ' ILE . 0.2 OUTLIER -121.29 140.9 43.96 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.233 0 CA-C-O 121.084 0.469 . . . . 0.0 110.577 -176.233 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 355' ' ' ILE . . . . . 0.89 ' HB ' ' HB2' ' A' ' 366' ' ' GLN . 3.1 mp . . . . . 0 C--N 1.315 -0.904 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.26 177.614 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 366' ' ' GLN . . . . . 0.89 ' HB2' ' HB ' ' A' ' 355' ' ' ILE . 41.2 mt-30 . . . . . 0 N--CA 1.451 -0.379 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 367' ' ' LYS . . . . . 0.415 ' HD3' ' HE2' ' A' ' 369' ' ' LYS . 26.2 ttmt -148.43 139.8 23.43 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.181 -0.463 . . . . 0.0 109.752 -178.777 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 368' ' ' PHE . . . . . . . . . . . . . 52.3 p90 -139.06 145.12 39.18 Favored 'General case' 0 C--N 1.321 -0.663 0 O-C-N 123.33 0.394 . . . . 0.0 110.365 176.69 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 369' ' ' LYS . . . . . 0.415 ' HE2' ' HD3' ' A' ' 367' ' ' LYS . 3.4 mptp? -106.74 131.94 53.29 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 175.626 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 370' ' ' ALA . . . . . 0.482 ' HB3' HG22 ' A' ' 351' ' ' VAL . . . -135.64 135.89 40.54 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.549 -172.325 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -92.89 133.88 35.65 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.761 176.233 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 372' ' ' ILE . . . . . 0.479 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 87.4 mt -82.17 108.11 14.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 121.191 0.52 . . . . 0.0 110.405 -178.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -109.61 81.18 1.4 Allowed 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.485 -0.78 . . . . 0.0 109.096 178.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 374' ' ' GLY . . . . . 0.599 ' HA2' ' HA3' ' A' ' 310' ' ' GLY . . . 53.79 118.95 0.01 OUTLIER Glycine 0 CA--C 1.524 0.61 0 CA-C-N 114.992 -1.004 . . . . 0.0 114.841 -176.108 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 375' ' ' ASN . . . . . 0.52 ' HB2' ' O ' ' A' ' 308' ' ' ALA . 40.2 t30 40.69 44.28 1.81 Allowed 'General case' 0 N--CA 1.47 0.566 0 CA-C-O 122.053 0.93 . . . . 0.0 112.182 175.506 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 156.66 167.79 18.41 Favored Glycine 0 N--CA 1.442 -0.931 0 C-N-CA 120.302 -0.952 . . . . 0.0 111.608 176.065 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 377' ' ' PHE . . . . . 0.446 ' CD2' HG11 ' A' ' 351' ' ' VAL . 2.3 p90 -133.44 143.8 49.08 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-O 121.34 0.59 . . . . 0.0 111.5 -179.18 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 378' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.67 125.29 47.31 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 114.887 -1.051 . . . . 0.0 108.262 174.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -142.26 -165.3 10.47 Favored Glycine 0 N--CA 1.44 -1.055 0 C-N-CA 120.361 -0.923 . . . . 0.0 112.587 -176.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 95.4 m -142.46 147.05 35.45 Favored 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 -176.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 381' ' ' TRP . . . . . . . . . . . . . 42.0 m95 . . . . . 0 C--N 1.331 -0.214 0 O-C-N 123.633 0.583 . . . . 0.0 111.43 178.9 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.666 0 CA-C-O 120.985 0.214 . . . . 0.0 113.327 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -89.73 159.07 17.25 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 -177.407 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 79.6 t -135.67 135.99 50.75 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 174.166 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 16.9 m -143.11 141.68 31.3 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.8 0.334 . . . . 0.0 110.692 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 391' ' ' GLY . . . . . 0.422 ' HA2' ' CA ' ' A' ' 403' ' ' GLY . . . -145.36 155.9 26.7 Favored Glycine 0 C--N 1.316 -0.581 0 N-CA-C 111.487 -0.645 . . . . 0.0 111.487 -178.515 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 392' ' ' ARG . . . . . 0.501 ' HD3' ' O ' ' A' ' 375' ' ' ASN . 25.0 tpp180 -117.07 135.62 53.59 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.768 0.318 . . . . 0.0 110.24 -175.751 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -85.12 165.23 17.63 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.951 176.317 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 394' ' ' TYR . . . . . 0.621 ' O ' ' HB3' ' A' ' 308' ' ' ALA . 4.8 m-85 -109.58 -177.38 3.26 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.99 -177.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 395' ' ' GLY . . . . . 0.479 ' O ' ' N ' ' A' ' 397' ' ' ALA . . . -37.83 160.72 0.01 OUTLIER Glycine 0 C--N 1.336 0.541 0 O-C-N 124.492 1.12 . . . . 0.0 114.922 -176.625 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_exo -17.25 -40.46 0.0 OUTLIER 'Trans proline' 0 C--N 1.353 0.78 1 C-N-CA 127.773 5.649 . . . . 0.0 118.501 -165.122 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 397' ' ' ALA . . . . . 0.499 ' HB3' ' HG3' ' A' ' 399' ' ' GLU . . . -81.16 -20.24 41.69 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 118.754 0.706 . . . . 0.0 111.633 -171.536 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 60.96 10.63 20.78 Favored Glycine 0 C--N 1.338 0.682 0 C-N-CA 121.409 -0.424 . . . . 0.0 112.725 176.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 399' ' ' GLU . . . . . 0.502 ' OE2' ' HG2' ' A' ' 424' ' ' LYS . 30.5 mt-10 -70.19 -8.93 53.82 Favored 'General case' 0 N--CA 1.451 -0.406 0 CA-C-O 121.66 0.743 . . . . 0.0 110.123 -178.378 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -117.54 128.36 54.89 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.82 175.16 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 401' ' ' VAL . . . . . 0.443 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 10.1 p -140.87 140.49 32.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.844 0.354 . . . . 0.0 110.517 177.888 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -142.16 131.34 23.38 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.269 178.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 403' ' ' GLY . . . . . 0.422 ' CA ' ' HA2' ' A' ' 391' ' ' GLY . . . -145.02 -169.04 13.2 Favored Glycine 0 N--CA 1.438 -1.18 0 C-N-CA 120.47 -0.872 . . . . 0.0 112.271 -177.153 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 404' ' ' LYS . . . . . 0.792 ' HG2' HG11 ' A' ' 419' ' ' VAL . 37.5 mtpt -148.8 169.11 21.22 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 -178.344 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 5.8 m-85 . . . . . 0 C--N 1.32 -0.712 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 177.287 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 417' ' ' PHE . . . . . 0.464 ' HB2' ' HB2' ' A' ' 326' ' ' PHE . 35.2 p90 . . . . . 0 N--CA 1.453 -0.304 0 CA-C-O 120.973 0.416 . . . . 0.0 111.144 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 418' ' ' GLY . . . . . 0.524 ' H ' ' HD2' ' A' ' 326' ' ' PHE . . . 83.93 76.49 1.16 Allowed Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.3 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 419' ' ' VAL . . . . . 0.792 HG11 ' HG2' ' A' ' 404' ' ' LYS . 16.0 m -115.64 160.06 15.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 110.429 -0.211 . . . . 0.0 110.429 178.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 38.7 p90 -138.41 158.65 43.86 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.068 0.461 . . . . 0.0 110.506 178.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 421' ' ' ALA . . . . . 0.566 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -146.44 136.68 23.7 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.346 176.627 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -130.34 139.97 11.38 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.566 -0.826 . . . . 0.0 111.71 -179.365 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 72.1 mttt -117.66 136.4 53.35 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.173 0.511 . . . . 0.0 110.616 179.476 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 424' ' ' LYS . . . . . 0.502 ' HG2' ' OE2' ' A' ' 399' ' ' GLU . 23.0 tptm -59.0 125.82 25.17 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 114.838 -1.074 . . . . 0.0 113.126 -174.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 . . . . . 0 N--CA 1.446 -0.651 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 166.27 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo . . . . . 0 N--CA 1.461 -0.404 0 CA-C-O 120.653 0.189 . . . . 0.0 112.249 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 308' ' ' ALA . . . . . 0.776 ' O ' ' HB3' ' A' ' 375' ' ' ASN . . . -49.09 160.42 0.21 Allowed 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.148 169.291 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 309' ' ' LYS . . . . . 0.602 ' N ' HD21 ' A' ' 313' ' ' LEU . 79.2 mttt -127.01 91.46 3.34 Favored 'General case' 0 C--O 1.217 -0.611 0 O-C-N 121.798 -0.564 . . . . 0.0 109.817 -176.564 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -56.74 -23.46 44.47 Favored Glycine 0 CA--C 1.52 0.391 0 N-CA-C 114.873 0.709 . . . . 0.0 114.873 -168.298 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -87.65 -12.03 46.7 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 117.44 0.62 . . . . 0.0 111.574 178.392 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 14.8 tpt -115.5 -35.57 4.54 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.767 0.794 . . . . 0.0 109.511 -175.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 313' ' ' LEU . . . . . 0.759 HD23 ' HB3' ' A' ' 308' ' ' ALA . 0.4 OUTLIER -83.39 134.85 34.87 Favored 'General case' 0 N--CA 1.436 -1.169 0 CA-C-N 114.717 -1.128 . . . . 0.0 108.057 176.147 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 314' ' ' ALA . . . . . 0.624 ' HA ' ' CB ' ' A' ' 346' ' ' PHE . . . -161.91 173.18 14.85 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.177 0.513 . . . . 0.0 112.187 -170.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 121.71 168.67 13.43 Favored Glycine 0 N--CA 1.448 -0.531 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.277 -177.412 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 14.0 p -100.24 130.41 46.36 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 117.409 0.604 . . . . 0.0 109.94 174.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 317' ' ' ALA . . . . . 0.406 ' CB ' ' HE3' ' A' ' 424' ' ' LYS . . . -139.62 150.62 45.19 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 112.241 0.46 . . . . 0.0 112.241 -170.688 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 7.5 p -125.68 122.48 62.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.229 175.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 19.5 m-85 -111.99 146.61 37.55 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.732 -178.464 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 320' ' ' ASN . . . . . 0.618 HD21 ' HG3' ' A' ' 425' ' ' GLU . 43.4 m-80 -129.97 137.29 50.23 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.108 175.665 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . 0.592 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -162.52 -163.02 14.33 Favored Glycine 0 N--CA 1.44 -1.055 0 C-N-CA 120.344 -0.932 . . . . 0.0 112.697 -178.745 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -117.93 146.17 44.16 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.654 0.264 . . . . 0.0 110.33 -175.305 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 323' ' ' VAL . . . . . 0.638 HG23 ' HB2' ' A' ' 340' ' ' PHE . 84.9 t -110.39 117.05 53.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.105 176.084 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 324' ' ' LEU . . . . . 0.426 HD12 ' CE1' ' A' ' 326' ' ' PHE . 0.2 OUTLIER -94.44 103.03 15.01 Favored 'General case' 0 C--N 1.312 -1.038 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 177.796 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 325' ' ' HIS . . . . . 0.42 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 8.3 p-80 -95.88 115.48 27.5 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.14 -179.199 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 326' ' ' PHE . . . . . 0.717 ' HB2' ' HD1' ' A' ' 417' ' ' PHE . 16.5 m-85 . . . . . 0 C--N 1.321 -0.654 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.895 -175.283 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 337' ' ' ARG . . . . . 0.437 ' HA ' ' O ' ' A' ' 323' ' ' VAL . 17.4 ptp180 . . . . . 0 N--CA 1.45 -0.467 0 CA-C-O 121.042 0.448 . . . . 0.0 110.786 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -113.21 -176.69 19.49 Favored Glycine 0 N--CA 1.443 -0.869 0 CA-C-N 115.422 -0.808 . . . . 0.0 111.554 178.226 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 339' ' ' ARG . . . . . . . . . . . . . 73.6 mtt180 -104.91 131.16 52.76 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 120.747 0.308 . . . . 0.0 110.358 -175.085 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 340' ' ' PHE . . . . . 0.638 ' HB2' HG23 ' A' ' 323' ' ' VAL . 55.2 t80 -132.85 137.27 46.65 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-O 121.252 0.548 . . . . 0.0 111.472 -176.346 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 341' ' ' ALA . . . . . . . . . . . . . . . -139.48 143.85 37.71 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.137 -0.938 . . . . 0.0 108.999 174.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . 0.925 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -136.33 120.04 17.26 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-O 121.039 0.447 . . . . 0.0 110.84 -177.012 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -102.43 102.86 13.21 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.327 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 344' ' ' VAL . . . . . 0.434 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.3 OUTLIER -115.95 124.78 72.67 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 CA-C-O 121.6 0.714 . . . . 0.0 111.83 -172.649 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -97.44 98.59 10.07 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 172.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 346' ' ' PHE . . . . . 0.624 ' CB ' ' HA ' ' A' ' 314' ' ' ALA . 72.7 m-85 -65.27 -26.76 68.23 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.689 0.28 . . . . 0.0 111.259 -176.188 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -65.75 -19.57 67.44 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.831 -0.7 . . . . 0.0 111.843 178.001 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 11.9 t -112.03 -6.67 14.16 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.986 0.422 . . . . 0.0 110.058 177.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 349' ' ' LYS . . . . . 0.591 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 37.5 mtmm 52.61 59.12 4.71 Favored 'General case' 0 C--O 1.227 -0.098 0 CA-C-N 115.064 -0.971 . . . . 0.0 111.159 -176.013 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 68.1 p -149.32 138.35 21.3 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.181 179.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 351' ' ' VAL . . . . . 0.434 ' HB ' ' HB ' ' A' ' 344' ' ' VAL . 0.9 OUTLIER -123.89 151.77 28.95 Favored 'Isoleucine or valine' 0 C--O 1.235 0.334 0 CA-C-O 121.05 0.452 . . . . 0.0 110.789 -178.497 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 352' ' ' ASP . . . . . 0.925 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 21.3 t70 -112.02 118.4 35.33 Favored 'General case' 0 C--O 1.213 -0.857 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.353 173.444 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -119.82 119.01 4.1 Favored Glycine 0 N--CA 1.442 -0.925 0 C-N-CA 120.257 -0.973 . . . . 0.0 112.173 -176.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 354' ' ' ILE . . . . . 0.533 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -114.81 129.64 70.61 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.065 0 CA-C-O 121.038 0.447 . . . . 0.0 110.103 -178.125 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 355' ' ' ILE . . . . . 0.431 HD12 ' HE2' ' A' ' 368' ' ' PHE . 3.7 mp . . . . . 0 C--N 1.323 -0.57 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.159 -177.741 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 . . . . . 0 CA--C 1.522 -0.101 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 19.3 pttp -148.23 151.33 35.29 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.191 0.519 . . . . 0.0 111.631 -179.121 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 368' ' ' PHE . . . . . 0.646 ' CD1' HG22 ' A' ' 389' ' ' VAL . 27.2 p90 -134.99 161.45 35.24 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.195 -0.911 . . . . 0.0 109.189 179.238 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 33.3 mtmm -131.62 150.9 51.99 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-O 121.264 0.554 . . . . 0.0 110.513 173.619 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -141.55 139.84 33.29 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.164 -173.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -92.69 130.73 38.23 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 174.223 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 372' ' ' ILE . . . . . 0.655 ' HA ' ' HB3' ' A' ' 377' ' ' PHE . 83.4 mt -79.45 108.17 12.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-O 121.758 0.79 . . . . 0.0 110.585 -176.322 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -110.58 82.38 1.58 Allowed 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 114.647 -1.16 . . . . 0.0 109.495 -178.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 59.48 119.29 0.01 OUTLIER Glycine 0 CA--C 1.52 0.402 0 CA-C-N 114.928 -1.033 . . . . 0.0 113.776 -177.146 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 375' ' ' ASN . . . . . 0.776 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 2.2 p-10 28.85 44.6 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 124.734 1.214 . . . . 0.0 114.123 177.238 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 160.59 -178.77 36.47 Favored Glycine 0 N--CA 1.442 -0.906 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 -178.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 377' ' ' PHE . . . . . 0.655 ' HB3' ' HA ' ' A' ' 372' ' ' ILE . 6.3 p90 -153.51 150.66 28.96 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 117.362 0.581 . . . . 0.0 111.783 -178.787 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 378' ' ' LYS . . . . . 0.461 ' HD3' ' H ' ' A' ' 378' ' ' LYS . 0.0 OUTLIER -117.77 140.59 49.47 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 171.102 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 379' ' ' GLY . . . . . 0.527 ' C ' HG23 ' A' ' 389' ' ' VAL . . . -149.06 -155.13 6.59 Favored Glycine 0 N--CA 1.44 -1.062 0 C-N-CA 120.504 -0.855 . . . . 0.0 112.235 -172.852 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 380' ' ' THR . . . . . 0.439 ' HA ' ' HA ' ' A' ' 388' ' ' ASP . 7.0 t -170.99 154.49 4.17 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 -173.52 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 381' ' ' TRP . . . . . 0.671 ' HD1' ' HA3' ' A' ' 387' ' ' GLY . 39.4 m95 . . . . . 0 C--N 1.327 -0.375 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.422 -179.597 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . 0.671 ' HA3' ' HD1' ' A' ' 381' ' ' TRP . . . . . . . . 0 N--CA 1.443 -0.881 0 N-CA-C 111.965 -0.454 . . . . 0.0 111.965 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 388' ' ' ASP . . . . . 0.439 ' HA ' ' HA ' ' A' ' 380' ' ' THR . 43.4 m-20 -107.73 147.33 30.92 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.027 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 389' ' ' VAL . . . . . 0.646 HG22 ' CD1' ' A' ' 368' ' ' PHE . 3.3 m -121.49 167.15 15.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 120.713 0.292 . . . . 0.0 111.589 -171.736 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 33.6 t -161.87 157.61 24.21 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 173.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -157.57 163.57 32.64 Favored Glycine 0 C--N 1.32 -0.308 0 N-CA-C 111.682 -0.567 . . . . 0.0 111.682 179.666 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 25.6 ttt180 -125.71 143.21 51.14 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.791 0.295 . . . . 0.0 110.313 -176.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 393' ' ' PHE . . . . . 0.582 ' CZ ' ' HE1' ' A' ' 346' ' ' PHE . 2.5 m-85 -92.92 157.45 16.34 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.432 0.634 . . . . 0.0 112.261 -175.433 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 394' ' ' TYR . . . . . 0.74 ' O ' ' HB1' ' A' ' 308' ' ' ALA . 1.2 m-85 -102.5 -176.5 3.12 Favored 'General case' 0 C--O 1.22 -0.5 0 CA-C-N 114.816 -1.083 . . . . 0.0 110.372 178.615 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 395' ' ' GLY . . . . . . . . . . . . . . . -36.67 153.64 0.01 OUTLIER Glycine 0 C--N 1.335 0.479 0 O-C-N 124.394 1.059 . . . . 0.0 114.941 -176.879 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_exo -16.15 -50.63 0.02 OUTLIER 'Trans proline' 0 C--N 1.351 0.691 1 C-N-CA 127.453 5.435 . . . . 0.0 117.724 -165.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 397' ' ' ALA . . . . . 0.563 ' HB3' ' HG2' ' A' ' 399' ' ' GLU . . . -75.46 -16.72 60.29 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 112.377 0.51 . . . . 0.0 112.377 -171.504 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 68.49 24.92 75.1 Favored Glycine 0 N--CA 1.447 -0.591 0 N-CA-C 111.769 -0.532 . . . . 0.0 111.769 179.538 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 399' ' ' GLU . . . . . 0.563 ' HG2' ' HB3' ' A' ' 397' ' ' ALA . 10.9 mm-40 -58.86 -16.54 17.86 Favored 'General case' 0 N--CA 1.463 0.208 0 C-N-CA 123.248 0.619 . . . . 0.0 111.557 -175.488 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -138.53 146.72 42.27 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 172.613 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 401' ' ' VAL . . . . . 0.474 HG21 ' CE2' ' A' ' 377' ' ' PHE . 7.3 p -144.54 133.01 17.92 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.398 177.032 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -124.61 132.22 53.44 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.332 -178.694 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -146.86 -172.14 16.82 Favored Glycine 0 N--CA 1.44 -1.049 0 C-N-CA 120.498 -0.858 . . . . 0.0 112.088 -179.139 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 404' ' ' LYS . . . . . 0.74 ' HG2' HG12 ' A' ' 419' ' ' VAL . 30.1 mtmt -146.51 158.43 43.9 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 179.815 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 405' ' ' TYR . . . . . 0.474 ' HB3' HG12 ' A' ' 389' ' ' VAL . 17.6 p90 . . . . . 0 C--N 1.32 -0.716 0 CA-C-O 121.222 0.534 . . . . 0.0 110.579 176.58 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 417' ' ' PHE . . . . . 0.717 ' HD1' ' HB2' ' A' ' 326' ' ' PHE . 71.5 m-85 . . . . . 0 N--CA 1.452 -0.366 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 418' ' ' GLY . . . . . 0.543 ' H ' ' HD2' ' A' ' 326' ' ' PHE . . . 81.8 76.86 1.06 Allowed Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 120.339 -0.934 . . . . 0.0 112.567 176.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 419' ' ' VAL . . . . . 0.74 HG12 ' HG2' ' A' ' 404' ' ' LYS . 18.9 m -106.43 152.84 7.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 N-CA-C 110.207 -0.294 . . . . 0.0 110.207 179.441 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -138.03 154.42 49.3 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 120.934 0.397 . . . . 0.0 110.273 -179.438 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 421' ' ' ALA . . . . . 0.592 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -142.24 136.02 29.42 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 177.112 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -118.1 135.6 11.76 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 120.67 -0.776 . . . . 0.0 111.974 -179.046 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 63.9 mttm -113.37 133.68 55.03 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.816 0.341 . . . . 0.0 110.359 -179.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 424' ' ' LYS . . . . . 0.406 ' HE3' ' CB ' ' A' ' 317' ' ' ALA . 23.6 tptm -60.92 112.05 1.9 Allowed 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.354 -177.736 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 425' ' ' GLU . . . . . 0.618 ' HG3' HD21 ' A' ' 320' ' ' ASN . 8.8 mm-40 . . . . . 0 C--N 1.324 -0.541 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.516 177.433 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 307' ' ' PRO . . . . . 0.56 ' C ' ' HA2' ' A' ' 395' ' ' GLY . 66.6 Cg_endo . . . . . 0 N--CA 1.453 -0.898 0 CA-C-O 120.753 0.23 . . . . 0.0 111.634 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 308' ' ' ALA . . . . . 0.575 ' HB1' HD23 ' A' ' 313' ' ' LEU . . . -61.11 161.1 9.07 Favored 'General case' 0 CA--C 1.515 -0.372 0 CA-C-O 121.372 0.606 . . . . 0.0 112.106 -175.513 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 309' ' ' LYS . . . . . . . . . . . . . 45.1 mttm -104.66 84.61 2.19 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 171.598 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 310' ' ' GLY . . . . . 0.695 ' HA3' ' O ' ' A' ' 374' ' ' GLY . . . -55.51 -34.25 59.81 Favored Glycine 0 CA--C 1.508 -0.35 0 CA-C-N 115.832 -0.622 . . . . 0.0 113.054 -173.623 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -45.6 -37.6 5.74 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 123.663 0.785 . . . . 0.0 112.288 175.629 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 73.2 mtm -131.08 31.75 4.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.718 0.294 . . . . 0.0 111.144 -177.381 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 313' ' ' LEU . . . . . 0.575 HD23 ' HB1' ' A' ' 308' ' ' ALA . 10.3 mt -65.79 -165.45 0.03 OUTLIER 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 112.387 0.514 . . . . 0.0 112.387 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -76.25 -168.98 1.05 Allowed 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -170.429 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . 0.622 ' O ' ' HB2' ' A' ' 346' ' ' PHE . . . -93.11 -122.64 3.3 Favored Glycine 0 C--O 1.223 -0.574 0 CA-C-N 115.019 -0.991 . . . . 0.0 111.469 178.278 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 18.0 p -96.56 131.68 42.94 Favored 'General case' 0 C--N 1.311 -1.074 0 O-C-N 122.28 -0.541 . . . . 0.0 110.912 177.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -142.92 162.2 36.11 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.587 -174.294 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 4.7 p -127.92 114.68 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.642 0 CA-C-O 121.452 0.644 . . . . 0.0 110.489 172.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 1.3 m-85 -98.89 155.42 17.4 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 175.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 320' ' ' ASN . . . . . 0.413 ' HA ' ' HA ' ' A' ' 341' ' ' ALA . 8.3 p30 -157.83 156.11 30.88 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 120.855 0.359 . . . . 0.0 110.75 173.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . 0.415 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -176.81 -150.24 8.17 Favored Glycine 0 N--CA 1.443 -0.846 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.145 -178.646 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 23.5 mm-40 -112.98 149.76 32.83 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.779 0.323 . . . . 0.0 110.861 -173.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 323' ' ' VAL . . . . . 0.62 HG23 HG21 ' A' ' 355' ' ' ILE . 55.5 t -108.52 118.29 55.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.051 174.091 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 324' ' ' LEU . . . . . . . . . . . . . 92.2 mt -97.61 103.48 15.42 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.896 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 325' ' ' HIS . . . . . . . . . . . . . 26.3 t60 -98.97 112.73 24.76 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 -178.144 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 326' ' ' PHE . . . . . 0.635 ' HB2' ' HB3' ' A' ' 417' ' ' PHE . 30.3 m-85 . . . . . 0 C--N 1.327 -0.409 0 CA-C-N 116.28 -0.418 . . . . 0.0 109.925 -173.78 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 337' ' ' ARG . . . . . . . . . . . . . 18.5 mtp180 . . . . . 0 N--CA 1.444 -0.726 0 CA-C-O 121.289 0.566 . . . . 0.0 111.054 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -98.53 165.37 21.34 Favored Glycine 0 N--CA 1.436 -1.318 0 N-CA-C 110.132 -1.187 . . . . 0.0 110.132 173.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 339' ' ' ARG . . . . . 0.517 ' HD2' ' N ' ' A' ' 339' ' ' ARG . 5.6 mpt_? -104.92 157.56 17.13 Favored 'General case' 0 C--N 1.313 -0.992 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 176.651 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 340' ' ' PHE . . . . . 0.737 ' HA ' ' O ' ' A' ' 354' ' ' ILE . 11.1 t80 -154.68 140.56 18.22 Favored 'General case' 0 C--N 1.313 -0.992 0 C-N-CA 120.496 -0.482 . . . . 0.0 111.35 -176.777 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 341' ' ' ALA . . . . . 0.413 ' HA ' ' HA ' ' A' ' 320' ' ' ASN . . . -136.81 165.75 25.2 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 174.351 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . 0.854 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -147.96 118.98 7.66 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-O 121.12 0.486 . . . . 0.0 111.222 -177.32 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 343' ' ' LYS . . . . . 0.517 ' HB3' ' HB2' ' A' ' 352' ' ' ASP . 27.0 tptp -87.28 98.0 11.09 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 174.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 344' ' ' VAL . . . . . 0.472 ' HA ' ' HA ' ' A' ' 351' ' ' VAL . 0.3 OUTLIER -115.95 117.31 55.12 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-O 121.816 0.817 . . . . 0.0 111.802 -172.718 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -95.44 94.11 7.61 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 114.282 -1.327 . . . . 0.0 108.591 175.48 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 346' ' ' PHE . . . . . 0.622 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 44.9 m-85 -65.54 -21.2 66.58 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.965 -174.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -62.28 -33.8 87.21 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.363 176.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 39.0 m -106.78 -6.57 17.67 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.163 0.506 . . . . 0.0 110.15 176.506 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 349' ' ' LYS . . . . . 0.744 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 22.4 mttm 53.79 62.71 2.49 Favored 'General case' 0 C--O 1.22 -0.466 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.89 -177.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 49.8 m -141.01 145.46 35.95 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.207 -0.906 . . . . 0.0 109.207 175.458 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 351' ' ' VAL . . . . . 0.507 ' O ' ' HG3' ' A' ' 369' ' ' LYS . 0.9 OUTLIER -129.27 156.47 41.81 Favored 'Isoleucine or valine' 0 C--O 1.235 0.327 0 CA-C-O 120.856 0.36 . . . . 0.0 110.526 -176.999 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 352' ' ' ASP . . . . . 0.854 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 1.8 m-20 -121.13 118.0 28.58 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 170.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -111.13 124.02 6.75 Favored Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.11 -1.043 . . . . 0.0 112.435 -175.68 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 354' ' ' ILE . . . . . 0.737 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 1.0 OUTLIER -112.99 129.51 68.52 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-O 120.686 0.279 . . . . 0.0 110.455 -178.063 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 355' ' ' ILE . . . . . 0.62 HG21 HG23 ' A' ' 323' ' ' VAL . 4.3 mm . . . . . 0 C--N 1.323 -0.555 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.022 179.126 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 17.2 mm100 . . . . . 0 N--CA 1.447 -0.591 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -153.63 154.37 34.07 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 176.216 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 368' ' ' PHE . . . . . 0.502 ' HB3' ' CE3' ' A' ' 381' ' ' TRP . 47.2 p90 -136.05 160.21 39.35 Favored 'General case' 0 C--N 1.319 -0.757 0 O-C-N 123.437 0.46 . . . . 0.0 109.836 -176.41 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 369' ' ' LYS . . . . . 0.507 ' HG3' ' O ' ' A' ' 351' ' ' VAL . 26.9 tttp -127.6 132.87 49.74 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 174.119 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 370' ' ' ALA . . . . . 0.443 ' HB2' HG23 ' A' ' 351' ' ' VAL . . . -128.85 148.46 50.89 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.182 -172.065 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -104.41 129.27 52.37 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.947 176.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 372' ' ' ILE . . . . . 0.744 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 93.3 mt -81.86 103.81 9.53 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.638 0 CA-C-O 121.925 0.869 . . . . 0.0 109.747 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 19.1 t0 -107.8 96.99 6.77 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 114.375 -1.284 . . . . 0.0 108.859 178.277 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 374' ' ' GLY . . . . . 0.695 ' O ' ' HA3' ' A' ' 310' ' ' GLY . . . 92.51 -123.32 7.24 Favored Glycine 0 N--CA 1.441 -0.981 0 C-N-CA 120.621 -0.799 . . . . 0.0 111.244 -174.254 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 375' ' ' ASN . . . . . . . . . . . . . 42.3 p-10 -114.15 35.63 4.07 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.925 0.869 . . . . 0.0 110.82 -175.244 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . -177.93 171.59 44.12 Favored Glycine 0 N--CA 1.443 -0.855 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 -176.295 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 377' ' ' PHE . . . . . 0.481 ' HD2' HG12 ' A' ' 372' ' ' ILE . 6.7 p90 -131.57 145.69 51.84 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 117.715 0.757 . . . . 0.0 112.616 -176.129 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 378' ' ' LYS . . . . . 0.446 ' HD2' ' N ' ' A' ' 378' ' ' LYS . 0.0 OUTLIER -119.68 134.33 55.27 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 114.578 -1.192 . . . . 0.0 108.167 171.676 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -150.3 -169.68 16.65 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.062 -1.066 . . . . 0.0 112.986 -175.597 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 15.1 t -147.46 153.68 39.86 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -175.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 381' ' ' TRP . . . . . 0.502 ' CE3' ' HB3' ' A' ' 368' ' ' PHE . 61.4 m95 . . . . . 0 C--N 1.33 -0.27 0 CA-C-O 120.985 0.421 . . . . 0.0 110.282 179.672 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.75 0 N-CA-C 112.105 -0.398 . . . . 0.0 112.105 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -142.16 134.82 28.29 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 110.204 -0.295 . . . . 0.0 110.204 -178.593 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 38.2 t -112.95 133.87 57.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.347 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 31.7 m -144.61 143.3 30.71 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.076 0.465 . . . . 0.0 111.224 178.229 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -157.4 157.17 27.89 Favored Glycine 0 N--CA 1.445 -0.763 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 178.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 11.3 ptp180 -136.02 150.74 49.32 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 117.405 0.602 . . . . 0.0 110.764 -175.3 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 393' ' ' PHE . . . . . 0.475 ' CD1' ' HB ' ' A' ' 401' ' ' VAL . 95.1 m-85 -84.49 167.75 16.09 Favored 'General case' 0 CA--C 1.496 -1.098 0 CA-C-O 122.134 0.969 . . . . 0.0 111.184 -178.084 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 394' ' ' TYR . . . . . 0.577 ' HD1' ' N ' ' A' ' 394' ' ' TYR . 0.6 OUTLIER -97.56 -179.11 4.36 Favored 'General case' 0 N--CA 1.428 -1.562 0 N-CA-C 105.621 -1.992 . . . . 0.0 105.621 173.153 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 395' ' ' GLY . . . . . 0.56 ' HA2' ' C ' ' A' ' 307' ' ' PRO . . . -51.48 -148.16 0.0 OUTLIER Glycine 0 N--CA 1.474 1.168 0 O-C-N 124.497 1.123 . . . . 0.0 115.754 -172.314 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -57.67 -10.86 7.88 Favored 'Trans proline' 0 CA--C 1.539 0.729 0 C-N-CA 121.227 1.285 . . . . 0.0 111.042 176.192 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 397' ' ' ALA . . . . . 0.51 ' C ' ' H ' ' A' ' 399' ' ' GLU . . . -93.97 27.66 2.71 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 114.77 -1.104 . . . . 0.0 110.811 174.127 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . -53.6 8.54 0.01 OUTLIER Glycine 0 N--CA 1.469 0.87 0 C-N-CA 124.069 0.842 . . . . 0.0 114.599 176.079 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 399' ' ' GLU . . . . . 0.51 ' H ' ' C ' ' A' ' 397' ' ' ALA . 3.7 mp0 -59.97 -9.99 3.66 Favored 'General case' 0 C--N 1.323 -0.587 0 C-N-CA 123.929 0.892 . . . . 0.0 110.019 166.676 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 -119.21 125.05 48.24 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-N 115.344 -0.844 . . . . 0.0 109.439 174.15 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 401' ' ' VAL . . . . . 0.475 ' HB ' ' CD1' ' A' ' 393' ' ' PHE . 12.2 p -132.71 141.12 45.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 176.607 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -130.01 137.56 50.33 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-O 120.761 0.315 . . . . 0.0 110.679 178.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -144.88 177.03 23.62 Favored Glycine 0 N--CA 1.439 -1.161 0 C-N-CA 120.458 -0.877 . . . . 0.0 112.143 179.805 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 404' ' ' LYS . . . . . 0.441 ' CG ' HG13 ' A' ' 419' ' ' VAL . 0.0 OUTLIER -141.13 155.7 46.07 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 176.905 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 19.7 p90 . . . . . 0 C--N 1.313 -0.982 0 CA-C-O 120.977 0.417 . . . . 0.0 110.287 176.851 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 417' ' ' PHE . . . . . 0.635 ' HB3' ' HB2' ' A' ' 326' ' ' PHE . 73.8 m-85 . . . . . 0 N--CA 1.452 -0.344 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 82.8 76.99 1.1 Allowed Glycine 0 N--CA 1.449 -0.467 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.374 -177.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 419' ' ' VAL . . . . . 0.441 HG13 ' CG ' ' A' ' 404' ' ' LYS . 19.8 m -106.4 167.36 3.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 -179.34 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 45.9 p90 -148.24 162.69 38.98 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-O 120.796 0.331 . . . . 0.0 110.144 178.077 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 421' ' ' ALA . . . . . 0.415 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -142.85 135.39 27.67 Favored 'General case' 0 C--N 1.316 -0.877 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 177.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -122.95 135.72 10.2 Favored Glycine 0 N--CA 1.441 -1.021 0 C-N-CA 120.749 -0.739 . . . . 0.0 111.451 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 60.3 mttm -118.93 139.8 51.05 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-O 121.041 0.448 . . . . 0.0 110.354 179.442 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 424' ' ' LYS . . . . . . . . . . . . . 5.6 tppp? -60.06 122.41 14.3 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.011 -0.995 . . . . 0.0 111.86 -177.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 . . . . . 0 C--N 1.319 -0.756 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 166.758 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo . . . . . 0 N--CA 1.457 -0.626 0 N-CA-C 109.478 -1.008 . . . . 0.0 109.478 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 308' ' ' ALA . . . . . 0.734 ' O ' ' HB3' ' A' ' 375' ' ' ASN . . . -49.45 118.95 3.03 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 121.118 0.485 . . . . 0.0 111.366 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 309' ' ' LYS . . . . . 0.437 ' O ' ' HG ' ' A' ' 313' ' ' LEU . 24.8 mmmt -73.95 81.5 1.68 Allowed 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -177.578 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 310' ' ' GLY . . . . . 0.6 ' HA2' HD11 ' A' ' 313' ' ' LEU . . . -52.56 -40.48 55.06 Favored Glycine 0 C--N 1.333 0.387 0 O-C-N 123.332 0.395 . . . . 0.0 113.145 -174.445 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . 0.524 ' HG3' ' HG3' ' A' ' 312' ' ' MET . 10.1 pt-20 -56.63 -28.26 60.13 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 122.635 0.374 . . . . 0.0 111.923 177.307 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 312' ' ' MET . . . . . 0.524 ' HG3' ' HG3' ' A' ' 311' ' ' GLU . 76.3 mtm -113.83 1.97 14.96 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.687 0.28 . . . . 0.0 111.352 -177.424 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 313' ' ' LEU . . . . . 0.6 HD11 ' HA2' ' A' ' 310' ' ' GLY . 78.8 mt -72.69 131.04 41.87 Favored 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 175.598 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -143.9 143.67 31.38 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.569 -173.042 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 121.66 169.87 13.73 Favored Glycine 0 N--CA 1.445 -0.743 0 C-N-CA 120.981 -0.628 . . . . 0.0 111.843 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 25.4 p -107.32 133.04 52.44 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 175.242 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -142.03 160.26 40.58 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 121.271 0.557 . . . . 0.0 112.076 -172.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 6.1 p -129.13 115.93 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.878 174.512 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . 0.558 ' CZ ' ' HB2' ' A' ' 424' ' ' LYS . 2.0 m-85 -98.07 128.74 44.77 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 179.09 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 4.0 p30 -131.37 144.05 50.94 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 120.868 0.366 . . . . 0.0 110.727 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -173.67 -143.89 4.5 Favored Glycine 0 N--CA 1.443 -0.855 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.007 -179.722 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -119.48 147.81 43.99 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.832 0.349 . . . . 0.0 110.975 -175.163 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 323' ' ' VAL . . . . . 0.675 HG11 ' HB2' ' A' ' 340' ' ' PHE . 4.5 m -106.71 117.04 51.75 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 CA-C-N 115.846 -0.616 . . . . 0.0 109.391 168.027 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 324' ' ' LEU . . . . . 0.545 ' HB2' HG21 ' A' ' 419' ' ' VAL . 97.5 mt -91.63 101.94 14.57 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 177.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 325' ' ' HIS . . . . . 0.472 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 6.2 p80 -102.41 117.67 35.21 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.754 0.788 . . . . 0.0 109.766 -176.333 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 326' ' ' PHE . . . . . 0.782 ' HD2' ' HB3' ' A' ' 417' ' ' PHE . 58.4 m-85 . . . . . 0 C--N 1.322 -0.598 0 CA-C-N 114.649 -1.16 . . . . 0.0 111.22 -168.521 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 337' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.452 -0.365 0 CA-C-O 121.53 0.681 . . . . 0.0 111.487 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 338' ' ' GLY . . . . . 0.451 ' HA3' ' CG2' ' A' ' 323' ' ' VAL . . . -106.46 -175.42 23.29 Favored Glycine 0 N--CA 1.437 -1.251 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 170.032 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 339' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -111.29 131.56 55.06 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 117.222 0.511 . . . . 0.0 109.799 178.109 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 340' ' ' PHE . . . . . 0.675 ' HB2' HG11 ' A' ' 323' ' ' VAL . 10.9 t80 -127.37 133.53 50.02 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.793 -178.182 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 341' ' ' ALA . . . . . 0.456 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -131.9 160.7 34.94 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.613 175.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . 0.881 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -147.83 119.4 7.97 Favored 'General case' 0 N--CA 1.442 -0.844 0 CA-C-O 121.204 0.526 . . . . 0.0 110.446 -177.7 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 343' ' ' LYS . . . . . 0.424 ' HB3' ' HB2' ' A' ' 352' ' ' ASP . 6.3 tmtt? -91.68 98.74 11.82 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 178.363 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 344' ' ' VAL . . . . . 0.55 ' HB ' HG13 ' A' ' 351' ' ' VAL . 0.2 OUTLIER -118.51 128.52 75.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-O 121.794 0.806 . . . . 0.0 112.239 -172.189 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -108.14 110.62 22.32 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 114.489 -1.232 . . . . 0.0 108.419 174.443 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 346' ' ' PHE . . . . . 0.478 ' HZ ' ' OH ' ' A' ' 319' ' ' TYR . 64.8 m-85 -73.16 -18.74 61.24 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.705 0.288 . . . . 0.0 111.732 -176.291 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -62.77 -28.19 71.27 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.475 -0.869 . . . . 0.0 111.249 176.199 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 20.5 t -112.46 -10.12 13.76 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-N 115.897 -0.151 . . . . 0.0 110.974 177.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 349' ' ' LYS . . . . . 0.634 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 35.2 mttp 57.23 59.46 3.37 Favored 'General case' 0 C--O 1.224 -0.275 0 CA-C-O 121.58 0.705 . . . . 0.0 110.646 -178.308 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 8.6 t -146.86 152.61 39.01 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.296 177.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 351' ' ' VAL . . . . . 0.654 HG22 ' HB2' ' A' ' 370' ' ' ALA . 1.2 m -134.8 155.25 38.12 Favored 'Isoleucine or valine' 0 C--O 1.236 0.382 0 CA-C-O 121.205 0.526 . . . . 0.0 110.836 -176.786 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 352' ' ' ASP . . . . . 0.881 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 1.2 m-20 -110.7 117.91 34.74 Favored 'General case' 0 C--O 1.215 -0.728 0 CA-C-N 115.244 -0.889 . . . . 0.0 108.692 168.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -110.91 124.43 6.96 Favored Glycine 0 N--CA 1.441 -1.03 0 C-N-CA 120.193 -1.003 . . . . 0.0 111.562 -176.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 354' ' ' ILE . . . . . 0.453 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -122.05 129.73 75.15 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 CA-C-O 121.187 0.518 . . . . 0.0 109.85 -177.058 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 355' ' ' ILE . . . . . 0.637 HG21 HG22 ' A' ' 323' ' ' VAL . 4.2 mp . . . . . 0 C--N 1.32 -0.714 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.858 -178.57 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 43.9 mt-30 . . . . . 0 N--CA 1.457 -0.101 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -138.55 148.61 44.42 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 176.429 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 368' ' ' PHE . . . . . 0.442 ' HB3' ' CE3' ' A' ' 381' ' ' TRP . 34.4 p90 -140.83 149.99 42.72 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.0 0.429 . . . . 0.0 110.465 178.577 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 1.6 mptp? -104.9 138.1 41.66 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 173.473 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 370' ' ' ALA . . . . . 0.654 ' HB2' HG22 ' A' ' 351' ' ' VAL . . . -134.26 147.45 50.66 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.18 0.514 . . . . 0.0 111.574 -177.127 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -105.96 130.47 53.89 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.628 175.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 372' ' ' ILE . . . . . 0.634 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 87.6 mt -81.66 107.38 13.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 121.545 0.688 . . . . 0.0 110.755 -178.04 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 373' ' ' ASP . . . . . 0.476 ' HB2' ' HE2' ' A' ' 378' ' ' LYS . 28.5 t70 -111.46 80.2 1.29 Allowed 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.093 -0.958 . . . . 0.0 109.435 179.417 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 58.87 119.07 0.01 OUTLIER Glycine 0 CA--C 1.521 0.42 0 CA-C-N 114.889 -1.051 . . . . 0.0 113.76 -177.484 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 375' ' ' ASN . . . . . 0.734 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 2.4 p-10 29.86 46.05 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 113.912 1.078 . . . . 0.0 113.912 178.582 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 165.06 172.35 32.41 Favored Glycine 0 N--CA 1.445 -0.766 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 178.032 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 377' ' ' PHE . . . . . 0.465 ' CZ ' HG23 ' A' ' 401' ' ' VAL . 3.4 p90 -147.95 150.54 34.23 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.447 0.641 . . . . 0.0 111.793 179.185 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 378' ' ' LYS . . . . . 0.748 ' HD3' ' H ' ' A' ' 378' ' ' LYS . 0.3 OUTLIER -112.37 130.29 56.01 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 114.638 -1.164 . . . . 0.0 108.383 174.688 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -126.23 156.64 19.83 Favored Glycine 0 N--CA 1.444 -0.821 0 C-N-CA 120.4 -0.905 . . . . 0.0 113.248 -172.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 26.7 p -125.24 137.74 54.1 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.219 -0.491 . . . . 0.0 109.938 178.007 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 381' ' ' TRP . . . . . 0.442 ' CE3' ' HB3' ' A' ' 368' ' ' PHE . 41.2 m95 . . . . . 0 C--N 1.33 -0.242 0 CA-C-O 121.146 0.498 . . . . 0.0 110.943 -178.074 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.591 0 N-CA-C 111.647 -0.581 . . . . 0.0 111.647 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 20.6 m-20 -93.41 143.44 26.28 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 120.961 0.41 . . . . 0.0 110.64 -177.168 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 23.9 t -112.7 137.09 46.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.782 179.464 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 5.0 p -147.42 138.83 23.87 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.817 0.341 . . . . 0.0 111.459 -179.077 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -156.74 154.11 25.26 Favored Glycine 0 N--CA 1.445 -0.764 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 23.2 mtt180 -119.51 153.15 35.78 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.468 0.652 . . . . 0.0 111.952 -175.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -93.71 159.31 15.26 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 114.649 -1.159 . . . . 0.0 110.045 178.643 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 394' ' ' TYR . . . . . 0.661 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 3.5 m-85 -101.62 -178.45 3.73 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.723 -177.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 395' ' ' GLY . . . . . 0.407 ' O ' ' N ' ' A' ' 397' ' ' ALA . . . -42.52 168.47 0.01 OUTLIER Glycine 0 CA--C 1.524 0.594 0 O-C-N 124.048 0.842 . . . . 0.0 115.159 -175.046 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_exo -19.35 -45.17 0.02 OUTLIER 'Trans proline' 0 C--N 1.356 0.924 1 C-N-CA 127.204 5.269 . . . . 0.0 117.588 -167.23 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 397' ' ' ALA . . . . . 0.407 ' N ' ' O ' ' A' ' 395' ' ' GLY . . . -72.25 -21.26 61.41 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -174.17 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 54.33 19.13 11.33 Favored Glycine 0 C--O 1.219 -0.837 0 CA-C-N 115.918 -0.583 . . . . 0.0 113.777 174.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 399' ' ' GLU . . . . . 0.88 ' HG3' ' HB3' ' A' ' 424' ' ' LYS . 23.0 tt0 -79.7 -10.66 59.82 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.538 0.685 . . . . 0.0 110.161 -174.312 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -118.54 125.7 50.41 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.864 178.458 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 401' ' ' VAL . . . . . 0.465 HG23 ' CZ ' ' A' ' 377' ' ' PHE . 12.9 p -130.36 141.12 47.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.64 178.01 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -145.43 139.01 26.6 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.847 -177.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -167.75 -163.83 22.35 Favored Glycine 0 N--CA 1.444 -0.799 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.1 179.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 404' ' ' LYS . . . . . 0.554 ' HG2' HG13 ' A' ' 419' ' ' VAL . 21.2 mtmt -146.89 158.98 44.06 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 19.1 p90 . . . . . 0 C--N 1.318 -0.775 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 170.329 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 417' ' ' PHE . . . . . 0.782 ' HB3' ' HD2' ' A' ' 326' ' ' PHE . 99.0 m-85 . . . . . 0 N--CA 1.435 -1.185 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 418' ' ' GLY . . . . . 0.505 ' H ' ' HD2' ' A' ' 326' ' ' PHE . . . 81.95 77.07 1.06 Allowed Glycine 0 N--CA 1.436 -1.311 0 C-N-CA 118.212 -1.947 . . . . 0.0 110.771 -174.58 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 419' ' ' VAL . . . . . 0.592 HG11 ' HE2' ' A' ' 326' ' ' PHE . 13.0 m -104.73 161.54 4.77 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -175.264 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 420' ' ' PHE . . . . . 0.401 ' HB3' HG13 ' A' ' 323' ' ' VAL . 49.5 p90 -139.27 147.74 42.09 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.109 0.48 . . . . 0.0 110.645 -178.405 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -137.44 134.61 36.04 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 174.254 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -132.0 134.75 7.79 Favored Glycine 0 N--CA 1.437 -1.257 0 C-N-CA 120.321 -0.942 . . . . 0.0 111.625 -177.695 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 17.2 mtpp -109.48 125.61 52.64 Favored 'General case' 0 C--N 1.314 -0.943 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 178.377 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 424' ' ' LYS . . . . . 0.88 ' HB3' ' HG3' ' A' ' 399' ' ' GLU . 8.0 tttm -66.53 117.88 9.35 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.855 -179.284 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 11.2 tp10 . . . . . 0 C--N 1.312 -1.025 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 173.762 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo . . . . . 0 N--CA 1.452 -0.937 0 CA-C-O 121.045 0.352 . . . . 0.0 111.947 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 308' ' ' ALA . . . . . 0.729 ' HB3' ' CD2' ' A' ' 313' ' ' LEU . . . -61.24 169.26 2.21 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.231 174.027 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 309' ' ' LYS . . . . . 0.685 ' H ' HD22 ' A' ' 313' ' ' LEU . 13.0 mptt -125.42 85.24 2.38 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 174.355 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -57.4 -19.71 34.36 Favored Glycine 0 N--CA 1.462 0.409 0 N-CA-C 114.28 0.472 . . . . 0.0 114.28 -168.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -87.35 -16.27 35.51 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.91 0.386 . . . . 0.0 111.227 179.15 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 47.9 tpp -110.95 -34.38 6.24 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.153 -175.067 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 313' ' ' LEU . . . . . 0.729 ' CD2' ' HB3' ' A' ' 308' ' ' ALA . 1.7 pp -83.45 137.09 34.06 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 175.471 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 314' ' ' ALA . . . . . 0.487 ' HA ' ' HB2' ' A' ' 346' ' ' PHE . . . -145.63 172.57 13.07 Favored 'General case' 0 C--N 1.318 -0.781 0 N-CA-C 112.62 0.6 . . . . 0.0 112.62 -166.049 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.31 176.5 15.77 Favored Glycine 0 N--CA 1.445 -0.758 0 CA-C-N 115.061 -0.972 . . . . 0.0 110.932 -177.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 15.7 p -108.0 134.01 51.5 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 170.619 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -139.45 161.12 38.24 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-O 121.204 0.526 . . . . 0.0 111.785 -172.273 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . 0.697 ' HA ' ' O ' ' A' ' 342' ' ' ALA . 7.7 p -141.22 124.12 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.936 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.51 173.818 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . 0.58 ' CE2' ' HB2' ' A' ' 424' ' ' LYS . 1.9 m-85 -102.18 143.76 31.58 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.605 -178.133 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 47.0 m-80 -127.78 132.6 49.49 Favored 'General case' 0 C--N 1.311 -1.073 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 176.132 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -165.12 -159.33 11.28 Favored Glycine 0 N--CA 1.442 -0.91 0 C-N-CA 120.218 -0.992 . . . . 0.0 112.167 -178.522 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -120.78 156.13 32.53 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 120.969 0.414 . . . . 0.0 110.298 -177.473 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 323' ' ' VAL . . . . . 0.771 HG23 HG12 ' A' ' 355' ' ' ILE . 41.0 t -119.45 118.32 56.94 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.621 -179.24 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 324' ' ' LEU . . . . . . . . . . . . . 96.4 mt -104.3 102.4 12.1 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.317 0.58 . . . . 0.0 110.149 -179.349 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 325' ' ' HIS . . . . . 0.479 ' HB3' ' OH ' ' A' ' 405' ' ' TYR . 6.3 p80 -108.1 132.06 53.97 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.523 176.524 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 326' ' ' PHE . . . . . 0.679 ' HD2' ' HB3' ' A' ' 417' ' ' PHE . 10.3 m-85 . . . . . 0 C--N 1.322 -0.592 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.695 -169.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 337' ' ' ARG . . . . . 0.594 ' HA ' ' O ' ' A' ' 323' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.451 -0.391 0 CA-C-O 121.416 0.627 . . . . 0.0 111.503 . . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -103.69 -177.97 25.86 Favored Glycine 0 N--CA 1.442 -0.904 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.949 174.355 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 339' ' ' ARG . . . . . 0.45 ' O ' ' HA ' ' A' ' 355' ' ' ILE . 75.4 mtp180 -114.18 127.49 55.92 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 120.952 0.406 . . . . 0.0 109.911 -177.575 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 340' ' ' PHE . . . . . 0.572 ' HB2' HG22 ' A' ' 323' ' ' VAL . 29.6 t80 -126.85 139.91 52.74 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.257 -169.412 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 341' ' ' ALA . . . . . 0.514 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -139.04 155.75 47.71 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 114.587 -1.188 . . . . 0.0 108.844 172.662 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . 0.842 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -143.12 117.82 9.85 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.14 0.495 . . . . 0.0 111.405 -177.368 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 343' ' ' LYS . . . . . 0.642 ' HB3' ' HB3' ' A' ' 352' ' ' ASP . 3.6 tppp? -96.07 98.95 10.76 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 114.851 -1.068 . . . . 0.0 108.943 -179.699 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 344' ' ' VAL . . . . . 0.652 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.6 OUTLIER -123.33 128.33 74.75 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 N-CA-C 113.099 0.777 . . . . 0.0 113.099 -169.56 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 345' ' ' ASP . . . . . 0.409 ' HB2' ' HB3' ' A' ' 348' ' ' SER . 1.8 m-20 -100.41 107.64 19.44 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 174.159 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 346' ' ' PHE . . . . . 0.487 ' HB2' ' HA ' ' A' ' 314' ' ' ALA . 38.0 m-85 -64.79 -36.58 84.77 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.807 0.337 . . . . 0.0 111.204 -176.391 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -68.62 -14.8 67.78 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.406 -178.544 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 348' ' ' SER . . . . . 0.409 ' HB3' ' HB2' ' A' ' 345' ' ' ASP . 44.2 t -109.13 -9.6 15.03 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.292 0.568 . . . . 0.0 110.135 179.219 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 349' ' ' LYS . . . . . 0.437 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 31.8 mtmm 52.44 55.36 9.22 Favored 'General case' 0 N--CA 1.462 0.137 0 CA-C-N 114.966 -1.016 . . . . 0.0 111.326 -176.07 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 8.6 t -146.72 145.69 30.07 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.508 179.518 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 351' ' ' VAL . . . . . 0.652 ' HB ' ' HB ' ' A' ' 344' ' ' VAL . 0.6 OUTLIER -136.46 146.65 28.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.956 0.408 . . . . 0.0 110.432 -177.042 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 352' ' ' ASP . . . . . 0.842 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 36.8 t70 -108.6 117.47 34.26 Favored 'General case' 0 C--O 1.211 -0.929 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 172.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -116.04 114.28 3.06 Favored Glycine 0 C--N 1.302 -1.334 0 C-N-CA 120.242 -0.98 . . . . 0.0 112.031 -176.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 354' ' ' ILE . . . . . 0.532 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -113.65 129.08 70.12 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 CA-C-O 120.977 0.418 . . . . 0.0 110.475 -175.495 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 355' ' ' ILE . . . . . 0.771 HG12 HG23 ' A' ' 323' ' ' VAL . 5.1 mp . . . . . 0 C--N 1.325 -0.497 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.95 177.715 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 21.6 mp0 . . . . . 0 N--CA 1.444 -0.731 0 CA-C-O 121.363 0.602 . . . . 0.0 109.934 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 25.4 pttm -114.96 146.99 40.62 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.665 178.54 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 368' ' ' PHE . . . . . 0.407 ' HB3' ' CE3' ' A' ' 381' ' ' TRP . 44.6 p90 -124.68 157.96 34.32 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 178.048 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 8.0 ttpt -126.05 134.96 51.26 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 173.538 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -136.14 144.87 45.28 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.095 -173.583 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -96.92 134.92 39.64 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 175.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 372' ' ' ILE . . . . . 0.437 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 66.8 mt -79.75 105.71 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.619 0 CA-C-O 121.884 0.85 . . . . 0.0 110.739 -177.804 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 373' ' ' ASP . . . . . 0.417 ' HB3' ' HD3' ' A' ' 378' ' ' LYS . 32.1 t70 -108.27 80.69 1.39 Allowed 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 114.492 -1.231 . . . . 0.0 109.19 -178.217 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 62.97 118.83 0.01 OUTLIER Glycine 0 CA--C 1.523 0.541 0 CA-C-N 114.54 -1.209 . . . . 0.0 113.488 -176.705 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 375' ' ' ASN . . . . . 0.695 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 3.1 p-10 28.92 46.67 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 124.363 1.065 . . . . 0.0 113.631 178.211 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 158.71 178.89 33.15 Favored Glycine 0 N--CA 1.442 -0.914 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 179.551 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 377' ' ' PHE . . . . . 0.61 ' CZ ' HG22 ' A' ' 401' ' ' VAL . 4.0 p90 -140.62 150.99 44.27 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 117.797 0.798 . . . . 0.0 112.127 -176.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 378' ' ' LYS . . . . . 0.417 ' HD3' ' HB3' ' A' ' 373' ' ' ASP . 0.0 OUTLIER -125.96 134.77 51.42 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 176.562 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -161.19 -158.6 9.46 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.178 -1.011 . . . . 0.0 112.853 -177.016 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 15.2 t -150.13 166.45 29.76 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.706 0.289 . . . . 0.0 110.383 -177.288 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 381' ' ' TRP . . . . . 0.786 ' HD1' ' HA3' ' A' ' 387' ' ' GLY . 49.5 m95 . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.856 -178.502 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . 0.786 ' HA3' ' HD1' ' A' ' 381' ' ' TRP . . . . . . . . 0 N--CA 1.446 -0.656 0 N-CA-C 112.087 -0.405 . . . . 0.0 112.087 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -82.49 138.86 34.22 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 110.304 -0.258 . . . . 0.0 110.304 178.664 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 44.5 t -132.17 128.56 59.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.493 0.187 . . . . 0.0 110.694 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 18.2 m -133.94 151.34 51.45 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.726 -0.215 . . . . 0.0 110.673 179.245 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 391' ' ' GLY . . . . . 0.513 ' HA2' ' HA3' ' A' ' 403' ' ' GLY . . . -158.59 151.52 22.56 Favored Glycine 0 N--CA 1.454 -0.141 0 C-N-CA 121.227 -0.511 . . . . 0.0 111.859 175.795 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 5.7 mpt_? -120.3 146.87 45.69 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.873 0.368 . . . . 0.0 110.862 -176.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -91.07 158.39 16.69 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.95 -179.814 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 394' ' ' TYR . . . . . 0.671 ' O ' ' HB1' ' A' ' 308' ' ' ALA . 2.9 m-85 -102.18 -177.19 3.33 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.188 -0.915 . . . . 0.0 110.058 177.262 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 395' ' ' GLY . . . . . 0.421 ' O ' ' N ' ' A' ' 397' ' ' ALA . . . -37.98 159.33 0.01 OUTLIER Glycine 0 CA--C 1.525 0.705 0 O-C-N 124.224 0.953 . . . . 0.0 115.169 -175.539 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_exo -18.1 -42.65 0.01 OUTLIER 'Trans proline' 0 C--N 1.352 0.723 1 C-N-CA 127.729 5.62 . . . . 0.0 118.213 -168.136 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 397' ' ' ALA . . . . . 0.421 ' N ' ' O ' ' A' ' 395' ' ' GLY . . . -78.51 -19.44 52.97 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 118.402 0.546 . . . . 0.0 112.457 -173.106 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 62.41 12.1 37.57 Favored Glycine 0 C--O 1.216 -0.977 0 CA-C-O 119.355 -0.691 . . . . 0.0 114.221 176.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 399' ' ' GLU . . . . . 0.726 ' HG3' ' HD3' ' A' ' 424' ' ' LYS . 1.1 mp0 -63.54 -10.57 18.7 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 118.189 0.994 . . . . 0.0 111.314 -178.161 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -122.55 128.32 50.6 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 121.041 0.448 . . . . 0.0 110.003 176.107 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 401' ' ' VAL . . . . . 0.61 HG22 ' CZ ' ' A' ' 377' ' ' PHE . 12.2 p -131.89 138.01 53.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.758 175.866 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -141.67 132.01 25.09 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.083 -178.647 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 403' ' ' GLY . . . . . 0.513 ' HA3' ' HA2' ' A' ' 391' ' ' GLY . . . -151.29 -173.76 21.49 Favored Glycine 0 N--CA 1.439 -1.136 0 C-N-CA 120.089 -1.053 . . . . 0.0 112.426 -178.055 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 404' ' ' LYS . . . . . 0.826 ' HG2' HG12 ' A' ' 419' ' ' VAL . 30.3 mtpt -145.73 155.66 43.11 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -179.684 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 405' ' ' TYR . . . . . 0.479 ' OH ' ' HB3' ' A' ' 325' ' ' HIS . 50.7 p90 . . . . . 0 C--N 1.314 -0.974 0 CA-C-O 121.011 0.434 . . . . 0.0 110.525 -179.232 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 417' ' ' PHE . . . . . 0.679 ' HB3' ' HD2' ' A' ' 326' ' ' PHE . 66.1 m-85 . . . . . 0 N--CA 1.456 -0.128 0 N-CA-C 110.472 -0.196 . . . . 0.0 110.472 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 418' ' ' GLY . . . . . 0.424 ' HA2' ' HA ' ' A' ' 325' ' ' HIS . . . 82.31 77.1 1.07 Allowed Glycine 0 C--O 1.224 -0.489 0 C-N-CA 120.746 -0.74 . . . . 0.0 113.125 176.214 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 419' ' ' VAL . . . . . 0.826 HG12 ' HG2' ' A' ' 404' ' ' LYS . 23.8 m -109.71 157.61 10.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 120.903 0.382 . . . . 0.0 110.822 -179.715 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 40.8 p90 -146.4 154.8 42.04 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.952 0.406 . . . . 0.0 110.535 177.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -148.83 136.54 20.54 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.48 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -133.18 140.62 11.98 Favored Glycine 0 N--CA 1.445 -0.711 0 C-N-CA 120.196 -1.002 . . . . 0.0 112.582 -177.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 25.1 mmmt -101.9 123.83 46.49 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 176.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 424' ' ' LYS . . . . . 0.726 ' HD3' ' HG3' ' A' ' 399' ' ' GLU . 72.1 tttt -70.16 117.25 11.48 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 116.55 -0.296 . . . . 0.0 110.572 -179.591 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 . . . . . 0 C--N 1.323 -0.572 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 -179.502 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo . . . . . 0 N--CA 1.462 -0.337 0 N-CA-C 111.315 -0.302 . . . . 0.0 111.315 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 308' ' ' ALA . . . . . 0.728 ' HB1' ' O ' ' A' ' 394' ' ' TYR . . . -54.18 159.54 1.86 Allowed 'General case' 0 N--CA 1.467 0.385 0 CA-C-O 121.48 0.657 . . . . 0.0 112.282 175.804 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 309' ' ' LYS . . . . . 0.635 ' O ' ' HG ' ' A' ' 313' ' ' LEU . 35.0 mtmt -123.55 98.91 6.05 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.357 176.746 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 310' ' ' GLY . . . . . 0.616 ' HA2' HD11 ' A' ' 313' ' ' LEU . . . -60.04 -37.75 93.23 Favored Glycine 0 C--O 1.227 -0.304 0 CA-C-N 116.093 -0.503 . . . . 0.0 114.128 -170.314 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -72.61 -20.03 61.36 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.86 0.33 . . . . 0.0 110.856 179.115 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 26.0 ttt -91.46 -21.61 20.84 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.143 0.497 . . . . 0.0 109.95 177.302 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 313' ' ' LEU . . . . . 0.635 ' HG ' ' O ' ' A' ' 309' ' ' LYS . 96.1 mt -66.19 138.95 58.05 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.332 178.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -156.32 139.2 15.28 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.303 -174.326 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 121.01 167.88 13.39 Favored Glycine 0 N--CA 1.443 -0.845 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.929 177.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 28.5 p -100.05 134.22 43.28 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 174.715 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 317' ' ' ALA . . . . . 0.536 ' HB2' ' HD3' ' A' ' 424' ' ' LYS . . . -138.6 152.57 48.25 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 121.053 0.454 . . . . 0.0 111.731 -174.833 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 7.3 p -121.59 113.24 38.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.441 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.263 177.5 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . 0.675 ' HH ' ' HZ ' ' A' ' 346' ' ' PHE . 21.4 m-85 -103.16 132.52 49.36 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.925 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 44.6 m-80 -124.81 139.56 53.73 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.077 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . 0.592 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -169.25 -145.93 4.83 Favored Glycine 0 N--CA 1.441 -1.014 0 C-N-CA 120.577 -0.82 . . . . 0.0 112.397 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -135.04 161.92 33.93 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 120.978 0.418 . . . . 0.0 110.947 -173.66 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 323' ' ' VAL . . . . . 0.611 HG23 ' HB2' ' A' ' 340' ' ' PHE . 68.9 t -121.12 117.89 54.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.163 178.331 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 324' ' ' LEU . . . . . . . . . . . . . 2.0 tt -98.53 103.27 15.2 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 176.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 325' ' ' HIS . . . . . 0.432 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 18.3 t-160 -88.58 113.32 24.03 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 -179.307 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 326' ' ' PHE . . . . . 0.685 ' HE2' HG12 ' A' ' 419' ' ' VAL . 88.4 m-85 . . . . . 0 C--N 1.321 -0.641 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.008 -177.85 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 337' ' ' ARG . . . . . . . . . . . . . 39.1 ttt180 . . . . . 0 N--CA 1.449 -0.524 0 CA-C-O 121.036 0.446 . . . . 0.0 110.346 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -103.26 -177.0 26.41 Favored Glycine 0 N--CA 1.446 -0.695 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 179.037 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 339' ' ' ARG . . . . . . . . . . . . . 66.7 mtp180 -110.28 164.5 12.6 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 178.379 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 340' ' ' PHE . . . . . 0.611 ' HB2' HG23 ' A' ' 323' ' ' VAL . 41.1 t80 -152.43 142.73 22.49 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 121.255 0.55 . . . . 0.0 111.096 -178.275 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 341' ' ' ALA . . . . . . . . . . . . . . . -138.59 156.25 47.63 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.206 -0.906 . . . . 0.0 109.025 174.063 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . 0.88 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -145.94 118.94 8.76 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-O 121.304 0.573 . . . . 0.0 110.173 -179.729 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 343' ' ' LYS . . . . . 0.454 ' HE2' ' HB3' ' A' ' 343' ' ' LYS . 4.8 tmmm? -102.96 103.14 13.23 Favored 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 -179.625 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 344' ' ' VAL . . . . . 0.441 ' HA ' ' HA ' ' A' ' 351' ' ' VAL . 0.2 OUTLIER -117.14 132.77 65.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-O 121.485 0.66 . . . . 0.0 112.639 -169.224 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -102.48 100.08 10.17 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 114.515 -1.22 . . . . 0.0 108.7 172.541 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 346' ' ' PHE . . . . . 0.675 ' HZ ' ' HH ' ' A' ' 319' ' ' TYR . 74.5 m-85 -67.88 -23.19 65.1 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.527 0.204 . . . . 0.0 111.184 -177.875 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -63.9 -25.27 69.11 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.016 178.315 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 37.9 m -112.58 -4.43 14.15 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.912 0.387 . . . . 0.0 110.567 177.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 349' ' ' LYS . . . . . 0.641 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 31.4 mtmm 55.69 59.3 3.91 Favored 'General case' 0 C--O 1.226 -0.179 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.892 -178.02 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 52.9 p -148.84 141.28 24.24 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.282 -179.326 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 351' ' ' VAL . . . . . 0.441 ' HA ' ' HA ' ' A' ' 344' ' ' VAL . 1.0 OUTLIER -127.57 151.84 34.9 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 CA-C-O 121.126 0.489 . . . . 0.0 110.986 -176.21 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 352' ' ' ASP . . . . . 0.88 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 19.5 t70 -108.59 119.07 38.44 Favored 'General case' 0 C--O 1.211 -0.954 0 CA-C-N 115.184 -0.917 . . . . 0.0 109.338 171.92 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -115.33 130.22 9.02 Favored Glycine 0 N--CA 1.441 -1.02 0 C-N-CA 120.473 -0.87 . . . . 0.0 111.658 -178.72 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 354' ' ' ILE . . . . . 0.457 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -131.52 129.62 62.0 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 CA-C-O 120.973 0.416 . . . . 0.0 110.196 -176.973 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 355' ' ' ILE . . . . . 0.579 HG13 HG21 ' A' ' 323' ' ' VAL . 2.3 mp . . . . . 0 C--N 1.318 -0.763 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.416 178.295 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 90.6 mt-30 . . . . . 0 N--CA 1.452 -0.363 0 CA-C-O 121.305 0.574 . . . . 0.0 111.372 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -123.85 144.63 49.62 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.565 179.48 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 368' ' ' PHE . . . . . 0.48 ' HB3' ' CE3' ' A' ' 381' ' ' TRP . 33.2 p90 -140.17 150.74 44.58 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.963 0.411 . . . . 0.0 109.996 175.364 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 369' ' ' LYS . . . . . 0.728 ' HD3' ' HA ' ' A' ' 352' ' ' ASP . 0.0 OUTLIER -123.61 135.19 53.81 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 175.962 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 370' ' ' ALA . . . . . 0.44 ' HB3' HG21 ' A' ' 351' ' ' VAL . . . -132.11 152.23 51.35 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.478 -0.783 . . . . 0.0 111.213 -172.287 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -109.06 134.82 51.17 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.656 176.369 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 372' ' ' ILE . . . . . 0.641 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 95.5 mt -82.75 108.91 16.04 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-O 121.171 0.51 . . . . 0.0 110.939 -178.042 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -126.4 84.23 2.25 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-O 121.612 0.72 . . . . 0.0 110.288 178.361 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 79.07 121.22 0.3 Allowed Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.145 -0.934 . . . . 0.0 112.267 -177.188 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 375' ' ' ASN . . . . . 0.515 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 17.7 p30 1.8 60.38 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 125.6 1.56 . . . . 0.0 114.986 -171.92 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 157.55 -174.28 34.98 Favored Glycine 0 N--CA 1.438 -1.172 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 179.068 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 377' ' ' PHE . . . . . 0.508 ' CZ ' HG22 ' A' ' 401' ' ' VAL . 1.6 p90 -142.34 148.71 38.39 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.327 0.584 . . . . 0.0 111.625 -179.345 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 378' ' ' LYS . . . . . . . . . . . . . 2.7 tmtm? -123.64 112.63 17.64 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 176.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -135.59 -165.6 10.74 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.428 -0.891 . . . . 0.0 112.627 -175.677 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 15.0 t -144.93 159.67 42.55 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.86 0.362 . . . . 0.0 110.449 -177.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 381' ' ' TRP . . . . . 0.48 ' CE3' ' HB3' ' A' ' 368' ' ' PHE . 48.3 m95 . . . . . 0 C--N 1.326 -0.436 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.512 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.675 0 N-CA-C 112.448 -0.261 . . . . 0.0 112.448 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -94.19 167.54 11.49 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.517 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 22.2 t -128.35 121.18 54.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 175.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 390' ' ' SER . . . . . 0.405 ' O ' ' HA3' ' A' ' 403' ' ' GLY . 39.5 m -117.98 155.61 29.97 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.521 -0.309 . . . . 0.0 110.698 -177.375 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -165.64 144.67 9.42 Favored Glycine 0 N--CA 1.451 -0.349 0 N-CA-C 111.541 -0.623 . . . . 0.0 111.541 177.291 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 13.7 ptp180 -116.09 152.31 33.87 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.044 0.45 . . . . 0.0 110.895 -177.142 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 10.7 m-85 -98.1 157.59 16.05 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.889 0.852 . . . . 0.0 111.81 -175.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 394' ' ' TYR . . . . . 0.728 ' O ' ' HB1' ' A' ' 308' ' ' ALA . 6.2 m-85 -102.94 -171.95 2.03 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 114.119 -1.4 . . . . 0.0 111.247 -175.075 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 395' ' ' GLY . . . . . 0.435 ' O ' ' N ' ' A' ' 397' ' ' ALA . . . -33.15 157.59 0.01 OUTLIER Glycine 0 C--N 1.34 0.792 0 O-C-N 124.576 1.173 . . . . 0.0 114.215 -178.316 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -46.37 -17.98 0.41 Allowed 'Trans proline' 0 N--CA 1.482 0.818 1 C-N-CA 125.674 4.249 . . . . 0.0 116.831 -149.843 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 397' ' ' ALA . . . . . 0.466 ' HB2' ' HG3' ' A' ' 399' ' ' GLU . . . -90.89 -17.9 25.69 Favored 'General case' 0 C--N 1.316 -0.872 0 C-N-CA 120.728 -0.389 . . . . 0.0 111.83 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 72.74 16.35 77.95 Favored Glycine 0 C--N 1.336 0.56 0 C-N-CA 121.178 -0.534 . . . . 0.0 112.544 173.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 399' ' ' GLU . . . . . 0.482 ' HG2' ' CE ' ' A' ' 424' ' ' LYS . 28.5 mt-10 -67.7 -10.78 55.41 Favored 'General case' 0 C--N 1.332 -0.18 0 C-N-CA 122.902 0.481 . . . . 0.0 111.115 -174.766 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -123.31 136.02 54.48 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 173.1 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 401' ' ' VAL . . . . . 0.508 HG22 ' CZ ' ' A' ' 377' ' ' PHE . 14.0 p -140.15 143.1 30.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.137 177.413 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -143.19 138.81 29.98 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.181 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 403' ' ' GLY . . . . . 0.405 ' HA3' ' O ' ' A' ' 390' ' ' SER . . . -157.25 -176.2 29.04 Favored Glycine 0 N--CA 1.441 -0.985 0 C-N-CA 120.379 -0.915 . . . . 0.0 112.185 -178.897 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 404' ' ' LYS . . . . . 0.826 ' HG2' HG11 ' A' ' 419' ' ' VAL . 52.2 mttt -145.34 158.85 43.75 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 -178.516 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 36.2 p90 . . . . . 0 C--N 1.322 -0.61 0 CA-C-O 121.043 0.449 . . . . 0.0 111.34 179.658 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 417' ' ' PHE . . . . . 0.641 ' HA ' ' HD2' ' A' ' 326' ' ' PHE . 28.3 m-85 . . . . . 0 N--CA 1.447 -0.593 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 418' ' ' GLY . . . . . 0.556 ' H ' ' HD2' ' A' ' 326' ' ' PHE . . . 78.51 76.82 0.9 Allowed Glycine 0 N--CA 1.441 -1.018 0 C-N-CA 120.068 -1.063 . . . . 0.0 111.211 -174.468 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 419' ' ' VAL . . . . . 0.826 HG11 ' HG2' ' A' ' 404' ' ' LYS . 32.3 m -105.47 153.12 7.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-O 120.705 0.288 . . . . 0.0 110.388 -177.791 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 51.9 p90 -135.69 155.01 51.08 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.893 179.104 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 421' ' ' ALA . . . . . 0.592 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -143.72 136.1 26.96 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.089 179.384 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -129.98 133.6 7.5 Favored Glycine 0 N--CA 1.44 -1.044 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.038 -179.048 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 63.0 mttm -111.81 125.72 54.31 Favored 'General case' 0 C--N 1.313 -0.979 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 177.211 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 424' ' ' LYS . . . . . 0.582 ' HB2' ' CE2' ' A' ' 319' ' ' TYR . 27.2 ttpp -70.23 122.3 19.24 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 120.893 0.378 . . . . 0.0 110.101 178.551 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 . . . . . 0 C--N 1.313 -0.989 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 176.685 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo . . . . . 0 N--CA 1.457 -0.618 0 N-CA-C 112.848 0.288 . . . . 0.0 112.848 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 308' ' ' ALA . . . . . 0.741 ' HB3' ' O ' ' A' ' 394' ' ' TYR . . . -58.13 157.23 8.43 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.844 170.621 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 309' ' ' LYS . . . . . 0.57 ' N ' HD21 ' A' ' 313' ' ' LEU . 63.1 mttp -128.43 98.42 5.04 Favored 'General case' 0 C--O 1.222 -0.364 0 C-N-CA 121.022 -0.271 . . . . 0.0 110.425 -176.328 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -48.23 -43.23 25.77 Favored Glycine 0 CA--C 1.519 0.304 0 N-CA-C 114.978 0.751 . . . . 0.0 114.978 -167.784 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -76.45 -9.46 58.67 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 112.846 0.684 . . . . 0.0 112.846 -177.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 312' ' ' MET . . . . . 0.707 ' HE1' ' HA ' ' A' ' 312' ' ' MET . 2.5 tpt -113.93 -37.39 4.51 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.72 0.771 . . . . 0.0 109.654 -177.396 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 313' ' ' LEU . . . . . 0.731 HD23 ' HB2' ' A' ' 308' ' ' ALA . 0.6 OUTLIER -81.39 129.99 34.86 Favored 'General case' 0 N--CA 1.44 -0.938 0 CA-C-N 114.677 -1.147 . . . . 0.0 109.143 178.161 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 314' ' ' ALA . . . . . 0.622 ' HA ' ' CB ' ' A' ' 346' ' ' PHE . . . -159.19 175.57 13.28 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.989 -170.726 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.4 160.77 11.27 Favored Glycine 0 N--CA 1.447 -0.597 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -177.621 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 18.7 p -96.87 125.12 41.08 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 173.258 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 317' ' ' ALA . . . . . 0.429 ' HB2' ' HE1' ' A' ' 319' ' ' TYR . . . -132.08 149.67 52.35 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 113.15 0.796 . . . . 0.0 113.15 -163.417 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 7.7 p -118.95 113.64 42.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 CA-C-N 115.039 -0.982 . . . . 0.0 110.338 176.067 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . 0.499 ' HH ' ' HZ ' ' A' ' 346' ' ' PHE . 27.1 m-85 -108.04 140.68 40.84 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.583 177.454 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -142.75 143.78 32.37 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.65 174.671 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -166.32 -150.26 6.27 Favored Glycine 0 N--CA 1.443 -0.863 0 C-N-CA 120.931 -0.652 . . . . 0.0 111.874 -178.153 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -129.49 147.81 51.33 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.124 0.488 . . . . 0.0 111.038 -176.541 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 323' ' ' VAL . . . . . 0.586 ' O ' ' HA ' ' A' ' 337' ' ' ARG . 54.6 t -106.14 142.31 19.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.331 -178.876 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 324' ' ' LEU . . . . . . . . . . . . . 17.2 tp -124.87 103.95 8.34 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 110.21 -0.293 . . . . 0.0 110.21 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 325' ' ' HIS . . . . . 0.578 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 3.2 p-80 -103.21 117.19 33.97 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.501 0.667 . . . . 0.0 111.429 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 326' ' ' PHE . . . . . 0.592 ' HD1' ' H ' ' A' ' 418' ' ' GLY . 22.9 m-85 . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 114.705 -1.134 . . . . 0.0 110.351 -173.119 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 337' ' ' ARG . . . . . 0.586 ' HA ' ' O ' ' A' ' 323' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.45 -0.427 0 CA-C-O 121.187 0.517 . . . . 0.0 110.82 . . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -136.12 178.55 18.67 Favored Glycine 0 N--CA 1.443 -0.889 0 CA-C-N 115.392 -0.822 . . . . 0.0 111.178 176.113 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 339' ' ' ARG . . . . . 0.572 ' O ' ' HA ' ' A' ' 355' ' ' ILE . 57.8 mtp180 -104.02 132.89 49.82 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 -179.093 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 340' ' ' PHE . . . . . 0.557 ' HB2' HG23 ' A' ' 323' ' ' VAL . 36.8 t80 -133.9 132.2 40.01 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 121.057 0.456 . . . . 0.0 111.108 -175.848 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 341' ' ' ALA . . . . . . . . . . . . . . . -134.72 168.39 19.11 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 172.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -155.22 139.65 16.79 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.095 0.474 . . . . 0.0 111.023 -176.48 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 343' ' ' LYS . . . . . 0.513 ' HB3' ' HB2' ' A' ' 352' ' ' ASP . 24.9 tptp -115.97 97.32 6.02 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 179.222 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 344' ' ' VAL . . . . . 0.642 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.9 OUTLIER -121.05 135.61 60.68 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 CA-C-O 121.526 0.679 . . . . 0.0 111.627 -170.234 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -117.04 101.13 8.23 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-N 114.884 -1.053 . . . . 0.0 108.284 -178.653 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 346' ' ' PHE . . . . . 0.674 ' O ' ' HE3' ' A' ' 349' ' ' LYS . 67.4 m-85 -69.75 -25.96 64.07 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 -173.476 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -64.01 -22.15 66.46 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.533 -0.841 . . . . 0.0 111.917 176.579 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 48.2 t -108.84 -4.24 17.02 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.033 0.444 . . . . 0.0 110.499 178.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 349' ' ' LYS . . . . . 0.674 ' HE3' ' O ' ' A' ' 346' ' ' PHE . 8.2 mmpt? 49.7 50.98 17.36 Favored 'General case' 0 C--O 1.226 -0.176 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.581 -172.187 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 8.3 m -134.08 146.31 50.18 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.104 -178.178 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 351' ' ' VAL . . . . . 0.642 ' HB ' ' HB ' ' A' ' 344' ' ' VAL . 0.1 OUTLIER -149.36 133.92 9.51 Favored 'Isoleucine or valine' 0 C--O 1.236 0.365 0 CA-C-O 121.531 0.681 . . . . 0.0 112.552 -175.617 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 352' ' ' ASP . . . . . 0.625 ' HA ' ' HD3' ' A' ' 369' ' ' LYS . 1.5 m-20 -95.24 155.48 16.72 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 114.676 -1.147 . . . . 0.0 108.961 173.21 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 353' ' ' GLY . . . . . 0.501 ' C ' ' HB3' ' A' ' 367' ' ' LYS . . . -142.38 152.17 23.53 Favored Glycine 0 N--CA 1.44 -1.091 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 172.508 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 354' ' ' ILE . . . . . 0.469 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -146.78 130.12 9.1 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 116.964 0.382 . . . . 0.0 110.087 -179.643 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 355' ' ' ILE . . . . . 0.856 HD13 ' HE2' ' A' ' 367' ' ' LYS . 82.5 mt . . . . . 0 N--CA 1.449 -0.51 0 CA-C-O 121.064 0.459 . . . . 0.0 111.919 178.32 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 82.5 mt-30 . . . . . 0 N--CA 1.454 -0.255 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 367' ' ' LYS . . . . . 0.95 ' HA ' ' HZ3' ' A' ' 381' ' ' TRP . 19.3 tttm -131.03 172.91 11.54 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.096 0.474 . . . . 0.0 110.899 176.165 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 368' ' ' PHE . . . . . 0.833 ' H ' ' HG2' ' A' ' 367' ' ' LYS . 0.1 OUTLIER -73.89 163.16 28.28 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.113 -0.949 . . . . 0.0 111.814 -172.306 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 369' ' ' LYS . . . . . 0.625 ' HD3' ' HA ' ' A' ' 352' ' ' ASP . 0.0 OUTLIER -113.86 134.23 54.93 Favored 'General case' 0 C--N 1.314 -0.957 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 169.171 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 370' ' ' ALA . . . . . 0.661 ' HB1' ' CE2' ' A' ' 368' ' ' PHE . . . -130.2 162.85 27.98 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 113.095 0.776 . . . . 0.0 113.095 -172.579 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -116.73 135.93 53.37 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 114.657 -1.156 . . . . 0.0 108.924 171.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 372' ' ' ILE . . . . . 0.512 HG13 HG12 ' A' ' 351' ' ' VAL . 83.0 mt -82.69 115.04 24.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.142 0.496 . . . . 0.0 111.06 -177.004 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -104.92 83.38 1.99 Allowed 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.333 177.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 79.67 -118.8 4.82 Favored Glycine 0 N--CA 1.446 -0.678 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.559 -179.664 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 375' ' ' ASN . . . . . 0.466 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 3.2 p-10 -98.81 50.21 0.97 Allowed 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.65 0.738 . . . . 0.0 111.425 -176.147 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 165.08 175.05 35.42 Favored Glycine 0 N--CA 1.445 -0.716 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 -179.155 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 377' ' ' PHE . . . . . 0.539 ' CZ ' HG23 ' A' ' 401' ' ' VAL . 3.7 p90 -140.99 153.16 45.44 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.551 0.691 . . . . 0.0 111.703 177.918 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 378' ' ' LYS . . . . . 0.404 ' HB3' ' HE2' ' A' ' 378' ' ' LYS . 15.6 ptpt -131.99 138.38 48.24 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 114.498 -1.228 . . . . 0.0 108.484 175.677 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -151.55 -161.76 10.31 Favored Glycine 0 N--CA 1.443 -0.85 0 C-N-CA 120.068 -1.063 . . . . 0.0 112.61 -176.374 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 380' ' ' THR . . . . . 0.414 ' C ' ' HB2' ' A' ' 368' ' ' PHE . 6.5 t -144.57 140.62 28.89 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.811 0.339 . . . . 0.0 110.942 -175.254 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 381' ' ' TRP . . . . . 0.95 ' HZ3' ' HA ' ' A' ' 367' ' ' LYS . 50.4 m95 . . . . . 0 N--CA 1.465 0.323 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.98 178.439 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.638 0 N-CA-C 112.341 -0.303 . . . . 0.0 112.341 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -93.74 154.13 17.95 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 178.617 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 389' ' ' VAL . . . . . 0.529 ' HB ' ' CD2' ' A' ' 368' ' ' PHE . 20.0 t -131.39 139.57 50.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.057 -179.095 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 10.8 m -141.6 141.03 33.46 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.659 0.266 . . . . 0.0 110.791 178.308 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -141.05 152.64 23.34 Favored Glycine 0 C--O 1.236 0.221 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.981 179.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 9.7 ptm180 -115.61 144.73 43.48 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 -175.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 393' ' ' PHE . . . . . 0.518 ' CZ ' ' HE1' ' A' ' 346' ' ' PHE . 1.2 m-85 -94.55 154.84 17.19 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.429 0.633 . . . . 0.0 111.979 -175.104 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 394' ' ' TYR . . . . . 0.741 ' O ' ' HB3' ' A' ' 308' ' ' ALA . 3.5 m-85 -102.73 -176.78 3.19 Favored 'General case' 0 C--O 1.216 -0.686 0 CA-C-N 114.775 -1.102 . . . . 0.0 110.816 -178.823 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 395' ' ' GLY . . . . . . . . . . . . . . . -37.77 161.35 0.01 OUTLIER Glycine 0 C--N 1.335 0.505 0 O-C-N 124.333 1.021 . . . . 0.0 115.099 -175.816 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_exo -11.13 -57.03 0.0 OUTLIER 'Trans proline' 0 C--N 1.347 0.467 1 C-N-CA 127.386 5.391 . . . . 0.0 117.517 -162.393 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 397' ' ' ALA . . . . . 0.682 ' HB3' ' HG3' ' A' ' 399' ' ' GLU . . . -84.96 -11.12 56.22 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 112.678 0.621 . . . . 0.0 112.678 -167.391 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 67.2 22.18 72.48 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.226 -179.142 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 399' ' ' GLU . . . . . 0.682 ' HG3' ' HB3' ' A' ' 397' ' ' ALA . 50.5 mt-10 -63.63 -14.4 51.38 Favored 'General case' 0 CA--C 1.521 -0.154 0 CA-C-O 121.12 0.486 . . . . 0.0 111.148 -177.222 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -121.77 133.48 54.92 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 170.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 401' ' ' VAL . . . . . 0.539 HG23 ' CZ ' ' A' ' 377' ' ' PHE . 9.9 p -140.99 135.0 32.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.85 176.147 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -131.25 139.59 49.67 Favored 'General case' 0 C--N 1.315 -0.935 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.771 178.293 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -162.89 156.04 27.61 Favored Glycine 0 N--CA 1.437 -1.272 0 C-N-CA 120.304 -0.95 . . . . 0.0 111.105 -174.149 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 404' ' ' LYS . . . . . 0.979 ' HG2' HG22 ' A' ' 419' ' ' VAL . 17.5 mtmt -123.9 162.73 22.74 Favored 'General case' 0 C--N 1.31 -1.144 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 -174.36 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 405' ' ' TYR . . . . . 0.533 ' CG ' ' HZ2' ' A' ' 381' ' ' TRP . 25.4 p90 . . . . . 0 C--N 1.315 -0.918 0 CA-C-O 121.225 0.536 . . . . 0.0 111.466 179.22 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 417' ' ' PHE . . . . . 0.489 ' HB3' ' HB2' ' A' ' 326' ' ' PHE . 87.9 m-85 . . . . . 0 N--CA 1.45 -0.456 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 418' ' ' GLY . . . . . 0.592 ' H ' ' HD1' ' A' ' 326' ' ' PHE . . . 83.33 76.83 1.13 Allowed Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.024 -1.084 . . . . 0.0 110.933 -169.721 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 419' ' ' VAL . . . . . 0.979 HG22 ' HG2' ' A' ' 404' ' ' LYS . 8.4 p -107.33 166.03 4.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-O 121.28 0.562 . . . . 0.0 110.605 -177.576 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 420' ' ' PHE . . . . . 0.482 ' H ' HG21 ' A' ' 419' ' ' VAL . 41.8 p90 -140.76 157.53 45.29 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.224 -0.898 . . . . 0.0 109.904 177.218 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -142.69 136.06 28.63 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 177.122 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -121.74 138.42 12.27 Favored Glycine 0 N--CA 1.446 -0.668 0 C-N-CA 120.562 -0.828 . . . . 0.0 112.177 -177.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -110.78 127.11 55.24 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 178.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 424' ' ' LYS . . . . . 0.493 ' HB3' ' HB3' ' A' ' 399' ' ' GLU . 23.2 tptm -66.85 115.28 6.45 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.835 0.35 . . . . 0.0 110.603 176.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 . . . . . 0 C--N 1.319 -0.744 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 175.427 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 307' ' ' PRO . . . . . 0.686 ' HA ' ' HA2' ' A' ' 395' ' ' GLY . 98.0 Cg_exo . . . . . 0 C--O 1.235 0.365 0 N-CA-C 111.645 -0.175 . . . . 0.0 111.645 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 308' ' ' ALA . . . . . 0.601 ' O ' ' HB3' ' A' ' 375' ' ' ASN . . . -31.44 106.6 0.04 OUTLIER 'General case' 0 CA--C 1.506 -0.727 0 O-C-N 124.923 1.39 . . . . 0.0 112.844 -165.591 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 309' ' ' LYS . . . . . 0.507 ' HE3' ' OE2' ' A' ' 311' ' ' GLU . 23.4 tptt -69.62 91.76 0.62 Allowed 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 115.222 -0.899 . . . . 0.0 109.97 -173.311 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 310' ' ' GLY . . . . . 0.628 ' HA2' HD13 ' A' ' 313' ' ' LEU . . . -60.6 -30.32 71.84 Favored Glycine 0 C--N 1.331 0.264 0 CA-C-N 115.578 -0.737 . . . . 0.0 114.086 -169.241 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . 0.507 ' OE2' ' HE3' ' A' ' 309' ' ' LYS . 4.8 pm0 -72.42 -17.06 61.83 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 120.74 0.305 . . . . 0.0 111.069 179.15 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 312' ' ' MET . . . . . 0.48 ' HE3' ' HG2' ' A' ' 309' ' ' LYS . 66.2 mtm -117.13 -0.18 12.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.797 0.332 . . . . 0.0 110.922 178.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 313' ' ' LEU . . . . . 0.628 HD13 ' HA2' ' A' ' 310' ' ' GLY . 83.8 mt -70.93 134.37 47.17 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 173.34 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -149.66 137.92 20.59 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.331 -173.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.77 171.95 14.49 Favored Glycine 0 N--CA 1.444 -0.799 0 N-CA-C 111.385 -0.686 . . . . 0.0 111.385 179.401 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 42.5 p -102.61 149.4 24.46 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 173.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -142.78 148.28 36.92 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 121.16 0.505 . . . . 0.0 112.32 -175.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . 0.512 ' O ' ' HA ' ' A' ' 424' ' ' LYS . 13.8 t -114.56 104.32 16.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.913 175.329 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . 0.449 ' OH ' ' HZ ' ' A' ' 346' ' ' PHE . 60.3 m-85 -97.88 127.33 43.76 Favored 'General case' 0 C--N 1.312 -1.05 0 C-N-CA 120.264 -0.574 . . . . 0.0 110.046 177.168 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 320' ' ' ASN . . . . . 0.411 ' ND2' ' HB2' ' A' ' 425' ' ' GLU . 7.6 p30 -138.31 145.16 40.87 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 178.799 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -172.14 -152.28 8.4 Favored Glycine 0 N--CA 1.44 -1.083 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.856 -177.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -114.49 143.74 44.46 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 120.897 0.38 . . . . 0.0 110.779 -174.413 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 323' ' ' VAL . . . . . 0.612 HG21 ' HB2' ' A' ' 340' ' ' PHE . 59.1 t -106.8 116.62 50.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.935 175.258 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 324' ' ' LEU . . . . . 0.52 HD12 ' HG2' ' A' ' 337' ' ' ARG . 24.9 tp -97.53 102.69 14.51 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-O 121.139 0.495 . . . . 0.0 109.889 -179.505 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 325' ' ' HIS . . . . . . . . . . . . . 1.3 p-80 -105.03 114.72 29.09 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.344 0.592 . . . . 0.0 109.73 176.691 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 326' ' ' PHE . . . . . 0.722 ' HD1' ' HB2' ' A' ' 417' ' ' PHE . 31.3 m-85 . . . . . 0 C--N 1.322 -0.626 0 CA-C-N 115.168 -0.924 . . . . 0.0 110.96 -170.167 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 337' ' ' ARG . . . . . 0.52 ' HG2' HD12 ' A' ' 324' ' ' LEU . 24.2 mtm180 . . . . . 0 N--CA 1.45 -0.438 0 CA-C-O 121.428 0.632 . . . . 0.0 110.664 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -95.21 -177.12 37.62 Favored Glycine 0 N--CA 1.439 -1.111 0 CA-C-N 115.222 -0.899 . . . . 0.0 111.613 176.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 339' ' ' ARG . . . . . . . . . . . . . 56.1 mtp180 -106.09 133.48 50.73 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 -176.133 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 340' ' ' PHE . . . . . 0.612 ' HB2' HG21 ' A' ' 323' ' ' VAL . 26.1 t80 -132.43 139.46 48.03 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-O 120.986 0.422 . . . . 0.0 111.342 -176.226 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 341' ' ' ALA . . . . . . . . . . . . . . . -142.86 165.85 26.24 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.223 -0.899 . . . . 0.0 109.374 174.509 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -157.18 134.09 10.19 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-O 120.875 0.369 . . . . 0.0 110.901 -174.296 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 4.5 tppp? -108.03 102.8 11.94 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.06 178.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 344' ' ' VAL . . . . . 0.647 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.3 OUTLIER -125.83 133.34 69.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 CA-C-O 121.703 0.763 . . . . 0.0 112.553 -172.08 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -102.31 121.9 43.19 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 114.586 -1.188 . . . . 0.0 108.176 172.082 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 346' ' ' PHE . . . . . 0.449 ' HZ ' ' OH ' ' A' ' 319' ' ' TYR . 33.1 m-85 -72.3 -37.92 68.84 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 120.979 -0.288 . . . . 0.0 110.931 -179.108 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -61.0 -30.51 73.65 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.111 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 47.8 t -97.88 -10.02 25.35 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 123.008 -0.113 . . . . 0.0 110.783 -179.666 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 349' ' ' LYS . . . . . 0.48 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 29.0 mtmt 47.35 55.69 7.9 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-O 121.62 0.724 . . . . 0.0 111.266 -176.22 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 29.1 m -147.52 138.94 23.81 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.632 179.483 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 351' ' ' VAL . . . . . 0.647 ' HB ' ' HB ' ' A' ' 344' ' ' VAL . 0.6 OUTLIER -130.1 148.46 33.17 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 CA-C-O 121.288 0.566 . . . . 0.0 111.379 -174.894 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 352' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -100.46 151.78 21.15 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 107.179 -1.415 . . . . 0.0 107.179 165.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 353' ' ' GLY . . . . . 0.633 ' HA3' ' CE1' ' A' ' 368' ' ' PHE . . . -142.52 138.17 8.26 Favored Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.483 -0.865 . . . . 0.0 111.541 175.217 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 354' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -121.68 129.74 75.23 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-O 121.185 0.516 . . . . 0.0 109.818 178.669 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 355' ' ' ILE . . . . . 0.752 HG13 ' CZ3' ' A' ' 381' ' ' TRP . 7.0 mm . . . . . 0 C--N 1.32 -0.711 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.591 -174.23 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 79.4 mt-30 . . . . . 0 N--CA 1.448 -0.537 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 8.7 ptpp? -147.22 168.94 20.42 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 368' ' ' PHE . . . . . 0.633 ' CE1' ' HA3' ' A' ' 353' ' ' GLY . 31.6 p90 -151.49 156.08 39.86 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 175.164 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 1.7 mptp? -118.94 130.77 55.89 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 175.838 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 370' ' ' ALA . . . . . 0.515 ' HA ' ' HA3' ' A' ' 379' ' ' GLY . . . -135.75 141.47 44.83 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.104 -175.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -102.51 136.04 43.05 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.724 176.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 372' ' ' ILE . . . . . 0.48 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 74.9 mt -81.18 114.26 21.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 121.545 0.688 . . . . 0.0 110.528 -177.801 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 373' ' ' ASP . . . . . 0.416 ' HB2' ' HE3' ' A' ' 378' ' ' LYS . 36.0 t70 -117.11 80.75 1.53 Allowed 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 114.704 -1.135 . . . . 0.0 109.158 -178.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 61.18 119.12 0.01 OUTLIER Glycine 0 CA--C 1.52 0.372 0 CA-C-N 114.968 -1.014 . . . . 0.0 113.408 -175.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 375' ' ' ASN . . . . . 0.601 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 3.6 p-10 26.13 48.1 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 124.582 1.153 . . . . 0.0 114.08 179.519 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 162.95 171.45 29.19 Favored Glycine 0 N--CA 1.444 -0.81 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 178.771 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 377' ' ' PHE . . . . . 0.405 ' CD2' HG11 ' A' ' 351' ' ' VAL . 4.0 p90 -138.83 147.94 43.11 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.458 0.647 . . . . 0.0 111.983 -179.245 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 378' ' ' LYS . . . . . 0.416 ' HE3' ' HB2' ' A' ' 373' ' ' ASP . 0.0 OUTLIER -130.59 133.13 45.93 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 114.775 -1.102 . . . . 0.0 109.659 173.468 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 379' ' ' GLY . . . . . 0.515 ' HA3' ' HA ' ' A' ' 370' ' ' ALA . . . -154.85 -158.36 8.67 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.489 -176.472 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -138.17 151.85 48.12 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 120.74 0.305 . . . . 0.0 111.489 -173.835 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 381' ' ' TRP . . . . . 0.752 ' CZ3' HG13 ' A' ' 355' ' ' ILE . 19.3 m95 . . . . . 0 C--O 1.233 0.211 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.992 176.668 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.496 0 N-CA-C 111.865 -0.494 . . . . 0.0 111.865 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -90.9 137.42 32.38 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.056 0.455 . . . . 0.0 110.992 -177.4 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 29.5 t -128.98 115.37 36.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.58 177.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 2.4 p -139.11 137.51 36.22 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.355 0.598 . . . . 0.0 112.477 -175.316 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -147.84 159.33 27.99 Favored Glycine 0 N--CA 1.447 -0.614 0 CA-C-N 115.474 -0.785 . . . . 0.0 111.515 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 392' ' ' ARG . . . . . 0.414 ' N ' ' HD2' ' A' ' 392' ' ' ARG . 8.2 mpt_? -117.01 142.43 46.96 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.05 0.453 . . . . 0.0 111.076 -174.423 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 393' ' ' PHE . . . . . 0.405 ' CD1' ' HB ' ' A' ' 401' ' ' VAL . 21.0 m-85 -82.34 163.09 21.98 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 115.295 -0.866 . . . . 0.0 109.671 176.626 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 394' ' ' TYR . . . . . 0.45 ' HD1' ' N ' ' A' ' 394' ' ' TYR . 1.2 m-85 -100.77 -176.99 3.34 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 176.094 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 395' ' ' GLY . . . . . 0.686 ' HA2' ' HA ' ' A' ' 307' ' ' PRO . . . -52.74 -146.96 0.0 OUTLIER Glycine 0 CA--C 1.527 0.836 0 O-C-N 124.062 0.851 . . . . 0.0 114.755 -176.256 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -59.22 -11.49 13.25 Favored 'Trans proline' 0 CA--C 1.536 0.605 0 C-N-CA 121.515 1.477 . . . . 0.0 111.051 179.389 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 397' ' ' ALA . . . . . 0.411 ' C ' ' H ' ' A' ' 399' ' ' GLU . . . -94.82 28.79 2.56 Favored 'General case' 0 N--CA 1.453 -0.316 0 CA-C-N 114.798 -1.092 . . . . 0.0 110.557 175.767 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . -57.78 2.42 0.14 Allowed Glycine 0 C--N 1.338 0.646 0 CA-C-N 115.923 -0.58 . . . . 0.0 113.657 -179.681 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 399' ' ' GLU . . . . . 0.805 ' HG2' ' HD3' ' A' ' 424' ' ' LYS . 35.7 mt-10 -58.73 -9.22 1.63 Allowed 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 123.401 0.68 . . . . 0.0 109.756 166.114 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -115.02 125.68 53.87 Favored 'General case' 0 N--CA 1.447 -0.62 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.437 171.001 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 401' ' ' VAL . . . . . 0.405 ' HB ' ' CD1' ' A' ' 393' ' ' PHE . 9.7 p -135.09 146.57 30.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.725 178.128 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -142.19 135.07 28.58 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.82 0.343 . . . . 0.0 110.896 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -153.14 -177.91 27.18 Favored Glycine 0 N--CA 1.44 -1.089 0 C-N-CA 120.667 -0.777 . . . . 0.0 112.085 -178.368 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 404' ' ' LYS . . . . . 0.856 ' HG2' HG11 ' A' ' 419' ' ' VAL . 70.2 mttt -142.0 163.01 34.04 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 -179.562 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 29.2 p90 . . . . . 0 C--N 1.32 -0.711 0 CA-C-O 121.218 0.533 . . . . 0.0 111.208 178.988 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 417' ' ' PHE . . . . . 0.722 ' HB2' ' HD1' ' A' ' 326' ' ' PHE . 47.8 p90 . . . . . 0 N--CA 1.449 -0.513 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 81.54 71.23 1.3 Allowed Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.53 -0.843 . . . . 0.0 112.278 177.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 419' ' ' VAL . . . . . 0.856 HG11 ' HG2' ' A' ' 404' ' ' LYS . 22.9 m -109.72 153.04 11.6 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 178.819 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 420' ' ' PHE . . . . . 0.409 ' HB3' HG23 ' A' ' 323' ' ' VAL . 38.3 p90 -142.4 160.45 40.24 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 121.358 0.599 . . . . 0.0 110.873 179.408 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -139.45 136.11 34.29 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 114.943 -1.026 . . . . 0.0 109.076 177.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -118.94 132.44 9.65 Favored Glycine 0 N--CA 1.441 -1.007 0 C-N-CA 120.607 -0.806 . . . . 0.0 111.681 -178.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 35.2 mtmt -116.18 124.6 50.69 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 179.181 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 424' ' ' LYS . . . . . 0.805 ' HD3' ' HG2' ' A' ' 399' ' ' GLU . 46.2 tttm -67.48 125.57 26.57 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.69 -177.795 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 425' ' ' GLU . . . . . 0.411 ' HB2' ' ND2' ' A' ' 320' ' ' ASN . 26.2 tt0 . . . . . 0 N--CA 1.444 -0.762 0 CA-C-O 121.416 0.627 . . . . 0.0 111.138 -172.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_exo . . . . . 0 CA--C 1.528 0.224 0 N-CA-C 111.216 -0.34 . . . . 0.0 111.216 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 308' ' ' ALA . . . . . 0.696 ' HB3' ' O ' ' A' ' 394' ' ' TYR . . . -48.07 152.51 0.8 Allowed 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 112.968 0.729 . . . . 0.0 112.968 -177.92 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 309' ' ' LYS . . . . . 0.57 ' O ' ' HG ' ' A' ' 313' ' ' LEU . 29.9 mmmt -108.87 107.9 18.48 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.489 177.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 310' ' ' GLY . . . . . 0.567 ' HA2' HD13 ' A' ' 313' ' ' LEU . . . -64.91 -34.89 91.09 Favored Glycine 0 CA--C 1.516 0.133 0 C-N-CA 121.355 -0.45 . . . . 0.0 113.705 -172.737 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 2.9 pm0 -71.72 -25.56 62.12 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.234 0.54 . . . . 0.0 110.031 178.692 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 312' ' ' MET . . . . . 0.437 ' HB3' ' HB2' ' A' ' 309' ' ' LYS . 27.6 ttt -87.11 -18.06 31.37 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.461 -179.45 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 313' ' ' LEU . . . . . 0.57 ' HG ' ' O ' ' A' ' 309' ' ' LYS . 96.1 mt -66.55 139.96 57.95 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.554 179.167 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -159.62 135.64 8.75 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.011 -176.384 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.5 177.69 15.94 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.918 -0.658 . . . . 0.0 111.592 178.168 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 38.7 p -108.75 142.16 39.7 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 117.303 0.551 . . . . 0.0 110.471 174.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -146.68 155.28 42.31 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.258 -179.093 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 318' ' ' VAL . . . . . 0.543 ' HA ' ' O ' ' A' ' 342' ' ' ALA . 2.5 p -132.94 119.71 38.17 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-O 121.285 0.564 . . . . 0.0 110.732 174.504 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 319' ' ' TYR . . . . . 0.522 ' HH ' ' HZ ' ' A' ' 346' ' ' PHE . 76.8 m-85 -104.51 128.35 52.42 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.956 -178.671 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 4.5 p30 -127.75 141.84 51.48 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.142 179.297 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -167.03 -140.98 3.02 Favored Glycine 0 N--CA 1.442 -0.913 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.28 -178.194 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 31.0 mt-10 -118.66 150.38 39.82 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.831 0.348 . . . . 0.0 111.051 -173.577 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 323' ' ' VAL . . . . . 0.585 HG22 ' HB2' ' A' ' 340' ' ' PHE . 56.1 t -109.9 120.95 61.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.925 172.644 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 324' ' ' LEU . . . . . 0.414 ' HB2' HG23 ' A' ' 419' ' ' VAL . 95.7 mt -101.87 104.21 14.94 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.092 -179.624 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 325' ' ' HIS . . . . . 0.435 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 28.1 t-80 -96.21 138.83 33.25 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.187 -0.461 . . . . 0.0 109.814 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 326' ' ' PHE . . . . . 0.531 ' HE2' HG11 ' A' ' 419' ' ' VAL . 10.8 m-85 . . . . . 0 C--N 1.321 -0.67 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.587 -176.35 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 337' ' ' ARG . . . . . 0.474 ' HA ' ' O ' ' A' ' 323' ' ' VAL . 51.2 mtm180 . . . . . 0 CA--C 1.516 -0.338 0 CA-C-O 121.254 0.549 . . . . 0.0 111.576 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -107.57 -177.12 22.49 Favored Glycine 0 N--CA 1.444 -0.83 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.092 176.707 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 339' ' ' ARG . . . . . 0.513 ' O ' ' HA ' ' A' ' 355' ' ' ILE . 40.0 mtp-105 -104.45 153.46 21.08 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 340' ' ' PHE . . . . . 0.585 ' HB2' HG22 ' A' ' 323' ' ' VAL . 53.0 t80 -143.41 137.52 28.71 Favored 'General case' 0 C--N 1.317 -0.848 0 CA-C-O 121.139 0.495 . . . . 0.0 111.484 -178.51 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 341' ' ' ALA . . . . . . . . . . . . . . . -141.05 163.49 32.84 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.228 -0.896 . . . . 0.0 108.889 173.334 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 342' ' ' ALA . . . . . 0.82 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -155.9 118.14 4.09 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 120.871 0.367 . . . . 0.0 110.667 -176.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 343' ' ' LYS . . . . . 0.49 ' C ' ' HD3' ' A' ' 343' ' ' LYS . 12.7 tmtt? -94.3 103.35 15.36 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 178.223 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 344' ' ' VAL . . . . . 1.009 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.2 OUTLIER -119.4 132.83 68.1 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.109 0 CA-C-O 121.607 0.718 . . . . 0.0 112.105 -172.716 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -109.16 118.69 37.39 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.885 -1.052 . . . . 0.0 108.247 175.563 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 346' ' ' PHE . . . . . 0.522 ' HZ ' ' HH ' ' A' ' 319' ' ' TYR . 70.4 m-85 -79.25 -24.59 42.9 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 111.584 0.216 . . . . 0.0 111.584 -175.509 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -69.52 -38.54 79.25 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.239 -0.981 . . . . 0.0 111.285 179.227 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 3.4 m -92.58 -9.74 40.04 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.002 0.43 . . . . 0.0 110.019 178.096 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 349' ' ' LYS . . . . . 0.625 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 10.1 mtmp? 52.03 58.67 5.19 Favored 'General case' 0 N--CA 1.456 -0.142 0 CA-C-N 115.439 -0.801 . . . . 0.0 110.394 -176.734 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 17.9 m -140.9 145.84 36.67 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.48 -179.211 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 351' ' ' VAL . . . . . 1.009 ' HB ' ' HB ' ' A' ' 344' ' ' VAL . 0.2 OUTLIER -141.83 139.0 31.38 Favored 'Isoleucine or valine' 0 C--O 1.237 0.396 0 CA-C-O 121.299 0.571 . . . . 0.0 111.559 -177.035 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 352' ' ' ASP . . . . . 0.82 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 1.5 m-20 -106.61 118.54 36.93 Favored 'General case' 0 C--O 1.214 -0.798 0 CA-C-N 115.057 -0.974 . . . . 0.0 109.304 179.637 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -110.1 143.24 16.73 Favored Glycine 0 C--N 1.313 -0.715 0 C-N-CA 120.23 -0.986 . . . . 0.0 111.873 -177.076 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 354' ' ' ILE . . . . . 0.518 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -140.29 129.92 27.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 CA-C-O 120.856 0.36 . . . . 0.0 110.362 -177.962 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 355' ' ' ILE . . . . . 0.541 HG21 HG23 ' A' ' 323' ' ' VAL . 3.3 mp . . . . . 0 C--N 1.326 -0.419 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.329 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 14.6 mm100 . . . . . 0 N--CA 1.447 -0.577 0 CA-C-O 121.624 0.726 . . . . 0.0 111.076 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 44.9 mttp -125.74 147.72 49.29 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 114.599 -1.182 . . . . 0.0 110.394 -170.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 368' ' ' PHE . . . . . 0.672 ' CD1' HG21 ' A' ' 389' ' ' VAL . 41.9 p90 -126.39 160.23 31.05 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 177.371 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 369' ' ' LYS . . . . . 0.553 ' HD3' ' HA ' ' A' ' 352' ' ' ASP . 2.0 tppt? -125.96 147.39 49.53 Favored 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 173.442 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -141.58 147.71 38.12 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.83 0.347 . . . . 0.0 111.123 -176.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -105.45 127.57 53.07 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.079 177.759 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 372' ' ' ILE . . . . . 0.625 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 84.0 mt -82.8 121.32 35.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-O 121.008 0.433 . . . . 0.0 111.257 -178.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -137.91 105.27 5.5 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 170.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 92.88 -155.2 22.37 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 110.349 -1.1 . . . . 0.0 110.349 -168.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 375' ' ' ASN . . . . . 0.544 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 21.8 p-10 -94.33 42.6 1.1 Allowed 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 117.533 0.666 . . . . 0.0 110.681 178.718 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . -170.37 164.48 37.77 Favored Glycine 0 N--CA 1.441 -1.016 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -178.789 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 377' ' ' PHE . . . . . 0.504 ' CD2' HG12 ' A' ' 351' ' ' VAL . 8.8 p90 -136.91 139.0 41.26 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-O 120.964 0.412 . . . . 0.0 110.939 -179.307 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 378' ' ' LYS . . . . . . . . . . . . . 63.7 mttm -112.72 137.09 51.52 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.293 172.081 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 379' ' ' GLY . . . . . 0.615 ' C ' HG22 ' A' ' 389' ' ' VAL . . . -144.53 -154.73 6.22 Favored Glycine 0 N--CA 1.437 -1.283 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.097 -172.432 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 12.7 t -169.16 154.66 6.09 Favored 'General case' 0 C--N 1.313 -1.016 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 -173.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 381' ' ' TRP . . . . . 0.885 ' HD1' ' HA3' ' A' ' 387' ' ' GLY . 38.8 m95 . . . . . 0 C--N 1.327 -0.373 0 CA-C-O 121.299 0.571 . . . . 0.0 110.87 178.337 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 387' ' ' GLY . . . . . 0.885 ' HA3' ' HD1' ' A' ' 381' ' ' TRP . . . . . . . . 0 N--CA 1.446 -0.69 0 N-CA-C 112.637 -0.185 . . . . 0.0 112.637 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -96.18 128.04 42.74 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 178.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 389' ' ' VAL . . . . . 0.672 HG21 ' CD1' ' A' ' 368' ' ' PHE . 3.5 m -117.28 160.48 16.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 C-N-CA 120.87 -0.332 . . . . 0.0 110.714 -176.589 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 390' ' ' SER . . . . . 0.51 ' O ' ' HA3' ' A' ' 403' ' ' GLY . 24.7 t -157.44 158.46 35.87 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.245 178.622 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -170.13 153.15 20.82 Favored Glycine 0 C--N 1.32 -0.329 0 N-CA-C 111.443 -0.663 . . . . 0.0 111.443 178.666 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 4.3 ptm180 -131.92 149.32 52.47 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 117.319 0.56 . . . . 0.0 110.751 -176.706 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -89.88 166.11 13.7 Favored 'General case' 0 CA--C 1.498 -1.037 0 CA-C-O 122.424 1.107 . . . . 0.0 111.786 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 394' ' ' TYR . . . . . 0.696 ' O ' ' HB3' ' A' ' 308' ' ' ALA . 0.5 OUTLIER -101.86 -176.15 3.05 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 112.709 -2.042 . . . . 0.0 108.923 176.949 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 395' ' ' GLY . . . . . 0.42 ' O ' ' N ' ' A' ' 397' ' ' ALA . . . -36.26 158.38 0.01 OUTLIER Glycine 0 N--CA 1.461 0.304 0 O-C-N 124.71 1.256 . . . . 0.0 115.045 -175.06 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -22.95 -42.42 0.03 OUTLIER 'Trans proline' 0 C--N 1.358 1.032 1 C-N-CA 127.322 5.348 . . . . 0.0 117.178 -161.711 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 397' ' ' ALA . . . . . 0.42 ' N ' ' O ' ' A' ' 395' ' ' GLY . . . -73.04 -19.46 61.18 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 -175.068 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 57.85 25.06 55.54 Favored Glycine 0 C--N 1.34 0.767 0 CA-C-N 116.186 -0.461 . . . . 0.0 112.887 176.165 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 399' ' ' GLU . . . . . 0.442 ' HA ' ' HE1' ' A' ' 319' ' ' TYR . 51.3 mt-10 -71.3 -8.37 53.21 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 122.956 0.502 . . . . 0.0 112.024 -174.03 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 400' ' ' GLU . . . . . 0.437 ' HG2' ' CE1' ' A' ' 394' ' ' TYR . 5.2 tt0 -131.9 144.29 50.75 Favored 'General case' 0 N--CA 1.433 -1.284 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 171.438 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 401' ' ' VAL . . . . . 0.473 HG22 ' CZ ' ' A' ' 377' ' ' PHE . 14.8 p -142.08 136.73 29.9 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.107 0 CA-C-N 115.012 -0.995 . . . . 0.0 109.722 179.019 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -135.7 138.94 43.27 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.122 -178.74 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 403' ' ' GLY . . . . . 0.51 ' HA3' ' O ' ' A' ' 390' ' ' SER . . . -161.06 -161.09 11.25 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 120.747 -0.739 . . . . 0.0 111.646 178.424 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 404' ' ' LYS . . . . . 0.733 ' HG2' HG13 ' A' ' 419' ' ' VAL . 28.4 mtmm -144.45 161.71 38.36 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.557 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 34.9 p90 . . . . . 0 C--N 1.318 -0.776 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 171.915 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 417' ' ' PHE . . . . . 0.489 ' CD1' ' HB2' ' A' ' 326' ' ' PHE . 32.7 m-85 . . . . . 0 N--CA 1.454 -0.243 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 418' ' ' GLY . . . . . 0.435 ' HA2' ' HA ' ' A' ' 325' ' ' HIS . . . 83.82 78.17 1.11 Allowed Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 119.904 -1.141 . . . . 0.0 112.678 -178.262 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 419' ' ' VAL . . . . . 0.733 HG13 ' HG2' ' A' ' 404' ' ' LYS . 13.5 m -105.03 163.29 4.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.832 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 29.9 p90 -143.38 153.71 42.97 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-O 121.406 0.622 . . . . 0.0 111.234 -178.133 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -142.81 136.15 28.5 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.259 -0.882 . . . . 0.0 109.037 176.664 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -124.05 134.71 9.34 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.399 -0.905 . . . . 0.0 112.327 -178.341 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 423' ' ' LYS . . . . . 0.403 ' O ' ' HA ' ' A' ' 319' ' ' TYR . 44.6 mtpt -104.8 140.18 38.48 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 120.753 0.311 . . . . 0.0 110.198 178.722 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 424' ' ' LYS . . . . . 0.403 ' HB2' ' HE1' ' A' ' 319' ' ' TYR . 26.0 tptp -58.14 116.25 3.43 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.626 -0.716 . . . . 0.0 111.8 179.652 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 425' ' ' GLU . . . . . 0.504 ' HB3' HG11 ' A' ' 318' ' ' VAL . 19.8 tp10 . . . . . 0 C--N 1.325 -0.473 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 169.009 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 276' ' ' ASN . . . . . 0.533 ' HA ' ' OE2' ' A' ' 292' ' ' GLU . 17.2 p30 . . . . . 0 N--CA 1.483 1.189 0 CA-C-O 121.348 0.594 . . . . 0.0 110.013 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 15.6 tt -81.67 15.27 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.313 -171.798 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 278' ' ' PHE . . . . . . . . . . . . . 25.1 p90 -79.03 -21.52 46.76 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.451 176.091 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 279' ' ' ALA . . . . . 0.569 ' HB2' ' HA ' ' A' ' 283' ' ' ASN . . . -144.43 64.08 11.68 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.199 178.435 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 280' ' ' PRO . . . . . 0.466 ' O ' ' HB2' ' A' ' 281' ' ' GLU . 4.5 Cg_endo -84.23 144.9 10.71 Favored 'Trans proline' 0 N--CA 1.455 -0.768 0 C-N-CA 123.08 2.52 . . . . 0.0 111.403 179.462 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . 0.466 ' HB2' ' O ' ' A' ' 280' ' ' PRO . 1.6 mp0 70.83 -64.01 0.39 Allowed 'General case' 0 N--CA 1.469 0.52 0 O-C-N 123.61 0.569 . . . . 0.0 110.774 -178.301 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -107.77 93.35 0.81 Allowed Glycine 0 N--CA 1.446 -0.665 0 CA-C-N 115.78 -0.645 . . . . 0.0 111.873 177.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 283' ' ' ASN . . . . . 0.569 ' HA ' ' HB2' ' A' ' 279' ' ' ALA . 2.6 p-10 -71.42 108.03 4.64 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.49 0.662 . . . . 0.0 110.161 178.228 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 70.9 m-85 -72.99 99.31 2.69 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.995 -175.554 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 3.3 ptp180 -92.93 2.32 56.84 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.824 -0.626 . . . . 0.0 109.714 177.146 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 4.9 m-85 -79.06 -42.48 26.32 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.347 -0.842 . . . . 0.0 108.738 177.574 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . 0.524 HD12 ' HB3' ' A' ' 306' ' ' GLU . 21.5 tp -166.25 128.94 1.95 Allowed 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 115.072 -0.967 . . . . 0.0 109.544 175.914 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 288' ' ' THR . . . . . 0.536 ' H ' ' HB2' ' A' ' 304' ' ' GLN . 6.0 m -172.37 143.66 1.45 Allowed 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 123.354 0.661 . . . . 0.0 109.473 179.084 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 289' ' ' TYR . . . . . . . . . . . . . 46.6 t80 -136.42 128.26 29.21 Favored 'General case' 0 N--CA 1.443 -0.808 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 171.849 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 144.43 158.4 7.6 Favored Glycine 0 C--N 1.312 -0.785 0 N-CA-C 111.355 -0.698 . . . . 0.0 111.355 -177.011 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 291' ' ' ALA . . . . . 0.413 ' HB1' ' OH ' ' A' ' 299' ' ' TYR . . . -156.17 130.15 8.57 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.866 0.333 . . . . 0.0 111.284 -177.646 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 292' ' ' GLU . . . . . 0.533 ' OE2' ' HA ' ' A' ' 276' ' ' ASN . 44.7 mt-10 -137.1 119.43 15.72 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.231 -0.44 . . . . 0.0 109.999 175.916 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 293' ' ' LYS . . . . . . . . . . . . . 5.2 tppp? -88.02 139.49 30.45 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.495 -0.321 . . . . 0.0 110.612 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 294' ' ' LEU . . . . . 0.458 ' HB2' ' O ' ' A' ' 298' ' ' SER . 6.5 mp -82.25 115.7 59.28 Favored Pre-proline 0 C--N 1.327 -0.375 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 173.954 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 295' ' ' PRO . . . . . 0.408 ' HD3' ' HA ' ' A' ' 294' ' ' LEU . 21.7 Cg_exo -65.27 100.39 0.38 Allowed 'Trans proline' 0 C--O 1.236 0.387 0 C-N-CA 122.576 2.184 . . . . 0.0 111.096 179.088 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . 80.69 48.28 6.3 Favored Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 120.679 -0.772 . . . . 0.0 111.433 -174.27 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . -166.43 -140.94 3.01 Favored Glycine 0 N--CA 1.443 -0.888 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.8 -178.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 298' ' ' SER . . . . . 0.458 ' O ' ' HB2' ' A' ' 294' ' ' LEU . 8.3 t -94.42 -175.45 3.64 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.078 0.466 . . . . 0.0 110.901 -175.509 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 299' ' ' TYR . . . . . 0.413 ' OH ' ' HB1' ' A' ' 291' ' ' ALA . 1.3 t80 -139.32 135.78 34.14 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 176.09 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 300' ' ' ALA . . . . . 0.461 ' HB3' ' ND2' ' A' ' 276' ' ' ASN . . . -144.19 110.51 5.5 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.178 179.477 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 301' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -142.15 162.68 34.86 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.427 178.066 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 302' ' ' ARG . . . . . 0.549 ' NE ' ' HA ' ' A' ' 302' ' ' ARG . 2.3 mmp_? -136.78 131.8 33.86 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 174.378 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 303' ' ' VAL . . . . . . . . . . . . . 3.4 p -113.43 96.44 4.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 122.073 0.939 . . . . 0.0 110.487 178.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 304' ' ' GLN . . . . . 0.536 ' HB2' ' H ' ' A' ' 288' ' ' THR . 5.1 mp0 -121.94 151.86 40.29 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 114.855 -1.066 . . . . 0.0 109.814 177.47 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -102.94 119.44 6.43 Favored Glycine 0 N--CA 1.444 -0.814 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.692 -177.641 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 306' ' ' GLU . . . . . 0.524 ' HB3' HD12 ' A' ' 287' ' ' LEU . 6.0 pt-20 -116.35 84.31 14.27 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-O 121.598 0.713 . . . . 0.0 109.845 173.678 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -91.0 122.41 0.78 Allowed 'Trans proline' 0 N--CA 1.444 -1.414 0 C-N-CA 122.591 2.194 . . . . 0.0 111.575 175.009 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . 0.662 ' HB3' ' O ' ' A' ' 394' ' ' TYR . . . -59.47 163.54 4.01 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.15 -0.62 . . . . 0.0 109.974 168.828 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 309' ' ' LYS . . . . . 0.526 ' HB3' ' HB2' ' A' ' 312' ' ' MET . 10.8 tptp -123.96 93.45 3.93 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 174.1 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 310' ' ' GLY . . . . . 0.633 ' HA2' HD11 ' A' ' 313' ' ' LEU . . . -57.24 -34.02 66.47 Favored Glycine 0 C--N 1.332 0.315 0 C-N-CA 121.147 -0.549 . . . . 0.0 113.013 -173.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . 0.417 ' HA ' ' HE3' ' A' ' 349' ' ' LYS . 11.2 pt-20 -62.82 -26.9 68.97 Favored 'General case' 0 C--N 1.319 -0.755 0 C-N-CA 122.483 0.313 . . . . 0.0 111.581 174.807 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 312' ' ' MET . . . . . 0.526 ' HB2' ' HB3' ' A' ' 309' ' ' LYS . 90.0 mtp -102.37 -6.37 23.1 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.921 0.391 . . . . 0.0 110.567 -179.77 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 313' ' ' LEU . . . . . 0.633 HD11 ' HA2' ' A' ' 310' ' ' GLY . 92.4 mt -75.26 133.2 41.4 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.729 176.876 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -143.68 137.09 27.97 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.017 -173.822 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.53 -159.53 15.28 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 121.001 -0.618 . . . . 0.0 111.665 178.994 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 12.7 p -123.89 156.17 36.76 Favored 'General case' 0 C--N 1.317 -0.806 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 173.462 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -146.51 160.41 42.15 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 120.918 0.39 . . . . 0.0 110.694 176.657 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . 0.567 ' HA ' ' O ' ' A' ' 342' ' ' ALA . 8.7 p -138.78 113.75 8.5 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.691 172.849 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . 0.567 ' HE2' HG11 ' A' ' 344' ' ' VAL . 55.4 m-85 -98.08 127.46 44.04 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.331 -177.256 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -115.79 132.4 56.65 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.478 174.459 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . 0.478 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -166.27 -143.17 3.65 Favored Glycine 0 N--CA 1.438 -1.197 0 C-N-CA 120.697 -0.763 . . . . 0.0 111.948 -179.143 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -136.94 164.67 27.78 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 120.927 0.394 . . . . 0.0 111.236 -173.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 323' ' ' VAL . . . . . 0.578 HG23 ' HB2' ' A' ' 340' ' ' PHE . 75.2 t -126.34 116.42 45.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.53 178.792 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 324' ' ' LEU . . . . . 0.416 ' HB2' HG23 ' A' ' 419' ' ' VAL . 93.7 mt -89.4 101.76 14.43 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 175.486 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 325' ' ' HIS . . . . . 0.49 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 1.9 p80 -102.24 114.76 29.19 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.493 0.663 . . . . 0.0 110.066 -179.123 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 326' ' ' PHE . . . . . 0.506 ' HB2' ' HB3' ' A' ' 417' ' ' PHE . 49.0 m-85 -88.16 124.33 33.7 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 114.734 -1.121 . . . . 0.0 110.897 -170.011 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 327' ' ' HIS . . . . . . . . . . . . . 31.2 p-80 -150.31 106.57 3.47 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 176.636 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 328' ' ' THR . . . . . . . . . . . . . 30.2 m -146.49 97.38 2.92 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.195 0.521 . . . . 0.0 110.937 179.113 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 329' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -106.41 115.4 30.14 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 107.351 -1.352 . . . . 0.0 107.351 169.157 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 330' ' ' ASN . . . . . . . . . . . . . 22.7 p-10 30.96 54.72 0.2 Allowed 'General case' 0 N--CA 1.477 0.876 0 O-C-N 124.333 1.021 . . . . 0.0 111.139 -167.873 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 331' ' ' GLY . . . . . . . . . . . . . . . -101.73 138.34 13.83 Favored Glycine 0 N--CA 1.444 -0.785 0 CA-C-N 115.01 -0.995 . . . . 0.0 113.332 -170.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 332' ' ' ARG . . . . . 0.561 ' N ' ' HD2' ' A' ' 333' ' ' PRO . 67.5 mtp180 -84.68 -42.84 0.7 Allowed Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 115.385 -0.407 . . . . 0.0 111.828 177.956 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 333' ' ' PRO . . . . . 0.561 ' HD2' ' N ' ' A' ' 332' ' ' ARG . 45.7 Cg_endo -68.74 -173.93 0.65 Allowed 'Trans proline' 0 C--N 1.36 1.132 0 C-N-CA 122.11 1.873 . . . . 0.0 112.674 175.472 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 334' ' ' TYR . . . . . 0.684 ' HB2' ' HD2' ' A' ' 335' ' ' PRO . 36.1 p90 -122.59 168.81 10.96 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.815 -178.609 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 335' ' ' PRO . . . . . 0.684 ' HD2' ' HB2' ' A' ' 334' ' ' TYR . 6.1 Cg_endo -48.55 144.41 14.09 Favored 'Trans proline' 0 C--N 1.353 0.77 0 C-N-CA 123.15 2.566 . . . . 0.0 113.038 179.165 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 336' ' ' THR . . . . . . . . . . . . . 1.6 m -94.34 151.97 19.0 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.579 -177.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 337' ' ' ARG . . . . . . . . . . . . . 54.6 mtp180 -102.48 112.63 25.44 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.957 0.408 . . . . 0.0 110.707 -178.756 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -96.82 -176.81 35.22 Favored Glycine 0 N--CA 1.447 -0.591 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 173.951 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 339' ' ' ARG . . . . . 0.613 ' HB2' ' HB2' ' A' ' 356' ' ' ASP . 29.0 mtm180 -112.41 163.31 14.58 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 118.055 0.928 . . . . 0.0 110.213 179.393 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 340' ' ' PHE . . . . . 0.578 ' HB2' HG23 ' A' ' 323' ' ' VAL . 30.7 t80 -151.67 140.13 20.55 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.83 0.347 . . . . 0.0 111.137 -179.243 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 341' ' ' ALA . . . . . 0.555 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -137.25 152.55 49.94 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.12 175.364 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . 0.926 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -143.83 118.3 9.71 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.044 0.45 . . . . 0.0 111.513 -178.375 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . 0.512 ' HB3' ' HB2' ' A' ' 352' ' ' ASP . 55.7 tptt -96.52 103.61 15.54 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.109 177.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 344' ' ' VAL . . . . . 0.567 HG11 ' HE2' ' A' ' 319' ' ' TYR . 0.7 OUTLIER -122.86 140.33 46.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -170.691 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -114.4 121.31 43.19 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.839 -1.073 . . . . 0.0 108.46 171.164 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 346' ' ' PHE . . . . . . . . . . . . . 51.8 m-85 -76.7 -17.04 59.34 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 111.734 0.272 . . . . 0.0 111.734 -175.301 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -75.29 -42.12 29.14 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.461 -0.876 . . . . 0.0 111.269 178.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 55.9 m -88.37 -10.93 47.7 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-O 120.811 0.339 . . . . 0.0 110.108 177.33 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 349' ' ' LYS . . . . . 0.626 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 48.4 mttm 51.24 58.81 5.12 Favored 'General case' 0 CA--C 1.52 -0.198 0 CA-C-O 121.863 0.84 . . . . 0.0 109.896 -179.723 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 50.7 m -147.77 146.02 29.02 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 114.777 -1.101 . . . . 0.0 109.607 176.958 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 351' ' ' VAL . . . . . 0.635 HG21 ' HB1' ' A' ' 370' ' ' ALA . 1.3 m -129.69 156.35 41.97 Favored 'Isoleucine or valine' 0 C--O 1.237 0.427 0 CA-C-O 121.181 0.515 . . . . 0.0 110.461 -176.451 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 352' ' ' ASP . . . . . 0.926 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 0.9 OUTLIER -109.48 117.37 33.81 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 170.481 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -114.7 117.08 3.95 Favored Glycine 0 N--CA 1.444 -0.792 0 C-N-CA 120.218 -0.991 . . . . 0.0 112.136 -177.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 354' ' ' ILE . . . . . 0.504 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -117.65 133.14 65.39 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.127 0 CA-C-N 115.321 -0.439 . . . . 0.0 109.916 -176.995 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 355' ' ' ILE . . . . . 0.524 ' HB ' ' HB3' ' A' ' 366' ' ' GLN . 3.4 mp -116.14 113.2 42.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.797 -178.016 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 356' ' ' ASP . . . . . 0.613 ' HB2' ' HB2' ' A' ' 339' ' ' ARG . 20.4 m-20 -68.43 100.72 1.12 Allowed 'General case' 0 C--O 1.238 0.5 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 175.34 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 15.9 t -70.83 -32.4 69.44 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.472 -0.786 . . . . 0.0 110.064 -177.781 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 358' ' ' GLY . . . . . . . . . . . . . . . 124.43 -41.64 1.69 Allowed Glycine 0 N--CA 1.448 -0.514 0 N-CA-C 111.107 -0.797 . . . . 0.0 111.107 -178.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 359' ' ' ASP . . . . . 0.481 ' OD2' ' HB3' ' A' ' 362' ' ' HIS . 20.8 t70 -133.39 68.31 1.5 Allowed 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 122.153 0.978 . . . . 0.0 108.843 174.381 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 360' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -78.02 -20.8 51.78 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 114.921 -1.036 . . . . 0.0 111.303 -174.505 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 361' ' ' LEU . . . . . . . . . . . . . 93.8 mt -83.86 -11.13 57.41 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.373 -176.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 362' ' ' HIS . . . . . 0.481 ' HB3' ' OD2' ' A' ' 359' ' ' ASP . 47.2 t60 -129.77 -66.16 0.81 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.712 -0.222 . . . . 0.0 111.408 179.018 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 363' ' ' MET . . . . . . . . . . . . . 15.1 tpt -55.55 -48.92 73.96 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 120.769 0.319 . . . . 0.0 110.789 179.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 364' ' ' GLY . . . . . . . . . . . . . . . 153.43 135.29 2.12 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 120.394 -0.908 . . . . 0.0 112.31 176.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 365' ' ' THR . . . . . . . . . . . . . 5.9 m -78.81 132.54 36.91 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 178.973 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 366' ' ' GLN . . . . . 0.524 ' HB3' ' HB ' ' A' ' 355' ' ' ILE . 17.5 tp60 -106.18 117.63 34.52 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 -179.734 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 37.5 ttpt -156.54 136.98 13.04 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.427 -176.344 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 368' ' ' PHE . . . . . 0.415 ' HB3' ' CE3' ' A' ' 381' ' ' TRP . 46.9 p90 -129.51 156.42 44.17 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.095 0.474 . . . . 0.0 109.978 178.876 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 4.0 tptp -116.62 131.59 56.91 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 175.149 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . 0.635 ' HB1' HG21 ' A' ' 351' ' ' VAL . . . -128.87 140.77 51.53 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 112.193 0.442 . . . . 0.0 112.193 -170.994 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -101.31 130.83 47.54 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.603 175.311 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 372' ' ' ILE . . . . . 0.626 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 84.2 mt -80.8 105.17 10.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.842 0.829 . . . . 0.0 110.08 -179.24 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -113.63 83.93 1.93 Allowed 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 114.337 -1.301 . . . . 0.0 108.944 -177.16 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 374' ' ' GLY . . . . . 0.555 ' O ' ' HA3' ' A' ' 310' ' ' GLY . . . 101.34 -141.79 15.46 Favored Glycine 0 N--CA 1.444 -0.811 0 CA-C-N 115.159 -0.928 . . . . 0.0 111.117 -174.15 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 375' ' ' ASN . . . . . . . . . . . . . 30.9 p-10 -97.57 59.56 1.52 Allowed 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 122.582 1.182 . . . . 0.0 109.545 179.034 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 162.1 178.43 35.98 Favored Glycine 0 N--CA 1.443 -0.893 0 CA-C-N 113.993 -1.458 . . . . 0.0 109.959 -174.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 377' ' ' PHE . . . . . 0.474 ' CZ ' HG23 ' A' ' 401' ' ' VAL . 4.8 p90 -139.45 150.99 45.86 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 117.655 0.728 . . . . 0.0 112.155 -178.412 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 378' ' ' LYS . . . . . 0.434 ' HD2' ' N ' ' A' ' 378' ' ' LYS . 0.0 OUTLIER -115.06 129.5 56.71 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 172.818 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 379' ' ' GLY . . . . . 0.511 ' HA2' ' HA ' ' A' ' 370' ' ' ALA . . . -126.33 169.3 18.28 Favored Glycine 0 N--CA 1.444 -0.777 0 C-N-CA 119.997 -1.097 . . . . 0.0 113.411 -171.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 11.3 p -131.19 140.17 49.86 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.118 -0.541 . . . . 0.0 109.872 178.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 381' ' ' TRP . . . . . 0.512 ' CB ' ' HA3' ' A' ' 385' ' ' GLY . 73.7 m95 -66.18 139.62 58.13 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.701 179.496 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 382' ' ' THR . . . . . 0.41 ' O ' HG21 ' A' ' 382' ' ' THR . 13.8 t -66.28 112.87 4.2 Favored 'General case' 0 CA--C 1.536 0.405 0 CA-C-O 121.4 0.619 . . . . 0.0 111.696 -173.99 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 383' ' ' GLU . . . . . . . . . . . . . 20.1 mm-40 62.14 -88.56 0.03 OUTLIER 'General case' 0 C--O 1.234 0.288 0 CA-C-N 115.063 -0.971 . . . . 0.0 112.498 177.125 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 384' ' ' ASN . . . . . . . . . . . . . 44.4 t-20 -91.52 74.48 5.96 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.072 0.463 . . . . 0.0 110.509 -174.126 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 385' ' ' GLY . . . . . 0.512 ' HA3' ' CB ' ' A' ' 381' ' ' TRP . . . -154.56 89.18 0.12 Allowed Glycine 0 N--CA 1.444 -0.803 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.18 178.072 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 386' ' ' GLY . . . . . . . . . . . . . . . -75.33 72.42 1.68 Allowed Glycine 0 CA--C 1.519 0.303 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.464 178.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -164.03 148.8 15.29 Favored Glycine 0 N--CA 1.445 -0.737 0 C-N-CA 121.092 -0.575 . . . . 0.0 112.27 179.304 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -99.66 138.94 36.04 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.817 0.342 . . . . 0.0 110.594 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 389' ' ' VAL . . . . . 0.464 HG22 ' HB3' ' A' ' 405' ' ' TYR . 22.1 t -109.53 144.81 17.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 177.641 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 14.7 m -147.44 139.64 24.43 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.52 0.2 . . . . 0.0 110.557 175.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -145.08 150.14 22.31 Favored Glycine 0 C--N 1.32 -0.326 0 N-CA-C 111.692 -0.563 . . . . 0.0 111.692 179.38 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 392' ' ' ARG . . . . . 0.626 ' HD3' ' O ' ' A' ' 393' ' ' PHE . 4.5 tmt_? -118.67 136.55 53.85 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -175.501 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 393' ' ' PHE . . . . . 0.626 ' O ' ' HD3' ' A' ' 392' ' ' ARG . 8.1 m-85 -82.24 159.76 23.13 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.263 -177.693 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 394' ' ' TYR . . . . . 0.662 ' O ' ' HB3' ' A' ' 308' ' ' ALA . 2.4 m-85 -100.81 -174.67 2.68 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.861 -177.164 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 395' ' ' GLY . . . . . 0.455 ' CA ' ' HB2' ' A' ' 306' ' ' GLU . . . -38.42 170.45 0.01 OUTLIER Glycine 0 C--N 1.335 0.487 0 O-C-N 124.277 0.985 . . . . 0.0 114.985 -177.718 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -51.52 -15.11 2.35 Favored 'Trans proline' 0 N--CA 1.477 0.502 0 C-N-CA 124.384 3.389 . . . . 0.0 115.526 -163.853 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 397' ' ' ALA . . . . . . . . . . . . . . . -80.22 -20.49 44.54 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 111.735 0.272 . . . . 0.0 111.735 177.299 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 56.23 18.62 21.46 Favored Glycine 0 C--N 1.34 0.763 0 CA-C-N 116.09 -0.505 . . . . 0.0 114.081 175.046 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 399' ' ' GLU . . . . . 0.887 ' HG3' ' HB3' ' A' ' 424' ' ' LYS . 17.7 tt0 -73.15 -19.15 61.19 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.193 0.52 . . . . 0.0 110.838 -177.751 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -116.7 137.47 52.17 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-O 121.18 0.514 . . . . 0.0 110.362 177.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 401' ' ' VAL . . . . . 0.474 HG23 ' CZ ' ' A' ' 377' ' ' PHE . 9.0 p -139.46 134.55 39.67 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.546 173.423 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -131.14 135.18 47.24 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.172 -179.335 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -151.05 -176.64 24.12 Favored Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.177 -1.011 . . . . 0.0 112.152 -177.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 404' ' ' LYS . . . . . 0.707 ' HG2' HG12 ' A' ' 419' ' ' VAL . 27.0 mttm -147.69 162.47 39.1 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 -179.352 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 405' ' ' TYR . . . . . 0.464 ' HB3' HG22 ' A' ' 389' ' ' VAL . 6.9 p90 -124.36 151.22 44.64 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 121.251 0.548 . . . . 0.0 111.593 175.644 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 406' ' ' SER . . . . . 0.479 ' OG ' ' HA3' ' A' ' 415' ' ' GLY . 28.1 t -129.08 112.89 14.47 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.279 -176.679 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -87.47 140.57 29.39 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.84 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 408' ' ' ARG . . . . . 0.487 ' N ' ' HD3' ' A' ' 409' ' ' PRO . 36.1 mmt180 -136.18 58.21 21.14 Favored Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.531 174.775 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 409' ' ' PRO . . . . . 0.487 ' HD3' ' N ' ' A' ' 408' ' ' ARG . 10.2 Cg_endo -90.19 -59.05 0.02 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 122.865 2.376 . . . . 0.0 113.116 -176.266 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 410' ' ' THR . . . . . 0.462 ' HB ' ' H ' ' A' ' 411' ' ' ASP . 11.0 p -87.56 -151.24 0.18 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.5 -175.369 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 411' ' ' ASP . . . . . 0.462 ' H ' ' HB ' ' A' ' 410' ' ' THR . 17.9 t70 -61.38 91.3 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.22 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.757 177.219 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 412' ' ' ALA . . . . . . . . . . . . . . . 61.74 -78.82 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.18 0 O-C-N 123.83 0.706 . . . . 0.0 111.202 -176.944 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 413' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 71.04 132.88 0.04 OUTLIER 'General case' 0 C--N 1.333 -0.146 0 C-N-CA 123.576 0.751 . . . . 0.0 110.76 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 414' ' ' LYS . . . . . . . . . . . . . 52.2 mtpt -80.78 123.13 27.97 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.042 -175.57 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 415' ' ' GLY . . . . . 0.479 ' HA3' ' OG ' ' A' ' 406' ' ' SER . . . -102.84 178.32 25.88 Favored Glycine 0 N--CA 1.443 -0.874 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 175.702 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 416' ' ' GLY . . . . . . . . . . . . . . . 106.2 -25.75 22.53 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.554 -0.832 . . . . 0.0 111.234 -179.53 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 417' ' ' PHE . . . . . 0.506 ' HB3' ' HB2' ' A' ' 326' ' ' PHE . 64.1 m-85 -77.17 158.72 30.21 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 174.4 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 418' ' ' GLY . . . . . 0.49 ' HA2' ' HA ' ' A' ' 325' ' ' HIS . . . 82.4 77.32 1.07 Allowed Glycine 0 N--CA 1.442 -0.935 0 C-N-CA 119.78 -1.2 . . . . 0.0 111.447 -175.454 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 419' ' ' VAL . . . . . 0.707 HG12 ' HG2' ' A' ' 404' ' ' LYS . 19.7 m -105.08 146.96 11.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 -178.109 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 420' ' ' PHE . . . . . 0.444 ' HB3' HG22 ' A' ' 323' ' ' VAL . 47.0 p90 -130.29 161.07 32.06 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 121.023 0.44 . . . . 0.0 110.696 -179.299 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 421' ' ' ALA . . . . . 0.478 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -153.92 136.54 15.17 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.025 179.821 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -132.54 141.67 13.06 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.187 -1.006 . . . . 0.0 113.052 -177.336 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 72.3 mmtt -102.46 125.56 49.22 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 175.722 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 424' ' ' LYS . . . . . 0.887 ' HB3' ' HG3' ' A' ' 399' ' ' GLU . 80.0 tttt -63.16 105.72 0.75 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.272 0.558 . . . . 0.0 110.626 178.16 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -76.57 113.56 14.33 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.53 -0.759 . . . . 0.0 109.984 -179.708 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 426' ' ' GLN . . . . . . . . . . . . . 48.0 mt-30 -103.47 109.11 20.63 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.403 -0.817 . . . . 0.0 109.55 177.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 427' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -64.65 -13.73 55.2 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.328 -0.397 . . . . 0.0 111.091 -176.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . 0.682 ' HG ' ' HB2' ' A' ' 431' ' ' HIS . 29.7 tp -76.27 -13.24 60.17 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.854 179.339 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 429' ' ' GLU . . . . . . . . . . . . . 69.6 mm-40 59.52 39.68 21.37 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.744 178.548 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 430' ' ' HIS . . . . . . . . . . . . . 49.8 m80 73.5 -51.46 0.7 Allowed 'General case' 0 N--CA 1.475 0.789 0 C-N-CA 123.283 0.633 . . . . 0.0 110.818 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . 0.682 ' HB2' ' HG ' ' A' ' 428' ' ' LEU . 25.9 t-80 60.15 77.81 0.3 Allowed 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 123.402 0.681 . . . . 0.0 112.073 170.551 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 432' ' ' HIS . . . . . . . . . . . . . 36.0 m80 -134.27 -78.71 0.46 Allowed 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.214 174.004 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 433' ' ' HIS . . . . . . . . . . . . . 12.7 t-80 -176.86 -36.42 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.633 -0.258 . . . . 0.0 111.008 -178.674 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 434' ' ' HIS . . . . . . . . . . . . . 24.2 p80 -150.22 -179.82 7.5 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.825 0.345 . . . . 0.0 110.934 -178.556 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 435' ' ' HIS . . . . . . . . . . . . . 17.9 p80 . . . . . 0 C--O 1.243 0.757 0 CA-C-N 115.604 -0.726 . . . . 0.0 109.206 172.539 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 276' ' ' ASN . . . . . 0.439 ' ND2' ' HB3' ' A' ' 298' ' ' SER . 0.9 OUTLIER . . . . . 0 N--CA 1.483 1.218 0 N-CA-C 111.542 0.201 . . . . 0.0 111.542 . . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . 0.441 ' O ' HG21 ' A' ' 277' ' ' ILE . 25.7 mm -98.03 4.9 9.62 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.35 0 CA-C-O 121.54 0.686 . . . . 0.0 110.889 -174.655 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 278' ' ' PHE . . . . . . . . . . . . . 48.5 p90 -95.16 4.51 53.54 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.52 -176.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 279' ' ' ALA . . . . . 0.886 ' HB3' ' HB3' ' A' ' 301' ' ' LEU . . . -101.05 132.54 21.86 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-O 120.881 0.372 . . . . 0.0 111.954 -174.061 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 280' ' ' PRO . . . . . 0.485 ' HD2' ' O ' ' A' ' 302' ' ' ARG . 33.1 Cg_exo -58.47 147.06 87.98 Favored 'Trans proline' 0 N--CA 1.463 -0.299 0 C-N-CA 122.642 2.228 . . . . 0.0 110.509 168.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 27.1 tt0 -66.5 -19.7 65.85 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.012 -0.54 . . . . 0.0 112.245 -171.724 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -76.9 111.35 3.25 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.673 -0.775 . . . . 0.0 111.907 178.538 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 283' ' ' ASN . . . . . . . . . . . . . 40.5 m-80 -79.09 82.91 5.21 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.198 0.523 . . . . 0.0 110.685 -177.917 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 77.5 m-85 -96.11 146.12 24.92 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.9 178.135 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . 0.511 ' HA ' ' CE2' ' A' ' 289' ' ' TYR . 0.0 OUTLIER -140.5 44.17 1.86 Allowed 'General case' 0 CA--C 1.534 0.363 0 CA-C-O 121.396 0.617 . . . . 0.0 111.517 -175.189 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 76.6 m-85 -120.22 -34.87 3.57 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.302 0.572 . . . . 0.0 110.902 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . . . . . . . . . 7.2 mp -93.74 -178.48 4.7 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.216 -0.902 . . . . 0.0 110.573 -176.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 288' ' ' THR . . . . . . . . . . . . . 25.0 m -77.71 139.14 39.38 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 175.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 289' ' ' TYR . . . . . 1.002 ' HB3' ' HA ' ' A' ' 302' ' ' ARG . 42.6 m-85 -140.95 178.22 7.51 Favored 'General case' 0 C--N 1.327 -0.404 0 O-C-N 123.605 0.566 . . . . 0.0 110.185 -175.015 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . 0.714 ' O ' ' HB2' ' A' ' 301' ' ' LEU . . . -136.85 134.1 6.9 Favored Glycine 0 CA--C 1.495 -1.217 0 N-CA-C 107.459 -2.256 . . . . 0.0 107.459 175.161 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 291' ' ' ALA . . . . . 0.62 ' HB3' ' O ' ' A' ' 301' ' ' LEU . . . -155.49 131.95 10.35 Favored 'General case' 0 C--N 1.31 -1.123 0 CA-C-N 117.748 0.774 . . . . 0.0 111.025 -162.599 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 292' ' ' GLU . . . . . 0.571 ' H ' ' CD2' ' A' ' 301' ' ' LEU . 4.0 pm0 -123.76 109.65 13.94 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 162.234 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 293' ' ' LYS . . . . . 0.685 ' HB2' ' HB3' ' A' ' 300' ' ' ALA . 63.7 tttp -95.41 127.82 41.76 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.335 -173.7 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 294' ' ' LEU . . . . . 0.619 HD23 ' HB2' ' A' ' 298' ' ' SER . 3.9 mm? -110.11 141.76 24.5 Favored Pre-proline 0 C--N 1.318 -0.786 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.133 174.408 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 295' ' ' PRO . . . . . 0.424 ' HD3' ' HA ' ' A' ' 294' ' ' LEU . 7.3 Cg_exo -74.3 41.14 0.65 Allowed 'Trans proline' 0 CA--C 1.53 0.277 0 C-N-CA 123.27 2.647 . . . . 0.0 112.658 -178.284 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . 156.43 91.98 0.09 OUTLIER Glycine 0 N--CA 1.444 -0.77 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.184 -178.34 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 116.41 -95.41 0.68 Allowed Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 121.012 -0.613 . . . . 0.0 111.827 178.321 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 298' ' ' SER . . . . . 0.619 ' HB2' HD23 ' A' ' 294' ' ' LEU . 15.5 m -64.23 137.94 58.19 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.017 0.437 . . . . 0.0 110.316 178.959 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 299' ' ' TYR . . . . . . . . . . . . . 19.3 p90 -113.13 175.04 5.61 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.26 -172.359 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 300' ' ' ALA . . . . . 0.685 ' HB3' ' HB2' ' A' ' 293' ' ' LYS . . . -80.52 113.72 18.9 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.938 179.25 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 301' ' ' LEU . . . . . 0.886 ' HB3' ' HB3' ' A' ' 279' ' ' ALA . 0.3 OUTLIER -80.19 166.77 21.1 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 122.014 0.912 . . . . 0.0 112.157 -172.548 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 302' ' ' ARG . . . . . 1.002 ' HA ' ' HB3' ' A' ' 289' ' ' TYR . 14.9 mmt180 -137.71 122.74 19.06 Favored 'General case' 0 C--N 1.31 -1.121 0 CA-C-N 114.456 -1.247 . . . . 0.0 108.275 -178.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 303' ' ' VAL . . . . . 0.661 ' O ' ' HA ' ' A' ' 289' ' ' TYR . 9.2 p -145.12 138.92 22.19 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.329 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -178.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 304' ' ' GLN . . . . . . . . . . . . . 50.6 mt-30 -90.12 162.12 15.45 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 172.813 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -94.42 115.23 4.99 Favored Glycine 0 N--CA 1.444 -0.814 0 C-N-CA 120.379 -0.915 . . . . 0.0 112.088 -175.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 306' ' ' GLU . . . . . 0.508 ' O ' ' HA2' ' A' ' 395' ' ' GLY . 7.3 pt-20 -116.48 173.03 3.3 Favored Pre-proline 0 C--N 1.323 -0.587 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 178.829 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . 0.42 ' HD2' ' HB2' ' A' ' 306' ' ' GLU . 52.8 Cg_exo -56.52 124.51 16.43 Favored 'Trans proline' 0 CA--C 1.533 0.441 0 C-N-CA 122.008 1.805 . . . . 0.0 112.672 174.339 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . 0.621 ' HB3' ' O ' ' A' ' 394' ' ' TYR . . . -47.51 153.88 0.5 Allowed 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 121.137 0.494 . . . . 0.0 111.965 170.091 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 309' ' ' LYS . . . . . 0.661 ' O ' ' HG ' ' A' ' 313' ' ' LEU . 65.9 mmtt -91.76 88.28 6.62 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 178.157 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 310' ' ' GLY . . . . . 0.599 ' HA3' ' HA2' ' A' ' 374' ' ' GLY . . . -58.31 -40.22 93.73 Favored Glycine 0 C--N 1.333 0.41 0 C-N-CA 121.616 -0.326 . . . . 0.0 113.818 -171.213 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . 0.406 ' HG2' ' HG2' ' A' ' 312' ' ' MET . 0.2 OUTLIER -72.61 -19.97 61.37 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.818 0.342 . . . . 0.0 110.95 -178.4 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 312' ' ' MET . . . . . 0.406 ' HG2' ' HG2' ' A' ' 311' ' ' GLU . 78.3 mmm -108.43 6.48 26.3 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.812 0.339 . . . . 0.0 111.192 -178.687 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 313' ' ' LEU . . . . . 0.661 ' HG ' ' O ' ' A' ' 309' ' ' LYS . 91.9 mt -75.47 133.8 40.99 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 175.224 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -151.61 139.4 19.85 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.773 -172.939 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.23 161.81 11.63 Favored Glycine 0 N--CA 1.448 -0.556 0 N-CA-C 111.306 -0.718 . . . . 0.0 111.306 178.822 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 21.7 p -97.82 135.01 40.19 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 173.044 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -133.47 151.51 51.79 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.78 -172.166 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -120.75 110.4 28.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.439 -0.8 . . . . 0.0 109.384 175.956 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . 0.749 ' HH ' ' HZ ' ' A' ' 346' ' ' PHE . 90.9 m-85 -99.18 127.49 45.16 Favored 'General case' 0 C--N 1.312 -1.04 0 C-N-CA 120.327 -0.549 . . . . 0.0 110.424 178.327 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 48.0 m-80 -120.85 132.74 55.17 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.377 178.834 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . 0.566 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -166.53 -154.18 8.2 Favored Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.54 -179.598 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 3.7 mp0 -116.12 153.95 30.87 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.056 0.455 . . . . 0.0 111.122 -174.168 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 323' ' ' VAL . . . . . 0.524 HG22 ' HB2' ' A' ' 340' ' ' PHE . 72.5 t -112.06 117.44 55.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.355 -0.839 . . . . 0.0 109.208 172.397 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 324' ' ' LEU . . . . . 0.458 ' HB2' HG23 ' A' ' 419' ' ' VAL . 93.7 mt -95.69 104.31 16.22 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.129 0.49 . . . . 0.0 110.298 -177.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 325' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -98.52 113.98 26.21 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 179.512 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 326' ' ' PHE . . . . . 0.524 ' HD2' ' H ' ' A' ' 418' ' ' GLY . 57.9 m-85 -89.29 150.08 22.76 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.377 -174.954 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 327' ' ' HIS . . . . . . . . . . . . . 1.8 p-80 -157.92 115.64 3.02 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.886 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 328' ' ' THR . . . . . . . . . . . . . 6.5 p -89.31 99.57 12.54 Favored 'General case' 0 N--CA 1.445 -0.724 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 173.214 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 329' ' ' GLU . . . . . 0.494 ' HG3' ' HD3' ' A' ' 332' ' ' ARG . 63.9 mm-40 -104.6 173.38 6.33 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.043 -177.097 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 330' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -60.77 -58.45 8.38 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 177.086 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 331' ' ' GLY . . . . . . . . . . . . . . . -143.68 89.39 0.17 Allowed Glycine 0 N--CA 1.446 -0.637 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 174.064 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 332' ' ' ARG . . . . . 0.494 ' HD3' ' HG3' ' A' ' 329' ' ' GLU . 77.7 ttt180 -177.74 78.06 0.23 Allowed Pre-proline 0 C--N 1.325 -0.492 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -173.838 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 333' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -83.73 -179.47 4.16 Favored 'Trans proline' 0 N--CA 1.46 -0.452 0 C-N-CA 122.946 2.431 . . . . 0.0 113.031 -175.548 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 334' ' ' TYR . . . . . 0.435 ' HA ' ' HD3' ' A' ' 335' ' ' PRO . 79.2 m-85 73.5 116.51 0.03 OUTLIER Pre-proline 0 C--O 1.235 0.293 0 CA-C-N 115.094 -0.957 . . . . 0.0 112.076 176.812 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 335' ' ' PRO . . . . . 0.435 ' HD3' ' HA ' ' A' ' 334' ' ' TYR . 13.8 Cg_exo -68.87 128.82 17.45 Favored 'Trans proline' 0 N--CA 1.461 -0.44 0 C-N-CA 122.817 2.345 . . . . 0.0 111.056 175.229 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 336' ' ' THR . . . . . . . . . . . . . 23.2 p -70.89 139.22 50.71 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.332 -178.158 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 337' ' ' ARG . . . . . . . . . . . . . 51.9 mtm180 -101.42 112.31 24.8 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.911 0.386 . . . . 0.0 110.268 -177.721 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -90.52 -177.13 44.36 Favored Glycine 0 N--CA 1.44 -1.08 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 172.827 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 339' ' ' ARG . . . . . 0.864 ' HB2' ' HB3' ' A' ' 356' ' ' ASP . 65.1 mtt180 -104.49 154.92 19.28 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 176.237 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 340' ' ' PHE . . . . . 0.524 ' HB2' HG22 ' A' ' 323' ' ' VAL . 27.0 t80 -148.74 139.02 22.42 Favored 'General case' 0 C--N 1.309 -1.16 0 CA-C-O 121.165 0.507 . . . . 0.0 110.494 179.161 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 341' ' ' ALA . . . . . 0.69 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -136.84 164.2 28.87 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 114.967 -1.015 . . . . 0.0 108.908 175.809 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . 0.846 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -151.76 120.11 6.39 Favored 'General case' 0 C--N 1.314 -0.943 0 N-CA-C 109.654 -0.499 . . . . 0.0 109.654 -179.758 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 13.0 tptm -100.81 98.43 8.95 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 344' ' ' VAL . . . . . 0.485 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.2 OUTLIER -118.45 136.93 54.05 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 CA-C-N 115.833 -0.621 . . . . 0.0 112.176 -169.576 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 10.4 t0 -107.23 113.0 26.13 Favored 'General case' 0 C--N 1.321 -0.63 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 171.194 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 346' ' ' PHE . . . . . 0.749 ' HZ ' ' HH ' ' A' ' 319' ' ' TYR . 48.4 m-85 -74.77 -27.64 60.42 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 111.701 0.26 . . . . 0.0 111.701 -176.091 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -61.87 -33.36 85.13 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.695 -0.764 . . . . 0.0 111.654 177.198 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 6.8 t -101.59 -4.48 26.57 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-O 120.688 0.28 . . . . 0.0 111.083 178.162 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 349' ' ' LYS . . . . . 0.479 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 10.0 mtmp? 51.28 59.05 4.88 Favored 'General case' 0 N--CA 1.466 0.362 0 C-N-CA 123.148 0.579 . . . . 0.0 111.543 -178.265 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 40.2 m -149.6 140.51 22.83 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.14 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 351' ' ' VAL . . . . . 0.485 ' HB ' ' HB ' ' A' ' 344' ' ' VAL . 0.8 OUTLIER -129.08 156.43 41.68 Favored 'Isoleucine or valine' 0 C--O 1.236 0.369 0 CA-C-O 121.289 0.566 . . . . 0.0 111.147 -175.665 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 352' ' ' ASP . . . . . 0.846 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 17.9 t70 -111.72 119.19 37.79 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.981 -1.009 . . . . 0.0 108.414 166.493 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -111.31 120.81 5.57 Favored Glycine 0 C--N 1.306 -1.11 0 C-N-CA 120.621 -0.8 . . . . 0.0 111.369 -178.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 354' ' ' ILE . . . . . 0.518 HG12 ' N ' ' A' ' 355' ' ' ILE . 0.2 OUTLIER -121.29 140.9 43.96 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.233 0 CA-C-O 121.084 0.469 . . . . 0.0 110.577 -176.233 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 355' ' ' ILE . . . . . 0.89 ' HB ' ' HB2' ' A' ' 366' ' ' GLN . 3.1 mp -114.2 98.27 6.74 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.26 177.614 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 356' ' ' ASP . . . . . 0.864 ' HB3' ' HB2' ' A' ' 339' ' ' ARG . 18.5 t70 -78.68 92.3 4.75 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.061 -0.972 . . . . 0.0 108.908 178.217 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 81.2 p -70.56 -29.37 65.8 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.392 -174.057 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 358' ' ' GLY . . . . . . . . . . . . . . . 94.87 -5.56 69.22 Favored Glycine 0 N--CA 1.444 -0.785 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 -174.365 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 359' ' ' ASP . . . . . . . . . . . . . 25.9 t70 -129.18 26.89 5.42 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 122.106 0.955 . . . . 0.0 108.459 176.754 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 360' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -61.12 -28.78 69.34 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 114.58 -1.191 . . . . 0.0 111.121 -176.816 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 361' ' ' LEU . . . . . 0.421 HD23 ' N ' ' A' ' 361' ' ' LEU . 3.2 mm? -73.76 -27.0 60.94 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-N 115.965 -0.562 . . . . 0.0 111.643 179.623 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 362' ' ' HIS . . . . . . . . . . . . . 72.4 m-70 -100.7 -73.35 0.64 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.711 0.291 . . . . 0.0 110.654 -175.641 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 363' ' ' MET . . . . . . . . . . . . . 53.9 ttp -66.25 -47.61 73.16 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.612 -179.584 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 364' ' ' GLY . . . . . . . . . . . . . . . 139.68 160.48 8.36 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.978 -0.63 . . . . 0.0 111.738 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 365' ' ' THR . . . . . . . . . . . . . 8.9 t -92.82 152.64 19.32 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 179.265 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 366' ' ' GLN . . . . . 0.89 ' HB2' ' HB ' ' A' ' 355' ' ' ILE . 41.2 mt-30 -114.65 130.83 56.85 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 179.069 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 367' ' ' LYS . . . . . 0.783 ' HB3' ' HG2' ' A' ' 383' ' ' GLU . 26.2 ttmt -148.43 139.8 23.43 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.181 -0.463 . . . . 0.0 109.752 -178.777 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 368' ' ' PHE . . . . . . . . . . . . . 52.3 p90 -139.06 145.12 39.18 Favored 'General case' 0 C--N 1.321 -0.663 0 O-C-N 123.33 0.394 . . . . 0.0 110.365 176.69 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 369' ' ' LYS . . . . . 0.415 ' HE2' ' HD3' ' A' ' 367' ' ' LYS . 3.4 mptp? -106.74 131.94 53.29 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 175.626 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . 0.482 ' HB3' HG22 ' A' ' 351' ' ' VAL . . . -135.64 135.89 40.54 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.549 -172.325 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -92.89 133.88 35.65 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.761 176.233 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 372' ' ' ILE . . . . . 0.479 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 87.4 mt -82.17 108.11 14.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 121.191 0.52 . . . . 0.0 110.405 -178.961 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -109.61 81.18 1.4 Allowed 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.485 -0.78 . . . . 0.0 109.096 178.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 374' ' ' GLY . . . . . 0.599 ' HA2' ' HA3' ' A' ' 310' ' ' GLY . . . 53.79 118.95 0.01 OUTLIER Glycine 0 CA--C 1.524 0.61 0 CA-C-N 114.992 -1.004 . . . . 0.0 114.841 -176.108 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 375' ' ' ASN . . . . . 0.52 ' HB2' ' O ' ' A' ' 308' ' ' ALA . 40.2 t30 40.69 44.28 1.81 Allowed 'General case' 0 N--CA 1.47 0.566 0 CA-C-O 122.053 0.93 . . . . 0.0 112.182 175.506 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 156.66 167.79 18.41 Favored Glycine 0 N--CA 1.442 -0.931 0 C-N-CA 120.302 -0.952 . . . . 0.0 111.608 176.065 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 377' ' ' PHE . . . . . 0.446 ' CD2' HG11 ' A' ' 351' ' ' VAL . 2.3 p90 -133.44 143.8 49.08 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-O 121.34 0.59 . . . . 0.0 111.5 -179.18 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 378' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.67 125.29 47.31 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 114.887 -1.051 . . . . 0.0 108.262 174.983 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -142.26 -165.3 10.47 Favored Glycine 0 N--CA 1.44 -1.055 0 C-N-CA 120.361 -0.923 . . . . 0.0 112.587 -176.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 95.4 m -142.46 147.05 35.45 Favored 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 -176.719 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 381' ' ' TRP . . . . . 0.609 ' HB3' ' HB3' ' A' ' 384' ' ' ASN . 42.0 m95 -56.25 117.37 3.72 Favored 'General case' 0 C--N 1.331 -0.214 0 O-C-N 123.633 0.583 . . . . 0.0 111.43 178.9 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 382' ' ' THR . . . . . . . . . . . . . 71.0 m -83.49 -58.18 2.93 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.803 -176.742 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 383' ' ' GLU . . . . . 0.783 ' HG2' ' HB3' ' A' ' 367' ' ' LYS . 57.9 mm-40 -85.82 53.99 2.97 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.694 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 384' ' ' ASN . . . . . 0.609 ' HB3' ' HB3' ' A' ' 381' ' ' TRP . 4.6 t30 -175.7 -45.04 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.113 -176.587 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 385' ' ' GLY . . . . . . . . . . . . . . . 60.24 55.74 28.46 Favored Glycine 0 C--N 1.331 0.29 0 C-N-CA 120.636 -0.792 . . . . 0.0 111.417 -176.387 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 386' ' ' GLY . . . . . . . . . . . . . . . -118.01 -96.73 1.83 Allowed Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.608 -0.806 . . . . 0.0 113.153 -173.787 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -107.37 -170.86 22.12 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.539 -0.839 . . . . 0.0 113.327 -174.322 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 388' ' ' ASP . . . . . 0.55 ' HB2' ' HB3' ' A' ' 406' ' ' SER . 6.6 m-20 -89.73 159.07 17.25 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 -177.407 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 79.6 t -135.67 135.99 50.75 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 174.166 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 16.9 m -143.11 141.68 31.3 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.8 0.334 . . . . 0.0 110.692 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 391' ' ' GLY . . . . . 0.422 ' HA2' ' CA ' ' A' ' 403' ' ' GLY . . . -145.36 155.9 26.7 Favored Glycine 0 C--N 1.316 -0.581 0 N-CA-C 111.487 -0.645 . . . . 0.0 111.487 -178.515 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 392' ' ' ARG . . . . . 0.501 ' HD3' ' O ' ' A' ' 375' ' ' ASN . 25.0 tpp180 -117.07 135.62 53.59 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.768 0.318 . . . . 0.0 110.24 -175.751 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -85.12 165.23 17.63 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.951 176.317 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 394' ' ' TYR . . . . . 0.621 ' O ' ' HB3' ' A' ' 308' ' ' ALA . 4.8 m-85 -109.58 -177.38 3.26 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.99 -177.947 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 395' ' ' GLY . . . . . 0.508 ' HA2' ' O ' ' A' ' 306' ' ' GLU . . . -37.83 160.72 0.01 OUTLIER Glycine 0 C--N 1.336 0.541 0 O-C-N 124.492 1.12 . . . . 0.0 114.922 -176.625 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_exo -17.25 -40.46 0.0 OUTLIER 'Trans proline' 0 C--N 1.353 0.78 1 C-N-CA 127.773 5.649 . . . . 0.0 118.501 -165.122 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 397' ' ' ALA . . . . . 0.499 ' HB3' ' HG3' ' A' ' 399' ' ' GLU . . . -81.16 -20.24 41.69 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 118.754 0.706 . . . . 0.0 111.633 -171.536 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 60.96 10.63 20.78 Favored Glycine 0 C--N 1.338 0.682 0 C-N-CA 121.409 -0.424 . . . . 0.0 112.725 176.668 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 399' ' ' GLU . . . . . 0.502 ' OE2' ' HG2' ' A' ' 424' ' ' LYS . 30.5 mt-10 -70.19 -8.93 53.82 Favored 'General case' 0 N--CA 1.451 -0.406 0 CA-C-O 121.66 0.743 . . . . 0.0 110.123 -178.378 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -117.54 128.36 54.89 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.82 175.16 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 401' ' ' VAL . . . . . 0.443 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 10.1 p -140.87 140.49 32.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.844 0.354 . . . . 0.0 110.517 177.888 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -142.16 131.34 23.38 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.269 178.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 403' ' ' GLY . . . . . 0.422 ' CA ' ' HA2' ' A' ' 391' ' ' GLY . . . -145.02 -169.04 13.2 Favored Glycine 0 N--CA 1.438 -1.18 0 C-N-CA 120.47 -0.872 . . . . 0.0 112.271 -177.153 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 404' ' ' LYS . . . . . 0.792 ' HG2' HG11 ' A' ' 419' ' ' VAL . 37.5 mtpt -148.8 169.11 21.22 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 -178.344 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 5.8 m-85 -113.54 134.75 54.52 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 177.287 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 406' ' ' SER . . . . . 0.55 ' HB3' ' HB2' ' A' ' 388' ' ' ASP . 47.5 t -95.04 103.65 15.5 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 86.6 m-85 -82.95 105.96 14.38 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.281 0.563 . . . . 0.0 110.329 -179.62 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 408' ' ' ARG . . . . . 0.571 ' HB2' ' HD3' ' A' ' 409' ' ' PRO . 98.3 mtt180 -62.21 -47.63 89.59 Favored Pre-proline 0 CA--C 1.536 0.408 0 CA-C-N 115.07 -0.968 . . . . 0.0 111.938 -179.782 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 409' ' ' PRO . . . . . 0.571 ' HD3' ' HB2' ' A' ' 408' ' ' ARG . 12.4 Cg_exo -71.83 56.73 2.43 Favored 'Trans proline' 0 C--N 1.358 1.068 0 C-N-CA 122.312 2.008 . . . . 0.0 112.848 178.09 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 410' ' ' THR . . . . . . . . . . . . . 2.0 p -109.21 -58.09 2.08 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.585 173.627 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 411' ' ' ASP . . . . . . . . . . . . . 37.1 t70 -172.14 -67.22 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.371 175.649 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 412' ' ' ALA . . . . . . . . . . . . . . . -161.24 -48.47 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.877 -0.601 . . . . 0.0 109.668 176.459 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 413' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -77.62 82.89 4.02 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 173.928 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 414' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -85.46 123.02 30.43 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.368 0.604 . . . . 0.0 111.777 -175.547 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 415' ' ' GLY . . . . . . . . . . . . . . . 147.1 133.36 2.4 Favored Glycine 0 N--CA 1.447 -0.574 0 CA-C-N 115.41 -0.814 . . . . 0.0 111.423 177.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 416' ' ' GLY . . . . . . . . . . . . . . . 164.96 -105.56 0.25 Allowed Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.289 -0.958 . . . . 0.0 112.481 178.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 417' ' ' PHE . . . . . 0.464 ' HB2' ' HB2' ' A' ' 326' ' ' PHE . 35.2 p90 -68.49 167.08 15.59 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.973 0.416 . . . . 0.0 111.144 -178.304 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 418' ' ' GLY . . . . . 0.524 ' H ' ' HD2' ' A' ' 326' ' ' PHE . . . 83.93 76.49 1.16 Allowed Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.3 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 419' ' ' VAL . . . . . 0.792 HG11 ' HG2' ' A' ' 404' ' ' LYS . 16.0 m -115.64 160.06 15.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 110.429 -0.211 . . . . 0.0 110.429 178.992 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 38.7 p90 -138.41 158.65 43.86 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.068 0.461 . . . . 0.0 110.506 178.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 421' ' ' ALA . . . . . 0.566 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -146.44 136.68 23.7 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.346 176.627 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -130.34 139.97 11.38 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.566 -0.826 . . . . 0.0 111.71 -179.365 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 72.1 mttt -117.66 136.4 53.35 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.173 0.511 . . . . 0.0 110.616 179.476 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 424' ' ' LYS . . . . . 0.502 ' HG2' ' OE2' ' A' ' 399' ' ' GLU . 23.0 tptm -59.0 125.82 25.17 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 114.838 -1.074 . . . . 0.0 113.126 -174.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -88.29 118.06 27.63 Favored 'General case' 0 N--CA 1.446 -0.651 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 166.27 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 426' ' ' GLN . . . . . . . . . . . . . 26.4 mp0 -67.03 144.43 56.17 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.213 0.53 . . . . 0.0 110.85 -177.096 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 427' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -84.54 26.48 0.79 Allowed 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.884 -177.273 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 62.1 tp -65.09 -52.8 53.4 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.965 -178.548 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 429' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 54.4 63.04 2.3 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-O 121.664 0.745 . . . . 0.0 109.954 -178.25 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 430' ' ' HIS . . . . . . . . . . . . . 72.8 t60 -70.11 -49.59 49.26 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.426 -178.07 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 32.0 t-80 -175.84 -52.74 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 177.699 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 432' ' ' HIS . . . . . . . . . . . . . 51.6 t60 -68.34 139.7 55.88 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.481 173.517 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 433' ' ' HIS . . . . . . . . . . . . . 6.0 t-160 64.1 69.36 0.53 Allowed 'General case' 0 N--CA 1.463 0.194 0 O-C-N 123.707 0.629 . . . . 0.0 109.82 179.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 434' ' ' HIS . . . . . . . . . . . . . 1.6 t-80 -75.56 -12.63 60.26 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.601 -175.937 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 435' ' ' HIS . . . . . . . . . . . . . 5.8 t60 . . . . . 0 C--O 1.247 0.943 0 CA-C-O 118.644 -0.693 . . . . 0.0 109.655 -179.889 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 276' ' ' ASN . . . . . . . . . . . . . 7.6 t30 . . . . . 0 N--CA 1.479 0.976 0 CA-C-O 120.404 0.145 . . . . 0.0 111.055 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 38.1 pt -80.03 38.36 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.434 0 N-CA-C 113.674 0.991 . . . . 0.0 113.674 -172.379 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 278' ' ' PHE . . . . . 0.434 ' HE1' ' HA3' ' A' ' 290' ' ' GLY . 10.4 p90 -80.77 -11.63 59.58 Favored 'General case' 0 C--N 1.327 -0.396 0 O-C-N 122.198 -0.314 . . . . 0.0 111.821 -178.503 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 279' ' ' ALA . . . . . 0.612 ' HB3' ' HA ' ' A' ' 304' ' ' GLN . . . -126.95 78.22 74.19 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 120.902 0.382 . . . . 0.0 110.151 176.335 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 280' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -83.97 120.62 2.67 Favored 'Trans proline' 0 N--CA 1.457 -0.628 0 C-N-CA 122.629 2.219 . . . . 0.0 113.635 -175.551 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 5.3 mm-40 72.76 161.92 0.25 Allowed 'General case' 0 N--CA 1.469 0.507 0 CA-C-O 121.635 0.731 . . . . 0.0 112.91 174.093 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 87.07 99.12 0.84 Allowed Glycine 0 N--CA 1.444 -0.786 0 CA-C-N 115.031 -0.986 . . . . 0.0 112.329 179.563 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 283' ' ' ASN . . . . . . . . . . . . . 62.1 t30 -79.33 83.5 5.35 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.942 0.401 . . . . 0.0 110.29 178.28 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . 0.943 ' HB2' HG22 ' A' ' 303' ' ' VAL . 55.6 m-85 -101.08 146.79 26.99 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 175.866 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 38.2 ttp180 -132.67 18.76 4.26 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.347 0.594 . . . . 0.0 110.521 -173.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 77.8 m-85 -137.13 35.92 2.55 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.656 0.741 . . . . 0.0 110.013 -177.085 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . 0.452 ' HB2' ' HB ' ' A' ' 303' ' ' VAL . 36.7 mt -134.77 -179.59 5.7 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 114.624 -1.171 . . . . 0.0 110.668 -177.021 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 288' ' ' THR . . . . . . . . . . . . . 2.8 m -70.86 149.57 46.66 Favored 'General case' 0 C--O 1.218 -0.587 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 178.158 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 289' ' ' TYR . . . . . 0.581 ' HA ' ' HA ' ' A' ' 303' ' ' VAL . 2.0 m-85 -102.29 150.22 23.53 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 121.878 0.847 . . . . 0.0 112.927 -169.59 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . 0.434 ' HA3' ' HE1' ' A' ' 278' ' ' PHE . . . -156.93 -153.22 6.57 Favored Glycine 0 N--CA 1.44 -1.038 0 CA-C-N 113.852 -1.522 . . . . 0.0 110.436 -173.983 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 291' ' ' ALA . . . . . . . . . . . . . . . -121.65 154.08 37.29 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.267 0.556 . . . . 0.0 112.322 -176.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 292' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -133.64 158.2 43.82 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 173.45 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 293' ' ' LYS . . . . . . . . . . . . . 28.1 tptp -103.58 135.75 44.59 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.129 0.49 . . . . 0.0 111.451 -176.682 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 294' ' ' LEU . . . . . . . . . . . . . 69.7 mt -104.17 135.51 19.33 Favored Pre-proline 0 C--N 1.32 -0.69 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.204 173.607 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 295' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -54.25 106.14 0.16 Allowed 'Trans proline' 0 C--O 1.234 0.312 0 C-N-CA 122.943 2.429 . . . . 0.0 112.267 -179.329 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . 129.65 -139.39 10.92 Favored Glycine 0 N--CA 1.444 -0.783 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 -177.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . -108.42 38.23 3.43 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.875 -0.679 . . . . 0.0 112.527 -179.334 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 298' ' ' SER . . . . . . . . . . . . . 20.1 m -127.49 151.01 49.4 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.14 0.495 . . . . 0.0 111.447 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 299' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -117.95 154.2 32.33 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.458 174.982 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 300' ' ' ALA . . . . . . . . . . . . . . . -122.4 149.44 43.81 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.667 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 301' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -110.55 115.3 29.37 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.358 0.599 . . . . 0.0 110.171 178.853 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 302' ' ' ARG . . . . . 0.662 ' HG3' ' H ' ' A' ' 303' ' ' VAL . 16.4 tpp180 -146.94 -178.89 6.44 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 303' ' ' VAL . . . . . 0.943 HG22 ' HB2' ' A' ' 284' ' ' TYR . 33.6 m -70.05 142.58 15.67 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.897 0 CA-C-O 121.709 0.766 . . . . 0.0 112.397 -171.419 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 304' ' ' GLN . . . . . 0.612 ' HA ' ' HB3' ' A' ' 279' ' ' ALA . 0.7 OUTLIER -91.43 120.8 32.58 Favored 'General case' 0 N--CA 1.444 -0.745 0 CA-C-N 114.543 -1.208 . . . . 0.0 108.16 172.82 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -94.95 144.73 17.36 Favored Glycine 0 N--CA 1.44 -1.046 0 C-N-CA 120.121 -1.038 . . . . 0.0 113.146 -172.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 306' ' ' GLU . . . . . 0.634 ' O ' ' HA2' ' A' ' 395' ' ' GLY . 5.4 mm-40 -114.73 86.3 12.76 Favored Pre-proline 0 C--N 1.32 -0.682 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 173.541 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo -60.98 122.87 11.86 Favored 'Trans proline' 0 N--CA 1.461 -0.404 0 C-N-CA 122.458 2.105 . . . . 0.0 112.249 -174.784 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . 0.776 ' O ' ' HB3' ' A' ' 375' ' ' ASN . . . -49.09 160.42 0.21 Allowed 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.148 169.291 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 309' ' ' LYS . . . . . 0.602 ' N ' HD21 ' A' ' 313' ' ' LEU . 79.2 mttt -127.01 91.46 3.34 Favored 'General case' 0 C--O 1.217 -0.611 0 O-C-N 121.798 -0.564 . . . . 0.0 109.817 -176.564 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -56.74 -23.46 44.47 Favored Glycine 0 CA--C 1.52 0.391 0 N-CA-C 114.873 0.709 . . . . 0.0 114.873 -168.298 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -87.65 -12.03 46.7 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 117.44 0.62 . . . . 0.0 111.574 178.392 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 14.8 tpt -115.5 -35.57 4.54 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.767 0.794 . . . . 0.0 109.511 -175.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 313' ' ' LEU . . . . . 0.759 HD23 ' HB3' ' A' ' 308' ' ' ALA . 0.4 OUTLIER -83.39 134.85 34.87 Favored 'General case' 0 N--CA 1.436 -1.169 0 CA-C-N 114.717 -1.128 . . . . 0.0 108.057 176.147 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 314' ' ' ALA . . . . . 0.624 ' HA ' ' CB ' ' A' ' 346' ' ' PHE . . . -161.91 173.18 14.85 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.177 0.513 . . . . 0.0 112.187 -170.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 121.71 168.67 13.43 Favored Glycine 0 N--CA 1.448 -0.531 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.277 -177.412 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 14.0 p -100.24 130.41 46.36 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 117.409 0.604 . . . . 0.0 109.94 174.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 317' ' ' ALA . . . . . 0.406 ' CB ' ' HE3' ' A' ' 424' ' ' LYS . . . -139.62 150.62 45.19 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 112.241 0.46 . . . . 0.0 112.241 -170.688 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 7.5 p -125.68 122.48 62.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.229 175.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 19.5 m-85 -111.99 146.61 37.55 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.732 -178.464 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 320' ' ' ASN . . . . . 0.618 HD21 ' HG3' ' A' ' 425' ' ' GLU . 43.4 m-80 -129.97 137.29 50.23 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.108 175.665 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . 0.592 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -162.52 -163.02 14.33 Favored Glycine 0 N--CA 1.44 -1.055 0 C-N-CA 120.344 -0.932 . . . . 0.0 112.697 -178.745 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -117.93 146.17 44.16 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.654 0.264 . . . . 0.0 110.33 -175.305 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 323' ' ' VAL . . . . . 0.638 HG23 ' HB2' ' A' ' 340' ' ' PHE . 84.9 t -110.39 117.05 53.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.105 176.084 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 324' ' ' LEU . . . . . 0.426 HD12 ' CE1' ' A' ' 326' ' ' PHE . 0.2 OUTLIER -94.44 103.03 15.01 Favored 'General case' 0 C--N 1.312 -1.038 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 177.796 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 325' ' ' HIS . . . . . 0.42 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 8.3 p-80 -95.88 115.48 27.5 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.14 -179.199 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 326' ' ' PHE . . . . . 0.717 ' HB2' ' HD1' ' A' ' 417' ' ' PHE . 16.5 m-85 -95.5 158.51 15.42 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.895 -175.283 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 327' ' ' HIS . . . . . 0.664 ' HB2' ' HG3' ' A' ' 329' ' ' GLU . 19.0 m80 -135.67 159.67 40.92 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 107.861 -1.163 . . . . 0.0 107.861 174.129 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 328' ' ' THR . . . . . . . . . . . . . 11.0 m -82.68 93.69 7.42 Favored 'General case' 0 N--CA 1.442 -0.828 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 170.099 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 329' ' ' GLU . . . . . 0.664 ' HG3' ' HB2' ' A' ' 327' ' ' HIS . 43.9 mt-10 -110.2 174.36 5.9 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.232 -0.894 . . . . 0.0 111.548 -173.549 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 330' ' ' ASN . . . . . . . . . . . . . 28.2 p30 -72.93 -10.75 60.14 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.954 -177.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 331' ' ' GLY . . . . . . . . . . . . . . . -144.9 160.54 28.02 Favored Glycine 0 N--CA 1.445 -0.706 0 C-N-CA 120.953 -0.641 . . . . 0.0 111.604 178.967 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 332' ' ' ARG . . . . . 0.543 ' HA ' ' HD3' ' A' ' 332' ' ' ARG . 11.1 mmt180 -92.03 -11.61 0.17 Allowed Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 114.393 1.257 . . . . 0.0 114.393 178.88 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 333' ' ' PRO . . . . . 0.464 ' CD ' ' N ' ' A' ' 332' ' ' ARG . 39.0 Cg_exo -66.31 -151.13 0.02 OUTLIER 'Trans proline' 0 C--N 1.357 1.001 0 CA-C-N 120.819 1.328 . . . . 0.0 111.027 160.025 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 334' ' ' TYR . . . . . 0.612 ' N ' ' HD3' ' A' ' 335' ' ' PRO . 98.0 m-85 59.99 49.13 2.1 Favored Pre-proline 0 CA--C 1.537 0.479 0 N-CA-C 112.625 0.602 . . . . 0.0 112.625 178.995 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 335' ' ' PRO . . . . . 0.612 ' HD3' ' N ' ' A' ' 334' ' ' TYR . 6.1 Cg_endo -87.06 127.53 2.57 Favored 'Trans proline' 0 N--CA 1.452 -0.939 0 C-N-CA 121.833 1.688 . . . . 0.0 111.439 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 336' ' ' THR . . . . . . . . . . . . . 1.1 p -118.96 139.1 52.23 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.113 0.482 . . . . 0.0 111.388 179.475 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 337' ' ' ARG . . . . . 0.437 ' HA ' ' O ' ' A' ' 323' ' ' VAL . 17.4 ptp180 -119.25 142.92 47.61 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.786 -175.241 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -113.21 -176.69 19.49 Favored Glycine 0 N--CA 1.443 -0.869 0 CA-C-N 115.422 -0.808 . . . . 0.0 111.554 178.226 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 339' ' ' ARG . . . . . 0.411 ' HB2' ' HB3' ' A' ' 356' ' ' ASP . 73.6 mtt180 -104.91 131.16 52.76 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 120.747 0.308 . . . . 0.0 110.358 -175.085 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 340' ' ' PHE . . . . . 0.638 ' HB2' HG23 ' A' ' 323' ' ' VAL . 55.2 t80 -132.85 137.27 46.65 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-O 121.252 0.548 . . . . 0.0 111.472 -176.346 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 341' ' ' ALA . . . . . . . . . . . . . . . -139.48 143.85 37.71 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.137 -0.938 . . . . 0.0 108.999 174.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . 0.925 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -136.33 120.04 17.26 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-O 121.039 0.447 . . . . 0.0 110.84 -177.012 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -102.43 102.86 13.21 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.327 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 344' ' ' VAL . . . . . 0.434 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.3 OUTLIER -115.95 124.78 72.67 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 CA-C-O 121.6 0.714 . . . . 0.0 111.83 -172.649 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -97.44 98.59 10.07 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 172.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 346' ' ' PHE . . . . . 0.624 ' CB ' ' HA ' ' A' ' 314' ' ' ALA . 72.7 m-85 -65.27 -26.76 68.23 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.689 0.28 . . . . 0.0 111.259 -176.188 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -65.75 -19.57 67.44 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.831 -0.7 . . . . 0.0 111.843 178.001 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 11.9 t -112.03 -6.67 14.16 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.986 0.422 . . . . 0.0 110.058 177.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 349' ' ' LYS . . . . . 0.591 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 37.5 mtmm 52.61 59.12 4.71 Favored 'General case' 0 C--O 1.227 -0.098 0 CA-C-N 115.064 -0.971 . . . . 0.0 111.159 -176.013 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 68.1 p -149.32 138.35 21.3 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.181 179.809 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 351' ' ' VAL . . . . . 0.434 ' HB ' ' HB ' ' A' ' 344' ' ' VAL . 0.9 OUTLIER -123.89 151.77 28.95 Favored 'Isoleucine or valine' 0 C--O 1.235 0.334 0 CA-C-O 121.05 0.452 . . . . 0.0 110.789 -178.497 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 352' ' ' ASP . . . . . 0.925 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 21.3 t70 -112.02 118.4 35.33 Favored 'General case' 0 C--O 1.213 -0.857 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.353 173.444 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -119.82 119.01 4.1 Favored Glycine 0 N--CA 1.442 -0.925 0 C-N-CA 120.257 -0.973 . . . . 0.0 112.173 -176.781 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 354' ' ' ILE . . . . . 0.653 HD13 HG21 ' A' ' 365' ' ' THR . 0.0 OUTLIER -114.81 129.64 70.61 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.065 0 CA-C-O 121.038 0.447 . . . . 0.0 110.103 -178.125 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 355' ' ' ILE . . . . . 0.431 HD12 ' HE2' ' A' ' 368' ' ' PHE . 3.7 mp -120.7 113.87 41.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.159 -177.741 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 356' ' ' ASP . . . . . 0.411 ' HB3' ' HB2' ' A' ' 339' ' ' ARG . 10.2 t70 -102.79 141.78 35.02 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.429 176.024 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 23.2 t -110.88 8.72 22.32 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.384 178.309 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 358' ' ' GLY . . . . . . . . . . . . . . . 113.83 24.43 4.61 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.95 -0.643 . . . . 0.0 112.976 177.32 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 359' ' ' ASP . . . . . 0.405 ' HB3' ' N ' ' A' ' 364' ' ' GLY . 14.0 t70 -153.0 104.54 2.84 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.069 0.461 . . . . 0.0 110.726 178.9 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 360' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -83.56 -9.38 58.97 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-O 121.062 0.458 . . . . 0.0 111.09 -179.157 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 361' ' ' LEU . . . . . . . . . . . . . 90.5 mt -71.39 -35.6 71.1 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.809 -174.681 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 362' ' ' HIS . . . . . . . . . . . . . 55.7 t-80 -178.65 -43.72 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 111.818 0.303 . . . . 0.0 111.818 178.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 363' ' ' MET . . . . . . . . . . . . . 15.7 tpt -78.42 -37.94 42.63 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 112.516 0.561 . . . . 0.0 112.516 -167.472 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 364' ' ' GLY . . . . . 0.405 ' N ' ' HB3' ' A' ' 359' ' ' ASP . . . -88.79 -42.28 5.75 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 119.962 -1.114 . . . . 0.0 113.134 -170.291 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 365' ' ' THR . . . . . 0.653 HG21 HD13 ' A' ' 354' ' ' ILE . 89.7 m -84.4 98.97 10.35 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.267 0.556 . . . . 0.0 112.496 -175.039 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 -109.53 165.43 11.67 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 168.702 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 19.3 pttp -148.23 151.33 35.29 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.191 0.519 . . . . 0.0 111.631 -179.121 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 368' ' ' PHE . . . . . 0.646 ' CD1' HG22 ' A' ' 389' ' ' VAL . 27.2 p90 -134.99 161.45 35.24 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.195 -0.911 . . . . 0.0 109.189 179.238 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 33.3 mtmm -131.62 150.9 51.99 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-O 121.264 0.554 . . . . 0.0 110.513 173.619 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -141.55 139.84 33.29 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.164 -173.701 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -92.69 130.73 38.23 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 174.223 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 372' ' ' ILE . . . . . 0.655 ' HA ' ' HB3' ' A' ' 377' ' ' PHE . 83.4 mt -79.45 108.17 12.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-O 121.758 0.79 . . . . 0.0 110.585 -176.322 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -110.58 82.38 1.58 Allowed 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 114.647 -1.16 . . . . 0.0 109.495 -178.712 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 59.48 119.29 0.01 OUTLIER Glycine 0 CA--C 1.52 0.402 0 CA-C-N 114.928 -1.033 . . . . 0.0 113.776 -177.146 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 375' ' ' ASN . . . . . 0.776 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 2.2 p-10 28.85 44.6 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 124.734 1.214 . . . . 0.0 114.123 177.238 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 160.59 -178.77 36.47 Favored Glycine 0 N--CA 1.442 -0.906 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 -178.693 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 377' ' ' PHE . . . . . 0.655 ' HB3' ' HA ' ' A' ' 372' ' ' ILE . 6.3 p90 -153.51 150.66 28.96 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 117.362 0.581 . . . . 0.0 111.783 -178.787 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 378' ' ' LYS . . . . . 0.461 ' HD3' ' H ' ' A' ' 378' ' ' LYS . 0.0 OUTLIER -117.77 140.59 49.47 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 171.102 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 379' ' ' GLY . . . . . 0.527 ' C ' HG23 ' A' ' 389' ' ' VAL . . . -149.06 -155.13 6.59 Favored Glycine 0 N--CA 1.44 -1.062 0 C-N-CA 120.504 -0.855 . . . . 0.0 112.235 -172.852 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 380' ' ' THR . . . . . 0.439 ' HA ' ' HA ' ' A' ' 388' ' ' ASP . 7.0 t -170.99 154.49 4.17 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 -173.52 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 381' ' ' TRP . . . . . 0.671 ' HD1' ' HA3' ' A' ' 387' ' ' GLY . 39.4 m95 -65.78 132.66 49.26 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.422 -179.597 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 382' ' ' THR . . . . . . . . . . . . . 19.4 m -87.29 -23.12 24.77 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.846 176.782 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 383' ' ' GLU . . . . . . . . . . . . . 28.4 mm-40 -100.34 -19.43 16.31 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.633 -175.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 384' ' ' ASN . . . . . . . . . . . . . 14.9 m120 -114.09 166.27 11.79 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.907 0.384 . . . . 0.0 110.719 -174.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 385' ' ' GLY . . . . . . . . . . . . . . . -126.28 75.35 0.41 Allowed Glycine 0 N--CA 1.445 -0.721 0 N-CA-C 111.549 -0.62 . . . . 0.0 111.549 177.9 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 386' ' ' GLY . . . . . . . . . . . . . . . 147.72 40.32 0.04 OUTLIER Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.668 -0.777 . . . . 0.0 111.95 -177.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . 0.671 ' HA3' ' HD1' ' A' ' 381' ' ' TRP . . . -154.03 114.38 0.62 Allowed Glycine 0 N--CA 1.443 -0.881 0 C-N-CA 121.108 -0.568 . . . . 0.0 111.965 178.562 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 388' ' ' ASP . . . . . 0.439 ' HA ' ' HA ' ' A' ' 380' ' ' THR . 43.4 m-20 -107.73 147.33 30.92 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.027 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 389' ' ' VAL . . . . . 0.646 HG22 ' CD1' ' A' ' 368' ' ' PHE . 3.3 m -121.49 167.15 15.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 120.713 0.292 . . . . 0.0 111.589 -171.736 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 33.6 t -161.87 157.61 24.21 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 173.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -157.57 163.57 32.64 Favored Glycine 0 C--N 1.32 -0.308 0 N-CA-C 111.682 -0.567 . . . . 0.0 111.682 179.666 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 25.6 ttt180 -125.71 143.21 51.14 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.791 0.295 . . . . 0.0 110.313 -176.775 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 393' ' ' PHE . . . . . 0.582 ' CZ ' ' HE1' ' A' ' 346' ' ' PHE . 2.5 m-85 -92.92 157.45 16.34 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.432 0.634 . . . . 0.0 112.261 -175.433 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 394' ' ' TYR . . . . . 0.74 ' O ' ' HB1' ' A' ' 308' ' ' ALA . 1.2 m-85 -102.5 -176.5 3.12 Favored 'General case' 0 C--O 1.22 -0.5 0 CA-C-N 114.816 -1.083 . . . . 0.0 110.372 178.615 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 395' ' ' GLY . . . . . 0.634 ' HA2' ' O ' ' A' ' 306' ' ' GLU . . . -36.67 153.64 0.01 OUTLIER Glycine 0 C--N 1.335 0.479 0 O-C-N 124.394 1.059 . . . . 0.0 114.941 -176.879 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_exo -16.15 -50.63 0.02 OUTLIER 'Trans proline' 0 C--N 1.351 0.691 1 C-N-CA 127.453 5.435 . . . . 0.0 117.724 -165.911 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 397' ' ' ALA . . . . . 0.563 ' HB3' ' HG2' ' A' ' 399' ' ' GLU . . . -75.46 -16.72 60.29 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 112.377 0.51 . . . . 0.0 112.377 -171.504 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 68.49 24.92 75.1 Favored Glycine 0 N--CA 1.447 -0.591 0 N-CA-C 111.769 -0.532 . . . . 0.0 111.769 179.538 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 399' ' ' GLU . . . . . 0.563 ' HG2' ' HB3' ' A' ' 397' ' ' ALA . 10.9 mm-40 -58.86 -16.54 17.86 Favored 'General case' 0 N--CA 1.463 0.208 0 C-N-CA 123.248 0.619 . . . . 0.0 111.557 -175.488 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 35.1 mt-10 -138.53 146.72 42.27 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 172.613 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 401' ' ' VAL . . . . . 0.474 HG21 ' CE2' ' A' ' 377' ' ' PHE . 7.3 p -144.54 133.01 17.92 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.398 177.032 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -124.61 132.22 53.44 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.332 -178.694 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -146.86 -172.14 16.82 Favored Glycine 0 N--CA 1.44 -1.049 0 C-N-CA 120.498 -0.858 . . . . 0.0 112.088 -179.139 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 404' ' ' LYS . . . . . 0.74 ' HG2' HG12 ' A' ' 419' ' ' VAL . 30.1 mtmt -146.51 158.43 43.9 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 179.815 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 405' ' ' TYR . . . . . 0.474 ' HB3' HG12 ' A' ' 389' ' ' VAL . 17.6 p90 -119.83 134.25 55.3 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 121.222 0.534 . . . . 0.0 110.579 176.58 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 406' ' ' SER . . . . . 0.495 ' O ' ' HA2' ' A' ' 387' ' ' GLY . 41.9 t -94.56 104.52 16.47 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.399 -177.388 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 48.7 p90 -120.11 140.04 51.66 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 175.472 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 408' ' ' ARG . . . . . 0.611 ' HD3' ' O ' ' A' ' 408' ' ' ARG . 0.0 OUTLIER -101.58 111.53 64.0 Favored Pre-proline 0 C--N 1.32 -0.711 0 CA-C-O 121.392 0.615 . . . . 0.0 111.262 179.079 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 409' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -72.08 -34.26 8.5 Favored 'Trans proline' 0 N--CA 1.463 -0.318 0 C-N-CA 122.763 2.309 . . . . 0.0 110.585 172.889 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 410' ' ' THR . . . . . . . . . . . . . 27.9 m -150.27 -46.71 0.13 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.412 176.093 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 411' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -142.72 -174.09 4.06 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.602 -179.546 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 412' ' ' ALA . . . . . . . . . . . . . . . 70.48 106.16 0.06 Allowed 'General case' 0 N--CA 1.465 0.316 0 O-C-N 124.156 0.91 . . . . 0.0 111.703 -179.112 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 413' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -103.12 38.49 1.75 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.896 0.855 . . . . 0.0 109.01 177.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 414' ' ' LYS . . . . . . . . . . . . . 56.6 mtpt -124.58 158.89 31.92 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.018 -0.992 . . . . 0.0 109.554 -176.932 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 415' ' ' GLY . . . . . . . . . . . . . . . -86.27 131.99 10.86 Favored Glycine 0 N--CA 1.447 -0.622 0 C-N-CA 120.265 -0.969 . . . . 0.0 111.987 -178.115 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 416' ' ' GLY . . . . . . . . . . . . . . . -163.13 -59.1 0.02 OUTLIER Glycine 0 N--CA 1.447 -0.597 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.15 -178.082 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 417' ' ' PHE . . . . . 0.717 ' HD1' ' HB2' ' A' ' 326' ' ' PHE . 71.5 m-85 -87.64 145.92 25.96 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 178.591 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 418' ' ' GLY . . . . . 0.543 ' H ' ' HD2' ' A' ' 326' ' ' PHE . . . 81.8 76.86 1.06 Allowed Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 120.339 -0.934 . . . . 0.0 112.567 176.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 419' ' ' VAL . . . . . 0.74 HG12 ' HG2' ' A' ' 404' ' ' LYS . 18.9 m -106.43 152.84 7.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 N-CA-C 110.207 -0.294 . . . . 0.0 110.207 179.441 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 40.9 p90 -138.03 154.42 49.3 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 120.934 0.397 . . . . 0.0 110.273 -179.438 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 421' ' ' ALA . . . . . 0.592 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -142.24 136.02 29.42 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 177.112 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -118.1 135.6 11.76 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 120.67 -0.776 . . . . 0.0 111.974 -179.046 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 63.9 mttm -113.37 133.68 55.03 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.816 0.341 . . . . 0.0 110.359 -179.086 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 424' ' ' LYS . . . . . 0.406 ' HE3' ' CB ' ' A' ' 317' ' ' ALA . 23.6 tptm -60.92 112.05 1.9 Allowed 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.354 -177.736 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 425' ' ' GLU . . . . . 0.618 ' HG3' HD21 ' A' ' 320' ' ' ASN . 8.8 mm-40 -101.99 113.53 26.85 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.516 177.433 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 426' ' ' GLN . . . . . 0.459 ' HB3' ' HG ' ' A' ' 428' ' ' LEU . 27.0 mp0 -75.75 143.75 41.84 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.38 -179.259 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 427' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -69.71 -12.74 61.87 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.968 -175.367 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . 0.459 ' HG ' ' HB3' ' A' ' 426' ' ' GLN . 3.5 pp -69.9 -3.17 14.72 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.425 -177.576 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 429' ' ' GLU . . . . . 0.681 ' OE2' ' HA ' ' A' ' 431' ' ' HIS . 0.2 OUTLIER -66.28 145.53 55.64 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.939 0.4 . . . . 0.0 110.951 -178.523 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 430' ' ' HIS . . . . . . . . . . . . . 40.5 t60 -63.61 95.68 0.11 Allowed 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 167.338 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . 0.681 ' HA ' ' OE2' ' A' ' 429' ' ' GLU . 1.4 t60 -41.51 101.69 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.248 0 O-C-N 124.447 1.092 . . . . 0.0 112.587 -164.092 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 432' ' ' HIS . . . . . . . . . . . . . 68.0 m80 -85.04 -34.66 22.25 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.32 -176.525 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 433' ' ' HIS . . . . . . . . . . . . . 44.9 m-70 -93.98 106.21 18.2 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 177.51 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 434' ' ' HIS . . . . . . . . . . . . . 14.9 p80 -61.55 115.1 3.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.276 0.56 . . . . 0.0 109.819 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 435' ' ' HIS . . . . . . . . . . . . . 44.7 t-80 . . . . . 0 C--O 1.25 1.132 0 CA-C-O 118.405 -0.807 . . . . 0.0 109.077 -175.939 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 276' ' ' ASN . . . . . . . . . . . . . 2.0 m-20 . . . . . 0 N--CA 1.485 1.309 0 CA-C-O 120.666 0.269 . . . . 0.0 110.488 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 13.0 mt -88.99 37.23 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.442 0 CA-C-O 121.807 0.813 . . . . 0.0 110.827 -176.39 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 278' ' ' PHE . . . . . . . . . . . . . 36.4 m-85 -89.57 72.96 7.81 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.487 0.661 . . . . 0.0 109.531 176.756 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -75.85 145.32 77.78 Favored Pre-proline 0 C--N 1.325 -0.476 0 CA-C-N 115.19 -0.913 . . . . 0.0 111.537 -174.749 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 280' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_exo -61.72 125.36 16.48 Favored 'Trans proline' 0 C--O 1.235 0.36 0 C-N-CA 122.99 2.46 . . . . 0.0 111.829 176.583 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . 0.457 ' HG2' ' O ' ' A' ' 281' ' ' GLU . 22.5 tt0 66.08 15.9 10.25 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 121.857 0.837 . . . . 0.0 110.606 -178.944 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -148.14 31.45 1.3 Allowed Glycine 0 N--CA 1.445 -0.704 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.616 179.348 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 283' ' ' ASN . . . . . . . . . . . . . 28.6 p30 -80.37 147.19 31.15 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.038 0.446 . . . . 0.0 110.044 179.179 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . 0.455 ' O ' ' HD2' ' A' ' 302' ' ' ARG . 20.2 m-85 -101.08 103.89 15.0 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.736 -176.812 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . 0.613 ' HD3' ' O ' ' A' ' 285' ' ' ARG . 3.4 tmt_? -123.61 -6.05 8.1 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 177.084 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 45.4 t80 -50.51 -56.78 10.08 Favored 'General case' 0 CA--C 1.521 -0.139 0 CA-C-N 115.179 -0.919 . . . . 0.0 109.361 177.356 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . 0.42 ' C ' ' HG1' ' A' ' 288' ' ' THR . 28.9 tp -152.82 127.57 9.5 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 170.33 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 288' ' ' THR . . . . . 0.531 ' O ' ' HG3' ' A' ' 304' ' ' GLN . 33.6 m -165.57 160.2 17.39 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -174.285 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 289' ' ' TYR . . . . . 0.735 ' O ' ' HB3' ' A' ' 301' ' ' LEU . 0.0 OUTLIER -125.61 -175.94 3.47 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 177.411 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . 0.461 ' CA ' HG22 ' A' ' 303' ' ' VAL . . . -73.16 177.43 42.65 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.095 -1.05 . . . . 0.0 113.637 -166.275 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 291' ' ' ALA . . . . . 1.018 ' HA ' ' H ' ' A' ' 301' ' ' LEU . . . -93.45 114.32 26.69 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.588 -0.306 . . . . 0.0 111.279 -163.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 292' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -125.37 109.19 12.46 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 169.066 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 293' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -95.42 109.05 21.29 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.217 0.532 . . . . 0.0 111.363 -171.934 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 294' ' ' LEU . . . . . 0.56 HD23 ' HB2' ' A' ' 298' ' ' SER . 3.9 mm? -110.09 158.42 35.16 Favored Pre-proline 0 C--N 1.321 -0.648 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.353 175.318 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 295' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_exo -51.11 -55.69 3.79 Favored 'Trans proline' 0 C--O 1.237 0.44 0 C-N-CA 122.322 2.014 . . . . 0.0 112.194 178.073 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . -135.19 150.1 20.11 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.029 179.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 91.69 -72.91 1.65 Allowed Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.866 -0.683 . . . . 0.0 111.95 178.701 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 298' ' ' SER . . . . . 0.56 ' HB2' HD23 ' A' ' 294' ' ' LEU . 6.3 m -94.83 142.86 26.97 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.719 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 299' ' ' TYR . . . . . . . . . . . . . 19.1 p90 -140.54 178.11 7.55 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 -176.144 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 300' ' ' ALA . . . . . . . . . . . . . . . -77.78 126.25 30.58 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.345 0.593 . . . . 0.0 111.142 -173.903 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 301' ' ' LEU . . . . . 1.018 ' H ' ' HA ' ' A' ' 291' ' ' ALA . 7.4 mp -121.54 168.91 11.2 Favored 'General case' 0 CA--C 1.538 0.487 0 CA-C-N 114.616 -1.174 . . . . 0.0 111.767 -174.013 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 302' ' ' ARG . . . . . 0.455 ' HD2' ' O ' ' A' ' 284' ' ' TYR . 8.7 ptp180 -114.77 131.05 56.92 Favored 'General case' 0 C--N 1.318 -0.788 0 O-C-N 121.88 -0.513 . . . . 0.0 111.914 -174.469 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 303' ' ' VAL . . . . . 0.461 HG22 ' CA ' ' A' ' 290' ' ' GLY . 16.4 t -76.79 107.0 7.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.14 -179.339 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 304' ' ' GLN . . . . . 0.531 ' HG3' ' O ' ' A' ' 288' ' ' THR . 4.6 pp0? -91.53 175.32 6.95 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 168.501 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -92.06 106.32 3.38 Favored Glycine 0 N--CA 1.444 -0.818 0 C-N-CA 119.53 -1.319 . . . . 0.0 112.223 -173.43 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 306' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -84.88 135.63 39.75 Favored Pre-proline 0 C--N 1.325 -0.481 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 -178.109 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . 0.56 ' C ' ' HA2' ' A' ' 395' ' ' GLY . 66.6 Cg_endo -89.33 167.21 5.32 Favored 'Trans proline' 0 N--CA 1.453 -0.898 0 C-N-CA 122.832 2.354 . . . . 0.0 111.634 173.046 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . 0.575 ' HB1' HD23 ' A' ' 313' ' ' LEU . . . -61.11 161.1 9.07 Favored 'General case' 0 CA--C 1.515 -0.372 0 CA-C-O 121.372 0.606 . . . . 0.0 112.106 -175.513 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 309' ' ' LYS . . . . . . . . . . . . . 45.1 mttm -104.66 84.61 2.19 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 171.598 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 310' ' ' GLY . . . . . 0.695 ' HA3' ' O ' ' A' ' 374' ' ' GLY . . . -55.51 -34.25 59.81 Favored Glycine 0 CA--C 1.508 -0.35 0 CA-C-N 115.832 -0.622 . . . . 0.0 113.054 -173.623 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -45.6 -37.6 5.74 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 123.663 0.785 . . . . 0.0 112.288 175.629 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 73.2 mtm -131.08 31.75 4.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.718 0.294 . . . . 0.0 111.144 -177.381 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 313' ' ' LEU . . . . . 0.575 HD23 ' HB1' ' A' ' 308' ' ' ALA . 10.3 mt -65.79 -165.45 0.03 OUTLIER 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 112.387 0.514 . . . . 0.0 112.387 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -76.25 -168.98 1.05 Allowed 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -170.429 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . 0.622 ' O ' ' HB2' ' A' ' 346' ' ' PHE . . . -93.11 -122.64 3.3 Favored Glycine 0 C--O 1.223 -0.574 0 CA-C-N 115.019 -0.991 . . . . 0.0 111.469 178.278 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 18.0 p -96.56 131.68 42.94 Favored 'General case' 0 C--N 1.311 -1.074 0 O-C-N 122.28 -0.541 . . . . 0.0 110.912 177.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -142.92 162.2 36.11 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.587 -174.294 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 4.7 p -127.92 114.68 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.642 0 CA-C-O 121.452 0.644 . . . . 0.0 110.489 172.854 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 1.3 m-85 -98.89 155.42 17.4 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 175.925 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 320' ' ' ASN . . . . . 0.413 ' HA ' ' HA ' ' A' ' 341' ' ' ALA . 8.3 p30 -157.83 156.11 30.88 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 120.855 0.359 . . . . 0.0 110.75 173.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . 0.415 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -176.81 -150.24 8.17 Favored Glycine 0 N--CA 1.443 -0.846 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.145 -178.646 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 23.5 mm-40 -112.98 149.76 32.83 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.779 0.323 . . . . 0.0 110.861 -173.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 323' ' ' VAL . . . . . 0.62 HG23 HG21 ' A' ' 355' ' ' ILE . 55.5 t -108.52 118.29 55.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.051 174.091 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 324' ' ' LEU . . . . . . . . . . . . . 92.2 mt -97.61 103.48 15.42 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.896 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 325' ' ' HIS . . . . . . . . . . . . . 26.3 t60 -98.97 112.73 24.76 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 -178.144 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 326' ' ' PHE . . . . . 0.635 ' HB2' ' HB3' ' A' ' 417' ' ' PHE . 30.3 m-85 -92.2 142.81 27.07 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.28 -0.418 . . . . 0.0 109.925 -173.78 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 327' ' ' HIS . . . . . . . . . . . . . 47.3 p-80 -176.2 118.38 0.14 Allowed 'General case' 0 C--N 1.327 -0.384 0 O-C-N 123.475 0.484 . . . . 0.0 110.538 178.913 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 328' ' ' THR . . . . . . . . . . . . . 5.1 t -84.77 101.75 12.49 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.932 0.872 . . . . 0.0 109.144 174.591 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 329' ' ' GLU . . . . . . . . . . . . . 42.8 tt0 -105.33 94.14 5.06 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.619 -175.642 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 330' ' ' ASN . . . . . . . . . . . . . 54.4 t30 56.68 42.33 27.08 Favored 'General case' 0 CA--C 1.528 0.102 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.009 177.355 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 331' ' ' GLY . . . . . 0.656 ' O ' ' HD3' ' A' ' 333' ' ' PRO . . . 134.68 -175.49 20.49 Favored Glycine 0 N--CA 1.444 -0.79 0 C-N-CA 120.379 -0.915 . . . . 0.0 111.578 -175.791 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 332' ' ' ARG . . . . . . . . . . . . . 8.5 mpt_? -91.74 100.31 3.25 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-O 120.646 0.26 . . . . 0.0 110.49 175.1 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 333' ' ' PRO . . . . . 0.656 ' HD3' ' O ' ' A' ' 331' ' ' GLY . 85.1 Cg_endo -98.06 177.36 0.44 Allowed 'Trans proline' 0 N--CA 1.449 -1.139 0 C-N-CA 123.339 2.693 . . . . 0.0 111.767 178.512 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 334' ' ' TYR . . . . . 0.437 ' OH ' ' HD2' ' A' ' 337' ' ' ARG . 60.6 t80 -88.49 120.73 70.4 Favored Pre-proline 0 C--N 1.322 -0.611 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 174.857 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 335' ' ' PRO . . . . . 0.427 ' HD2' ' HA ' ' A' ' 334' ' ' TYR . 8.8 Cg_endo -50.85 128.95 26.02 Favored 'Trans proline' 0 N--CA 1.462 -0.351 0 C-N-CA 122.776 2.317 . . . . 0.0 111.527 179.256 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 336' ' ' THR . . . . . . . . . . . . . 6.1 p -67.98 137.98 55.55 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-O 121.03 0.443 . . . . 0.0 110.294 -176.471 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 337' ' ' ARG . . . . . 0.437 ' HD2' ' OH ' ' A' ' 334' ' ' TYR . 18.5 mtp180 -105.31 113.44 27.02 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.054 -173.887 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -98.53 165.37 21.34 Favored Glycine 0 N--CA 1.436 -1.318 0 N-CA-C 110.132 -1.187 . . . . 0.0 110.132 173.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 339' ' ' ARG . . . . . 0.822 ' HB2' ' HB2' ' A' ' 356' ' ' ASP . 5.6 mpt_? -104.92 157.56 17.13 Favored 'General case' 0 C--N 1.313 -0.992 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 176.651 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 340' ' ' PHE . . . . . 0.737 ' HA ' ' O ' ' A' ' 354' ' ' ILE . 11.1 t80 -154.68 140.56 18.22 Favored 'General case' 0 C--N 1.313 -0.992 0 C-N-CA 120.496 -0.482 . . . . 0.0 111.35 -176.777 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 341' ' ' ALA . . . . . 0.413 ' HA ' ' HA ' ' A' ' 320' ' ' ASN . . . -136.81 165.75 25.2 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 174.351 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . 0.854 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -147.96 118.98 7.66 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-O 121.12 0.486 . . . . 0.0 111.222 -177.32 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . 0.517 ' HB3' ' HB2' ' A' ' 352' ' ' ASP . 27.0 tptp -87.28 98.0 11.09 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 174.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 344' ' ' VAL . . . . . 0.472 ' HA ' ' HA ' ' A' ' 351' ' ' VAL . 0.3 OUTLIER -115.95 117.31 55.12 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-O 121.816 0.817 . . . . 0.0 111.802 -172.718 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -95.44 94.11 7.61 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 114.282 -1.327 . . . . 0.0 108.591 175.48 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 346' ' ' PHE . . . . . 0.622 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 44.9 m-85 -65.54 -21.2 66.58 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.965 -174.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -62.28 -33.8 87.21 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.363 176.529 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 39.0 m -106.78 -6.57 17.67 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.163 0.506 . . . . 0.0 110.15 176.506 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 349' ' ' LYS . . . . . 0.744 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 22.4 mttm 53.79 62.71 2.49 Favored 'General case' 0 C--O 1.22 -0.466 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.89 -177.908 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 49.8 m -141.01 145.46 35.95 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.207 -0.906 . . . . 0.0 109.207 175.458 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 351' ' ' VAL . . . . . 0.507 ' O ' ' HG3' ' A' ' 369' ' ' LYS . 0.9 OUTLIER -129.27 156.47 41.81 Favored 'Isoleucine or valine' 0 C--O 1.235 0.327 0 CA-C-O 120.856 0.36 . . . . 0.0 110.526 -176.999 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 352' ' ' ASP . . . . . 0.854 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 1.8 m-20 -121.13 118.0 28.58 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 170.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -111.13 124.02 6.75 Favored Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.11 -1.043 . . . . 0.0 112.435 -175.68 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 354' ' ' ILE . . . . . 0.737 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 1.0 OUTLIER -112.99 129.51 68.52 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-O 120.686 0.279 . . . . 0.0 110.455 -178.063 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 355' ' ' ILE . . . . . 0.62 HG21 HG23 ' A' ' 323' ' ' VAL . 4.3 mm -107.29 97.63 5.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.022 179.126 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 356' ' ' ASP . . . . . 0.822 ' HB2' ' HB2' ' A' ' 339' ' ' ARG . 16.8 m-20 -75.24 93.22 2.81 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.27 -0.423 . . . . 0.0 109.966 175.992 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 15.6 m -71.52 -13.86 61.93 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.941 178.677 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 358' ' ' GLY . . . . . . . . . . . . . . . 144.4 -35.16 1.57 Allowed Glycine 0 N--CA 1.446 -0.681 0 C-N-CA 120.757 -0.735 . . . . 0.0 111.81 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 359' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -141.02 99.24 3.55 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.061 0.457 . . . . 0.0 110.492 178.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 360' ' ' ASP . . . . . 0.632 ' HA ' ' OG1' ' A' ' 365' ' ' THR . 31.8 t70 -83.42 -7.56 59.54 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.361 175.807 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 361' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -73.06 -36.09 66.82 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 115.665 -0.698 . . . . 0.0 112.578 -170.665 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 362' ' ' HIS . . . . . . . . . . . . . 23.2 t-80 -167.79 -14.95 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.245 0 N-CA-C 112.8 0.667 . . . . 0.0 112.8 178.511 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 363' ' ' MET . . . . . . . . . . . . . 54.7 ttp -59.65 -32.18 70.21 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.79 0.328 . . . . 0.0 111.672 -176.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 364' ' ' GLY . . . . . . . . . . . . . . . 114.18 72.44 0.56 Allowed Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.662 -0.78 . . . . 0.0 111.777 179.416 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 365' ' ' THR . . . . . 0.632 ' OG1' ' HA ' ' A' ' 360' ' ' ASP . 0.0 OUTLIER -78.35 158.05 28.91 Favored 'General case' 0 N--CA 1.435 -1.194 0 CA-C-O 120.886 0.374 . . . . 0.0 111.277 -177.65 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 17.2 mm100 -107.85 141.8 38.88 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 177.672 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -153.63 154.37 34.07 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 176.216 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 368' ' ' PHE . . . . . 0.502 ' HB3' ' CE3' ' A' ' 381' ' ' TRP . 47.2 p90 -136.05 160.21 39.35 Favored 'General case' 0 C--N 1.319 -0.757 0 O-C-N 123.437 0.46 . . . . 0.0 109.836 -176.41 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 369' ' ' LYS . . . . . 0.507 ' HG3' ' O ' ' A' ' 351' ' ' VAL . 26.9 tttp -127.6 132.87 49.74 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 174.119 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . 0.443 ' HB2' HG23 ' A' ' 351' ' ' VAL . . . -128.85 148.46 50.89 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.182 -172.065 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -104.41 129.27 52.37 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.947 176.964 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 372' ' ' ILE . . . . . 0.744 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 93.3 mt -81.86 103.81 9.53 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.638 0 CA-C-O 121.925 0.869 . . . . 0.0 109.747 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 19.1 t0 -107.8 96.99 6.77 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 114.375 -1.284 . . . . 0.0 108.859 178.277 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 374' ' ' GLY . . . . . 0.695 ' O ' ' HA3' ' A' ' 310' ' ' GLY . . . 92.51 -123.32 7.24 Favored Glycine 0 N--CA 1.441 -0.981 0 C-N-CA 120.621 -0.799 . . . . 0.0 111.244 -174.254 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 375' ' ' ASN . . . . . . . . . . . . . 42.3 p-10 -114.15 35.63 4.07 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.925 0.869 . . . . 0.0 110.82 -175.244 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . -177.93 171.59 44.12 Favored Glycine 0 N--CA 1.443 -0.855 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 -176.295 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 377' ' ' PHE . . . . . 0.481 ' HD2' HG12 ' A' ' 372' ' ' ILE . 6.7 p90 -131.57 145.69 51.84 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 117.715 0.757 . . . . 0.0 112.616 -176.129 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 378' ' ' LYS . . . . . 0.446 ' HD2' ' N ' ' A' ' 378' ' ' LYS . 0.0 OUTLIER -119.68 134.33 55.27 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 114.578 -1.192 . . . . 0.0 108.167 171.676 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -150.3 -169.68 16.65 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.062 -1.066 . . . . 0.0 112.986 -175.597 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 15.1 t -147.46 153.68 39.86 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -175.849 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 381' ' ' TRP . . . . . 0.502 ' CE3' ' HB3' ' A' ' 368' ' ' PHE . 61.4 m95 -59.65 130.29 46.09 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.985 0.421 . . . . 0.0 110.282 179.672 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 382' ' ' THR . . . . . . . . . . . . . 37.5 m -61.3 -35.77 78.26 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.154 -0.93 . . . . 0.0 112.944 -169.099 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 383' ' ' GLU . . . . . 0.482 ' OE1' ' HB3' ' A' ' 381' ' ' TRP . 0.0 OUTLIER -87.51 -49.2 7.35 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.545 -0.462 . . . . 0.0 110.708 -179.548 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 384' ' ' ASN . . . . . . . . . . . . . 40.0 t-20 -166.93 -72.68 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 175.882 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 385' ' ' GLY . . . . . 0.444 ' HA3' ' HB2' ' A' ' 381' ' ' TRP . . . 78.75 -65.46 3.48 Favored Glycine 0 N--CA 1.45 -0.42 0 CA-C-N 116.076 -0.511 . . . . 0.0 112.856 178.557 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 386' ' ' GLY . . . . . . . . . . . . . . . 86.36 27.76 29.47 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.931 -0.652 . . . . 0.0 111.738 -177.03 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -145.61 -157.95 7.49 Favored Glycine 0 N--CA 1.445 -0.75 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.105 -178.069 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -142.16 134.82 28.29 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 110.204 -0.295 . . . . 0.0 110.204 -178.593 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 38.2 t -112.95 133.87 57.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.347 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 31.7 m -144.61 143.3 30.71 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.076 0.465 . . . . 0.0 111.224 178.229 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -157.4 157.17 27.89 Favored Glycine 0 N--CA 1.445 -0.763 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 178.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 11.3 ptp180 -136.02 150.74 49.32 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 117.405 0.602 . . . . 0.0 110.764 -175.3 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 393' ' ' PHE . . . . . 0.475 ' CD1' ' HB ' ' A' ' 401' ' ' VAL . 95.1 m-85 -84.49 167.75 16.09 Favored 'General case' 0 CA--C 1.496 -1.098 0 CA-C-O 122.134 0.969 . . . . 0.0 111.184 -178.084 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 394' ' ' TYR . . . . . 0.577 ' HD1' ' N ' ' A' ' 394' ' ' TYR . 0.6 OUTLIER -97.56 -179.11 4.36 Favored 'General case' 0 N--CA 1.428 -1.562 0 N-CA-C 105.621 -1.992 . . . . 0.0 105.621 173.153 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 395' ' ' GLY . . . . . 0.56 ' HA2' ' C ' ' A' ' 307' ' ' PRO . . . -51.48 -148.16 0.0 OUTLIER Glycine 0 N--CA 1.474 1.168 0 O-C-N 124.497 1.123 . . . . 0.0 115.754 -172.314 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -57.67 -10.86 7.88 Favored 'Trans proline' 0 CA--C 1.539 0.729 0 C-N-CA 121.227 1.285 . . . . 0.0 111.042 176.192 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 397' ' ' ALA . . . . . 0.51 ' C ' ' H ' ' A' ' 399' ' ' GLU . . . -93.97 27.66 2.71 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 114.77 -1.104 . . . . 0.0 110.811 174.127 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . -53.6 8.54 0.01 OUTLIER Glycine 0 N--CA 1.469 0.87 0 C-N-CA 124.069 0.842 . . . . 0.0 114.599 176.079 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 399' ' ' GLU . . . . . 0.51 ' H ' ' C ' ' A' ' 397' ' ' ALA . 3.7 mp0 -59.97 -9.99 3.66 Favored 'General case' 0 C--N 1.323 -0.587 0 C-N-CA 123.929 0.892 . . . . 0.0 110.019 166.676 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 -119.21 125.05 48.24 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-N 115.344 -0.844 . . . . 0.0 109.439 174.15 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 401' ' ' VAL . . . . . 0.475 ' HB ' ' CD1' ' A' ' 393' ' ' PHE . 12.2 p -132.71 141.12 45.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 176.607 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -130.01 137.56 50.33 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-O 120.761 0.315 . . . . 0.0 110.679 178.902 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -144.88 177.03 23.62 Favored Glycine 0 N--CA 1.439 -1.161 0 C-N-CA 120.458 -0.877 . . . . 0.0 112.143 179.805 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 404' ' ' LYS . . . . . 0.441 ' CG ' HG13 ' A' ' 419' ' ' VAL . 0.0 OUTLIER -141.13 155.7 46.07 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 176.905 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 19.7 p90 -119.42 133.58 55.64 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-O 120.977 0.417 . . . . 0.0 110.287 176.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 49.1 m -92.29 103.84 16.25 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 177.359 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 37.5 p90 -66.38 149.67 50.05 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.976 177.27 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 408' ' ' ARG . . . . . . . . . . . . . 37.6 ttt180 -59.78 117.45 23.19 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.517 -179.649 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 409' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_exo -66.31 84.64 0.27 Allowed 'Trans proline' 0 N--CA 1.464 -0.225 0 C-N-CA 123.059 2.506 . . . . 0.0 112.128 -178.7 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 410' ' ' THR . . . . . 0.423 ' C ' ' H ' ' A' ' 412' ' ' ALA . 9.8 m -91.71 99.84 12.66 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.865 179.003 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 411' ' ' ASP . . . . . . . . . . . . . 26.4 t70 73.7 -36.62 0.35 Allowed 'General case' 0 N--CA 1.471 0.612 0 C-N-CA 123.831 0.852 . . . . 0.0 110.95 -176.195 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 412' ' ' ALA . . . . . 0.423 ' H ' ' C ' ' A' ' 410' ' ' THR . . . -59.17 139.13 57.23 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.488 175.031 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 413' ' ' GLU . . . . . 0.622 ' HG2' ' HG2' ' A' ' 414' ' ' LYS . 0.5 OUTLIER -80.25 -23.85 40.54 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.202 -172.035 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 414' ' ' LYS . . . . . 0.622 ' HG2' ' HG2' ' A' ' 413' ' ' GLU . 21.9 pttp -156.25 166.46 33.37 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.985 0.421 . . . . 0.0 111.089 -178.044 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 415' ' ' GLY . . . . . . . . . . . . . . . -139.74 179.36 18.92 Favored Glycine 0 N--CA 1.448 -0.506 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.205 -179.411 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 416' ' ' GLY . . . . . . . . . . . . . . . 142.62 -10.54 2.41 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.269 -0.967 . . . . 0.0 112.388 -178.213 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 417' ' ' PHE . . . . . 0.635 ' HB3' ' HB2' ' A' ' 326' ' ' PHE . 73.8 m-85 -81.81 170.16 16.03 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 175.427 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 82.8 76.99 1.1 Allowed Glycine 0 N--CA 1.449 -0.467 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.374 -177.938 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 419' ' ' VAL . . . . . 0.441 HG13 ' CG ' ' A' ' 404' ' ' LYS . 19.8 m -106.4 167.36 3.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 -179.34 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 45.9 p90 -148.24 162.69 38.98 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-O 120.796 0.331 . . . . 0.0 110.144 178.077 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 421' ' ' ALA . . . . . 0.415 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -142.85 135.39 27.67 Favored 'General case' 0 C--N 1.316 -0.877 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 177.994 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -122.95 135.72 10.2 Favored Glycine 0 N--CA 1.441 -1.021 0 C-N-CA 120.749 -0.739 . . . . 0.0 111.451 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 60.3 mttm -118.93 139.8 51.05 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-O 121.041 0.448 . . . . 0.0 110.354 179.442 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 424' ' ' LYS . . . . . . . . . . . . . 5.6 tppp? -60.06 122.41 14.3 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.011 -0.995 . . . . 0.0 111.86 -177.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -103.18 112.92 26.02 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 166.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 426' ' ' GLN . . . . . 0.706 ' HB2' HD23 ' A' ' 428' ' ' LEU . 10.6 pt20 -109.59 130.69 55.49 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.659 0.742 . . . . 0.0 111.286 -171.742 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 427' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -84.87 9.52 14.1 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.16 -0.927 . . . . 0.0 110.317 -175.94 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . 0.706 HD23 ' HB2' ' A' ' 426' ' ' GLN . 3.6 mm? -67.73 -16.06 63.94 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.408 -0.814 . . . . 0.0 110.831 179.585 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 429' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -61.92 -32.2 72.57 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.552 0.691 . . . . 0.0 110.062 174.086 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 430' ' ' HIS . . . . . . . . . . . . . 36.4 m80 -94.67 145.09 25.08 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.569 -176.394 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 76.2 t60 -149.19 119.1 7.1 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.069 0.461 . . . . 0.0 111.164 178.662 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 432' ' ' HIS . . . . . . . . . . . . . 39.1 m-70 -131.46 165.86 22.6 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 175.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 433' ' ' HIS . . . . . . . . . . . . . 3.1 t-160 -162.34 -35.7 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.905 0.383 . . . . 0.0 110.874 176.958 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 434' ' ' HIS . . . . . . . . . . . . . 26.6 t-80 -85.85 -39.89 16.55 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 175.094 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 435' ' ' HIS . . . . . . . . . . . . . 72.5 t60 . . . . . 0 C--O 1.25 1.102 0 CA-C-O 117.725 -1.131 . . . . 0.0 108.764 174.018 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 276' ' ' ASN . . . . . 0.435 ' CG ' ' HD2' ' A' ' 299' ' ' TYR . 56.2 t30 . . . . . 0 N--CA 1.48 1.059 0 CA-C-O 121.178 0.514 . . . . 0.0 110.681 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 10.5 tp -99.6 -16.27 7.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 121.306 0.574 . . . . 0.0 110.49 178.151 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 278' ' ' PHE . . . . . 0.441 ' HE2' ' N ' ' A' ' 301' ' ' LEU . 28.3 p90 38.5 31.92 0.05 OUTLIER 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 125.244 1.418 . . . . 0.0 114.168 178.12 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -168.5 149.1 4.34 Favored Pre-proline 0 N--CA 1.452 -0.329 0 CA-C-N 116.679 -0.237 . . . . 0.0 110.652 -178.214 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 280' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -65.46 128.42 20.21 Favored 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 122.481 2.121 . . . . 0.0 110.519 171.551 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . 0.41 ' HA ' HD13 ' A' ' 287' ' ' LEU . 43.3 mt-10 -62.85 92.24 0.05 OUTLIER 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.696 0.76 . . . . 0.0 111.756 -176.935 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 156.53 32.41 0.02 OUTLIER Glycine 0 N--CA 1.444 -0.789 0 CA-C-N 114.668 -1.151 . . . . 0.0 110.402 -178.609 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 283' ' ' ASN . . . . . 0.484 ' H ' HD12 ' A' ' 287' ' ' LEU . 15.2 t-20 -133.43 147.62 51.73 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 -179.194 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . 0.46 ' C ' ' H ' ' A' ' 286' ' ' TYR . 2.3 m-85 -100.21 145.16 28.38 Favored 'General case' 0 C--N 1.316 -0.86 0 C-N-CA 120.554 -0.458 . . . . 0.0 111.114 -173.588 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 17.9 mmm180 73.38 -27.48 0.19 Allowed 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.206 -172.186 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.46 ' H ' ' C ' ' A' ' 284' ' ' TYR . 35.8 m-85 -80.62 -22.66 40.38 Favored 'General case' 0 N--CA 1.444 -0.745 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 163.606 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . 0.608 HD22 ' HA ' ' A' ' 304' ' ' GLN . 5.8 mp -116.85 129.03 55.82 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.613 165.866 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 288' ' ' THR . . . . . 0.536 ' N ' ' HG3' ' A' ' 304' ' ' GLN . 9.1 m -168.51 171.73 8.74 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 105.97 -1.863 . . . . 0.0 105.97 -178.276 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 289' ' ' TYR . . . . . 0.407 ' N ' HG22 ' A' ' 288' ' ' THR . 12.2 m-85 -108.55 117.19 33.53 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 119.167 0.894 . . . . 0.0 109.671 167.737 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 122.43 136.18 4.83 Favored Glycine 0 C--N 1.334 0.446 0 C-N-CA 120.553 -0.832 . . . . 0.0 111.292 -178.188 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 291' ' ' ALA . . . . . 0.807 ' HB2' ' HA ' ' A' ' 301' ' ' LEU . . . -165.71 164.85 18.93 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 112.076 0.399 . . . . 0.0 112.076 -172.171 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 292' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -127.28 114.48 17.68 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.416 173.485 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 293' ' ' LYS . . . . . 0.414 ' HE3' ' HB3' ' A' ' 299' ' ' TYR . 88.5 tttt -75.82 126.86 31.81 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 175.748 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 294' ' ' LEU . . . . . 0.613 HD23 ' HB2' ' A' ' 298' ' ' SER . 7.2 mp -65.72 124.18 86.75 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-O 120.743 0.306 . . . . 0.0 110.573 -175.045 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 295' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 294' ' ' LEU . 17.0 Cg_exo -67.68 81.33 0.45 Allowed 'Trans proline' 0 C--O 1.235 0.357 0 C-N-CA 123.229 2.619 . . . . 0.0 112.164 -178.608 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . 165.51 -109.76 0.38 Allowed Glycine 0 N--CA 1.443 -0.868 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.948 178.963 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . -97.94 -41.3 3.34 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.908 -0.663 . . . . 0.0 113.324 -176.335 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 298' ' ' SER . . . . . 0.613 ' HB2' HD23 ' A' ' 294' ' ' LEU . 69.3 m -80.08 152.29 29.42 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.477 0.656 . . . . 0.0 111.663 -174.592 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 299' ' ' TYR . . . . . 0.435 ' HD2' ' CG ' ' A' ' 276' ' ' ASN . 13.8 p90 -134.89 135.38 41.58 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.23 -0.896 . . . . 0.0 108.893 178.587 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 300' ' ' ALA . . . . . . . . . . . . . . . -157.37 119.84 3.88 Favored 'General case' 0 C--N 1.331 -0.225 0 C-N-CA 120.985 -0.286 . . . . 0.0 111.76 -176.44 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 301' ' ' LEU . . . . . 0.807 ' HA ' ' HB2' ' A' ' 291' ' ' ALA . 1.8 pp -143.33 155.77 44.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.133 0.492 . . . . 0.0 111.209 171.017 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 302' ' ' ARG . . . . . 0.576 ' H ' ' HB3' ' A' ' 291' ' ' ALA . 80.9 mtm180 -108.87 134.59 51.35 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.717 -178.556 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 303' ' ' VAL . . . . . 0.418 HG23 HD12 ' A' ' 301' ' ' LEU . 95.7 t -132.95 124.18 49.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.296 175.938 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 304' ' ' GLN . . . . . 0.608 ' HA ' HD22 ' A' ' 287' ' ' LEU . 10.8 mt-30 -90.5 141.78 28.41 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.28 176.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -97.34 105.66 3.21 Favored Glycine 0 N--CA 1.446 -0.651 0 N-CA-C 110.457 -1.057 . . . . 0.0 110.457 173.068 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 306' ' ' GLU . . . . . . . . . . . . . 34.9 mm-40 -103.57 134.73 19.59 Favored Pre-proline 0 C--N 1.321 -0.631 0 CA-C-O 120.849 0.357 . . . . 0.0 111.683 -173.524 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -78.57 160.98 28.28 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 122.24 1.96 . . . . 0.0 109.478 164.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . 0.734 ' O ' ' HB3' ' A' ' 375' ' ' ASN . . . -49.45 118.95 3.03 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 121.118 0.485 . . . . 0.0 111.366 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 309' ' ' LYS . . . . . 0.437 ' O ' ' HG ' ' A' ' 313' ' ' LEU . 24.8 mmmt -73.95 81.5 1.68 Allowed 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -177.578 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 310' ' ' GLY . . . . . 0.6 ' HA2' HD11 ' A' ' 313' ' ' LEU . . . -52.56 -40.48 55.06 Favored Glycine 0 C--N 1.333 0.387 0 O-C-N 123.332 0.395 . . . . 0.0 113.145 -174.445 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . 0.524 ' HG3' ' HG3' ' A' ' 312' ' ' MET . 10.1 pt-20 -56.63 -28.26 60.13 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 122.635 0.374 . . . . 0.0 111.923 177.307 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 312' ' ' MET . . . . . 0.524 ' HG3' ' HG3' ' A' ' 311' ' ' GLU . 76.3 mtm -113.83 1.97 14.96 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.687 0.28 . . . . 0.0 111.352 -177.424 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 313' ' ' LEU . . . . . 0.6 HD11 ' HA2' ' A' ' 310' ' ' GLY . 78.8 mt -72.69 131.04 41.87 Favored 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 175.598 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -143.9 143.67 31.38 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.569 -173.042 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 121.66 169.87 13.73 Favored Glycine 0 N--CA 1.445 -0.743 0 C-N-CA 120.981 -0.628 . . . . 0.0 111.843 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 25.4 p -107.32 133.04 52.44 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 175.242 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -142.03 160.26 40.58 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 121.271 0.557 . . . . 0.0 112.076 -172.912 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 6.1 p -129.13 115.93 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.878 174.512 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . 0.558 ' CZ ' ' HB2' ' A' ' 424' ' ' LYS . 2.0 m-85 -98.07 128.74 44.77 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 179.09 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 4.0 p30 -131.37 144.05 50.94 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 120.868 0.366 . . . . 0.0 110.727 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -173.67 -143.89 4.5 Favored Glycine 0 N--CA 1.443 -0.855 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.007 -179.722 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -119.48 147.81 43.99 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.832 0.349 . . . . 0.0 110.975 -175.163 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 323' ' ' VAL . . . . . 0.675 HG11 ' HB2' ' A' ' 340' ' ' PHE . 4.5 m -106.71 117.04 51.75 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 CA-C-N 115.846 -0.616 . . . . 0.0 109.391 168.027 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 324' ' ' LEU . . . . . 0.545 ' HB2' HG21 ' A' ' 419' ' ' VAL . 97.5 mt -91.63 101.94 14.57 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 177.895 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 325' ' ' HIS . . . . . 0.472 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 6.2 p80 -102.41 117.67 35.21 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.754 0.788 . . . . 0.0 109.766 -176.333 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 326' ' ' PHE . . . . . 0.782 ' HD2' ' HB3' ' A' ' 417' ' ' PHE . 58.4 m-85 -94.27 173.68 7.52 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.649 -1.16 . . . . 0.0 111.22 -168.521 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 327' ' ' HIS . . . . . . . . . . . . . 8.2 p-80 -173.73 148.63 1.5 Allowed 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.112 -174.428 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 328' ' ' THR . . . . . . . . . . . . . 15.8 p -64.73 122.25 16.43 Favored 'General case' 0 C--N 1.327 -0.378 0 O-C-N 123.263 0.352 . . . . 0.0 110.128 177.233 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 329' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -63.48 128.15 34.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.266 0.555 . . . . 0.0 111.637 -174.539 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 330' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -96.34 -32.57 12.32 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.219 173.469 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 331' ' ' GLY . . . . . . . . . . . . . . . -173.29 117.32 0.64 Allowed Glycine 0 N--CA 1.442 -0.901 0 CA-C-N 115.21 -0.905 . . . . 0.0 111.341 178.947 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 332' ' ' ARG . . . . . 0.416 ' NH2' ' HB2' ' A' ' 334' ' ' TYR . 0.2 OUTLIER 68.49 88.55 0.1 Allowed Pre-proline 0 C--N 1.33 -0.282 0 C-N-CA 122.888 0.475 . . . . 0.0 109.986 -179.026 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 333' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo -60.94 110.39 0.84 Allowed 'Trans proline' 0 C--N 1.343 0.243 0 C-N-CA 123.016 2.477 . . . . 0.0 112.809 -176.142 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 334' ' ' TYR . . . . . 0.416 ' HB2' ' NH2' ' A' ' 332' ' ' ARG . 86.8 t80 -132.83 113.51 13.87 Favored Pre-proline 0 C--N 1.322 -0.618 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.767 177.038 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 335' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_exo -70.22 126.83 13.44 Favored 'Trans proline' 0 N--CA 1.456 -0.686 0 C-N-CA 122.126 1.884 . . . . 0.0 109.978 171.254 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 336' ' ' THR . . . . . . . . . . . . . 1.3 m -97.96 148.33 23.58 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -176.683 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 337' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.97 135.03 54.19 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.53 0.681 . . . . 0.0 111.487 -176.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 338' ' ' GLY . . . . . 0.451 ' HA3' ' CG2' ' A' ' 323' ' ' VAL . . . -106.46 -175.42 23.29 Favored Glycine 0 N--CA 1.437 -1.251 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 170.032 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 339' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -111.29 131.56 55.06 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 117.222 0.511 . . . . 0.0 109.799 178.109 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 340' ' ' PHE . . . . . 0.675 ' HB2' HG11 ' A' ' 323' ' ' VAL . 10.9 t80 -127.37 133.53 50.02 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.793 -178.182 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 341' ' ' ALA . . . . . 0.456 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -131.9 160.7 34.94 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.613 175.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . 0.881 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -147.83 119.4 7.97 Favored 'General case' 0 N--CA 1.442 -0.844 0 CA-C-O 121.204 0.526 . . . . 0.0 110.446 -177.7 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . 0.424 ' HB3' ' HB2' ' A' ' 352' ' ' ASP . 6.3 tmtt? -91.68 98.74 11.82 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 178.363 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 344' ' ' VAL . . . . . 0.55 ' HB ' HG13 ' A' ' 351' ' ' VAL . 0.2 OUTLIER -118.51 128.52 75.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-O 121.794 0.806 . . . . 0.0 112.239 -172.189 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -108.14 110.62 22.32 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 114.489 -1.232 . . . . 0.0 108.419 174.443 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 346' ' ' PHE . . . . . 0.478 ' HZ ' ' OH ' ' A' ' 319' ' ' TYR . 64.8 m-85 -73.16 -18.74 61.24 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.705 0.288 . . . . 0.0 111.732 -176.291 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -62.77 -28.19 71.27 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.475 -0.869 . . . . 0.0 111.249 176.199 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 20.5 t -112.46 -10.12 13.76 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-N 115.897 -0.151 . . . . 0.0 110.974 177.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 349' ' ' LYS . . . . . 0.634 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 35.2 mttp 57.23 59.46 3.37 Favored 'General case' 0 C--O 1.224 -0.275 0 CA-C-O 121.58 0.705 . . . . 0.0 110.646 -178.308 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 8.6 t -146.86 152.61 39.01 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.296 177.755 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 351' ' ' VAL . . . . . 0.654 HG22 ' HB2' ' A' ' 370' ' ' ALA . 1.2 m -134.8 155.25 38.12 Favored 'Isoleucine or valine' 0 C--O 1.236 0.382 0 CA-C-O 121.205 0.526 . . . . 0.0 110.836 -176.786 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 352' ' ' ASP . . . . . 0.881 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 1.2 m-20 -110.7 117.91 34.74 Favored 'General case' 0 C--O 1.215 -0.728 0 CA-C-N 115.244 -0.889 . . . . 0.0 108.692 168.925 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -110.91 124.43 6.96 Favored Glycine 0 N--CA 1.441 -1.03 0 C-N-CA 120.193 -1.003 . . . . 0.0 111.562 -176.954 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 354' ' ' ILE . . . . . 0.453 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -122.05 129.73 75.15 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 CA-C-O 121.187 0.518 . . . . 0.0 109.85 -177.058 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 355' ' ' ILE . . . . . 0.637 HG21 HG22 ' A' ' 323' ' ' VAL . 4.2 mp -122.34 108.7 22.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.858 -178.57 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 356' ' ' ASP . . . . . 0.457 ' HA ' ' O ' ' A' ' 364' ' ' GLY . 0.0 OUTLIER -121.24 134.42 55.18 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 175.142 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 23.8 m -105.61 9.8 33.18 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.524 -179.123 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 358' ' ' GLY . . . . . . . . . . . . . . . 85.1 11.87 75.12 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 120.745 -0.741 . . . . 0.0 111.728 -176.408 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 359' ' ' ASP . . . . . 0.795 ' HB2' ' HA3' ' A' ' 364' ' ' GLY . 52.6 m-20 -116.7 52.46 0.94 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.211 0.529 . . . . 0.0 109.607 179.207 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 360' ' ' ASP . . . . . 0.642 ' HA ' ' OG1' ' A' ' 365' ' ' THR . 2.2 m-20 -62.1 -19.51 63.06 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 115.107 -0.951 . . . . 0.0 112.342 -175.403 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 361' ' ' LEU . . . . . . . . . . . . . 89.6 mt -82.54 8.21 12.38 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.598 -0.274 . . . . 0.0 111.516 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 362' ' ' HIS . . . . . 0.496 ' HB3' ' H ' ' A' ' 363' ' ' MET . 0.1 OUTLIER -160.59 -128.97 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 120.974 -0.29 . . . . 0.0 111.115 176.732 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 363' ' ' MET . . . . . 0.496 ' H ' ' HB3' ' A' ' 362' ' ' HIS . 0.0 OUTLIER -78.48 -4.19 47.27 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 112.346 0.499 . . . . 0.0 112.346 -173.5 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 364' ' ' GLY . . . . . 0.795 ' HA3' ' HB2' ' A' ' 359' ' ' ASP . . . -75.47 4.21 43.69 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 121.008 -0.615 . . . . 0.0 113.544 -172.693 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 365' ' ' THR . . . . . 0.642 ' OG1' ' HA ' ' A' ' 360' ' ' ASP . 32.5 m -129.17 119.04 23.4 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.999 0.399 . . . . 0.0 110.949 178.363 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 43.9 mt-30 -140.05 149.01 42.62 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.907 177.927 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -138.55 148.61 44.42 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 176.429 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 368' ' ' PHE . . . . . 0.442 ' HB3' ' CE3' ' A' ' 381' ' ' TRP . 34.4 p90 -140.83 149.99 42.72 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.0 0.429 . . . . 0.0 110.465 178.577 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 1.6 mptp? -104.9 138.1 41.66 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 173.473 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . 0.654 ' HB2' HG22 ' A' ' 351' ' ' VAL . . . -134.26 147.45 50.66 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.18 0.514 . . . . 0.0 111.574 -177.127 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -105.96 130.47 53.89 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.628 175.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 372' ' ' ILE . . . . . 0.634 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 87.6 mt -81.66 107.38 13.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 121.545 0.688 . . . . 0.0 110.755 -178.04 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . 0.476 ' HB2' ' HE2' ' A' ' 378' ' ' LYS . 28.5 t70 -111.46 80.2 1.29 Allowed 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.093 -0.958 . . . . 0.0 109.435 179.417 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 58.87 119.07 0.01 OUTLIER Glycine 0 CA--C 1.521 0.42 0 CA-C-N 114.889 -1.051 . . . . 0.0 113.76 -177.484 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 375' ' ' ASN . . . . . 0.734 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 2.4 p-10 29.86 46.05 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 113.912 1.078 . . . . 0.0 113.912 178.582 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 165.06 172.35 32.41 Favored Glycine 0 N--CA 1.445 -0.766 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 178.032 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 377' ' ' PHE . . . . . 0.465 ' CZ ' HG23 ' A' ' 401' ' ' VAL . 3.4 p90 -147.95 150.54 34.23 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.447 0.641 . . . . 0.0 111.793 179.185 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 378' ' ' LYS . . . . . 0.748 ' HD3' ' H ' ' A' ' 378' ' ' LYS . 0.3 OUTLIER -112.37 130.29 56.01 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 114.638 -1.164 . . . . 0.0 108.383 174.688 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -126.23 156.64 19.83 Favored Glycine 0 N--CA 1.444 -0.821 0 C-N-CA 120.4 -0.905 . . . . 0.0 113.248 -172.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 26.7 p -125.24 137.74 54.1 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.219 -0.491 . . . . 0.0 109.938 178.007 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 381' ' ' TRP . . . . . 0.442 ' CE3' ' HB3' ' A' ' 368' ' ' PHE . 41.2 m95 -60.61 121.01 11.11 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.146 0.498 . . . . 0.0 110.943 -178.074 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 382' ' ' THR . . . . . . . . . . . . . 4.2 m -104.34 55.11 0.72 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.815 -0.629 . . . . 0.0 111.35 -171.447 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 383' ' ' GLU . . . . . . . . . . . . . 28.5 tt0 -177.61 -56.79 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.765 174.468 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 384' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -153.46 148.93 27.2 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 178.334 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 385' ' ' GLY . . . . . . . . . . . . . . . 109.91 135.1 7.04 Favored Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 120.64 -0.79 . . . . 0.0 112.318 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 386' ' ' GLY . . . . . . . . . . . . . . . -113.38 41.27 2.25 Favored Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 120.995 -0.621 . . . . 0.0 112.055 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -112.21 153.33 17.45 Favored Glycine 0 N--CA 1.447 -0.591 0 C-N-CA 120.965 -0.636 . . . . 0.0 111.647 179.545 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 20.6 m-20 -93.41 143.44 26.28 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 120.961 0.41 . . . . 0.0 110.64 -177.168 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 23.9 t -112.7 137.09 46.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.782 179.464 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 5.0 p -147.42 138.83 23.87 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.817 0.341 . . . . 0.0 111.459 -179.077 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -156.74 154.11 25.26 Favored Glycine 0 N--CA 1.445 -0.764 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 23.2 mtt180 -119.51 153.15 35.78 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.468 0.652 . . . . 0.0 111.952 -175.945 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -93.71 159.31 15.26 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 114.649 -1.159 . . . . 0.0 110.045 178.643 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 394' ' ' TYR . . . . . 0.661 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 3.5 m-85 -101.62 -178.45 3.73 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.723 -177.972 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 395' ' ' GLY . . . . . 0.407 ' O ' ' N ' ' A' ' 397' ' ' ALA . . . -42.52 168.47 0.01 OUTLIER Glycine 0 CA--C 1.524 0.594 0 O-C-N 124.048 0.842 . . . . 0.0 115.159 -175.046 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_exo -19.35 -45.17 0.02 OUTLIER 'Trans proline' 0 C--N 1.356 0.924 1 C-N-CA 127.204 5.269 . . . . 0.0 117.588 -167.23 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 397' ' ' ALA . . . . . 0.407 ' N ' ' O ' ' A' ' 395' ' ' GLY . . . -72.25 -21.26 61.41 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -174.17 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 54.33 19.13 11.33 Favored Glycine 0 C--O 1.219 -0.837 0 CA-C-N 115.918 -0.583 . . . . 0.0 113.777 174.437 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 399' ' ' GLU . . . . . 0.88 ' HG3' ' HB3' ' A' ' 424' ' ' LYS . 23.0 tt0 -79.7 -10.66 59.82 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.538 0.685 . . . . 0.0 110.161 -174.312 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -118.54 125.7 50.41 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.864 178.458 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 401' ' ' VAL . . . . . 0.465 HG23 ' CZ ' ' A' ' 377' ' ' PHE . 12.9 p -130.36 141.12 47.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.64 178.01 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -145.43 139.01 26.6 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.847 -177.678 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -167.75 -163.83 22.35 Favored Glycine 0 N--CA 1.444 -0.799 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.1 179.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 404' ' ' LYS . . . . . 0.554 ' HG2' HG13 ' A' ' 419' ' ' VAL . 21.2 mtmt -146.89 158.98 44.06 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 19.1 p90 -114.74 134.75 54.85 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 170.329 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 406' ' ' SER . . . . . 0.401 ' OG ' ' HA2' ' A' ' 416' ' ' GLY . 40.0 m -149.06 125.61 11.0 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.021 0.439 . . . . 0.0 111.724 -174.569 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 27.3 p90 -93.13 106.62 18.56 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 166.89 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 408' ' ' ARG . . . . . . . . . . . . . 14.2 ptm180 -136.03 72.19 61.16 Favored Pre-proline 0 C--N 1.322 -0.603 0 N-CA-C 112.757 0.651 . . . . 0.0 112.757 -172.65 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 409' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_exo -63.52 -44.06 15.45 Favored 'Trans proline' 0 C--N 1.347 0.49 0 C-N-CA 122.267 1.978 . . . . 0.0 109.67 169.64 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 410' ' ' THR . . . . . 0.546 ' HB ' ' HD3' ' A' ' 414' ' ' LYS . 2.4 m -94.86 129.85 41.68 Favored 'General case' 0 N--CA 1.445 -0.684 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 168.199 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 411' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -84.01 30.6 0.51 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.954 0.407 . . . . 0.0 111.101 -178.18 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 412' ' ' ALA . . . . . . . . . . . . . . . -154.66 138.74 16.45 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.117 178.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 413' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 50.01 23.56 1.14 Allowed 'General case' 0 N--CA 1.479 0.983 0 C-N-CA 124.535 1.134 . . . . 0.0 112.581 178.203 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 414' ' ' LYS . . . . . 0.546 ' HD3' ' HB ' ' A' ' 410' ' ' THR . 12.2 mptt -106.42 -171.56 1.92 Allowed 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 176.148 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 415' ' ' GLY . . . . . . . . . . . . . . . -67.94 131.11 28.08 Favored Glycine 0 N--CA 1.444 -0.803 0 C-N-CA 119.625 -1.274 . . . . 0.0 111.165 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 416' ' ' GLY . . . . . 0.401 ' HA2' ' OG ' ' A' ' 406' ' ' SER . . . -165.86 21.68 0.12 Allowed Glycine 0 N--CA 1.446 -0.64 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 -177.0 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 417' ' ' PHE . . . . . 0.782 ' HB3' ' HD2' ' A' ' 326' ' ' PHE . 99.0 m-85 -126.65 -176.24 3.63 Favored 'General case' 0 N--CA 1.435 -1.185 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 -179.545 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 418' ' ' GLY . . . . . 0.505 ' H ' ' HD2' ' A' ' 326' ' ' PHE . . . 81.95 77.07 1.06 Allowed Glycine 0 N--CA 1.436 -1.311 0 C-N-CA 118.212 -1.947 . . . . 0.0 110.771 -174.58 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 419' ' ' VAL . . . . . 0.592 HG11 ' HE2' ' A' ' 326' ' ' PHE . 13.0 m -104.73 161.54 4.77 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -175.264 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 420' ' ' PHE . . . . . 0.401 ' HB3' HG13 ' A' ' 323' ' ' VAL . 49.5 p90 -139.27 147.74 42.09 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.109 0.48 . . . . 0.0 110.645 -178.405 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -137.44 134.61 36.04 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 174.254 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -132.0 134.75 7.79 Favored Glycine 0 N--CA 1.437 -1.257 0 C-N-CA 120.321 -0.942 . . . . 0.0 111.625 -177.695 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 17.2 mtpp -109.48 125.61 52.64 Favored 'General case' 0 C--N 1.314 -0.943 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 178.377 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 424' ' ' LYS . . . . . 0.88 ' HB3' ' HG3' ' A' ' 399' ' ' GLU . 8.0 tttm -66.53 117.88 9.35 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.855 -179.284 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 11.2 tp10 -100.46 113.27 25.91 Favored 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 173.762 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 426' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 -73.9 80.5 1.65 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.574 0.702 . . . . 0.0 109.642 175.603 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 427' ' ' ASP . . . . . . . . . . . . . 51.8 t0 -62.06 124.69 21.49 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 114.563 -1.199 . . . . 0.0 110.949 -177.02 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . 0.473 ' O ' ' HB3' ' A' ' 429' ' ' GLU . 52.8 tp -67.55 -39.96 84.97 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 114.794 -1.094 . . . . 0.0 109.688 176.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 429' ' ' GLU . . . . . 0.473 ' HB3' ' O ' ' A' ' 428' ' ' LEU . 2.4 pp20? 167.83 -25.57 0.0 OUTLIER 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 114.556 -1.202 . . . . 0.0 108.037 178.387 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 430' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER 66.45 -70.51 0.1 Allowed 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 114.858 -1.064 . . . . 0.0 111.986 175.94 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 30.6 t-80 -165.03 72.34 0.19 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.004 0.431 . . . . 0.0 110.695 -179.571 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 432' ' ' HIS . . . . . . . . . . . . . 81.2 m-70 -106.95 -4.44 19.09 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.018 0.437 . . . . 0.0 110.13 173.057 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 433' ' ' HIS . . . . . . . . . . . . . 44.6 m-70 -97.11 96.48 8.48 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.872 178.483 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 434' ' ' HIS . . . . . . . . . . . . . 4.6 t-80 -110.65 -23.79 10.88 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 172.637 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 435' ' ' HIS . . . . . . . . . . . . . 5.1 p-80 . . . . . 0 C--O 1.246 0.882 0 CA-C-N 114.692 -1.14 . . . . 0.0 109.271 173.497 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 276' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 . . . . . 0 N--CA 1.483 1.179 0 CA-C-O 120.399 0.142 . . . . 0.0 111.153 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 70.3 mt -95.7 -74.43 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.304 0 CA-C-O 121.218 0.532 . . . . 0.0 111.463 -177.744 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 278' ' ' PHE . . . . . . . . . . . . . 58.2 m-85 -63.52 -31.95 73.26 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.061 -0.972 . . . . 0.0 111.117 -178.486 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -136.16 87.52 23.21 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.721 179.165 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 280' ' ' PRO . . . . . 0.489 ' O ' ' HB2' ' A' ' 281' ' ' GLU . 1.0 OUTLIER -84.04 117.77 2.27 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 122.672 2.248 . . . . 0.0 111.286 174.584 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . 0.489 ' HB2' ' O ' ' A' ' 280' ' ' PRO . 26.1 tt0 170.51 -43.86 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.284 0 O-C-N 123.662 0.601 . . . . 0.0 110.219 -179.57 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -176.71 -148.91 7.35 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.146 -179.538 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 283' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -102.36 84.38 2.45 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 120.872 0.368 . . . . 0.0 111.289 -177.488 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 82.4 m-85 -92.0 120.06 32.3 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 176.082 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . 0.458 ' HA ' ' NE ' ' A' ' 302' ' ' ARG . 17.8 ptp180 -133.16 -13.06 2.78 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.914 -172.894 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 42.5 m-85 -74.77 -68.49 0.54 Allowed 'General case' 0 C--N 1.324 -0.51 0 C-N-CA 120.565 -0.454 . . . . 0.0 110.111 176.569 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . 0.499 HD13 ' HG3' ' A' ' 304' ' ' GLN . 3.5 mm? -115.58 127.21 55.07 Favored 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 120.814 -0.355 . . . . 0.0 110.93 177.392 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 288' ' ' THR . . . . . 0.725 ' HB ' ' CB ' ' A' ' 302' ' ' ARG . 59.8 m -170.17 152.96 4.36 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 176.434 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 289' ' ' TYR . . . . . . . . . . . . . 84.3 m-85 -138.17 122.46 18.2 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 176.568 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . 0.426 ' O ' ' HA ' ' A' ' 301' ' ' LEU . . . 158.08 168.39 20.31 Favored Glycine 0 N--CA 1.444 -0.781 0 C-N-CA 119.015 -1.564 . . . . 0.0 112.524 170.704 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 291' ' ' ALA . . . . . 0.56 ' HA ' ' CD1' ' A' ' 301' ' ' LEU . . . -143.84 111.09 5.82 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-O 120.996 0.427 . . . . 0.0 111.717 178.041 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 292' ' ' GLU . . . . . 0.416 ' O ' ' HB3' ' A' ' 300' ' ' ALA . 29.1 tt0 -163.8 121.05 1.77 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.292 -0.867 . . . . 0.0 108.977 169.161 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 293' ' ' LYS . . . . . . . . . . . . . 31.1 ttpt -118.14 125.32 50.01 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.225 -177.136 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 294' ' ' LEU . . . . . 0.766 ' HB3' ' HB3' ' A' ' 298' ' ' SER . 6.1 tt -86.87 118.97 70.87 Favored Pre-proline 0 N--CA 1.442 -0.854 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 -179.148 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 295' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_exo -65.9 97.59 0.34 Allowed 'Trans proline' 0 N--CA 1.464 -0.235 0 C-N-CA 122.803 2.336 . . . . 0.0 111.387 179.155 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . 157.25 15.41 0.04 OUTLIER Glycine 0 N--CA 1.445 -0.7 0 CA-C-N 115.681 -0.69 . . . . 0.0 112.356 -177.119 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 115.9 -24.66 10.0 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.572 -0.823 . . . . 0.0 113.383 177.786 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 298' ' ' SER . . . . . 0.766 ' HB3' ' HB3' ' A' ' 294' ' ' LEU . 8.7 t -82.89 167.87 17.61 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 117.063 0.431 . . . . 0.0 110.901 -174.544 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 299' ' ' TYR . . . . . . . . . . . . . 1.3 p90 -159.56 142.97 14.42 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.252 -173.769 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 300' ' ' ALA . . . . . 0.622 ' O ' HD13 ' A' ' 301' ' ' LEU . . . -152.07 90.14 1.5 Allowed 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 120.441 -0.504 . . . . 0.0 111.185 171.677 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 301' ' ' LEU . . . . . 0.622 HD13 ' O ' ' A' ' 300' ' ' ALA . 0.5 OUTLIER -139.59 150.1 44.61 Favored 'General case' 0 CA--C 1.512 -0.489 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 172.28 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 302' ' ' ARG . . . . . 0.725 ' CB ' ' HB ' ' A' ' 288' ' ' THR . 15.1 tpp180 -164.99 127.74 2.24 Favored 'General case' 0 C--N 1.317 -0.832 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 168.298 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 303' ' ' VAL . . . . . . . . . . . . . 17.5 m -111.88 122.38 66.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 121.108 0.48 . . . . 0.0 110.992 -179.641 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 304' ' ' GLN . . . . . 0.499 ' HG3' HD13 ' A' ' 287' ' ' LEU . 75.6 mm-40 -138.26 160.34 39.71 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.294 177.702 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . 0.624 ' O ' ' HD3' ' A' ' 307' ' ' PRO . . . -94.15 -171.37 38.36 Favored Glycine 0 N--CA 1.444 -0.816 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 175.54 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 306' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -88.48 106.02 11.37 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 117.268 0.534 . . . . 0.0 110.381 -179.842 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . 0.624 ' HD3' ' O ' ' A' ' 305' ' ' GLY . 85.2 Cg_endo -89.27 149.33 5.46 Favored 'Trans proline' 0 N--CA 1.452 -0.937 0 C-N-CA 122.848 2.365 . . . . 0.0 111.947 178.283 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . 0.729 ' HB3' ' CD2' ' A' ' 313' ' ' LEU . . . -61.24 169.26 2.21 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.231 174.027 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 309' ' ' LYS . . . . . 0.685 ' H ' HD22 ' A' ' 313' ' ' LEU . 13.0 mptt -125.42 85.24 2.38 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 174.355 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -57.4 -19.71 34.36 Favored Glycine 0 N--CA 1.462 0.409 0 N-CA-C 114.28 0.472 . . . . 0.0 114.28 -168.83 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -87.35 -16.27 35.51 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.91 0.386 . . . . 0.0 111.227 179.15 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 47.9 tpp -110.95 -34.38 6.24 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.153 -175.067 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 313' ' ' LEU . . . . . 0.729 ' CD2' ' HB3' ' A' ' 308' ' ' ALA . 1.7 pp -83.45 137.09 34.06 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 175.471 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 314' ' ' ALA . . . . . 0.487 ' HA ' ' HB2' ' A' ' 346' ' ' PHE . . . -145.63 172.57 13.07 Favored 'General case' 0 C--N 1.318 -0.781 0 N-CA-C 112.62 0.6 . . . . 0.0 112.62 -166.049 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.31 176.5 15.77 Favored Glycine 0 N--CA 1.445 -0.758 0 CA-C-N 115.061 -0.972 . . . . 0.0 110.932 -177.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 15.7 p -108.0 134.01 51.5 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 170.619 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -139.45 161.12 38.24 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-O 121.204 0.526 . . . . 0.0 111.785 -172.273 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . 0.697 ' HA ' ' O ' ' A' ' 342' ' ' ALA . 7.7 p -141.22 124.12 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.936 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.51 173.818 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . 0.58 ' CE2' ' HB2' ' A' ' 424' ' ' LYS . 1.9 m-85 -102.18 143.76 31.58 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.605 -178.133 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 47.0 m-80 -127.78 132.6 49.49 Favored 'General case' 0 C--N 1.311 -1.073 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 176.132 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -165.12 -159.33 11.28 Favored Glycine 0 N--CA 1.442 -0.91 0 C-N-CA 120.218 -0.992 . . . . 0.0 112.167 -178.522 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -120.78 156.13 32.53 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 120.969 0.414 . . . . 0.0 110.298 -177.473 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 323' ' ' VAL . . . . . 0.771 HG23 HG12 ' A' ' 355' ' ' ILE . 41.0 t -119.45 118.32 56.94 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.621 -179.24 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 324' ' ' LEU . . . . . . . . . . . . . 96.4 mt -104.3 102.4 12.1 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.317 0.58 . . . . 0.0 110.149 -179.349 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 325' ' ' HIS . . . . . 0.479 ' HB3' ' OH ' ' A' ' 405' ' ' TYR . 6.3 p80 -108.1 132.06 53.97 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.523 176.524 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 326' ' ' PHE . . . . . 0.679 ' HD2' ' HB3' ' A' ' 417' ' ' PHE . 10.3 m-85 -106.52 150.15 26.41 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.695 -169.395 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 327' ' ' HIS . . . . . . . . . . . . . 10.9 p-80 -166.37 150.94 7.79 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.119 175.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 328' ' ' THR . . . . . . . . . . . . . 9.5 p -84.52 100.69 11.54 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.222 0.534 . . . . 0.0 111.772 -174.601 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 329' ' ' GLU . . . . . 0.524 ' HG3' ' CE2' ' A' ' 334' ' ' TYR . 6.5 mm-40 -88.75 93.45 9.58 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.033 177.664 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 330' ' ' ASN . . . . . . . . . . . . . 7.4 t30 67.65 -66.49 0.21 Allowed 'General case' 0 N--CA 1.467 0.405 0 C-N-CA 123.279 0.632 . . . . 0.0 110.886 -175.734 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 331' ' ' GLY . . . . . 0.598 ' O ' ' HB2' ' A' ' 332' ' ' ARG . . . -177.69 88.32 0.07 OUTLIER Glycine 0 N--CA 1.446 -0.683 0 N-CA-C 110.702 -0.959 . . . . 0.0 110.702 176.751 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 332' ' ' ARG . . . . . 0.598 ' HB2' ' O ' ' A' ' 331' ' ' GLY . 0.0 OUTLIER 156.61 90.97 0.0 OUTLIER Pre-proline 0 N--CA 1.465 0.286 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 -175.248 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 333' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -72.08 70.54 2.99 Favored 'Trans proline' 0 C--O 1.234 0.295 0 C-N-CA 122.783 2.322 . . . . 0.0 112.676 -177.457 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 334' ' ' TYR . . . . . 0.524 ' CE2' ' HG3' ' A' ' 329' ' ' GLU . 51.3 p90 -77.53 135.15 65.12 Favored Pre-proline 0 N--CA 1.453 -0.282 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 175.232 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 335' ' ' PRO . . . . . 0.409 ' HD3' ' HA ' ' A' ' 334' ' ' TYR . 2.8 Cg_endo -79.64 125.65 6.28 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 122.138 1.892 . . . . 0.0 112.232 -176.265 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 336' ' ' THR . . . . . . . . . . . . . 4.9 p -87.01 138.82 31.17 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.132 172.635 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 337' ' ' ARG . . . . . 0.594 ' HA ' ' O ' ' A' ' 323' ' ' VAL . 0.0 OUTLIER -115.7 124.22 50.28 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-O 121.416 0.627 . . . . 0.0 111.503 -172.428 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -103.69 -177.97 25.86 Favored Glycine 0 N--CA 1.442 -0.904 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.949 174.355 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 339' ' ' ARG . . . . . 0.45 ' O ' ' HA ' ' A' ' 355' ' ' ILE . 75.4 mtp180 -114.18 127.49 55.92 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 120.952 0.406 . . . . 0.0 109.911 -177.575 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 340' ' ' PHE . . . . . 0.572 ' HB2' HG22 ' A' ' 323' ' ' VAL . 29.6 t80 -126.85 139.91 52.74 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.257 -169.412 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 341' ' ' ALA . . . . . 0.514 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -139.04 155.75 47.71 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 114.587 -1.188 . . . . 0.0 108.844 172.662 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . 0.842 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -143.12 117.82 9.85 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.14 0.495 . . . . 0.0 111.405 -177.368 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . 0.642 ' HB3' ' HB3' ' A' ' 352' ' ' ASP . 3.6 tppp? -96.07 98.95 10.76 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 114.851 -1.068 . . . . 0.0 108.943 -179.699 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 344' ' ' VAL . . . . . 0.652 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.6 OUTLIER -123.33 128.33 74.75 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 N-CA-C 113.099 0.777 . . . . 0.0 113.099 -169.56 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 345' ' ' ASP . . . . . 0.409 ' HB2' ' HB3' ' A' ' 348' ' ' SER . 1.8 m-20 -100.41 107.64 19.44 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 174.159 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 346' ' ' PHE . . . . . 0.487 ' HB2' ' HA ' ' A' ' 314' ' ' ALA . 38.0 m-85 -64.79 -36.58 84.77 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.807 0.337 . . . . 0.0 111.204 -176.391 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -68.62 -14.8 67.78 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.406 -178.544 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 348' ' ' SER . . . . . 0.409 ' HB3' ' HB2' ' A' ' 345' ' ' ASP . 44.2 t -109.13 -9.6 15.03 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.292 0.568 . . . . 0.0 110.135 179.219 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 349' ' ' LYS . . . . . 0.437 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 31.8 mtmm 52.44 55.36 9.22 Favored 'General case' 0 N--CA 1.462 0.137 0 CA-C-N 114.966 -1.016 . . . . 0.0 111.326 -176.07 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 8.6 t -146.72 145.69 30.07 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.508 179.518 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 351' ' ' VAL . . . . . 0.652 ' HB ' ' HB ' ' A' ' 344' ' ' VAL . 0.6 OUTLIER -136.46 146.65 28.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.956 0.408 . . . . 0.0 110.432 -177.042 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 352' ' ' ASP . . . . . 0.842 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 36.8 t70 -108.6 117.47 34.26 Favored 'General case' 0 C--O 1.211 -0.929 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 172.927 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -116.04 114.28 3.06 Favored Glycine 0 C--N 1.302 -1.334 0 C-N-CA 120.242 -0.98 . . . . 0.0 112.031 -176.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 354' ' ' ILE . . . . . 0.532 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -113.65 129.08 70.12 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 CA-C-O 120.977 0.418 . . . . 0.0 110.475 -175.495 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 355' ' ' ILE . . . . . 0.771 HG12 HG23 ' A' ' 323' ' ' VAL . 5.1 mp -127.5 111.78 26.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.95 177.715 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 356' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -103.25 142.64 33.83 Favored 'General case' 0 C--N 1.323 -0.583 0 C-N-CA 120.164 -0.614 . . . . 0.0 109.688 175.028 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 20.2 m -92.67 10.22 31.54 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.236 -175.784 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 358' ' ' GLY . . . . . . . . . . . . . . . 78.08 -0.09 74.54 Favored Glycine 0 N--CA 1.453 -0.211 0 N-CA-C 111.381 -0.688 . . . . 0.0 111.381 -174.176 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 359' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -148.39 100.98 3.2 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.07 -0.565 . . . . 0.0 109.667 -179.303 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 360' ' ' ASP . . . . . 0.416 ' O ' ' HA2' ' A' ' 364' ' ' GLY . 32.8 t70 -83.26 -23.91 32.5 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 121.051 0.453 . . . . 0.0 111.493 -178.083 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 361' ' ' LEU . . . . . . . . . . . . . 2.2 mm? -76.78 -34.88 57.96 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 112.543 0.571 . . . . 0.0 112.543 -170.785 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 362' ' ' HIS . . . . . . . . . . . . . 42.5 m80 -111.42 -57.16 2.29 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.942 0.401 . . . . 0.0 110.666 -175.121 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 363' ' ' MET . . . . . 0.854 ' HA ' ' HE2' ' A' ' 363' ' ' MET . 9.8 mmt -77.39 -53.33 7.79 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 177.256 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 364' ' ' GLY . . . . . 0.416 ' HA2' ' O ' ' A' ' 360' ' ' ASP . . . 110.98 170.33 19.26 Favored Glycine 0 N--CA 1.441 -1.032 0 CA-C-N 115.331 -0.85 . . . . 0.0 112.55 175.87 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 365' ' ' THR . . . . . . . . . . . . . 31.7 m -107.16 112.76 25.8 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 170.595 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 21.6 mp0 -105.43 117.56 34.33 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 121.363 0.602 . . . . 0.0 109.934 -173.512 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 25.4 pttm -114.96 146.99 40.62 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.665 178.54 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 368' ' ' PHE . . . . . 0.436 ' HA ' ' H ' ' A' ' 382' ' ' THR . 44.6 p90 -124.68 157.96 34.32 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 178.048 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 8.0 ttpt -126.05 134.96 51.26 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 173.538 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -136.14 144.87 45.28 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.095 -173.583 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -96.92 134.92 39.64 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 175.847 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 372' ' ' ILE . . . . . 0.437 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 66.8 mt -79.75 105.71 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.619 0 CA-C-O 121.884 0.85 . . . . 0.0 110.739 -177.804 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . 0.417 ' HB3' ' HD3' ' A' ' 378' ' ' LYS . 32.1 t70 -108.27 80.69 1.39 Allowed 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 114.492 -1.231 . . . . 0.0 109.19 -178.217 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 62.97 118.83 0.01 OUTLIER Glycine 0 CA--C 1.523 0.541 0 CA-C-N 114.54 -1.209 . . . . 0.0 113.488 -176.705 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 375' ' ' ASN . . . . . 0.695 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 3.1 p-10 28.92 46.67 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 124.363 1.065 . . . . 0.0 113.631 178.211 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 158.71 178.89 33.15 Favored Glycine 0 N--CA 1.442 -0.914 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 179.551 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 377' ' ' PHE . . . . . 0.61 ' CZ ' HG22 ' A' ' 401' ' ' VAL . 4.0 p90 -140.62 150.99 44.27 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 117.797 0.798 . . . . 0.0 112.127 -176.981 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 378' ' ' LYS . . . . . 0.417 ' HD3' ' HB3' ' A' ' 373' ' ' ASP . 0.0 OUTLIER -125.96 134.77 51.42 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 176.562 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -161.19 -158.6 9.46 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.178 -1.011 . . . . 0.0 112.853 -177.016 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 15.2 t -150.13 166.45 29.76 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.706 0.289 . . . . 0.0 110.383 -177.288 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 381' ' ' TRP . . . . . 0.786 ' HD1' ' HA3' ' A' ' 387' ' ' GLY . 49.5 m95 -67.62 121.11 15.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.856 -178.502 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 382' ' ' THR . . . . . 0.436 ' H ' ' HA ' ' A' ' 368' ' ' PHE . 22.7 m 60.73 -85.88 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 114.774 -1.103 . . . . 0.0 112.533 179.46 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 383' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -133.01 -48.85 0.86 Allowed 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 -176.249 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 384' ' ' ASN . . . . . . . . . . . . . 44.9 t-20 -163.17 72.09 0.29 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.185 -0.916 . . . . 0.0 108.864 172.254 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 385' ' ' GLY . . . . . . . . . . . . . . . -88.3 2.63 85.23 Favored Glycine 0 N--CA 1.451 -0.315 0 CA-C-N 115.624 -0.716 . . . . 0.0 112.34 -179.146 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 386' ' ' GLY . . . . . . . . . . . . . . . 86.49 -14.94 53.55 Favored Glycine 0 N--CA 1.453 -0.175 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.667 179.554 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . 0.786 ' HA3' ' HD1' ' A' ' 381' ' ' TRP . . . -88.17 126.61 8.17 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.087 -179.486 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -82.49 138.86 34.22 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 110.304 -0.258 . . . . 0.0 110.304 178.664 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 44.5 t -132.17 128.56 59.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.493 0.187 . . . . 0.0 110.694 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 18.2 m -133.94 151.34 51.45 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.726 -0.215 . . . . 0.0 110.673 179.245 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 391' ' ' GLY . . . . . 0.513 ' HA2' ' HA3' ' A' ' 403' ' ' GLY . . . -158.59 151.52 22.56 Favored Glycine 0 N--CA 1.454 -0.141 0 C-N-CA 121.227 -0.511 . . . . 0.0 111.859 175.795 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 5.7 mpt_? -120.3 146.87 45.69 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.873 0.368 . . . . 0.0 110.862 -176.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -91.07 158.39 16.69 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.95 -179.814 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 394' ' ' TYR . . . . . 0.671 ' O ' ' HB1' ' A' ' 308' ' ' ALA . 2.9 m-85 -102.18 -177.19 3.33 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.188 -0.915 . . . . 0.0 110.058 177.262 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 395' ' ' GLY . . . . . 0.421 ' O ' ' N ' ' A' ' 397' ' ' ALA . . . -37.98 159.33 0.01 OUTLIER Glycine 0 CA--C 1.525 0.705 0 O-C-N 124.224 0.953 . . . . 0.0 115.169 -175.539 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_exo -18.1 -42.65 0.01 OUTLIER 'Trans proline' 0 C--N 1.352 0.723 1 C-N-CA 127.729 5.62 . . . . 0.0 118.213 -168.136 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 397' ' ' ALA . . . . . 0.421 ' N ' ' O ' ' A' ' 395' ' ' GLY . . . -78.51 -19.44 52.97 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 118.402 0.546 . . . . 0.0 112.457 -173.106 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 62.41 12.1 37.57 Favored Glycine 0 C--O 1.216 -0.977 0 CA-C-O 119.355 -0.691 . . . . 0.0 114.221 176.624 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 399' ' ' GLU . . . . . 0.726 ' HG3' ' HD3' ' A' ' 424' ' ' LYS . 1.1 mp0 -63.54 -10.57 18.7 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 118.189 0.994 . . . . 0.0 111.314 -178.161 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -122.55 128.32 50.6 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 121.041 0.448 . . . . 0.0 110.003 176.107 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 401' ' ' VAL . . . . . 0.61 HG22 ' CZ ' ' A' ' 377' ' ' PHE . 12.2 p -131.89 138.01 53.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.758 175.866 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -141.67 132.01 25.09 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.083 -178.647 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 403' ' ' GLY . . . . . 0.513 ' HA3' ' HA2' ' A' ' 391' ' ' GLY . . . -151.29 -173.76 21.49 Favored Glycine 0 N--CA 1.439 -1.136 0 C-N-CA 120.089 -1.053 . . . . 0.0 112.426 -178.055 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 404' ' ' LYS . . . . . 0.826 ' HG2' HG12 ' A' ' 419' ' ' VAL . 30.3 mtpt -145.73 155.66 43.11 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -179.684 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 405' ' ' TYR . . . . . 0.479 ' OH ' ' HB3' ' A' ' 325' ' ' HIS . 50.7 p90 -131.43 147.42 52.55 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-O 121.011 0.434 . . . . 0.0 110.525 -179.232 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 28.3 m -84.3 103.31 13.37 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.14 -178.422 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 31.8 t80 -81.45 106.87 13.75 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 178.318 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 408' ' ' ARG . . . . . 0.444 ' HA ' ' HD2' ' A' ' 409' ' ' PRO . 22.9 mmm180 67.81 118.11 0.03 OUTLIER Pre-proline 0 N--CA 1.464 0.247 0 O-C-N 124.174 0.921 . . . . 0.0 110.69 -174.424 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 409' ' ' PRO . . . . . 0.444 ' HD2' ' HA ' ' A' ' 408' ' ' ARG . 11.6 Cg_endo -54.1 112.94 1.12 Allowed 'Trans proline' 0 C--O 1.236 0.383 0 C-N-CA 123.264 2.643 . . . . 0.0 112.9 -177.653 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 410' ' ' THR . . . . . . . . . . . . . 2.6 m -62.1 129.23 39.85 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.25 177.317 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 411' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -76.63 67.08 2.7 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 121.483 0.659 . . . . 0.0 111.06 -177.27 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 412' ' ' ALA . . . . . . . . . . . . . . . 178.87 -69.99 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 114.895 -1.048 . . . . 0.0 108.214 178.076 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 413' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -151.88 119.47 6.07 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 171.063 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 414' ' ' LYS . . . . . 0.439 ' HD2' ' H ' ' A' ' 414' ' ' LYS . 0.0 OUTLIER -70.39 134.17 47.6 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.072 0.463 . . . . 0.0 111.808 -169.739 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 415' ' ' GLY . . . . . . . . . . . . . . . 146.84 133.83 2.49 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.601 176.415 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 416' ' ' GLY . . . . . . . . . . . . . . . -177.76 -101.66 0.15 Allowed Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.04 -1.076 . . . . 0.0 112.78 178.473 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 417' ' ' PHE . . . . . 0.679 ' HB3' ' HD2' ' A' ' 326' ' ' PHE . 66.1 m-85 -84.36 -175.4 5.77 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 122.254 0.222 . . . . 0.0 110.472 -177.346 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 418' ' ' GLY . . . . . 0.424 ' HA2' ' HA ' ' A' ' 325' ' ' HIS . . . 82.31 77.1 1.07 Allowed Glycine 0 C--O 1.224 -0.489 0 C-N-CA 120.746 -0.74 . . . . 0.0 113.125 176.214 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 419' ' ' VAL . . . . . 0.826 HG12 ' HG2' ' A' ' 404' ' ' LYS . 23.8 m -109.71 157.61 10.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 120.903 0.382 . . . . 0.0 110.822 -179.715 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 40.8 p90 -146.4 154.8 42.04 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.952 0.406 . . . . 0.0 110.535 177.58 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -148.83 136.54 20.54 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.48 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -133.18 140.62 11.98 Favored Glycine 0 N--CA 1.445 -0.711 0 C-N-CA 120.196 -1.002 . . . . 0.0 112.582 -177.668 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 25.1 mmmt -101.9 123.83 46.49 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 176.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 424' ' ' LYS . . . . . 0.726 ' HD3' ' HG3' ' A' ' 399' ' ' GLU . 72.1 tttt -70.16 117.25 11.48 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 116.55 -0.296 . . . . 0.0 110.572 -179.591 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -73.9 114.12 11.84 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 -179.502 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 426' ' ' GLN . . . . . . . . . . . . . 5.7 tp-100 -86.78 144.34 27.1 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.39 -175.092 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 427' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -79.34 92.82 5.21 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 177.193 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . 0.584 ' HB2' ' OE2' ' A' ' 429' ' ' GLU . 70.1 mt -84.7 -65.69 0.98 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.939 -173.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 429' ' ' GLU . . . . . 0.584 ' OE2' ' HB2' ' A' ' 428' ' ' LEU . 1.8 mp0 -68.49 157.44 35.92 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 178.345 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 430' ' ' HIS . . . . . 0.422 ' HB3' ' O ' ' A' ' 429' ' ' GLU . 8.9 t60 73.4 -51.33 0.7 Allowed 'General case' 0 N--CA 1.472 0.642 0 O-C-N 123.484 0.49 . . . . 0.0 112.152 174.28 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 23.2 t-80 -75.74 -4.29 39.64 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.911 -171.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 432' ' ' HIS . . . . . . . . . . . . . 20.7 m170 -109.05 -53.84 2.6 Favored 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 120.719 -0.392 . . . . 0.0 111.951 -179.403 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 433' ' ' HIS . . . . . . . . . . . . . 91.0 m-70 -120.14 142.0 49.34 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.24 0.543 . . . . 0.0 111.721 -176.878 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 434' ' ' HIS . . . . . . . . . . . . . 56.9 t-80 -150.27 110.45 4.16 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.819 175.453 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 435' ' ' HIS . . . . . . . . . . . . . 9.5 m170 . . . . . 0 C--O 1.246 0.886 0 CA-C-O 118.38 -0.819 . . . . 0.0 110.086 177.74 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 276' ' ' ASN . . . . . 0.515 HD21 ' HE1' ' A' ' 278' ' ' PHE . 15.8 m120 . . . . . 0 N--CA 1.482 1.125 0 CA-C-O 121.183 0.516 . . . . 0.0 110.425 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 17.3 mt -83.9 42.6 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 CA-C-N 115.529 -0.759 . . . . 0.0 110.699 -177.711 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 278' ' ' PHE . . . . . 0.521 ' HZ ' ' O ' ' A' ' 300' ' ' ALA . 79.3 m-85 -35.66 121.9 0.63 Allowed 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 115.235 -0.893 . . . . 0.0 113.108 -177.715 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -68.95 111.09 7.34 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 115.26 -0.882 . . . . 0.0 109.989 177.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 280' ' ' PRO . . . . . . . . . . . . . 68.5 Cg_endo -82.37 120.2 3.2 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 122.593 2.195 . . . . 0.0 113.447 -173.208 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 173.56 -52.56 0.01 OUTLIER 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.007 -0.997 . . . . 0.0 108.404 176.281 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -164.08 160.21 33.11 Favored Glycine 0 N--CA 1.445 -0.734 0 CA-C-N 114.618 -1.173 . . . . 0.0 110.336 176.477 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 283' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -82.49 83.39 7.56 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.748 0.785 . . . . 0.0 110.202 178.899 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . 0.601 ' HB2' HD21 ' A' ' 287' ' ' LEU . 65.1 m-85 -89.97 144.13 26.19 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.445 179.463 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . 0.526 ' HA ' ' HH ' ' A' ' 289' ' ' TYR . 28.8 ttt180 -130.48 21.29 5.16 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 121.754 0.788 . . . . 0.0 110.521 -174.247 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 69.5 t80 -111.05 -2.71 15.79 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 122.439 1.114 . . . . 0.0 108.903 178.482 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . 0.601 HD21 ' HB2' ' A' ' 284' ' ' TYR . 1.2 pp -101.3 -178.35 3.71 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 113.747 -1.569 . . . . 0.0 109.696 178.91 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 288' ' ' THR . . . . . 0.706 ' HB ' ' HA ' ' A' ' 304' ' ' GLN . 4.3 m -69.06 157.54 36.62 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 -175.022 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 289' ' ' TYR . . . . . 0.793 ' HA ' ' H ' ' A' ' 303' ' ' VAL . 1.9 m-30 -137.79 164.11 29.71 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.42 0.628 . . . . 0.0 112.512 -175.357 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 158.05 131.74 1.33 Allowed Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 114.679 -1.146 . . . . 0.0 111.418 169.939 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 291' ' ' ALA . . . . . 0.974 ' HB3' ' HA ' ' A' ' 301' ' ' LEU . . . -169.07 166.27 11.0 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-N 116.64 0.22 . . . . 0.0 110.886 176.35 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 292' ' ' GLU . . . . . . . . . . . . . 57.7 mm-40 -110.18 109.0 19.34 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 177.273 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 293' ' ' LYS . . . . . 0.474 ' HB2' ' HA ' ' A' ' 300' ' ' ALA . 59.8 tttm -81.29 112.61 18.76 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.38 0.609 . . . . 0.0 112.023 -171.953 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 294' ' ' LEU . . . . . 0.629 HD11 ' HB2' ' A' ' 298' ' ' SER . 10.6 mp -122.02 161.7 41.13 Favored Pre-proline 0 C--N 1.32 -0.709 0 CA-C-N 114.963 -1.017 . . . . 0.0 108.477 171.671 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 295' ' ' PRO . . . . . . . . . . . . . 8.9 Cg_exo -73.15 -8.44 22.06 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.551 2.167 . . . . 0.0 111.752 176.453 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . -165.15 141.49 7.08 Favored Glycine 0 N--CA 1.45 -0.413 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.779 178.149 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 89.81 -76.21 1.73 Allowed Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.79 -0.719 . . . . 0.0 111.883 -179.49 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 298' ' ' SER . . . . . 0.629 ' HB2' HD11 ' A' ' 294' ' ' LEU . 35.1 m -89.74 148.94 22.96 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 176.0 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 299' ' ' TYR . . . . . . . . . . . . . 57.2 m-85 -122.43 177.21 5.5 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.935 0.398 . . . . 0.0 111.972 -172.593 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 300' ' ' ALA . . . . . 0.521 ' O ' ' HZ ' ' A' ' 278' ' ' PHE . . . -75.9 163.41 27.23 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.339 -175.143 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 301' ' ' LEU . . . . . 0.974 ' HA ' ' HB3' ' A' ' 291' ' ' ALA . 1.2 pt? -78.26 113.4 16.2 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 113.717 1.006 . . . . 0.0 113.717 -161.04 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 302' ' ' ARG . . . . . 0.727 ' HG3' ' CE1' ' A' ' 289' ' ' TYR . 18.6 ttp180 -164.12 113.49 1.21 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 114.734 -1.121 . . . . 0.0 108.793 162.133 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 303' ' ' VAL . . . . . 0.793 ' H ' ' HA ' ' A' ' 289' ' ' TYR . 11.6 p -153.91 126.36 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.61 0 N-CA-C 111.944 0.349 . . . . 0.0 111.944 167.527 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 304' ' ' GLN . . . . . 0.706 ' HA ' ' HB ' ' A' ' 288' ' ' THR . 6.5 pt20 -88.3 135.97 33.2 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.246 0.545 . . . . 0.0 111.283 -177.419 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . 0.538 ' H ' ' HB ' ' A' ' 288' ' ' THR . . . -174.41 107.12 0.24 Allowed Glycine 0 N--CA 1.446 -0.682 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.51 177.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 306' ' ' GLU . . . . . 0.921 ' HB3' ' HD3' ' A' ' 396' ' ' PRO . 34.6 tt0 -146.33 136.72 12.19 Favored Pre-proline 0 C--N 1.324 -0.517 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 -176.873 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -75.05 129.97 12.79 Favored 'Trans proline' 0 N--CA 1.462 -0.337 0 C-N-CA 121.997 1.798 . . . . 0.0 111.315 175.408 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . 0.728 ' HB1' ' O ' ' A' ' 394' ' ' TYR . . . -54.18 159.54 1.86 Allowed 'General case' 0 N--CA 1.467 0.385 0 CA-C-O 121.48 0.657 . . . . 0.0 112.282 175.804 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 309' ' ' LYS . . . . . 0.635 ' O ' ' HG ' ' A' ' 313' ' ' LEU . 35.0 mtmt -123.55 98.91 6.05 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.357 176.746 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 310' ' ' GLY . . . . . 0.616 ' HA2' HD11 ' A' ' 313' ' ' LEU . . . -60.04 -37.75 93.23 Favored Glycine 0 C--O 1.227 -0.304 0 CA-C-N 116.093 -0.503 . . . . 0.0 114.128 -170.314 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 1.3 pm0 -72.61 -20.03 61.36 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.86 0.33 . . . . 0.0 110.856 179.115 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 26.0 ttt -91.46 -21.61 20.84 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.143 0.497 . . . . 0.0 109.95 177.302 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 313' ' ' LEU . . . . . 0.635 ' HG ' ' O ' ' A' ' 309' ' ' LYS . 96.1 mt -66.19 138.95 58.05 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.332 178.998 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -156.32 139.2 15.28 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.303 -174.326 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 121.01 167.88 13.39 Favored Glycine 0 N--CA 1.443 -0.845 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.929 177.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 28.5 p -100.05 134.22 43.28 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 174.715 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 317' ' ' ALA . . . . . 0.536 ' HB2' ' HD3' ' A' ' 424' ' ' LYS . . . -138.6 152.57 48.25 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 121.053 0.454 . . . . 0.0 111.731 -174.833 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 7.3 p -121.59 113.24 38.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.441 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.263 177.5 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . 0.675 ' HH ' ' HZ ' ' A' ' 346' ' ' PHE . 21.4 m-85 -103.16 132.52 49.36 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.925 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 44.6 m-80 -124.81 139.56 53.73 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.077 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . 0.592 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -169.25 -145.93 4.83 Favored Glycine 0 N--CA 1.441 -1.014 0 C-N-CA 120.577 -0.82 . . . . 0.0 112.397 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -135.04 161.92 33.93 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 120.978 0.418 . . . . 0.0 110.947 -173.66 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 323' ' ' VAL . . . . . 0.611 HG23 ' HB2' ' A' ' 340' ' ' PHE . 68.9 t -121.12 117.89 54.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.163 178.331 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 324' ' ' LEU . . . . . . . . . . . . . 2.0 tt -98.53 103.27 15.2 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 176.631 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 325' ' ' HIS . . . . . 0.432 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 18.3 t-160 -88.58 113.32 24.03 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 -179.307 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 326' ' ' PHE . . . . . 0.685 ' HE2' HG12 ' A' ' 419' ' ' VAL . 88.4 m-85 -82.15 162.24 22.52 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.008 -177.85 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 327' ' ' HIS . . . . . . . . . . . . . 32.3 p-80 -175.74 -174.0 0.65 Allowed 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.375 -0.83 . . . . 0.0 108.769 -173.786 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 328' ' ' THR . . . . . . . . . . . . . 17.9 p -47.47 159.93 0.13 Allowed 'General case' 0 C--O 1.236 0.369 0 O-C-N 123.706 0.629 . . . . 0.0 112.035 179.337 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 329' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -57.54 161.78 3.34 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-N 115.577 -0.738 . . . . 0.0 112.622 -171.691 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 330' ' ' ASN . . . . . 0.504 ' OD1' ' HA ' ' A' ' 334' ' ' TYR . 11.4 t30 -76.95 85.95 3.49 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.11 -0.95 . . . . 0.0 111.298 -172.905 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 331' ' ' GLY . . . . . 0.439 ' O ' ' HD3' ' A' ' 333' ' ' PRO . . . -150.23 93.72 0.15 Allowed Glycine 0 N--CA 1.443 -0.87 0 N-CA-C 111.063 -0.815 . . . . 0.0 111.063 174.09 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 332' ' ' ARG . . . . . 0.73 ' HB3' ' HD3' ' A' ' 333' ' ' PRO . 48.3 ttt180 104.45 -66.19 0.0 OUTLIER Pre-proline 0 N--CA 1.482 1.162 0 C-N-CA 125.295 1.438 . . . . 0.0 112.81 -178.935 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 333' ' ' PRO . . . . . 0.73 ' HD3' ' HB3' ' A' ' 332' ' ' ARG . 4.4 Cg_exo -75.81 -23.88 12.1 Favored 'Trans proline' 0 C--N 1.358 1.034 0 C-N-CA 121.822 1.681 . . . . 0.0 113.412 -175.547 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 334' ' ' TYR . . . . . 0.784 ' HB3' ' HD2' ' A' ' 335' ' ' PRO . 62.7 m-85 66.5 174.81 0.07 OUTLIER Pre-proline 0 CA--C 1.538 0.496 0 O-C-N 123.478 0.486 . . . . 0.0 110.484 -177.841 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 335' ' ' PRO . . . . . 0.784 ' HD2' ' HB3' ' A' ' 334' ' ' TYR . 68.4 Cg_endo -75.23 151.14 38.15 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 121.976 1.784 . . . . 0.0 111.674 177.531 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 336' ' ' THR . . . . . 0.507 HG21 ' CE1' ' A' ' 362' ' ' HIS . 25.5 p -112.8 138.32 49.8 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 120.269 -0.572 . . . . 0.0 111.012 179.414 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 337' ' ' ARG . . . . . . . . . . . . . 39.1 ttt180 -131.85 112.84 12.81 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.346 -174.849 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 338' ' ' GLY . . . . . 0.843 ' HA2' ' HA3' ' A' ' 358' ' ' GLY . . . -103.26 -177.0 26.41 Favored Glycine 0 N--CA 1.446 -0.695 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 179.037 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 339' ' ' ARG . . . . . 0.966 ' HB2' ' HB3' ' A' ' 356' ' ' ASP . 66.7 mtp180 -110.28 164.5 12.6 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 178.379 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 340' ' ' PHE . . . . . 0.611 ' HB2' HG23 ' A' ' 323' ' ' VAL . 41.1 t80 -152.43 142.73 22.49 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 121.255 0.55 . . . . 0.0 111.096 -178.275 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 341' ' ' ALA . . . . . . . . . . . . . . . -138.59 156.25 47.63 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.206 -0.906 . . . . 0.0 109.025 174.063 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . 0.88 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -145.94 118.94 8.76 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-O 121.304 0.573 . . . . 0.0 110.173 -179.729 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . 0.454 ' HE2' ' HB3' ' A' ' 343' ' ' LYS . 4.8 tmmm? -102.96 103.14 13.23 Favored 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 -179.625 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 344' ' ' VAL . . . . . 0.441 ' HA ' ' HA ' ' A' ' 351' ' ' VAL . 0.2 OUTLIER -117.14 132.77 65.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-O 121.485 0.66 . . . . 0.0 112.639 -169.224 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -102.48 100.08 10.17 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 114.515 -1.22 . . . . 0.0 108.7 172.541 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 346' ' ' PHE . . . . . 0.675 ' HZ ' ' HH ' ' A' ' 319' ' ' TYR . 74.5 m-85 -67.88 -23.19 65.1 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.527 0.204 . . . . 0.0 111.184 -177.875 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -63.9 -25.27 69.11 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.016 178.315 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 37.9 m -112.58 -4.43 14.15 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.912 0.387 . . . . 0.0 110.567 177.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 349' ' ' LYS . . . . . 0.641 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 31.4 mtmm 55.69 59.3 3.91 Favored 'General case' 0 C--O 1.226 -0.179 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.892 -178.02 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 52.9 p -148.84 141.28 24.24 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.282 -179.326 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 351' ' ' VAL . . . . . 0.441 ' HA ' ' HA ' ' A' ' 344' ' ' VAL . 1.0 OUTLIER -127.57 151.84 34.9 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 CA-C-O 121.126 0.489 . . . . 0.0 110.986 -176.21 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 352' ' ' ASP . . . . . 0.88 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 19.5 t70 -108.59 119.07 38.44 Favored 'General case' 0 C--O 1.211 -0.954 0 CA-C-N 115.184 -0.917 . . . . 0.0 109.338 171.92 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -115.33 130.22 9.02 Favored Glycine 0 N--CA 1.441 -1.02 0 C-N-CA 120.473 -0.87 . . . . 0.0 111.658 -178.72 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 354' ' ' ILE . . . . . 0.457 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -131.52 129.62 62.0 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 CA-C-O 120.973 0.416 . . . . 0.0 110.196 -176.973 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 355' ' ' ILE . . . . . 0.579 HG13 HG21 ' A' ' 323' ' ' VAL . 2.3 mp -101.6 111.36 31.04 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.416 178.295 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 356' ' ' ASP . . . . . 0.966 ' HB3' ' HB2' ' A' ' 339' ' ' ARG . 9.1 t70 -74.4 154.39 38.83 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.481 -175.806 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 3.6 m -52.99 12.09 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.994 0 N-CA-C 117.177 2.288 . . . . 0.0 117.177 -163.407 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 358' ' ' GLY . . . . . 0.843 ' HA3' ' HA2' ' A' ' 338' ' ' GLY . . . -52.65 -44.0 59.82 Favored Glycine 0 CA--C 1.525 0.657 0 CA-C-N 118.767 0.712 . . . . 0.0 113.007 177.647 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 359' ' ' ASP . . . . . 0.575 ' OD2' ' HB2' ' A' ' 362' ' ' HIS . 20.9 t70 -110.93 35.46 3.51 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 121.757 0.789 . . . . 0.0 109.691 178.984 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 360' ' ' ASP . . . . . 0.702 ' HA ' ' HA2' ' A' ' 364' ' ' GLY . 18.5 t70 -65.44 -25.17 67.4 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.953 -178.031 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 361' ' ' LEU . . . . . . . . . . . . . 92.0 mt -76.45 -5.66 48.37 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.663 -178.149 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 362' ' ' HIS . . . . . 0.575 ' HB2' ' OD2' ' A' ' 359' ' ' ASP . 34.8 m80 -125.5 -74.35 0.61 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.765 0.317 . . . . 0.0 110.568 178.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 363' ' ' MET . . . . . . . . . . . . . 21.7 mmt -78.76 -39.72 35.27 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.041 0.448 . . . . 0.0 110.663 178.018 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 364' ' ' GLY . . . . . 0.702 ' HA2' ' HA ' ' A' ' 360' ' ' ASP . . . 101.45 -169.58 20.59 Favored Glycine 0 N--CA 1.448 -0.562 0 CA-C-N 115.648 -0.705 . . . . 0.0 111.492 -178.588 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 365' ' ' THR . . . . . . . . . . . . . 23.1 m -83.96 98.43 9.8 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 173.419 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 90.6 mt-30 -106.38 145.51 31.62 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.305 0.574 . . . . 0.0 111.372 -172.808 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -123.85 144.63 49.62 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.565 179.48 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 368' ' ' PHE . . . . . 0.48 ' HB3' ' CE3' ' A' ' 381' ' ' TRP . 33.2 p90 -140.17 150.74 44.58 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.963 0.411 . . . . 0.0 109.996 175.364 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 369' ' ' LYS . . . . . 0.728 ' HD3' ' HA ' ' A' ' 352' ' ' ASP . 0.0 OUTLIER -123.61 135.19 53.81 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 175.962 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . 0.44 ' HB3' HG21 ' A' ' 351' ' ' VAL . . . -132.11 152.23 51.35 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.478 -0.783 . . . . 0.0 111.213 -172.287 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -109.06 134.82 51.17 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.656 176.369 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 372' ' ' ILE . . . . . 0.641 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 95.5 mt -82.75 108.91 16.04 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-O 121.171 0.51 . . . . 0.0 110.939 -178.042 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -126.4 84.23 2.25 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-O 121.612 0.72 . . . . 0.0 110.288 178.361 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 79.07 121.22 0.3 Allowed Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.145 -0.934 . . . . 0.0 112.267 -177.188 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 375' ' ' ASN . . . . . 0.515 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 17.7 p30 1.8 60.38 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 125.6 1.56 . . . . 0.0 114.986 -171.92 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 157.55 -174.28 34.98 Favored Glycine 0 N--CA 1.438 -1.172 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 179.068 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 377' ' ' PHE . . . . . 0.508 ' CZ ' HG22 ' A' ' 401' ' ' VAL . 1.6 p90 -142.34 148.71 38.39 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.327 0.584 . . . . 0.0 111.625 -179.345 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 378' ' ' LYS . . . . . . . . . . . . . 2.7 tmtm? -123.64 112.63 17.64 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 176.733 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -135.59 -165.6 10.74 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.428 -0.891 . . . . 0.0 112.627 -175.677 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 15.0 t -144.93 159.67 42.55 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.86 0.362 . . . . 0.0 110.449 -177.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 381' ' ' TRP . . . . . 0.48 ' CE3' ' HB3' ' A' ' 368' ' ' PHE . 48.3 m95 -64.23 126.49 27.92 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.512 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 382' ' ' THR . . . . . . . . . . . . . 9.4 m -83.18 65.36 8.19 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 177.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 383' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -157.04 -75.84 0.09 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.426 -0.806 . . . . 0.0 109.638 -176.19 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 384' ' ' ASN . . . . . . . . . . . . . 25.3 t-20 -113.2 -61.38 1.75 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.125 -176.395 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 385' ' ' GLY . . . . . . . . . . . . . . . 134.67 -156.87 22.69 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 386' ' ' GLY . . . . . . . . . . . . . . . 72.16 -82.99 0.53 Allowed Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 121.298 -0.477 . . . . 0.0 112.463 179.148 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.47 128.73 39.02 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 121.18 -0.533 . . . . 0.0 112.448 -179.132 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -94.19 167.54 11.49 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.517 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 22.2 t -128.35 121.18 54.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 175.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 390' ' ' SER . . . . . 0.405 ' O ' ' HA3' ' A' ' 403' ' ' GLY . 39.5 m -117.98 155.61 29.97 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.521 -0.309 . . . . 0.0 110.698 -177.375 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -165.64 144.67 9.42 Favored Glycine 0 N--CA 1.451 -0.349 0 N-CA-C 111.541 -0.623 . . . . 0.0 111.541 177.291 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 13.7 ptp180 -116.09 152.31 33.87 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.044 0.45 . . . . 0.0 110.895 -177.142 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 10.7 m-85 -98.1 157.59 16.05 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.889 0.852 . . . . 0.0 111.81 -175.857 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 394' ' ' TYR . . . . . 0.728 ' O ' ' HB1' ' A' ' 308' ' ' ALA . 6.2 m-85 -102.94 -171.95 2.03 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 114.119 -1.4 . . . . 0.0 111.247 -175.075 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 395' ' ' GLY . . . . . 0.796 ' HA2' ' O ' ' A' ' 306' ' ' GLU . . . -33.15 157.59 0.01 OUTLIER Glycine 0 C--N 1.34 0.792 0 O-C-N 124.576 1.173 . . . . 0.0 114.215 -178.316 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 396' ' ' PRO . . . . . 0.921 ' HD3' ' HB3' ' A' ' 306' ' ' GLU . 12.2 Cg_endo -46.37 -17.98 0.41 Allowed 'Trans proline' 0 N--CA 1.482 0.818 1 C-N-CA 125.674 4.249 . . . . 0.0 116.831 -149.843 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 397' ' ' ALA . . . . . 0.466 ' HB2' ' HG3' ' A' ' 399' ' ' GLU . . . -90.89 -17.9 25.69 Favored 'General case' 0 C--N 1.316 -0.872 0 C-N-CA 120.728 -0.389 . . . . 0.0 111.83 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 72.74 16.35 77.95 Favored Glycine 0 C--N 1.336 0.56 0 C-N-CA 121.178 -0.534 . . . . 0.0 112.544 173.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 399' ' ' GLU . . . . . 0.482 ' HG2' ' CE ' ' A' ' 424' ' ' LYS . 28.5 mt-10 -67.7 -10.78 55.41 Favored 'General case' 0 C--N 1.332 -0.18 0 C-N-CA 122.902 0.481 . . . . 0.0 111.115 -174.766 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -123.31 136.02 54.48 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 173.1 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 401' ' ' VAL . . . . . 0.508 HG22 ' CZ ' ' A' ' 377' ' ' PHE . 14.0 p -140.15 143.1 30.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.137 177.413 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -143.19 138.81 29.98 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.181 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 403' ' ' GLY . . . . . 0.405 ' HA3' ' O ' ' A' ' 390' ' ' SER . . . -157.25 -176.2 29.04 Favored Glycine 0 N--CA 1.441 -0.985 0 C-N-CA 120.379 -0.915 . . . . 0.0 112.185 -178.897 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 404' ' ' LYS . . . . . 0.826 ' HG2' HG11 ' A' ' 419' ' ' VAL . 52.2 mttt -145.34 158.85 43.75 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 -178.516 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 36.2 p90 -119.72 161.56 20.52 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.043 0.449 . . . . 0.0 111.34 179.658 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 19.2 t -83.9 111.34 19.15 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.673 178.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . 0.554 ' HE2' ' H ' ' A' ' 411' ' ' ASP . 19.7 p90 -60.31 135.09 57.63 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 114.918 -1.037 . . . . 0.0 111.929 -178.072 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 408' ' ' ARG . . . . . 0.534 ' HB2' ' HD3' ' A' ' 409' ' ' PRO . 57.1 mtp180 -42.56 -54.14 8.58 Favored Pre-proline 0 N--CA 1.471 0.612 0 N-CA-C 114.222 1.193 . . . . 0.0 114.222 -173.415 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 409' ' ' PRO . . . . . 0.534 ' HD3' ' HB2' ' A' ' 408' ' ' ARG . 55.1 Cg_exo -53.96 -36.07 82.62 Favored 'Trans proline' 0 C--N 1.358 1.053 0 C-N-CA 122.379 2.052 . . . . 0.0 113.084 -177.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 410' ' ' THR . . . . . . . . . . . . . 4.9 m 49.38 64.2 1.84 Allowed 'General case' 0 C--O 1.236 0.35 0 CA-C-O 121.225 0.536 . . . . 0.0 110.88 -178.031 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 411' ' ' ASP . . . . . 0.554 ' H ' ' HE2' ' A' ' 407' ' ' TYR . 15.2 m-20 -72.74 -49.74 29.02 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.365 -179.49 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 412' ' ' ALA . . . . . . . . . . . . . . . -121.19 152.77 38.41 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.577 -0.738 . . . . 0.0 109.956 178.132 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 413' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -76.39 64.35 2.11 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.752 -177.494 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 414' ' ' LYS . . . . . . . . . . . . . 45.1 mtmt -143.42 127.45 17.44 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.446 179.06 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 415' ' ' GLY . . . . . . . . . . . . . . . -90.11 132.17 11.13 Favored Glycine 0 N--CA 1.441 -1.003 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 167.748 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 416' ' ' GLY . . . . . 0.553 ' HA2' ' HD3' ' A' ' 404' ' ' LYS . . . 177.76 -40.57 0.09 OUTLIER Glycine 0 N--CA 1.446 -0.663 0 C-N-CA 119.647 -1.263 . . . . 0.0 113.048 -174.68 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 417' ' ' PHE . . . . . 0.641 ' HA ' ' HD2' ' A' ' 326' ' ' PHE . 28.3 m-85 -80.31 141.39 35.52 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 178.418 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 418' ' ' GLY . . . . . 0.556 ' H ' ' HD2' ' A' ' 326' ' ' PHE . . . 78.51 76.82 0.9 Allowed Glycine 0 N--CA 1.441 -1.018 0 C-N-CA 120.068 -1.063 . . . . 0.0 111.211 -174.468 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 419' ' ' VAL . . . . . 0.826 HG11 ' HG2' ' A' ' 404' ' ' LYS . 32.3 m -105.47 153.12 7.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-O 120.705 0.288 . . . . 0.0 110.388 -177.791 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 51.9 p90 -135.69 155.01 51.08 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.893 179.104 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 421' ' ' ALA . . . . . 0.592 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -143.72 136.1 26.96 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.089 179.384 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -129.98 133.6 7.5 Favored Glycine 0 N--CA 1.44 -1.044 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.038 -179.048 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 63.0 mttm -111.81 125.72 54.31 Favored 'General case' 0 C--N 1.313 -0.979 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 177.211 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 424' ' ' LYS . . . . . 0.582 ' HB2' ' CE2' ' A' ' 319' ' ' TYR . 27.2 ttpp -70.23 122.3 19.24 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 120.893 0.378 . . . . 0.0 110.101 178.551 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -97.28 126.31 42.41 Favored 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 176.685 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 426' ' ' GLN . . . . . . . . . . . . . 64.2 mt-30 -81.71 80.25 8.08 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.517 -178.228 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 427' ' ' ASP . . . . . . . . . . . . . 12.3 t70 76.43 136.4 0.06 Allowed 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 114.16 -1.382 . . . . 0.0 110.585 -177.191 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 96.0 mt -63.92 -30.92 71.96 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.353 -0.84 . . . . 0.0 111.415 -177.28 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 429' ' ' GLU . . . . . . . . . . . . . 42.6 mm-40 -92.67 63.96 4.07 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.496 0.665 . . . . 0.0 109.516 175.536 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 430' ' ' HIS . . . . . . . . . . . . . 36.1 t60 -82.87 70.27 9.83 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.81 -173.351 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 73.4 m-70 -100.05 39.39 1.34 Allowed 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 179.076 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 432' ' ' HIS . . . . . . . . . . . . . 46.8 t-80 -53.19 -37.59 62.08 Favored 'General case' 0 CA--C 1.529 0.141 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.789 -178.003 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 433' ' ' HIS . . . . . . . . . . . . . 44.7 t-80 -136.58 -51.13 0.68 Allowed 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 174.758 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 434' ' ' HIS . . . . . 0.532 ' O ' ' HB2' ' A' ' 435' ' ' HIS . 25.6 t60 -179.78 -56.35 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 106.534 -1.654 . . . . 0.0 106.534 169.105 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 435' ' ' HIS . . . . . 0.532 ' HB2' ' O ' ' A' ' 434' ' ' HIS . 4.6 t-160 . . . . . 0 C--O 1.248 0.987 0 CA-C-N 114.18 -1.373 . . . . 0.0 108.665 165.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 276' ' ' ASN . . . . . . . . . . . . . 30.3 p-10 . . . . . 0 N--CA 1.479 1.023 0 N-CA-C 111.354 0.131 . . . . 0.0 111.354 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . 0.556 HD11 ' HB3' ' A' ' 293' ' ' LYS . 7.0 mt -84.55 40.43 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -169.801 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 278' ' ' PHE . . . . . . . . . . . . . 51.1 p90 -63.92 138.88 58.67 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.203 -0.665 . . . . 0.0 109.203 175.394 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -162.32 97.01 1.17 Allowed Pre-proline 0 C--N 1.33 -0.26 0 CA-C-O 120.726 0.298 . . . . 0.0 111.661 -176.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 280' ' ' PRO . . . . . . . . . . . . . 89.3 Cg_endo -85.16 162.83 11.49 Favored 'Trans proline' 0 CA--C 1.534 0.515 0 C-N-CA 123.091 2.527 . . . . 0.0 113.471 176.484 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . 0.667 ' HB2' ' HE2' ' A' ' 284' ' ' TYR . 31.9 mt-10 76.91 -151.43 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.501 0 CA-C-N 115.221 -0.9 . . . . 0.0 112.717 169.688 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -82.17 -150.92 8.84 Favored Glycine 0 C--N 1.338 0.651 0 N-CA-C 114.791 0.676 . . . . 0.0 114.791 -166.324 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 283' ' ' ASN . . . . . 0.547 ' HA ' ' O ' ' A' ' 286' ' ' TYR . 16.9 p-10 -89.9 83.52 6.16 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.531 0.682 . . . . 0.0 112.594 -170.384 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . 0.667 ' HE2' ' HB2' ' A' ' 281' ' ' GLU . 18.3 m-85 -101.47 98.88 9.16 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.649 -0.705 . . . . 0.0 109.28 173.977 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . 0.831 ' HB2' ' HD2' ' A' ' 302' ' ' ARG . 5.1 ttp180 65.06 49.48 2.03 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 -168.639 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.547 ' O ' ' HA ' ' A' ' 283' ' ' ASN . 83.6 t80 75.88 -49.33 0.61 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 114.966 -1.015 . . . . 0.0 109.411 -167.377 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . 0.503 ' C ' ' HG1' ' A' ' 288' ' ' THR . 13.7 tp 179.1 123.85 0.05 Allowed 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 124.141 0.977 . . . . 0.0 108.538 170.082 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 288' ' ' THR . . . . . 0.503 ' HG1' ' C ' ' A' ' 287' ' ' LEU . 38.3 m -174.03 130.14 0.39 Allowed 'General case' 0 N--CA 1.452 -0.34 0 O-C-N 123.542 0.526 . . . . 0.0 110.016 179.097 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 289' ' ' TYR . . . . . . . . . . . . . 2.7 t80 -146.01 116.59 7.6 Favored 'General case' 0 C--N 1.313 -0.992 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 164.233 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 108.42 -151.06 17.06 Favored Glycine 0 N--CA 1.437 -1.269 0 C-N-CA 118.823 -1.656 . . . . 0.0 110.574 -172.239 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 291' ' ' ALA . . . . . 0.679 ' HA ' HD13 ' A' ' 301' ' ' LEU . . . -93.91 136.92 33.7 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-O 121.337 0.589 . . . . 0.0 111.021 -177.956 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 292' ' ' GLU . . . . . 0.577 ' HG3' ' HB2' ' A' ' 300' ' ' ALA . 8.7 pt-20 -109.5 164.53 12.43 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 175.604 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 293' ' ' LYS . . . . . 0.556 ' HB3' HD11 ' A' ' 277' ' ' ILE . 53.6 tptt -116.9 134.15 55.12 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 121.15 0.5 . . . . 0.0 111.197 -178.091 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 294' ' ' LEU . . . . . 0.586 ' HB2' ' HB2' ' A' ' 298' ' ' SER . 61.6 mt -103.85 145.12 30.04 Favored Pre-proline 0 C--N 1.319 -0.735 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.345 176.624 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 295' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -54.5 97.05 0.05 OUTLIER 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 123.15 2.566 . . . . 0.0 112.092 179.136 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . 142.73 -140.56 9.92 Favored Glycine 0 N--CA 1.445 -0.741 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 -175.375 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . -105.22 3.18 40.48 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 120.523 -0.846 . . . . 0.0 112.081 179.352 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 298' ' ' SER . . . . . 0.586 ' HB2' ' HB2' ' A' ' 294' ' ' LEU . 6.1 m -81.45 143.26 32.22 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.273 0.558 . . . . 0.0 111.914 -174.701 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 299' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -122.59 142.35 50.73 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 108.231 -1.026 . . . . 0.0 108.231 172.798 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 300' ' ' ALA . . . . . 0.577 ' HB2' ' HG3' ' A' ' 292' ' ' GLU . . . -132.82 161.87 33.0 Favored 'General case' 0 C--N 1.319 -0.738 0 C-N-CA 120.777 -0.369 . . . . 0.0 111.652 -178.132 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 301' ' ' LEU . . . . . 0.679 HD13 ' HA ' ' A' ' 291' ' ' ALA . 2.5 mm? -121.84 123.33 41.52 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 175.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 302' ' ' ARG . . . . . 0.831 ' HD2' ' HB2' ' A' ' 285' ' ' ARG . 0.0 OUTLIER -128.07 125.0 38.44 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 172.787 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 303' ' ' VAL . . . . . . . . . . . . . 2.2 m -140.56 148.87 21.69 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.917 0 CA-C-N 116.223 -0.444 . . . . 0.0 109.85 175.021 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 304' ' ' GLN . . . . . 0.607 ' HB2' ' HD1' ' A' ' 284' ' ' TYR . 18.7 mm-40 -125.51 116.76 22.3 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 121.123 0.487 . . . . 0.0 110.277 178.801 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . 0.402 ' O ' ' HD3' ' A' ' 307' ' ' PRO . . . -176.81 169.27 41.63 Favored Glycine 0 N--CA 1.446 -0.687 0 CA-C-N 115.049 -0.978 . . . . 0.0 110.844 -179.321 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 306' ' ' GLU . . . . . 0.434 ' HB3' ' CA ' ' A' ' 395' ' ' GLY . 10.7 mp0 -114.2 90.67 20.82 Favored Pre-proline 0 C--N 1.323 -0.561 0 CA-C-N 117.063 0.432 . . . . 0.0 110.221 176.991 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . 0.402 ' HD3' ' O ' ' A' ' 305' ' ' GLY . 10.2 Cg_endo -90.86 122.58 0.83 Allowed 'Trans proline' 0 N--CA 1.457 -0.618 0 C-N-CA 123.441 2.761 . . . . 0.0 112.848 177.475 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . 0.741 ' HB3' ' O ' ' A' ' 394' ' ' TYR . . . -58.13 157.23 8.43 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.844 170.621 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 309' ' ' LYS . . . . . 0.57 ' N ' HD21 ' A' ' 313' ' ' LEU . 63.1 mttp -128.43 98.42 5.04 Favored 'General case' 0 C--O 1.222 -0.364 0 C-N-CA 121.022 -0.271 . . . . 0.0 110.425 -176.328 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -48.23 -43.23 25.77 Favored Glycine 0 CA--C 1.519 0.304 0 N-CA-C 114.978 0.751 . . . . 0.0 114.978 -167.784 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -76.45 -9.46 58.67 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 112.846 0.684 . . . . 0.0 112.846 -177.989 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 312' ' ' MET . . . . . 0.707 ' HE1' ' HA ' ' A' ' 312' ' ' MET . 2.5 tpt -113.93 -37.39 4.51 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.72 0.771 . . . . 0.0 109.654 -177.396 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 313' ' ' LEU . . . . . 0.731 HD23 ' HB2' ' A' ' 308' ' ' ALA . 0.6 OUTLIER -81.39 129.99 34.86 Favored 'General case' 0 N--CA 1.44 -0.938 0 CA-C-N 114.677 -1.147 . . . . 0.0 109.143 178.161 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 314' ' ' ALA . . . . . 0.622 ' HA ' ' CB ' ' A' ' 346' ' ' PHE . . . -159.19 175.57 13.28 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.989 -170.726 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.4 160.77 11.27 Favored Glycine 0 N--CA 1.447 -0.597 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -177.621 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 18.7 p -96.87 125.12 41.08 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 173.258 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 317' ' ' ALA . . . . . 0.429 ' HB2' ' HE1' ' A' ' 319' ' ' TYR . . . -132.08 149.67 52.35 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 113.15 0.796 . . . . 0.0 113.15 -163.417 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 7.7 p -118.95 113.64 42.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 CA-C-N 115.039 -0.982 . . . . 0.0 110.338 176.067 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . 0.499 ' HH ' ' HZ ' ' A' ' 346' ' ' PHE . 27.1 m-85 -108.04 140.68 40.84 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.583 177.454 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -142.75 143.78 32.37 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.65 174.671 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -166.32 -150.26 6.27 Favored Glycine 0 N--CA 1.443 -0.863 0 C-N-CA 120.931 -0.652 . . . . 0.0 111.874 -178.153 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -129.49 147.81 51.33 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.124 0.488 . . . . 0.0 111.038 -176.541 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 323' ' ' VAL . . . . . 0.586 ' O ' ' HA ' ' A' ' 337' ' ' ARG . 54.6 t -106.14 142.31 19.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.331 -178.876 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 324' ' ' LEU . . . . . . . . . . . . . 17.2 tp -124.87 103.95 8.34 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 110.21 -0.293 . . . . 0.0 110.21 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 325' ' ' HIS . . . . . 0.633 ' NE2' ' HB ' ' A' ' 336' ' ' THR . 3.2 p-80 -103.21 117.19 33.97 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.501 0.667 . . . . 0.0 111.429 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 326' ' ' PHE . . . . . 0.592 ' HD1' ' H ' ' A' ' 418' ' ' GLY . 22.9 m-85 -89.71 129.85 36.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 114.705 -1.134 . . . . 0.0 110.351 -173.119 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 327' ' ' HIS . . . . . . . . . . . . . 51.4 p-80 -176.26 172.53 2.29 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.139 -0.482 . . . . 0.0 109.863 -178.244 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 328' ' ' THR . . . . . . . . . . . . . 58.1 m -93.08 100.14 12.61 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 172.392 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 329' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 -81.58 159.56 24.05 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.212 -176.087 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 330' ' ' ASN . . . . . . . . . . . . . 32.9 m-80 -80.82 52.79 1.79 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.578 0.704 . . . . 0.0 109.426 177.806 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 331' ' ' GLY . . . . . . . . . . . . . . . -174.56 -176.41 42.89 Favored Glycine 0 N--CA 1.443 -0.89 0 CA-C-N 114.923 -1.035 . . . . 0.0 110.807 -176.218 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 332' ' ' ARG . . . . . 0.481 ' N ' ' HD2' ' A' ' 333' ' ' PRO . 95.9 mtt180 -77.05 -38.32 1.93 Allowed Pre-proline 0 C--N 1.319 -0.719 0 N-CA-C 112.683 0.623 . . . . 0.0 112.683 179.782 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 333' ' ' PRO . . . . . 0.481 ' HD2' ' N ' ' A' ' 332' ' ' ARG . 59.8 Cg_endo -74.35 86.46 1.32 Allowed 'Trans proline' 0 C--N 1.354 0.837 0 C-N-CA 121.462 1.441 . . . . 0.0 111.911 172.341 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 334' ' ' TYR . . . . . 0.744 ' HB2' ' HD3' ' A' ' 335' ' ' PRO . 78.7 m-85 -62.4 -53.68 55.71 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.304 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 335' ' ' PRO . . . . . 0.744 ' HD3' ' HB2' ' A' ' 334' ' ' TYR . 3.4 Cg_exo -80.39 127.08 6.43 Favored 'Trans proline' 0 N--CA 1.451 -1.012 0 C-N-CA 121.572 1.515 . . . . 0.0 110.427 172.457 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 336' ' ' THR . . . . . 0.633 ' HB ' ' NE2' ' A' ' 325' ' ' HIS . 0.3 OUTLIER -119.68 147.54 44.44 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 -177.141 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 337' ' ' ARG . . . . . 0.586 ' HA ' ' O ' ' A' ' 323' ' ' VAL . 0.0 OUTLIER -102.56 157.7 16.75 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.187 0.517 . . . . 0.0 110.82 -177.105 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -136.12 178.55 18.67 Favored Glycine 0 N--CA 1.443 -0.889 0 CA-C-N 115.392 -0.822 . . . . 0.0 111.178 176.113 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 339' ' ' ARG . . . . . 0.572 ' O ' ' HA ' ' A' ' 355' ' ' ILE . 57.8 mtp180 -104.02 132.89 49.82 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 -179.093 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 340' ' ' PHE . . . . . 0.557 ' HB2' HG23 ' A' ' 323' ' ' VAL . 36.8 t80 -133.9 132.2 40.01 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 121.057 0.456 . . . . 0.0 111.108 -175.848 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 341' ' ' ALA . . . . . . . . . . . . . . . -134.72 168.39 19.11 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 172.263 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -155.22 139.65 16.79 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.095 0.474 . . . . 0.0 111.023 -176.48 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . 0.513 ' HB3' ' HB2' ' A' ' 352' ' ' ASP . 24.9 tptp -115.97 97.32 6.02 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 179.222 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 344' ' ' VAL . . . . . 0.642 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.9 OUTLIER -121.05 135.61 60.68 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 CA-C-O 121.526 0.679 . . . . 0.0 111.627 -170.234 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -117.04 101.13 8.23 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-N 114.884 -1.053 . . . . 0.0 108.284 -178.653 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 346' ' ' PHE . . . . . 0.674 ' O ' ' HE3' ' A' ' 349' ' ' LYS . 67.4 m-85 -69.75 -25.96 64.07 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 -173.476 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -64.01 -22.15 66.46 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.533 -0.841 . . . . 0.0 111.917 176.579 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 48.2 t -108.84 -4.24 17.02 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.033 0.444 . . . . 0.0 110.499 178.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 349' ' ' LYS . . . . . 0.674 ' HE3' ' O ' ' A' ' 346' ' ' PHE . 8.2 mmpt? 49.7 50.98 17.36 Favored 'General case' 0 C--O 1.226 -0.176 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.581 -172.187 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 8.3 m -134.08 146.31 50.18 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.104 -178.178 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 351' ' ' VAL . . . . . 0.642 ' HB ' ' HB ' ' A' ' 344' ' ' VAL . 0.1 OUTLIER -149.36 133.92 9.51 Favored 'Isoleucine or valine' 0 C--O 1.236 0.365 0 CA-C-O 121.531 0.681 . . . . 0.0 112.552 -175.617 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 352' ' ' ASP . . . . . 0.625 ' HA ' ' HD3' ' A' ' 369' ' ' LYS . 1.5 m-20 -95.24 155.48 16.72 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 114.676 -1.147 . . . . 0.0 108.961 173.21 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 353' ' ' GLY . . . . . 0.501 ' C ' ' HB3' ' A' ' 367' ' ' LYS . . . -142.38 152.17 23.53 Favored Glycine 0 N--CA 1.44 -1.091 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 172.508 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 354' ' ' ILE . . . . . 0.469 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -146.78 130.12 9.1 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 116.964 0.382 . . . . 0.0 110.087 -179.643 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 355' ' ' ILE . . . . . 0.856 HD13 ' HE2' ' A' ' 367' ' ' LYS . 82.5 mt -126.16 125.99 68.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 CA-C-O 121.064 0.459 . . . . 0.0 111.919 178.32 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 356' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -109.8 120.41 42.39 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.285 -0.871 . . . . 0.0 108.857 174.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 23.8 t -85.71 1.49 49.23 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.267 0.556 . . . . 0.0 110.6 -177.021 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 358' ' ' GLY . . . . . . . . . . . . . . . 129.08 -32.03 3.35 Favored Glycine 0 N--CA 1.444 -0.807 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 -178.497 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 359' ' ' ASP . . . . . 0.572 ' OD2' ' HB2' ' A' ' 362' ' ' HIS . 9.5 t70 -133.44 95.57 3.53 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.485 0.659 . . . . 0.0 110.894 178.753 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 360' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -83.65 -24.43 31.37 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.594 175.734 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 361' ' ' LEU . . . . . 0.41 HD23 ' N ' ' A' ' 361' ' ' LEU . 3.1 mm? -74.45 -35.4 63.33 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 113.052 0.76 . . . . 0.0 113.052 -171.373 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 362' ' ' HIS . . . . . 0.572 ' HB2' ' OD2' ' A' ' 359' ' ' ASP . 98.1 m-70 -107.79 -59.33 1.85 Allowed 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.426 -0.51 . . . . 0.0 111.25 -177.42 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 363' ' ' MET . . . . . . . . . . . . . 26.2 mmt -62.35 -29.47 70.49 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.451 -179.238 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 364' ' ' GLY . . . . . . . . . . . . . . . 67.49 74.5 0.56 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.788 -0.72 . . . . 0.0 111.579 -179.752 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 365' ' ' THR . . . . . . . . . . . . . 3.2 m -101.49 115.05 29.63 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.051 0.453 . . . . 0.0 110.447 -175.664 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 82.5 mt-30 -120.98 178.55 4.68 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.859 179.574 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 367' ' ' LYS . . . . . 0.95 ' HA ' ' HZ3' ' A' ' 381' ' ' TRP . 19.3 tttm -131.03 172.91 11.54 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.096 0.474 . . . . 0.0 110.899 176.165 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 368' ' ' PHE . . . . . 0.833 ' H ' ' HG2' ' A' ' 367' ' ' LYS . 0.1 OUTLIER -73.89 163.16 28.28 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.113 -0.949 . . . . 0.0 111.814 -172.306 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 369' ' ' LYS . . . . . 0.625 ' HD3' ' HA ' ' A' ' 352' ' ' ASP . 0.0 OUTLIER -113.86 134.23 54.93 Favored 'General case' 0 C--N 1.314 -0.957 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 169.171 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . 0.661 ' HB1' ' CE2' ' A' ' 368' ' ' PHE . . . -130.2 162.85 27.98 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 113.095 0.776 . . . . 0.0 113.095 -172.579 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -116.73 135.93 53.37 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 114.657 -1.156 . . . . 0.0 108.924 171.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 372' ' ' ILE . . . . . 0.512 HG13 HG12 ' A' ' 351' ' ' VAL . 83.0 mt -82.69 115.04 24.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.142 0.496 . . . . 0.0 111.06 -177.004 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -104.92 83.38 1.99 Allowed 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.333 177.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 79.67 -118.8 4.82 Favored Glycine 0 N--CA 1.446 -0.678 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.559 -179.664 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 375' ' ' ASN . . . . . 0.466 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 3.2 p-10 -98.81 50.21 0.97 Allowed 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.65 0.738 . . . . 0.0 111.425 -176.147 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 165.08 175.05 35.42 Favored Glycine 0 N--CA 1.445 -0.716 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 -179.155 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 377' ' ' PHE . . . . . 0.539 ' CZ ' HG23 ' A' ' 401' ' ' VAL . 3.7 p90 -140.99 153.16 45.44 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.551 0.691 . . . . 0.0 111.703 177.918 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 378' ' ' LYS . . . . . 0.404 ' HB3' ' HE2' ' A' ' 378' ' ' LYS . 15.6 ptpt -131.99 138.38 48.24 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 114.498 -1.228 . . . . 0.0 108.484 175.677 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -151.55 -161.76 10.31 Favored Glycine 0 N--CA 1.443 -0.85 0 C-N-CA 120.068 -1.063 . . . . 0.0 112.61 -176.374 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 380' ' ' THR . . . . . 0.414 ' C ' ' HB2' ' A' ' 368' ' ' PHE . 6.5 t -144.57 140.62 28.89 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.811 0.339 . . . . 0.0 110.942 -175.254 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 381' ' ' TRP . . . . . 0.95 ' HZ3' ' HA ' ' A' ' 367' ' ' LYS . 50.4 m95 -56.82 145.43 29.54 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.98 178.439 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 382' ' ' THR . . . . . . . . . . . . . 25.8 p -78.28 -5.77 53.02 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.077 -0.511 . . . . 0.0 112.305 179.261 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 383' ' ' GLU . . . . . 0.588 ' HG3' ' HB3' ' A' ' 381' ' ' TRP . 0.0 OUTLIER -82.02 52.98 2.09 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 121.222 0.534 . . . . 0.0 110.655 178.344 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 384' ' ' ASN . . . . . 0.546 ' HB2' ' O ' ' A' ' 383' ' ' GLU . 10.9 m120 80.21 -39.7 0.18 Allowed 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 114.683 -1.144 . . . . 0.0 111.322 -173.446 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 385' ' ' GLY . . . . . . . . . . . . . . . 115.87 52.46 0.39 Allowed Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.669 -0.777 . . . . 0.0 111.875 179.304 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 386' ' ' GLY . . . . . . . . . . . . . . . -81.48 -19.85 65.45 Favored Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.275 -178.589 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -137.3 147.88 19.48 Favored Glycine 0 N--CA 1.446 -0.638 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.341 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -93.74 154.13 17.95 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 178.617 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 389' ' ' VAL . . . . . 0.529 ' HB ' ' CD2' ' A' ' 368' ' ' PHE . 20.0 t -131.39 139.57 50.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.057 -179.095 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 10.8 m -141.6 141.03 33.46 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.659 0.266 . . . . 0.0 110.791 178.308 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -141.05 152.64 23.34 Favored Glycine 0 C--O 1.236 0.221 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.981 179.458 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 9.7 ptm180 -115.61 144.73 43.48 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 -175.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 393' ' ' PHE . . . . . 0.518 ' CZ ' ' HE1' ' A' ' 346' ' ' PHE . 1.2 m-85 -94.55 154.84 17.19 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.429 0.633 . . . . 0.0 111.979 -175.104 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 394' ' ' TYR . . . . . 0.741 ' O ' ' HB3' ' A' ' 308' ' ' ALA . 3.5 m-85 -102.73 -176.78 3.19 Favored 'General case' 0 C--O 1.216 -0.686 0 CA-C-N 114.775 -1.102 . . . . 0.0 110.816 -178.823 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 395' ' ' GLY . . . . . 0.434 ' CA ' ' HB3' ' A' ' 306' ' ' GLU . . . -37.77 161.35 0.01 OUTLIER Glycine 0 C--N 1.335 0.505 0 O-C-N 124.333 1.021 . . . . 0.0 115.099 -175.816 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_exo -11.13 -57.03 0.0 OUTLIER 'Trans proline' 0 C--N 1.347 0.467 1 C-N-CA 127.386 5.391 . . . . 0.0 117.517 -162.393 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 397' ' ' ALA . . . . . 0.682 ' HB3' ' HG3' ' A' ' 399' ' ' GLU . . . -84.96 -11.12 56.22 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 112.678 0.621 . . . . 0.0 112.678 -167.391 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 67.2 22.18 72.48 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.226 -179.142 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 399' ' ' GLU . . . . . 0.682 ' HG3' ' HB3' ' A' ' 397' ' ' ALA . 50.5 mt-10 -63.63 -14.4 51.38 Favored 'General case' 0 CA--C 1.521 -0.154 0 CA-C-O 121.12 0.486 . . . . 0.0 111.148 -177.222 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -121.77 133.48 54.92 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 170.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 401' ' ' VAL . . . . . 0.539 HG23 ' CZ ' ' A' ' 377' ' ' PHE . 9.9 p -140.99 135.0 32.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.85 176.147 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -131.25 139.59 49.67 Favored 'General case' 0 C--N 1.315 -0.935 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.771 178.293 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -162.89 156.04 27.61 Favored Glycine 0 N--CA 1.437 -1.272 0 C-N-CA 120.304 -0.95 . . . . 0.0 111.105 -174.149 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 404' ' ' LYS . . . . . 0.979 ' HG2' HG22 ' A' ' 419' ' ' VAL . 17.5 mtmt -123.9 162.73 22.74 Favored 'General case' 0 C--N 1.31 -1.144 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 -174.36 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 405' ' ' TYR . . . . . 0.533 ' CG ' ' HZ2' ' A' ' 381' ' ' TRP . 25.4 p90 -126.13 147.18 49.67 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-O 121.225 0.536 . . . . 0.0 111.466 179.22 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 7.9 m -88.84 103.48 16.03 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.768 176.667 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . 0.407 ' H ' ' HD1' ' A' ' 407' ' ' TYR . 3.3 p90 -87.54 138.71 31.24 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.385 0.612 . . . . 0.0 110.659 -178.775 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 408' ' ' ARG . . . . . . . . . . . . . 36.9 mtm180 -57.73 -44.49 99.49 Favored Pre-proline 0 N--CA 1.468 0.445 0 CA-C-N 114.502 -1.226 . . . . 0.0 114.148 -174.916 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 409' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -70.12 68.01 1.92 Allowed 'Trans proline' 0 C--N 1.354 0.825 0 C-N-CA 122.074 1.849 . . . . 0.0 112.137 176.778 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 410' ' ' THR . . . . . . . . . . . . . 3.4 t -67.13 87.72 0.16 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.736 0.779 . . . . 0.0 111.463 -178.182 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 411' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -77.31 -25.48 51.28 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.451 179.412 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 412' ' ' ALA . . . . . . . . . . . . . . . -98.1 -178.02 3.92 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.415 178.128 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 413' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 -61.94 -57.26 12.4 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.424 0.63 . . . . 0.0 111.245 -178.902 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 414' ' ' LYS . . . . . . . . . . . . . 13.8 pttp -118.98 142.17 48.02 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.371 -0.831 . . . . 0.0 111.06 -175.366 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 415' ' ' GLY . . . . . . . . . . . . . . . -73.12 145.11 35.78 Favored Glycine 0 N--CA 1.446 -0.683 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 175.71 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 416' ' ' GLY . . . . . . . . . . . . . . . 157.5 -20.88 0.4 Allowed Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.767 -175.043 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 417' ' ' PHE . . . . . 0.489 ' HB3' ' HB2' ' A' ' 326' ' ' PHE . 87.9 m-85 -71.5 163.45 27.7 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 173.823 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 418' ' ' GLY . . . . . 0.592 ' H ' ' HD1' ' A' ' 326' ' ' PHE . . . 83.33 76.83 1.13 Allowed Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.024 -1.084 . . . . 0.0 110.933 -169.721 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 419' ' ' VAL . . . . . 0.979 HG22 ' HG2' ' A' ' 404' ' ' LYS . 8.4 p -107.33 166.03 4.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-O 121.28 0.562 . . . . 0.0 110.605 -177.576 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 420' ' ' PHE . . . . . 0.482 ' H ' HG21 ' A' ' 419' ' ' VAL . 41.8 p90 -140.76 157.53 45.29 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.224 -0.898 . . . . 0.0 109.904 177.218 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -142.69 136.06 28.63 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 177.122 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -121.74 138.42 12.27 Favored Glycine 0 N--CA 1.446 -0.668 0 C-N-CA 120.562 -0.828 . . . . 0.0 112.177 -177.726 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -110.78 127.11 55.24 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 178.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 424' ' ' LYS . . . . . 0.493 ' HB3' ' HB3' ' A' ' 399' ' ' GLU . 23.2 tptm -66.85 115.28 6.45 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.835 0.35 . . . . 0.0 110.603 176.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -98.86 113.24 25.28 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 175.427 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 426' ' ' GLN . . . . . . . . . . . . . 19.3 mp0 -86.39 78.57 9.24 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 179.704 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 427' ' ' ASP . . . . . 0.54 ' HA ' ' HB2' ' A' ' 430' ' ' HIS . 26.1 t70 -103.39 60.26 0.76 Allowed 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.418 0.628 . . . . 0.0 110.43 -177.9 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -70.66 -64.05 0.97 Allowed 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 176.025 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 429' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -128.77 20.72 5.99 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.934 173.663 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 430' ' ' HIS . . . . . 0.54 ' HB2' ' HA ' ' A' ' 427' ' ' ASP . 6.2 m-70 -71.74 -173.79 1.04 Allowed 'General case' 0 C--O 1.232 0.162 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.654 -176.013 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 76.5 m80 60.51 52.33 4.69 Favored 'General case' 0 C--O 1.233 0.228 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 -168.39 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 432' ' ' HIS . . . . . . . . . . . . . 62.7 m170 -59.35 131.79 52.04 Favored 'General case' 0 CA--C 1.517 -0.293 0 CA-C-N 114.032 -1.44 . . . . 0.0 111.837 -173.039 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 433' ' ' HIS . . . . . 0.5 ' O ' ' HB2' ' A' ' 434' ' ' HIS . 15.6 t60 -137.08 87.17 2.26 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 176.358 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 434' ' ' HIS . . . . . 0.5 ' HB2' ' O ' ' A' ' 433' ' ' HIS . 71.6 m-70 74.83 -47.79 0.63 Allowed 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 123.712 0.805 . . . . 0.0 109.667 -167.732 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 435' ' ' HIS . . . . . . . . . . . . . 24.1 m80 . . . . . 0 C--O 1.246 0.918 0 CA-C-O 118.484 -0.769 . . . . 0.0 109.274 172.674 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 276' ' ' ASN . . . . . 0.512 ' ND2' ' HA ' ' A' ' 299' ' ' TYR . 96.8 m-20 . . . . . 0 N--CA 1.482 1.141 0 N-CA-C 110.784 -0.08 . . . . 0.0 110.784 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 2.4 mp -110.02 -53.05 5.97 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.306 0 CA-C-O 121.259 0.552 . . . . 0.0 110.976 177.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 278' ' ' PHE . . . . . 0.629 ' HE1' ' HE1' ' A' ' 299' ' ' TYR . 31.4 p90 -81.84 13.51 3.21 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.307 178.109 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -149.81 123.92 4.6 Favored Pre-proline 0 C--N 1.326 -0.452 0 CA-C-N 115.234 -0.894 . . . . 0.0 109.416 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 280' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_exo -63.06 162.21 26.97 Favored 'Trans proline' 0 N--CA 1.473 0.279 0 C-N-CA 123.302 2.668 . . . . 0.0 112.299 -179.708 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -59.36 102.93 0.15 Allowed 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.107 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 152.14 -160.06 28.68 Favored Glycine 0 N--CA 1.446 -0.645 0 N-CA-C 111.28 -0.728 . . . . 0.0 111.28 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 283' ' ' ASN . . . . . . . . . . . . . 21.4 p-10 -132.27 84.58 2.17 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.935 0.874 . . . . 0.0 110.497 177.508 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 63.5 m-85 -85.37 113.8 21.95 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.198 -179.718 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . 0.413 HH11 ' HD3' ' A' ' 285' ' ' ARG . 11.5 ptp180 -92.59 -0.06 57.36 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.551 0.691 . . . . 0.0 109.886 176.821 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -98.98 11.81 37.85 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.019 -0.991 . . . . 0.0 108.839 171.194 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . 0.848 ' HG ' ' H ' ' A' ' 288' ' ' THR . 16.2 tp -74.23 175.51 7.5 Favored 'General case' 0 N--CA 1.442 -0.868 0 CA-C-N 114.715 -1.13 . . . . 0.0 110.533 -179.085 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 288' ' ' THR . . . . . 0.848 ' H ' ' HG ' ' A' ' 287' ' ' LEU . 26.7 m -89.74 166.1 13.78 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.927 -0.579 . . . . 0.0 109.514 -179.774 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 289' ' ' TYR . . . . . 0.706 ' N ' ' HB2' ' A' ' 304' ' ' GLN . 0.1 OUTLIER -102.12 123.46 46.02 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 -172.11 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . -179.27 152.12 10.82 Favored Glycine 0 N--CA 1.444 -0.8 0 N-CA-C 110.639 -0.985 . . . . 0.0 110.639 -178.453 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 291' ' ' ALA . . . . . . . . . . . . . . . -145.02 113.6 6.71 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 -175.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 292' ' ' GLU . . . . . . . . . . . . . 23.7 mt-10 -146.76 110.01 4.78 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.671 168.78 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 293' ' ' LYS . . . . . 0.782 ' HA ' ' HB3' ' A' ' 299' ' ' TYR . 36.9 ttpt -97.94 136.52 38.1 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 -178.962 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 294' ' ' LEU . . . . . 0.575 ' O ' HD12 ' A' ' 294' ' ' LEU . 0.0 OUTLIER -73.62 139.52 77.76 Favored Pre-proline 0 C--N 1.329 -0.323 0 C-N-CA 119.578 -0.849 . . . . 0.0 110.629 -174.784 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 295' ' ' PRO . . . . . 0.446 ' HD3' ' HA ' ' A' ' 294' ' ' LEU . 38.0 Cg_exo -60.57 89.92 0.09 OUTLIER 'Trans proline' 0 C--N 1.349 0.568 0 C-N-CA 123.258 2.638 . . . . 0.0 111.485 178.553 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . 169.17 -26.01 0.11 Allowed Glycine 0 N--CA 1.441 -1.019 0 N-CA-C 110.435 -1.066 . . . . 0.0 110.435 -172.405 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 111.82 -11.01 27.55 Favored Glycine 0 N--CA 1.442 -0.905 0 C-N-CA 120.529 -0.843 . . . . 0.0 113.841 171.159 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 298' ' ' SER . . . . . . . . . . . . . 43.9 m -107.04 83.76 1.88 Allowed 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.879 0.847 . . . . 0.0 112.032 -174.509 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 299' ' ' TYR . . . . . 0.782 ' HB3' ' HA ' ' A' ' 293' ' ' LYS . 0.4 OUTLIER -166.97 171.19 11.4 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 114.649 -1.16 . . . . 0.0 109.439 178.81 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 300' ' ' ALA . . . . . 0.473 ' H ' ' HD1' ' A' ' 299' ' ' TYR . . . -158.04 161.48 38.05 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.783 -168.68 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 301' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -129.84 135.53 48.5 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.14 177.199 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 302' ' ' ARG . . . . . 0.636 ' HB3' HD22 ' A' ' 287' ' ' LEU . 3.8 tpp180 -114.43 166.5 11.62 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 -178.107 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 303' ' ' VAL . . . . . . . . . . . . . 35.1 m -106.81 149.32 10.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 CA-C-O 121.414 0.626 . . . . 0.0 112.553 -168.116 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 304' ' ' GLN . . . . . 0.706 ' HB2' ' N ' ' A' ' 289' ' ' TYR . 8.3 tt0 -108.37 150.73 26.97 Favored 'General case' 0 N--CA 1.444 -0.755 0 CA-C-N 114.795 -1.093 . . . . 0.0 108.657 172.699 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . 0.674 ' H ' ' HG3' ' A' ' 396' ' ' PRO . . . -95.15 178.01 35.54 Favored Glycine 0 N--CA 1.436 -1.343 0 C-N-CA 120.294 -0.955 . . . . 0.0 111.827 177.623 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 306' ' ' GLU . . . . . 0.711 ' HB2' ' HD2' ' A' ' 307' ' ' PRO . 12.7 pt-20 -83.52 -177.9 1.07 Allowed Pre-proline 0 C--N 1.315 -0.933 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 176.673 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . 0.711 ' HD2' ' HB2' ' A' ' 306' ' ' GLU . 98.0 Cg_exo -46.36 136.09 15.34 Favored 'Trans proline' 0 C--N 1.358 1.032 0 C-N-CA 122.097 1.865 . . . . 0.0 111.645 176.168 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . 0.601 ' O ' ' HB3' ' A' ' 375' ' ' ASN . . . -31.44 106.6 0.04 OUTLIER 'General case' 0 CA--C 1.506 -0.727 0 O-C-N 124.923 1.39 . . . . 0.0 112.844 -165.591 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 309' ' ' LYS . . . . . 0.507 ' HE3' ' OE2' ' A' ' 311' ' ' GLU . 23.4 tptt -69.62 91.76 0.62 Allowed 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 115.222 -0.899 . . . . 0.0 109.97 -173.311 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 310' ' ' GLY . . . . . 0.628 ' HA2' HD13 ' A' ' 313' ' ' LEU . . . -60.6 -30.32 71.84 Favored Glycine 0 C--N 1.331 0.264 0 CA-C-N 115.578 -0.737 . . . . 0.0 114.086 -169.241 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . 0.507 ' OE2' ' HE3' ' A' ' 309' ' ' LYS . 4.8 pm0 -72.42 -17.06 61.83 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 120.74 0.305 . . . . 0.0 111.069 179.15 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 312' ' ' MET . . . . . 0.48 ' HE3' ' HG2' ' A' ' 309' ' ' LYS . 66.2 mtm -117.13 -0.18 12.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.797 0.332 . . . . 0.0 110.922 178.952 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 313' ' ' LEU . . . . . 0.628 HD13 ' HA2' ' A' ' 310' ' ' GLY . 83.8 mt -70.93 134.37 47.17 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 173.34 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -149.66 137.92 20.59 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.331 -173.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.77 171.95 14.49 Favored Glycine 0 N--CA 1.444 -0.799 0 N-CA-C 111.385 -0.686 . . . . 0.0 111.385 179.401 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 42.5 p -102.61 149.4 24.46 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 173.996 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -142.78 148.28 36.92 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 121.16 0.505 . . . . 0.0 112.32 -175.258 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . 0.512 ' O ' ' HA ' ' A' ' 424' ' ' LYS . 13.8 t -114.56 104.32 16.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.913 175.329 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . 0.449 ' OH ' ' HZ ' ' A' ' 346' ' ' PHE . 60.3 m-85 -97.88 127.33 43.76 Favored 'General case' 0 C--N 1.312 -1.05 0 C-N-CA 120.264 -0.574 . . . . 0.0 110.046 177.168 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 320' ' ' ASN . . . . . 0.411 ' ND2' ' HB2' ' A' ' 425' ' ' GLU . 7.6 p30 -138.31 145.16 40.87 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 178.799 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -172.14 -152.28 8.4 Favored Glycine 0 N--CA 1.44 -1.083 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.856 -177.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -114.49 143.74 44.46 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 120.897 0.38 . . . . 0.0 110.779 -174.413 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 323' ' ' VAL . . . . . 0.612 HG21 ' HB2' ' A' ' 340' ' ' PHE . 59.1 t -106.8 116.62 50.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.935 175.258 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 324' ' ' LEU . . . . . 0.595 HD13 ' HB2' ' A' ' 335' ' ' PRO . 24.9 tp -97.53 102.69 14.51 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-O 121.139 0.495 . . . . 0.0 109.889 -179.505 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 325' ' ' HIS . . . . . . . . . . . . . 1.3 p-80 -105.03 114.72 29.09 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.344 0.592 . . . . 0.0 109.73 176.691 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 326' ' ' PHE . . . . . 0.722 ' HD1' ' HB2' ' A' ' 417' ' ' PHE . 31.3 m-85 -82.9 114.69 21.37 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.168 -0.924 . . . . 0.0 110.96 -170.167 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 327' ' ' HIS . . . . . . . . . . . . . 76.1 m80 -110.79 105.23 14.01 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 171.05 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 328' ' ' THR . . . . . 0.537 HG23 ' HA ' ' A' ' 332' ' ' ARG . 22.1 p -137.01 96.01 3.22 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.253 0.549 . . . . 0.0 109.65 172.829 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 329' ' ' GLU . . . . . 0.403 ' O ' ' HB3' ' A' ' 330' ' ' ASN . 39.5 mt-10 -108.99 120.39 42.39 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.619 -0.718 . . . . 0.0 109.675 178.34 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 330' ' ' ASN . . . . . 0.403 ' HB3' ' O ' ' A' ' 329' ' ' GLU . 54.2 t30 72.94 -57.92 0.62 Allowed 'General case' 0 N--CA 1.468 0.453 0 O-C-N 123.903 0.752 . . . . 0.0 110.721 -176.049 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 331' ' ' GLY . . . . . 0.445 ' O ' ' HD3' ' A' ' 333' ' ' PRO . . . -124.32 174.72 17.0 Favored Glycine 0 N--CA 1.449 -0.497 0 N-CA-C 111.757 -0.537 . . . . 0.0 111.757 177.695 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 332' ' ' ARG . . . . . 0.537 ' HA ' HG23 ' A' ' 328' ' ' THR . 72.5 mtp180 -108.38 96.86 20.1 Favored Pre-proline 0 C--N 1.325 -0.483 0 N-CA-C 110.247 -0.279 . . . . 0.0 110.247 178.853 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 333' ' ' PRO . . . . . 0.445 ' HD3' ' O ' ' A' ' 331' ' ' GLY . 1.1 Cg_endo -84.07 -79.05 0.0 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 123.045 2.497 . . . . 0.0 113.006 -178.325 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 334' ' ' TYR . . . . . . . . . . . . . 86.1 t80 -161.27 126.23 2.15 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.333 -177.074 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 335' ' ' PRO . . . . . 0.595 ' HB2' HD13 ' A' ' 324' ' ' LEU . 5.2 Cg_exo -80.17 127.89 7.0 Favored 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 122.697 2.265 . . . . 0.0 111.137 174.971 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 336' ' ' THR . . . . . . . . . . . . . 4.8 p -94.88 139.18 31.67 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.088 0.471 . . . . 0.0 111.126 -179.044 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 337' ' ' ARG . . . . . 0.52 ' HG2' HD12 ' A' ' 324' ' ' LEU . 24.2 mtm180 -103.81 128.67 51.23 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.428 0.632 . . . . 0.0 110.664 178.151 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -95.21 -177.12 37.62 Favored Glycine 0 N--CA 1.439 -1.111 0 CA-C-N 115.222 -0.899 . . . . 0.0 111.613 176.969 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 339' ' ' ARG . . . . . 0.445 ' HB2' ' HB3' ' A' ' 356' ' ' ASP . 56.1 mtp180 -106.09 133.48 50.73 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 -176.133 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 340' ' ' PHE . . . . . 0.612 ' HB2' HG21 ' A' ' 323' ' ' VAL . 26.1 t80 -132.43 139.46 48.03 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-O 120.986 0.422 . . . . 0.0 111.342 -176.226 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 341' ' ' ALA . . . . . . . . . . . . . . . -142.86 165.85 26.24 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.223 -0.899 . . . . 0.0 109.374 174.509 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -157.18 134.09 10.19 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-O 120.875 0.369 . . . . 0.0 110.901 -174.296 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 4.5 tppp? -108.03 102.8 11.94 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.06 178.799 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 344' ' ' VAL . . . . . 0.647 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.3 OUTLIER -125.83 133.34 69.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 CA-C-O 121.703 0.763 . . . . 0.0 112.553 -172.08 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -102.31 121.9 43.19 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 114.586 -1.188 . . . . 0.0 108.176 172.082 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 346' ' ' PHE . . . . . 0.449 ' HZ ' ' OH ' ' A' ' 319' ' ' TYR . 33.1 m-85 -72.3 -37.92 68.84 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 120.979 -0.288 . . . . 0.0 110.931 -179.108 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -61.0 -30.51 73.65 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.111 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 47.8 t -97.88 -10.02 25.35 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 123.008 -0.113 . . . . 0.0 110.783 -179.666 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 349' ' ' LYS . . . . . 0.48 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 29.0 mtmt 47.35 55.69 7.9 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-O 121.62 0.724 . . . . 0.0 111.266 -176.22 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 29.1 m -147.52 138.94 23.81 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.632 179.483 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 351' ' ' VAL . . . . . 0.647 ' HB ' ' HB ' ' A' ' 344' ' ' VAL . 0.6 OUTLIER -130.1 148.46 33.17 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 CA-C-O 121.288 0.566 . . . . 0.0 111.379 -174.894 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 352' ' ' ASP . . . . . . . . . . . . . 6.3 m-20 -100.46 151.78 21.15 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 107.179 -1.415 . . . . 0.0 107.179 165.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 353' ' ' GLY . . . . . 0.633 ' HA3' ' CE1' ' A' ' 368' ' ' PHE . . . -142.52 138.17 8.26 Favored Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.483 -0.865 . . . . 0.0 111.541 175.217 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 354' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -121.68 129.74 75.23 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-O 121.185 0.516 . . . . 0.0 109.818 178.669 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 355' ' ' ILE . . . . . 0.752 HG13 ' CZ3' ' A' ' 381' ' ' TRP . 7.0 mm -119.34 98.94 6.88 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.591 -174.23 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 356' ' ' ASP . . . . . 0.445 ' HB3' ' HB2' ' A' ' 339' ' ' ARG . 12.2 t0 -95.54 139.0 32.43 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 176.382 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 24.1 t -91.02 -8.15 49.9 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.365 0.602 . . . . 0.0 109.492 179.095 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 358' ' ' GLY . . . . . . . . . . . . . . . 106.82 -9.96 40.77 Favored Glycine 0 N--CA 1.444 -0.82 0 N-CA-C 110.075 -1.21 . . . . 0.0 110.075 -173.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 359' ' ' ASP . . . . . 0.483 ' HB3' ' HB2' ' A' ' 362' ' ' HIS . 13.6 m-20 -120.92 45.29 2.29 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 114.662 -0.769 . . . . 0.0 110.336 -175.537 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 360' ' ' ASP . . . . . 0.464 ' OD1' ' HB ' ' A' ' 365' ' ' THR . 9.6 t70 -56.19 -35.08 66.85 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 121.131 0.491 . . . . 0.0 110.694 176.773 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 361' ' ' LEU . . . . . . . . . . . . . 93.0 mt -77.9 -0.95 29.45 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.548 -179.314 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 362' ' ' HIS . . . . . 0.483 ' HB2' ' HB3' ' A' ' 359' ' ' ASP . 22.1 m170 -105.05 -89.76 0.41 Allowed 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.642 0.258 . . . . 0.0 110.53 -179.397 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 363' ' ' MET . . . . . . . . . . . . . 3.6 mpp? -79.23 -18.58 52.58 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.227 0.537 . . . . 0.0 110.457 -179.096 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 364' ' ' GLY . . . . . . . . . . . . . . . 104.01 170.75 25.2 Favored Glycine 0 N--CA 1.443 -0.855 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -174.814 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 365' ' ' THR . . . . . 0.464 ' HB ' ' OD1' ' A' ' 360' ' ' ASP . 12.1 t -93.33 154.68 17.84 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 120.922 0.391 . . . . 0.0 110.411 179.23 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 79.4 mt-30 -107.28 162.94 13.44 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 178.091 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 367' ' ' LYS . . . . . 0.419 ' HG3' ' HA ' ' A' ' 382' ' ' THR . 8.7 ptpp? -147.22 168.94 20.42 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.138 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 368' ' ' PHE . . . . . 0.633 ' CE1' ' HA3' ' A' ' 353' ' ' GLY . 31.6 p90 -151.49 156.08 39.86 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 175.164 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 1.7 mptp? -118.94 130.77 55.89 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 175.838 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . 0.515 ' HA ' ' HA3' ' A' ' 379' ' ' GLY . . . -135.75 141.47 44.83 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.104 -175.884 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -102.51 136.04 43.05 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.724 176.747 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 372' ' ' ILE . . . . . 0.48 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 74.9 mt -81.18 114.26 21.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 121.545 0.688 . . . . 0.0 110.528 -177.801 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . 0.416 ' HB2' ' HE3' ' A' ' 378' ' ' LYS . 36.0 t70 -117.11 80.75 1.53 Allowed 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 114.704 -1.135 . . . . 0.0 109.158 -178.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 61.18 119.12 0.01 OUTLIER Glycine 0 CA--C 1.52 0.372 0 CA-C-N 114.968 -1.014 . . . . 0.0 113.408 -175.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 375' ' ' ASN . . . . . 0.601 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 3.6 p-10 26.13 48.1 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 124.582 1.153 . . . . 0.0 114.08 179.519 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 162.95 171.45 29.19 Favored Glycine 0 N--CA 1.444 -0.81 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 178.771 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 377' ' ' PHE . . . . . 0.405 ' CD2' HG11 ' A' ' 351' ' ' VAL . 4.0 p90 -138.83 147.94 43.11 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.458 0.647 . . . . 0.0 111.983 -179.245 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 378' ' ' LYS . . . . . 0.416 ' HE3' ' HB2' ' A' ' 373' ' ' ASP . 0.0 OUTLIER -130.59 133.13 45.93 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 114.775 -1.102 . . . . 0.0 109.659 173.468 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 379' ' ' GLY . . . . . 0.515 ' HA3' ' HA ' ' A' ' 370' ' ' ALA . . . -154.85 -158.36 8.67 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.489 -176.472 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -138.17 151.85 48.12 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 120.74 0.305 . . . . 0.0 111.489 -173.835 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 381' ' ' TRP . . . . . 0.752 ' CZ3' HG13 ' A' ' 355' ' ' ILE . 19.3 m95 -56.36 139.19 49.39 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.992 176.668 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 382' ' ' THR . . . . . 0.419 ' HA ' ' HG3' ' A' ' 367' ' ' LYS . 8.0 m 63.86 -78.35 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.244 -176.153 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 383' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -163.29 -32.87 0.04 OUTLIER 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.8 175.295 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 384' ' ' ASN . . . . . . . . . . . . . 27.5 p30 -155.61 19.39 0.4 Allowed 'General case' 0 C--O 1.233 0.222 0 N-CA-C 112.192 0.441 . . . . 0.0 112.192 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 385' ' ' GLY . . . . . . . . . . . . . . . -148.61 125.93 2.17 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.221 -0.99 . . . . 0.0 112.782 -176.559 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 386' ' ' GLY . . . . . . . . . . . . . . . 134.38 -70.48 0.51 Allowed Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.985 -0.626 . . . . 0.0 112.493 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . 174.05 -175.32 46.55 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 121.122 -0.561 . . . . 0.0 111.865 -178.734 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -90.9 137.42 32.38 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.056 0.455 . . . . 0.0 110.992 -177.4 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 29.5 t -128.98 115.37 36.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.58 177.765 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 2.4 p -139.11 137.51 36.22 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.355 0.598 . . . . 0.0 112.477 -175.316 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -147.84 159.33 27.99 Favored Glycine 0 N--CA 1.447 -0.614 0 CA-C-N 115.474 -0.785 . . . . 0.0 111.515 179.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 392' ' ' ARG . . . . . 0.414 ' N ' ' HD2' ' A' ' 392' ' ' ARG . 8.2 mpt_? -117.01 142.43 46.96 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.05 0.453 . . . . 0.0 111.076 -174.423 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 393' ' ' PHE . . . . . 0.405 ' CD1' ' HB ' ' A' ' 401' ' ' VAL . 21.0 m-85 -82.34 163.09 21.98 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 115.295 -0.866 . . . . 0.0 109.671 176.626 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 394' ' ' TYR . . . . . 0.45 ' HD1' ' N ' ' A' ' 394' ' ' TYR . 1.2 m-85 -100.77 -176.99 3.34 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 176.094 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 395' ' ' GLY . . . . . 0.686 ' HA2' ' HA ' ' A' ' 307' ' ' PRO . . . -52.74 -146.96 0.0 OUTLIER Glycine 0 CA--C 1.527 0.836 0 O-C-N 124.062 0.851 . . . . 0.0 114.755 -176.256 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 396' ' ' PRO . . . . . 0.674 ' HG3' ' H ' ' A' ' 305' ' ' GLY . 19.4 Cg_endo -59.22 -11.49 13.25 Favored 'Trans proline' 0 CA--C 1.536 0.605 0 C-N-CA 121.515 1.477 . . . . 0.0 111.051 179.389 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 397' ' ' ALA . . . . . 0.411 ' C ' ' H ' ' A' ' 399' ' ' GLU . . . -94.82 28.79 2.56 Favored 'General case' 0 N--CA 1.453 -0.316 0 CA-C-N 114.798 -1.092 . . . . 0.0 110.557 175.767 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . -57.78 2.42 0.14 Allowed Glycine 0 C--N 1.338 0.646 0 CA-C-N 115.923 -0.58 . . . . 0.0 113.657 -179.681 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 399' ' ' GLU . . . . . 0.805 ' HG2' ' HD3' ' A' ' 424' ' ' LYS . 35.7 mt-10 -58.73 -9.22 1.63 Allowed 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 123.401 0.68 . . . . 0.0 109.756 166.114 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -115.02 125.68 53.87 Favored 'General case' 0 N--CA 1.447 -0.62 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.437 171.001 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 401' ' ' VAL . . . . . 0.405 ' HB ' ' CD1' ' A' ' 393' ' ' PHE . 9.7 p -135.09 146.57 30.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.725 178.128 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -142.19 135.07 28.58 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.82 0.343 . . . . 0.0 110.896 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -153.14 -177.91 27.18 Favored Glycine 0 N--CA 1.44 -1.089 0 C-N-CA 120.667 -0.777 . . . . 0.0 112.085 -178.368 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 404' ' ' LYS . . . . . 0.856 ' HG2' HG11 ' A' ' 419' ' ' VAL . 70.2 mttt -142.0 163.01 34.04 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 -179.562 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 29.2 p90 -125.35 153.01 43.99 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.218 0.533 . . . . 0.0 111.208 178.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 4.9 p -90.37 116.09 28.06 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.028 177.144 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . 0.42 ' O ' ' CB ' ' A' ' 408' ' ' ARG . 28.8 t80 -151.07 152.79 33.94 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 -178.152 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 408' ' ' ARG . . . . . 0.91 ' HB3' ' HD3' ' A' ' 409' ' ' PRO . 40.3 ttt180 106.44 -68.45 0.0 OUTLIER Pre-proline 0 N--CA 1.482 1.148 0 O-C-N 125.122 1.514 . . . . 0.0 110.763 -178.647 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 409' ' ' PRO . . . . . 0.91 ' HD3' ' HB3' ' A' ' 408' ' ' ARG . 6.5 Cg_exo -73.95 126.99 11.05 Favored 'Trans proline' 0 C--N 1.356 0.966 0 C-N-CA 121.789 1.659 . . . . 0.0 111.345 178.134 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 410' ' ' THR . . . . . . . . . . . . . 14.5 m -76.9 -27.28 54.89 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.15 -176.265 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 411' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -127.89 71.53 1.37 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.225 0.536 . . . . 0.0 110.294 -178.658 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 412' ' ' ALA . . . . . 0.529 ' HB2' ' HB2' ' A' ' 409' ' ' PRO . . . -166.13 148.91 7.21 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.119 -179.766 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 413' ' ' GLU . . . . . . . . . . . . . 38.8 mm-40 -110.83 36.36 3.16 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.384 -177.769 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 414' ' ' LYS . . . . . 0.47 ' HB2' ' HZ2' ' A' ' 414' ' ' LYS . 4.9 ttmp? -130.82 128.84 41.48 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.792 0.329 . . . . 0.0 111.121 -177.2 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 415' ' ' GLY . . . . . . . . . . . . . . . -105.47 133.11 11.42 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.716 -0.754 . . . . 0.0 111.668 175.222 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 416' ' ' GLY . . . . . . . . . . . . . . . -110.13 -55.61 0.53 Allowed Glycine 0 N--CA 1.446 -0.692 0 C-N-CA 120.724 -0.751 . . . . 0.0 111.327 179.759 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 417' ' ' PHE . . . . . 0.722 ' HB2' ' HD1' ' A' ' 326' ' ' PHE . 47.8 p90 -98.99 177.99 5.08 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 175.326 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 81.54 71.23 1.3 Allowed Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.53 -0.843 . . . . 0.0 112.278 177.804 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 419' ' ' VAL . . . . . 0.856 HG11 ' HG2' ' A' ' 404' ' ' LYS . 22.9 m -109.72 153.04 11.6 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 178.819 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 420' ' ' PHE . . . . . 0.409 ' HB3' HG23 ' A' ' 323' ' ' VAL . 38.3 p90 -142.4 160.45 40.24 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 121.358 0.599 . . . . 0.0 110.873 179.408 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -139.45 136.11 34.29 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 114.943 -1.026 . . . . 0.0 109.076 177.873 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -118.94 132.44 9.65 Favored Glycine 0 N--CA 1.441 -1.007 0 C-N-CA 120.607 -0.806 . . . . 0.0 111.681 -178.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 35.2 mtmt -116.18 124.6 50.69 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 179.181 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 424' ' ' LYS . . . . . 0.805 ' HD3' ' HG2' ' A' ' 399' ' ' GLU . 46.2 tttm -67.48 125.57 26.57 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.69 -177.795 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 425' ' ' GLU . . . . . 0.411 ' HB2' ' ND2' ' A' ' 320' ' ' ASN . 26.2 tt0 -86.58 111.79 20.96 Favored 'General case' 0 N--CA 1.444 -0.762 0 CA-C-O 121.416 0.627 . . . . 0.0 111.138 -172.012 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 426' ' ' GLN . . . . . . . . . . . . . 46.0 mt-30 -103.83 -179.11 3.85 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.263 -0.881 . . . . 0.0 108.776 170.597 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 427' ' ' ASP . . . . . 0.464 ' CG ' ' H ' ' A' ' 428' ' ' LEU . 29.2 t70 67.66 -175.08 0.19 Allowed 'General case' 0 CA--C 1.54 0.59 0 O-C-N 123.538 0.524 . . . . 0.0 110.191 -178.198 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . 0.464 ' H ' ' CG ' ' A' ' 427' ' ' ASP . 7.1 mp -85.52 -26.48 26.19 Favored 'General case' 0 C--N 1.327 -0.393 0 O-C-N 122.087 -0.383 . . . . 0.0 110.713 178.229 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 429' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -137.79 -103.31 0.19 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.047 0.451 . . . . 0.0 109.91 178.459 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 430' ' ' HIS . . . . . . . . . . . . . 55.8 m-70 -147.0 77.36 1.46 Allowed 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 107.88 -1.156 . . . . 0.0 107.88 175.095 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 9.9 t60 -66.39 -17.25 64.67 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.299 -174.102 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 432' ' ' HIS . . . . . . . . . . . . . 77.0 m-70 -78.09 62.02 2.75 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.267 0.556 . . . . 0.0 109.574 172.004 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 433' ' ' HIS . . . . . . . . . . . . . 9.8 t60 -91.86 -53.27 4.35 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.21 -176.327 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 434' ' ' HIS . . . . . . . . . . . . . 39.4 t-80 -85.82 -12.81 49.89 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.174 0.511 . . . . 0.0 109.986 179.367 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 435' ' ' HIS . . . . . . . . . . . . . 67.9 t60 . . . . . 0 C--O 1.248 0.999 0 CA-C-O 118.298 -0.858 . . . . 0.0 109.93 179.188 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 276' ' ' ASN . . . . . 0.427 ' OD1' ' HE2' ' A' ' 293' ' ' LYS . 15.4 t-20 . . . . . 0 N--CA 1.482 1.162 0 CA-C-O 121.303 0.573 . . . . 0.0 109.867 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 10.9 tp -98.1 -18.59 6.29 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.128 0 CA-C-O 121.558 0.694 . . . . 0.0 110.395 178.574 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 278' ' ' PHE . . . . . . . . . . . . . 7.8 p90 -89.96 44.05 1.18 Allowed 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.353 -178.789 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -75.5 148.84 83.45 Favored Pre-proline 0 C--N 1.326 -0.415 0 CA-C-N 115.202 -0.908 . . . . 0.0 110.245 178.395 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 280' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -65.01 161.92 34.8 Favored 'Trans proline' 0 N--CA 1.464 -0.229 0 C-N-CA 123.105 2.537 . . . . 0.0 112.846 -178.566 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 281' ' ' GLU . . . . . 0.43 ' HB3' ' HE2' ' A' ' 284' ' ' TYR . 45.0 tt0 -43.35 -57.36 3.07 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.505 -0.771 . . . . 0.0 111.998 -178.541 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -114.08 -94.81 2.07 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.853 -0.689 . . . . 0.0 111.795 178.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 283' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -154.73 90.26 1.3 Allowed 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 177.22 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 284' ' ' TYR . . . . . 0.74 ' HD1' ' HE1' ' A' ' 286' ' ' TYR . 98.6 m-85 -101.04 111.3 23.47 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.404 0.621 . . . . 0.0 110.992 -172.527 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 285' ' ' ARG . . . . . 0.482 ' HD3' ' N ' ' A' ' 285' ' ' ARG . 0.0 OUTLIER -120.3 -10.99 9.24 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.574 -0.739 . . . . 0.0 112.001 -173.637 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 286' ' ' TYR . . . . . 0.74 ' HE1' ' HD1' ' A' ' 284' ' ' TYR . 25.9 p90 -58.78 -51.7 68.85 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 121.205 0.526 . . . . 0.0 110.268 178.983 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 287' ' ' LEU . . . . . 0.536 ' HG ' ' CD2' ' A' ' 286' ' ' TYR . 3.9 pp -168.04 131.11 1.57 Allowed 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 172.47 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 288' ' ' THR . . . . . 0.491 HG23 ' N ' ' A' ' 289' ' ' TYR . 22.2 m -155.0 161.82 41.26 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.032 -174.205 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 289' ' ' TYR . . . . . 0.491 ' N ' HG23 ' A' ' 288' ' ' THR . 5.7 t80 -126.18 119.34 27.23 Favored 'General case' 0 N--CA 1.435 -1.212 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 169.095 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 130.47 -155.59 21.19 Favored Glycine 0 N--CA 1.443 -0.854 0 C-N-CA 120.282 -0.961 . . . . 0.0 112.428 -177.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 291' ' ' ALA . . . . . . . . . . . . . . . -100.79 163.69 12.2 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.182 0.515 . . . . 0.0 111.714 -176.357 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 292' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -145.81 157.27 43.93 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 114.959 -1.019 . . . . 0.0 108.281 176.783 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 293' ' ' LYS . . . . . 0.427 ' HE2' ' OD1' ' A' ' 276' ' ' ASN . 18.0 tppt? -112.58 139.46 48.15 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-O 120.927 0.394 . . . . 0.0 110.358 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 294' ' ' LEU . . . . . 0.509 HD21 ' HB2' ' A' ' 300' ' ' ALA . 0.7 OUTLIER -114.84 143.27 29.74 Favored Pre-proline 0 C--N 1.322 -0.621 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.259 176.343 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 295' ' ' PRO . . . . . . . . . . . . . 87.2 Cg_exo -48.81 102.96 0.05 OUTLIER 'Trans proline' 0 C--N 1.352 0.728 0 C-N-CA 123.742 2.961 . . . . 0.0 112.862 -177.914 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . 143.83 -131.34 4.41 Favored Glycine 0 N--CA 1.443 -0.89 0 CA-C-N 115.37 -0.832 . . . . 0.0 111.096 -177.003 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . -132.26 29.66 3.29 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.319 -179.834 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 298' ' ' SER . . . . . 0.461 ' HB2' HD12 ' A' ' 294' ' ' LEU . 50.8 m -108.34 167.58 9.93 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-N 116.974 0.387 . . . . 0.0 110.571 -178.783 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 299' ' ' TYR . . . . . . . . . . . . . 14.0 m-85 -122.2 137.91 54.66 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 300' ' ' ALA . . . . . 0.509 ' HB2' HD21 ' A' ' 294' ' ' LEU . . . -120.71 153.76 36.51 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 120.733 0.301 . . . . 0.0 110.842 179.007 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 301' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -121.73 141.17 51.44 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 173.452 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 302' ' ' ARG . . . . . 0.747 ' HE ' ' HA ' ' A' ' 302' ' ' ARG . 2.2 mmp_? -120.49 140.58 51.23 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 120.68 -0.408 . . . . 0.0 110.824 -179.029 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 303' ' ' VAL . . . . . . . . . . . . . 23.4 m -120.57 149.05 23.42 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.796 -175.815 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 304' ' ' GLN . . . . . 0.461 ' HB3' ' HB2' ' A' ' 287' ' ' LEU . 3.5 pt20 -125.82 176.09 7.18 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 114.986 -1.006 . . . . 0.0 108.908 173.817 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -91.22 118.14 5.34 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.351 -0.928 . . . . 0.0 112.012 -173.954 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 306' ' ' GLU . . . . . 0.788 ' O ' ' HA2' ' A' ' 395' ' ' GLY . 43.5 tt0 -145.72 128.74 8.21 Favored Pre-proline 0 N--CA 1.447 -0.58 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 -173.873 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_exo -51.97 126.05 18.98 Favored 'Trans proline' 0 CA--C 1.528 0.224 0 C-N-CA 122.235 1.956 . . . . 0.0 111.216 174.177 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 308' ' ' ALA . . . . . 0.696 ' HB3' ' O ' ' A' ' 394' ' ' TYR . . . -48.07 152.51 0.8 Allowed 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 112.968 0.729 . . . . 0.0 112.968 -177.92 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 309' ' ' LYS . . . . . 0.57 ' O ' ' HG ' ' A' ' 313' ' ' LEU . 29.9 mmmt -108.87 107.9 18.48 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.489 177.896 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 310' ' ' GLY . . . . . 0.567 ' HA2' HD13 ' A' ' 313' ' ' LEU . . . -64.91 -34.89 91.09 Favored Glycine 0 CA--C 1.516 0.133 0 C-N-CA 121.355 -0.45 . . . . 0.0 113.705 -172.737 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 2.9 pm0 -71.72 -25.56 62.12 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.234 0.54 . . . . 0.0 110.031 178.692 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 312' ' ' MET . . . . . 0.437 ' HB3' ' HB2' ' A' ' 309' ' ' LYS . 27.6 ttt -87.11 -18.06 31.37 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.461 -179.45 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 313' ' ' LEU . . . . . 0.57 ' HG ' ' O ' ' A' ' 309' ' ' LYS . 96.1 mt -66.55 139.96 57.95 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.554 179.167 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -159.62 135.64 8.75 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.011 -176.384 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.5 177.69 15.94 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.918 -0.658 . . . . 0.0 111.592 178.168 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 38.7 p -108.75 142.16 39.7 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 117.303 0.551 . . . . 0.0 110.471 174.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -146.68 155.28 42.31 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.258 -179.093 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 318' ' ' VAL . . . . . 0.543 ' HA ' ' O ' ' A' ' 342' ' ' ALA . 2.5 p -132.94 119.71 38.17 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-O 121.285 0.564 . . . . 0.0 110.732 174.504 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 319' ' ' TYR . . . . . 0.522 ' HH ' ' HZ ' ' A' ' 346' ' ' PHE . 76.8 m-85 -104.51 128.35 52.42 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.956 -178.671 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 4.5 p30 -127.75 141.84 51.48 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.142 179.297 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -167.03 -140.98 3.02 Favored Glycine 0 N--CA 1.442 -0.913 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.28 -178.194 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 31.0 mt-10 -118.66 150.38 39.82 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.831 0.348 . . . . 0.0 111.051 -173.577 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 323' ' ' VAL . . . . . 0.585 HG22 ' HB2' ' A' ' 340' ' ' PHE . 56.1 t -109.9 120.95 61.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.925 172.644 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 324' ' ' LEU . . . . . 0.414 ' HB2' HG23 ' A' ' 419' ' ' VAL . 95.7 mt -101.87 104.21 14.94 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.092 -179.624 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 325' ' ' HIS . . . . . 0.724 ' HB3' ' HB ' ' A' ' 336' ' ' THR . 28.1 t-80 -96.21 138.83 33.25 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.187 -0.461 . . . . 0.0 109.814 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 326' ' ' PHE . . . . . 0.531 ' HE2' HG11 ' A' ' 419' ' ' VAL . 10.8 m-85 -126.31 175.05 8.11 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.587 -176.35 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 327' ' ' HIS . . . . . . . . . . . . . 4.9 p-80 -160.81 -176.34 5.47 Favored 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 107.626 -1.25 . . . . 0.0 107.626 179.002 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 328' ' ' THR . . . . . . . . . . . . . 9.2 t -53.95 114.09 1.46 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.545 0.688 . . . . 0.0 109.74 176.24 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 329' ' ' GLU . . . . . 0.473 ' O ' ' HB2' ' A' ' 330' ' ' ASN . 0.0 OUTLIER -95.41 175.18 6.67 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.363 -177.181 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 330' ' ' ASN . . . . . 0.473 ' HB2' ' O ' ' A' ' 329' ' ' GLU . 94.9 m-20 74.25 3.64 4.39 Favored 'General case' 0 N--CA 1.469 0.477 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 -163.825 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 331' ' ' GLY . . . . . . . . . . . . . . . -145.4 96.43 0.18 Allowed Glycine 0 N--CA 1.438 -1.231 0 N-CA-C 109.459 -1.457 . . . . 0.0 109.459 174.544 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 332' ' ' ARG . . . . . 0.401 ' HB3' ' CE1' ' A' ' 334' ' ' TYR . 6.4 mpt_? 65.64 73.51 0.41 Allowed Pre-proline 0 N--CA 1.466 0.356 0 CA-C-O 121.397 0.618 . . . . 0.0 110.081 -171.658 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 333' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -83.92 39.5 0.8 Allowed 'Trans proline' 0 N--CA 1.462 -0.368 0 C-N-CA 123.581 2.854 . . . . 0.0 113.342 -172.458 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 334' ' ' TYR . . . . . 0.401 ' CE1' ' HB3' ' A' ' 332' ' ' ARG . 40.5 p90 -107.15 128.61 25.71 Favored Pre-proline 0 C--N 1.323 -0.553 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 176.189 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 335' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -81.12 129.59 6.92 Favored 'Trans proline' 0 N--CA 1.461 -0.436 0 C-N-CA 122.641 2.228 . . . . 0.0 112.424 179.445 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 336' ' ' THR . . . . . 0.724 ' HB ' ' HB3' ' A' ' 325' ' ' HIS . 0.2 OUTLIER -72.58 140.1 47.86 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 175.825 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 337' ' ' ARG . . . . . 0.474 ' HA ' ' O ' ' A' ' 323' ' ' VAL . 51.2 mtm180 -128.7 112.99 14.81 Favored 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 120.298 -0.561 . . . . 0.0 111.576 -174.689 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -107.57 -177.12 22.49 Favored Glycine 0 N--CA 1.444 -0.83 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.092 176.707 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 339' ' ' ARG . . . . . 0.805 ' HB2' ' HB2' ' A' ' 356' ' ' ASP . 40.0 mtp-105 -104.45 153.46 21.08 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 340' ' ' PHE . . . . . 0.585 ' HB2' HG22 ' A' ' 323' ' ' VAL . 53.0 t80 -143.41 137.52 28.71 Favored 'General case' 0 C--N 1.317 -0.848 0 CA-C-O 121.139 0.495 . . . . 0.0 111.484 -178.51 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 341' ' ' ALA . . . . . . . . . . . . . . . -141.05 163.49 32.84 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.228 -0.896 . . . . 0.0 108.889 173.334 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 342' ' ' ALA . . . . . 0.82 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -155.9 118.14 4.09 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 120.871 0.367 . . . . 0.0 110.667 -176.926 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 343' ' ' LYS . . . . . 0.49 ' C ' ' HD3' ' A' ' 343' ' ' LYS . 12.7 tmtt? -94.3 103.35 15.36 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 178.223 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 344' ' ' VAL . . . . . 1.009 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.2 OUTLIER -119.4 132.83 68.1 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.109 0 CA-C-O 121.607 0.718 . . . . 0.0 112.105 -172.716 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -109.16 118.69 37.39 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.885 -1.052 . . . . 0.0 108.247 175.563 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 346' ' ' PHE . . . . . 0.522 ' HZ ' ' HH ' ' A' ' 319' ' ' TYR . 70.4 m-85 -79.25 -24.59 42.9 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 111.584 0.216 . . . . 0.0 111.584 -175.509 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -69.52 -38.54 79.25 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.239 -0.981 . . . . 0.0 111.285 179.227 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 3.4 m -92.58 -9.74 40.04 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.002 0.43 . . . . 0.0 110.019 178.096 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 349' ' ' LYS . . . . . 0.625 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 10.1 mtmp? 52.03 58.67 5.19 Favored 'General case' 0 N--CA 1.456 -0.142 0 CA-C-N 115.439 -0.801 . . . . 0.0 110.394 -176.734 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 17.9 m -140.9 145.84 36.67 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.48 -179.211 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 351' ' ' VAL . . . . . 1.009 ' HB ' ' HB ' ' A' ' 344' ' ' VAL . 0.2 OUTLIER -141.83 139.0 31.38 Favored 'Isoleucine or valine' 0 C--O 1.237 0.396 0 CA-C-O 121.299 0.571 . . . . 0.0 111.559 -177.035 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 352' ' ' ASP . . . . . 0.82 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 1.5 m-20 -106.61 118.54 36.93 Favored 'General case' 0 C--O 1.214 -0.798 0 CA-C-N 115.057 -0.974 . . . . 0.0 109.304 179.637 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -110.1 143.24 16.73 Favored Glycine 0 C--N 1.313 -0.715 0 C-N-CA 120.23 -0.986 . . . . 0.0 111.873 -177.076 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 354' ' ' ILE . . . . . 0.518 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -140.29 129.92 27.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 CA-C-O 120.856 0.36 . . . . 0.0 110.362 -177.962 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 355' ' ' ILE . . . . . 0.541 HG21 HG23 ' A' ' 323' ' ' VAL . 3.3 mp -119.34 111.07 31.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.329 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 356' ' ' ASP . . . . . 0.805 ' HB2' ' HB2' ' A' ' 339' ' ' ARG . 7.4 m-20 -69.1 120.74 15.42 Favored 'General case' 0 CA--C 1.512 -0.502 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.454 177.05 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 27.7 t -89.71 -6.32 56.18 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.854 176.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 358' ' ' GLY . . . . . . . . . . . . . . . 104.57 -68.1 0.27 Allowed Glycine 0 N--CA 1.448 -0.556 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.732 -179.114 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 359' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -100.32 81.23 2.34 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.381 0.61 . . . . 0.0 110.014 178.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 360' ' ' ASP . . . . . 0.419 ' O ' ' HA2' ' A' ' 364' ' ' GLY . 20.1 t70 -61.83 -27.07 68.51 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.762 178.175 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 361' ' ' LEU . . . . . . . . . . . . . 96.3 mt -78.66 -15.39 58.55 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.193 -179.364 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 362' ' ' HIS . . . . . . . . . . . . . 4.5 t-160 -108.14 -79.09 0.58 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.759 -0.2 . . . . 0.0 110.469 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 363' ' ' MET . . . . . . . . . . . . . 90.6 mtp -78.97 -29.87 44.12 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.139 0.495 . . . . 0.0 110.836 -179.261 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 364' ' ' GLY . . . . . 0.419 ' HA2' ' O ' ' A' ' 360' ' ' ASP . . . 96.42 135.2 8.34 Favored Glycine 0 N--CA 1.445 -0.744 0 CA-C-N 115.489 -0.778 . . . . 0.0 112.348 179.136 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 365' ' ' THR . . . . . 0.525 HG21 ' HA ' ' A' ' 356' ' ' ASP . 7.6 m -82.42 119.05 23.69 Favored 'General case' 0 N--CA 1.445 -0.718 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 171.197 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 14.6 mm100 -103.78 145.37 30.19 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.624 0.726 . . . . 0.0 111.076 -166.556 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 44.9 mttp -125.74 147.72 49.29 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 114.599 -1.182 . . . . 0.0 110.394 -170.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 368' ' ' PHE . . . . . 0.672 ' CD1' HG21 ' A' ' 389' ' ' VAL . 41.9 p90 -126.39 160.23 31.05 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 177.371 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 369' ' ' LYS . . . . . 0.553 ' HD3' ' HA ' ' A' ' 352' ' ' ASP . 2.0 tppt? -125.96 147.39 49.53 Favored 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 173.442 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -141.58 147.71 38.12 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.83 0.347 . . . . 0.0 111.123 -176.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -105.45 127.57 53.07 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.079 177.759 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 372' ' ' ILE . . . . . 0.625 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 84.0 mt -82.8 121.32 35.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-O 121.008 0.433 . . . . 0.0 111.257 -178.905 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -137.91 105.27 5.5 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 170.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 92.88 -155.2 22.37 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 110.349 -1.1 . . . . 0.0 110.349 -168.012 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 375' ' ' ASN . . . . . 0.544 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 21.8 p-10 -94.33 42.6 1.1 Allowed 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 117.533 0.666 . . . . 0.0 110.681 178.718 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . -170.37 164.48 37.77 Favored Glycine 0 N--CA 1.441 -1.016 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -178.789 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 377' ' ' PHE . . . . . 0.504 ' CD2' HG12 ' A' ' 351' ' ' VAL . 8.8 p90 -136.91 139.0 41.26 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-O 120.964 0.412 . . . . 0.0 110.939 -179.307 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 378' ' ' LYS . . . . . . . . . . . . . 63.7 mttm -112.72 137.09 51.52 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.293 172.081 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 379' ' ' GLY . . . . . 0.615 ' C ' HG22 ' A' ' 389' ' ' VAL . . . -144.53 -154.73 6.22 Favored Glycine 0 N--CA 1.437 -1.283 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.097 -172.432 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 12.7 t -169.16 154.66 6.09 Favored 'General case' 0 C--N 1.313 -1.016 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 -173.534 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 381' ' ' TRP . . . . . 0.885 ' HD1' ' HA3' ' A' ' 387' ' ' GLY . 38.8 m95 -62.16 154.47 27.14 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.299 0.571 . . . . 0.0 110.87 178.337 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 382' ' ' THR . . . . . . . . . . . . . 12.3 t -62.13 -8.29 5.31 Favored 'General case' 0 CA--C 1.538 0.514 0 CA-C-N 115.386 -0.825 . . . . 0.0 111.407 173.402 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 383' ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -117.59 156.17 28.58 Favored 'General case' 0 C--N 1.333 -0.132 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 174.563 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 384' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -88.01 27.88 1.13 Allowed 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.187 0.439 . . . . 0.0 112.187 -173.08 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 385' ' ' GLY . . . . . . . . . . . . . . . -78.02 41.59 2.0 Allowed Glycine 0 CA--C 1.52 0.404 0 C-N-CA 120.787 -0.721 . . . . 0.0 113.06 -178.108 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 386' ' ' GLY . . . . . 0.468 ' HA3' ' O ' ' A' ' 408' ' ' ARG . . . 57.9 24.06 52.91 Favored Glycine 0 C--N 1.331 0.255 0 C-N-CA 121.802 -0.237 . . . . 0.0 113.015 179.643 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 387' ' ' GLY . . . . . 0.885 ' HA3' ' HD1' ' A' ' 381' ' ' TRP . . . -86.73 93.62 1.89 Allowed Glycine 0 N--CA 1.446 -0.69 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.637 -177.019 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -96.18 128.04 42.74 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 178.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 389' ' ' VAL . . . . . 0.672 HG21 ' CD1' ' A' ' 368' ' ' PHE . 3.5 m -117.28 160.48 16.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 C-N-CA 120.87 -0.332 . . . . 0.0 110.714 -176.589 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 390' ' ' SER . . . . . 0.51 ' O ' ' HA3' ' A' ' 403' ' ' GLY . 24.7 t -157.44 158.46 35.87 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.245 178.622 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -170.13 153.15 20.82 Favored Glycine 0 C--N 1.32 -0.329 0 N-CA-C 111.443 -0.663 . . . . 0.0 111.443 178.666 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 4.3 ptm180 -131.92 149.32 52.47 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 117.319 0.56 . . . . 0.0 110.751 -176.706 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -89.88 166.11 13.7 Favored 'General case' 0 CA--C 1.498 -1.037 0 CA-C-O 122.424 1.107 . . . . 0.0 111.786 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 394' ' ' TYR . . . . . 0.696 ' O ' ' HB3' ' A' ' 308' ' ' ALA . 0.5 OUTLIER -101.86 -176.15 3.05 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 112.709 -2.042 . . . . 0.0 108.923 176.949 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 395' ' ' GLY . . . . . 0.788 ' HA2' ' O ' ' A' ' 306' ' ' GLU . . . -36.26 158.38 0.01 OUTLIER Glycine 0 N--CA 1.461 0.304 0 O-C-N 124.71 1.256 . . . . 0.0 115.045 -175.06 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -22.95 -42.42 0.03 OUTLIER 'Trans proline' 0 C--N 1.358 1.032 1 C-N-CA 127.322 5.348 . . . . 0.0 117.178 -161.711 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 397' ' ' ALA . . . . . 0.42 ' N ' ' O ' ' A' ' 395' ' ' GLY . . . -73.04 -19.46 61.18 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 -175.068 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 57.85 25.06 55.54 Favored Glycine 0 C--N 1.34 0.767 0 CA-C-N 116.186 -0.461 . . . . 0.0 112.887 176.165 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 399' ' ' GLU . . . . . 0.442 ' HA ' ' HE1' ' A' ' 319' ' ' TYR . 51.3 mt-10 -71.3 -8.37 53.21 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 122.956 0.502 . . . . 0.0 112.024 -174.03 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 400' ' ' GLU . . . . . 0.437 ' HG2' ' CE1' ' A' ' 394' ' ' TYR . 5.2 tt0 -131.9 144.29 50.75 Favored 'General case' 0 N--CA 1.433 -1.284 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 171.438 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 401' ' ' VAL . . . . . 0.473 HG22 ' CZ ' ' A' ' 377' ' ' PHE . 14.8 p -142.08 136.73 29.9 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.107 0 CA-C-N 115.012 -0.995 . . . . 0.0 109.722 179.019 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -135.7 138.94 43.27 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.122 -178.74 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 403' ' ' GLY . . . . . 0.51 ' HA3' ' O ' ' A' ' 390' ' ' SER . . . -161.06 -161.09 11.25 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 120.747 -0.739 . . . . 0.0 111.646 178.424 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 404' ' ' LYS . . . . . 0.733 ' HG2' HG13 ' A' ' 419' ' ' VAL . 28.4 mtmm -144.45 161.71 38.36 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.557 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 34.9 p90 -120.41 133.21 55.47 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 171.915 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 46.2 m -116.22 103.78 10.86 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 116.508 -0.314 . . . . 0.0 110.549 -178.444 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 407' ' ' TYR . . . . . 0.481 ' HA ' ' HA2' ' A' ' 387' ' ' GLY . 10.4 p90 -82.49 127.18 33.07 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 174.975 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 408' ' ' ARG . . . . . 0.468 ' O ' ' HA3' ' A' ' 386' ' ' GLY . 29.1 ttp180 -138.62 79.23 29.67 Favored Pre-proline 0 C--N 1.319 -0.75 0 CA-C-N 115.804 -0.634 . . . . 0.0 109.912 -177.841 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 409' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -90.29 -7.66 4.19 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 123.059 2.506 . . . . 0.0 112.004 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 410' ' ' THR . . . . . . . . . . . . . 15.0 m -121.28 128.02 51.94 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.954 -179.686 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 411' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -75.54 83.93 2.6 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.335 0.588 . . . . 0.0 110.402 176.211 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 412' ' ' ALA . . . . . . . . . . . . . . . -146.3 -54.34 0.26 Allowed 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.255 -0.884 . . . . 0.0 109.571 178.01 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 413' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -151.17 163.06 39.69 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.581 179.1 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 414' ' ' LYS . . . . . . . . . . . . . 36.3 mtmm -89.82 158.34 17.52 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.879 0.371 . . . . 0.0 110.781 -179.014 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 415' ' ' GLY . . . . . . . . . . . . . . . -75.64 178.82 47.51 Favored Glycine 0 N--CA 1.448 -0.517 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.193 178.317 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 416' ' ' GLY . . . . . . . . . . . . . . . -175.58 -37.18 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.884 -0.674 . . . . 0.0 111.661 -178.406 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 417' ' ' PHE . . . . . 0.489 ' CD1' ' HB2' ' A' ' 326' ' ' PHE . 32.7 m-85 -68.82 159.37 32.56 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 175.76 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 418' ' ' GLY . . . . . 0.435 ' HA2' ' HA ' ' A' ' 325' ' ' HIS . . . 83.82 78.17 1.11 Allowed Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 119.904 -1.141 . . . . 0.0 112.678 -178.262 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 419' ' ' VAL . . . . . 0.733 HG13 ' HG2' ' A' ' 404' ' ' LYS . 13.5 m -105.03 163.29 4.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.832 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 29.9 p90 -143.38 153.71 42.97 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-O 121.406 0.622 . . . . 0.0 111.234 -178.133 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -142.81 136.15 28.5 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.259 -0.882 . . . . 0.0 109.037 176.664 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -124.05 134.71 9.34 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.399 -0.905 . . . . 0.0 112.327 -178.341 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 423' ' ' LYS . . . . . 0.403 ' O ' ' HA ' ' A' ' 319' ' ' TYR . 44.6 mtpt -104.8 140.18 38.48 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 120.753 0.311 . . . . 0.0 110.198 178.722 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 424' ' ' LYS . . . . . 0.403 ' HB2' ' HE1' ' A' ' 319' ' ' TYR . 26.0 tptp -58.14 116.25 3.43 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.626 -0.716 . . . . 0.0 111.8 179.652 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 425' ' ' GLU . . . . . 0.504 ' HB3' HG11 ' A' ' 318' ' ' VAL . 19.8 tp10 -64.94 112.71 3.42 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 169.009 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 426' ' ' GLN . . . . . . . . . . . . . 3.1 tp-100 -88.16 127.99 35.44 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 121.352 0.596 . . . . 0.0 111.086 -172.802 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 427' ' ' ASP . . . . . . . . . . . . . 9.0 p-10 -107.4 -161.76 0.8 Allowed 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.263 -0.88 . . . . 0.0 109.476 176.601 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 428' ' ' LEU . . . . . 0.502 ' H ' ' CD1' ' A' ' 428' ' ' LEU . 0.0 OUTLIER -72.12 -14.94 61.97 Favored 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 121.086 -0.246 . . . . 0.0 111.162 179.976 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 429' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 66.62 -81.17 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.381 0 C-N-CA 123.298 0.639 . . . . 0.0 111.123 179.503 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 430' ' ' HIS . . . . . . . . . . . . . 96.0 m-70 -141.67 111.76 6.82 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 431' ' ' HIS . . . . . 0.462 ' O ' ' HB2' ' A' ' 432' ' ' HIS . 75.3 t60 -69.37 141.19 54.23 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 179.779 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 432' ' ' HIS . . . . . 0.462 ' HB2' ' O ' ' A' ' 431' ' ' HIS . 43.4 m170 76.08 -75.91 0.06 Allowed 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 123.641 0.776 . . . . 0.0 110.59 -174.429 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 433' ' ' HIS . . . . . . . . . . . . . 48.0 m80 -149.23 167.34 26.27 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 179.172 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 434' ' ' HIS . . . . . . . . . . . . . 5.2 p80 -63.43 -27.06 69.03 Favored 'General case' 0 C--N 1.332 -0.186 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 174.477 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 435' ' ' HIS . . . . . . . . . . . . . 55.4 t-80 . . . . . 0 C--O 1.244 0.777 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.021 176.64 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo . . . . . 0 N--CA 1.444 -1.414 0 N-CA-C 111.575 -0.202 . . . . 0.0 111.575 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 308' ' ' ALA . . . . . 0.675 ' HB2' ' O ' ' A' ' 394' ' ' TYR . . . -59.47 163.54 4.01 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.15 -0.62 . . . . 0.0 109.974 168.828 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 309' ' ' LYS . . . . . 0.537 ' HB3' ' HB2' ' A' ' 312' ' ' MET . 10.8 tptp -123.96 93.45 3.93 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 174.1 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 310' ' ' GLY . . . . . 0.7 ' HA2' HD12 ' A' ' 313' ' ' LEU . . . -57.24 -34.02 66.47 Favored Glycine 0 C--N 1.332 0.315 0 C-N-CA 121.147 -0.549 . . . . 0.0 113.013 -173.934 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 311' ' ' GLU . . . . . 0.425 ' HA ' ' HE3' ' A' ' 349' ' ' LYS . 11.2 pt-20 -62.82 -26.9 68.97 Favored 'General case' 0 C--N 1.319 -0.755 0 C-N-CA 122.483 0.313 . . . . 0.0 111.581 174.807 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 312' ' ' MET . . . . . 0.537 ' HB2' ' HB3' ' A' ' 309' ' ' LYS . 90.0 mtp -102.37 -6.37 23.1 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.921 0.391 . . . . 0.0 110.567 -179.77 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 313' ' ' LEU . . . . . 0.7 HD12 ' HA2' ' A' ' 310' ' ' GLY . 92.4 mt -75.26 133.2 41.4 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.729 176.876 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -143.68 137.09 27.97 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.017 -173.822 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.53 -159.53 15.28 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 121.001 -0.618 . . . . 0.0 111.665 178.994 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 12.7 p -123.89 156.17 36.76 Favored 'General case' 0 C--N 1.317 -0.806 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 173.462 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 317' ' ' ALA . . . . . 0.402 ' HB3' HG13 ' A' ' 344' ' ' VAL . . . -146.51 160.41 42.15 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 120.918 0.39 . . . . 0.0 110.694 176.657 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 318' ' ' VAL . . . . . 0.582 ' HA ' ' O ' ' A' ' 342' ' ' ALA . 8.7 p -138.78 113.75 8.5 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.691 172.849 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 319' ' ' TYR . . . . . 0.731 ' HE2' HG11 ' A' ' 344' ' ' VAL . 55.4 m-85 -98.08 127.46 44.04 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.331 -177.256 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -115.79 132.4 56.65 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.478 174.459 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 321' ' ' GLY . . . . . 0.48 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -166.27 -143.17 3.65 Favored Glycine 0 N--CA 1.438 -1.197 0 C-N-CA 120.697 -0.763 . . . . 0.0 111.948 -179.143 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -136.94 164.67 27.78 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 120.927 0.394 . . . . 0.0 111.236 -173.845 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 323' ' ' VAL . . . . . 0.608 HG23 ' HB2' ' A' ' 340' ' ' PHE . 75.2 t -126.34 116.42 45.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.53 178.792 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 324' ' ' LEU . . . . . 0.426 ' HB2' HG22 ' A' ' 419' ' ' VAL . 93.7 mt -89.4 101.76 14.43 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 175.486 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 325' ' ' HIS . . . . . 0.52 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 10.5 p-80 -102.24 114.76 29.19 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.493 0.663 . . . . 0.0 110.066 -179.123 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 326' ' ' PHE . . . . . 0.5 ' HB2' ' HB3' ' A' ' 417' ' ' PHE . 49.0 m-85 . . . . . 0 C--N 1.323 -0.552 0 CA-C-N 114.734 -1.121 . . . . 0.0 110.897 -170.011 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 337' ' ' ARG . . . . . . . . . . . . . 54.6 mtp180 . . . . . 0 N--CA 1.454 -0.23 0 CA-C-O 120.957 0.408 . . . . 0.0 110.707 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -96.82 -176.81 35.22 Favored Glycine 0 N--CA 1.447 -0.591 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 173.951 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 339' ' ' ARG . . . . . . . . . . . . . 29.0 mtm180 -112.41 163.31 14.58 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 118.055 0.928 . . . . 0.0 110.213 179.393 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 340' ' ' PHE . . . . . 0.608 ' HB2' HG23 ' A' ' 323' ' ' VAL . 30.7 t80 -151.67 140.13 20.55 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.83 0.347 . . . . 0.0 111.137 -179.243 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 341' ' ' ALA . . . . . 0.562 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -137.25 152.55 49.94 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.12 175.364 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 342' ' ' ALA . . . . . 0.929 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -143.83 118.3 9.71 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.044 0.45 . . . . 0.0 111.513 -178.375 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 343' ' ' LYS . . . . . 0.525 ' HB3' ' HB2' ' A' ' 352' ' ' ASP . 55.7 tptt -96.52 103.61 15.54 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.109 177.946 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 344' ' ' VAL . . . . . 0.731 HG11 ' HE2' ' A' ' 319' ' ' TYR . 0.7 OUTLIER -122.86 140.33 46.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -170.691 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -114.4 121.31 43.19 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.839 -1.073 . . . . 0.0 108.46 171.164 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 346' ' ' PHE . . . . . . . . . . . . . 51.8 m-85 -76.7 -17.04 59.34 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 111.734 0.272 . . . . 0.0 111.734 -175.301 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -75.29 -42.12 29.14 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.461 -0.876 . . . . 0.0 111.269 178.568 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 55.9 m -88.37 -10.93 47.7 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-O 120.811 0.339 . . . . 0.0 110.108 177.33 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 349' ' ' LYS . . . . . 0.64 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 48.4 mttm 51.24 58.81 5.12 Favored 'General case' 0 CA--C 1.52 -0.198 0 CA-C-O 121.863 0.84 . . . . 0.0 109.896 -179.723 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 50.7 m -147.77 146.02 29.02 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 114.777 -1.101 . . . . 0.0 109.607 176.958 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 351' ' ' VAL . . . . . 0.782 HG22 ' HB3' ' A' ' 370' ' ' ALA . 1.3 m -129.69 156.35 41.97 Favored 'Isoleucine or valine' 0 C--O 1.237 0.427 0 CA-C-O 121.181 0.515 . . . . 0.0 110.461 -176.451 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 352' ' ' ASP . . . . . 0.929 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 0.9 OUTLIER -109.48 117.37 33.81 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 170.481 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -114.7 117.08 3.95 Favored Glycine 0 N--CA 1.444 -0.792 0 C-N-CA 120.218 -0.991 . . . . 0.0 112.136 -177.546 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 354' ' ' ILE . . . . . 0.526 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -117.65 133.14 65.39 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.127 0 CA-C-N 115.321 -0.439 . . . . 0.0 109.916 -176.995 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 355' ' ' ILE . . . . . 0.514 ' HB ' ' HB3' ' A' ' 366' ' ' GLN . 3.4 mp . . . . . 0 C--N 1.32 -0.71 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.797 -178.016 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 366' ' ' GLN . . . . . 0.514 ' HB3' ' HB ' ' A' ' 355' ' ' ILE . 17.5 tp60 . . . . . 0 N--CA 1.45 -0.471 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 37.5 ttpt -156.54 136.98 13.04 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.427 -176.344 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 368' ' ' PHE . . . . . 0.424 ' HB3' ' CE3' ' A' ' 381' ' ' TRP . 46.9 p90 -129.51 156.42 44.17 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.095 0.474 . . . . 0.0 109.978 178.876 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 4.0 tptp -116.62 131.59 56.91 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 175.149 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 370' ' ' ALA . . . . . 0.782 ' HB3' HG22 ' A' ' 351' ' ' VAL . . . -128.87 140.77 51.53 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 112.193 0.442 . . . . 0.0 112.193 -170.994 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -101.31 130.83 47.54 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.603 175.311 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 372' ' ' ILE . . . . . 0.64 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 84.2 mt -80.8 105.17 10.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.842 0.829 . . . . 0.0 110.08 -179.24 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -113.63 83.93 1.93 Allowed 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 114.337 -1.301 . . . . 0.0 108.944 -177.16 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 374' ' ' GLY . . . . . 0.56 ' O ' ' HA3' ' A' ' 310' ' ' GLY . . . 101.34 -141.79 15.46 Favored Glycine 0 N--CA 1.444 -0.811 0 CA-C-N 115.159 -0.928 . . . . 0.0 111.117 -174.15 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 375' ' ' ASN . . . . . . . . . . . . . 30.9 p-10 -97.57 59.56 1.52 Allowed 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 122.582 1.182 . . . . 0.0 109.545 179.034 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 162.1 178.43 35.98 Favored Glycine 0 N--CA 1.443 -0.893 0 CA-C-N 113.993 -1.458 . . . . 0.0 109.959 -174.318 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 377' ' ' PHE . . . . . 0.472 ' CZ ' HG21 ' A' ' 401' ' ' VAL . 4.8 p90 -139.45 150.99 45.86 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 117.655 0.728 . . . . 0.0 112.155 -178.412 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 378' ' ' LYS . . . . . 0.442 ' HD2' ' N ' ' A' ' 378' ' ' LYS . 0.0 OUTLIER -115.06 129.5 56.71 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 172.818 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 379' ' ' GLY . . . . . 0.513 ' HA2' ' HA ' ' A' ' 370' ' ' ALA . . . -126.33 169.3 18.28 Favored Glycine 0 N--CA 1.444 -0.777 0 C-N-CA 119.997 -1.097 . . . . 0.0 113.411 -171.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 11.3 p -131.19 140.17 49.86 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.118 -0.541 . . . . 0.0 109.872 178.907 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 381' ' ' TRP . . . . . 0.488 ' CZ3' ' HG3' ' A' ' 366' ' ' GLN . 73.7 m95 . . . . . 0 C--N 1.327 -0.401 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.701 179.496 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.737 0 N-CA-C 112.27 -0.332 . . . . 0.0 112.27 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -99.66 138.94 36.04 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.817 0.342 . . . . 0.0 110.594 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 389' ' ' VAL . . . . . 0.49 HG22 ' HB3' ' A' ' 405' ' ' TYR . 22.1 t -109.53 144.81 17.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 177.641 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 14.7 m -147.44 139.64 24.43 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.52 0.2 . . . . 0.0 110.557 175.999 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -145.08 150.14 22.31 Favored Glycine 0 C--N 1.32 -0.326 0 N-CA-C 111.692 -0.563 . . . . 0.0 111.692 179.38 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 392' ' ' ARG . . . . . 0.64 ' HD3' ' O ' ' A' ' 393' ' ' PHE . 4.5 tmt_? -118.67 136.55 53.85 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -175.501 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 393' ' ' PHE . . . . . 0.64 ' O ' ' HD3' ' A' ' 392' ' ' ARG . 8.1 m-85 -82.24 159.76 23.13 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.263 -177.693 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 394' ' ' TYR . . . . . 0.675 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 2.4 m-85 -100.81 -174.67 2.68 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.861 -177.164 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 395' ' ' GLY . . . . . . . . . . . . . . . -38.42 170.45 0.01 OUTLIER Glycine 0 C--N 1.335 0.487 0 O-C-N 124.277 0.985 . . . . 0.0 114.985 -177.718 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -51.52 -15.11 2.35 Favored 'Trans proline' 0 N--CA 1.477 0.502 0 C-N-CA 124.384 3.389 . . . . 0.0 115.526 -163.853 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 397' ' ' ALA . . . . . . . . . . . . . . . -80.22 -20.49 44.54 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 111.735 0.272 . . . . 0.0 111.735 177.299 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 56.23 18.62 21.46 Favored Glycine 0 C--N 1.34 0.763 0 CA-C-N 116.09 -0.505 . . . . 0.0 114.081 175.046 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 399' ' ' GLU . . . . . 0.908 ' HG3' ' HB3' ' A' ' 424' ' ' LYS . 17.7 tt0 -73.15 -19.15 61.19 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.193 0.52 . . . . 0.0 110.838 -177.751 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -116.7 137.47 52.17 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-O 121.18 0.514 . . . . 0.0 110.362 177.974 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 401' ' ' VAL . . . . . 0.472 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 9.0 p -139.46 134.55 39.67 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.546 173.423 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -131.14 135.18 47.24 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.172 -179.335 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -151.05 -176.64 24.12 Favored Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.177 -1.011 . . . . 0.0 112.152 -177.987 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 404' ' ' LYS . . . . . 0.675 ' HG2' HG12 ' A' ' 419' ' ' VAL . 27.0 mttm -147.69 162.47 39.1 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 -179.352 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 405' ' ' TYR . . . . . 0.49 ' HB3' HG22 ' A' ' 389' ' ' VAL . 6.9 p90 . . . . . 0 C--N 1.318 -0.77 0 CA-C-O 121.251 0.548 . . . . 0.0 111.593 175.644 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 417' ' ' PHE . . . . . 0.5 ' HB3' ' HB2' ' A' ' 326' ' ' PHE . 64.1 m-85 . . . . . 0 N--CA 1.447 -0.605 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 418' ' ' GLY . . . . . 0.52 ' HA2' ' HA ' ' A' ' 325' ' ' HIS . . . 82.4 77.32 1.07 Allowed Glycine 0 N--CA 1.442 -0.935 0 C-N-CA 119.78 -1.2 . . . . 0.0 111.447 -175.454 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 419' ' ' VAL . . . . . 0.675 HG12 ' HG2' ' A' ' 404' ' ' LYS . 19.7 m -105.08 146.96 11.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 -178.109 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 420' ' ' PHE . . . . . 0.48 ' HB3' HG22 ' A' ' 323' ' ' VAL . 47.0 p90 -130.29 161.07 32.06 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 121.023 0.44 . . . . 0.0 110.696 -179.299 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 421' ' ' ALA . . . . . 0.48 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -153.92 136.54 15.17 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.025 179.821 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -132.54 141.67 13.06 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.187 -1.006 . . . . 0.0 113.052 -177.336 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 72.3 mmtt -102.46 125.56 49.22 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 175.722 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 424' ' ' LYS . . . . . 0.908 ' HB3' ' HG3' ' A' ' 399' ' ' GLU . 80.0 tttt -63.16 105.72 0.75 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.272 0.558 . . . . 0.0 110.626 178.16 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 . . . . . 0 C--N 1.321 -0.673 0 CA-C-N 115.53 -0.759 . . . . 0.0 109.984 -179.708 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo . . . . . 0 CA--C 1.533 0.441 0 N-CA-C 112.672 0.22 . . . . 0.0 112.672 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 308' ' ' ALA . . . . . 0.626 ' HB2' ' O ' ' A' ' 394' ' ' TYR . . . -47.51 153.88 0.5 Allowed 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 121.137 0.494 . . . . 0.0 111.965 170.091 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 309' ' ' LYS . . . . . 0.677 ' O ' ' HG ' ' A' ' 313' ' ' LEU . 65.9 mmtt -91.76 88.28 6.62 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 178.157 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 310' ' ' GLY . . . . . 0.627 ' HA2' HD12 ' A' ' 313' ' ' LEU . . . -58.31 -40.22 93.73 Favored Glycine 0 C--N 1.333 0.41 0 C-N-CA 121.616 -0.326 . . . . 0.0 113.818 -171.213 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 311' ' ' GLU . . . . . 0.408 ' HG2' ' HG2' ' A' ' 312' ' ' MET . 0.2 OUTLIER -72.61 -19.97 61.37 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.818 0.342 . . . . 0.0 110.95 -178.4 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 312' ' ' MET . . . . . 0.408 ' HG2' ' HG2' ' A' ' 311' ' ' GLU . 78.3 mmm -108.43 6.48 26.3 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.812 0.339 . . . . 0.0 111.192 -178.687 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 313' ' ' LEU . . . . . 0.677 ' HG ' ' O ' ' A' ' 309' ' ' LYS . 91.9 mt -75.47 133.8 40.99 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 175.224 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -151.61 139.4 19.85 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.773 -172.939 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.23 161.81 11.63 Favored Glycine 0 N--CA 1.448 -0.556 0 N-CA-C 111.306 -0.718 . . . . 0.0 111.306 178.822 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 21.7 p -97.82 135.01 40.19 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 173.044 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -133.47 151.51 51.79 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.78 -172.166 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -120.75 110.4 28.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.439 -0.8 . . . . 0.0 109.384 175.956 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 319' ' ' TYR . . . . . 0.707 ' O ' ' HA ' ' A' ' 341' ' ' ALA . 90.9 m-85 -99.18 127.49 45.16 Favored 'General case' 0 C--N 1.312 -1.04 0 C-N-CA 120.327 -0.549 . . . . 0.0 110.424 178.327 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 48.0 m-80 -120.85 132.74 55.17 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.377 178.834 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 321' ' ' GLY . . . . . 0.566 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -166.53 -154.18 8.2 Favored Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.54 -179.598 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 3.7 mp0 -116.12 153.95 30.87 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.056 0.455 . . . . 0.0 111.122 -174.168 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 323' ' ' VAL . . . . . 0.559 HG23 ' HB2' ' A' ' 340' ' ' PHE . 72.5 t -112.06 117.44 55.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.355 -0.839 . . . . 0.0 109.208 172.397 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 324' ' ' LEU . . . . . 0.47 ' HB2' HG22 ' A' ' 419' ' ' VAL . 93.7 mt -95.69 104.31 16.22 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.129 0.49 . . . . 0.0 110.298 -177.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 325' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -98.52 113.98 26.21 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 179.512 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 326' ' ' PHE . . . . . 0.515 ' HD2' ' H ' ' A' ' 418' ' ' GLY . 57.9 m-85 . . . . . 0 C--N 1.321 -0.636 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.377 -174.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 337' ' ' ARG . . . . . . . . . . . . . 51.9 mtm180 . . . . . 0 N--CA 1.45 -0.438 0 CA-C-O 120.911 0.386 . . . . 0.0 110.268 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -90.52 -177.13 44.36 Favored Glycine 0 N--CA 1.44 -1.08 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 172.827 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 339' ' ' ARG . . . . . . . . . . . . . 65.1 mtt180 -104.49 154.92 19.28 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 176.237 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 340' ' ' PHE . . . . . 0.559 ' HB2' HG23 ' A' ' 323' ' ' VAL . 27.0 t80 -148.74 139.02 22.42 Favored 'General case' 0 C--N 1.309 -1.16 0 CA-C-O 121.165 0.507 . . . . 0.0 110.494 179.161 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 341' ' ' ALA . . . . . 0.707 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -136.84 164.2 28.87 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 114.967 -1.015 . . . . 0.0 108.908 175.809 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 342' ' ' ALA . . . . . 0.849 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -151.76 120.11 6.39 Favored 'General case' 0 C--N 1.314 -0.943 0 N-CA-C 109.654 -0.499 . . . . 0.0 109.654 -179.758 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 13.0 tptm -100.81 98.43 8.95 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.727 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 344' ' ' VAL . . . . . 0.491 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.2 OUTLIER -118.45 136.93 54.05 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 CA-C-N 115.833 -0.621 . . . . 0.0 112.176 -169.576 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 10.4 t0 -107.23 113.0 26.13 Favored 'General case' 0 C--N 1.321 -0.63 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 171.194 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 346' ' ' PHE . . . . . . . . . . . . . 48.4 m-85 -74.77 -27.64 60.42 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 111.701 0.26 . . . . 0.0 111.701 -176.091 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -61.87 -33.36 85.13 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.695 -0.764 . . . . 0.0 111.654 177.198 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 6.8 t -101.59 -4.48 26.57 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-O 120.688 0.28 . . . . 0.0 111.083 178.162 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 349' ' ' LYS . . . . . 0.479 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 10.0 mtmp? 51.28 59.05 4.88 Favored 'General case' 0 N--CA 1.466 0.362 0 C-N-CA 123.148 0.579 . . . . 0.0 111.543 -178.265 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 40.2 m -149.6 140.51 22.83 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.14 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 351' ' ' VAL . . . . . 0.517 HG22 ' HB3' ' A' ' 370' ' ' ALA . 0.8 OUTLIER -129.08 156.43 41.68 Favored 'Isoleucine or valine' 0 C--O 1.236 0.369 0 CA-C-O 121.289 0.566 . . . . 0.0 111.147 -175.665 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 352' ' ' ASP . . . . . 0.849 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 17.9 t70 -111.72 119.19 37.79 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.981 -1.009 . . . . 0.0 108.414 166.493 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -111.31 120.81 5.57 Favored Glycine 0 C--N 1.306 -1.11 0 C-N-CA 120.621 -0.8 . . . . 0.0 111.369 -178.78 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 354' ' ' ILE . . . . . 0.536 HG12 ' N ' ' A' ' 355' ' ' ILE . 0.2 OUTLIER -121.29 140.9 43.96 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.233 0 CA-C-O 121.084 0.469 . . . . 0.0 110.577 -176.233 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 355' ' ' ILE . . . . . 0.916 ' HB ' ' HB2' ' A' ' 366' ' ' GLN . 3.1 mp . . . . . 0 C--N 1.315 -0.904 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.26 177.614 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 366' ' ' GLN . . . . . 0.916 ' HB2' ' HB ' ' A' ' 355' ' ' ILE . 41.2 mt-30 . . . . . 0 N--CA 1.451 -0.379 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 367' ' ' LYS . . . . . 0.436 ' HD3' ' HE2' ' A' ' 369' ' ' LYS . 26.2 ttmt -148.43 139.8 23.43 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.181 -0.463 . . . . 0.0 109.752 -178.777 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 368' ' ' PHE . . . . . . . . . . . . . 52.3 p90 -139.06 145.12 39.18 Favored 'General case' 0 C--N 1.321 -0.663 0 O-C-N 123.33 0.394 . . . . 0.0 110.365 176.69 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 369' ' ' LYS . . . . . 0.436 ' HE2' ' HD3' ' A' ' 367' ' ' LYS . 3.4 mptp? -106.74 131.94 53.29 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 175.626 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 370' ' ' ALA . . . . . 0.517 ' HB3' HG22 ' A' ' 351' ' ' VAL . . . -135.64 135.89 40.54 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.549 -172.325 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -92.89 133.88 35.65 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.761 176.233 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 372' ' ' ILE . . . . . 0.479 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 87.4 mt -82.17 108.11 14.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 121.191 0.52 . . . . 0.0 110.405 -178.961 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -109.61 81.18 1.4 Allowed 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.485 -0.78 . . . . 0.0 109.096 178.955 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 374' ' ' GLY . . . . . 0.623 ' HA2' ' HA3' ' A' ' 310' ' ' GLY . . . 53.79 118.95 0.01 OUTLIER Glycine 0 CA--C 1.524 0.61 0 CA-C-N 114.992 -1.004 . . . . 0.0 114.841 -176.108 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 375' ' ' ASN . . . . . 0.526 ' HB2' ' O ' ' A' ' 308' ' ' ALA . 40.2 t30 40.69 44.28 1.81 Allowed 'General case' 0 N--CA 1.47 0.566 0 CA-C-O 122.053 0.93 . . . . 0.0 112.182 175.506 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 156.66 167.79 18.41 Favored Glycine 0 N--CA 1.442 -0.931 0 C-N-CA 120.302 -0.952 . . . . 0.0 111.608 176.065 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 377' ' ' PHE . . . . . 0.507 ' CD2' HG11 ' A' ' 351' ' ' VAL . 2.3 p90 -133.44 143.8 49.08 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-O 121.34 0.59 . . . . 0.0 111.5 -179.18 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 378' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.67 125.29 47.31 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 114.887 -1.051 . . . . 0.0 108.262 174.983 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -142.26 -165.3 10.47 Favored Glycine 0 N--CA 1.44 -1.055 0 C-N-CA 120.361 -0.923 . . . . 0.0 112.587 -176.626 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 95.4 m -142.46 147.05 35.45 Favored 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 -176.719 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 381' ' ' TRP . . . . . . . . . . . . . 42.0 m95 . . . . . 0 C--N 1.331 -0.214 0 O-C-N 123.633 0.583 . . . . 0.0 111.43 178.9 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.666 0 CA-C-O 120.985 0.214 . . . . 0.0 113.327 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -89.73 159.07 17.25 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 -177.407 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 79.6 t -135.67 135.99 50.75 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 174.166 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 16.9 m -143.11 141.68 31.3 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.8 0.334 . . . . 0.0 110.692 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 391' ' ' GLY . . . . . 0.435 ' HA2' ' CA ' ' A' ' 403' ' ' GLY . . . -145.36 155.9 26.7 Favored Glycine 0 C--N 1.316 -0.581 0 N-CA-C 111.487 -0.645 . . . . 0.0 111.487 -178.515 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 392' ' ' ARG . . . . . 0.526 ' HD3' ' O ' ' A' ' 375' ' ' ASN . 25.0 tpp180 -117.07 135.62 53.59 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.768 0.318 . . . . 0.0 110.24 -175.751 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -85.12 165.23 17.63 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.951 176.317 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 394' ' ' TYR . . . . . 0.626 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 4.8 m-85 -109.58 -177.38 3.26 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.99 -177.947 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 395' ' ' GLY . . . . . 0.479 ' O ' ' N ' ' A' ' 397' ' ' ALA . . . -37.83 160.72 0.01 OUTLIER Glycine 0 C--N 1.336 0.541 0 O-C-N 124.492 1.12 . . . . 0.0 114.922 -176.625 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_exo -17.25 -40.46 0.0 OUTLIER 'Trans proline' 0 C--N 1.353 0.78 1 C-N-CA 127.773 5.649 . . . . 0.0 118.501 -165.122 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 397' ' ' ALA . . . . . 0.552 ' HB1' ' HG3' ' A' ' 399' ' ' GLU . . . -81.16 -20.24 41.69 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 118.754 0.706 . . . . 0.0 111.633 -171.536 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 60.96 10.63 20.78 Favored Glycine 0 C--N 1.338 0.682 0 C-N-CA 121.409 -0.424 . . . . 0.0 112.725 176.668 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 399' ' ' GLU . . . . . 0.552 ' HG3' ' HB1' ' A' ' 397' ' ' ALA . 30.5 mt-10 -70.19 -8.93 53.82 Favored 'General case' 0 N--CA 1.451 -0.406 0 CA-C-O 121.66 0.743 . . . . 0.0 110.123 -178.378 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 400' ' ' GLU . . . . . 0.408 ' HB2' ' HB2' ' A' ' 394' ' ' TYR . 41.9 mt-10 -117.54 128.36 54.89 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.82 175.16 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 401' ' ' VAL . . . . . 0.46 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 10.1 p -140.87 140.49 32.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.844 0.354 . . . . 0.0 110.517 177.888 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -142.16 131.34 23.38 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.269 178.793 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 403' ' ' GLY . . . . . 0.435 ' CA ' ' HA2' ' A' ' 391' ' ' GLY . . . -145.02 -169.04 13.2 Favored Glycine 0 N--CA 1.438 -1.18 0 C-N-CA 120.47 -0.872 . . . . 0.0 112.271 -177.153 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 404' ' ' LYS . . . . . 0.775 ' HG2' HG12 ' A' ' 419' ' ' VAL . 37.5 mtpt -148.8 169.11 21.22 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 -178.344 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 5.8 m-85 . . . . . 0 C--N 1.32 -0.712 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 177.287 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 417' ' ' PHE . . . . . 0.478 ' HB2' ' HB2' ' A' ' 326' ' ' PHE . 35.2 p90 . . . . . 0 N--CA 1.453 -0.304 0 CA-C-O 120.973 0.416 . . . . 0.0 111.144 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 418' ' ' GLY . . . . . 0.515 ' H ' ' HD2' ' A' ' 326' ' ' PHE . . . 83.93 76.49 1.16 Allowed Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.3 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 419' ' ' VAL . . . . . 0.775 HG12 ' HG2' ' A' ' 404' ' ' LYS . 16.0 m -115.64 160.06 15.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 110.429 -0.211 . . . . 0.0 110.429 178.992 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 38.7 p90 -138.41 158.65 43.86 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.068 0.461 . . . . 0.0 110.506 178.898 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 421' ' ' ALA . . . . . 0.566 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -146.44 136.68 23.7 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.346 176.627 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -130.34 139.97 11.38 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.566 -0.826 . . . . 0.0 111.71 -179.365 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 72.1 mttt -117.66 136.4 53.35 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.173 0.511 . . . . 0.0 110.616 179.476 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 424' ' ' LYS . . . . . 0.513 ' HG2' ' OE2' ' A' ' 399' ' ' GLU . 23.0 tptm -59.0 125.82 25.17 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 114.838 -1.074 . . . . 0.0 113.126 -174.864 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 . . . . . 0 N--CA 1.446 -0.651 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 166.27 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo . . . . . 0 N--CA 1.461 -0.404 0 CA-C-O 120.653 0.189 . . . . 0.0 112.249 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 308' ' ' ALA . . . . . 0.787 ' O ' ' HB3' ' A' ' 375' ' ' ASN . . . -49.09 160.42 0.21 Allowed 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.148 169.291 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 309' ' ' LYS . . . . . 0.582 ' N ' HD23 ' A' ' 313' ' ' LEU . 79.2 mttt -127.01 91.46 3.34 Favored 'General case' 0 C--O 1.217 -0.611 0 O-C-N 121.798 -0.564 . . . . 0.0 109.817 -176.564 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -56.74 -23.46 44.47 Favored Glycine 0 CA--C 1.52 0.391 0 N-CA-C 114.873 0.709 . . . . 0.0 114.873 -168.298 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -87.65 -12.03 46.7 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 117.44 0.62 . . . . 0.0 111.574 178.392 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 14.8 tpt -115.5 -35.57 4.54 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.767 0.794 . . . . 0.0 109.511 -175.92 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 313' ' ' LEU . . . . . 0.78 HD22 ' HB1' ' A' ' 308' ' ' ALA . 0.4 OUTLIER -83.39 134.85 34.87 Favored 'General case' 0 N--CA 1.436 -1.169 0 CA-C-N 114.717 -1.128 . . . . 0.0 108.057 176.147 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 314' ' ' ALA . . . . . 0.644 ' HA ' ' CB ' ' A' ' 346' ' ' PHE . . . -161.91 173.18 14.85 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.177 0.513 . . . . 0.0 112.187 -170.989 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 121.71 168.67 13.43 Favored Glycine 0 N--CA 1.448 -0.531 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.277 -177.412 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 14.0 p -100.24 130.41 46.36 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 117.409 0.604 . . . . 0.0 109.94 174.901 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 317' ' ' ALA . . . . . 0.404 ' CB ' ' HE3' ' A' ' 424' ' ' LYS . . . -139.62 150.62 45.19 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 112.241 0.46 . . . . 0.0 112.241 -170.688 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 7.5 p -125.68 122.48 62.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.229 175.658 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 319' ' ' TYR . . . . . 0.413 ' O ' ' HA ' ' A' ' 341' ' ' ALA . 19.5 m-85 -111.99 146.61 37.55 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.732 -178.464 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 320' ' ' ASN . . . . . 0.455 ' HB2' ' HG3' ' A' ' 425' ' ' GLU . 17.1 m120 -129.97 137.29 50.23 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.108 175.665 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 321' ' ' GLY . . . . . 0.598 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -162.52 -163.02 14.33 Favored Glycine 0 N--CA 1.44 -1.055 0 C-N-CA 120.344 -0.932 . . . . 0.0 112.697 -178.745 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -117.93 146.17 44.16 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.654 0.264 . . . . 0.0 110.33 -175.305 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 323' ' ' VAL . . . . . 0.671 HG23 ' HB2' ' A' ' 340' ' ' PHE . 84.9 t -110.39 117.05 53.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.105 176.084 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 324' ' ' LEU . . . . . 0.436 HD12 ' CE1' ' A' ' 326' ' ' PHE . 0.2 OUTLIER -94.44 103.03 15.01 Favored 'General case' 0 C--N 1.312 -1.038 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 177.796 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 325' ' ' HIS . . . . . 0.437 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 8.3 p-80 -95.88 115.48 27.5 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.14 -179.199 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 326' ' ' PHE . . . . . 0.737 ' HB2' ' HD1' ' A' ' 417' ' ' PHE . 16.5 m-85 . . . . . 0 C--N 1.321 -0.654 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.895 -175.283 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 337' ' ' ARG . . . . . 0.453 ' HA ' ' O ' ' A' ' 323' ' ' VAL . 17.4 ptp180 . . . . . 0 N--CA 1.45 -0.467 0 CA-C-O 121.042 0.448 . . . . 0.0 110.786 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -113.21 -176.69 19.49 Favored Glycine 0 N--CA 1.443 -0.869 0 CA-C-N 115.422 -0.808 . . . . 0.0 111.554 178.226 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 339' ' ' ARG . . . . . . . . . . . . . 73.6 mtt180 -104.91 131.16 52.76 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 120.747 0.308 . . . . 0.0 110.358 -175.085 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 340' ' ' PHE . . . . . 0.671 ' HB2' HG23 ' A' ' 323' ' ' VAL . 55.2 t80 -132.85 137.27 46.65 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-O 121.252 0.548 . . . . 0.0 111.472 -176.346 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 341' ' ' ALA . . . . . 0.413 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -139.48 143.85 37.71 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.137 -0.938 . . . . 0.0 108.999 174.512 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 342' ' ' ALA . . . . . 0.932 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -136.33 120.04 17.26 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-O 121.039 0.447 . . . . 0.0 110.84 -177.012 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -102.43 102.86 13.21 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.327 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 344' ' ' VAL . . . . . 0.446 ' HA ' ' HA ' ' A' ' 351' ' ' VAL . 0.3 OUTLIER -115.95 124.78 72.67 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 CA-C-O 121.6 0.714 . . . . 0.0 111.83 -172.649 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -97.44 98.59 10.07 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 172.917 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 346' ' ' PHE . . . . . 0.644 ' CB ' ' HA ' ' A' ' 314' ' ' ALA . 72.7 m-85 -65.27 -26.76 68.23 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.689 0.28 . . . . 0.0 111.259 -176.188 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -65.75 -19.57 67.44 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.831 -0.7 . . . . 0.0 111.843 178.001 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 11.9 t -112.03 -6.67 14.16 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.986 0.422 . . . . 0.0 110.058 177.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 349' ' ' LYS . . . . . 0.59 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 37.5 mtmm 52.61 59.12 4.71 Favored 'General case' 0 C--O 1.227 -0.098 0 CA-C-N 115.064 -0.971 . . . . 0.0 111.159 -176.013 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 68.1 p -149.32 138.35 21.3 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.181 179.809 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 351' ' ' VAL . . . . . 0.446 ' HA ' ' HA ' ' A' ' 344' ' ' VAL . 0.9 OUTLIER -123.89 151.77 28.95 Favored 'Isoleucine or valine' 0 C--O 1.235 0.334 0 CA-C-O 121.05 0.452 . . . . 0.0 110.789 -178.497 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 352' ' ' ASP . . . . . 0.932 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 21.3 t70 -112.02 118.4 35.33 Favored 'General case' 0 C--O 1.213 -0.857 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.353 173.444 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -119.82 119.01 4.1 Favored Glycine 0 N--CA 1.442 -0.925 0 C-N-CA 120.257 -0.973 . . . . 0.0 112.173 -176.781 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 354' ' ' ILE . . . . . 0.549 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -114.81 129.64 70.61 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.065 0 CA-C-O 121.038 0.447 . . . . 0.0 110.103 -178.125 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 355' ' ' ILE . . . . . 0.44 HD11 ' HE2' ' A' ' 368' ' ' PHE . 3.7 mp . . . . . 0 C--N 1.323 -0.57 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.159 -177.741 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 . . . . . 0 CA--C 1.522 -0.101 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 19.3 pttp -148.23 151.33 35.29 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.191 0.519 . . . . 0.0 111.631 -179.121 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 368' ' ' PHE . . . . . 0.659 ' CD1' HG21 ' A' ' 389' ' ' VAL . 27.2 p90 -134.99 161.45 35.24 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.195 -0.911 . . . . 0.0 109.189 179.238 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 33.3 mtmm -131.62 150.9 51.99 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-O 121.264 0.554 . . . . 0.0 110.513 173.619 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -141.55 139.84 33.29 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.164 -173.701 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -92.69 130.73 38.23 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 174.223 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 372' ' ' ILE . . . . . 0.67 ' HA ' ' HB3' ' A' ' 377' ' ' PHE . 83.4 mt -79.45 108.17 12.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-O 121.758 0.79 . . . . 0.0 110.585 -176.322 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -110.58 82.38 1.58 Allowed 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 114.647 -1.16 . . . . 0.0 109.495 -178.712 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 59.48 119.29 0.01 OUTLIER Glycine 0 CA--C 1.52 0.402 0 CA-C-N 114.928 -1.033 . . . . 0.0 113.776 -177.146 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 375' ' ' ASN . . . . . 0.787 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 2.2 p-10 28.85 44.6 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 124.734 1.214 . . . . 0.0 114.123 177.238 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 160.59 -178.77 36.47 Favored Glycine 0 N--CA 1.442 -0.906 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 -178.693 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 377' ' ' PHE . . . . . 0.67 ' HB3' ' HA ' ' A' ' 372' ' ' ILE . 6.3 p90 -153.51 150.66 28.96 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 117.362 0.581 . . . . 0.0 111.783 -178.787 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 378' ' ' LYS . . . . . 0.555 ' H ' ' HD3' ' A' ' 378' ' ' LYS . 0.0 OUTLIER -117.77 140.59 49.47 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 171.102 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 379' ' ' GLY . . . . . 0.54 ' C ' HG22 ' A' ' 389' ' ' VAL . . . -149.06 -155.13 6.59 Favored Glycine 0 N--CA 1.44 -1.062 0 C-N-CA 120.504 -0.855 . . . . 0.0 112.235 -172.852 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 380' ' ' THR . . . . . 0.456 ' HA ' ' HA ' ' A' ' 388' ' ' ASP . 7.0 t -170.99 154.49 4.17 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 -173.52 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 381' ' ' TRP . . . . . 0.672 ' HD1' ' HA3' ' A' ' 387' ' ' GLY . 39.4 m95 . . . . . 0 C--N 1.327 -0.375 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.422 -179.597 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 387' ' ' GLY . . . . . 0.672 ' HA3' ' HD1' ' A' ' 381' ' ' TRP . . . . . . . . 0 N--CA 1.443 -0.881 0 N-CA-C 111.965 -0.454 . . . . 0.0 111.965 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 388' ' ' ASP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 380' ' ' THR . 43.4 m-20 -107.73 147.33 30.92 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.027 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 389' ' ' VAL . . . . . 0.659 HG21 ' CD1' ' A' ' 368' ' ' PHE . 3.3 m -121.49 167.15 15.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 120.713 0.292 . . . . 0.0 111.589 -171.736 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 33.6 t -161.87 157.61 24.21 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 173.669 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -157.57 163.57 32.64 Favored Glycine 0 C--N 1.32 -0.308 0 N-CA-C 111.682 -0.567 . . . . 0.0 111.682 179.666 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 25.6 ttt180 -125.71 143.21 51.14 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.791 0.295 . . . . 0.0 110.313 -176.775 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 393' ' ' PHE . . . . . 0.582 ' CZ ' ' HE1' ' A' ' 346' ' ' PHE . 2.5 m-85 -92.92 157.45 16.34 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.432 0.634 . . . . 0.0 112.261 -175.433 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 394' ' ' TYR . . . . . 0.729 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 1.2 m-85 -102.5 -176.5 3.12 Favored 'General case' 0 C--O 1.22 -0.5 0 CA-C-N 114.816 -1.083 . . . . 0.0 110.372 178.615 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 395' ' ' GLY . . . . . . . . . . . . . . . -36.67 153.64 0.01 OUTLIER Glycine 0 C--N 1.335 0.479 0 O-C-N 124.394 1.059 . . . . 0.0 114.941 -176.879 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_exo -16.15 -50.63 0.02 OUTLIER 'Trans proline' 0 C--N 1.351 0.691 1 C-N-CA 127.453 5.435 . . . . 0.0 117.724 -165.911 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 397' ' ' ALA . . . . . 0.537 ' HB3' ' HG2' ' A' ' 399' ' ' GLU . . . -75.46 -16.72 60.29 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 112.377 0.51 . . . . 0.0 112.377 -171.504 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 68.49 24.92 75.1 Favored Glycine 0 N--CA 1.447 -0.591 0 N-CA-C 111.769 -0.532 . . . . 0.0 111.769 179.538 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 399' ' ' GLU . . . . . 0.537 ' HG2' ' HB3' ' A' ' 397' ' ' ALA . 10.9 mm-40 -58.86 -16.54 17.86 Favored 'General case' 0 N--CA 1.463 0.208 0 C-N-CA 123.248 0.619 . . . . 0.0 111.557 -175.488 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 400' ' ' GLU . . . . . 0.409 ' HA ' ' O ' ' A' ' 422' ' ' GLY . 35.1 mt-10 -138.53 146.72 42.27 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 172.613 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 401' ' ' VAL . . . . . 0.488 HG21 ' CE2' ' A' ' 377' ' ' PHE . 7.3 p -144.54 133.01 17.92 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.398 177.032 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -124.61 132.22 53.44 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.332 -178.694 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -146.86 -172.14 16.82 Favored Glycine 0 N--CA 1.44 -1.049 0 C-N-CA 120.498 -0.858 . . . . 0.0 112.088 -179.139 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 404' ' ' LYS . . . . . 0.739 ' HG2' HG12 ' A' ' 419' ' ' VAL . 30.1 mtmt -146.51 158.43 43.9 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 179.815 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 405' ' ' TYR . . . . . 0.5 ' HB3' HG12 ' A' ' 389' ' ' VAL . 17.6 p90 . . . . . 0 C--N 1.32 -0.716 0 CA-C-O 121.222 0.534 . . . . 0.0 110.579 176.58 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 417' ' ' PHE . . . . . 0.737 ' HD1' ' HB2' ' A' ' 326' ' ' PHE . 71.5 m-85 . . . . . 0 N--CA 1.452 -0.366 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 418' ' ' GLY . . . . . 0.512 ' H ' ' HD2' ' A' ' 326' ' ' PHE . . . 81.8 76.86 1.06 Allowed Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 120.339 -0.934 . . . . 0.0 112.567 176.992 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 419' ' ' VAL . . . . . 0.739 HG12 ' HG2' ' A' ' 404' ' ' LYS . 18.9 m -106.43 152.84 7.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 N-CA-C 110.207 -0.294 . . . . 0.0 110.207 179.441 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 420' ' ' PHE . . . . . 0.419 ' HB3' HG22 ' A' ' 323' ' ' VAL . 40.9 p90 -138.03 154.42 49.3 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 120.934 0.397 . . . . 0.0 110.273 -179.438 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 421' ' ' ALA . . . . . 0.598 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -142.24 136.02 29.42 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 177.112 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 422' ' ' GLY . . . . . 0.409 ' O ' ' HA ' ' A' ' 400' ' ' GLU . . . -118.1 135.6 11.76 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 120.67 -0.776 . . . . 0.0 111.974 -179.046 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 63.9 mttm -113.37 133.68 55.03 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.816 0.341 . . . . 0.0 110.359 -179.086 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 424' ' ' LYS . . . . . 0.404 ' HE3' ' CB ' ' A' ' 317' ' ' ALA . 23.6 tptm -60.92 112.05 1.9 Allowed 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.354 -177.736 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 425' ' ' GLU . . . . . 0.455 ' HG3' ' HB2' ' A' ' 320' ' ' ASN . 8.8 mm-40 . . . . . 0 C--N 1.324 -0.541 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.516 177.433 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 307' ' ' PRO . . . . . 0.568 ' C ' ' HA2' ' A' ' 395' ' ' GLY . 66.6 Cg_endo . . . . . 0 N--CA 1.453 -0.898 0 CA-C-O 120.753 0.23 . . . . 0.0 111.634 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 308' ' ' ALA . . . . . 0.59 ' HB1' HD21 ' A' ' 313' ' ' LEU . . . -61.11 161.1 9.07 Favored 'General case' 0 CA--C 1.515 -0.372 0 CA-C-O 121.372 0.606 . . . . 0.0 112.106 -175.513 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 309' ' ' LYS . . . . . . . . . . . . . 45.1 mttm -104.66 84.61 2.19 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 171.598 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 310' ' ' GLY . . . . . 0.705 ' HA3' ' O ' ' A' ' 374' ' ' GLY . . . -55.51 -34.25 59.81 Favored Glycine 0 CA--C 1.508 -0.35 0 CA-C-N 115.832 -0.622 . . . . 0.0 113.054 -173.623 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -45.6 -37.6 5.74 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 123.663 0.785 . . . . 0.0 112.288 175.629 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 73.2 mtm -131.08 31.75 4.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.718 0.294 . . . . 0.0 111.144 -177.381 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 313' ' ' LEU . . . . . 0.611 HD12 ' HA2' ' A' ' 310' ' ' GLY . 10.3 mt -65.79 -165.45 0.03 OUTLIER 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 112.387 0.514 . . . . 0.0 112.387 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -76.25 -168.98 1.05 Allowed 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -170.429 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 315' ' ' GLY . . . . . 0.616 ' O ' ' HB2' ' A' ' 346' ' ' PHE . . . -93.11 -122.64 3.3 Favored Glycine 0 C--O 1.223 -0.574 0 CA-C-N 115.019 -0.991 . . . . 0.0 111.469 178.278 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 18.0 p -96.56 131.68 42.94 Favored 'General case' 0 C--N 1.311 -1.074 0 O-C-N 122.28 -0.541 . . . . 0.0 110.912 177.684 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -142.92 162.2 36.11 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.587 -174.294 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 4.7 p -127.92 114.68 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.642 0 CA-C-O 121.452 0.644 . . . . 0.0 110.489 172.854 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 1.3 m-85 -98.89 155.42 17.4 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 175.925 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 320' ' ' ASN . . . . . 0.435 ' HA ' ' HA ' ' A' ' 341' ' ' ALA . 2.1 p-10 -157.83 156.11 30.88 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 120.855 0.359 . . . . 0.0 110.75 173.825 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 321' ' ' GLY . . . . . 0.412 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -176.81 -150.24 8.17 Favored Glycine 0 N--CA 1.443 -0.846 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.145 -178.646 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 23.5 mm-40 -112.98 149.76 32.83 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.779 0.323 . . . . 0.0 110.861 -173.431 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 323' ' ' VAL . . . . . 0.685 HG21 HG23 ' A' ' 355' ' ' ILE . 55.5 t -108.52 118.29 55.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.051 174.091 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 324' ' ' LEU . . . . . . . . . . . . . 92.2 mt -97.61 103.48 15.42 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.896 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 325' ' ' HIS . . . . . . . . . . . . . 26.3 t60 -98.97 112.73 24.76 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 -178.144 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 326' ' ' PHE . . . . . 0.625 ' HB2' ' HB3' ' A' ' 417' ' ' PHE . 30.3 m-85 . . . . . 0 C--N 1.327 -0.409 0 CA-C-N 116.28 -0.418 . . . . 0.0 109.925 -173.78 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 337' ' ' ARG . . . . . . . . . . . . . 18.5 mtp180 . . . . . 0 N--CA 1.444 -0.726 0 CA-C-O 121.289 0.566 . . . . 0.0 111.054 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -98.53 165.37 21.34 Favored Glycine 0 N--CA 1.436 -1.318 0 N-CA-C 110.132 -1.187 . . . . 0.0 110.132 173.734 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 339' ' ' ARG . . . . . 0.524 ' HD2' ' N ' ' A' ' 339' ' ' ARG . 5.6 mpt_? -104.92 157.56 17.13 Favored 'General case' 0 C--N 1.313 -0.992 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 176.651 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 340' ' ' PHE . . . . . 0.75 ' HA ' ' O ' ' A' ' 354' ' ' ILE . 11.1 t80 -154.68 140.56 18.22 Favored 'General case' 0 C--N 1.313 -0.992 0 C-N-CA 120.496 -0.482 . . . . 0.0 111.35 -176.777 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 341' ' ' ALA . . . . . 0.435 ' HA ' ' HA ' ' A' ' 320' ' ' ASN . . . -136.81 165.75 25.2 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 174.351 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 342' ' ' ALA . . . . . 0.861 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -147.96 118.98 7.66 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-O 121.12 0.486 . . . . 0.0 111.222 -177.32 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 343' ' ' LYS . . . . . 0.531 ' HB3' ' HB2' ' A' ' 352' ' ' ASP . 27.0 tptp -87.28 98.0 11.09 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 174.96 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 344' ' ' VAL . . . . . 0.488 ' HA ' ' HA ' ' A' ' 351' ' ' VAL . 0.3 OUTLIER -115.95 117.31 55.12 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-O 121.816 0.817 . . . . 0.0 111.802 -172.718 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -95.44 94.11 7.61 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 114.282 -1.327 . . . . 0.0 108.591 175.48 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 346' ' ' PHE . . . . . 0.616 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 44.9 m-85 -65.54 -21.2 66.58 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.965 -174.976 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -62.28 -33.8 87.21 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.363 176.529 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 39.0 m -106.78 -6.57 17.67 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.163 0.506 . . . . 0.0 110.15 176.506 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 349' ' ' LYS . . . . . 0.775 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 22.4 mttm 53.79 62.71 2.49 Favored 'General case' 0 C--O 1.22 -0.466 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.89 -177.908 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 49.8 m -141.01 145.46 35.95 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.207 -0.906 . . . . 0.0 109.207 175.458 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 351' ' ' VAL . . . . . 0.517 HG22 ' HB3' ' A' ' 370' ' ' ALA . 0.9 OUTLIER -129.27 156.47 41.81 Favored 'Isoleucine or valine' 0 C--O 1.235 0.327 0 CA-C-O 120.856 0.36 . . . . 0.0 110.526 -176.999 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 352' ' ' ASP . . . . . 0.861 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 1.8 m-20 -121.13 118.0 28.58 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 170.99 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 353' ' ' GLY . . . . . 0.403 ' HA2' ' O ' ' A' ' 341' ' ' ALA . . . -111.13 124.02 6.75 Favored Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.11 -1.043 . . . . 0.0 112.435 -175.68 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 354' ' ' ILE . . . . . 0.75 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 1.0 OUTLIER -112.99 129.51 68.52 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-O 120.686 0.279 . . . . 0.0 110.455 -178.063 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 355' ' ' ILE . . . . . 0.685 HG23 HG21 ' A' ' 323' ' ' VAL . 4.3 mm . . . . . 0 C--N 1.323 -0.555 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.022 179.126 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 89.6 mm-40 . . . . . 0 N--CA 1.447 -0.591 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -153.63 154.37 34.07 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 176.216 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 368' ' ' PHE . . . . . 0.507 ' HB3' ' CE3' ' A' ' 381' ' ' TRP . 47.2 p90 -136.05 160.21 39.35 Favored 'General case' 0 C--N 1.319 -0.757 0 O-C-N 123.437 0.46 . . . . 0.0 109.836 -176.41 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 369' ' ' LYS . . . . . 0.513 ' HG3' ' O ' ' A' ' 351' ' ' VAL . 26.9 tttp -127.6 132.87 49.74 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 174.119 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 370' ' ' ALA . . . . . 0.517 ' HB3' HG22 ' A' ' 351' ' ' VAL . . . -128.85 148.46 50.89 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.182 -172.065 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -104.41 129.27 52.37 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.947 176.964 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 372' ' ' ILE . . . . . 0.775 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 93.3 mt -81.86 103.81 9.53 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.638 0 CA-C-O 121.925 0.869 . . . . 0.0 109.747 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 19.1 t0 -107.8 96.99 6.77 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 114.375 -1.284 . . . . 0.0 108.859 178.277 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 374' ' ' GLY . . . . . 0.705 ' O ' ' HA3' ' A' ' 310' ' ' GLY . . . 92.51 -123.32 7.24 Favored Glycine 0 N--CA 1.441 -0.981 0 C-N-CA 120.621 -0.799 . . . . 0.0 111.244 -174.254 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 375' ' ' ASN . . . . . 0.4 HD22 ' HB2' ' A' ' 307' ' ' PRO . 42.3 p-10 -114.15 35.63 4.07 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.925 0.869 . . . . 0.0 110.82 -175.244 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . -177.93 171.59 44.12 Favored Glycine 0 N--CA 1.443 -0.855 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 -176.295 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 377' ' ' PHE . . . . . 0.486 ' HD2' HG12 ' A' ' 372' ' ' ILE . 6.7 p90 -131.57 145.69 51.84 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 117.715 0.757 . . . . 0.0 112.616 -176.129 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 378' ' ' LYS . . . . . 0.461 ' H ' ' HD2' ' A' ' 378' ' ' LYS . 0.0 OUTLIER -119.68 134.33 55.27 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 114.578 -1.192 . . . . 0.0 108.167 171.676 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -150.3 -169.68 16.65 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.062 -1.066 . . . . 0.0 112.986 -175.597 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 15.1 t -147.46 153.68 39.86 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -175.849 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 381' ' ' TRP . . . . . 0.507 ' CE3' ' HB3' ' A' ' 368' ' ' PHE . 61.4 m95 . . . . . 0 C--N 1.33 -0.27 0 CA-C-O 120.985 0.421 . . . . 0.0 110.282 179.672 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.75 0 N-CA-C 112.105 -0.398 . . . . 0.0 112.105 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -142.16 134.82 28.29 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 110.204 -0.295 . . . . 0.0 110.204 -178.593 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 38.2 t -112.95 133.87 57.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.347 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 31.7 m -144.61 143.3 30.71 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.076 0.465 . . . . 0.0 111.224 178.229 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -157.4 157.17 27.89 Favored Glycine 0 N--CA 1.445 -0.763 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 178.63 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 11.3 ptp180 -136.02 150.74 49.32 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 117.405 0.602 . . . . 0.0 110.764 -175.3 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 393' ' ' PHE . . . . . 0.481 ' CD1' ' HB ' ' A' ' 401' ' ' VAL . 95.1 m-85 -84.49 167.75 16.09 Favored 'General case' 0 CA--C 1.496 -1.098 0 CA-C-O 122.134 0.969 . . . . 0.0 111.184 -178.084 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 394' ' ' TYR . . . . . 0.569 ' HD1' ' N ' ' A' ' 394' ' ' TYR . 0.6 OUTLIER -97.56 -179.11 4.36 Favored 'General case' 0 N--CA 1.428 -1.562 0 N-CA-C 105.621 -1.992 . . . . 0.0 105.621 173.153 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 395' ' ' GLY . . . . . 0.568 ' HA2' ' C ' ' A' ' 307' ' ' PRO . . . -51.48 -148.16 0.0 OUTLIER Glycine 0 N--CA 1.474 1.168 0 O-C-N 124.497 1.123 . . . . 0.0 115.754 -172.314 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -57.67 -10.86 7.88 Favored 'Trans proline' 0 CA--C 1.539 0.729 0 C-N-CA 121.227 1.285 . . . . 0.0 111.042 176.192 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 397' ' ' ALA . . . . . 0.489 ' C ' ' H ' ' A' ' 399' ' ' GLU . . . -93.97 27.66 2.71 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 114.77 -1.104 . . . . 0.0 110.811 174.127 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . -53.6 8.54 0.01 OUTLIER Glycine 0 N--CA 1.469 0.87 0 C-N-CA 124.069 0.842 . . . . 0.0 114.599 176.079 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 399' ' ' GLU . . . . . 0.489 ' H ' ' C ' ' A' ' 397' ' ' ALA . 3.7 mp0 -59.97 -9.99 3.66 Favored 'General case' 0 C--N 1.323 -0.587 0 C-N-CA 123.929 0.892 . . . . 0.0 110.019 166.676 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 -119.21 125.05 48.24 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-N 115.344 -0.844 . . . . 0.0 109.439 174.15 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 401' ' ' VAL . . . . . 0.481 ' HB ' ' CD1' ' A' ' 393' ' ' PHE . 12.2 p -132.71 141.12 45.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 176.607 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -130.01 137.56 50.33 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-O 120.761 0.315 . . . . 0.0 110.679 178.902 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -144.88 177.03 23.62 Favored Glycine 0 N--CA 1.439 -1.161 0 C-N-CA 120.458 -0.877 . . . . 0.0 112.143 179.805 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 404' ' ' LYS . . . . . 0.454 ' CG ' HG12 ' A' ' 419' ' ' VAL . 0.0 OUTLIER -141.13 155.7 46.07 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 176.905 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 19.7 p90 . . . . . 0 C--N 1.313 -0.982 0 CA-C-O 120.977 0.417 . . . . 0.0 110.287 176.851 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 417' ' ' PHE . . . . . 0.625 ' HB3' ' HB2' ' A' ' 326' ' ' PHE . 73.8 m-85 . . . . . 0 N--CA 1.452 -0.344 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 82.8 76.99 1.1 Allowed Glycine 0 N--CA 1.449 -0.467 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.374 -177.938 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 419' ' ' VAL . . . . . 0.454 HG12 ' CG ' ' A' ' 404' ' ' LYS . 19.8 m -106.4 167.36 3.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 -179.34 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 45.9 p90 -148.24 162.69 38.98 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-O 120.796 0.331 . . . . 0.0 110.144 178.077 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 421' ' ' ALA . . . . . 0.412 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -142.85 135.39 27.67 Favored 'General case' 0 C--N 1.316 -0.877 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 177.994 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -122.95 135.72 10.2 Favored Glycine 0 N--CA 1.441 -1.021 0 C-N-CA 120.749 -0.739 . . . . 0.0 111.451 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 60.3 mttm -118.93 139.8 51.05 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-O 121.041 0.448 . . . . 0.0 110.354 179.442 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 424' ' ' LYS . . . . . . . . . . . . . 5.6 tppp? -60.06 122.41 14.3 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.011 -0.995 . . . . 0.0 111.86 -177.904 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 . . . . . 0 C--N 1.319 -0.756 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 166.758 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo . . . . . 0 N--CA 1.457 -0.626 0 N-CA-C 109.478 -1.008 . . . . 0.0 109.478 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 308' ' ' ALA . . . . . 0.753 ' HB1' HD11 ' A' ' 313' ' ' LEU . . . -49.45 118.95 3.03 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 121.118 0.485 . . . . 0.0 111.366 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 309' ' ' LYS . . . . . 0.452 ' O ' ' HG ' ' A' ' 313' ' ' LEU . 24.8 mmmt -73.95 81.5 1.68 Allowed 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -177.578 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 310' ' ' GLY . . . . . 0.708 ' HA2' HD12 ' A' ' 313' ' ' LEU . . . -52.56 -40.48 55.06 Favored Glycine 0 C--N 1.333 0.387 0 O-C-N 123.332 0.395 . . . . 0.0 113.145 -174.445 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 311' ' ' GLU . . . . . 0.552 ' HG3' ' HG3' ' A' ' 312' ' ' MET . 10.1 pt-20 -56.63 -28.26 60.13 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 122.635 0.374 . . . . 0.0 111.923 177.307 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 312' ' ' MET . . . . . 0.552 ' HG3' ' HG3' ' A' ' 311' ' ' GLU . 76.3 mtm -113.83 1.97 14.96 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.687 0.28 . . . . 0.0 111.352 -177.424 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 313' ' ' LEU . . . . . 0.753 HD11 ' HB1' ' A' ' 308' ' ' ALA . 78.8 mt -72.69 131.04 41.87 Favored 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 175.598 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -143.9 143.67 31.38 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.569 -173.042 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 121.66 169.87 13.73 Favored Glycine 0 N--CA 1.445 -0.743 0 C-N-CA 120.981 -0.628 . . . . 0.0 111.843 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 25.4 p -107.32 133.04 52.44 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 175.242 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -142.03 160.26 40.58 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 121.271 0.557 . . . . 0.0 112.076 -172.912 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 6.1 p -129.13 115.93 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.878 174.512 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 319' ' ' TYR . . . . . 0.578 ' CZ ' ' HB2' ' A' ' 424' ' ' LYS . 2.0 m-85 -98.07 128.74 44.77 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 179.09 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -131.37 144.05 50.94 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 120.868 0.366 . . . . 0.0 110.727 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -173.67 -143.89 4.5 Favored Glycine 0 N--CA 1.443 -0.855 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.007 -179.722 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -119.48 147.81 43.99 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.832 0.349 . . . . 0.0 110.975 -175.163 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 323' ' ' VAL . . . . . 0.717 HG13 ' HB2' ' A' ' 340' ' ' PHE . 4.5 m -106.71 117.04 51.75 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 CA-C-N 115.846 -0.616 . . . . 0.0 109.391 168.027 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 324' ' ' LEU . . . . . 0.544 ' HB2' HG22 ' A' ' 419' ' ' VAL . 97.5 mt -91.63 101.94 14.57 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 177.895 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 325' ' ' HIS . . . . . 0.489 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 6.2 p80 -102.41 117.67 35.21 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.754 0.788 . . . . 0.0 109.766 -176.333 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 326' ' ' PHE . . . . . 0.782 ' HD2' ' HB3' ' A' ' 417' ' ' PHE . 58.4 m-85 . . . . . 0 C--N 1.322 -0.598 0 CA-C-N 114.649 -1.16 . . . . 0.0 111.22 -168.521 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 337' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.452 -0.365 0 CA-C-O 121.53 0.681 . . . . 0.0 111.487 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 338' ' ' GLY . . . . . 0.412 ' HA3' ' CG2' ' A' ' 323' ' ' VAL . . . -106.46 -175.42 23.29 Favored Glycine 0 N--CA 1.437 -1.251 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 170.032 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 339' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -111.29 131.56 55.06 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 117.222 0.511 . . . . 0.0 109.799 178.109 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 340' ' ' PHE . . . . . 0.717 ' HB2' HG13 ' A' ' 323' ' ' VAL . 10.9 t80 -127.37 133.53 50.02 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.793 -178.182 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 341' ' ' ALA . . . . . 0.471 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -131.9 160.7 34.94 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.613 175.991 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 342' ' ' ALA . . . . . 0.889 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -147.83 119.4 7.97 Favored 'General case' 0 N--CA 1.442 -0.844 0 CA-C-O 121.204 0.526 . . . . 0.0 110.446 -177.7 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 343' ' ' LYS . . . . . 0.442 ' HB3' ' HB2' ' A' ' 352' ' ' ASP . 6.3 tmtt? -91.68 98.74 11.82 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 178.363 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 344' ' ' VAL . . . . . 0.617 ' HB ' HG12 ' A' ' 351' ' ' VAL . 0.2 OUTLIER -118.51 128.52 75.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-O 121.794 0.806 . . . . 0.0 112.239 -172.189 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -108.14 110.62 22.32 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 114.489 -1.232 . . . . 0.0 108.419 174.443 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 346' ' ' PHE . . . . . 0.478 ' HZ ' ' OH ' ' A' ' 319' ' ' TYR . 64.8 m-85 -73.16 -18.74 61.24 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.705 0.288 . . . . 0.0 111.732 -176.291 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -62.77 -28.19 71.27 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.475 -0.869 . . . . 0.0 111.249 176.199 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 20.5 t -112.46 -10.12 13.76 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-N 115.897 -0.151 . . . . 0.0 110.974 177.72 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 349' ' ' LYS . . . . . 0.643 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 35.2 mttp 57.23 59.46 3.37 Favored 'General case' 0 C--O 1.224 -0.275 0 CA-C-O 121.58 0.705 . . . . 0.0 110.646 -178.308 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 8.6 t -146.86 152.61 39.01 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.296 177.755 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 351' ' ' VAL . . . . . 0.728 HG22 ' HB3' ' A' ' 370' ' ' ALA . 1.2 m -134.8 155.25 38.12 Favored 'Isoleucine or valine' 0 C--O 1.236 0.382 0 CA-C-O 121.205 0.526 . . . . 0.0 110.836 -176.786 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 352' ' ' ASP . . . . . 0.889 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 1.2 m-20 -110.7 117.91 34.74 Favored 'General case' 0 C--O 1.215 -0.728 0 CA-C-N 115.244 -0.889 . . . . 0.0 108.692 168.925 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -110.91 124.43 6.96 Favored Glycine 0 N--CA 1.441 -1.03 0 C-N-CA 120.193 -1.003 . . . . 0.0 111.562 -176.954 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 354' ' ' ILE . . . . . 0.472 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -122.05 129.73 75.15 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 CA-C-O 121.187 0.518 . . . . 0.0 109.85 -177.058 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 355' ' ' ILE . . . . . 0.617 HG23 HG21 ' A' ' 323' ' ' VAL . 4.2 mp . . . . . 0 C--N 1.32 -0.714 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.858 -178.57 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 43.9 mt-30 . . . . . 0 N--CA 1.457 -0.101 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -138.55 148.61 44.42 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 176.429 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 368' ' ' PHE . . . . . 0.451 ' HB3' ' CE3' ' A' ' 381' ' ' TRP . 34.4 p90 -140.83 149.99 42.72 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.0 0.429 . . . . 0.0 110.465 178.577 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 1.6 mptp? -104.9 138.1 41.66 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 173.473 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 370' ' ' ALA . . . . . 0.728 ' HB3' HG22 ' A' ' 351' ' ' VAL . . . -134.26 147.45 50.66 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.18 0.514 . . . . 0.0 111.574 -177.127 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -105.96 130.47 53.89 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.628 175.966 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 372' ' ' ILE . . . . . 0.643 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 87.6 mt -81.66 107.38 13.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 121.545 0.688 . . . . 0.0 110.755 -178.04 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 373' ' ' ASP . . . . . 0.494 ' HB2' ' HE2' ' A' ' 378' ' ' LYS . 28.5 t70 -111.46 80.2 1.29 Allowed 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.093 -0.958 . . . . 0.0 109.435 179.417 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 58.87 119.07 0.01 OUTLIER Glycine 0 CA--C 1.521 0.42 0 CA-C-N 114.889 -1.051 . . . . 0.0 113.76 -177.484 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 375' ' ' ASN . . . . . 0.732 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 2.4 p-10 29.86 46.05 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 113.912 1.078 . . . . 0.0 113.912 178.582 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 165.06 172.35 32.41 Favored Glycine 0 N--CA 1.445 -0.766 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 178.032 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 377' ' ' PHE . . . . . 0.464 ' CZ ' HG21 ' A' ' 401' ' ' VAL . 3.4 p90 -147.95 150.54 34.23 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.447 0.641 . . . . 0.0 111.793 179.185 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 378' ' ' LYS . . . . . 0.821 ' H ' ' HD3' ' A' ' 378' ' ' LYS . 0.3 OUTLIER -112.37 130.29 56.01 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 114.638 -1.164 . . . . 0.0 108.383 174.688 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -126.23 156.64 19.83 Favored Glycine 0 N--CA 1.444 -0.821 0 C-N-CA 120.4 -0.905 . . . . 0.0 113.248 -172.804 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 26.7 p -125.24 137.74 54.1 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.219 -0.491 . . . . 0.0 109.938 178.007 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 381' ' ' TRP . . . . . 0.451 ' CE3' ' HB3' ' A' ' 368' ' ' PHE . 41.2 m95 . . . . . 0 C--N 1.33 -0.242 0 CA-C-O 121.146 0.498 . . . . 0.0 110.943 -178.074 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.591 0 N-CA-C 111.647 -0.581 . . . . 0.0 111.647 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 20.6 m-20 -93.41 143.44 26.28 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 120.961 0.41 . . . . 0.0 110.64 -177.168 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 389' ' ' VAL . . . . . 0.412 HG22 ' HB3' ' A' ' 405' ' ' TYR . 23.9 t -112.7 137.09 46.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.782 179.464 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 5.0 p -147.42 138.83 23.87 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.817 0.341 . . . . 0.0 111.459 -179.077 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -156.74 154.11 25.26 Favored Glycine 0 N--CA 1.445 -0.764 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 23.2 mtt180 -119.51 153.15 35.78 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.468 0.652 . . . . 0.0 111.952 -175.945 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -93.71 159.31 15.26 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 114.649 -1.159 . . . . 0.0 110.045 178.643 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 394' ' ' TYR . . . . . 0.631 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 3.5 m-85 -101.62 -178.45 3.73 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.723 -177.972 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 395' ' ' GLY . . . . . 0.407 ' O ' ' N ' ' A' ' 397' ' ' ALA . . . -42.52 168.47 0.01 OUTLIER Glycine 0 CA--C 1.524 0.594 0 O-C-N 124.048 0.842 . . . . 0.0 115.159 -175.046 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_exo -19.35 -45.17 0.02 OUTLIER 'Trans proline' 0 C--N 1.356 0.924 1 C-N-CA 127.204 5.269 . . . . 0.0 117.588 -167.23 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 397' ' ' ALA . . . . . 0.407 ' N ' ' O ' ' A' ' 395' ' ' GLY . . . -72.25 -21.26 61.41 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -174.17 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 54.33 19.13 11.33 Favored Glycine 0 C--O 1.219 -0.837 0 CA-C-N 115.918 -0.583 . . . . 0.0 113.777 174.437 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 399' ' ' GLU . . . . . 0.882 ' HG3' ' HB3' ' A' ' 424' ' ' LYS . 23.0 tt0 -79.7 -10.66 59.82 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.538 0.685 . . . . 0.0 110.161 -174.312 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -118.54 125.7 50.41 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.864 178.458 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 401' ' ' VAL . . . . . 0.464 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 12.9 p -130.36 141.12 47.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.64 178.01 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -145.43 139.01 26.6 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.847 -177.678 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -167.75 -163.83 22.35 Favored Glycine 0 N--CA 1.444 -0.799 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.1 179.474 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 404' ' ' LYS . . . . . 0.553 ' HG2' HG12 ' A' ' 419' ' ' VAL . 21.2 mtmt -146.89 158.98 44.06 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.801 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 405' ' ' TYR . . . . . 0.412 ' HB3' HG22 ' A' ' 389' ' ' VAL . 19.1 p90 . . . . . 0 C--N 1.318 -0.775 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 170.329 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 417' ' ' PHE . . . . . 0.782 ' HB3' ' HD2' ' A' ' 326' ' ' PHE . 99.0 m-85 . . . . . 0 N--CA 1.435 -1.185 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 418' ' ' GLY . . . . . 0.496 ' H ' ' HD2' ' A' ' 326' ' ' PHE . . . 81.95 77.07 1.06 Allowed Glycine 0 N--CA 1.436 -1.311 0 C-N-CA 118.212 -1.947 . . . . 0.0 110.771 -174.58 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 419' ' ' VAL . . . . . 0.584 HG13 ' HE2' ' A' ' 326' ' ' PHE . 13.0 m -104.73 161.54 4.77 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -175.264 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 420' ' ' PHE . . . . . 0.437 ' HB3' HG12 ' A' ' 323' ' ' VAL . 49.5 p90 -139.27 147.74 42.09 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.109 0.48 . . . . 0.0 110.645 -178.405 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -137.44 134.61 36.04 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 174.254 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -132.0 134.75 7.79 Favored Glycine 0 N--CA 1.437 -1.257 0 C-N-CA 120.321 -0.942 . . . . 0.0 111.625 -177.695 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 17.2 mtpp -109.48 125.61 52.64 Favored 'General case' 0 C--N 1.314 -0.943 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 178.377 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 424' ' ' LYS . . . . . 0.882 ' HB3' ' HG3' ' A' ' 399' ' ' GLU . 8.0 tttm -66.53 117.88 9.35 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.855 -179.284 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 11.2 tp10 . . . . . 0 C--N 1.312 -1.025 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 173.762 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo . . . . . 0 N--CA 1.452 -0.937 0 CA-C-O 121.045 0.352 . . . . 0.0 111.947 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 308' ' ' ALA . . . . . 0.755 ' HB1' ' CD2' ' A' ' 313' ' ' LEU . . . -61.24 169.26 2.21 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.231 174.027 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 309' ' ' LYS . . . . . 0.7 ' H ' HD23 ' A' ' 313' ' ' LEU . 13.0 mptt -125.42 85.24 2.38 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 174.355 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -57.4 -19.71 34.36 Favored Glycine 0 N--CA 1.462 0.409 0 N-CA-C 114.28 0.472 . . . . 0.0 114.28 -168.83 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -87.35 -16.27 35.51 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.91 0.386 . . . . 0.0 111.227 179.15 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 47.9 tpp -110.95 -34.38 6.24 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.153 -175.067 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 313' ' ' LEU . . . . . 0.755 ' CD2' ' HB1' ' A' ' 308' ' ' ALA . 1.7 pp -83.45 137.09 34.06 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 175.471 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 314' ' ' ALA . . . . . 0.53 ' HA ' ' HB2' ' A' ' 346' ' ' PHE . . . -145.63 172.57 13.07 Favored 'General case' 0 C--N 1.318 -0.781 0 N-CA-C 112.62 0.6 . . . . 0.0 112.62 -166.049 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.31 176.5 15.77 Favored Glycine 0 N--CA 1.445 -0.758 0 CA-C-N 115.061 -0.972 . . . . 0.0 110.932 -177.917 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 15.7 p -108.0 134.01 51.5 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 170.619 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -139.45 161.12 38.24 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-O 121.204 0.526 . . . . 0.0 111.785 -172.273 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 318' ' ' VAL . . . . . 0.713 ' HA ' ' O ' ' A' ' 342' ' ' ALA . 7.7 p -141.22 124.12 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.936 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.51 173.818 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 319' ' ' TYR . . . . . 0.595 ' CE2' ' HB2' ' A' ' 424' ' ' LYS . 1.9 m-85 -102.18 143.76 31.58 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.605 -178.133 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 47.0 m-80 -127.78 132.6 49.49 Favored 'General case' 0 C--N 1.311 -1.073 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 176.132 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -165.12 -159.33 11.28 Favored Glycine 0 N--CA 1.442 -0.91 0 C-N-CA 120.218 -0.992 . . . . 0.0 112.167 -178.522 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -120.78 156.13 32.53 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 120.969 0.414 . . . . 0.0 110.298 -177.473 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 323' ' ' VAL . . . . . 0.831 HG21 HG12 ' A' ' 355' ' ' ILE . 41.0 t -119.45 118.32 56.94 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.621 -179.24 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 324' ' ' LEU . . . . . . . . . . . . . 96.4 mt -104.3 102.4 12.1 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.317 0.58 . . . . 0.0 110.149 -179.349 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 325' ' ' HIS . . . . . 0.489 ' HB3' ' OH ' ' A' ' 405' ' ' TYR . 6.3 p80 -108.1 132.06 53.97 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.523 176.524 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 326' ' ' PHE . . . . . 0.672 ' HD2' ' HB3' ' A' ' 417' ' ' PHE . 10.3 m-85 . . . . . 0 C--N 1.322 -0.592 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.695 -169.395 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 337' ' ' ARG . . . . . 0.6 ' HA ' ' O ' ' A' ' 323' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.451 -0.391 0 CA-C-O 121.416 0.627 . . . . 0.0 111.503 . . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -103.69 -177.97 25.86 Favored Glycine 0 N--CA 1.442 -0.904 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.949 174.355 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 339' ' ' ARG . . . . . 0.442 ' O ' ' HA ' ' A' ' 355' ' ' ILE . 75.4 mtp180 -114.18 127.49 55.92 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 120.952 0.406 . . . . 0.0 109.911 -177.575 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 340' ' ' PHE . . . . . 0.617 ' HB2' HG23 ' A' ' 323' ' ' VAL . 29.6 t80 -126.85 139.91 52.74 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.257 -169.412 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 341' ' ' ALA . . . . . 0.533 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -139.04 155.75 47.71 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 114.587 -1.188 . . . . 0.0 108.844 172.662 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 342' ' ' ALA . . . . . 0.848 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -143.12 117.82 9.85 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.14 0.495 . . . . 0.0 111.405 -177.368 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 343' ' ' LYS . . . . . 0.677 ' HB3' ' HB3' ' A' ' 352' ' ' ASP . 3.6 tppp? -96.07 98.95 10.76 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 114.851 -1.068 . . . . 0.0 108.943 -179.699 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 344' ' ' VAL . . . . . 0.653 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.6 OUTLIER -123.33 128.33 74.75 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 N-CA-C 113.099 0.777 . . . . 0.0 113.099 -169.56 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 345' ' ' ASP . . . . . 0.445 ' HB2' ' HB3' ' A' ' 348' ' ' SER . 1.8 m-20 -100.41 107.64 19.44 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 174.159 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 346' ' ' PHE . . . . . 0.53 ' HB2' ' HA ' ' A' ' 314' ' ' ALA . 38.0 m-85 -64.79 -36.58 84.77 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.807 0.337 . . . . 0.0 111.204 -176.391 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -68.62 -14.8 67.78 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.406 -178.544 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 348' ' ' SER . . . . . 0.445 ' HB3' ' HB2' ' A' ' 345' ' ' ASP . 44.2 t -109.13 -9.6 15.03 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.292 0.568 . . . . 0.0 110.135 179.219 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 349' ' ' LYS . . . . . 0.441 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 31.8 mtmm 52.44 55.36 9.22 Favored 'General case' 0 N--CA 1.462 0.137 0 CA-C-N 114.966 -1.016 . . . . 0.0 111.326 -176.07 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 8.6 t -146.72 145.69 30.07 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.508 179.518 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 351' ' ' VAL . . . . . 0.653 ' HB ' ' HB ' ' A' ' 344' ' ' VAL . 0.6 OUTLIER -136.46 146.65 28.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.956 0.408 . . . . 0.0 110.432 -177.042 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 352' ' ' ASP . . . . . 0.848 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 36.8 t70 -108.6 117.47 34.26 Favored 'General case' 0 C--O 1.211 -0.929 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 172.927 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -116.04 114.28 3.06 Favored Glycine 0 C--N 1.302 -1.334 0 C-N-CA 120.242 -0.98 . . . . 0.0 112.031 -176.668 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 354' ' ' ILE . . . . . 0.558 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -113.65 129.08 70.12 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 CA-C-O 120.977 0.418 . . . . 0.0 110.475 -175.495 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 355' ' ' ILE . . . . . 0.831 HG12 HG21 ' A' ' 323' ' ' VAL . 5.1 mp . . . . . 0 C--N 1.325 -0.497 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.95 177.715 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 366' ' ' GLN . . . . . 0.576 HE21 ' N ' ' A' ' 366' ' ' GLN . 0.0 OUTLIER . . . . . 0 N--CA 1.444 -0.731 0 CA-C-O 121.363 0.602 . . . . 0.0 109.934 . . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 25.4 pttm -114.96 146.99 40.62 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.665 178.54 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 368' ' ' PHE . . . . . 0.414 ' HB3' ' CE3' ' A' ' 381' ' ' TRP . 44.6 p90 -124.68 157.96 34.32 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 178.048 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 8.0 ttpt -126.05 134.96 51.26 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 173.538 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -136.14 144.87 45.28 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.095 -173.583 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -96.92 134.92 39.64 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 175.847 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 372' ' ' ILE . . . . . 0.441 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 66.8 mt -79.75 105.71 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.619 0 CA-C-O 121.884 0.85 . . . . 0.0 110.739 -177.804 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 373' ' ' ASP . . . . . 0.445 ' HB3' ' HD3' ' A' ' 378' ' ' LYS . 32.1 t70 -108.27 80.69 1.39 Allowed 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 114.492 -1.231 . . . . 0.0 109.19 -178.217 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 62.97 118.83 0.01 OUTLIER Glycine 0 CA--C 1.523 0.541 0 CA-C-N 114.54 -1.209 . . . . 0.0 113.488 -176.705 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 375' ' ' ASN . . . . . 0.705 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 3.1 p-10 28.92 46.67 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 124.363 1.065 . . . . 0.0 113.631 178.211 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 158.71 178.89 33.15 Favored Glycine 0 N--CA 1.442 -0.914 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 179.551 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 377' ' ' PHE . . . . . 0.607 ' CZ ' HG21 ' A' ' 401' ' ' VAL . 4.0 p90 -140.62 150.99 44.27 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 117.797 0.798 . . . . 0.0 112.127 -176.981 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 378' ' ' LYS . . . . . 0.445 ' HD3' ' HB3' ' A' ' 373' ' ' ASP . 0.0 OUTLIER -125.96 134.77 51.42 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 176.562 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -161.19 -158.6 9.46 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.178 -1.011 . . . . 0.0 112.853 -177.016 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 15.2 t -150.13 166.45 29.76 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.706 0.289 . . . . 0.0 110.383 -177.288 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 381' ' ' TRP . . . . . 0.791 ' HD1' ' HA3' ' A' ' 387' ' ' GLY . 49.5 m95 . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.856 -178.502 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 387' ' ' GLY . . . . . 0.791 ' HA3' ' HD1' ' A' ' 381' ' ' TRP . . . . . . . . 0 N--CA 1.446 -0.656 0 N-CA-C 112.087 -0.405 . . . . 0.0 112.087 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -82.49 138.86 34.22 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 110.304 -0.258 . . . . 0.0 110.304 178.664 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 44.5 t -132.17 128.56 59.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.493 0.187 . . . . 0.0 110.694 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 18.2 m -133.94 151.34 51.45 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.726 -0.215 . . . . 0.0 110.673 179.245 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 391' ' ' GLY . . . . . 0.552 ' HA2' ' HA3' ' A' ' 403' ' ' GLY . . . -158.59 151.52 22.56 Favored Glycine 0 N--CA 1.454 -0.141 0 C-N-CA 121.227 -0.511 . . . . 0.0 111.859 175.795 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 5.7 mpt_? -120.3 146.87 45.69 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.873 0.368 . . . . 0.0 110.862 -176.913 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -91.07 158.39 16.69 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.95 -179.814 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 394' ' ' TYR . . . . . 0.66 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 2.9 m-85 -102.18 -177.19 3.33 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.188 -0.915 . . . . 0.0 110.058 177.262 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 395' ' ' GLY . . . . . 0.421 ' O ' ' N ' ' A' ' 397' ' ' ALA . . . -37.98 159.33 0.01 OUTLIER Glycine 0 CA--C 1.525 0.705 0 O-C-N 124.224 0.953 . . . . 0.0 115.169 -175.539 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_exo -18.1 -42.65 0.01 OUTLIER 'Trans proline' 0 C--N 1.352 0.723 1 C-N-CA 127.729 5.62 . . . . 0.0 118.213 -168.136 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 397' ' ' ALA . . . . . 0.421 ' N ' ' O ' ' A' ' 395' ' ' GLY . . . -78.51 -19.44 52.97 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 118.402 0.546 . . . . 0.0 112.457 -173.106 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 62.41 12.1 37.57 Favored Glycine 0 C--O 1.216 -0.977 0 CA-C-O 119.355 -0.691 . . . . 0.0 114.221 176.624 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 399' ' ' GLU . . . . . 0.716 ' HG3' ' HD3' ' A' ' 424' ' ' LYS . 1.1 mp0 -63.54 -10.57 18.7 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 118.189 0.994 . . . . 0.0 111.314 -178.161 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -122.55 128.32 50.6 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 121.041 0.448 . . . . 0.0 110.003 176.107 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 401' ' ' VAL . . . . . 0.607 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 12.2 p -131.89 138.01 53.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.758 175.866 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -141.67 132.01 25.09 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.083 -178.647 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 403' ' ' GLY . . . . . 0.552 ' HA3' ' HA2' ' A' ' 391' ' ' GLY . . . -151.29 -173.76 21.49 Favored Glycine 0 N--CA 1.439 -1.136 0 C-N-CA 120.089 -1.053 . . . . 0.0 112.426 -178.055 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 404' ' ' LYS . . . . . 0.82 ' HG2' HG12 ' A' ' 419' ' ' VAL . 30.3 mtpt -145.73 155.66 43.11 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -179.684 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 405' ' ' TYR . . . . . 0.489 ' OH ' ' HB3' ' A' ' 325' ' ' HIS . 50.7 p90 . . . . . 0 C--N 1.314 -0.974 0 CA-C-O 121.011 0.434 . . . . 0.0 110.525 -179.232 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 417' ' ' PHE . . . . . 0.672 ' HB3' ' HD2' ' A' ' 326' ' ' PHE . 66.1 m-85 . . . . . 0 N--CA 1.456 -0.128 0 N-CA-C 110.472 -0.196 . . . . 0.0 110.472 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 418' ' ' GLY . . . . . 0.455 ' HA2' ' HA ' ' A' ' 325' ' ' HIS . . . 82.31 77.1 1.07 Allowed Glycine 0 C--O 1.224 -0.489 0 C-N-CA 120.746 -0.74 . . . . 0.0 113.125 176.214 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 419' ' ' VAL . . . . . 0.82 HG12 ' HG2' ' A' ' 404' ' ' LYS . 23.8 m -109.71 157.61 10.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 120.903 0.382 . . . . 0.0 110.822 -179.715 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 40.8 p90 -146.4 154.8 42.04 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.952 0.406 . . . . 0.0 110.535 177.58 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -148.83 136.54 20.54 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.48 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -133.18 140.62 11.98 Favored Glycine 0 N--CA 1.445 -0.711 0 C-N-CA 120.196 -1.002 . . . . 0.0 112.582 -177.668 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 25.1 mmmt -101.9 123.83 46.49 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 176.82 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 424' ' ' LYS . . . . . 0.716 ' HD3' ' HG3' ' A' ' 399' ' ' GLU . 72.1 tttt -70.16 117.25 11.48 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 116.55 -0.296 . . . . 0.0 110.572 -179.591 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 . . . . . 0 C--N 1.323 -0.572 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 -179.502 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo . . . . . 0 N--CA 1.462 -0.337 0 N-CA-C 111.315 -0.302 . . . . 0.0 111.315 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 308' ' ' ALA . . . . . 0.703 ' HB2' ' O ' ' A' ' 394' ' ' TYR . . . -54.18 159.54 1.86 Allowed 'General case' 0 N--CA 1.467 0.385 0 CA-C-O 121.48 0.657 . . . . 0.0 112.282 175.804 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 309' ' ' LYS . . . . . 0.649 ' O ' ' HG ' ' A' ' 313' ' ' LEU . 35.0 mtmt -123.55 98.91 6.05 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.357 176.746 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 310' ' ' GLY . . . . . 0.694 ' HA2' HD12 ' A' ' 313' ' ' LEU . . . -60.04 -37.75 93.23 Favored Glycine 0 C--O 1.227 -0.304 0 CA-C-N 116.093 -0.503 . . . . 0.0 114.128 -170.314 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 311' ' ' GLU . . . . . 0.454 ' H ' ' CD ' ' A' ' 311' ' ' GLU . 1.3 pm0 -72.61 -20.03 61.36 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.86 0.33 . . . . 0.0 110.856 179.115 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 26.0 ttt -91.46 -21.61 20.84 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.143 0.497 . . . . 0.0 109.95 177.302 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 313' ' ' LEU . . . . . 0.694 HD12 ' HA2' ' A' ' 310' ' ' GLY . 96.1 mt -66.19 138.95 58.05 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.332 178.998 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -156.32 139.2 15.28 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.303 -174.326 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 121.01 167.88 13.39 Favored Glycine 0 N--CA 1.443 -0.845 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.929 177.976 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 28.5 p -100.05 134.22 43.28 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 174.715 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 317' ' ' ALA . . . . . 0.56 ' HB1' ' HD3' ' A' ' 424' ' ' LYS . . . -138.6 152.57 48.25 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 121.053 0.454 . . . . 0.0 111.731 -174.833 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 7.3 p -121.59 113.24 38.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.441 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.263 177.5 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 319' ' ' TYR . . . . . 0.598 ' CE2' ' HB2' ' A' ' 424' ' ' LYS . 21.4 m-85 -103.16 132.52 49.36 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.925 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 44.6 m-80 -124.81 139.56 53.73 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.077 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 321' ' ' GLY . . . . . 0.591 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -169.25 -145.93 4.83 Favored Glycine 0 N--CA 1.441 -1.014 0 C-N-CA 120.577 -0.82 . . . . 0.0 112.397 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -135.04 161.92 33.93 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 120.978 0.418 . . . . 0.0 110.947 -173.66 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 323' ' ' VAL . . . . . 0.649 HG23 ' HB2' ' A' ' 340' ' ' PHE . 68.9 t -121.12 117.89 54.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.163 178.331 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 324' ' ' LEU . . . . . . . . . . . . . 2.0 tt -98.53 103.27 15.2 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 176.631 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 325' ' ' HIS . . . . . 0.446 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 18.3 t-160 -88.58 113.32 24.03 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 -179.307 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 326' ' ' PHE . . . . . 0.664 ' HE2' HG13 ' A' ' 419' ' ' VAL . 88.4 m-85 . . . . . 0 C--N 1.321 -0.641 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.008 -177.85 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 337' ' ' ARG . . . . . . . . . . . . . 39.1 ttt180 . . . . . 0 N--CA 1.449 -0.524 0 CA-C-O 121.036 0.446 . . . . 0.0 110.346 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -103.26 -177.0 26.41 Favored Glycine 0 N--CA 1.446 -0.695 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 179.037 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 339' ' ' ARG . . . . . . . . . . . . . 66.7 mtp180 -110.28 164.5 12.6 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 178.379 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 340' ' ' PHE . . . . . 0.649 ' HB2' HG23 ' A' ' 323' ' ' VAL . 41.1 t80 -152.43 142.73 22.49 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 121.255 0.55 . . . . 0.0 111.096 -178.275 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 341' ' ' ALA . . . . . . . . . . . . . . . -138.59 156.25 47.63 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.206 -0.906 . . . . 0.0 109.025 174.063 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 342' ' ' ALA . . . . . 0.884 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -145.94 118.94 8.76 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-O 121.304 0.573 . . . . 0.0 110.173 -179.729 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 343' ' ' LYS . . . . . 0.438 ' HE2' ' HB3' ' A' ' 343' ' ' LYS . 4.8 tmmm? -102.96 103.14 13.23 Favored 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 -179.625 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 344' ' ' VAL . . . . . 0.443 ' HA ' ' HA ' ' A' ' 351' ' ' VAL . 0.2 OUTLIER -117.14 132.77 65.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-O 121.485 0.66 . . . . 0.0 112.639 -169.224 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -102.48 100.08 10.17 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 114.515 -1.22 . . . . 0.0 108.7 172.541 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 346' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -67.88 -23.19 65.1 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.527 0.204 . . . . 0.0 111.184 -177.875 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -63.9 -25.27 69.11 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.016 178.315 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 37.9 m -112.58 -4.43 14.15 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.912 0.387 . . . . 0.0 110.567 177.709 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 349' ' ' LYS . . . . . 0.645 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 31.4 mtmm 55.69 59.3 3.91 Favored 'General case' 0 C--O 1.226 -0.179 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.892 -178.02 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 52.9 p -148.84 141.28 24.24 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.282 -179.326 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 351' ' ' VAL . . . . . 0.51 HG22 ' HB3' ' A' ' 370' ' ' ALA . 1.0 OUTLIER -127.57 151.84 34.9 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 CA-C-O 121.126 0.489 . . . . 0.0 110.986 -176.21 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 352' ' ' ASP . . . . . 0.884 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 19.5 t70 -108.59 119.07 38.44 Favored 'General case' 0 C--O 1.211 -0.954 0 CA-C-N 115.184 -0.917 . . . . 0.0 109.338 171.92 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -115.33 130.22 9.02 Favored Glycine 0 N--CA 1.441 -1.02 0 C-N-CA 120.473 -0.87 . . . . 0.0 111.658 -178.72 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 354' ' ' ILE . . . . . 0.475 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -131.52 129.62 62.0 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 CA-C-O 120.973 0.416 . . . . 0.0 110.196 -176.973 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 355' ' ' ILE . . . . . 0.605 HG13 HG21 ' A' ' 323' ' ' VAL . 2.3 mp . . . . . 0 C--N 1.318 -0.763 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.416 178.295 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 90.6 mt-30 . . . . . 0 N--CA 1.452 -0.363 0 CA-C-O 121.305 0.574 . . . . 0.0 111.372 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -123.85 144.63 49.62 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.565 179.48 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 368' ' ' PHE . . . . . 0.493 ' HB3' ' CE3' ' A' ' 381' ' ' TRP . 33.2 p90 -140.17 150.74 44.58 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.963 0.411 . . . . 0.0 109.996 175.364 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 369' ' ' LYS . . . . . 0.766 ' HD3' ' HA ' ' A' ' 352' ' ' ASP . 0.0 OUTLIER -123.61 135.19 53.81 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 175.962 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 370' ' ' ALA . . . . . 0.529 ' HB1' ' HB2' ' A' ' 377' ' ' PHE . . . -132.11 152.23 51.35 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.478 -0.783 . . . . 0.0 111.213 -172.287 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -109.06 134.82 51.17 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.656 176.369 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 372' ' ' ILE . . . . . 0.645 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 95.5 mt -82.75 108.91 16.04 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-O 121.171 0.51 . . . . 0.0 110.939 -178.042 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -126.4 84.23 2.25 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-O 121.612 0.72 . . . . 0.0 110.288 178.361 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 79.07 121.22 0.3 Allowed Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.145 -0.934 . . . . 0.0 112.267 -177.188 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 375' ' ' ASN . . . . . 0.524 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 17.7 p30 1.8 60.38 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 125.6 1.56 . . . . 0.0 114.986 -171.92 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 157.55 -174.28 34.98 Favored Glycine 0 N--CA 1.438 -1.172 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 179.068 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 377' ' ' PHE . . . . . 0.529 ' HB2' ' HB1' ' A' ' 370' ' ' ALA . 1.6 p90 -142.34 148.71 38.39 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.327 0.584 . . . . 0.0 111.625 -179.345 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 378' ' ' LYS . . . . . . . . . . . . . 2.7 tmtm? -123.64 112.63 17.64 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 176.733 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -135.59 -165.6 10.74 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.428 -0.891 . . . . 0.0 112.627 -175.677 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 15.0 t -144.93 159.67 42.55 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.86 0.362 . . . . 0.0 110.449 -177.516 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 381' ' ' TRP . . . . . 0.493 ' CE3' ' HB3' ' A' ' 368' ' ' PHE . 48.3 m95 . . . . . 0 C--N 1.326 -0.436 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.512 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.675 0 N-CA-C 112.448 -0.261 . . . . 0.0 112.448 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -94.19 167.54 11.49 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.517 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 22.2 t -128.35 121.18 54.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 175.996 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 390' ' ' SER . . . . . 0.417 ' O ' ' HA3' ' A' ' 403' ' ' GLY . 39.5 m -117.98 155.61 29.97 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.521 -0.309 . . . . 0.0 110.698 -177.375 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -165.64 144.67 9.42 Favored Glycine 0 N--CA 1.451 -0.349 0 N-CA-C 111.541 -0.623 . . . . 0.0 111.541 177.291 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 13.7 ptp180 -116.09 152.31 33.87 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.044 0.45 . . . . 0.0 110.895 -177.142 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 10.7 m-85 -98.1 157.59 16.05 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.889 0.852 . . . . 0.0 111.81 -175.857 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 394' ' ' TYR . . . . . 0.703 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 6.2 m-85 -102.94 -171.95 2.03 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 114.119 -1.4 . . . . 0.0 111.247 -175.075 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 395' ' ' GLY . . . . . 0.435 ' O ' ' N ' ' A' ' 397' ' ' ALA . . . -33.15 157.59 0.01 OUTLIER Glycine 0 C--N 1.34 0.792 0 O-C-N 124.576 1.173 . . . . 0.0 114.215 -178.316 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -46.37 -17.98 0.41 Allowed 'Trans proline' 0 N--CA 1.482 0.818 1 C-N-CA 125.674 4.249 . . . . 0.0 116.831 -149.843 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 397' ' ' ALA . . . . . 0.435 ' N ' ' O ' ' A' ' 395' ' ' GLY . . . -90.89 -17.9 25.69 Favored 'General case' 0 C--N 1.316 -0.872 0 C-N-CA 120.728 -0.389 . . . . 0.0 111.83 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 72.74 16.35 77.95 Favored Glycine 0 C--N 1.336 0.56 0 C-N-CA 121.178 -0.534 . . . . 0.0 112.544 173.811 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 399' ' ' GLU . . . . . 0.478 ' HG2' ' CE ' ' A' ' 424' ' ' LYS . 28.5 mt-10 -67.7 -10.78 55.41 Favored 'General case' 0 C--N 1.332 -0.18 0 C-N-CA 122.902 0.481 . . . . 0.0 111.115 -174.766 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -123.31 136.02 54.48 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 173.1 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 401' ' ' VAL . . . . . 0.52 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 14.0 p -140.15 143.1 30.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.137 177.413 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -143.19 138.81 29.98 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.181 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 403' ' ' GLY . . . . . 0.417 ' HA3' ' O ' ' A' ' 390' ' ' SER . . . -157.25 -176.2 29.04 Favored Glycine 0 N--CA 1.441 -0.985 0 C-N-CA 120.379 -0.915 . . . . 0.0 112.185 -178.897 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 404' ' ' LYS . . . . . 0.841 ' HG2' HG12 ' A' ' 419' ' ' VAL . 52.2 mttt -145.34 158.85 43.75 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 -178.516 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 36.2 p90 . . . . . 0 C--N 1.322 -0.61 0 CA-C-O 121.043 0.449 . . . . 0.0 111.34 179.658 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 417' ' ' PHE . . . . . 0.66 ' HA ' ' HD2' ' A' ' 326' ' ' PHE . 28.3 m-85 . . . . . 0 N--CA 1.447 -0.593 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 418' ' ' GLY . . . . . 0.514 ' H ' ' HD2' ' A' ' 326' ' ' PHE . . . 78.51 76.82 0.9 Allowed Glycine 0 N--CA 1.441 -1.018 0 C-N-CA 120.068 -1.063 . . . . 0.0 111.211 -174.468 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 419' ' ' VAL . . . . . 0.841 HG12 ' HG2' ' A' ' 404' ' ' LYS . 32.3 m -105.47 153.12 7.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-O 120.705 0.288 . . . . 0.0 110.388 -177.791 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 51.9 p90 -135.69 155.01 51.08 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.893 179.104 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 421' ' ' ALA . . . . . 0.591 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -143.72 136.1 26.96 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.089 179.384 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -129.98 133.6 7.5 Favored Glycine 0 N--CA 1.44 -1.044 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.038 -179.048 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 63.0 mttm -111.81 125.72 54.31 Favored 'General case' 0 C--N 1.313 -0.979 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 177.211 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 424' ' ' LYS . . . . . 0.598 ' HB2' ' CE2' ' A' ' 319' ' ' TYR . 27.2 ttpp -70.23 122.3 19.24 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 120.893 0.378 . . . . 0.0 110.101 178.551 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 . . . . . 0 C--N 1.313 -0.989 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 176.685 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo . . . . . 0 N--CA 1.457 -0.618 0 N-CA-C 112.848 0.288 . . . . 0.0 112.848 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 308' ' ' ALA . . . . . 0.895 ' HB1' HD22 ' A' ' 313' ' ' LEU . . . -58.13 157.23 8.43 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.844 170.621 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 309' ' ' LYS . . . . . 0.498 ' N ' HD23 ' A' ' 313' ' ' LEU . 63.1 mttp -128.43 98.42 5.04 Favored 'General case' 0 C--O 1.222 -0.364 0 C-N-CA 121.022 -0.271 . . . . 0.0 110.425 -176.328 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -48.23 -43.23 25.77 Favored Glycine 0 CA--C 1.519 0.304 0 N-CA-C 114.978 0.751 . . . . 0.0 114.978 -167.784 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -76.45 -9.46 58.67 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 112.846 0.684 . . . . 0.0 112.846 -177.989 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 2.5 tpt -113.93 -37.39 4.51 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.72 0.771 . . . . 0.0 109.654 -177.396 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 313' ' ' LEU . . . . . 0.895 HD22 ' HB1' ' A' ' 308' ' ' ALA . 0.6 OUTLIER -81.39 129.99 34.86 Favored 'General case' 0 N--CA 1.44 -0.938 0 CA-C-N 114.677 -1.147 . . . . 0.0 109.143 178.161 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 314' ' ' ALA . . . . . 0.643 ' HA ' ' CB ' ' A' ' 346' ' ' PHE . . . -159.19 175.57 13.28 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.989 -170.726 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.4 160.77 11.27 Favored Glycine 0 N--CA 1.447 -0.597 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -177.621 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 18.7 p -96.87 125.12 41.08 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 173.258 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -132.08 149.67 52.35 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 113.15 0.796 . . . . 0.0 113.15 -163.417 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 7.7 p -118.95 113.64 42.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 CA-C-N 115.039 -0.982 . . . . 0.0 110.338 176.067 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 319' ' ' TYR . . . . . 0.46 ' CE2' ' HB2' ' A' ' 424' ' ' LYS . 27.1 m-85 -108.04 140.68 40.84 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.583 177.454 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -142.75 143.78 32.37 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.65 174.671 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -166.32 -150.26 6.27 Favored Glycine 0 N--CA 1.443 -0.863 0 C-N-CA 120.931 -0.652 . . . . 0.0 111.874 -178.153 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -129.49 147.81 51.33 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.124 0.488 . . . . 0.0 111.038 -176.541 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 323' ' ' VAL . . . . . 0.581 ' O ' ' HA ' ' A' ' 337' ' ' ARG . 54.6 t -106.14 142.31 19.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.331 -178.876 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 324' ' ' LEU . . . . . . . . . . . . . 17.2 tp -124.87 103.95 8.34 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 110.21 -0.293 . . . . 0.0 110.21 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 325' ' ' HIS . . . . . 0.612 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 3.2 p-80 -103.21 117.19 33.97 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.501 0.667 . . . . 0.0 111.429 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 326' ' ' PHE . . . . . 0.605 ' HD1' ' H ' ' A' ' 418' ' ' GLY . 22.9 m-85 . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 114.705 -1.134 . . . . 0.0 110.351 -173.119 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 337' ' ' ARG . . . . . 0.581 ' HA ' ' O ' ' A' ' 323' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.45 -0.427 0 CA-C-O 121.187 0.517 . . . . 0.0 110.82 . . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -136.12 178.55 18.67 Favored Glycine 0 N--CA 1.443 -0.889 0 CA-C-N 115.392 -0.822 . . . . 0.0 111.178 176.113 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 339' ' ' ARG . . . . . 0.582 ' O ' ' HA ' ' A' ' 355' ' ' ILE . 57.8 mtp180 -104.02 132.89 49.82 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 -179.093 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 340' ' ' PHE . . . . . 0.574 ' HB2' HG23 ' A' ' 323' ' ' VAL . 36.8 t80 -133.9 132.2 40.01 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 121.057 0.456 . . . . 0.0 111.108 -175.848 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 341' ' ' ALA . . . . . . . . . . . . . . . -134.72 168.39 19.11 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 172.263 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -155.22 139.65 16.79 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.095 0.474 . . . . 0.0 111.023 -176.48 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 343' ' ' LYS . . . . . 0.525 ' HB3' ' HB2' ' A' ' 352' ' ' ASP . 24.9 tptp -115.97 97.32 6.02 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 179.222 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 344' ' ' VAL . . . . . 0.698 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.9 OUTLIER -121.05 135.61 60.68 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 CA-C-O 121.526 0.679 . . . . 0.0 111.627 -170.234 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -117.04 101.13 8.23 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-N 114.884 -1.053 . . . . 0.0 108.284 -178.653 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 346' ' ' PHE . . . . . 0.689 ' O ' ' HE3' ' A' ' 349' ' ' LYS . 67.4 m-85 -69.75 -25.96 64.07 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 -173.476 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -64.01 -22.15 66.46 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.533 -0.841 . . . . 0.0 111.917 176.579 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 48.2 t -108.84 -4.24 17.02 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.033 0.444 . . . . 0.0 110.499 178.968 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 349' ' ' LYS . . . . . 0.689 ' HE3' ' O ' ' A' ' 346' ' ' PHE . 8.2 mmpt? 49.7 50.98 17.36 Favored 'General case' 0 C--O 1.226 -0.176 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.581 -172.187 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 8.3 m -134.08 146.31 50.18 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.104 -178.178 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 351' ' ' VAL . . . . . 0.698 ' HB ' ' HB ' ' A' ' 344' ' ' VAL . 0.1 OUTLIER -149.36 133.92 9.51 Favored 'Isoleucine or valine' 0 C--O 1.236 0.365 0 CA-C-O 121.531 0.681 . . . . 0.0 112.552 -175.617 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 352' ' ' ASP . . . . . 0.646 ' HA ' ' HD3' ' A' ' 369' ' ' LYS . 1.5 m-20 -95.24 155.48 16.72 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 114.676 -1.147 . . . . 0.0 108.961 173.21 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 353' ' ' GLY . . . . . 0.521 ' C ' ' HB3' ' A' ' 367' ' ' LYS . . . -142.38 152.17 23.53 Favored Glycine 0 N--CA 1.44 -1.091 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 172.508 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 354' ' ' ILE . . . . . 0.484 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -146.78 130.12 9.1 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 116.964 0.382 . . . . 0.0 110.087 -179.643 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 355' ' ' ILE . . . . . 0.894 HD11 ' HE2' ' A' ' 367' ' ' LYS . 82.5 mt . . . . . 0 N--CA 1.449 -0.51 0 CA-C-O 121.064 0.459 . . . . 0.0 111.919 178.32 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 82.5 mt-30 . . . . . 0 N--CA 1.454 -0.255 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 367' ' ' LYS . . . . . 0.975 ' HA ' ' HZ3' ' A' ' 381' ' ' TRP . 19.3 tttm -131.03 172.91 11.54 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.096 0.474 . . . . 0.0 110.899 176.165 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 368' ' ' PHE . . . . . 0.826 ' H ' ' HG2' ' A' ' 367' ' ' LYS . 0.1 OUTLIER -73.89 163.16 28.28 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.113 -0.949 . . . . 0.0 111.814 -172.306 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 369' ' ' LYS . . . . . 0.646 ' HD3' ' HA ' ' A' ' 352' ' ' ASP . 0.0 OUTLIER -113.86 134.23 54.93 Favored 'General case' 0 C--N 1.314 -0.957 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 169.171 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 370' ' ' ALA . . . . . 0.672 ' HB2' ' CE2' ' A' ' 368' ' ' PHE . . . -130.2 162.85 27.98 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 113.095 0.776 . . . . 0.0 113.095 -172.579 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -116.73 135.93 53.37 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 114.657 -1.156 . . . . 0.0 108.924 171.401 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 372' ' ' ILE . . . . . 0.546 HG13 HG12 ' A' ' 351' ' ' VAL . 83.0 mt -82.69 115.04 24.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.142 0.496 . . . . 0.0 111.06 -177.004 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -104.92 83.38 1.99 Allowed 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.333 177.891 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 79.67 -118.8 4.82 Favored Glycine 0 N--CA 1.446 -0.678 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.559 -179.664 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 375' ' ' ASN . . . . . 0.484 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 3.2 p-10 -98.81 50.21 0.97 Allowed 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.65 0.738 . . . . 0.0 111.425 -176.147 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 165.08 175.05 35.42 Favored Glycine 0 N--CA 1.445 -0.716 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 -179.155 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 377' ' ' PHE . . . . . 0.553 ' CZ ' HG21 ' A' ' 401' ' ' VAL . 3.7 p90 -140.99 153.16 45.44 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.551 0.691 . . . . 0.0 111.703 177.918 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 378' ' ' LYS . . . . . . . . . . . . . 15.6 ptpt -131.99 138.38 48.24 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 114.498 -1.228 . . . . 0.0 108.484 175.677 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -151.55 -161.76 10.31 Favored Glycine 0 N--CA 1.443 -0.85 0 C-N-CA 120.068 -1.063 . . . . 0.0 112.61 -176.374 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 380' ' ' THR . . . . . 0.435 ' C ' ' HB2' ' A' ' 368' ' ' PHE . 6.5 t -144.57 140.62 28.89 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.811 0.339 . . . . 0.0 110.942 -175.254 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 381' ' ' TRP . . . . . 0.975 ' HZ3' ' HA ' ' A' ' 367' ' ' LYS . 50.4 m95 . . . . . 0 N--CA 1.465 0.323 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.98 178.439 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.638 0 N-CA-C 112.341 -0.303 . . . . 0.0 112.341 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -93.74 154.13 17.95 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 178.617 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 389' ' ' VAL . . . . . 0.532 ' HB ' ' CD2' ' A' ' 368' ' ' PHE . 20.0 t -131.39 139.57 50.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.057 -179.095 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 10.8 m -141.6 141.03 33.46 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.659 0.266 . . . . 0.0 110.791 178.308 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -141.05 152.64 23.34 Favored Glycine 0 C--O 1.236 0.221 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.981 179.458 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 9.7 ptm180 -115.61 144.73 43.48 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 -175.821 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 393' ' ' PHE . . . . . 0.519 ' CZ ' ' HE1' ' A' ' 346' ' ' PHE . 1.2 m-85 -94.55 154.84 17.19 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.429 0.633 . . . . 0.0 111.979 -175.104 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 394' ' ' TYR . . . . . 0.719 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 3.5 m-85 -102.73 -176.78 3.19 Favored 'General case' 0 C--O 1.216 -0.686 0 CA-C-N 114.775 -1.102 . . . . 0.0 110.816 -178.823 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 395' ' ' GLY . . . . . . . . . . . . . . . -37.77 161.35 0.01 OUTLIER Glycine 0 C--N 1.335 0.505 0 O-C-N 124.333 1.021 . . . . 0.0 115.099 -175.816 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_exo -11.13 -57.03 0.0 OUTLIER 'Trans proline' 0 C--N 1.347 0.467 1 C-N-CA 127.386 5.391 . . . . 0.0 117.517 -162.393 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 397' ' ' ALA . . . . . 0.63 ' HB3' ' HG3' ' A' ' 399' ' ' GLU . . . -84.96 -11.12 56.22 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 112.678 0.621 . . . . 0.0 112.678 -167.391 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 67.2 22.18 72.48 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.226 -179.142 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 399' ' ' GLU . . . . . 0.63 ' HG3' ' HB3' ' A' ' 397' ' ' ALA . 50.5 mt-10 -63.63 -14.4 51.38 Favored 'General case' 0 CA--C 1.521 -0.154 0 CA-C-O 121.12 0.486 . . . . 0.0 111.148 -177.222 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -121.77 133.48 54.92 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 170.558 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 401' ' ' VAL . . . . . 0.553 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 9.9 p -140.99 135.0 32.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.85 176.147 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -131.25 139.59 49.67 Favored 'General case' 0 C--N 1.315 -0.935 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.771 178.293 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -162.89 156.04 27.61 Favored Glycine 0 N--CA 1.437 -1.272 0 C-N-CA 120.304 -0.95 . . . . 0.0 111.105 -174.149 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 404' ' ' LYS . . . . . 0.987 ' HG2' HG23 ' A' ' 419' ' ' VAL . 17.5 mtmt -123.9 162.73 22.74 Favored 'General case' 0 C--N 1.31 -1.144 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 -174.36 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 405' ' ' TYR . . . . . 0.539 ' CG ' ' HZ2' ' A' ' 381' ' ' TRP . 25.4 p90 . . . . . 0 C--N 1.315 -0.918 0 CA-C-O 121.225 0.536 . . . . 0.0 111.466 179.22 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 417' ' ' PHE . . . . . 0.473 ' HB3' ' HB2' ' A' ' 326' ' ' PHE . 87.9 m-85 . . . . . 0 N--CA 1.45 -0.456 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 418' ' ' GLY . . . . . 0.612 ' HA2' ' HA ' ' A' ' 325' ' ' HIS . . . 83.33 76.83 1.13 Allowed Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.024 -1.084 . . . . 0.0 110.933 -169.721 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 419' ' ' VAL . . . . . 0.987 HG23 ' HG2' ' A' ' 404' ' ' LYS . 8.4 p -107.33 166.03 4.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-O 121.28 0.562 . . . . 0.0 110.605 -177.576 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 420' ' ' PHE . . . . . 0.445 ' H ' HG22 ' A' ' 419' ' ' VAL . 41.8 p90 -140.76 157.53 45.29 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.224 -0.898 . . . . 0.0 109.904 177.218 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -142.69 136.06 28.63 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 177.122 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -121.74 138.42 12.27 Favored Glycine 0 N--CA 1.446 -0.668 0 C-N-CA 120.562 -0.828 . . . . 0.0 112.177 -177.726 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -110.78 127.11 55.24 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 178.629 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 424' ' ' LYS . . . . . 0.506 ' HB3' ' HB3' ' A' ' 399' ' ' GLU . 23.2 tptm -66.85 115.28 6.45 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.835 0.35 . . . . 0.0 110.603 176.972 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 . . . . . 0 C--N 1.319 -0.744 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 175.427 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 307' ' ' PRO . . . . . 0.757 ' HA ' ' HA2' ' A' ' 395' ' ' GLY . 98.0 Cg_exo . . . . . 0 C--O 1.235 0.365 0 N-CA-C 111.645 -0.175 . . . . 0.0 111.645 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 308' ' ' ALA . . . . . 0.713 ' HB1' HD11 ' A' ' 313' ' ' LEU . . . -31.44 106.6 0.04 OUTLIER 'General case' 0 CA--C 1.506 -0.727 0 O-C-N 124.923 1.39 . . . . 0.0 112.844 -165.591 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 309' ' ' LYS . . . . . 0.509 ' HE3' ' OE2' ' A' ' 311' ' ' GLU . 23.4 tptt -69.62 91.76 0.62 Allowed 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 115.222 -0.899 . . . . 0.0 109.97 -173.311 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 310' ' ' GLY . . . . . 0.72 ' HA2' HD12 ' A' ' 313' ' ' LEU . . . -60.6 -30.32 71.84 Favored Glycine 0 C--N 1.331 0.264 0 CA-C-N 115.578 -0.737 . . . . 0.0 114.086 -169.241 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 311' ' ' GLU . . . . . 0.509 ' OE2' ' HE3' ' A' ' 309' ' ' LYS . 4.8 pm0 -72.42 -17.06 61.83 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 120.74 0.305 . . . . 0.0 111.069 179.15 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 66.2 mtm -117.13 -0.18 12.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.797 0.332 . . . . 0.0 110.922 178.952 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 313' ' ' LEU . . . . . 0.72 HD12 ' HA2' ' A' ' 310' ' ' GLY . 83.8 mt -70.93 134.37 47.17 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 173.34 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -149.66 137.92 20.59 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.331 -173.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.77 171.95 14.49 Favored Glycine 0 N--CA 1.444 -0.799 0 N-CA-C 111.385 -0.686 . . . . 0.0 111.385 179.401 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 42.5 p -102.61 149.4 24.46 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 173.996 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -142.78 148.28 36.92 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 121.16 0.505 . . . . 0.0 112.32 -175.258 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 318' ' ' VAL . . . . . 0.534 ' O ' ' HA ' ' A' ' 424' ' ' LYS . 13.8 t -114.56 104.32 16.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.913 175.329 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 319' ' ' TYR . . . . . 0.508 ' HH ' ' HZ ' ' A' ' 346' ' ' PHE . 60.3 m-85 -97.88 127.33 43.76 Favored 'General case' 0 C--N 1.312 -1.05 0 C-N-CA 120.264 -0.574 . . . . 0.0 110.046 177.168 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 -138.31 145.16 40.87 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 178.799 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -172.14 -152.28 8.4 Favored Glycine 0 N--CA 1.44 -1.083 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.856 -177.696 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -114.49 143.74 44.46 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 120.897 0.38 . . . . 0.0 110.779 -174.413 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 323' ' ' VAL . . . . . 0.644 HG23 ' HB2' ' A' ' 340' ' ' PHE . 59.1 t -106.8 116.62 50.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.935 175.258 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 324' ' ' LEU . . . . . 0.507 HD13 ' HG2' ' A' ' 337' ' ' ARG . 24.9 tp -97.53 102.69 14.51 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-O 121.139 0.495 . . . . 0.0 109.889 -179.505 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 325' ' ' HIS . . . . . . . . . . . . . 1.3 p-80 -105.03 114.72 29.09 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.344 0.592 . . . . 0.0 109.73 176.691 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 326' ' ' PHE . . . . . 0.735 ' HD1' ' HB2' ' A' ' 417' ' ' PHE . 31.3 m-85 . . . . . 0 C--N 1.322 -0.626 0 CA-C-N 115.168 -0.924 . . . . 0.0 110.96 -170.167 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 337' ' ' ARG . . . . . 0.513 ' HA ' ' O ' ' A' ' 323' ' ' VAL . 24.2 mtm180 . . . . . 0 N--CA 1.45 -0.438 0 CA-C-O 121.428 0.632 . . . . 0.0 110.664 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -95.21 -177.12 37.62 Favored Glycine 0 N--CA 1.439 -1.111 0 CA-C-N 115.222 -0.899 . . . . 0.0 111.613 176.969 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 339' ' ' ARG . . . . . . . . . . . . . 56.1 mtp180 -106.09 133.48 50.73 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 -176.133 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 340' ' ' PHE . . . . . 0.644 ' HB2' HG23 ' A' ' 323' ' ' VAL . 26.1 t80 -132.43 139.46 48.03 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-O 120.986 0.422 . . . . 0.0 111.342 -176.226 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 341' ' ' ALA . . . . . . . . . . . . . . . -142.86 165.85 26.24 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.223 -0.899 . . . . 0.0 109.374 174.509 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -157.18 134.09 10.19 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-O 120.875 0.369 . . . . 0.0 110.901 -174.296 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 343' ' ' LYS . . . . . 0.401 ' HB3' ' HB2' ' A' ' 352' ' ' ASP . 4.5 tppp? -108.03 102.8 11.94 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.06 178.799 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 344' ' ' VAL . . . . . 0.659 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.3 OUTLIER -125.83 133.34 69.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 CA-C-O 121.703 0.763 . . . . 0.0 112.553 -172.08 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -102.31 121.9 43.19 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 114.586 -1.188 . . . . 0.0 108.176 172.082 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 346' ' ' PHE . . . . . 0.508 ' HZ ' ' HH ' ' A' ' 319' ' ' TYR . 33.1 m-85 -72.3 -37.92 68.84 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 120.979 -0.288 . . . . 0.0 110.931 -179.108 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -61.0 -30.51 73.65 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.111 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 47.8 t -97.88 -10.02 25.35 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 123.008 -0.113 . . . . 0.0 110.783 -179.666 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 349' ' ' LYS . . . . . 0.481 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 29.0 mtmt 47.35 55.69 7.9 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-O 121.62 0.724 . . . . 0.0 111.266 -176.22 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 29.1 m -147.52 138.94 23.81 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.632 179.483 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 351' ' ' VAL . . . . . 0.659 ' HB ' ' HB ' ' A' ' 344' ' ' VAL . 0.6 OUTLIER -130.1 148.46 33.17 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 CA-C-O 121.288 0.566 . . . . 0.0 111.379 -174.894 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 352' ' ' ASP . . . . . 0.401 ' HB2' ' HB3' ' A' ' 343' ' ' LYS . 6.3 m-20 -100.46 151.78 21.15 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 107.179 -1.415 . . . . 0.0 107.179 165.915 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 353' ' ' GLY . . . . . 0.64 ' HA3' ' CE1' ' A' ' 368' ' ' PHE . . . -142.52 138.17 8.26 Favored Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.483 -0.865 . . . . 0.0 111.541 175.217 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 354' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -121.68 129.74 75.23 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-O 121.185 0.516 . . . . 0.0 109.818 178.669 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 355' ' ' ILE . . . . . 0.765 HG13 ' CZ3' ' A' ' 381' ' ' TRP . 7.0 mm . . . . . 0 C--N 1.32 -0.711 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.591 -174.23 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 79.4 mt-30 . . . . . 0 N--CA 1.448 -0.537 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 8.7 ptpp? -147.22 168.94 20.42 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 368' ' ' PHE . . . . . 0.64 ' CE1' ' HA3' ' A' ' 353' ' ' GLY . 31.6 p90 -151.49 156.08 39.86 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 175.164 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 1.7 mptp? -118.94 130.77 55.89 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 175.838 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 370' ' ' ALA . . . . . 0.518 ' HA ' ' HA3' ' A' ' 379' ' ' GLY . . . -135.75 141.47 44.83 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.104 -175.884 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -102.51 136.04 43.05 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.724 176.747 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 372' ' ' ILE . . . . . 0.481 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 74.9 mt -81.18 114.26 21.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 121.545 0.688 . . . . 0.0 110.528 -177.801 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 373' ' ' ASP . . . . . 0.424 ' HB2' ' HE3' ' A' ' 378' ' ' LYS . 36.0 t70 -117.11 80.75 1.53 Allowed 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 114.704 -1.135 . . . . 0.0 109.158 -178.834 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 61.18 119.12 0.01 OUTLIER Glycine 0 CA--C 1.52 0.372 0 CA-C-N 114.968 -1.014 . . . . 0.0 113.408 -175.73 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 375' ' ' ASN . . . . . 0.598 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 3.6 p-10 26.13 48.1 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 124.582 1.153 . . . . 0.0 114.08 179.519 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 162.95 171.45 29.19 Favored Glycine 0 N--CA 1.444 -0.81 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 178.771 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 377' ' ' PHE . . . . . 0.43 ' CD2' HG11 ' A' ' 351' ' ' VAL . 4.0 p90 -138.83 147.94 43.11 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.458 0.647 . . . . 0.0 111.983 -179.245 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 378' ' ' LYS . . . . . 0.424 ' HE3' ' HB2' ' A' ' 373' ' ' ASP . 0.0 OUTLIER -130.59 133.13 45.93 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 114.775 -1.102 . . . . 0.0 109.659 173.468 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 379' ' ' GLY . . . . . 0.518 ' HA3' ' HA ' ' A' ' 370' ' ' ALA . . . -154.85 -158.36 8.67 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.489 -176.472 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -138.17 151.85 48.12 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 120.74 0.305 . . . . 0.0 111.489 -173.835 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 381' ' ' TRP . . . . . 0.765 ' CZ3' HG13 ' A' ' 355' ' ' ILE . 19.3 m95 . . . . . 0 C--O 1.233 0.211 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.992 176.668 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.496 0 N-CA-C 111.865 -0.494 . . . . 0.0 111.865 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -90.9 137.42 32.38 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.056 0.455 . . . . 0.0 110.992 -177.4 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 29.5 t -128.98 115.37 36.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.58 177.765 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 2.4 p -139.11 137.51 36.22 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.355 0.598 . . . . 0.0 112.477 -175.316 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 391' ' ' GLY . . . . . 0.405 ' CA ' ' HA3' ' A' ' 403' ' ' GLY . . . -147.84 159.33 27.99 Favored Glycine 0 N--CA 1.447 -0.614 0 CA-C-N 115.474 -0.785 . . . . 0.0 111.515 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 392' ' ' ARG . . . . . 0.417 ' HD2' ' N ' ' A' ' 392' ' ' ARG . 8.2 mpt_? -117.01 142.43 46.96 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.05 0.453 . . . . 0.0 111.076 -174.423 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 393' ' ' PHE . . . . . 0.414 ' CD1' ' HB ' ' A' ' 401' ' ' VAL . 21.0 m-85 -82.34 163.09 21.98 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 115.295 -0.866 . . . . 0.0 109.671 176.626 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 394' ' ' TYR . . . . . 0.437 ' HD1' ' N ' ' A' ' 394' ' ' TYR . 1.2 m-85 -100.77 -176.99 3.34 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 176.094 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 395' ' ' GLY . . . . . 0.757 ' HA2' ' HA ' ' A' ' 307' ' ' PRO . . . -52.74 -146.96 0.0 OUTLIER Glycine 0 CA--C 1.527 0.836 0 O-C-N 124.062 0.851 . . . . 0.0 114.755 -176.256 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 396' ' ' PRO . . . . . 0.404 ' HD2' ' HA3' ' A' ' 395' ' ' GLY . 19.4 Cg_endo -59.22 -11.49 13.25 Favored 'Trans proline' 0 CA--C 1.536 0.605 0 C-N-CA 121.515 1.477 . . . . 0.0 111.051 179.389 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 397' ' ' ALA . . . . . . . . . . . . . . . -94.82 28.79 2.56 Favored 'General case' 0 N--CA 1.453 -0.316 0 CA-C-N 114.798 -1.092 . . . . 0.0 110.557 175.767 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . -57.78 2.42 0.14 Allowed Glycine 0 C--N 1.338 0.646 0 CA-C-N 115.923 -0.58 . . . . 0.0 113.657 -179.681 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 399' ' ' GLU . . . . . 0.815 ' HG2' ' HD3' ' A' ' 424' ' ' LYS . 35.7 mt-10 -58.73 -9.22 1.63 Allowed 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 123.401 0.68 . . . . 0.0 109.756 166.114 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -115.02 125.68 53.87 Favored 'General case' 0 N--CA 1.447 -0.62 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.437 171.001 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 401' ' ' VAL . . . . . 0.414 ' HB ' ' CD1' ' A' ' 393' ' ' PHE . 9.7 p -135.09 146.57 30.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.725 178.128 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -142.19 135.07 28.58 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.82 0.343 . . . . 0.0 110.896 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 403' ' ' GLY . . . . . 0.405 ' HA3' ' CA ' ' A' ' 391' ' ' GLY . . . -153.14 -177.91 27.18 Favored Glycine 0 N--CA 1.44 -1.089 0 C-N-CA 120.667 -0.777 . . . . 0.0 112.085 -178.368 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 404' ' ' LYS . . . . . 0.844 ' HG2' HG12 ' A' ' 419' ' ' VAL . 70.2 mttt -142.0 163.01 34.04 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 -179.562 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 29.2 p90 . . . . . 0 C--N 1.32 -0.711 0 CA-C-O 121.218 0.533 . . . . 0.0 111.208 178.988 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 417' ' ' PHE . . . . . 0.735 ' HB2' ' HD1' ' A' ' 326' ' ' PHE . 47.8 p90 . . . . . 0 N--CA 1.449 -0.513 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 81.54 71.23 1.3 Allowed Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.53 -0.843 . . . . 0.0 112.278 177.804 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 419' ' ' VAL . . . . . 0.844 HG12 ' HG2' ' A' ' 404' ' ' LYS . 22.9 m -109.72 153.04 11.6 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 178.819 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 420' ' ' PHE . . . . . 0.437 ' HB3' HG22 ' A' ' 323' ' ' VAL . 38.3 p90 -142.4 160.45 40.24 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 121.358 0.599 . . . . 0.0 110.873 179.408 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -139.45 136.11 34.29 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 114.943 -1.026 . . . . 0.0 109.076 177.873 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -118.94 132.44 9.65 Favored Glycine 0 N--CA 1.441 -1.007 0 C-N-CA 120.607 -0.806 . . . . 0.0 111.681 -178.812 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 35.2 mtmt -116.18 124.6 50.69 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 179.181 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 424' ' ' LYS . . . . . 0.815 ' HD3' ' HG2' ' A' ' 399' ' ' GLU . 46.2 tttm -67.48 125.57 26.57 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.69 -177.795 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 26.2 tt0 . . . . . 0 N--CA 1.444 -0.762 0 CA-C-O 121.416 0.627 . . . . 0.0 111.138 -172.012 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_exo . . . . . 0 CA--C 1.528 0.224 0 N-CA-C 111.216 -0.34 . . . . 0.0 111.216 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 308' ' ' ALA . . . . . 0.689 ' HB2' ' O ' ' A' ' 394' ' ' TYR . . . -48.07 152.51 0.8 Allowed 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 112.968 0.729 . . . . 0.0 112.968 -177.92 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 309' ' ' LYS . . . . . 0.583 ' O ' ' HG ' ' A' ' 313' ' ' LEU . 29.9 mmmt -108.87 107.9 18.48 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.489 177.896 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 310' ' ' GLY . . . . . 0.608 ' HA2' HD12 ' A' ' 313' ' ' LEU . . . -64.91 -34.89 91.09 Favored Glycine 0 CA--C 1.516 0.133 0 C-N-CA 121.355 -0.45 . . . . 0.0 113.705 -172.737 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 2.9 pm0 -71.72 -25.56 62.12 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.234 0.54 . . . . 0.0 110.031 178.692 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 312' ' ' MET . . . . . 0.475 ' HB3' ' HB2' ' A' ' 309' ' ' LYS . 27.6 ttt -87.11 -18.06 31.37 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.461 -179.45 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 313' ' ' LEU . . . . . 0.608 HD12 ' HA2' ' A' ' 310' ' ' GLY . 96.1 mt -66.55 139.96 57.95 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.554 179.167 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -159.62 135.64 8.75 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.011 -176.384 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.5 177.69 15.94 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.918 -0.658 . . . . 0.0 111.592 178.168 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 38.7 p -108.75 142.16 39.7 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 117.303 0.551 . . . . 0.0 110.471 174.845 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -146.68 155.28 42.31 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.258 -179.093 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 318' ' ' VAL . . . . . 0.561 ' HA ' ' O ' ' A' ' 342' ' ' ALA . 2.5 p -132.94 119.71 38.17 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-O 121.285 0.564 . . . . 0.0 110.732 174.504 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 319' ' ' TYR . . . . . 0.477 ' HE1' ' HA ' ' A' ' 399' ' ' GLU . 76.8 m-85 -104.51 128.35 52.42 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.956 -178.671 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -127.75 141.84 51.48 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.142 179.297 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -167.03 -140.98 3.02 Favored Glycine 0 N--CA 1.442 -0.913 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.28 -178.194 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 31.0 mt-10 -118.66 150.38 39.82 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.831 0.348 . . . . 0.0 111.051 -173.577 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 323' ' ' VAL . . . . . 0.626 HG23 ' HB2' ' A' ' 340' ' ' PHE . 56.1 t -109.9 120.95 61.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.925 172.644 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 324' ' ' LEU . . . . . 0.449 ' HB2' HG22 ' A' ' 419' ' ' VAL . 95.7 mt -101.87 104.21 14.94 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.092 -179.624 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 325' ' ' HIS . . . . . 0.448 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 28.1 t-80 -96.21 138.83 33.25 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.187 -0.461 . . . . 0.0 109.814 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 326' ' ' PHE . . . . . 0.558 ' HE2' HG13 ' A' ' 419' ' ' VAL . 10.8 m-85 . . . . . 0 C--N 1.321 -0.67 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.587 -176.35 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 337' ' ' ARG . . . . . 0.483 ' HA ' ' O ' ' A' ' 323' ' ' VAL . 51.2 mtm180 . . . . . 0 CA--C 1.516 -0.338 0 CA-C-O 121.254 0.549 . . . . 0.0 111.576 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -107.57 -177.12 22.49 Favored Glycine 0 N--CA 1.444 -0.83 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.092 176.707 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 339' ' ' ARG . . . . . 0.503 ' O ' ' HA ' ' A' ' 355' ' ' ILE . 40.0 mtp-105 -104.45 153.46 21.08 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 340' ' ' PHE . . . . . 0.626 ' HB2' HG23 ' A' ' 323' ' ' VAL . 53.0 t80 -143.41 137.52 28.71 Favored 'General case' 0 C--N 1.317 -0.848 0 CA-C-O 121.139 0.495 . . . . 0.0 111.484 -178.51 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 341' ' ' ALA . . . . . 0.401 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -141.05 163.49 32.84 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.228 -0.896 . . . . 0.0 108.889 173.334 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 342' ' ' ALA . . . . . 0.821 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -155.9 118.14 4.09 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 120.871 0.367 . . . . 0.0 110.667 -176.926 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 343' ' ' LYS . . . . . 0.502 ' C ' ' HD3' ' A' ' 343' ' ' LYS . 12.7 tmtt? -94.3 103.35 15.36 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 178.223 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 344' ' ' VAL . . . . . 1.026 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.2 OUTLIER -119.4 132.83 68.1 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.109 0 CA-C-O 121.607 0.718 . . . . 0.0 112.105 -172.716 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -109.16 118.69 37.39 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.885 -1.052 . . . . 0.0 108.247 175.563 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 346' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -79.25 -24.59 42.9 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 111.584 0.216 . . . . 0.0 111.584 -175.509 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -69.52 -38.54 79.25 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.239 -0.981 . . . . 0.0 111.285 179.227 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 3.4 m -92.58 -9.74 40.04 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.002 0.43 . . . . 0.0 110.019 178.096 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 349' ' ' LYS . . . . . 0.621 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 10.1 mtmp? 52.03 58.67 5.19 Favored 'General case' 0 N--CA 1.456 -0.142 0 CA-C-N 115.439 -0.801 . . . . 0.0 110.394 -176.734 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 17.9 m -140.9 145.84 36.67 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.48 -179.211 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 351' ' ' VAL . . . . . 1.026 ' HB ' ' HB ' ' A' ' 344' ' ' VAL . 0.2 OUTLIER -141.83 139.0 31.38 Favored 'Isoleucine or valine' 0 C--O 1.237 0.396 0 CA-C-O 121.299 0.571 . . . . 0.0 111.559 -177.035 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 352' ' ' ASP . . . . . 0.821 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 1.5 m-20 -106.61 118.54 36.93 Favored 'General case' 0 C--O 1.214 -0.798 0 CA-C-N 115.057 -0.974 . . . . 0.0 109.304 179.637 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -110.1 143.24 16.73 Favored Glycine 0 C--N 1.313 -0.715 0 C-N-CA 120.23 -0.986 . . . . 0.0 111.873 -177.076 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 354' ' ' ILE . . . . . 0.536 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -140.29 129.92 27.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 CA-C-O 120.856 0.36 . . . . 0.0 110.362 -177.962 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 355' ' ' ILE . . . . . 0.59 HG23 HG21 ' A' ' 323' ' ' VAL . 3.3 mp . . . . . 0 C--N 1.326 -0.419 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.329 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 14.6 mm100 . . . . . 0 N--CA 1.447 -0.577 0 CA-C-O 121.624 0.726 . . . . 0.0 111.076 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 44.9 mttp -125.74 147.72 49.29 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 114.599 -1.182 . . . . 0.0 110.394 -170.697 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 368' ' ' PHE . . . . . 0.685 ' CD1' HG21 ' A' ' 389' ' ' VAL . 41.9 p90 -126.39 160.23 31.05 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 177.371 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 369' ' ' LYS . . . . . 0.589 ' HD3' ' HA ' ' A' ' 352' ' ' ASP . 2.0 tppt? -125.96 147.39 49.53 Favored 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 173.442 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 370' ' ' ALA . . . . . 0.435 ' HB1' ' HB2' ' A' ' 377' ' ' PHE . . . -141.58 147.71 38.12 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.83 0.347 . . . . 0.0 111.123 -176.697 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -105.45 127.57 53.07 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.079 177.759 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 372' ' ' ILE . . . . . 0.621 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 84.0 mt -82.8 121.32 35.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-O 121.008 0.433 . . . . 0.0 111.257 -178.905 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -137.91 105.27 5.5 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 170.786 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 92.88 -155.2 22.37 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 110.349 -1.1 . . . . 0.0 110.349 -168.012 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 375' ' ' ASN . . . . . 0.552 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 21.8 p-10 -94.33 42.6 1.1 Allowed 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 117.533 0.666 . . . . 0.0 110.681 178.718 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . -170.37 164.48 37.77 Favored Glycine 0 N--CA 1.441 -1.016 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -178.789 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 377' ' ' PHE . . . . . 0.512 ' CD2' HG11 ' A' ' 351' ' ' VAL . 8.8 p90 -136.91 139.0 41.26 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-O 120.964 0.412 . . . . 0.0 110.939 -179.307 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 378' ' ' LYS . . . . . . . . . . . . . 63.7 mttm -112.72 137.09 51.52 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.293 172.081 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 379' ' ' GLY . . . . . 0.627 ' C ' HG22 ' A' ' 389' ' ' VAL . . . -144.53 -154.73 6.22 Favored Glycine 0 N--CA 1.437 -1.283 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.097 -172.432 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 12.7 t -169.16 154.66 6.09 Favored 'General case' 0 C--N 1.313 -1.016 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 -173.534 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 381' ' ' TRP . . . . . 0.901 ' HD1' ' HA3' ' A' ' 387' ' ' GLY . 38.8 m95 . . . . . 0 C--N 1.327 -0.373 0 CA-C-O 121.299 0.571 . . . . 0.0 110.87 178.337 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 387' ' ' GLY . . . . . 0.901 ' HA3' ' HD1' ' A' ' 381' ' ' TRP . . . . . . . . 0 N--CA 1.446 -0.69 0 N-CA-C 112.637 -0.185 . . . . 0.0 112.637 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -96.18 128.04 42.74 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 178.994 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 389' ' ' VAL . . . . . 0.685 HG21 ' CD1' ' A' ' 368' ' ' PHE . 3.5 m -117.28 160.48 16.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 C-N-CA 120.87 -0.332 . . . . 0.0 110.714 -176.589 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 390' ' ' SER . . . . . 0.521 ' O ' ' HA3' ' A' ' 403' ' ' GLY . 24.7 t -157.44 158.46 35.87 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.245 178.622 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -170.13 153.15 20.82 Favored Glycine 0 C--N 1.32 -0.329 0 N-CA-C 111.443 -0.663 . . . . 0.0 111.443 178.666 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 4.3 ptm180 -131.92 149.32 52.47 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 117.319 0.56 . . . . 0.0 110.751 -176.706 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -89.88 166.11 13.7 Favored 'General case' 0 CA--C 1.498 -1.037 0 CA-C-O 122.424 1.107 . . . . 0.0 111.786 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 394' ' ' TYR . . . . . 0.689 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 0.5 OUTLIER -101.86 -176.15 3.05 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 112.709 -2.042 . . . . 0.0 108.923 176.949 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 395' ' ' GLY . . . . . 0.42 ' O ' ' N ' ' A' ' 397' ' ' ALA . . . -36.26 158.38 0.01 OUTLIER Glycine 0 N--CA 1.461 0.304 0 O-C-N 124.71 1.256 . . . . 0.0 115.045 -175.06 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -22.95 -42.42 0.03 OUTLIER 'Trans proline' 0 C--N 1.358 1.032 1 C-N-CA 127.322 5.348 . . . . 0.0 117.178 -161.711 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 397' ' ' ALA . . . . . 0.42 ' N ' ' O ' ' A' ' 395' ' ' GLY . . . -73.04 -19.46 61.18 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 -175.068 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 57.85 25.06 55.54 Favored Glycine 0 C--N 1.34 0.767 0 CA-C-N 116.186 -0.461 . . . . 0.0 112.887 176.165 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 399' ' ' GLU . . . . . 0.477 ' HA ' ' HE1' ' A' ' 319' ' ' TYR . 51.3 mt-10 -71.3 -8.37 53.21 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 122.956 0.502 . . . . 0.0 112.024 -174.03 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 400' ' ' GLU . . . . . 0.451 ' HG2' ' CE1' ' A' ' 394' ' ' TYR . 5.2 tt0 -131.9 144.29 50.75 Favored 'General case' 0 N--CA 1.433 -1.284 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 171.438 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 401' ' ' VAL . . . . . 0.492 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 14.8 p -142.08 136.73 29.9 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.107 0 CA-C-N 115.012 -0.995 . . . . 0.0 109.722 179.019 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -135.7 138.94 43.27 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.122 -178.74 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 403' ' ' GLY . . . . . 0.521 ' HA3' ' O ' ' A' ' 390' ' ' SER . . . -161.06 -161.09 11.25 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 120.747 -0.739 . . . . 0.0 111.646 178.424 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 404' ' ' LYS . . . . . 0.7 ' HG2' HG12 ' A' ' 419' ' ' VAL . 28.4 mtmm -144.45 161.71 38.36 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.557 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 34.9 p90 . . . . . 0 C--N 1.318 -0.776 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 171.915 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 417' ' ' PHE . . . . . 0.506 ' CD1' ' HB2' ' A' ' 326' ' ' PHE . 32.7 m-85 . . . . . 0 N--CA 1.454 -0.243 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 418' ' ' GLY . . . . . 0.448 ' HA2' ' HA ' ' A' ' 325' ' ' HIS . . . 83.82 78.17 1.11 Allowed Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 119.904 -1.141 . . . . 0.0 112.678 -178.262 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 419' ' ' VAL . . . . . 0.7 HG12 ' HG2' ' A' ' 404' ' ' LYS . 13.5 m -105.03 163.29 4.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.832 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 29.9 p90 -143.38 153.71 42.97 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-O 121.406 0.622 . . . . 0.0 111.234 -178.133 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -142.81 136.15 28.5 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.259 -0.882 . . . . 0.0 109.037 176.664 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -124.05 134.71 9.34 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.399 -0.905 . . . . 0.0 112.327 -178.341 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 423' ' ' LYS . . . . . 0.451 ' HE2' ' HB3' ' A' ' 423' ' ' LYS . 44.6 mtpt -104.8 140.18 38.48 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 120.753 0.311 . . . . 0.0 110.198 178.722 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 424' ' ' LYS . . . . . 0.408 ' HB2' ' HE1' ' A' ' 319' ' ' TYR . 26.0 tptp -58.14 116.25 3.43 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.626 -0.716 . . . . 0.0 111.8 179.652 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 425' ' ' GLU . . . . . 0.535 ' HB3' HG13 ' A' ' 318' ' ' VAL . 19.8 tp10 . . . . . 0 C--N 1.325 -0.473 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 169.009 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 276' ' ' ASN . . . . . 0.513 ' HA ' ' OE2' ' A' ' 292' ' ' GLU . 17.2 p30 . . . . . 0 N--CA 1.483 1.189 0 CA-C-O 121.348 0.594 . . . . 0.0 110.013 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 15.6 tt -81.67 15.27 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.313 -171.798 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 278' ' ' PHE . . . . . . . . . . . . . 25.1 p90 -79.03 -21.52 46.76 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.451 176.091 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 279' ' ' ALA . . . . . 0.622 ' HB1' ' HA ' ' A' ' 283' ' ' ASN . . . -144.43 64.08 11.68 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.199 178.435 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 280' ' ' PRO . . . . . 0.47 ' O ' ' HB2' ' A' ' 281' ' ' GLU . 4.5 Cg_endo -84.23 144.9 10.71 Favored 'Trans proline' 0 N--CA 1.455 -0.768 0 C-N-CA 123.08 2.52 . . . . 0.0 111.403 179.462 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 281' ' ' GLU . . . . . 0.47 ' HB2' ' O ' ' A' ' 280' ' ' PRO . 1.6 mp0 70.83 -64.01 0.39 Allowed 'General case' 0 N--CA 1.469 0.52 0 O-C-N 123.61 0.569 . . . . 0.0 110.774 -178.301 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -107.77 93.35 0.81 Allowed Glycine 0 N--CA 1.446 -0.665 0 CA-C-N 115.78 -0.645 . . . . 0.0 111.873 177.63 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 283' ' ' ASN . . . . . 0.622 ' HA ' ' HB1' ' A' ' 279' ' ' ALA . 2.6 p-10 -71.42 108.03 4.64 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.49 0.662 . . . . 0.0 110.161 178.228 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 70.9 m-85 -72.99 99.31 2.69 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.995 -175.554 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 3.3 ptp180 -92.93 2.32 56.84 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.824 -0.626 . . . . 0.0 109.714 177.146 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 4.9 m-85 -79.06 -42.48 26.32 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.347 -0.842 . . . . 0.0 108.738 177.574 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 287' ' ' LEU . . . . . 0.521 HD11 ' HB3' ' A' ' 306' ' ' GLU . 21.5 tp -166.25 128.94 1.95 Allowed 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 115.072 -0.967 . . . . 0.0 109.544 175.914 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 288' ' ' THR . . . . . 0.589 ' H ' ' HB2' ' A' ' 304' ' ' GLN . 6.0 m -172.37 143.66 1.45 Allowed 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 123.354 0.661 . . . . 0.0 109.473 179.084 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 289' ' ' TYR . . . . . . . . . . . . . 46.6 t80 -136.42 128.26 29.21 Favored 'General case' 0 N--CA 1.443 -0.808 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 171.849 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 144.43 158.4 7.6 Favored Glycine 0 C--N 1.312 -0.785 0 N-CA-C 111.355 -0.698 . . . . 0.0 111.355 -177.011 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 291' ' ' ALA . . . . . 0.433 ' HB1' ' OH ' ' A' ' 299' ' ' TYR . . . -156.17 130.15 8.57 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.866 0.333 . . . . 0.0 111.284 -177.646 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 292' ' ' GLU . . . . . 0.513 ' OE2' ' HA ' ' A' ' 276' ' ' ASN . 44.7 mt-10 -137.1 119.43 15.72 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.231 -0.44 . . . . 0.0 109.999 175.916 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 293' ' ' LYS . . . . . . . . . . . . . 5.2 tppp? -88.02 139.49 30.45 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.495 -0.321 . . . . 0.0 110.612 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 294' ' ' LEU . . . . . 0.461 ' HB2' ' O ' ' A' ' 298' ' ' SER . 6.5 mp -82.25 115.7 59.28 Favored Pre-proline 0 C--N 1.327 -0.375 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 173.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 295' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 294' ' ' LEU . 21.7 Cg_exo -65.27 100.39 0.38 Allowed 'Trans proline' 0 C--O 1.236 0.387 0 C-N-CA 122.576 2.184 . . . . 0.0 111.096 179.088 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . 80.69 48.28 6.3 Favored Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 120.679 -0.772 . . . . 0.0 111.433 -174.27 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . -166.43 -140.94 3.01 Favored Glycine 0 N--CA 1.443 -0.888 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.8 -178.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 298' ' ' SER . . . . . 0.461 ' O ' ' HB2' ' A' ' 294' ' ' LEU . 8.3 t -94.42 -175.45 3.64 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.078 0.466 . . . . 0.0 110.901 -175.509 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 299' ' ' TYR . . . . . 0.433 ' OH ' ' HB1' ' A' ' 291' ' ' ALA . 1.3 t80 -139.32 135.78 34.14 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 176.09 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 300' ' ' ALA . . . . . 0.486 ' HB3' ' ND2' ' A' ' 276' ' ' ASN . . . -144.19 110.51 5.5 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.178 179.477 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 301' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -142.15 162.68 34.86 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.427 178.066 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 302' ' ' ARG . . . . . 0.571 ' NE ' ' HA ' ' A' ' 302' ' ' ARG . 2.3 mmp_? -136.78 131.8 33.86 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 174.378 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 303' ' ' VAL . . . . . . . . . . . . . 3.4 p -113.43 96.44 4.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 122.073 0.939 . . . . 0.0 110.487 178.916 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 304' ' ' GLN . . . . . 0.589 ' HB2' ' H ' ' A' ' 288' ' ' THR . 5.1 mp0 -121.94 151.86 40.29 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 114.855 -1.066 . . . . 0.0 109.814 177.47 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -102.94 119.44 6.43 Favored Glycine 0 N--CA 1.444 -0.814 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.692 -177.641 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 306' ' ' GLU . . . . . 0.521 ' HB3' HD11 ' A' ' 287' ' ' LEU . 6.0 pt-20 -116.35 84.31 14.27 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-O 121.598 0.713 . . . . 0.0 109.845 173.678 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -91.0 122.41 0.78 Allowed 'Trans proline' 0 N--CA 1.444 -1.414 0 C-N-CA 122.591 2.194 . . . . 0.0 111.575 175.009 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 308' ' ' ALA . . . . . 0.675 ' HB2' ' O ' ' A' ' 394' ' ' TYR . . . -59.47 163.54 4.01 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.15 -0.62 . . . . 0.0 109.974 168.828 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 309' ' ' LYS . . . . . 0.537 ' HB3' ' HB2' ' A' ' 312' ' ' MET . 10.8 tptp -123.96 93.45 3.93 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 174.1 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 310' ' ' GLY . . . . . 0.7 ' HA2' HD12 ' A' ' 313' ' ' LEU . . . -57.24 -34.02 66.47 Favored Glycine 0 C--N 1.332 0.315 0 C-N-CA 121.147 -0.549 . . . . 0.0 113.013 -173.934 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 311' ' ' GLU . . . . . 0.425 ' HA ' ' HE3' ' A' ' 349' ' ' LYS . 11.2 pt-20 -62.82 -26.9 68.97 Favored 'General case' 0 C--N 1.319 -0.755 0 C-N-CA 122.483 0.313 . . . . 0.0 111.581 174.807 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 312' ' ' MET . . . . . 0.537 ' HB2' ' HB3' ' A' ' 309' ' ' LYS . 90.0 mtp -102.37 -6.37 23.1 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.921 0.391 . . . . 0.0 110.567 -179.77 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 313' ' ' LEU . . . . . 0.7 HD12 ' HA2' ' A' ' 310' ' ' GLY . 92.4 mt -75.26 133.2 41.4 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.729 176.876 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -143.68 137.09 27.97 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.017 -173.822 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.53 -159.53 15.28 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 121.001 -0.618 . . . . 0.0 111.665 178.994 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 12.7 p -123.89 156.17 36.76 Favored 'General case' 0 C--N 1.317 -0.806 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 173.462 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 317' ' ' ALA . . . . . 0.402 ' HB3' HG13 ' A' ' 344' ' ' VAL . . . -146.51 160.41 42.15 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 120.918 0.39 . . . . 0.0 110.694 176.657 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 318' ' ' VAL . . . . . 0.582 ' HA ' ' O ' ' A' ' 342' ' ' ALA . 8.7 p -138.78 113.75 8.5 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.691 172.849 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 319' ' ' TYR . . . . . 0.731 ' HE2' HG11 ' A' ' 344' ' ' VAL . 55.4 m-85 -98.08 127.46 44.04 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.331 -177.256 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -115.79 132.4 56.65 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.478 174.459 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 321' ' ' GLY . . . . . 0.48 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -166.27 -143.17 3.65 Favored Glycine 0 N--CA 1.438 -1.197 0 C-N-CA 120.697 -0.763 . . . . 0.0 111.948 -179.143 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -136.94 164.67 27.78 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 120.927 0.394 . . . . 0.0 111.236 -173.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 323' ' ' VAL . . . . . 0.608 HG23 ' HB2' ' A' ' 340' ' ' PHE . 75.2 t -126.34 116.42 45.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.53 178.792 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 324' ' ' LEU . . . . . 0.426 ' HB2' HG22 ' A' ' 419' ' ' VAL . 93.7 mt -89.4 101.76 14.43 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 175.486 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 325' ' ' HIS . . . . . 0.52 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 1.9 p80 -102.24 114.76 29.19 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.493 0.663 . . . . 0.0 110.066 -179.123 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 326' ' ' PHE . . . . . 0.5 ' HB2' ' HB3' ' A' ' 417' ' ' PHE . 49.0 m-85 -88.16 124.33 33.7 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 114.734 -1.121 . . . . 0.0 110.897 -170.011 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 327' ' ' HIS . . . . . . . . . . . . . 31.2 p-80 -150.31 106.57 3.47 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 176.636 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 328' ' ' THR . . . . . . . . . . . . . 30.2 m -146.49 97.38 2.92 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.195 0.521 . . . . 0.0 110.937 179.113 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 329' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -106.41 115.4 30.14 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 107.351 -1.352 . . . . 0.0 107.351 169.157 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 330' ' ' ASN . . . . . . . . . . . . . 22.7 p-10 30.96 54.72 0.2 Allowed 'General case' 0 N--CA 1.477 0.876 0 O-C-N 124.333 1.021 . . . . 0.0 111.139 -167.873 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 331' ' ' GLY . . . . . . . . . . . . . . . -101.73 138.34 13.83 Favored Glycine 0 N--CA 1.444 -0.785 0 CA-C-N 115.01 -0.995 . . . . 0.0 113.332 -170.725 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 332' ' ' ARG . . . . . 0.571 ' N ' ' HD2' ' A' ' 333' ' ' PRO . 67.5 mtp180 -84.68 -42.84 0.7 Allowed Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 115.385 -0.407 . . . . 0.0 111.828 177.956 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 333' ' ' PRO . . . . . 0.571 ' HD2' ' N ' ' A' ' 332' ' ' ARG . 45.7 Cg_endo -68.74 -173.93 0.65 Allowed 'Trans proline' 0 C--N 1.36 1.132 0 C-N-CA 122.11 1.873 . . . . 0.0 112.674 175.472 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 334' ' ' TYR . . . . . 0.692 ' HB2' ' HD2' ' A' ' 335' ' ' PRO . 36.1 p90 -122.59 168.81 10.96 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.815 -178.609 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 335' ' ' PRO . . . . . 0.692 ' HD2' ' HB2' ' A' ' 334' ' ' TYR . 6.1 Cg_endo -48.55 144.41 14.09 Favored 'Trans proline' 0 C--N 1.353 0.77 0 C-N-CA 123.15 2.566 . . . . 0.0 113.038 179.165 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 336' ' ' THR . . . . . 0.408 ' HB ' ' NE2' ' A' ' 325' ' ' HIS . 1.6 m -94.34 151.97 19.0 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.579 -177.923 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 337' ' ' ARG . . . . . . . . . . . . . 54.6 mtp180 -102.48 112.63 25.44 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.957 0.408 . . . . 0.0 110.707 -178.756 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -96.82 -176.81 35.22 Favored Glycine 0 N--CA 1.447 -0.591 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 173.951 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 339' ' ' ARG . . . . . 0.591 ' HB2' ' HB2' ' A' ' 356' ' ' ASP . 29.0 mtm180 -112.41 163.31 14.58 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 118.055 0.928 . . . . 0.0 110.213 179.393 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 340' ' ' PHE . . . . . 0.608 ' HB2' HG23 ' A' ' 323' ' ' VAL . 30.7 t80 -151.67 140.13 20.55 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.83 0.347 . . . . 0.0 111.137 -179.243 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 341' ' ' ALA . . . . . 0.562 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -137.25 152.55 49.94 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.12 175.364 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 342' ' ' ALA . . . . . 0.929 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -143.83 118.3 9.71 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.044 0.45 . . . . 0.0 111.513 -178.375 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 343' ' ' LYS . . . . . 0.525 ' HB3' ' HB2' ' A' ' 352' ' ' ASP . 55.7 tptt -96.52 103.61 15.54 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.109 177.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 344' ' ' VAL . . . . . 0.731 HG11 ' HE2' ' A' ' 319' ' ' TYR . 0.7 OUTLIER -122.86 140.33 46.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -170.691 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -114.4 121.31 43.19 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.839 -1.073 . . . . 0.0 108.46 171.164 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 346' ' ' PHE . . . . . . . . . . . . . 51.8 m-85 -76.7 -17.04 59.34 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 111.734 0.272 . . . . 0.0 111.734 -175.301 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -75.29 -42.12 29.14 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.461 -0.876 . . . . 0.0 111.269 178.568 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 55.9 m -88.37 -10.93 47.7 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-O 120.811 0.339 . . . . 0.0 110.108 177.33 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 349' ' ' LYS . . . . . 0.64 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 48.4 mttm 51.24 58.81 5.12 Favored 'General case' 0 CA--C 1.52 -0.198 0 CA-C-O 121.863 0.84 . . . . 0.0 109.896 -179.723 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 50.7 m -147.77 146.02 29.02 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 114.777 -1.101 . . . . 0.0 109.607 176.958 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 351' ' ' VAL . . . . . 0.782 HG22 ' HB3' ' A' ' 370' ' ' ALA . 1.3 m -129.69 156.35 41.97 Favored 'Isoleucine or valine' 0 C--O 1.237 0.427 0 CA-C-O 121.181 0.515 . . . . 0.0 110.461 -176.451 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 352' ' ' ASP . . . . . 0.929 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 0.9 OUTLIER -109.48 117.37 33.81 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 170.481 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -114.7 117.08 3.95 Favored Glycine 0 N--CA 1.444 -0.792 0 C-N-CA 120.218 -0.991 . . . . 0.0 112.136 -177.546 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 354' ' ' ILE . . . . . 0.526 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -117.65 133.14 65.39 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.127 0 CA-C-N 115.321 -0.439 . . . . 0.0 109.916 -176.995 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 355' ' ' ILE . . . . . 0.514 ' HB ' ' HB3' ' A' ' 366' ' ' GLN . 3.4 mp -116.14 113.2 42.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.797 -178.016 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 356' ' ' ASP . . . . . 0.591 ' HB2' ' HB2' ' A' ' 339' ' ' ARG . 20.4 m-20 -68.43 100.72 1.12 Allowed 'General case' 0 C--O 1.238 0.5 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 175.34 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 15.9 t -70.83 -32.4 69.44 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.472 -0.786 . . . . 0.0 110.064 -177.781 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 358' ' ' GLY . . . . . . . . . . . . . . . 124.43 -41.64 1.69 Allowed Glycine 0 N--CA 1.448 -0.514 0 N-CA-C 111.107 -0.797 . . . . 0.0 111.107 -178.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 359' ' ' ASP . . . . . 0.48 ' OD2' ' HB3' ' A' ' 362' ' ' HIS . 20.8 t70 -133.39 68.31 1.5 Allowed 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 122.153 0.978 . . . . 0.0 108.843 174.381 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 360' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -78.02 -20.8 51.78 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 114.921 -1.036 . . . . 0.0 111.303 -174.505 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 361' ' ' LEU . . . . . . . . . . . . . 93.8 mt -83.86 -11.13 57.41 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.373 -176.854 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 362' ' ' HIS . . . . . 0.48 ' HB3' ' OD2' ' A' ' 359' ' ' ASP . 47.2 t60 -129.77 -66.16 0.81 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.712 -0.222 . . . . 0.0 111.408 179.018 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 363' ' ' MET . . . . . . . . . . . . . 15.1 tpt -55.55 -48.92 73.96 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 120.769 0.319 . . . . 0.0 110.789 179.867 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 364' ' ' GLY . . . . . . . . . . . . . . . 153.43 135.29 2.12 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 120.394 -0.908 . . . . 0.0 112.31 176.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 365' ' ' THR . . . . . . . . . . . . . 5.9 m -78.81 132.54 36.91 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 178.973 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 366' ' ' GLN . . . . . 0.514 ' HB3' ' HB ' ' A' ' 355' ' ' ILE . 17.5 tp60 -106.18 117.63 34.52 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 -179.734 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 37.5 ttpt -156.54 136.98 13.04 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.427 -176.344 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 368' ' ' PHE . . . . . 0.424 ' HB3' ' CE3' ' A' ' 381' ' ' TRP . 46.9 p90 -129.51 156.42 44.17 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.095 0.474 . . . . 0.0 109.978 178.876 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 4.0 tptp -116.62 131.59 56.91 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 175.149 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 370' ' ' ALA . . . . . 0.782 ' HB3' HG22 ' A' ' 351' ' ' VAL . . . -128.87 140.77 51.53 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 112.193 0.442 . . . . 0.0 112.193 -170.994 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -101.31 130.83 47.54 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.603 175.311 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 372' ' ' ILE . . . . . 0.64 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 84.2 mt -80.8 105.17 10.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.842 0.829 . . . . 0.0 110.08 -179.24 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -113.63 83.93 1.93 Allowed 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 114.337 -1.301 . . . . 0.0 108.944 -177.16 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 374' ' ' GLY . . . . . 0.56 ' O ' ' HA3' ' A' ' 310' ' ' GLY . . . 101.34 -141.79 15.46 Favored Glycine 0 N--CA 1.444 -0.811 0 CA-C-N 115.159 -0.928 . . . . 0.0 111.117 -174.15 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 375' ' ' ASN . . . . . . . . . . . . . 30.9 p-10 -97.57 59.56 1.52 Allowed 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 122.582 1.182 . . . . 0.0 109.545 179.034 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 162.1 178.43 35.98 Favored Glycine 0 N--CA 1.443 -0.893 0 CA-C-N 113.993 -1.458 . . . . 0.0 109.959 -174.318 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 377' ' ' PHE . . . . . 0.472 ' CZ ' HG21 ' A' ' 401' ' ' VAL . 4.8 p90 -139.45 150.99 45.86 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 117.655 0.728 . . . . 0.0 112.155 -178.412 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 378' ' ' LYS . . . . . 0.442 ' HD2' ' N ' ' A' ' 378' ' ' LYS . 0.0 OUTLIER -115.06 129.5 56.71 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 172.818 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 379' ' ' GLY . . . . . 0.513 ' HA2' ' HA ' ' A' ' 370' ' ' ALA . . . -126.33 169.3 18.28 Favored Glycine 0 N--CA 1.444 -0.777 0 C-N-CA 119.997 -1.097 . . . . 0.0 113.411 -171.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 11.3 p -131.19 140.17 49.86 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.118 -0.541 . . . . 0.0 109.872 178.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 381' ' ' TRP . . . . . 0.516 ' CB ' ' HA3' ' A' ' 385' ' ' GLY . 73.7 m95 -66.18 139.62 58.13 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.701 179.496 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 382' ' ' THR . . . . . . . . . . . . . 13.8 t -66.28 112.87 4.2 Favored 'General case' 0 CA--C 1.536 0.405 0 CA-C-O 121.4 0.619 . . . . 0.0 111.696 -173.99 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 383' ' ' GLU . . . . . . . . . . . . . 20.1 mm-40 62.14 -88.56 0.03 OUTLIER 'General case' 0 C--O 1.234 0.288 0 CA-C-N 115.063 -0.971 . . . . 0.0 112.498 177.125 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 384' ' ' ASN . . . . . . . . . . . . . 44.4 t-20 -91.52 74.48 5.96 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.072 0.463 . . . . 0.0 110.509 -174.126 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 385' ' ' GLY . . . . . 0.516 ' HA3' ' CB ' ' A' ' 381' ' ' TRP . . . -154.56 89.18 0.12 Allowed Glycine 0 N--CA 1.444 -0.803 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.18 178.072 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 386' ' ' GLY . . . . . . . . . . . . . . . -75.33 72.42 1.68 Allowed Glycine 0 CA--C 1.519 0.303 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.464 178.665 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -164.03 148.8 15.29 Favored Glycine 0 N--CA 1.445 -0.737 0 C-N-CA 121.092 -0.575 . . . . 0.0 112.27 179.304 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -99.66 138.94 36.04 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.817 0.342 . . . . 0.0 110.594 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 389' ' ' VAL . . . . . 0.49 HG22 ' HB3' ' A' ' 405' ' ' TYR . 22.1 t -109.53 144.81 17.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 177.641 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 14.7 m -147.44 139.64 24.43 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.52 0.2 . . . . 0.0 110.557 175.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -145.08 150.14 22.31 Favored Glycine 0 C--N 1.32 -0.326 0 N-CA-C 111.692 -0.563 . . . . 0.0 111.692 179.38 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 392' ' ' ARG . . . . . 0.64 ' HD3' ' O ' ' A' ' 393' ' ' PHE . 4.5 tmt_? -118.67 136.55 53.85 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -175.501 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 393' ' ' PHE . . . . . 0.64 ' O ' ' HD3' ' A' ' 392' ' ' ARG . 8.1 m-85 -82.24 159.76 23.13 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.263 -177.693 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 394' ' ' TYR . . . . . 0.675 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 2.4 m-85 -100.81 -174.67 2.68 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.861 -177.164 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 395' ' ' GLY . . . . . 0.454 ' CA ' ' HB2' ' A' ' 306' ' ' GLU . . . -38.42 170.45 0.01 OUTLIER Glycine 0 C--N 1.335 0.487 0 O-C-N 124.277 0.985 . . . . 0.0 114.985 -177.718 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -51.52 -15.11 2.35 Favored 'Trans proline' 0 N--CA 1.477 0.502 0 C-N-CA 124.384 3.389 . . . . 0.0 115.526 -163.853 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 397' ' ' ALA . . . . . . . . . . . . . . . -80.22 -20.49 44.54 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 111.735 0.272 . . . . 0.0 111.735 177.299 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 56.23 18.62 21.46 Favored Glycine 0 C--N 1.34 0.763 0 CA-C-N 116.09 -0.505 . . . . 0.0 114.081 175.046 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 399' ' ' GLU . . . . . 0.908 ' HG3' ' HB3' ' A' ' 424' ' ' LYS . 17.7 tt0 -73.15 -19.15 61.19 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.193 0.52 . . . . 0.0 110.838 -177.751 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -116.7 137.47 52.17 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-O 121.18 0.514 . . . . 0.0 110.362 177.974 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 401' ' ' VAL . . . . . 0.472 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 9.0 p -139.46 134.55 39.67 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.546 173.423 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -131.14 135.18 47.24 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.172 -179.335 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -151.05 -176.64 24.12 Favored Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.177 -1.011 . . . . 0.0 112.152 -177.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 404' ' ' LYS . . . . . 0.675 ' HG2' HG12 ' A' ' 419' ' ' VAL . 27.0 mttm -147.69 162.47 39.1 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 -179.352 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 405' ' ' TYR . . . . . 0.49 ' HB3' HG22 ' A' ' 389' ' ' VAL . 6.9 p90 -124.36 151.22 44.64 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 121.251 0.548 . . . . 0.0 111.593 175.644 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 406' ' ' SER . . . . . 0.482 ' OG ' ' HA3' ' A' ' 415' ' ' GLY . 28.1 t -129.08 112.89 14.47 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.279 -176.679 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -87.47 140.57 29.39 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.84 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 408' ' ' ARG . . . . . 0.478 ' N ' ' HD3' ' A' ' 409' ' ' PRO . 36.1 mmt180 -136.18 58.21 21.14 Favored Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.531 174.775 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 409' ' ' PRO . . . . . 0.478 ' HD3' ' N ' ' A' ' 408' ' ' ARG . 10.2 Cg_endo -90.19 -59.05 0.02 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 122.865 2.376 . . . . 0.0 113.116 -176.266 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 410' ' ' THR . . . . . 0.475 ' HB ' ' H ' ' A' ' 411' ' ' ASP . 11.0 p -87.56 -151.24 0.18 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.5 -175.369 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 411' ' ' ASP . . . . . 0.475 ' H ' ' HB ' ' A' ' 410' ' ' THR . 17.9 t70 -61.38 91.3 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.22 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.757 177.219 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 412' ' ' ALA . . . . . . . . . . . . . . . 61.74 -78.82 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.18 0 O-C-N 123.83 0.706 . . . . 0.0 111.202 -176.944 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 413' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 71.04 132.88 0.04 OUTLIER 'General case' 0 C--N 1.333 -0.146 0 C-N-CA 123.576 0.751 . . . . 0.0 110.76 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 414' ' ' LYS . . . . . . . . . . . . . 52.2 mtpt -80.78 123.13 27.97 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.042 -175.57 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 415' ' ' GLY . . . . . 0.482 ' HA3' ' OG ' ' A' ' 406' ' ' SER . . . -102.84 178.32 25.88 Favored Glycine 0 N--CA 1.443 -0.874 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 175.702 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 416' ' ' GLY . . . . . . . . . . . . . . . 106.2 -25.75 22.53 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.554 -0.832 . . . . 0.0 111.234 -179.53 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 417' ' ' PHE . . . . . 0.5 ' HB3' ' HB2' ' A' ' 326' ' ' PHE . 64.1 m-85 -77.17 158.72 30.21 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 174.4 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 418' ' ' GLY . . . . . 0.52 ' HA2' ' HA ' ' A' ' 325' ' ' HIS . . . 82.4 77.32 1.07 Allowed Glycine 0 N--CA 1.442 -0.935 0 C-N-CA 119.78 -1.2 . . . . 0.0 111.447 -175.454 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 419' ' ' VAL . . . . . 0.675 HG12 ' HG2' ' A' ' 404' ' ' LYS . 19.7 m -105.08 146.96 11.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 -178.109 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 420' ' ' PHE . . . . . 0.48 ' HB3' HG22 ' A' ' 323' ' ' VAL . 47.0 p90 -130.29 161.07 32.06 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 121.023 0.44 . . . . 0.0 110.696 -179.299 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 421' ' ' ALA . . . . . 0.48 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -153.92 136.54 15.17 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.025 179.821 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -132.54 141.67 13.06 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.187 -1.006 . . . . 0.0 113.052 -177.336 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 72.3 mmtt -102.46 125.56 49.22 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 175.722 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 424' ' ' LYS . . . . . 0.908 ' HB3' ' HG3' ' A' ' 399' ' ' GLU . 80.0 tttt -63.16 105.72 0.75 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.272 0.558 . . . . 0.0 110.626 178.16 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -76.57 113.56 14.33 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.53 -0.759 . . . . 0.0 109.984 -179.708 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 426' ' ' GLN . . . . . . . . . . . . . 48.0 mt-30 -103.47 109.11 20.63 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.403 -0.817 . . . . 0.0 109.55 177.827 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 427' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -64.65 -13.73 55.2 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.328 -0.397 . . . . 0.0 111.091 -176.725 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 428' ' ' LEU . . . . . 0.709 ' HG ' ' HB2' ' A' ' 431' ' ' HIS . 29.7 tp -76.27 -13.24 60.17 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.854 179.339 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 429' ' ' GLU . . . . . . . . . . . . . 69.6 mm-40 59.52 39.68 21.37 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.744 178.548 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 430' ' ' HIS . . . . . . . . . . . . . 49.8 m80 73.5 -51.46 0.7 Allowed 'General case' 0 N--CA 1.475 0.789 0 C-N-CA 123.283 0.633 . . . . 0.0 110.818 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 431' ' ' HIS . . . . . 0.709 ' HB2' ' HG ' ' A' ' 428' ' ' LEU . 25.9 t-80 60.15 77.81 0.3 Allowed 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 123.402 0.681 . . . . 0.0 112.073 170.551 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 432' ' ' HIS . . . . . . . . . . . . . 36.0 m80 -134.27 -78.71 0.46 Allowed 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.214 174.004 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 433' ' ' HIS . . . . . . . . . . . . . 12.7 t-80 -176.86 -36.42 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.633 -0.258 . . . . 0.0 111.008 -178.674 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 434' ' ' HIS . . . . . . . . . . . . . 24.2 p80 -150.22 -179.82 7.5 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.825 0.345 . . . . 0.0 110.934 -178.556 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 435' ' ' HIS . . . . . . . . . . . . . 17.9 p80 . . . . . 0 C--O 1.243 0.757 0 CA-C-N 115.604 -0.726 . . . . 0.0 109.206 172.539 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 276' ' ' ASN . . . . . 0.453 ' CG ' HD11 ' A' ' 301' ' ' LEU . 0.9 OUTLIER . . . . . 0 N--CA 1.483 1.218 0 N-CA-C 111.542 0.201 . . . . 0.0 111.542 . . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.43 HG22 ' O ' ' A' ' 277' ' ' ILE . 25.7 mm -98.03 4.9 9.62 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.35 0 CA-C-O 121.54 0.686 . . . . 0.0 110.889 -174.655 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 278' ' ' PHE . . . . . . . . . . . . . 48.5 p90 -95.16 4.51 53.54 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.52 -176.0 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 279' ' ' ALA . . . . . 0.936 ' HB2' ' HB3' ' A' ' 301' ' ' LEU . . . -101.05 132.54 21.86 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-O 120.881 0.372 . . . . 0.0 111.954 -174.061 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 280' ' ' PRO . . . . . 0.511 ' HD2' ' O ' ' A' ' 302' ' ' ARG . 33.1 Cg_exo -58.47 147.06 87.98 Favored 'Trans proline' 0 N--CA 1.463 -0.299 0 C-N-CA 122.642 2.228 . . . . 0.0 110.509 168.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 27.1 tt0 -66.5 -19.7 65.85 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.012 -0.54 . . . . 0.0 112.245 -171.724 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -76.9 111.35 3.25 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.673 -0.775 . . . . 0.0 111.907 178.538 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 283' ' ' ASN . . . . . . . . . . . . . 40.5 m-80 -79.09 82.91 5.21 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.198 0.523 . . . . 0.0 110.685 -177.917 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 77.5 m-85 -96.11 146.12 24.92 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.9 178.135 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 285' ' ' ARG . . . . . 0.514 ' HA ' ' CE2' ' A' ' 289' ' ' TYR . 0.0 OUTLIER -140.5 44.17 1.86 Allowed 'General case' 0 CA--C 1.534 0.363 0 CA-C-O 121.396 0.617 . . . . 0.0 111.517 -175.189 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 76.6 m-85 -120.22 -34.87 3.57 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.302 0.572 . . . . 0.0 110.902 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 287' ' ' LEU . . . . . . . . . . . . . 7.2 mp -93.74 -178.48 4.7 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.216 -0.902 . . . . 0.0 110.573 -176.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 288' ' ' THR . . . . . . . . . . . . . 25.0 m -77.71 139.14 39.38 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 175.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 289' ' ' TYR . . . . . 1.025 ' HB3' ' HA ' ' A' ' 302' ' ' ARG . 42.6 m-85 -140.95 178.22 7.51 Favored 'General case' 0 C--N 1.327 -0.404 0 O-C-N 123.605 0.566 . . . . 0.0 110.185 -175.015 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.727 ' O ' ' HB2' ' A' ' 301' ' ' LEU . . . -136.85 134.1 6.9 Favored Glycine 0 CA--C 1.495 -1.217 0 N-CA-C 107.459 -2.256 . . . . 0.0 107.459 175.161 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 291' ' ' ALA . . . . . 0.637 ' HB2' ' O ' ' A' ' 301' ' ' LEU . . . -155.49 131.95 10.35 Favored 'General case' 0 C--N 1.31 -1.123 0 CA-C-N 117.748 0.774 . . . . 0.0 111.025 -162.599 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 292' ' ' GLU . . . . . 0.586 ' H ' ' CD2' ' A' ' 301' ' ' LEU . 4.0 pm0 -123.76 109.65 13.94 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 162.234 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 293' ' ' LYS . . . . . 0.71 ' HB2' ' HB2' ' A' ' 300' ' ' ALA . 63.7 tttp -95.41 127.82 41.76 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.335 -173.7 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 294' ' ' LEU . . . . . 0.653 HD23 ' HB2' ' A' ' 298' ' ' SER . 3.9 mm? -110.11 141.76 24.5 Favored Pre-proline 0 C--N 1.318 -0.786 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.133 174.408 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 295' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 294' ' ' LEU . 7.3 Cg_exo -74.3 41.14 0.65 Allowed 'Trans proline' 0 CA--C 1.53 0.277 0 C-N-CA 123.27 2.647 . . . . 0.0 112.658 -178.284 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . 156.43 91.98 0.09 OUTLIER Glycine 0 N--CA 1.444 -0.77 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.184 -178.34 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 116.41 -95.41 0.68 Allowed Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 121.012 -0.613 . . . . 0.0 111.827 178.321 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 298' ' ' SER . . . . . 0.653 ' HB2' HD23 ' A' ' 294' ' ' LEU . 15.5 m -64.23 137.94 58.19 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.017 0.437 . . . . 0.0 110.316 178.959 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 299' ' ' TYR . . . . . . . . . . . . . 19.3 p90 -113.13 175.04 5.61 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.26 -172.359 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 300' ' ' ALA . . . . . 0.71 ' HB2' ' HB2' ' A' ' 293' ' ' LYS . . . -80.52 113.72 18.9 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.938 179.25 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 301' ' ' LEU . . . . . 0.936 ' HB3' ' HB2' ' A' ' 279' ' ' ALA . 0.3 OUTLIER -80.19 166.77 21.1 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 122.014 0.912 . . . . 0.0 112.157 -172.548 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 302' ' ' ARG . . . . . 1.025 ' HA ' ' HB3' ' A' ' 289' ' ' TYR . 14.9 mmt180 -137.71 122.74 19.06 Favored 'General case' 0 C--N 1.31 -1.121 0 CA-C-N 114.456 -1.247 . . . . 0.0 108.275 -178.886 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 303' ' ' VAL . . . . . 0.663 ' O ' ' HA ' ' A' ' 289' ' ' TYR . 9.2 p -145.12 138.92 22.19 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.329 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -178.94 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 304' ' ' GLN . . . . . . . . . . . . . 50.6 mt-30 -90.12 162.12 15.45 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 172.813 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -94.42 115.23 4.99 Favored Glycine 0 N--CA 1.444 -0.814 0 C-N-CA 120.379 -0.915 . . . . 0.0 112.088 -175.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 306' ' ' GLU . . . . . 0.518 ' O ' ' HA2' ' A' ' 395' ' ' GLY . 7.3 pt-20 -116.48 173.03 3.3 Favored Pre-proline 0 C--N 1.323 -0.587 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 178.829 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 307' ' ' PRO . . . . . 0.441 ' HD2' ' HB2' ' A' ' 306' ' ' GLU . 52.8 Cg_exo -56.52 124.51 16.43 Favored 'Trans proline' 0 CA--C 1.533 0.441 0 C-N-CA 122.008 1.805 . . . . 0.0 112.672 174.339 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 308' ' ' ALA . . . . . 0.626 ' HB2' ' O ' ' A' ' 394' ' ' TYR . . . -47.51 153.88 0.5 Allowed 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 121.137 0.494 . . . . 0.0 111.965 170.091 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 309' ' ' LYS . . . . . 0.677 ' O ' ' HG ' ' A' ' 313' ' ' LEU . 65.9 mmtt -91.76 88.28 6.62 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 178.157 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 310' ' ' GLY . . . . . 0.627 ' HA2' HD12 ' A' ' 313' ' ' LEU . . . -58.31 -40.22 93.73 Favored Glycine 0 C--N 1.333 0.41 0 C-N-CA 121.616 -0.326 . . . . 0.0 113.818 -171.213 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 311' ' ' GLU . . . . . 0.408 ' HG2' ' HG2' ' A' ' 312' ' ' MET . 0.2 OUTLIER -72.61 -19.97 61.37 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.818 0.342 . . . . 0.0 110.95 -178.4 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 312' ' ' MET . . . . . 0.408 ' HG2' ' HG2' ' A' ' 311' ' ' GLU . 78.3 mmm -108.43 6.48 26.3 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.812 0.339 . . . . 0.0 111.192 -178.687 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 313' ' ' LEU . . . . . 0.677 ' HG ' ' O ' ' A' ' 309' ' ' LYS . 91.9 mt -75.47 133.8 40.99 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 175.224 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -151.61 139.4 19.85 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.773 -172.939 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.23 161.81 11.63 Favored Glycine 0 N--CA 1.448 -0.556 0 N-CA-C 111.306 -0.718 . . . . 0.0 111.306 178.822 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 21.7 p -97.82 135.01 40.19 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 173.044 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -133.47 151.51 51.79 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.78 -172.166 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -120.75 110.4 28.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.439 -0.8 . . . . 0.0 109.384 175.956 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 319' ' ' TYR . . . . . 0.707 ' O ' ' HA ' ' A' ' 341' ' ' ALA . 90.9 m-85 -99.18 127.49 45.16 Favored 'General case' 0 C--N 1.312 -1.04 0 C-N-CA 120.327 -0.549 . . . . 0.0 110.424 178.327 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 48.0 m-80 -120.85 132.74 55.17 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.377 178.834 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 321' ' ' GLY . . . . . 0.566 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -166.53 -154.18 8.2 Favored Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.54 -179.598 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 3.7 mp0 -116.12 153.95 30.87 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.056 0.455 . . . . 0.0 111.122 -174.168 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 323' ' ' VAL . . . . . 0.559 HG23 ' HB2' ' A' ' 340' ' ' PHE . 72.5 t -112.06 117.44 55.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.355 -0.839 . . . . 0.0 109.208 172.397 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 324' ' ' LEU . . . . . 0.47 ' HB2' HG22 ' A' ' 419' ' ' VAL . 93.7 mt -95.69 104.31 16.22 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.129 0.49 . . . . 0.0 110.298 -177.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 325' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -98.52 113.98 26.21 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 179.512 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 326' ' ' PHE . . . . . 0.515 ' HD2' ' H ' ' A' ' 418' ' ' GLY . 57.9 m-85 -89.29 150.08 22.76 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.377 -174.954 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 327' ' ' HIS . . . . . . . . . . . . . 1.8 p-80 -157.92 115.64 3.02 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.886 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 328' ' ' THR . . . . . . . . . . . . . 6.5 p -89.31 99.57 12.54 Favored 'General case' 0 N--CA 1.445 -0.724 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 173.214 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 329' ' ' GLU . . . . . 0.512 ' HG3' ' HD3' ' A' ' 332' ' ' ARG . 63.9 mm-40 -104.6 173.38 6.33 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.043 -177.097 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 330' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -60.77 -58.45 8.38 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 177.086 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 331' ' ' GLY . . . . . . . . . . . . . . . -143.68 89.39 0.17 Allowed Glycine 0 N--CA 1.446 -0.637 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 174.064 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 332' ' ' ARG . . . . . 0.512 ' HD3' ' HG3' ' A' ' 329' ' ' GLU . 77.7 ttt180 -177.74 78.06 0.23 Allowed Pre-proline 0 C--N 1.325 -0.492 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -173.838 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 333' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -83.73 -179.47 4.16 Favored 'Trans proline' 0 N--CA 1.46 -0.452 0 C-N-CA 122.946 2.431 . . . . 0.0 113.031 -175.548 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 334' ' ' TYR . . . . . 0.449 ' HA ' ' HD3' ' A' ' 335' ' ' PRO . 79.2 m-85 73.5 116.51 0.03 OUTLIER Pre-proline 0 C--O 1.235 0.293 0 CA-C-N 115.094 -0.957 . . . . 0.0 112.076 176.812 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 335' ' ' PRO . . . . . 0.449 ' HD3' ' HA ' ' A' ' 334' ' ' TYR . 13.8 Cg_exo -68.87 128.82 17.45 Favored 'Trans proline' 0 N--CA 1.461 -0.44 0 C-N-CA 122.817 2.345 . . . . 0.0 111.056 175.229 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 336' ' ' THR . . . . . . . . . . . . . 23.2 p -70.89 139.22 50.71 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.332 -178.158 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 337' ' ' ARG . . . . . . . . . . . . . 51.9 mtm180 -101.42 112.31 24.8 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.911 0.386 . . . . 0.0 110.268 -177.721 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -90.52 -177.13 44.36 Favored Glycine 0 N--CA 1.44 -1.08 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 172.827 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 339' ' ' ARG . . . . . 0.886 ' HB2' ' HB3' ' A' ' 356' ' ' ASP . 65.1 mtt180 -104.49 154.92 19.28 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 176.237 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 340' ' ' PHE . . . . . 0.559 ' HB2' HG23 ' A' ' 323' ' ' VAL . 27.0 t80 -148.74 139.02 22.42 Favored 'General case' 0 C--N 1.309 -1.16 0 CA-C-O 121.165 0.507 . . . . 0.0 110.494 179.161 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 341' ' ' ALA . . . . . 0.707 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -136.84 164.2 28.87 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 114.967 -1.015 . . . . 0.0 108.908 175.809 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 342' ' ' ALA . . . . . 0.849 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -151.76 120.11 6.39 Favored 'General case' 0 C--N 1.314 -0.943 0 N-CA-C 109.654 -0.499 . . . . 0.0 109.654 -179.758 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 13.0 tptm -100.81 98.43 8.95 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.727 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 344' ' ' VAL . . . . . 0.491 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.2 OUTLIER -118.45 136.93 54.05 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 CA-C-N 115.833 -0.621 . . . . 0.0 112.176 -169.576 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 10.4 t0 -107.23 113.0 26.13 Favored 'General case' 0 C--N 1.321 -0.63 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 171.194 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 346' ' ' PHE . . . . . . . . . . . . . 48.4 m-85 -74.77 -27.64 60.42 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 111.701 0.26 . . . . 0.0 111.701 -176.091 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -61.87 -33.36 85.13 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.695 -0.764 . . . . 0.0 111.654 177.198 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 6.8 t -101.59 -4.48 26.57 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-O 120.688 0.28 . . . . 0.0 111.083 178.162 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 349' ' ' LYS . . . . . 0.479 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 10.0 mtmp? 51.28 59.05 4.88 Favored 'General case' 0 N--CA 1.466 0.362 0 C-N-CA 123.148 0.579 . . . . 0.0 111.543 -178.265 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 40.2 m -149.6 140.51 22.83 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.14 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 351' ' ' VAL . . . . . 0.517 HG22 ' HB3' ' A' ' 370' ' ' ALA . 0.8 OUTLIER -129.08 156.43 41.68 Favored 'Isoleucine or valine' 0 C--O 1.236 0.369 0 CA-C-O 121.289 0.566 . . . . 0.0 111.147 -175.665 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 352' ' ' ASP . . . . . 0.849 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 17.9 t70 -111.72 119.19 37.79 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.981 -1.009 . . . . 0.0 108.414 166.493 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -111.31 120.81 5.57 Favored Glycine 0 C--N 1.306 -1.11 0 C-N-CA 120.621 -0.8 . . . . 0.0 111.369 -178.78 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 354' ' ' ILE . . . . . 0.536 HG12 ' N ' ' A' ' 355' ' ' ILE . 0.2 OUTLIER -121.29 140.9 43.96 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.233 0 CA-C-O 121.084 0.469 . . . . 0.0 110.577 -176.233 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 355' ' ' ILE . . . . . 0.916 ' HB ' ' HB2' ' A' ' 366' ' ' GLN . 3.1 mp -114.2 98.27 6.74 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.26 177.614 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 356' ' ' ASP . . . . . 0.886 ' HB3' ' HB2' ' A' ' 339' ' ' ARG . 18.5 t70 -78.68 92.3 4.75 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.061 -0.972 . . . . 0.0 108.908 178.217 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 81.2 p -70.56 -29.37 65.8 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.392 -174.057 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 358' ' ' GLY . . . . . . . . . . . . . . . 94.87 -5.56 69.22 Favored Glycine 0 N--CA 1.444 -0.785 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 -174.365 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 359' ' ' ASP . . . . . 0.416 ' OD2' ' HB2' ' A' ' 362' ' ' HIS . 25.9 t70 -129.18 26.89 5.42 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 122.106 0.955 . . . . 0.0 108.459 176.754 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 360' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -61.12 -28.78 69.34 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 114.58 -1.191 . . . . 0.0 111.121 -176.816 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 361' ' ' LEU . . . . . 0.468 HD22 ' N ' ' A' ' 361' ' ' LEU . 3.2 mm? -73.76 -27.0 60.94 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-N 115.965 -0.562 . . . . 0.0 111.643 179.623 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 362' ' ' HIS . . . . . 0.416 ' HB2' ' OD2' ' A' ' 359' ' ' ASP . 72.4 m-70 -100.7 -73.35 0.64 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.711 0.291 . . . . 0.0 110.654 -175.641 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 363' ' ' MET . . . . . . . . . . . . . 53.9 ttp -66.25 -47.61 73.16 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.612 -179.584 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 364' ' ' GLY . . . . . . . . . . . . . . . 139.68 160.48 8.36 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.978 -0.63 . . . . 0.0 111.738 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 365' ' ' THR . . . . . . . . . . . . . 8.9 t -92.82 152.64 19.32 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 179.265 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 366' ' ' GLN . . . . . 0.916 ' HB2' ' HB ' ' A' ' 355' ' ' ILE . 41.2 mt-30 -114.65 130.83 56.85 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 179.069 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 367' ' ' LYS . . . . . 0.816 ' HB3' ' HG2' ' A' ' 383' ' ' GLU . 26.2 ttmt -148.43 139.8 23.43 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.181 -0.463 . . . . 0.0 109.752 -178.777 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 368' ' ' PHE . . . . . . . . . . . . . 52.3 p90 -139.06 145.12 39.18 Favored 'General case' 0 C--N 1.321 -0.663 0 O-C-N 123.33 0.394 . . . . 0.0 110.365 176.69 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 369' ' ' LYS . . . . . 0.436 ' HE2' ' HD3' ' A' ' 367' ' ' LYS . 3.4 mptp? -106.74 131.94 53.29 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 175.626 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 370' ' ' ALA . . . . . 0.517 ' HB3' HG22 ' A' ' 351' ' ' VAL . . . -135.64 135.89 40.54 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.549 -172.325 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -92.89 133.88 35.65 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.761 176.233 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 372' ' ' ILE . . . . . 0.479 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 87.4 mt -82.17 108.11 14.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 121.191 0.52 . . . . 0.0 110.405 -178.961 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -109.61 81.18 1.4 Allowed 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.485 -0.78 . . . . 0.0 109.096 178.955 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 374' ' ' GLY . . . . . 0.623 ' HA2' ' HA3' ' A' ' 310' ' ' GLY . . . 53.79 118.95 0.01 OUTLIER Glycine 0 CA--C 1.524 0.61 0 CA-C-N 114.992 -1.004 . . . . 0.0 114.841 -176.108 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 375' ' ' ASN . . . . . 0.526 ' HB2' ' O ' ' A' ' 308' ' ' ALA . 40.2 t30 40.69 44.28 1.81 Allowed 'General case' 0 N--CA 1.47 0.566 0 CA-C-O 122.053 0.93 . . . . 0.0 112.182 175.506 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 156.66 167.79 18.41 Favored Glycine 0 N--CA 1.442 -0.931 0 C-N-CA 120.302 -0.952 . . . . 0.0 111.608 176.065 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 377' ' ' PHE . . . . . 0.507 ' CD2' HG11 ' A' ' 351' ' ' VAL . 2.3 p90 -133.44 143.8 49.08 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-O 121.34 0.59 . . . . 0.0 111.5 -179.18 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 378' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.67 125.29 47.31 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 114.887 -1.051 . . . . 0.0 108.262 174.983 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -142.26 -165.3 10.47 Favored Glycine 0 N--CA 1.44 -1.055 0 C-N-CA 120.361 -0.923 . . . . 0.0 112.587 -176.626 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 95.4 m -142.46 147.05 35.45 Favored 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 -176.719 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 381' ' ' TRP . . . . . 0.633 ' HB3' ' HB3' ' A' ' 384' ' ' ASN . 42.0 m95 -56.25 117.37 3.72 Favored 'General case' 0 C--N 1.331 -0.214 0 O-C-N 123.633 0.583 . . . . 0.0 111.43 178.9 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 382' ' ' THR . . . . . . . . . . . . . 71.0 m -83.49 -58.18 2.93 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.803 -176.742 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 383' ' ' GLU . . . . . 0.816 ' HG2' ' HB3' ' A' ' 367' ' ' LYS . 57.9 mm-40 -85.82 53.99 2.97 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.694 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 384' ' ' ASN . . . . . 0.633 ' HB3' ' HB3' ' A' ' 381' ' ' TRP . 16.0 t-20 -175.7 -45.04 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.113 -176.587 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 385' ' ' GLY . . . . . . . . . . . . . . . 60.24 55.74 28.46 Favored Glycine 0 C--N 1.331 0.29 0 C-N-CA 120.636 -0.792 . . . . 0.0 111.417 -176.387 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 386' ' ' GLY . . . . . . . . . . . . . . . -118.01 -96.73 1.83 Allowed Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.608 -0.806 . . . . 0.0 113.153 -173.787 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 387' ' ' GLY . . . . . 0.437 ' H ' ' HD1' ' A' ' 381' ' ' TRP . . . -107.37 -170.86 22.12 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.539 -0.839 . . . . 0.0 113.327 -174.322 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 388' ' ' ASP . . . . . 0.565 ' HB2' ' HB3' ' A' ' 406' ' ' SER . 6.6 m-20 -89.73 159.07 17.25 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 -177.407 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 79.6 t -135.67 135.99 50.75 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 174.166 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 16.9 m -143.11 141.68 31.3 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.8 0.334 . . . . 0.0 110.692 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 391' ' ' GLY . . . . . 0.435 ' HA2' ' CA ' ' A' ' 403' ' ' GLY . . . -145.36 155.9 26.7 Favored Glycine 0 C--N 1.316 -0.581 0 N-CA-C 111.487 -0.645 . . . . 0.0 111.487 -178.515 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 392' ' ' ARG . . . . . 0.526 ' HD3' ' O ' ' A' ' 375' ' ' ASN . 25.0 tpp180 -117.07 135.62 53.59 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.768 0.318 . . . . 0.0 110.24 -175.751 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -85.12 165.23 17.63 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.951 176.317 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 394' ' ' TYR . . . . . 0.626 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 4.8 m-85 -109.58 -177.38 3.26 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.99 -177.947 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 395' ' ' GLY . . . . . 0.518 ' HA2' ' O ' ' A' ' 306' ' ' GLU . . . -37.83 160.72 0.01 OUTLIER Glycine 0 C--N 1.336 0.541 0 O-C-N 124.492 1.12 . . . . 0.0 114.922 -176.625 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_exo -17.25 -40.46 0.0 OUTLIER 'Trans proline' 0 C--N 1.353 0.78 1 C-N-CA 127.773 5.649 . . . . 0.0 118.501 -165.122 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 397' ' ' ALA . . . . . 0.552 ' HB1' ' HG3' ' A' ' 399' ' ' GLU . . . -81.16 -20.24 41.69 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 118.754 0.706 . . . . 0.0 111.633 -171.536 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 60.96 10.63 20.78 Favored Glycine 0 C--N 1.338 0.682 0 C-N-CA 121.409 -0.424 . . . . 0.0 112.725 176.668 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 399' ' ' GLU . . . . . 0.552 ' HG3' ' HB1' ' A' ' 397' ' ' ALA . 30.5 mt-10 -70.19 -8.93 53.82 Favored 'General case' 0 N--CA 1.451 -0.406 0 CA-C-O 121.66 0.743 . . . . 0.0 110.123 -178.378 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 400' ' ' GLU . . . . . 0.408 ' HB2' ' HB2' ' A' ' 394' ' ' TYR . 41.9 mt-10 -117.54 128.36 54.89 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.82 175.16 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 401' ' ' VAL . . . . . 0.46 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 10.1 p -140.87 140.49 32.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.844 0.354 . . . . 0.0 110.517 177.888 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -142.16 131.34 23.38 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.269 178.793 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 403' ' ' GLY . . . . . 0.435 ' CA ' ' HA2' ' A' ' 391' ' ' GLY . . . -145.02 -169.04 13.2 Favored Glycine 0 N--CA 1.438 -1.18 0 C-N-CA 120.47 -0.872 . . . . 0.0 112.271 -177.153 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 404' ' ' LYS . . . . . 0.775 ' HG2' HG12 ' A' ' 419' ' ' VAL . 37.5 mtpt -148.8 169.11 21.22 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 -178.344 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 5.8 m-85 -113.54 134.75 54.52 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 177.287 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 406' ' ' SER . . . . . 0.565 ' HB3' ' HB2' ' A' ' 388' ' ' ASP . 47.5 t -95.04 103.65 15.5 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 86.6 m-85 -82.95 105.96 14.38 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.281 0.563 . . . . 0.0 110.329 -179.62 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 408' ' ' ARG . . . . . 0.57 ' HB2' ' HD3' ' A' ' 409' ' ' PRO . 98.3 mtt180 -62.21 -47.63 89.59 Favored Pre-proline 0 CA--C 1.536 0.408 0 CA-C-N 115.07 -0.968 . . . . 0.0 111.938 -179.782 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 409' ' ' PRO . . . . . 0.57 ' HD3' ' HB2' ' A' ' 408' ' ' ARG . 12.4 Cg_exo -71.83 56.73 2.43 Favored 'Trans proline' 0 C--N 1.358 1.068 0 C-N-CA 122.312 2.008 . . . . 0.0 112.848 178.09 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 410' ' ' THR . . . . . . . . . . . . . 2.0 p -109.21 -58.09 2.08 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.585 173.627 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 411' ' ' ASP . . . . . . . . . . . . . 37.1 t70 -172.14 -67.22 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.371 175.649 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 412' ' ' ALA . . . . . . . . . . . . . . . -161.24 -48.47 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.877 -0.601 . . . . 0.0 109.668 176.459 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 413' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -77.62 82.89 4.02 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 173.928 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 414' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -85.46 123.02 30.43 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.368 0.604 . . . . 0.0 111.777 -175.547 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 415' ' ' GLY . . . . . . . . . . . . . . . 147.1 133.36 2.4 Favored Glycine 0 N--CA 1.447 -0.574 0 CA-C-N 115.41 -0.814 . . . . 0.0 111.423 177.826 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 416' ' ' GLY . . . . . . . . . . . . . . . 164.96 -105.56 0.25 Allowed Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.289 -0.958 . . . . 0.0 112.481 178.845 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 417' ' ' PHE . . . . . 0.478 ' HB2' ' HB2' ' A' ' 326' ' ' PHE . 35.2 p90 -68.49 167.08 15.59 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.973 0.416 . . . . 0.0 111.144 -178.304 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 418' ' ' GLY . . . . . 0.515 ' H ' ' HD2' ' A' ' 326' ' ' PHE . . . 83.93 76.49 1.16 Allowed Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.3 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 419' ' ' VAL . . . . . 0.775 HG12 ' HG2' ' A' ' 404' ' ' LYS . 16.0 m -115.64 160.06 15.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 110.429 -0.211 . . . . 0.0 110.429 178.992 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 38.7 p90 -138.41 158.65 43.86 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.068 0.461 . . . . 0.0 110.506 178.898 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 421' ' ' ALA . . . . . 0.566 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -146.44 136.68 23.7 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.346 176.627 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -130.34 139.97 11.38 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.566 -0.826 . . . . 0.0 111.71 -179.365 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 72.1 mttt -117.66 136.4 53.35 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.173 0.511 . . . . 0.0 110.616 179.476 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 424' ' ' LYS . . . . . 0.513 ' HG2' ' OE2' ' A' ' 399' ' ' GLU . 23.0 tptm -59.0 125.82 25.17 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 114.838 -1.074 . . . . 0.0 113.126 -174.864 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -88.29 118.06 27.63 Favored 'General case' 0 N--CA 1.446 -0.651 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 166.27 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 426' ' ' GLN . . . . . . . . . . . . . 26.4 mp0 -67.03 144.43 56.17 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.213 0.53 . . . . 0.0 110.85 -177.096 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 427' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -84.54 26.48 0.79 Allowed 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.884 -177.273 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 62.1 tp -65.09 -52.8 53.4 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.965 -178.548 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 429' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 54.4 63.04 2.3 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-O 121.664 0.745 . . . . 0.0 109.954 -178.25 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 430' ' ' HIS . . . . . . . . . . . . . 72.8 t60 -70.11 -49.59 49.26 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.426 -178.07 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 32.0 t-80 -175.84 -52.74 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 177.699 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 432' ' ' HIS . . . . . . . . . . . . . 51.6 t60 -68.34 139.7 55.88 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.481 173.517 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 433' ' ' HIS . . . . . . . . . . . . . 6.0 t-160 64.1 69.36 0.53 Allowed 'General case' 0 N--CA 1.463 0.194 0 O-C-N 123.707 0.629 . . . . 0.0 109.82 179.605 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 434' ' ' HIS . . . . . . . . . . . . . 1.6 t-80 -75.56 -12.63 60.26 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.601 -175.937 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 435' ' ' HIS . . . . . . . . . . . . . 5.8 t60 . . . . . 0 C--O 1.247 0.943 0 CA-C-O 118.644 -0.693 . . . . 0.0 109.655 -179.889 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 276' ' ' ASN . . . . . . . . . . . . . 7.6 t30 . . . . . 0 N--CA 1.479 0.976 0 CA-C-O 120.404 0.145 . . . . 0.0 111.055 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.407 HG22 ' HB2' ' A' ' 293' ' ' LYS . 38.1 pt -80.03 38.36 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.434 0 N-CA-C 113.674 0.991 . . . . 0.0 113.674 -172.379 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 278' ' ' PHE . . . . . 0.455 ' HE1' ' HA3' ' A' ' 290' ' ' GLY . 10.4 p90 -80.77 -11.63 59.58 Favored 'General case' 0 C--N 1.327 -0.396 0 O-C-N 122.198 -0.314 . . . . 0.0 111.821 -178.503 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 279' ' ' ALA . . . . . 0.629 ' HB2' ' HA ' ' A' ' 304' ' ' GLN . . . -126.95 78.22 74.19 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 120.902 0.382 . . . . 0.0 110.151 176.335 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 280' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -83.97 120.62 2.67 Favored 'Trans proline' 0 N--CA 1.457 -0.628 0 C-N-CA 122.629 2.219 . . . . 0.0 113.635 -175.551 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 5.3 mm-40 72.76 161.92 0.25 Allowed 'General case' 0 N--CA 1.469 0.507 0 CA-C-O 121.635 0.731 . . . . 0.0 112.91 174.093 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 87.07 99.12 0.84 Allowed Glycine 0 N--CA 1.444 -0.786 0 CA-C-N 115.031 -0.986 . . . . 0.0 112.329 179.563 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 283' ' ' ASN . . . . . . . . . . . . . 62.1 t30 -79.33 83.5 5.35 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.942 0.401 . . . . 0.0 110.29 178.28 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 284' ' ' TYR . . . . . 0.983 ' HB2' HG21 ' A' ' 303' ' ' VAL . 55.6 m-85 -101.08 146.79 26.99 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 175.866 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 38.2 ttp180 -132.67 18.76 4.26 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.347 0.594 . . . . 0.0 110.521 -173.732 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 77.8 m-85 -137.13 35.92 2.55 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.656 0.741 . . . . 0.0 110.013 -177.085 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 287' ' ' LEU . . . . . 0.47 ' HB2' ' HB ' ' A' ' 303' ' ' VAL . 36.7 mt -134.77 -179.59 5.7 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 114.624 -1.171 . . . . 0.0 110.668 -177.021 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 288' ' ' THR . . . . . . . . . . . . . 2.8 m -70.86 149.57 46.66 Favored 'General case' 0 C--O 1.218 -0.587 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 178.158 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 289' ' ' TYR . . . . . 0.61 ' HA ' ' HA ' ' A' ' 303' ' ' VAL . 2.0 m-85 -102.29 150.22 23.53 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 121.878 0.847 . . . . 0.0 112.927 -169.59 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.455 ' HA3' ' HE1' ' A' ' 278' ' ' PHE . . . -156.93 -153.22 6.57 Favored Glycine 0 N--CA 1.44 -1.038 0 CA-C-N 113.852 -1.522 . . . . 0.0 110.436 -173.983 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 291' ' ' ALA . . . . . . . . . . . . . . . -121.65 154.08 37.29 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.267 0.556 . . . . 0.0 112.322 -176.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 292' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -133.64 158.2 43.82 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 173.45 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 293' ' ' LYS . . . . . 0.407 ' HB2' HG22 ' A' ' 277' ' ' ILE . 28.1 tptp -103.58 135.75 44.59 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.129 0.49 . . . . 0.0 111.451 -176.682 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 294' ' ' LEU . . . . . . . . . . . . . 69.7 mt -104.17 135.51 19.33 Favored Pre-proline 0 C--N 1.32 -0.69 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.204 173.607 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 295' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -54.25 106.14 0.16 Allowed 'Trans proline' 0 C--O 1.234 0.312 0 C-N-CA 122.943 2.429 . . . . 0.0 112.267 -179.329 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . 129.65 -139.39 10.92 Favored Glycine 0 N--CA 1.444 -0.783 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 -177.671 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . -108.42 38.23 3.43 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.875 -0.679 . . . . 0.0 112.527 -179.334 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 298' ' ' SER . . . . . . . . . . . . . 20.1 m -127.49 151.01 49.4 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.14 0.495 . . . . 0.0 111.447 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 299' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -117.95 154.2 32.33 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.458 174.982 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 300' ' ' ALA . . . . . . . . . . . . . . . -122.4 149.44 43.81 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.667 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 301' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -110.55 115.3 29.37 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.358 0.599 . . . . 0.0 110.171 178.853 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 302' ' ' ARG . . . . . 0.631 ' HG3' ' H ' ' A' ' 303' ' ' VAL . 16.4 tpp180 -146.94 -178.89 6.44 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 303' ' ' VAL . . . . . 0.983 HG21 ' HB2' ' A' ' 284' ' ' TYR . 33.6 m -70.05 142.58 15.67 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.897 0 CA-C-O 121.709 0.766 . . . . 0.0 112.397 -171.419 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 304' ' ' GLN . . . . . 0.629 ' HA ' ' HB2' ' A' ' 279' ' ' ALA . 11.1 tm0? -91.43 120.8 32.58 Favored 'General case' 0 N--CA 1.444 -0.745 0 CA-C-N 114.543 -1.208 . . . . 0.0 108.16 172.82 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -94.95 144.73 17.36 Favored Glycine 0 N--CA 1.44 -1.046 0 C-N-CA 120.121 -1.038 . . . . 0.0 113.146 -172.672 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 306' ' ' GLU . . . . . 0.639 ' O ' ' HA2' ' A' ' 395' ' ' GLY . 5.4 mm-40 -114.73 86.3 12.76 Favored Pre-proline 0 C--N 1.32 -0.682 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 173.541 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo -60.98 122.87 11.86 Favored 'Trans proline' 0 N--CA 1.461 -0.404 0 C-N-CA 122.458 2.105 . . . . 0.0 112.249 -174.784 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 308' ' ' ALA . . . . . 0.787 ' O ' ' HB3' ' A' ' 375' ' ' ASN . . . -49.09 160.42 0.21 Allowed 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.148 169.291 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 309' ' ' LYS . . . . . 0.582 ' N ' HD23 ' A' ' 313' ' ' LEU . 79.2 mttt -127.01 91.46 3.34 Favored 'General case' 0 C--O 1.217 -0.611 0 O-C-N 121.798 -0.564 . . . . 0.0 109.817 -176.564 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -56.74 -23.46 44.47 Favored Glycine 0 CA--C 1.52 0.391 0 N-CA-C 114.873 0.709 . . . . 0.0 114.873 -168.298 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -87.65 -12.03 46.7 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 117.44 0.62 . . . . 0.0 111.574 178.392 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 14.8 tpt -115.5 -35.57 4.54 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.767 0.794 . . . . 0.0 109.511 -175.92 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 313' ' ' LEU . . . . . 0.78 HD22 ' HB1' ' A' ' 308' ' ' ALA . 0.4 OUTLIER -83.39 134.85 34.87 Favored 'General case' 0 N--CA 1.436 -1.169 0 CA-C-N 114.717 -1.128 . . . . 0.0 108.057 176.147 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 314' ' ' ALA . . . . . 0.644 ' HA ' ' CB ' ' A' ' 346' ' ' PHE . . . -161.91 173.18 14.85 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.177 0.513 . . . . 0.0 112.187 -170.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 121.71 168.67 13.43 Favored Glycine 0 N--CA 1.448 -0.531 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.277 -177.412 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 14.0 p -100.24 130.41 46.36 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 117.409 0.604 . . . . 0.0 109.94 174.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 317' ' ' ALA . . . . . 0.404 ' CB ' ' HE3' ' A' ' 424' ' ' LYS . . . -139.62 150.62 45.19 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 112.241 0.46 . . . . 0.0 112.241 -170.688 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 7.5 p -125.68 122.48 62.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.229 175.658 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 319' ' ' TYR . . . . . 0.413 ' O ' ' HA ' ' A' ' 341' ' ' ALA . 19.5 m-85 -111.99 146.61 37.55 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.732 -178.464 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 320' ' ' ASN . . . . . 0.455 ' HB2' ' HG3' ' A' ' 425' ' ' GLU . 17.1 m120 -129.97 137.29 50.23 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.108 175.665 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 321' ' ' GLY . . . . . 0.598 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -162.52 -163.02 14.33 Favored Glycine 0 N--CA 1.44 -1.055 0 C-N-CA 120.344 -0.932 . . . . 0.0 112.697 -178.745 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -117.93 146.17 44.16 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.654 0.264 . . . . 0.0 110.33 -175.305 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 323' ' ' VAL . . . . . 0.671 HG23 ' HB2' ' A' ' 340' ' ' PHE . 84.9 t -110.39 117.05 53.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.105 176.084 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 324' ' ' LEU . . . . . 0.436 HD12 ' CE1' ' A' ' 326' ' ' PHE . 0.2 OUTLIER -94.44 103.03 15.01 Favored 'General case' 0 C--N 1.312 -1.038 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 177.796 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 325' ' ' HIS . . . . . 0.437 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 8.3 p-80 -95.88 115.48 27.5 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.14 -179.199 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 326' ' ' PHE . . . . . 0.737 ' HB2' ' HD1' ' A' ' 417' ' ' PHE . 16.5 m-85 -95.5 158.51 15.42 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.895 -175.283 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 327' ' ' HIS . . . . . 0.689 ' HB2' ' HG3' ' A' ' 329' ' ' GLU . 19.0 m80 -135.67 159.67 40.92 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 107.861 -1.163 . . . . 0.0 107.861 174.129 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 328' ' ' THR . . . . . . . . . . . . . 11.0 m -82.68 93.69 7.42 Favored 'General case' 0 N--CA 1.442 -0.828 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 170.099 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 329' ' ' GLU . . . . . 0.689 ' HG3' ' HB2' ' A' ' 327' ' ' HIS . 43.9 mt-10 -110.2 174.36 5.9 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.232 -0.894 . . . . 0.0 111.548 -173.549 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 330' ' ' ASN . . . . . . . . . . . . . 28.2 p30 -72.93 -10.75 60.14 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.954 -177.885 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 331' ' ' GLY . . . . . . . . . . . . . . . -144.9 160.54 28.02 Favored Glycine 0 N--CA 1.445 -0.706 0 C-N-CA 120.953 -0.641 . . . . 0.0 111.604 178.967 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 332' ' ' ARG . . . . . 0.543 ' HA ' ' HD3' ' A' ' 332' ' ' ARG . 11.1 mmt180 -92.03 -11.61 0.17 Allowed Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 114.393 1.257 . . . . 0.0 114.393 178.88 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 333' ' ' PRO . . . . . 0.464 ' CD ' ' N ' ' A' ' 332' ' ' ARG . 39.0 Cg_exo -66.31 -151.13 0.02 OUTLIER 'Trans proline' 0 C--N 1.357 1.001 0 CA-C-N 120.819 1.328 . . . . 0.0 111.027 160.025 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 334' ' ' TYR . . . . . 0.611 ' N ' ' HD3' ' A' ' 335' ' ' PRO . 98.0 m-85 59.99 49.13 2.1 Favored Pre-proline 0 CA--C 1.537 0.479 0 N-CA-C 112.625 0.602 . . . . 0.0 112.625 178.995 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 335' ' ' PRO . . . . . 0.611 ' HD3' ' N ' ' A' ' 334' ' ' TYR . 6.1 Cg_endo -87.06 127.53 2.57 Favored 'Trans proline' 0 N--CA 1.452 -0.939 0 C-N-CA 121.833 1.688 . . . . 0.0 111.439 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 336' ' ' THR . . . . . . . . . . . . . 1.1 p -118.96 139.1 52.23 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.113 0.482 . . . . 0.0 111.388 179.475 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 337' ' ' ARG . . . . . 0.453 ' HA ' ' O ' ' A' ' 323' ' ' VAL . 17.4 ptp180 -119.25 142.92 47.61 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.786 -175.241 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -113.21 -176.69 19.49 Favored Glycine 0 N--CA 1.443 -0.869 0 CA-C-N 115.422 -0.808 . . . . 0.0 111.554 178.226 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 339' ' ' ARG . . . . . 0.426 ' HB2' ' HB3' ' A' ' 356' ' ' ASP . 73.6 mtt180 -104.91 131.16 52.76 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 120.747 0.308 . . . . 0.0 110.358 -175.085 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 340' ' ' PHE . . . . . 0.671 ' HB2' HG23 ' A' ' 323' ' ' VAL . 55.2 t80 -132.85 137.27 46.65 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-O 121.252 0.548 . . . . 0.0 111.472 -176.346 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 341' ' ' ALA . . . . . 0.413 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -139.48 143.85 37.71 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.137 -0.938 . . . . 0.0 108.999 174.512 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 342' ' ' ALA . . . . . 0.932 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -136.33 120.04 17.26 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-O 121.039 0.447 . . . . 0.0 110.84 -177.012 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -102.43 102.86 13.21 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.327 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 344' ' ' VAL . . . . . 0.446 ' HA ' ' HA ' ' A' ' 351' ' ' VAL . 0.3 OUTLIER -115.95 124.78 72.67 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 CA-C-O 121.6 0.714 . . . . 0.0 111.83 -172.649 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -97.44 98.59 10.07 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 172.917 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 346' ' ' PHE . . . . . 0.644 ' CB ' ' HA ' ' A' ' 314' ' ' ALA . 72.7 m-85 -65.27 -26.76 68.23 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.689 0.28 . . . . 0.0 111.259 -176.188 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -65.75 -19.57 67.44 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.831 -0.7 . . . . 0.0 111.843 178.001 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 11.9 t -112.03 -6.67 14.16 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.986 0.422 . . . . 0.0 110.058 177.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 349' ' ' LYS . . . . . 0.59 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 37.5 mtmm 52.61 59.12 4.71 Favored 'General case' 0 C--O 1.227 -0.098 0 CA-C-N 115.064 -0.971 . . . . 0.0 111.159 -176.013 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 68.1 p -149.32 138.35 21.3 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.181 179.809 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 351' ' ' VAL . . . . . 0.446 ' HA ' ' HA ' ' A' ' 344' ' ' VAL . 0.9 OUTLIER -123.89 151.77 28.95 Favored 'Isoleucine or valine' 0 C--O 1.235 0.334 0 CA-C-O 121.05 0.452 . . . . 0.0 110.789 -178.497 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 352' ' ' ASP . . . . . 0.932 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 21.3 t70 -112.02 118.4 35.33 Favored 'General case' 0 C--O 1.213 -0.857 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.353 173.444 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -119.82 119.01 4.1 Favored Glycine 0 N--CA 1.442 -0.925 0 C-N-CA 120.257 -0.973 . . . . 0.0 112.173 -176.781 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 354' ' ' ILE . . . . . 0.677 HD11 HG23 ' A' ' 365' ' ' THR . 0.0 OUTLIER -114.81 129.64 70.61 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.065 0 CA-C-O 121.038 0.447 . . . . 0.0 110.103 -178.125 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 355' ' ' ILE . . . . . 0.44 HD11 ' HE2' ' A' ' 368' ' ' PHE . 3.7 mp -120.7 113.87 41.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.159 -177.741 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 356' ' ' ASP . . . . . 0.426 ' HB3' ' HB2' ' A' ' 339' ' ' ARG . 10.2 t70 -102.79 141.78 35.02 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.429 176.024 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 23.2 t -110.88 8.72 22.32 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.384 178.309 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 358' ' ' GLY . . . . . 0.418 ' H ' ' CG ' ' A' ' 356' ' ' ASP . . . 113.83 24.43 4.61 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.95 -0.643 . . . . 0.0 112.976 177.32 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 359' ' ' ASP . . . . . 0.404 ' HB3' ' N ' ' A' ' 364' ' ' GLY . 14.0 t70 -153.0 104.54 2.84 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.069 0.461 . . . . 0.0 110.726 178.9 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 360' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -83.56 -9.38 58.97 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-O 121.062 0.458 . . . . 0.0 111.09 -179.157 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 361' ' ' LEU . . . . . . . . . . . . . 90.5 mt -71.39 -35.6 71.1 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.809 -174.681 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 362' ' ' HIS . . . . . . . . . . . . . 55.7 t-80 -178.65 -43.72 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 111.818 0.303 . . . . 0.0 111.818 178.86 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 363' ' ' MET . . . . . . . . . . . . . 15.7 tpt -78.42 -37.94 42.63 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 112.516 0.561 . . . . 0.0 112.516 -167.472 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 364' ' ' GLY . . . . . 0.404 ' N ' ' HB3' ' A' ' 359' ' ' ASP . . . -88.79 -42.28 5.75 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 119.962 -1.114 . . . . 0.0 113.134 -170.291 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 365' ' ' THR . . . . . 0.677 HG23 HD11 ' A' ' 354' ' ' ILE . 89.7 m -84.4 98.97 10.35 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.267 0.556 . . . . 0.0 112.496 -175.039 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 -109.53 165.43 11.67 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 168.702 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 19.3 pttp -148.23 151.33 35.29 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.191 0.519 . . . . 0.0 111.631 -179.121 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 368' ' ' PHE . . . . . 0.659 ' CD1' HG21 ' A' ' 389' ' ' VAL . 27.2 p90 -134.99 161.45 35.24 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.195 -0.911 . . . . 0.0 109.189 179.238 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 33.3 mtmm -131.62 150.9 51.99 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-O 121.264 0.554 . . . . 0.0 110.513 173.619 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -141.55 139.84 33.29 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.164 -173.701 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -92.69 130.73 38.23 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 174.223 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 372' ' ' ILE . . . . . 0.67 ' HA ' ' HB3' ' A' ' 377' ' ' PHE . 83.4 mt -79.45 108.17 12.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-O 121.758 0.79 . . . . 0.0 110.585 -176.322 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -110.58 82.38 1.58 Allowed 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 114.647 -1.16 . . . . 0.0 109.495 -178.712 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 59.48 119.29 0.01 OUTLIER Glycine 0 CA--C 1.52 0.402 0 CA-C-N 114.928 -1.033 . . . . 0.0 113.776 -177.146 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 375' ' ' ASN . . . . . 0.787 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 2.2 p-10 28.85 44.6 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 124.734 1.214 . . . . 0.0 114.123 177.238 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 160.59 -178.77 36.47 Favored Glycine 0 N--CA 1.442 -0.906 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 -178.693 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 377' ' ' PHE . . . . . 0.67 ' HB3' ' HA ' ' A' ' 372' ' ' ILE . 6.3 p90 -153.51 150.66 28.96 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 117.362 0.581 . . . . 0.0 111.783 -178.787 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 378' ' ' LYS . . . . . 0.555 ' H ' ' HD3' ' A' ' 378' ' ' LYS . 0.0 OUTLIER -117.77 140.59 49.47 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 171.102 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 379' ' ' GLY . . . . . 0.54 ' C ' HG22 ' A' ' 389' ' ' VAL . . . -149.06 -155.13 6.59 Favored Glycine 0 N--CA 1.44 -1.062 0 C-N-CA 120.504 -0.855 . . . . 0.0 112.235 -172.852 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 380' ' ' THR . . . . . 0.456 ' HA ' ' HA ' ' A' ' 388' ' ' ASP . 7.0 t -170.99 154.49 4.17 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 -173.52 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 381' ' ' TRP . . . . . 0.672 ' HD1' ' HA3' ' A' ' 387' ' ' GLY . 39.4 m95 -65.78 132.66 49.26 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.422 -179.597 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 382' ' ' THR . . . . . . . . . . . . . 19.4 m -87.29 -23.12 24.77 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.846 176.782 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 383' ' ' GLU . . . . . . . . . . . . . 28.4 mm-40 -100.34 -19.43 16.31 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.633 -175.345 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 384' ' ' ASN . . . . . . . . . . . . . 14.9 m120 -114.09 166.27 11.79 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.907 0.384 . . . . 0.0 110.719 -174.795 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 385' ' ' GLY . . . . . . . . . . . . . . . -126.28 75.35 0.41 Allowed Glycine 0 N--CA 1.445 -0.721 0 N-CA-C 111.549 -0.62 . . . . 0.0 111.549 177.9 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 386' ' ' GLY . . . . . . . . . . . . . . . 147.72 40.32 0.04 OUTLIER Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.668 -0.777 . . . . 0.0 111.95 -177.416 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 387' ' ' GLY . . . . . 0.672 ' HA3' ' HD1' ' A' ' 381' ' ' TRP . . . -154.03 114.38 0.62 Allowed Glycine 0 N--CA 1.443 -0.881 0 C-N-CA 121.108 -0.568 . . . . 0.0 111.965 178.562 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 388' ' ' ASP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 380' ' ' THR . 43.4 m-20 -107.73 147.33 30.92 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.027 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 389' ' ' VAL . . . . . 0.659 HG21 ' CD1' ' A' ' 368' ' ' PHE . 3.3 m -121.49 167.15 15.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 120.713 0.292 . . . . 0.0 111.589 -171.736 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 33.6 t -161.87 157.61 24.21 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 173.669 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -157.57 163.57 32.64 Favored Glycine 0 C--N 1.32 -0.308 0 N-CA-C 111.682 -0.567 . . . . 0.0 111.682 179.666 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 25.6 ttt180 -125.71 143.21 51.14 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.791 0.295 . . . . 0.0 110.313 -176.775 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 393' ' ' PHE . . . . . 0.582 ' CZ ' ' HE1' ' A' ' 346' ' ' PHE . 2.5 m-85 -92.92 157.45 16.34 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.432 0.634 . . . . 0.0 112.261 -175.433 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 394' ' ' TYR . . . . . 0.729 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 1.2 m-85 -102.5 -176.5 3.12 Favored 'General case' 0 C--O 1.22 -0.5 0 CA-C-N 114.816 -1.083 . . . . 0.0 110.372 178.615 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 395' ' ' GLY . . . . . 0.639 ' HA2' ' O ' ' A' ' 306' ' ' GLU . . . -36.67 153.64 0.01 OUTLIER Glycine 0 C--N 1.335 0.479 0 O-C-N 124.394 1.059 . . . . 0.0 114.941 -176.879 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_exo -16.15 -50.63 0.02 OUTLIER 'Trans proline' 0 C--N 1.351 0.691 1 C-N-CA 127.453 5.435 . . . . 0.0 117.724 -165.911 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 397' ' ' ALA . . . . . 0.537 ' HB3' ' HG2' ' A' ' 399' ' ' GLU . . . -75.46 -16.72 60.29 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 112.377 0.51 . . . . 0.0 112.377 -171.504 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 68.49 24.92 75.1 Favored Glycine 0 N--CA 1.447 -0.591 0 N-CA-C 111.769 -0.532 . . . . 0.0 111.769 179.538 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 399' ' ' GLU . . . . . 0.537 ' HG2' ' HB3' ' A' ' 397' ' ' ALA . 10.9 mm-40 -58.86 -16.54 17.86 Favored 'General case' 0 N--CA 1.463 0.208 0 C-N-CA 123.248 0.619 . . . . 0.0 111.557 -175.488 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 400' ' ' GLU . . . . . 0.409 ' HA ' ' O ' ' A' ' 422' ' ' GLY . 35.1 mt-10 -138.53 146.72 42.27 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 172.613 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 401' ' ' VAL . . . . . 0.488 HG21 ' CE2' ' A' ' 377' ' ' PHE . 7.3 p -144.54 133.01 17.92 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.398 177.032 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -124.61 132.22 53.44 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.332 -178.694 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -146.86 -172.14 16.82 Favored Glycine 0 N--CA 1.44 -1.049 0 C-N-CA 120.498 -0.858 . . . . 0.0 112.088 -179.139 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 404' ' ' LYS . . . . . 0.739 ' HG2' HG12 ' A' ' 419' ' ' VAL . 30.1 mtmt -146.51 158.43 43.9 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 179.815 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 405' ' ' TYR . . . . . 0.5 ' HB3' HG12 ' A' ' 389' ' ' VAL . 17.6 p90 -119.83 134.25 55.3 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 121.222 0.534 . . . . 0.0 110.579 176.58 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 406' ' ' SER . . . . . 0.505 ' O ' ' HA2' ' A' ' 387' ' ' GLY . 41.9 t -94.56 104.52 16.47 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.399 -177.388 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 48.7 p90 -120.11 140.04 51.66 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 175.472 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 408' ' ' ARG . . . . . 0.602 ' O ' ' HD3' ' A' ' 408' ' ' ARG . 0.0 OUTLIER -101.58 111.53 64.0 Favored Pre-proline 0 C--N 1.32 -0.711 0 CA-C-O 121.392 0.615 . . . . 0.0 111.262 179.079 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 409' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -72.08 -34.26 8.5 Favored 'Trans proline' 0 N--CA 1.463 -0.318 0 C-N-CA 122.763 2.309 . . . . 0.0 110.585 172.889 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 410' ' ' THR . . . . . . . . . . . . . 27.9 m -150.27 -46.71 0.13 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.412 176.093 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 411' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -142.72 -174.09 4.06 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.602 -179.546 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 412' ' ' ALA . . . . . . . . . . . . . . . 70.48 106.16 0.06 Allowed 'General case' 0 N--CA 1.465 0.316 0 O-C-N 124.156 0.91 . . . . 0.0 111.703 -179.112 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 413' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -103.12 38.49 1.75 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.896 0.855 . . . . 0.0 109.01 177.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 414' ' ' LYS . . . . . . . . . . . . . 56.6 mtpt -124.58 158.89 31.92 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.018 -0.992 . . . . 0.0 109.554 -176.932 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 415' ' ' GLY . . . . . . . . . . . . . . . -86.27 131.99 10.86 Favored Glycine 0 N--CA 1.447 -0.622 0 C-N-CA 120.265 -0.969 . . . . 0.0 111.987 -178.115 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 416' ' ' GLY . . . . . . . . . . . . . . . -163.13 -59.1 0.02 OUTLIER Glycine 0 N--CA 1.447 -0.597 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.15 -178.082 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 417' ' ' PHE . . . . . 0.737 ' HD1' ' HB2' ' A' ' 326' ' ' PHE . 71.5 m-85 -87.64 145.92 25.96 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 178.591 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 418' ' ' GLY . . . . . 0.512 ' H ' ' HD2' ' A' ' 326' ' ' PHE . . . 81.8 76.86 1.06 Allowed Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 120.339 -0.934 . . . . 0.0 112.567 176.992 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 419' ' ' VAL . . . . . 0.739 HG12 ' HG2' ' A' ' 404' ' ' LYS . 18.9 m -106.43 152.84 7.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 N-CA-C 110.207 -0.294 . . . . 0.0 110.207 179.441 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 420' ' ' PHE . . . . . 0.419 ' HB3' HG22 ' A' ' 323' ' ' VAL . 40.9 p90 -138.03 154.42 49.3 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 120.934 0.397 . . . . 0.0 110.273 -179.438 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 421' ' ' ALA . . . . . 0.598 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -142.24 136.02 29.42 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 177.112 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 422' ' ' GLY . . . . . 0.409 ' O ' ' HA ' ' A' ' 400' ' ' GLU . . . -118.1 135.6 11.76 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 120.67 -0.776 . . . . 0.0 111.974 -179.046 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 63.9 mttm -113.37 133.68 55.03 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.816 0.341 . . . . 0.0 110.359 -179.086 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 424' ' ' LYS . . . . . 0.404 ' HE3' ' CB ' ' A' ' 317' ' ' ALA . 23.6 tptm -60.92 112.05 1.9 Allowed 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.354 -177.736 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 425' ' ' GLU . . . . . 0.455 ' HG3' ' HB2' ' A' ' 320' ' ' ASN . 8.8 mm-40 -101.99 113.53 26.85 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.516 177.433 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 426' ' ' GLN . . . . . 0.475 ' HB3' ' HG ' ' A' ' 428' ' ' LEU . 27.0 mp0 -75.75 143.75 41.84 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.38 -179.259 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 427' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -69.71 -12.74 61.87 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.968 -175.367 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 428' ' ' LEU . . . . . 0.475 ' HG ' ' HB3' ' A' ' 426' ' ' GLN . 3.5 pp -69.9 -3.17 14.72 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.425 -177.576 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 429' ' ' GLU . . . . . 0.699 ' OE2' ' HA ' ' A' ' 431' ' ' HIS . 0.2 OUTLIER -66.28 145.53 55.64 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.939 0.4 . . . . 0.0 110.951 -178.523 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 430' ' ' HIS . . . . . . . . . . . . . 40.5 t60 -63.61 95.68 0.11 Allowed 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 167.338 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 431' ' ' HIS . . . . . 0.699 ' HA ' ' OE2' ' A' ' 429' ' ' GLU . 1.4 t60 -41.51 101.69 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.248 0 O-C-N 124.447 1.092 . . . . 0.0 112.587 -164.092 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 432' ' ' HIS . . . . . . . . . . . . . 68.0 m80 -85.04 -34.66 22.25 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.32 -176.525 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 433' ' ' HIS . . . . . . . . . . . . . 44.9 m-70 -93.98 106.21 18.2 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 177.51 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 434' ' ' HIS . . . . . . . . . . . . . 14.9 p80 -61.55 115.1 3.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.276 0.56 . . . . 0.0 109.819 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 435' ' ' HIS . . . . . . . . . . . . . 44.7 t-80 . . . . . 0 C--O 1.25 1.132 0 CA-C-O 118.405 -0.807 . . . . 0.0 109.077 -175.939 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 276' ' ' ASN . . . . . 0.595 HD21 ' N ' ' A' ' 276' ' ' ASN . 0.6 OUTLIER . . . . . 0 N--CA 1.485 1.309 0 CA-C-O 120.666 0.269 . . . . 0.0 110.488 . . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 13.0 mt -88.99 37.23 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.442 0 CA-C-O 121.807 0.813 . . . . 0.0 110.827 -176.39 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 278' ' ' PHE . . . . . . . . . . . . . 36.4 m-85 -89.57 72.96 7.81 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.487 0.661 . . . . 0.0 109.531 176.756 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 279' ' ' ALA . . . . . 0.417 ' HA ' ' HD3' ' A' ' 280' ' ' PRO . . . -75.85 145.32 77.78 Favored Pre-proline 0 C--N 1.325 -0.476 0 CA-C-N 115.19 -0.913 . . . . 0.0 111.537 -174.749 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 280' ' ' PRO . . . . . 0.417 ' HD3' ' HA ' ' A' ' 279' ' ' ALA . 36.2 Cg_exo -61.72 125.36 16.48 Favored 'Trans proline' 0 C--O 1.235 0.36 0 C-N-CA 122.99 2.46 . . . . 0.0 111.829 176.583 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 281' ' ' GLU . . . . . 0.445 ' O ' ' HG2' ' A' ' 281' ' ' GLU . 22.5 tt0 66.08 15.9 10.25 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 121.857 0.837 . . . . 0.0 110.606 -178.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -148.14 31.45 1.3 Allowed Glycine 0 N--CA 1.445 -0.704 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.616 179.348 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 283' ' ' ASN . . . . . . . . . . . . . 28.6 p30 -80.37 147.19 31.15 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.038 0.446 . . . . 0.0 110.044 179.179 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 284' ' ' TYR . . . . . 0.455 ' O ' ' HD2' ' A' ' 302' ' ' ARG . 20.2 m-85 -101.08 103.89 15.0 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.736 -176.812 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 285' ' ' ARG . . . . . 0.62 ' O ' ' HD3' ' A' ' 285' ' ' ARG . 3.4 tmt_? -123.61 -6.05 8.1 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 177.084 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 45.4 t80 -50.51 -56.78 10.08 Favored 'General case' 0 CA--C 1.521 -0.139 0 CA-C-N 115.179 -0.919 . . . . 0.0 109.361 177.356 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 287' ' ' LEU . . . . . . . . . . . . . 28.9 tp -152.82 127.57 9.5 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 170.33 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 288' ' ' THR . . . . . 0.546 ' O ' ' HG3' ' A' ' 304' ' ' GLN . 33.6 m -165.57 160.2 17.39 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -174.285 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 289' ' ' TYR . . . . . 0.748 ' O ' ' HB3' ' A' ' 301' ' ' LEU . 0.0 OUTLIER -125.61 -175.94 3.47 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 177.411 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.469 ' CA ' HG22 ' A' ' 303' ' ' VAL . . . -73.16 177.43 42.65 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.095 -1.05 . . . . 0.0 113.637 -166.275 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 291' ' ' ALA . . . . . 1.004 ' HA ' ' H ' ' A' ' 301' ' ' LEU . . . -93.45 114.32 26.69 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.588 -0.306 . . . . 0.0 111.279 -163.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 292' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -125.37 109.19 12.46 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 169.066 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 293' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -95.42 109.05 21.29 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.217 0.532 . . . . 0.0 111.363 -171.934 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 294' ' ' LEU . . . . . 0.597 HD23 ' HB2' ' A' ' 298' ' ' SER . 3.9 mm? -110.09 158.42 35.16 Favored Pre-proline 0 C--N 1.321 -0.648 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.353 175.318 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 295' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_exo -51.11 -55.69 3.79 Favored 'Trans proline' 0 C--O 1.237 0.44 0 C-N-CA 122.322 2.014 . . . . 0.0 112.194 178.073 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . -135.19 150.1 20.11 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.029 179.61 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 91.69 -72.91 1.65 Allowed Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.866 -0.683 . . . . 0.0 111.95 178.701 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 298' ' ' SER . . . . . 0.597 ' HB2' HD23 ' A' ' 294' ' ' LEU . 6.3 m -94.83 142.86 26.97 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.719 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 299' ' ' TYR . . . . . . . . . . . . . 19.1 p90 -140.54 178.11 7.55 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 -176.144 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 300' ' ' ALA . . . . . . . . . . . . . . . -77.78 126.25 30.58 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.345 0.593 . . . . 0.0 111.142 -173.903 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 301' ' ' LEU . . . . . 1.004 ' H ' ' HA ' ' A' ' 291' ' ' ALA . 7.4 mp -121.54 168.91 11.2 Favored 'General case' 0 CA--C 1.538 0.487 0 CA-C-N 114.616 -1.174 . . . . 0.0 111.767 -174.013 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 302' ' ' ARG . . . . . 0.455 ' HD2' ' O ' ' A' ' 284' ' ' TYR . 8.7 ptp180 -114.77 131.05 56.92 Favored 'General case' 0 C--N 1.318 -0.788 0 O-C-N 121.88 -0.513 . . . . 0.0 111.914 -174.469 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 303' ' ' VAL . . . . . 0.469 HG22 ' CA ' ' A' ' 290' ' ' GLY . 16.4 t -76.79 107.0 7.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.14 -179.339 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 304' ' ' GLN . . . . . 0.546 ' HG3' ' O ' ' A' ' 288' ' ' THR . 4.6 pp0? -91.53 175.32 6.95 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 168.501 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -92.06 106.32 3.38 Favored Glycine 0 N--CA 1.444 -0.818 0 C-N-CA 119.53 -1.319 . . . . 0.0 112.223 -173.43 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 306' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -84.88 135.63 39.75 Favored Pre-proline 0 C--N 1.325 -0.481 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 -178.109 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 307' ' ' PRO . . . . . 0.568 ' C ' ' HA2' ' A' ' 395' ' ' GLY . 66.6 Cg_endo -89.33 167.21 5.32 Favored 'Trans proline' 0 N--CA 1.453 -0.898 0 C-N-CA 122.832 2.354 . . . . 0.0 111.634 173.046 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 308' ' ' ALA . . . . . 0.59 ' HB1' HD21 ' A' ' 313' ' ' LEU . . . -61.11 161.1 9.07 Favored 'General case' 0 CA--C 1.515 -0.372 0 CA-C-O 121.372 0.606 . . . . 0.0 112.106 -175.513 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 309' ' ' LYS . . . . . . . . . . . . . 45.1 mttm -104.66 84.61 2.19 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 171.598 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 310' ' ' GLY . . . . . 0.705 ' HA3' ' O ' ' A' ' 374' ' ' GLY . . . -55.51 -34.25 59.81 Favored Glycine 0 CA--C 1.508 -0.35 0 CA-C-N 115.832 -0.622 . . . . 0.0 113.054 -173.623 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -45.6 -37.6 5.74 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 123.663 0.785 . . . . 0.0 112.288 175.629 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 73.2 mtm -131.08 31.75 4.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.718 0.294 . . . . 0.0 111.144 -177.381 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 313' ' ' LEU . . . . . 0.611 HD12 ' HA2' ' A' ' 310' ' ' GLY . 10.3 mt -65.79 -165.45 0.03 OUTLIER 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 112.387 0.514 . . . . 0.0 112.387 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -76.25 -168.98 1.05 Allowed 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -170.429 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 315' ' ' GLY . . . . . 0.616 ' O ' ' HB2' ' A' ' 346' ' ' PHE . . . -93.11 -122.64 3.3 Favored Glycine 0 C--O 1.223 -0.574 0 CA-C-N 115.019 -0.991 . . . . 0.0 111.469 178.278 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 18.0 p -96.56 131.68 42.94 Favored 'General case' 0 C--N 1.311 -1.074 0 O-C-N 122.28 -0.541 . . . . 0.0 110.912 177.684 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -142.92 162.2 36.11 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.587 -174.294 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 4.7 p -127.92 114.68 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.642 0 CA-C-O 121.452 0.644 . . . . 0.0 110.489 172.854 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 1.3 m-85 -98.89 155.42 17.4 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 175.925 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 320' ' ' ASN . . . . . 0.435 ' HA ' ' HA ' ' A' ' 341' ' ' ALA . 2.1 p-10 -157.83 156.11 30.88 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 120.855 0.359 . . . . 0.0 110.75 173.825 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 321' ' ' GLY . . . . . 0.412 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -176.81 -150.24 8.17 Favored Glycine 0 N--CA 1.443 -0.846 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.145 -178.646 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 23.5 mm-40 -112.98 149.76 32.83 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.779 0.323 . . . . 0.0 110.861 -173.431 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 323' ' ' VAL . . . . . 0.685 HG21 HG23 ' A' ' 355' ' ' ILE . 55.5 t -108.52 118.29 55.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.051 174.091 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 324' ' ' LEU . . . . . . . . . . . . . 92.2 mt -97.61 103.48 15.42 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.896 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 325' ' ' HIS . . . . . . . . . . . . . 26.3 t60 -98.97 112.73 24.76 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 -178.144 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 326' ' ' PHE . . . . . 0.625 ' HB2' ' HB3' ' A' ' 417' ' ' PHE . 30.3 m-85 -92.2 142.81 27.07 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.28 -0.418 . . . . 0.0 109.925 -173.78 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 327' ' ' HIS . . . . . . . . . . . . . 10.5 p80 -176.2 118.38 0.14 Allowed 'General case' 0 C--N 1.327 -0.384 0 O-C-N 123.475 0.484 . . . . 0.0 110.538 178.913 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 328' ' ' THR . . . . . . . . . . . . . 5.1 t -84.77 101.75 12.49 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.932 0.872 . . . . 0.0 109.144 174.591 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 329' ' ' GLU . . . . . 0.483 ' H ' ' HG3' ' A' ' 333' ' ' PRO . 42.8 tt0 -105.33 94.14 5.06 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.619 -175.642 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 330' ' ' ASN . . . . . . . . . . . . . 54.4 t30 56.68 42.33 27.08 Favored 'General case' 0 CA--C 1.528 0.102 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.009 177.355 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 331' ' ' GLY . . . . . 0.661 ' O ' ' HD3' ' A' ' 333' ' ' PRO . . . 134.68 -175.49 20.49 Favored Glycine 0 N--CA 1.444 -0.79 0 C-N-CA 120.379 -0.915 . . . . 0.0 111.578 -175.791 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 332' ' ' ARG . . . . . . . . . . . . . 8.5 mpt_? -91.74 100.31 3.25 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-O 120.646 0.26 . . . . 0.0 110.49 175.1 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 333' ' ' PRO . . . . . 0.661 ' HD3' ' O ' ' A' ' 331' ' ' GLY . 85.1 Cg_endo -98.06 177.36 0.44 Allowed 'Trans proline' 0 N--CA 1.449 -1.139 0 C-N-CA 123.339 2.693 . . . . 0.0 111.767 178.512 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 334' ' ' TYR . . . . . 0.453 ' OH ' ' HD2' ' A' ' 337' ' ' ARG . 60.6 t80 -88.49 120.73 70.4 Favored Pre-proline 0 C--N 1.322 -0.611 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 174.857 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 335' ' ' PRO . . . . . 0.432 ' HD2' ' HA ' ' A' ' 334' ' ' TYR . 8.8 Cg_endo -50.85 128.95 26.02 Favored 'Trans proline' 0 N--CA 1.462 -0.351 0 C-N-CA 122.776 2.317 . . . . 0.0 111.527 179.256 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 336' ' ' THR . . . . . . . . . . . . . 6.1 p -67.98 137.98 55.55 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-O 121.03 0.443 . . . . 0.0 110.294 -176.471 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 337' ' ' ARG . . . . . 0.453 ' HD2' ' OH ' ' A' ' 334' ' ' TYR . 18.5 mtp180 -105.31 113.44 27.02 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.054 -173.887 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -98.53 165.37 21.34 Favored Glycine 0 N--CA 1.436 -1.318 0 N-CA-C 110.132 -1.187 . . . . 0.0 110.132 173.734 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 339' ' ' ARG . . . . . 0.856 ' HB2' ' HB2' ' A' ' 356' ' ' ASP . 5.6 mpt_? -104.92 157.56 17.13 Favored 'General case' 0 C--N 1.313 -0.992 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 176.651 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 340' ' ' PHE . . . . . 0.75 ' HA ' ' O ' ' A' ' 354' ' ' ILE . 11.1 t80 -154.68 140.56 18.22 Favored 'General case' 0 C--N 1.313 -0.992 0 C-N-CA 120.496 -0.482 . . . . 0.0 111.35 -176.777 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 341' ' ' ALA . . . . . 0.435 ' HA ' ' HA ' ' A' ' 320' ' ' ASN . . . -136.81 165.75 25.2 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 174.351 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 342' ' ' ALA . . . . . 0.861 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -147.96 118.98 7.66 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-O 121.12 0.486 . . . . 0.0 111.222 -177.32 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 343' ' ' LYS . . . . . 0.531 ' HB3' ' HB2' ' A' ' 352' ' ' ASP . 27.0 tptp -87.28 98.0 11.09 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 174.96 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 344' ' ' VAL . . . . . 0.488 ' HA ' ' HA ' ' A' ' 351' ' ' VAL . 0.3 OUTLIER -115.95 117.31 55.12 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-O 121.816 0.817 . . . . 0.0 111.802 -172.718 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -95.44 94.11 7.61 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 114.282 -1.327 . . . . 0.0 108.591 175.48 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 346' ' ' PHE . . . . . 0.616 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 44.9 m-85 -65.54 -21.2 66.58 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.965 -174.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -62.28 -33.8 87.21 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.363 176.529 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 39.0 m -106.78 -6.57 17.67 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.163 0.506 . . . . 0.0 110.15 176.506 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 349' ' ' LYS . . . . . 0.775 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 22.4 mttm 53.79 62.71 2.49 Favored 'General case' 0 C--O 1.22 -0.466 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.89 -177.908 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 49.8 m -141.01 145.46 35.95 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.207 -0.906 . . . . 0.0 109.207 175.458 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 351' ' ' VAL . . . . . 0.517 HG22 ' HB3' ' A' ' 370' ' ' ALA . 0.9 OUTLIER -129.27 156.47 41.81 Favored 'Isoleucine or valine' 0 C--O 1.235 0.327 0 CA-C-O 120.856 0.36 . . . . 0.0 110.526 -176.999 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 352' ' ' ASP . . . . . 0.861 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 1.8 m-20 -121.13 118.0 28.58 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 170.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 353' ' ' GLY . . . . . 0.403 ' HA2' ' O ' ' A' ' 341' ' ' ALA . . . -111.13 124.02 6.75 Favored Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.11 -1.043 . . . . 0.0 112.435 -175.68 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 354' ' ' ILE . . . . . 0.75 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 1.0 OUTLIER -112.99 129.51 68.52 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-O 120.686 0.279 . . . . 0.0 110.455 -178.063 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 355' ' ' ILE . . . . . 0.685 HG23 HG21 ' A' ' 323' ' ' VAL . 4.3 mm -107.29 97.63 5.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.022 179.126 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 356' ' ' ASP . . . . . 0.856 ' HB2' ' HB2' ' A' ' 339' ' ' ARG . 16.8 m-20 -75.24 93.22 2.81 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.27 -0.423 . . . . 0.0 109.966 175.992 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 15.6 m -71.52 -13.86 61.93 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.941 178.677 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 358' ' ' GLY . . . . . . . . . . . . . . . 144.4 -35.16 1.57 Allowed Glycine 0 N--CA 1.446 -0.681 0 C-N-CA 120.757 -0.735 . . . . 0.0 111.81 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 359' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -141.02 99.24 3.55 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.061 0.457 . . . . 0.0 110.492 178.792 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 360' ' ' ASP . . . . . 0.649 ' HA ' ' OG1' ' A' ' 365' ' ' THR . 31.8 t70 -83.42 -7.56 59.54 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.361 175.807 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 361' ' ' LEU . . . . . 0.461 HD22 ' N ' ' A' ' 361' ' ' LEU . 2.9 mm? -73.06 -36.09 66.82 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 115.665 -0.698 . . . . 0.0 112.578 -170.665 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 362' ' ' HIS . . . . . . . . . . . . . 23.2 t-80 -167.79 -14.95 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.245 0 N-CA-C 112.8 0.667 . . . . 0.0 112.8 178.511 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 363' ' ' MET . . . . . . . . . . . . . 54.7 ttp -59.65 -32.18 70.21 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.79 0.328 . . . . 0.0 111.672 -176.484 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 364' ' ' GLY . . . . . . . . . . . . . . . 114.18 72.44 0.56 Allowed Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.662 -0.78 . . . . 0.0 111.777 179.416 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 365' ' ' THR . . . . . 0.649 ' OG1' ' HA ' ' A' ' 360' ' ' ASP . 0.0 OUTLIER -78.35 158.05 28.91 Favored 'General case' 0 N--CA 1.435 -1.194 0 CA-C-O 120.886 0.374 . . . . 0.0 111.277 -177.65 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 89.6 mm-40 -107.85 141.8 38.88 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 177.672 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -153.63 154.37 34.07 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 176.216 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 368' ' ' PHE . . . . . 0.507 ' HB3' ' CE3' ' A' ' 381' ' ' TRP . 47.2 p90 -136.05 160.21 39.35 Favored 'General case' 0 C--N 1.319 -0.757 0 O-C-N 123.437 0.46 . . . . 0.0 109.836 -176.41 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 369' ' ' LYS . . . . . 0.513 ' HG3' ' O ' ' A' ' 351' ' ' VAL . 26.9 tttp -127.6 132.87 49.74 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 174.119 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 370' ' ' ALA . . . . . 0.517 ' HB3' HG22 ' A' ' 351' ' ' VAL . . . -128.85 148.46 50.89 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.182 -172.065 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -104.41 129.27 52.37 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.947 176.964 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 372' ' ' ILE . . . . . 0.775 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 93.3 mt -81.86 103.81 9.53 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.638 0 CA-C-O 121.925 0.869 . . . . 0.0 109.747 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 19.1 t0 -107.8 96.99 6.77 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 114.375 -1.284 . . . . 0.0 108.859 178.277 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 374' ' ' GLY . . . . . 0.705 ' O ' ' HA3' ' A' ' 310' ' ' GLY . . . 92.51 -123.32 7.24 Favored Glycine 0 N--CA 1.441 -0.981 0 C-N-CA 120.621 -0.799 . . . . 0.0 111.244 -174.254 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 375' ' ' ASN . . . . . 0.4 HD22 ' HB2' ' A' ' 307' ' ' PRO . 42.3 p-10 -114.15 35.63 4.07 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.925 0.869 . . . . 0.0 110.82 -175.244 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . -177.93 171.59 44.12 Favored Glycine 0 N--CA 1.443 -0.855 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 -176.295 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 377' ' ' PHE . . . . . 0.486 ' HD2' HG12 ' A' ' 372' ' ' ILE . 6.7 p90 -131.57 145.69 51.84 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 117.715 0.757 . . . . 0.0 112.616 -176.129 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 378' ' ' LYS . . . . . 0.461 ' H ' ' HD2' ' A' ' 378' ' ' LYS . 0.0 OUTLIER -119.68 134.33 55.27 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 114.578 -1.192 . . . . 0.0 108.167 171.676 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -150.3 -169.68 16.65 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.062 -1.066 . . . . 0.0 112.986 -175.597 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 15.1 t -147.46 153.68 39.86 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -175.849 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 381' ' ' TRP . . . . . 0.507 ' CE3' ' HB3' ' A' ' 368' ' ' PHE . 61.4 m95 -59.65 130.29 46.09 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.985 0.421 . . . . 0.0 110.282 179.672 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 382' ' ' THR . . . . . . . . . . . . . 37.5 m -61.3 -35.77 78.26 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.154 -0.93 . . . . 0.0 112.944 -169.099 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 383' ' ' GLU . . . . . 0.501 ' OE1' ' HB3' ' A' ' 381' ' ' TRP . 0.0 OUTLIER -87.51 -49.2 7.35 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.545 -0.462 . . . . 0.0 110.708 -179.548 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 384' ' ' ASN . . . . . . . . . . . . . 40.0 t-20 -166.93 -72.68 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 175.882 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 385' ' ' GLY . . . . . 0.441 ' HA3' ' HB2' ' A' ' 381' ' ' TRP . . . 78.75 -65.46 3.48 Favored Glycine 0 N--CA 1.45 -0.42 0 CA-C-N 116.076 -0.511 . . . . 0.0 112.856 178.557 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 386' ' ' GLY . . . . . . . . . . . . . . . 86.36 27.76 29.47 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.931 -0.652 . . . . 0.0 111.738 -177.03 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -145.61 -157.95 7.49 Favored Glycine 0 N--CA 1.445 -0.75 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.105 -178.069 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -142.16 134.82 28.29 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 110.204 -0.295 . . . . 0.0 110.204 -178.593 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 38.2 t -112.95 133.87 57.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.347 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 31.7 m -144.61 143.3 30.71 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.076 0.465 . . . . 0.0 111.224 178.229 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -157.4 157.17 27.89 Favored Glycine 0 N--CA 1.445 -0.763 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 178.63 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 11.3 ptp180 -136.02 150.74 49.32 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 117.405 0.602 . . . . 0.0 110.764 -175.3 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 393' ' ' PHE . . . . . 0.481 ' CD1' ' HB ' ' A' ' 401' ' ' VAL . 95.1 m-85 -84.49 167.75 16.09 Favored 'General case' 0 CA--C 1.496 -1.098 0 CA-C-O 122.134 0.969 . . . . 0.0 111.184 -178.084 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 394' ' ' TYR . . . . . 0.569 ' HD1' ' N ' ' A' ' 394' ' ' TYR . 0.6 OUTLIER -97.56 -179.11 4.36 Favored 'General case' 0 N--CA 1.428 -1.562 0 N-CA-C 105.621 -1.992 . . . . 0.0 105.621 173.153 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 395' ' ' GLY . . . . . 0.568 ' HA2' ' C ' ' A' ' 307' ' ' PRO . . . -51.48 -148.16 0.0 OUTLIER Glycine 0 N--CA 1.474 1.168 0 O-C-N 124.497 1.123 . . . . 0.0 115.754 -172.314 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -57.67 -10.86 7.88 Favored 'Trans proline' 0 CA--C 1.539 0.729 0 C-N-CA 121.227 1.285 . . . . 0.0 111.042 176.192 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 397' ' ' ALA . . . . . 0.489 ' C ' ' H ' ' A' ' 399' ' ' GLU . . . -93.97 27.66 2.71 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 114.77 -1.104 . . . . 0.0 110.811 174.127 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . -53.6 8.54 0.01 OUTLIER Glycine 0 N--CA 1.469 0.87 0 C-N-CA 124.069 0.842 . . . . 0.0 114.599 176.079 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 399' ' ' GLU . . . . . 0.489 ' H ' ' C ' ' A' ' 397' ' ' ALA . 3.7 mp0 -59.97 -9.99 3.66 Favored 'General case' 0 C--N 1.323 -0.587 0 C-N-CA 123.929 0.892 . . . . 0.0 110.019 166.676 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 -119.21 125.05 48.24 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-N 115.344 -0.844 . . . . 0.0 109.439 174.15 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 401' ' ' VAL . . . . . 0.481 ' HB ' ' CD1' ' A' ' 393' ' ' PHE . 12.2 p -132.71 141.12 45.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 176.607 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -130.01 137.56 50.33 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-O 120.761 0.315 . . . . 0.0 110.679 178.902 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -144.88 177.03 23.62 Favored Glycine 0 N--CA 1.439 -1.161 0 C-N-CA 120.458 -0.877 . . . . 0.0 112.143 179.805 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 404' ' ' LYS . . . . . 0.454 ' CG ' HG12 ' A' ' 419' ' ' VAL . 0.0 OUTLIER -141.13 155.7 46.07 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 176.905 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 19.7 p90 -119.42 133.58 55.64 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-O 120.977 0.417 . . . . 0.0 110.287 176.851 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 49.1 m -92.29 103.84 16.25 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 177.359 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 37.5 p90 -66.38 149.67 50.05 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.976 177.27 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 408' ' ' ARG . . . . . 0.425 ' HA ' ' HD3' ' A' ' 409' ' ' PRO . 37.6 ttt180 -59.78 117.45 23.19 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.517 -179.649 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 409' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 408' ' ' ARG . 18.1 Cg_exo -66.31 84.64 0.27 Allowed 'Trans proline' 0 N--CA 1.464 -0.225 0 C-N-CA 123.059 2.506 . . . . 0.0 112.128 -178.7 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 410' ' ' THR . . . . . . . . . . . . . 9.8 m -91.71 99.84 12.66 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.865 179.003 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 411' ' ' ASP . . . . . . . . . . . . . 26.4 t70 73.7 -36.62 0.35 Allowed 'General case' 0 N--CA 1.471 0.612 0 C-N-CA 123.831 0.852 . . . . 0.0 110.95 -176.195 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 412' ' ' ALA . . . . . . . . . . . . . . . -59.17 139.13 57.23 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.488 175.031 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 413' ' ' GLU . . . . . 0.629 ' HG2' ' HG2' ' A' ' 414' ' ' LYS . 0.5 OUTLIER -80.25 -23.85 40.54 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.202 -172.035 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 414' ' ' LYS . . . . . 0.629 ' HG2' ' HG2' ' A' ' 413' ' ' GLU . 21.9 pttp -156.25 166.46 33.37 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.985 0.421 . . . . 0.0 111.089 -178.044 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 415' ' ' GLY . . . . . . . . . . . . . . . -139.74 179.36 18.92 Favored Glycine 0 N--CA 1.448 -0.506 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.205 -179.411 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 416' ' ' GLY . . . . . . . . . . . . . . . 142.62 -10.54 2.41 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.269 -0.967 . . . . 0.0 112.388 -178.213 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 417' ' ' PHE . . . . . 0.625 ' HB3' ' HB2' ' A' ' 326' ' ' PHE . 73.8 m-85 -81.81 170.16 16.03 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 175.427 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 82.8 76.99 1.1 Allowed Glycine 0 N--CA 1.449 -0.467 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.374 -177.938 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 419' ' ' VAL . . . . . 0.454 HG12 ' CG ' ' A' ' 404' ' ' LYS . 19.8 m -106.4 167.36 3.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 -179.34 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 45.9 p90 -148.24 162.69 38.98 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-O 120.796 0.331 . . . . 0.0 110.144 178.077 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 421' ' ' ALA . . . . . 0.412 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -142.85 135.39 27.67 Favored 'General case' 0 C--N 1.316 -0.877 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 177.994 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -122.95 135.72 10.2 Favored Glycine 0 N--CA 1.441 -1.021 0 C-N-CA 120.749 -0.739 . . . . 0.0 111.451 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 60.3 mttm -118.93 139.8 51.05 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-O 121.041 0.448 . . . . 0.0 110.354 179.442 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 424' ' ' LYS . . . . . . . . . . . . . 5.6 tppp? -60.06 122.41 14.3 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.011 -0.995 . . . . 0.0 111.86 -177.904 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -103.18 112.92 26.02 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 166.758 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 426' ' ' GLN . . . . . 0.731 ' HB2' HD23 ' A' ' 428' ' ' LEU . 10.6 pt20 -109.59 130.69 55.49 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.659 0.742 . . . . 0.0 111.286 -171.742 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 427' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -84.87 9.52 14.1 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.16 -0.927 . . . . 0.0 110.317 -175.94 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 428' ' ' LEU . . . . . 0.731 HD23 ' HB2' ' A' ' 426' ' ' GLN . 3.6 mm? -67.73 -16.06 63.94 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.408 -0.814 . . . . 0.0 110.831 179.585 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 429' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -61.92 -32.2 72.57 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.552 0.691 . . . . 0.0 110.062 174.086 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 430' ' ' HIS . . . . . . . . . . . . . 36.4 m80 -94.67 145.09 25.08 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.569 -176.394 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 76.2 t60 -149.19 119.1 7.1 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.069 0.461 . . . . 0.0 111.164 178.662 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 432' ' ' HIS . . . . . . . . . . . . . 39.1 m-70 -131.46 165.86 22.6 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 175.767 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 433' ' ' HIS . . . . . . . . . . . . . 3.1 t-160 -162.34 -35.7 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.905 0.383 . . . . 0.0 110.874 176.958 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 434' ' ' HIS . . . . . . . . . . . . . 26.6 t-80 -85.85 -39.89 16.55 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 175.094 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 435' ' ' HIS . . . . . . . . . . . . . 72.5 t60 . . . . . 0 C--O 1.25 1.102 0 CA-C-O 117.725 -1.131 . . . . 0.0 108.764 174.018 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 276' ' ' ASN . . . . . 0.435 ' CG ' ' HD2' ' A' ' 299' ' ' TYR . 56.2 t30 . . . . . 0 N--CA 1.48 1.059 0 CA-C-O 121.178 0.514 . . . . 0.0 110.681 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 10.5 tp -99.6 -16.27 7.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 121.306 0.574 . . . . 0.0 110.49 178.151 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 278' ' ' PHE . . . . . 0.44 ' HE2' ' N ' ' A' ' 301' ' ' LEU . 28.3 p90 38.5 31.92 0.05 OUTLIER 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 125.244 1.418 . . . . 0.0 114.168 178.12 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -168.5 149.1 4.34 Favored Pre-proline 0 N--CA 1.452 -0.329 0 CA-C-N 116.679 -0.237 . . . . 0.0 110.652 -178.214 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 280' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -65.46 128.42 20.21 Favored 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 122.481 2.121 . . . . 0.0 110.519 171.551 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 281' ' ' GLU . . . . . 0.44 ' HA ' HD11 ' A' ' 287' ' ' LEU . 43.3 mt-10 -62.85 92.24 0.05 OUTLIER 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.696 0.76 . . . . 0.0 111.756 -176.935 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 156.53 32.41 0.02 OUTLIER Glycine 0 N--CA 1.444 -0.789 0 CA-C-N 114.668 -1.151 . . . . 0.0 110.402 -178.609 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 283' ' ' ASN . . . . . 0.535 ' H ' HD13 ' A' ' 287' ' ' LEU . 15.2 t-20 -133.43 147.62 51.73 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 -179.194 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 284' ' ' TYR . . . . . 0.43 ' C ' ' H ' ' A' ' 286' ' ' TYR . 2.3 m-85 -100.21 145.16 28.38 Favored 'General case' 0 C--N 1.316 -0.86 0 C-N-CA 120.554 -0.458 . . . . 0.0 111.114 -173.588 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 17.9 mmm180 73.38 -27.48 0.19 Allowed 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.206 -172.186 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.43 ' H ' ' C ' ' A' ' 284' ' ' TYR . 35.8 m-85 -80.62 -22.66 40.38 Favored 'General case' 0 N--CA 1.444 -0.745 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 163.606 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 287' ' ' LEU . . . . . 0.623 HD23 ' HA ' ' A' ' 304' ' ' GLN . 5.8 mp -116.85 129.03 55.82 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.613 165.866 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 288' ' ' THR . . . . . 0.548 ' N ' ' HG3' ' A' ' 304' ' ' GLN . 9.1 m -168.51 171.73 8.74 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 105.97 -1.863 . . . . 0.0 105.97 -178.276 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 289' ' ' TYR . . . . . 0.414 ' N ' HG22 ' A' ' 288' ' ' THR . 12.2 m-85 -108.55 117.19 33.53 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 119.167 0.894 . . . . 0.0 109.671 167.737 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 122.43 136.18 4.83 Favored Glycine 0 C--N 1.334 0.446 0 C-N-CA 120.553 -0.832 . . . . 0.0 111.292 -178.188 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 291' ' ' ALA . . . . . 0.791 ' HB1' ' HA ' ' A' ' 301' ' ' LEU . . . -165.71 164.85 18.93 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 112.076 0.399 . . . . 0.0 112.076 -172.171 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 292' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -127.28 114.48 17.68 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.416 173.485 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 293' ' ' LYS . . . . . 0.452 ' HE3' ' HB3' ' A' ' 299' ' ' TYR . 88.5 tttt -75.82 126.86 31.81 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 175.748 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 294' ' ' LEU . . . . . 0.601 HD22 ' HB2' ' A' ' 298' ' ' SER . 7.2 mp -65.72 124.18 86.75 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-O 120.743 0.306 . . . . 0.0 110.573 -175.045 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 295' ' ' PRO . . . . . 0.507 ' HD3' ' HA ' ' A' ' 294' ' ' LEU . 17.0 Cg_exo -67.68 81.33 0.45 Allowed 'Trans proline' 0 C--O 1.235 0.357 0 C-N-CA 123.229 2.619 . . . . 0.0 112.164 -178.608 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . 165.51 -109.76 0.38 Allowed Glycine 0 N--CA 1.443 -0.868 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.948 178.963 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . -97.94 -41.3 3.34 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.908 -0.663 . . . . 0.0 113.324 -176.335 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 298' ' ' SER . . . . . 0.601 ' HB2' HD22 ' A' ' 294' ' ' LEU . 69.3 m -80.08 152.29 29.42 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.477 0.656 . . . . 0.0 111.663 -174.592 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 299' ' ' TYR . . . . . 0.452 ' HB3' ' HE3' ' A' ' 293' ' ' LYS . 13.8 p90 -134.89 135.38 41.58 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.23 -0.896 . . . . 0.0 108.893 178.587 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 300' ' ' ALA . . . . . 0.422 ' N ' HD21 ' A' ' 276' ' ' ASN . . . -157.37 119.84 3.88 Favored 'General case' 0 C--N 1.331 -0.225 0 C-N-CA 120.985 -0.286 . . . . 0.0 111.76 -176.44 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 301' ' ' LEU . . . . . 0.791 ' HA ' ' HB1' ' A' ' 291' ' ' ALA . 1.8 pp -143.33 155.77 44.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.133 0.492 . . . . 0.0 111.209 171.017 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 302' ' ' ARG . . . . . 0.607 ' H ' ' HB2' ' A' ' 291' ' ' ALA . 80.9 mtm180 -108.87 134.59 51.35 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.717 -178.556 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 303' ' ' VAL . . . . . 0.43 HG23 HD12 ' A' ' 301' ' ' LEU . 95.7 t -132.95 124.18 49.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.296 175.938 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 304' ' ' GLN . . . . . 0.623 ' HA ' HD23 ' A' ' 287' ' ' LEU . 44.7 mt-30 -90.5 141.78 28.41 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.28 176.839 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -97.34 105.66 3.21 Favored Glycine 0 N--CA 1.446 -0.651 0 N-CA-C 110.457 -1.057 . . . . 0.0 110.457 173.068 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 306' ' ' GLU . . . . . . . . . . . . . 34.9 mm-40 -103.57 134.73 19.59 Favored Pre-proline 0 C--N 1.321 -0.631 0 CA-C-O 120.849 0.357 . . . . 0.0 111.683 -173.524 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -78.57 160.98 28.28 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 122.24 1.96 . . . . 0.0 109.478 164.912 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 308' ' ' ALA . . . . . 0.753 ' HB1' HD11 ' A' ' 313' ' ' LEU . . . -49.45 118.95 3.03 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 121.118 0.485 . . . . 0.0 111.366 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 309' ' ' LYS . . . . . 0.452 ' O ' ' HG ' ' A' ' 313' ' ' LEU . 24.8 mmmt -73.95 81.5 1.68 Allowed 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -177.578 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 310' ' ' GLY . . . . . 0.708 ' HA2' HD12 ' A' ' 313' ' ' LEU . . . -52.56 -40.48 55.06 Favored Glycine 0 C--N 1.333 0.387 0 O-C-N 123.332 0.395 . . . . 0.0 113.145 -174.445 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 311' ' ' GLU . . . . . 0.552 ' HG3' ' HG3' ' A' ' 312' ' ' MET . 10.1 pt-20 -56.63 -28.26 60.13 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 122.635 0.374 . . . . 0.0 111.923 177.307 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 312' ' ' MET . . . . . 0.552 ' HG3' ' HG3' ' A' ' 311' ' ' GLU . 76.3 mtm -113.83 1.97 14.96 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.687 0.28 . . . . 0.0 111.352 -177.424 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 313' ' ' LEU . . . . . 0.753 HD11 ' HB1' ' A' ' 308' ' ' ALA . 78.8 mt -72.69 131.04 41.87 Favored 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 175.598 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -143.9 143.67 31.38 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.569 -173.042 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 121.66 169.87 13.73 Favored Glycine 0 N--CA 1.445 -0.743 0 C-N-CA 120.981 -0.628 . . . . 0.0 111.843 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 25.4 p -107.32 133.04 52.44 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 175.242 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -142.03 160.26 40.58 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 121.271 0.557 . . . . 0.0 112.076 -172.912 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 6.1 p -129.13 115.93 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.878 174.512 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 319' ' ' TYR . . . . . 0.578 ' CZ ' ' HB2' ' A' ' 424' ' ' LYS . 2.0 m-85 -98.07 128.74 44.77 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 179.09 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -131.37 144.05 50.94 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 120.868 0.366 . . . . 0.0 110.727 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -173.67 -143.89 4.5 Favored Glycine 0 N--CA 1.443 -0.855 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.007 -179.722 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -119.48 147.81 43.99 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.832 0.349 . . . . 0.0 110.975 -175.163 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 323' ' ' VAL . . . . . 0.717 HG13 ' HB2' ' A' ' 340' ' ' PHE . 4.5 m -106.71 117.04 51.75 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 CA-C-N 115.846 -0.616 . . . . 0.0 109.391 168.027 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 324' ' ' LEU . . . . . 0.544 ' HB2' HG22 ' A' ' 419' ' ' VAL . 97.5 mt -91.63 101.94 14.57 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 177.895 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 325' ' ' HIS . . . . . 0.489 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 6.2 p80 -102.41 117.67 35.21 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.754 0.788 . . . . 0.0 109.766 -176.333 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 326' ' ' PHE . . . . . 0.782 ' HD2' ' HB3' ' A' ' 417' ' ' PHE . 58.4 m-85 -94.27 173.68 7.52 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.649 -1.16 . . . . 0.0 111.22 -168.521 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 327' ' ' HIS . . . . . . . . . . . . . 8.2 p-80 -173.73 148.63 1.5 Allowed 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.112 -174.428 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 328' ' ' THR . . . . . . . . . . . . . 15.8 p -64.73 122.25 16.43 Favored 'General case' 0 C--N 1.327 -0.378 0 O-C-N 123.263 0.352 . . . . 0.0 110.128 177.233 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 329' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -63.48 128.15 34.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.266 0.555 . . . . 0.0 111.637 -174.539 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 330' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -96.34 -32.57 12.32 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.219 173.469 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 331' ' ' GLY . . . . . . . . . . . . . . . -173.29 117.32 0.64 Allowed Glycine 0 N--CA 1.442 -0.901 0 CA-C-N 115.21 -0.905 . . . . 0.0 111.341 178.947 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 332' ' ' ARG . . . . . 0.412 ' NH2' ' HB2' ' A' ' 334' ' ' TYR . 0.2 OUTLIER 68.49 88.55 0.1 Allowed Pre-proline 0 C--N 1.33 -0.282 0 C-N-CA 122.888 0.475 . . . . 0.0 109.986 -179.026 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 333' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo -60.94 110.39 0.84 Allowed 'Trans proline' 0 C--N 1.343 0.243 0 C-N-CA 123.016 2.477 . . . . 0.0 112.809 -176.142 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 334' ' ' TYR . . . . . 0.412 ' HB2' ' NH2' ' A' ' 332' ' ' ARG . 86.8 t80 -132.83 113.51 13.87 Favored Pre-proline 0 C--N 1.322 -0.618 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.767 177.038 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 335' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_exo -70.22 126.83 13.44 Favored 'Trans proline' 0 N--CA 1.456 -0.686 0 C-N-CA 122.126 1.884 . . . . 0.0 109.978 171.254 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 336' ' ' THR . . . . . . . . . . . . . 1.3 m -97.96 148.33 23.58 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -176.683 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 337' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.97 135.03 54.19 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.53 0.681 . . . . 0.0 111.487 -176.882 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 338' ' ' GLY . . . . . 0.412 ' HA3' ' CG2' ' A' ' 323' ' ' VAL . . . -106.46 -175.42 23.29 Favored Glycine 0 N--CA 1.437 -1.251 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 170.032 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 339' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -111.29 131.56 55.06 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 117.222 0.511 . . . . 0.0 109.799 178.109 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 340' ' ' PHE . . . . . 0.717 ' HB2' HG13 ' A' ' 323' ' ' VAL . 10.9 t80 -127.37 133.53 50.02 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.793 -178.182 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 341' ' ' ALA . . . . . 0.471 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -131.9 160.7 34.94 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.613 175.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 342' ' ' ALA . . . . . 0.889 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -147.83 119.4 7.97 Favored 'General case' 0 N--CA 1.442 -0.844 0 CA-C-O 121.204 0.526 . . . . 0.0 110.446 -177.7 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 343' ' ' LYS . . . . . 0.442 ' HB3' ' HB2' ' A' ' 352' ' ' ASP . 6.3 tmtt? -91.68 98.74 11.82 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 178.363 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 344' ' ' VAL . . . . . 0.617 ' HB ' HG12 ' A' ' 351' ' ' VAL . 0.2 OUTLIER -118.51 128.52 75.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-O 121.794 0.806 . . . . 0.0 112.239 -172.189 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -108.14 110.62 22.32 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 114.489 -1.232 . . . . 0.0 108.419 174.443 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 346' ' ' PHE . . . . . 0.478 ' HZ ' ' OH ' ' A' ' 319' ' ' TYR . 64.8 m-85 -73.16 -18.74 61.24 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.705 0.288 . . . . 0.0 111.732 -176.291 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -62.77 -28.19 71.27 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.475 -0.869 . . . . 0.0 111.249 176.199 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 20.5 t -112.46 -10.12 13.76 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-N 115.897 -0.151 . . . . 0.0 110.974 177.72 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 349' ' ' LYS . . . . . 0.643 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 35.2 mttp 57.23 59.46 3.37 Favored 'General case' 0 C--O 1.224 -0.275 0 CA-C-O 121.58 0.705 . . . . 0.0 110.646 -178.308 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 8.6 t -146.86 152.61 39.01 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.296 177.755 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 351' ' ' VAL . . . . . 0.728 HG22 ' HB3' ' A' ' 370' ' ' ALA . 1.2 m -134.8 155.25 38.12 Favored 'Isoleucine or valine' 0 C--O 1.236 0.382 0 CA-C-O 121.205 0.526 . . . . 0.0 110.836 -176.786 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 352' ' ' ASP . . . . . 0.889 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 1.2 m-20 -110.7 117.91 34.74 Favored 'General case' 0 C--O 1.215 -0.728 0 CA-C-N 115.244 -0.889 . . . . 0.0 108.692 168.925 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -110.91 124.43 6.96 Favored Glycine 0 N--CA 1.441 -1.03 0 C-N-CA 120.193 -1.003 . . . . 0.0 111.562 -176.954 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 354' ' ' ILE . . . . . 0.472 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -122.05 129.73 75.15 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 CA-C-O 121.187 0.518 . . . . 0.0 109.85 -177.058 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 355' ' ' ILE . . . . . 0.617 HG23 HG21 ' A' ' 323' ' ' VAL . 4.2 mp -122.34 108.7 22.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.858 -178.57 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 356' ' ' ASP . . . . . 0.466 ' HA ' ' O ' ' A' ' 364' ' ' GLY . 0.0 OUTLIER -121.24 134.42 55.18 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 175.142 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 23.8 m -105.61 9.8 33.18 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.524 -179.123 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 358' ' ' GLY . . . . . . . . . . . . . . . 85.1 11.87 75.12 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 120.745 -0.741 . . . . 0.0 111.728 -176.408 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 359' ' ' ASP . . . . . 0.822 ' HB2' ' HA3' ' A' ' 364' ' ' GLY . 52.6 m-20 -116.7 52.46 0.94 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.211 0.529 . . . . 0.0 109.607 179.207 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 360' ' ' ASP . . . . . 0.644 ' HA ' ' OG1' ' A' ' 365' ' ' THR . 2.2 m-20 -62.1 -19.51 63.06 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 115.107 -0.951 . . . . 0.0 112.342 -175.403 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 361' ' ' LEU . . . . . . . . . . . . . 89.6 mt -82.54 8.21 12.38 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.598 -0.274 . . . . 0.0 111.516 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 362' ' ' HIS . . . . . 0.463 ' HB3' ' H ' ' A' ' 363' ' ' MET . 0.1 OUTLIER -160.59 -128.97 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 120.974 -0.29 . . . . 0.0 111.115 176.732 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 363' ' ' MET . . . . . 0.463 ' H ' ' HB3' ' A' ' 362' ' ' HIS . 0.0 OUTLIER -78.48 -4.19 47.27 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 112.346 0.499 . . . . 0.0 112.346 -173.5 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 364' ' ' GLY . . . . . 0.822 ' HA3' ' HB2' ' A' ' 359' ' ' ASP . . . -75.47 4.21 43.69 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 121.008 -0.615 . . . . 0.0 113.544 -172.693 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 365' ' ' THR . . . . . 0.644 ' OG1' ' HA ' ' A' ' 360' ' ' ASP . 32.5 m -129.17 119.04 23.4 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.999 0.399 . . . . 0.0 110.949 178.363 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 43.9 mt-30 -140.05 149.01 42.62 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.907 177.927 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -138.55 148.61 44.42 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 176.429 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 368' ' ' PHE . . . . . 0.451 ' HB3' ' CE3' ' A' ' 381' ' ' TRP . 34.4 p90 -140.83 149.99 42.72 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.0 0.429 . . . . 0.0 110.465 178.577 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 1.6 mptp? -104.9 138.1 41.66 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 173.473 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 370' ' ' ALA . . . . . 0.728 ' HB3' HG22 ' A' ' 351' ' ' VAL . . . -134.26 147.45 50.66 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.18 0.514 . . . . 0.0 111.574 -177.127 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -105.96 130.47 53.89 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.628 175.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 372' ' ' ILE . . . . . 0.643 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 87.6 mt -81.66 107.38 13.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 121.545 0.688 . . . . 0.0 110.755 -178.04 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 373' ' ' ASP . . . . . 0.494 ' HB2' ' HE2' ' A' ' 378' ' ' LYS . 28.5 t70 -111.46 80.2 1.29 Allowed 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.093 -0.958 . . . . 0.0 109.435 179.417 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 58.87 119.07 0.01 OUTLIER Glycine 0 CA--C 1.521 0.42 0 CA-C-N 114.889 -1.051 . . . . 0.0 113.76 -177.484 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 375' ' ' ASN . . . . . 0.732 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 2.4 p-10 29.86 46.05 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 113.912 1.078 . . . . 0.0 113.912 178.582 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 165.06 172.35 32.41 Favored Glycine 0 N--CA 1.445 -0.766 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 178.032 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 377' ' ' PHE . . . . . 0.464 ' CZ ' HG21 ' A' ' 401' ' ' VAL . 3.4 p90 -147.95 150.54 34.23 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.447 0.641 . . . . 0.0 111.793 179.185 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 378' ' ' LYS . . . . . 0.821 ' H ' ' HD3' ' A' ' 378' ' ' LYS . 0.3 OUTLIER -112.37 130.29 56.01 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 114.638 -1.164 . . . . 0.0 108.383 174.688 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -126.23 156.64 19.83 Favored Glycine 0 N--CA 1.444 -0.821 0 C-N-CA 120.4 -0.905 . . . . 0.0 113.248 -172.804 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 26.7 p -125.24 137.74 54.1 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.219 -0.491 . . . . 0.0 109.938 178.007 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 381' ' ' TRP . . . . . 0.451 ' CE3' ' HB3' ' A' ' 368' ' ' PHE . 41.2 m95 -60.61 121.01 11.11 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.146 0.498 . . . . 0.0 110.943 -178.074 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 382' ' ' THR . . . . . . . . . . . . . 4.2 m -104.34 55.11 0.72 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.815 -0.629 . . . . 0.0 111.35 -171.447 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 383' ' ' GLU . . . . . . . . . . . . . 28.5 tt0 -177.61 -56.79 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.765 174.468 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 384' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -153.46 148.93 27.2 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 178.334 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 385' ' ' GLY . . . . . . . . . . . . . . . 109.91 135.1 7.04 Favored Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 120.64 -0.79 . . . . 0.0 112.318 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 386' ' ' GLY . . . . . . . . . . . . . . . -113.38 41.27 2.25 Favored Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 120.995 -0.621 . . . . 0.0 112.055 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -112.21 153.33 17.45 Favored Glycine 0 N--CA 1.447 -0.591 0 C-N-CA 120.965 -0.636 . . . . 0.0 111.647 179.545 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 20.6 m-20 -93.41 143.44 26.28 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 120.961 0.41 . . . . 0.0 110.64 -177.168 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 389' ' ' VAL . . . . . 0.412 HG22 ' HB3' ' A' ' 405' ' ' TYR . 23.9 t -112.7 137.09 46.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.782 179.464 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 5.0 p -147.42 138.83 23.87 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.817 0.341 . . . . 0.0 111.459 -179.077 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -156.74 154.11 25.26 Favored Glycine 0 N--CA 1.445 -0.764 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 23.2 mtt180 -119.51 153.15 35.78 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.468 0.652 . . . . 0.0 111.952 -175.945 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -93.71 159.31 15.26 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 114.649 -1.159 . . . . 0.0 110.045 178.643 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 394' ' ' TYR . . . . . 0.631 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 3.5 m-85 -101.62 -178.45 3.73 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.723 -177.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 395' ' ' GLY . . . . . 0.407 ' O ' ' N ' ' A' ' 397' ' ' ALA . . . -42.52 168.47 0.01 OUTLIER Glycine 0 CA--C 1.524 0.594 0 O-C-N 124.048 0.842 . . . . 0.0 115.159 -175.046 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_exo -19.35 -45.17 0.02 OUTLIER 'Trans proline' 0 C--N 1.356 0.924 1 C-N-CA 127.204 5.269 . . . . 0.0 117.588 -167.23 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 397' ' ' ALA . . . . . 0.407 ' N ' ' O ' ' A' ' 395' ' ' GLY . . . -72.25 -21.26 61.41 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -174.17 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 54.33 19.13 11.33 Favored Glycine 0 C--O 1.219 -0.837 0 CA-C-N 115.918 -0.583 . . . . 0.0 113.777 174.437 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 399' ' ' GLU . . . . . 0.882 ' HG3' ' HB3' ' A' ' 424' ' ' LYS . 23.0 tt0 -79.7 -10.66 59.82 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.538 0.685 . . . . 0.0 110.161 -174.312 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -118.54 125.7 50.41 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.864 178.458 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 401' ' ' VAL . . . . . 0.464 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 12.9 p -130.36 141.12 47.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.64 178.01 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -145.43 139.01 26.6 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.847 -177.678 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -167.75 -163.83 22.35 Favored Glycine 0 N--CA 1.444 -0.799 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.1 179.474 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 404' ' ' LYS . . . . . 0.553 ' HG2' HG12 ' A' ' 419' ' ' VAL . 21.2 mtmt -146.89 158.98 44.06 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.801 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 405' ' ' TYR . . . . . 0.412 ' HB3' HG22 ' A' ' 389' ' ' VAL . 19.1 p90 -114.74 134.75 54.85 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 170.329 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 406' ' ' SER . . . . . 0.407 ' OG ' ' HA2' ' A' ' 416' ' ' GLY . 40.0 m -149.06 125.61 11.0 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.021 0.439 . . . . 0.0 111.724 -174.569 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 27.3 p90 -93.13 106.62 18.56 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 166.89 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 408' ' ' ARG . . . . . . . . . . . . . 14.2 ptm180 -136.03 72.19 61.16 Favored Pre-proline 0 C--N 1.322 -0.603 0 N-CA-C 112.757 0.651 . . . . 0.0 112.757 -172.65 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 409' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_exo -63.52 -44.06 15.45 Favored 'Trans proline' 0 C--N 1.347 0.49 0 C-N-CA 122.267 1.978 . . . . 0.0 109.67 169.64 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 410' ' ' THR . . . . . 0.549 ' HB ' ' HD3' ' A' ' 414' ' ' LYS . 2.4 m -94.86 129.85 41.68 Favored 'General case' 0 N--CA 1.445 -0.684 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 168.199 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 411' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -84.01 30.6 0.51 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.954 0.407 . . . . 0.0 111.101 -178.18 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 412' ' ' ALA . . . . . . . . . . . . . . . -154.66 138.74 16.45 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.117 178.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 413' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 50.01 23.56 1.14 Allowed 'General case' 0 N--CA 1.479 0.983 0 C-N-CA 124.535 1.134 . . . . 0.0 112.581 178.203 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 414' ' ' LYS . . . . . 0.549 ' HD3' ' HB ' ' A' ' 410' ' ' THR . 12.2 mptt -106.42 -171.56 1.92 Allowed 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 176.148 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 415' ' ' GLY . . . . . . . . . . . . . . . -67.94 131.11 28.08 Favored Glycine 0 N--CA 1.444 -0.803 0 C-N-CA 119.625 -1.274 . . . . 0.0 111.165 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 416' ' ' GLY . . . . . 0.407 ' HA2' ' OG ' ' A' ' 406' ' ' SER . . . -165.86 21.68 0.12 Allowed Glycine 0 N--CA 1.446 -0.64 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 -177.0 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 417' ' ' PHE . . . . . 0.782 ' HB3' ' HD2' ' A' ' 326' ' ' PHE . 99.0 m-85 -126.65 -176.24 3.63 Favored 'General case' 0 N--CA 1.435 -1.185 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 -179.545 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 418' ' ' GLY . . . . . 0.496 ' H ' ' HD2' ' A' ' 326' ' ' PHE . . . 81.95 77.07 1.06 Allowed Glycine 0 N--CA 1.436 -1.311 0 C-N-CA 118.212 -1.947 . . . . 0.0 110.771 -174.58 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 419' ' ' VAL . . . . . 0.584 HG13 ' HE2' ' A' ' 326' ' ' PHE . 13.0 m -104.73 161.54 4.77 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -175.264 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 420' ' ' PHE . . . . . 0.437 ' HB3' HG12 ' A' ' 323' ' ' VAL . 49.5 p90 -139.27 147.74 42.09 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.109 0.48 . . . . 0.0 110.645 -178.405 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -137.44 134.61 36.04 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 174.254 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -132.0 134.75 7.79 Favored Glycine 0 N--CA 1.437 -1.257 0 C-N-CA 120.321 -0.942 . . . . 0.0 111.625 -177.695 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 17.2 mtpp -109.48 125.61 52.64 Favored 'General case' 0 C--N 1.314 -0.943 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 178.377 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 424' ' ' LYS . . . . . 0.882 ' HB3' ' HG3' ' A' ' 399' ' ' GLU . 8.0 tttm -66.53 117.88 9.35 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.855 -179.284 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 11.2 tp10 -100.46 113.27 25.91 Favored 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 173.762 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 426' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 -73.9 80.5 1.65 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.574 0.702 . . . . 0.0 109.642 175.603 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 427' ' ' ASP . . . . . . . . . . . . . 51.8 t0 -62.06 124.69 21.49 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 114.563 -1.199 . . . . 0.0 110.949 -177.02 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 428' ' ' LEU . . . . . 0.472 ' O ' ' HB3' ' A' ' 429' ' ' GLU . 52.8 tp -67.55 -39.96 84.97 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 114.794 -1.094 . . . . 0.0 109.688 176.899 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 429' ' ' GLU . . . . . 0.472 ' HB3' ' O ' ' A' ' 428' ' ' LEU . 2.4 pp20? 167.83 -25.57 0.0 OUTLIER 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 114.556 -1.202 . . . . 0.0 108.037 178.387 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 430' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER 66.45 -70.51 0.1 Allowed 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 114.858 -1.064 . . . . 0.0 111.986 175.94 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 30.6 t-80 -165.03 72.34 0.19 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.004 0.431 . . . . 0.0 110.695 -179.571 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 432' ' ' HIS . . . . . . . . . . . . . 81.2 m-70 -106.95 -4.44 19.09 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.018 0.437 . . . . 0.0 110.13 173.057 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 433' ' ' HIS . . . . . . . . . . . . . 44.6 m-70 -97.11 96.48 8.48 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.872 178.483 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 434' ' ' HIS . . . . . . . . . . . . . 4.6 t-80 -110.65 -23.79 10.88 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 172.637 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 435' ' ' HIS . . . . . . . . . . . . . 14.2 p80 . . . . . 0 C--O 1.246 0.882 0 CA-C-N 114.692 -1.14 . . . . 0.0 109.271 173.497 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 276' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 . . . . . 0 N--CA 1.483 1.179 0 CA-C-O 120.399 0.142 . . . . 0.0 111.153 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 70.3 mt -95.7 -74.43 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.304 0 CA-C-O 121.218 0.532 . . . . 0.0 111.463 -177.744 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 278' ' ' PHE . . . . . . . . . . . . . 58.2 m-85 -63.52 -31.95 73.26 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.061 -0.972 . . . . 0.0 111.117 -178.486 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -136.16 87.52 23.21 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.721 179.165 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 280' ' ' PRO . . . . . 0.498 ' O ' ' HB2' ' A' ' 281' ' ' GLU . 1.0 OUTLIER -84.04 117.77 2.27 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 122.672 2.248 . . . . 0.0 111.286 174.584 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 281' ' ' GLU . . . . . 0.498 ' HB2' ' O ' ' A' ' 280' ' ' PRO . 26.1 tt0 170.51 -43.86 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.284 0 O-C-N 123.662 0.601 . . . . 0.0 110.219 -179.57 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -176.71 -148.91 7.35 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.146 -179.538 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 283' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -102.36 84.38 2.45 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 120.872 0.368 . . . . 0.0 111.289 -177.488 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 82.4 m-85 -92.0 120.06 32.3 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 176.082 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 285' ' ' ARG . . . . . 0.472 ' HA ' ' NE ' ' A' ' 302' ' ' ARG . 17.8 ptp180 -133.16 -13.06 2.78 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.914 -172.894 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.424 ' HB3' HD22 ' A' ' 287' ' ' LEU . 42.5 m-85 -74.77 -68.49 0.54 Allowed 'General case' 0 C--N 1.324 -0.51 0 C-N-CA 120.565 -0.454 . . . . 0.0 110.111 176.569 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 287' ' ' LEU . . . . . 0.502 HD13 ' HG3' ' A' ' 304' ' ' GLN . 3.5 mm? -115.58 127.21 55.07 Favored 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 120.814 -0.355 . . . . 0.0 110.93 177.392 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 288' ' ' THR . . . . . 0.733 ' HB ' ' CB ' ' A' ' 302' ' ' ARG . 59.8 m -170.17 152.96 4.36 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 176.434 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 289' ' ' TYR . . . . . . . . . . . . . 84.3 m-85 -138.17 122.46 18.2 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 176.568 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 290' ' ' GLY . . . . . 0.415 ' O ' ' HA ' ' A' ' 301' ' ' LEU . . . 158.08 168.39 20.31 Favored Glycine 0 N--CA 1.444 -0.781 0 C-N-CA 119.015 -1.564 . . . . 0.0 112.524 170.704 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 291' ' ' ALA . . . . . 0.576 ' HA ' HD13 ' A' ' 301' ' ' LEU . . . -143.84 111.09 5.82 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-O 120.996 0.427 . . . . 0.0 111.717 178.041 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 292' ' ' GLU . . . . . 0.432 ' O ' ' HB3' ' A' ' 300' ' ' ALA . 29.1 tt0 -163.8 121.05 1.77 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.292 -0.867 . . . . 0.0 108.977 169.161 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 293' ' ' LYS . . . . . 0.401 ' HB3' ' HE2' ' A' ' 293' ' ' LYS . 31.1 ttpt -118.14 125.32 50.01 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.225 -177.136 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 294' ' ' LEU . . . . . 0.776 ' HB3' ' HB3' ' A' ' 298' ' ' SER . 6.1 tt -86.87 118.97 70.87 Favored Pre-proline 0 N--CA 1.442 -0.854 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 -179.148 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 295' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_exo -65.9 97.59 0.34 Allowed 'Trans proline' 0 N--CA 1.464 -0.235 0 C-N-CA 122.803 2.336 . . . . 0.0 111.387 179.155 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . 157.25 15.41 0.04 OUTLIER Glycine 0 N--CA 1.445 -0.7 0 CA-C-N 115.681 -0.69 . . . . 0.0 112.356 -177.119 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 115.9 -24.66 10.0 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.572 -0.823 . . . . 0.0 113.383 177.786 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 298' ' ' SER . . . . . 0.776 ' HB3' ' HB3' ' A' ' 294' ' ' LEU . 8.7 t -82.89 167.87 17.61 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 117.063 0.431 . . . . 0.0 110.901 -174.544 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 299' ' ' TYR . . . . . . . . . . . . . 1.3 p90 -159.56 142.97 14.42 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.252 -173.769 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 300' ' ' ALA . . . . . 0.631 ' O ' HD13 ' A' ' 301' ' ' LEU . . . -152.07 90.14 1.5 Allowed 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 120.441 -0.504 . . . . 0.0 111.185 171.677 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 301' ' ' LEU . . . . . 0.631 HD13 ' O ' ' A' ' 300' ' ' ALA . 0.5 OUTLIER -139.59 150.1 44.61 Favored 'General case' 0 CA--C 1.512 -0.489 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 172.28 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 302' ' ' ARG . . . . . 0.733 ' CB ' ' HB ' ' A' ' 288' ' ' THR . 15.1 tpp180 -164.99 127.74 2.24 Favored 'General case' 0 C--N 1.317 -0.832 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 168.298 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 303' ' ' VAL . . . . . . . . . . . . . 17.5 m -111.88 122.38 66.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 121.108 0.48 . . . . 0.0 110.992 -179.641 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 304' ' ' GLN . . . . . 0.502 ' HG3' HD13 ' A' ' 287' ' ' LEU . 75.6 mm-40 -138.26 160.34 39.71 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.294 177.702 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 305' ' ' GLY . . . . . 0.626 ' O ' ' HD3' ' A' ' 307' ' ' PRO . . . -94.15 -171.37 38.36 Favored Glycine 0 N--CA 1.444 -0.816 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 175.54 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 306' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -88.48 106.02 11.37 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 117.268 0.534 . . . . 0.0 110.381 -179.842 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 307' ' ' PRO . . . . . 0.626 ' HD3' ' O ' ' A' ' 305' ' ' GLY . 85.2 Cg_endo -89.27 149.33 5.46 Favored 'Trans proline' 0 N--CA 1.452 -0.937 0 C-N-CA 122.848 2.365 . . . . 0.0 111.947 178.283 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 308' ' ' ALA . . . . . 0.755 ' HB1' ' CD2' ' A' ' 313' ' ' LEU . . . -61.24 169.26 2.21 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.231 174.027 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 309' ' ' LYS . . . . . 0.7 ' H ' HD23 ' A' ' 313' ' ' LEU . 13.0 mptt -125.42 85.24 2.38 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 174.355 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -57.4 -19.71 34.36 Favored Glycine 0 N--CA 1.462 0.409 0 N-CA-C 114.28 0.472 . . . . 0.0 114.28 -168.83 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -87.35 -16.27 35.51 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.91 0.386 . . . . 0.0 111.227 179.15 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 47.9 tpp -110.95 -34.38 6.24 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.153 -175.067 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 313' ' ' LEU . . . . . 0.755 ' CD2' ' HB1' ' A' ' 308' ' ' ALA . 1.7 pp -83.45 137.09 34.06 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 175.471 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 314' ' ' ALA . . . . . 0.53 ' HA ' ' HB2' ' A' ' 346' ' ' PHE . . . -145.63 172.57 13.07 Favored 'General case' 0 C--N 1.318 -0.781 0 N-CA-C 112.62 0.6 . . . . 0.0 112.62 -166.049 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.31 176.5 15.77 Favored Glycine 0 N--CA 1.445 -0.758 0 CA-C-N 115.061 -0.972 . . . . 0.0 110.932 -177.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 15.7 p -108.0 134.01 51.5 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 170.619 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -139.45 161.12 38.24 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-O 121.204 0.526 . . . . 0.0 111.785 -172.273 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 318' ' ' VAL . . . . . 0.713 ' HA ' ' O ' ' A' ' 342' ' ' ALA . 7.7 p -141.22 124.12 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.936 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.51 173.818 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 319' ' ' TYR . . . . . 0.595 ' CE2' ' HB2' ' A' ' 424' ' ' LYS . 1.9 m-85 -102.18 143.76 31.58 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.605 -178.133 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 47.0 m-80 -127.78 132.6 49.49 Favored 'General case' 0 C--N 1.311 -1.073 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 176.132 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -165.12 -159.33 11.28 Favored Glycine 0 N--CA 1.442 -0.91 0 C-N-CA 120.218 -0.992 . . . . 0.0 112.167 -178.522 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -120.78 156.13 32.53 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 120.969 0.414 . . . . 0.0 110.298 -177.473 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 323' ' ' VAL . . . . . 0.831 HG21 HG12 ' A' ' 355' ' ' ILE . 41.0 t -119.45 118.32 56.94 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.621 -179.24 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 324' ' ' LEU . . . . . . . . . . . . . 96.4 mt -104.3 102.4 12.1 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.317 0.58 . . . . 0.0 110.149 -179.349 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 325' ' ' HIS . . . . . 0.489 ' HB3' ' OH ' ' A' ' 405' ' ' TYR . 28.0 p-80 -108.1 132.06 53.97 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.523 176.524 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 326' ' ' PHE . . . . . 0.672 ' HD2' ' HB3' ' A' ' 417' ' ' PHE . 10.3 m-85 -106.52 150.15 26.41 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.695 -169.395 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 327' ' ' HIS . . . . . . . . . . . . . 13.2 p80 -166.37 150.94 7.79 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.119 175.811 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 328' ' ' THR . . . . . . . . . . . . . 9.5 p -84.52 100.69 11.54 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.222 0.534 . . . . 0.0 111.772 -174.601 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 329' ' ' GLU . . . . . 0.526 ' HG3' ' CE2' ' A' ' 334' ' ' TYR . 6.5 mm-40 -88.75 93.45 9.58 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.033 177.664 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 330' ' ' ASN . . . . . . . . . . . . . 7.4 t30 67.65 -66.49 0.21 Allowed 'General case' 0 N--CA 1.467 0.405 0 C-N-CA 123.279 0.632 . . . . 0.0 110.886 -175.734 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 331' ' ' GLY . . . . . 0.599 ' O ' ' HB2' ' A' ' 332' ' ' ARG . . . -177.69 88.32 0.07 OUTLIER Glycine 0 N--CA 1.446 -0.683 0 N-CA-C 110.702 -0.959 . . . . 0.0 110.702 176.751 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 332' ' ' ARG . . . . . 0.599 ' HB2' ' O ' ' A' ' 331' ' ' GLY . 0.0 OUTLIER 156.61 90.97 0.0 OUTLIER Pre-proline 0 N--CA 1.465 0.286 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 -175.248 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 333' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -72.08 70.54 2.99 Favored 'Trans proline' 0 C--O 1.234 0.295 0 C-N-CA 122.783 2.322 . . . . 0.0 112.676 -177.457 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 334' ' ' TYR . . . . . 0.526 ' CE2' ' HG3' ' A' ' 329' ' ' GLU . 51.3 p90 -77.53 135.15 65.12 Favored Pre-proline 0 N--CA 1.453 -0.282 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 175.232 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 335' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 334' ' ' TYR . 2.8 Cg_endo -79.64 125.65 6.28 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 122.138 1.892 . . . . 0.0 112.232 -176.265 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 336' ' ' THR . . . . . . . . . . . . . 4.9 p -87.01 138.82 31.17 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.132 172.635 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 337' ' ' ARG . . . . . 0.6 ' HA ' ' O ' ' A' ' 323' ' ' VAL . 0.0 OUTLIER -115.7 124.22 50.28 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-O 121.416 0.627 . . . . 0.0 111.503 -172.428 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -103.69 -177.97 25.86 Favored Glycine 0 N--CA 1.442 -0.904 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.949 174.355 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 339' ' ' ARG . . . . . 0.442 ' O ' ' HA ' ' A' ' 355' ' ' ILE . 75.4 mtp180 -114.18 127.49 55.92 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 120.952 0.406 . . . . 0.0 109.911 -177.575 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 340' ' ' PHE . . . . . 0.617 ' HB2' HG23 ' A' ' 323' ' ' VAL . 29.6 t80 -126.85 139.91 52.74 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.257 -169.412 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 341' ' ' ALA . . . . . 0.533 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -139.04 155.75 47.71 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 114.587 -1.188 . . . . 0.0 108.844 172.662 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 342' ' ' ALA . . . . . 0.848 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -143.12 117.82 9.85 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.14 0.495 . . . . 0.0 111.405 -177.368 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 343' ' ' LYS . . . . . 0.677 ' HB3' ' HB3' ' A' ' 352' ' ' ASP . 3.6 tppp? -96.07 98.95 10.76 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 114.851 -1.068 . . . . 0.0 108.943 -179.699 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 344' ' ' VAL . . . . . 0.653 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.6 OUTLIER -123.33 128.33 74.75 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 N-CA-C 113.099 0.777 . . . . 0.0 113.099 -169.56 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 345' ' ' ASP . . . . . 0.445 ' HB2' ' HB3' ' A' ' 348' ' ' SER . 1.8 m-20 -100.41 107.64 19.44 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 174.159 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 346' ' ' PHE . . . . . 0.53 ' HB2' ' HA ' ' A' ' 314' ' ' ALA . 38.0 m-85 -64.79 -36.58 84.77 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.807 0.337 . . . . 0.0 111.204 -176.391 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -68.62 -14.8 67.78 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.406 -178.544 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 348' ' ' SER . . . . . 0.445 ' HB3' ' HB2' ' A' ' 345' ' ' ASP . 44.2 t -109.13 -9.6 15.03 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.292 0.568 . . . . 0.0 110.135 179.219 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 349' ' ' LYS . . . . . 0.441 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 31.8 mtmm 52.44 55.36 9.22 Favored 'General case' 0 N--CA 1.462 0.137 0 CA-C-N 114.966 -1.016 . . . . 0.0 111.326 -176.07 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 8.6 t -146.72 145.69 30.07 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.508 179.518 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 351' ' ' VAL . . . . . 0.653 ' HB ' ' HB ' ' A' ' 344' ' ' VAL . 0.6 OUTLIER -136.46 146.65 28.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.956 0.408 . . . . 0.0 110.432 -177.042 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 352' ' ' ASP . . . . . 0.848 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 36.8 t70 -108.6 117.47 34.26 Favored 'General case' 0 C--O 1.211 -0.929 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 172.927 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -116.04 114.28 3.06 Favored Glycine 0 C--N 1.302 -1.334 0 C-N-CA 120.242 -0.98 . . . . 0.0 112.031 -176.668 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 354' ' ' ILE . . . . . 0.558 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -113.65 129.08 70.12 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 CA-C-O 120.977 0.418 . . . . 0.0 110.475 -175.495 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 355' ' ' ILE . . . . . 0.831 HG12 HG21 ' A' ' 323' ' ' VAL . 5.1 mp -127.5 111.78 26.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.95 177.715 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 356' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -103.25 142.64 33.83 Favored 'General case' 0 C--N 1.323 -0.583 0 C-N-CA 120.164 -0.614 . . . . 0.0 109.688 175.028 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 20.2 m -92.67 10.22 31.54 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.236 -175.784 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 358' ' ' GLY . . . . . . . . . . . . . . . 78.08 -0.09 74.54 Favored Glycine 0 N--CA 1.453 -0.211 0 N-CA-C 111.381 -0.688 . . . . 0.0 111.381 -174.176 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 359' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -148.39 100.98 3.2 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.07 -0.565 . . . . 0.0 109.667 -179.303 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 360' ' ' ASP . . . . . 0.424 ' O ' ' HA2' ' A' ' 364' ' ' GLY . 32.8 t70 -83.26 -23.91 32.5 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 121.051 0.453 . . . . 0.0 111.493 -178.083 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 361' ' ' LEU . . . . . 0.48 HD22 ' H ' ' A' ' 361' ' ' LEU . 2.2 mm? -76.78 -34.88 57.96 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 112.543 0.571 . . . . 0.0 112.543 -170.785 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 362' ' ' HIS . . . . . . . . . . . . . 42.5 m80 -111.42 -57.16 2.29 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.942 0.401 . . . . 0.0 110.666 -175.121 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 363' ' ' MET . . . . . 0.518 ' HA ' ' CE ' ' A' ' 363' ' ' MET . 9.8 mmt -77.39 -53.33 7.79 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 177.256 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 364' ' ' GLY . . . . . 0.424 ' HA2' ' O ' ' A' ' 360' ' ' ASP . . . 110.98 170.33 19.26 Favored Glycine 0 N--CA 1.441 -1.032 0 CA-C-N 115.331 -0.85 . . . . 0.0 112.55 175.87 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 365' ' ' THR . . . . . . . . . . . . . 31.7 m -107.16 112.76 25.8 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 170.595 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 21.6 mp0 -105.43 117.56 34.33 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 121.363 0.602 . . . . 0.0 109.934 -173.512 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 25.4 pttm -114.96 146.99 40.62 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.665 178.54 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 368' ' ' PHE . . . . . 0.488 ' HA ' ' H ' ' A' ' 382' ' ' THR . 44.6 p90 -124.68 157.96 34.32 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 178.048 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 8.0 ttpt -126.05 134.96 51.26 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 173.538 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -136.14 144.87 45.28 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.095 -173.583 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -96.92 134.92 39.64 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 175.847 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 372' ' ' ILE . . . . . 0.441 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 66.8 mt -79.75 105.71 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.619 0 CA-C-O 121.884 0.85 . . . . 0.0 110.739 -177.804 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 373' ' ' ASP . . . . . 0.445 ' HB3' ' HD3' ' A' ' 378' ' ' LYS . 32.1 t70 -108.27 80.69 1.39 Allowed 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 114.492 -1.231 . . . . 0.0 109.19 -178.217 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 62.97 118.83 0.01 OUTLIER Glycine 0 CA--C 1.523 0.541 0 CA-C-N 114.54 -1.209 . . . . 0.0 113.488 -176.705 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 375' ' ' ASN . . . . . 0.705 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 3.1 p-10 28.92 46.67 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 124.363 1.065 . . . . 0.0 113.631 178.211 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 158.71 178.89 33.15 Favored Glycine 0 N--CA 1.442 -0.914 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 179.551 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 377' ' ' PHE . . . . . 0.607 ' CZ ' HG21 ' A' ' 401' ' ' VAL . 4.0 p90 -140.62 150.99 44.27 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 117.797 0.798 . . . . 0.0 112.127 -176.981 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 378' ' ' LYS . . . . . 0.445 ' HD3' ' HB3' ' A' ' 373' ' ' ASP . 0.0 OUTLIER -125.96 134.77 51.42 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 176.562 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -161.19 -158.6 9.46 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.178 -1.011 . . . . 0.0 112.853 -177.016 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 15.2 t -150.13 166.45 29.76 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.706 0.289 . . . . 0.0 110.383 -177.288 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 381' ' ' TRP . . . . . 0.791 ' HD1' ' HA3' ' A' ' 387' ' ' GLY . 49.5 m95 -67.62 121.11 15.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.856 -178.502 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 382' ' ' THR . . . . . 0.488 ' H ' ' HA ' ' A' ' 368' ' ' PHE . 22.7 m 60.73 -85.88 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 114.774 -1.103 . . . . 0.0 112.533 179.46 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 383' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -133.01 -48.85 0.86 Allowed 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 -176.249 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 384' ' ' ASN . . . . . . . . . . . . . 44.9 t-20 -163.17 72.09 0.29 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.185 -0.916 . . . . 0.0 108.864 172.254 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 385' ' ' GLY . . . . . . . . . . . . . . . -88.3 2.63 85.23 Favored Glycine 0 N--CA 1.451 -0.315 0 CA-C-N 115.624 -0.716 . . . . 0.0 112.34 -179.146 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 386' ' ' GLY . . . . . . . . . . . . . . . 86.49 -14.94 53.55 Favored Glycine 0 N--CA 1.453 -0.175 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.667 179.554 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 387' ' ' GLY . . . . . 0.791 ' HA3' ' HD1' ' A' ' 381' ' ' TRP . . . -88.17 126.61 8.17 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.087 -179.486 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -82.49 138.86 34.22 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 110.304 -0.258 . . . . 0.0 110.304 178.664 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 44.5 t -132.17 128.56 59.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.493 0.187 . . . . 0.0 110.694 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 18.2 m -133.94 151.34 51.45 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.726 -0.215 . . . . 0.0 110.673 179.245 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 391' ' ' GLY . . . . . 0.552 ' HA2' ' HA3' ' A' ' 403' ' ' GLY . . . -158.59 151.52 22.56 Favored Glycine 0 N--CA 1.454 -0.141 0 C-N-CA 121.227 -0.511 . . . . 0.0 111.859 175.795 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 5.7 mpt_? -120.3 146.87 45.69 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.873 0.368 . . . . 0.0 110.862 -176.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -91.07 158.39 16.69 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.95 -179.814 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 394' ' ' TYR . . . . . 0.66 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 2.9 m-85 -102.18 -177.19 3.33 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.188 -0.915 . . . . 0.0 110.058 177.262 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 395' ' ' GLY . . . . . 0.421 ' O ' ' N ' ' A' ' 397' ' ' ALA . . . -37.98 159.33 0.01 OUTLIER Glycine 0 CA--C 1.525 0.705 0 O-C-N 124.224 0.953 . . . . 0.0 115.169 -175.539 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_exo -18.1 -42.65 0.01 OUTLIER 'Trans proline' 0 C--N 1.352 0.723 1 C-N-CA 127.729 5.62 . . . . 0.0 118.213 -168.136 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 397' ' ' ALA . . . . . 0.421 ' N ' ' O ' ' A' ' 395' ' ' GLY . . . -78.51 -19.44 52.97 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 118.402 0.546 . . . . 0.0 112.457 -173.106 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 62.41 12.1 37.57 Favored Glycine 0 C--O 1.216 -0.977 0 CA-C-O 119.355 -0.691 . . . . 0.0 114.221 176.624 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 399' ' ' GLU . . . . . 0.716 ' HG3' ' HD3' ' A' ' 424' ' ' LYS . 1.1 mp0 -63.54 -10.57 18.7 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 118.189 0.994 . . . . 0.0 111.314 -178.161 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -122.55 128.32 50.6 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 121.041 0.448 . . . . 0.0 110.003 176.107 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 401' ' ' VAL . . . . . 0.607 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 12.2 p -131.89 138.01 53.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.758 175.866 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -141.67 132.01 25.09 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.083 -178.647 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 403' ' ' GLY . . . . . 0.552 ' HA3' ' HA2' ' A' ' 391' ' ' GLY . . . -151.29 -173.76 21.49 Favored Glycine 0 N--CA 1.439 -1.136 0 C-N-CA 120.089 -1.053 . . . . 0.0 112.426 -178.055 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 404' ' ' LYS . . . . . 0.82 ' HG2' HG12 ' A' ' 419' ' ' VAL . 30.3 mtpt -145.73 155.66 43.11 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -179.684 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 405' ' ' TYR . . . . . 0.489 ' OH ' ' HB3' ' A' ' 325' ' ' HIS . 50.7 p90 -131.43 147.42 52.55 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-O 121.011 0.434 . . . . 0.0 110.525 -179.232 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 28.3 m -84.3 103.31 13.37 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.14 -178.422 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 31.8 t80 -81.45 106.87 13.75 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 178.318 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 408' ' ' ARG . . . . . 0.458 ' HA ' ' HD2' ' A' ' 409' ' ' PRO . 22.9 mmm180 67.81 118.11 0.03 OUTLIER Pre-proline 0 N--CA 1.464 0.247 0 O-C-N 124.174 0.921 . . . . 0.0 110.69 -174.424 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 409' ' ' PRO . . . . . 0.458 ' HD2' ' HA ' ' A' ' 408' ' ' ARG . 11.6 Cg_endo -54.1 112.94 1.12 Allowed 'Trans proline' 0 C--O 1.236 0.383 0 C-N-CA 123.264 2.643 . . . . 0.0 112.9 -177.653 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 410' ' ' THR . . . . . . . . . . . . . 2.6 m -62.1 129.23 39.85 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.25 177.317 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 411' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -76.63 67.08 2.7 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 121.483 0.659 . . . . 0.0 111.06 -177.27 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 412' ' ' ALA . . . . . . . . . . . . . . . 178.87 -69.99 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 114.895 -1.048 . . . . 0.0 108.214 178.076 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 413' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -151.88 119.47 6.07 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 171.063 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 414' ' ' LYS . . . . . 0.463 ' HD2' ' H ' ' A' ' 414' ' ' LYS . 0.0 OUTLIER -70.39 134.17 47.6 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.072 0.463 . . . . 0.0 111.808 -169.739 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 415' ' ' GLY . . . . . . . . . . . . . . . 146.84 133.83 2.49 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.601 176.415 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 416' ' ' GLY . . . . . . . . . . . . . . . -177.76 -101.66 0.15 Allowed Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.04 -1.076 . . . . 0.0 112.78 178.473 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 417' ' ' PHE . . . . . 0.672 ' HB3' ' HD2' ' A' ' 326' ' ' PHE . 66.1 m-85 -84.36 -175.4 5.77 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 122.254 0.222 . . . . 0.0 110.472 -177.346 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 418' ' ' GLY . . . . . 0.455 ' HA2' ' HA ' ' A' ' 325' ' ' HIS . . . 82.31 77.1 1.07 Allowed Glycine 0 C--O 1.224 -0.489 0 C-N-CA 120.746 -0.74 . . . . 0.0 113.125 176.214 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 419' ' ' VAL . . . . . 0.82 HG12 ' HG2' ' A' ' 404' ' ' LYS . 23.8 m -109.71 157.61 10.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 120.903 0.382 . . . . 0.0 110.822 -179.715 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 40.8 p90 -146.4 154.8 42.04 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.952 0.406 . . . . 0.0 110.535 177.58 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -148.83 136.54 20.54 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.48 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -133.18 140.62 11.98 Favored Glycine 0 N--CA 1.445 -0.711 0 C-N-CA 120.196 -1.002 . . . . 0.0 112.582 -177.668 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 25.1 mmmt -101.9 123.83 46.49 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 176.82 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 424' ' ' LYS . . . . . 0.716 ' HD3' ' HG3' ' A' ' 399' ' ' GLU . 72.1 tttt -70.16 117.25 11.48 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 116.55 -0.296 . . . . 0.0 110.572 -179.591 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -73.9 114.12 11.84 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 -179.502 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 426' ' ' GLN . . . . . . . . . . . . . 5.7 tp-100 -86.78 144.34 27.1 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.39 -175.092 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 427' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -79.34 92.82 5.21 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 177.193 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 428' ' ' LEU . . . . . 0.597 ' HB2' ' OE2' ' A' ' 429' ' ' GLU . 70.1 mt -84.7 -65.69 0.98 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.939 -173.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 429' ' ' GLU . . . . . 0.597 ' OE2' ' HB2' ' A' ' 428' ' ' LEU . 1.8 mp0 -68.49 157.44 35.92 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 178.345 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 430' ' ' HIS . . . . . 0.434 ' HB3' ' O ' ' A' ' 429' ' ' GLU . 8.9 t60 73.4 -51.33 0.7 Allowed 'General case' 0 N--CA 1.472 0.642 0 O-C-N 123.484 0.49 . . . . 0.0 112.152 174.28 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 23.2 t-80 -75.74 -4.29 39.64 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.911 -171.978 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 432' ' ' HIS . . . . . . . . . . . . . 20.7 m170 -109.05 -53.84 2.6 Favored 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 120.719 -0.392 . . . . 0.0 111.951 -179.403 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 433' ' ' HIS . . . . . . . . . . . . . 91.0 m-70 -120.14 142.0 49.34 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.24 0.543 . . . . 0.0 111.721 -176.878 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 434' ' ' HIS . . . . . . . . . . . . . 56.9 t-80 -150.27 110.45 4.16 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.819 175.453 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 435' ' ' HIS . . . . . . . . . . . . . 9.5 m170 . . . . . 0 C--O 1.246 0.886 0 CA-C-O 118.38 -0.819 . . . . 0.0 110.086 177.74 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 276' ' ' ASN . . . . . . . . . . . . . 37.1 m-80 . . . . . 0 N--CA 1.482 1.125 0 CA-C-O 121.183 0.516 . . . . 0.0 110.425 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 17.3 mt -83.9 42.6 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 CA-C-N 115.529 -0.759 . . . . 0.0 110.699 -177.711 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 278' ' ' PHE . . . . . 0.515 ' HZ ' ' O ' ' A' ' 300' ' ' ALA . 79.3 m-85 -35.66 121.9 0.63 Allowed 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 115.235 -0.893 . . . . 0.0 113.108 -177.715 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -68.95 111.09 7.34 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 115.26 -0.882 . . . . 0.0 109.989 177.631 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 280' ' ' PRO . . . . . . . . . . . . . 68.5 Cg_endo -82.37 120.2 3.2 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 122.593 2.195 . . . . 0.0 113.447 -173.208 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 173.56 -52.56 0.01 OUTLIER 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.007 -0.997 . . . . 0.0 108.404 176.281 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -164.08 160.21 33.11 Favored Glycine 0 N--CA 1.445 -0.734 0 CA-C-N 114.618 -1.173 . . . . 0.0 110.336 176.477 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 283' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -82.49 83.39 7.56 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.748 0.785 . . . . 0.0 110.202 178.899 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 284' ' ' TYR . . . . . 0.609 ' HB2' HD21 ' A' ' 287' ' ' LEU . 65.1 m-85 -89.97 144.13 26.19 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.445 179.463 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 285' ' ' ARG . . . . . 0.428 ' HG3' ' CE2' ' A' ' 289' ' ' TYR . 28.8 ttt180 -130.48 21.29 5.16 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 121.754 0.788 . . . . 0.0 110.521 -174.247 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 69.5 t80 -111.05 -2.71 15.79 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 122.439 1.114 . . . . 0.0 108.903 178.482 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 287' ' ' LEU . . . . . 0.609 HD21 ' HB2' ' A' ' 284' ' ' TYR . 1.2 pp -101.3 -178.35 3.71 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 113.747 -1.569 . . . . 0.0 109.696 178.91 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 288' ' ' THR . . . . . 0.712 ' HB ' ' HA ' ' A' ' 304' ' ' GLN . 4.3 m -69.06 157.54 36.62 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 -175.022 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 289' ' ' TYR . . . . . 0.834 ' HA ' ' H ' ' A' ' 303' ' ' VAL . 1.9 m-30 -137.79 164.11 29.71 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.42 0.628 . . . . 0.0 112.512 -175.357 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 158.05 131.74 1.33 Allowed Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 114.679 -1.146 . . . . 0.0 111.418 169.939 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 291' ' ' ALA . . . . . 0.984 ' HB3' ' HA ' ' A' ' 301' ' ' LEU . . . -169.07 166.27 11.0 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-N 116.64 0.22 . . . . 0.0 110.886 176.35 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 292' ' ' GLU . . . . . . . . . . . . . 57.7 mm-40 -110.18 109.0 19.34 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 177.273 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 293' ' ' LYS . . . . . 0.472 ' HB2' ' HA ' ' A' ' 300' ' ' ALA . 59.8 tttm -81.29 112.61 18.76 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.38 0.609 . . . . 0.0 112.023 -171.953 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 294' ' ' LEU . . . . . 0.64 HD13 ' HB2' ' A' ' 298' ' ' SER . 10.6 mp -122.02 161.7 41.13 Favored Pre-proline 0 C--N 1.32 -0.709 0 CA-C-N 114.963 -1.017 . . . . 0.0 108.477 171.671 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 295' ' ' PRO . . . . . . . . . . . . . 8.9 Cg_exo -73.15 -8.44 22.06 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.551 2.167 . . . . 0.0 111.752 176.453 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . -165.15 141.49 7.08 Favored Glycine 0 N--CA 1.45 -0.413 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.779 178.149 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 89.81 -76.21 1.73 Allowed Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.79 -0.719 . . . . 0.0 111.883 -179.49 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 298' ' ' SER . . . . . 0.64 ' HB2' HD13 ' A' ' 294' ' ' LEU . 35.1 m -89.74 148.94 22.96 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 176.0 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 299' ' ' TYR . . . . . . . . . . . . . 57.2 m-85 -122.43 177.21 5.5 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.935 0.398 . . . . 0.0 111.972 -172.593 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 300' ' ' ALA . . . . . 0.515 ' O ' ' HZ ' ' A' ' 278' ' ' PHE . . . -75.9 163.41 27.23 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.339 -175.143 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 301' ' ' LEU . . . . . 0.984 ' HA ' ' HB3' ' A' ' 291' ' ' ALA . 1.2 pt? -78.26 113.4 16.2 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 113.717 1.006 . . . . 0.0 113.717 -161.04 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 302' ' ' ARG . . . . . 0.699 ' HG3' ' CE1' ' A' ' 289' ' ' TYR . 18.6 ttp180 -164.12 113.49 1.21 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 114.734 -1.121 . . . . 0.0 108.793 162.133 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 303' ' ' VAL . . . . . 0.834 ' H ' ' HA ' ' A' ' 289' ' ' TYR . 11.6 p -153.91 126.36 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.61 0 N-CA-C 111.944 0.349 . . . . 0.0 111.944 167.527 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 304' ' ' GLN . . . . . 0.712 ' HA ' ' HB ' ' A' ' 288' ' ' THR . 7.7 pt20 -88.3 135.97 33.2 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.246 0.545 . . . . 0.0 111.283 -177.419 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 305' ' ' GLY . . . . . 0.516 ' H ' ' HB ' ' A' ' 288' ' ' THR . . . -174.41 107.12 0.24 Allowed Glycine 0 N--CA 1.446 -0.682 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.51 177.981 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 306' ' ' GLU . . . . . 0.957 ' HB3' ' HD3' ' A' ' 396' ' ' PRO . 34.6 tt0 -146.33 136.72 12.19 Favored Pre-proline 0 C--N 1.324 -0.517 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 -176.873 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -75.05 129.97 12.79 Favored 'Trans proline' 0 N--CA 1.462 -0.337 0 C-N-CA 121.997 1.798 . . . . 0.0 111.315 175.408 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 308' ' ' ALA . . . . . 0.703 ' HB2' ' O ' ' A' ' 394' ' ' TYR . . . -54.18 159.54 1.86 Allowed 'General case' 0 N--CA 1.467 0.385 0 CA-C-O 121.48 0.657 . . . . 0.0 112.282 175.804 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 309' ' ' LYS . . . . . 0.649 ' O ' ' HG ' ' A' ' 313' ' ' LEU . 35.0 mtmt -123.55 98.91 6.05 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.357 176.746 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 310' ' ' GLY . . . . . 0.694 ' HA2' HD12 ' A' ' 313' ' ' LEU . . . -60.04 -37.75 93.23 Favored Glycine 0 C--O 1.227 -0.304 0 CA-C-N 116.093 -0.503 . . . . 0.0 114.128 -170.314 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 311' ' ' GLU . . . . . 0.454 ' H ' ' CD ' ' A' ' 311' ' ' GLU . 1.3 pm0 -72.61 -20.03 61.36 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.86 0.33 . . . . 0.0 110.856 179.115 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 26.0 ttt -91.46 -21.61 20.84 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.143 0.497 . . . . 0.0 109.95 177.302 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 313' ' ' LEU . . . . . 0.694 HD12 ' HA2' ' A' ' 310' ' ' GLY . 96.1 mt -66.19 138.95 58.05 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.332 178.998 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -156.32 139.2 15.28 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.303 -174.326 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 121.01 167.88 13.39 Favored Glycine 0 N--CA 1.443 -0.845 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.929 177.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 28.5 p -100.05 134.22 43.28 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 174.715 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 317' ' ' ALA . . . . . 0.56 ' HB1' ' HD3' ' A' ' 424' ' ' LYS . . . -138.6 152.57 48.25 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 121.053 0.454 . . . . 0.0 111.731 -174.833 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 7.3 p -121.59 113.24 38.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.441 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.263 177.5 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 319' ' ' TYR . . . . . 0.598 ' CE2' ' HB2' ' A' ' 424' ' ' LYS . 21.4 m-85 -103.16 132.52 49.36 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.925 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 44.6 m-80 -124.81 139.56 53.73 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.077 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 321' ' ' GLY . . . . . 0.591 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -169.25 -145.93 4.83 Favored Glycine 0 N--CA 1.441 -1.014 0 C-N-CA 120.577 -0.82 . . . . 0.0 112.397 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -135.04 161.92 33.93 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 120.978 0.418 . . . . 0.0 110.947 -173.66 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 323' ' ' VAL . . . . . 0.649 HG23 ' HB2' ' A' ' 340' ' ' PHE . 68.9 t -121.12 117.89 54.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.163 178.331 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 324' ' ' LEU . . . . . . . . . . . . . 2.0 tt -98.53 103.27 15.2 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 176.631 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 325' ' ' HIS . . . . . 0.446 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 18.3 t-160 -88.58 113.32 24.03 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 -179.307 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 326' ' ' PHE . . . . . 0.664 ' HE2' HG13 ' A' ' 419' ' ' VAL . 88.4 m-85 -82.15 162.24 22.52 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.008 -177.85 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 327' ' ' HIS . . . . . . . . . . . . . 32.3 p-80 -175.74 -174.0 0.65 Allowed 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.375 -0.83 . . . . 0.0 108.769 -173.786 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 328' ' ' THR . . . . . . . . . . . . . 17.9 p -47.47 159.93 0.13 Allowed 'General case' 0 C--O 1.236 0.369 0 O-C-N 123.706 0.629 . . . . 0.0 112.035 179.337 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 329' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -57.54 161.78 3.34 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-N 115.577 -0.738 . . . . 0.0 112.622 -171.691 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 330' ' ' ASN . . . . . 0.523 ' OD1' ' HA ' ' A' ' 334' ' ' TYR . 11.4 t30 -76.95 85.95 3.49 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.11 -0.95 . . . . 0.0 111.298 -172.905 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 331' ' ' GLY . . . . . 0.472 ' O ' ' HD3' ' A' ' 333' ' ' PRO . . . -150.23 93.72 0.15 Allowed Glycine 0 N--CA 1.443 -0.87 0 N-CA-C 111.063 -0.815 . . . . 0.0 111.063 174.09 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 332' ' ' ARG . . . . . 0.722 ' HB3' ' HD3' ' A' ' 333' ' ' PRO . 48.3 ttt180 104.45 -66.19 0.0 OUTLIER Pre-proline 0 N--CA 1.482 1.162 0 C-N-CA 125.295 1.438 . . . . 0.0 112.81 -178.935 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 333' ' ' PRO . . . . . 0.722 ' HD3' ' HB3' ' A' ' 332' ' ' ARG . 4.4 Cg_exo -75.81 -23.88 12.1 Favored 'Trans proline' 0 C--N 1.358 1.034 0 C-N-CA 121.822 1.681 . . . . 0.0 113.412 -175.547 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 334' ' ' TYR . . . . . 0.792 ' HB3' ' HD2' ' A' ' 335' ' ' PRO . 62.7 m-85 66.5 174.81 0.07 OUTLIER Pre-proline 0 CA--C 1.538 0.496 0 O-C-N 123.478 0.486 . . . . 0.0 110.484 -177.841 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 335' ' ' PRO . . . . . 0.792 ' HD2' ' HB3' ' A' ' 334' ' ' TYR . 68.4 Cg_endo -75.23 151.14 38.15 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 121.976 1.784 . . . . 0.0 111.674 177.531 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 336' ' ' THR . . . . . 0.518 HG21 ' CE1' ' A' ' 362' ' ' HIS . 25.5 p -112.8 138.32 49.8 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 120.269 -0.572 . . . . 0.0 111.012 179.414 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 337' ' ' ARG . . . . . . . . . . . . . 39.1 ttt180 -131.85 112.84 12.81 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.346 -174.849 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 338' ' ' GLY . . . . . 0.855 ' HA2' ' HA3' ' A' ' 358' ' ' GLY . . . -103.26 -177.0 26.41 Favored Glycine 0 N--CA 1.446 -0.695 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 179.037 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 339' ' ' ARG . . . . . 0.992 ' HB2' ' HB3' ' A' ' 356' ' ' ASP . 66.7 mtp180 -110.28 164.5 12.6 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 178.379 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 340' ' ' PHE . . . . . 0.649 ' HB2' HG23 ' A' ' 323' ' ' VAL . 41.1 t80 -152.43 142.73 22.49 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 121.255 0.55 . . . . 0.0 111.096 -178.275 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 341' ' ' ALA . . . . . . . . . . . . . . . -138.59 156.25 47.63 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.206 -0.906 . . . . 0.0 109.025 174.063 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 342' ' ' ALA . . . . . 0.884 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -145.94 118.94 8.76 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-O 121.304 0.573 . . . . 0.0 110.173 -179.729 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 343' ' ' LYS . . . . . 0.438 ' HE2' ' HB3' ' A' ' 343' ' ' LYS . 4.8 tmmm? -102.96 103.14 13.23 Favored 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 -179.625 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 344' ' ' VAL . . . . . 0.443 ' HA ' ' HA ' ' A' ' 351' ' ' VAL . 0.2 OUTLIER -117.14 132.77 65.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-O 121.485 0.66 . . . . 0.0 112.639 -169.224 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -102.48 100.08 10.17 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 114.515 -1.22 . . . . 0.0 108.7 172.541 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 346' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -67.88 -23.19 65.1 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.527 0.204 . . . . 0.0 111.184 -177.875 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -63.9 -25.27 69.11 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.016 178.315 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 37.9 m -112.58 -4.43 14.15 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.912 0.387 . . . . 0.0 110.567 177.709 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 349' ' ' LYS . . . . . 0.645 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 31.4 mtmm 55.69 59.3 3.91 Favored 'General case' 0 C--O 1.226 -0.179 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.892 -178.02 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 52.9 p -148.84 141.28 24.24 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.282 -179.326 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 351' ' ' VAL . . . . . 0.51 HG22 ' HB3' ' A' ' 370' ' ' ALA . 1.0 OUTLIER -127.57 151.84 34.9 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 CA-C-O 121.126 0.489 . . . . 0.0 110.986 -176.21 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 352' ' ' ASP . . . . . 0.884 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 19.5 t70 -108.59 119.07 38.44 Favored 'General case' 0 C--O 1.211 -0.954 0 CA-C-N 115.184 -0.917 . . . . 0.0 109.338 171.92 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -115.33 130.22 9.02 Favored Glycine 0 N--CA 1.441 -1.02 0 C-N-CA 120.473 -0.87 . . . . 0.0 111.658 -178.72 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 354' ' ' ILE . . . . . 0.475 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -131.52 129.62 62.0 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 CA-C-O 120.973 0.416 . . . . 0.0 110.196 -176.973 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 355' ' ' ILE . . . . . 0.605 HG13 HG21 ' A' ' 323' ' ' VAL . 2.3 mp -101.6 111.36 31.04 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.416 178.295 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 356' ' ' ASP . . . . . 0.992 ' HB3' ' HB2' ' A' ' 339' ' ' ARG . 9.1 t70 -74.4 154.39 38.83 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.481 -175.806 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 3.6 m -52.99 12.09 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.994 0 N-CA-C 117.177 2.288 . . . . 0.0 117.177 -163.407 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 358' ' ' GLY . . . . . 0.855 ' HA3' ' HA2' ' A' ' 338' ' ' GLY . . . -52.65 -44.0 59.82 Favored Glycine 0 CA--C 1.525 0.657 0 CA-C-N 118.767 0.712 . . . . 0.0 113.007 177.647 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 359' ' ' ASP . . . . . 0.589 ' OD2' ' HB2' ' A' ' 362' ' ' HIS . 20.9 t70 -110.93 35.46 3.51 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 121.757 0.789 . . . . 0.0 109.691 178.984 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 360' ' ' ASP . . . . . 0.697 ' HA ' ' HA2' ' A' ' 364' ' ' GLY . 18.5 t70 -65.44 -25.17 67.4 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.953 -178.031 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 361' ' ' LEU . . . . . . . . . . . . . 92.0 mt -76.45 -5.66 48.37 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.663 -178.149 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 362' ' ' HIS . . . . . 0.589 ' HB2' ' OD2' ' A' ' 359' ' ' ASP . 34.8 m80 -125.5 -74.35 0.61 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.765 0.317 . . . . 0.0 110.568 178.921 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 363' ' ' MET . . . . . . . . . . . . . 21.7 mmt -78.76 -39.72 35.27 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.041 0.448 . . . . 0.0 110.663 178.018 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 364' ' ' GLY . . . . . 0.697 ' HA2' ' HA ' ' A' ' 360' ' ' ASP . . . 101.45 -169.58 20.59 Favored Glycine 0 N--CA 1.448 -0.562 0 CA-C-N 115.648 -0.705 . . . . 0.0 111.492 -178.588 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 365' ' ' THR . . . . . . . . . . . . . 23.1 m -83.96 98.43 9.8 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 173.419 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 90.6 mt-30 -106.38 145.51 31.62 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.305 0.574 . . . . 0.0 111.372 -172.808 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -123.85 144.63 49.62 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.565 179.48 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 368' ' ' PHE . . . . . 0.493 ' HB3' ' CE3' ' A' ' 381' ' ' TRP . 33.2 p90 -140.17 150.74 44.58 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.963 0.411 . . . . 0.0 109.996 175.364 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 369' ' ' LYS . . . . . 0.766 ' HD3' ' HA ' ' A' ' 352' ' ' ASP . 0.0 OUTLIER -123.61 135.19 53.81 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 175.962 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 370' ' ' ALA . . . . . 0.529 ' HB1' ' HB2' ' A' ' 377' ' ' PHE . . . -132.11 152.23 51.35 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.478 -0.783 . . . . 0.0 111.213 -172.287 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -109.06 134.82 51.17 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.656 176.369 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 372' ' ' ILE . . . . . 0.645 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 95.5 mt -82.75 108.91 16.04 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-O 121.171 0.51 . . . . 0.0 110.939 -178.042 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -126.4 84.23 2.25 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-O 121.612 0.72 . . . . 0.0 110.288 178.361 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 79.07 121.22 0.3 Allowed Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.145 -0.934 . . . . 0.0 112.267 -177.188 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 375' ' ' ASN . . . . . 0.524 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 17.7 p30 1.8 60.38 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 125.6 1.56 . . . . 0.0 114.986 -171.92 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 157.55 -174.28 34.98 Favored Glycine 0 N--CA 1.438 -1.172 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 179.068 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 377' ' ' PHE . . . . . 0.529 ' HB2' ' HB1' ' A' ' 370' ' ' ALA . 1.6 p90 -142.34 148.71 38.39 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.327 0.584 . . . . 0.0 111.625 -179.345 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 378' ' ' LYS . . . . . . . . . . . . . 2.7 tmtm? -123.64 112.63 17.64 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 176.733 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -135.59 -165.6 10.74 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.428 -0.891 . . . . 0.0 112.627 -175.677 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 15.0 t -144.93 159.67 42.55 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.86 0.362 . . . . 0.0 110.449 -177.516 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 381' ' ' TRP . . . . . 0.493 ' CE3' ' HB3' ' A' ' 368' ' ' PHE . 48.3 m95 -64.23 126.49 27.92 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.512 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 382' ' ' THR . . . . . . . . . . . . . 9.4 m -83.18 65.36 8.19 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 177.821 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 383' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -157.04 -75.84 0.09 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.426 -0.806 . . . . 0.0 109.638 -176.19 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 384' ' ' ASN . . . . . . . . . . . . . 25.3 t-20 -113.2 -61.38 1.75 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.125 -176.395 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 385' ' ' GLY . . . . . . . . . . . . . . . 134.67 -156.87 22.69 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 386' ' ' GLY . . . . . . . . . . . . . . . 72.16 -82.99 0.53 Allowed Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 121.298 -0.477 . . . . 0.0 112.463 179.148 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.47 128.73 39.02 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 121.18 -0.533 . . . . 0.0 112.448 -179.132 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -94.19 167.54 11.49 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.517 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 22.2 t -128.35 121.18 54.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 175.996 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 390' ' ' SER . . . . . 0.417 ' O ' ' HA3' ' A' ' 403' ' ' GLY . 39.5 m -117.98 155.61 29.97 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.521 -0.309 . . . . 0.0 110.698 -177.375 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -165.64 144.67 9.42 Favored Glycine 0 N--CA 1.451 -0.349 0 N-CA-C 111.541 -0.623 . . . . 0.0 111.541 177.291 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 13.7 ptp180 -116.09 152.31 33.87 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.044 0.45 . . . . 0.0 110.895 -177.142 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 10.7 m-85 -98.1 157.59 16.05 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.889 0.852 . . . . 0.0 111.81 -175.857 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 394' ' ' TYR . . . . . 0.703 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 6.2 m-85 -102.94 -171.95 2.03 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 114.119 -1.4 . . . . 0.0 111.247 -175.075 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 395' ' ' GLY . . . . . 0.806 ' HA2' ' O ' ' A' ' 306' ' ' GLU . . . -33.15 157.59 0.01 OUTLIER Glycine 0 C--N 1.34 0.792 0 O-C-N 124.576 1.173 . . . . 0.0 114.215 -178.316 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 396' ' ' PRO . . . . . 0.957 ' HD3' ' HB3' ' A' ' 306' ' ' GLU . 12.2 Cg_endo -46.37 -17.98 0.41 Allowed 'Trans proline' 0 N--CA 1.482 0.818 1 C-N-CA 125.674 4.249 . . . . 0.0 116.831 -149.843 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 397' ' ' ALA . . . . . 0.435 ' N ' ' O ' ' A' ' 395' ' ' GLY . . . -90.89 -17.9 25.69 Favored 'General case' 0 C--N 1.316 -0.872 0 C-N-CA 120.728 -0.389 . . . . 0.0 111.83 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 72.74 16.35 77.95 Favored Glycine 0 C--N 1.336 0.56 0 C-N-CA 121.178 -0.534 . . . . 0.0 112.544 173.811 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 399' ' ' GLU . . . . . 0.478 ' HG2' ' CE ' ' A' ' 424' ' ' LYS . 28.5 mt-10 -67.7 -10.78 55.41 Favored 'General case' 0 C--N 1.332 -0.18 0 C-N-CA 122.902 0.481 . . . . 0.0 111.115 -174.766 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -123.31 136.02 54.48 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 173.1 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 401' ' ' VAL . . . . . 0.52 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 14.0 p -140.15 143.1 30.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.137 177.413 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -143.19 138.81 29.98 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.181 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 403' ' ' GLY . . . . . 0.417 ' HA3' ' O ' ' A' ' 390' ' ' SER . . . -157.25 -176.2 29.04 Favored Glycine 0 N--CA 1.441 -0.985 0 C-N-CA 120.379 -0.915 . . . . 0.0 112.185 -178.897 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 404' ' ' LYS . . . . . 0.841 ' HG2' HG12 ' A' ' 419' ' ' VAL . 52.2 mttt -145.34 158.85 43.75 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 -178.516 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 36.2 p90 -119.72 161.56 20.52 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.043 0.449 . . . . 0.0 111.34 179.658 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 19.2 t -83.9 111.34 19.15 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.673 178.837 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 407' ' ' TYR . . . . . 0.595 ' HE2' ' H ' ' A' ' 411' ' ' ASP . 19.7 p90 -60.31 135.09 57.63 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 114.918 -1.037 . . . . 0.0 111.929 -178.072 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 408' ' ' ARG . . . . . 0.558 ' HB2' ' HD3' ' A' ' 409' ' ' PRO . 57.1 mtp180 -42.56 -54.14 8.58 Favored Pre-proline 0 N--CA 1.471 0.612 0 N-CA-C 114.222 1.193 . . . . 0.0 114.222 -173.415 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 409' ' ' PRO . . . . . 0.558 ' HD3' ' HB2' ' A' ' 408' ' ' ARG . 55.1 Cg_exo -53.96 -36.07 82.62 Favored 'Trans proline' 0 C--N 1.358 1.053 0 C-N-CA 122.379 2.052 . . . . 0.0 113.084 -177.934 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 410' ' ' THR . . . . . . . . . . . . . 4.9 m 49.38 64.2 1.84 Allowed 'General case' 0 C--O 1.236 0.35 0 CA-C-O 121.225 0.536 . . . . 0.0 110.88 -178.031 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 411' ' ' ASP . . . . . 0.595 ' H ' ' HE2' ' A' ' 407' ' ' TYR . 15.2 m-20 -72.74 -49.74 29.02 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.365 -179.49 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 412' ' ' ALA . . . . . . . . . . . . . . . -121.19 152.77 38.41 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.577 -0.738 . . . . 0.0 109.956 178.132 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 413' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -76.39 64.35 2.11 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.752 -177.494 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 414' ' ' LYS . . . . . . . . . . . . . 45.1 mtmt -143.42 127.45 17.44 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.446 179.06 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 415' ' ' GLY . . . . . . . . . . . . . . . -90.11 132.17 11.13 Favored Glycine 0 N--CA 1.441 -1.003 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 167.748 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 416' ' ' GLY . . . . . 0.583 ' HA2' ' HD3' ' A' ' 404' ' ' LYS . . . 177.76 -40.57 0.09 OUTLIER Glycine 0 N--CA 1.446 -0.663 0 C-N-CA 119.647 -1.263 . . . . 0.0 113.048 -174.68 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 417' ' ' PHE . . . . . 0.66 ' HA ' ' HD2' ' A' ' 326' ' ' PHE . 28.3 m-85 -80.31 141.39 35.52 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 178.418 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 418' ' ' GLY . . . . . 0.514 ' H ' ' HD2' ' A' ' 326' ' ' PHE . . . 78.51 76.82 0.9 Allowed Glycine 0 N--CA 1.441 -1.018 0 C-N-CA 120.068 -1.063 . . . . 0.0 111.211 -174.468 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 419' ' ' VAL . . . . . 0.841 HG12 ' HG2' ' A' ' 404' ' ' LYS . 32.3 m -105.47 153.12 7.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-O 120.705 0.288 . . . . 0.0 110.388 -177.791 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 51.9 p90 -135.69 155.01 51.08 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.893 179.104 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 421' ' ' ALA . . . . . 0.591 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -143.72 136.1 26.96 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.089 179.384 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -129.98 133.6 7.5 Favored Glycine 0 N--CA 1.44 -1.044 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.038 -179.048 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 63.0 mttm -111.81 125.72 54.31 Favored 'General case' 0 C--N 1.313 -0.979 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 177.211 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 424' ' ' LYS . . . . . 0.598 ' HB2' ' CE2' ' A' ' 319' ' ' TYR . 27.2 ttpp -70.23 122.3 19.24 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 120.893 0.378 . . . . 0.0 110.101 178.551 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -97.28 126.31 42.41 Favored 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 176.685 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 426' ' ' GLN . . . . . . . . . . . . . 64.2 mt-30 -81.71 80.25 8.08 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.517 -178.228 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 427' ' ' ASP . . . . . . . . . . . . . 12.3 t70 76.43 136.4 0.06 Allowed 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 114.16 -1.382 . . . . 0.0 110.585 -177.191 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 96.0 mt -63.92 -30.92 71.96 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.353 -0.84 . . . . 0.0 111.415 -177.28 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 429' ' ' GLU . . . . . . . . . . . . . 42.6 mm-40 -92.67 63.96 4.07 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.496 0.665 . . . . 0.0 109.516 175.536 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 430' ' ' HIS . . . . . . . . . . . . . 36.1 t60 -82.87 70.27 9.83 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.81 -173.351 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 73.4 m-70 -100.05 39.39 1.34 Allowed 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 179.076 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 432' ' ' HIS . . . . . . . . . . . . . 46.8 t-80 -53.19 -37.59 62.08 Favored 'General case' 0 CA--C 1.529 0.141 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.789 -178.003 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 433' ' ' HIS . . . . . . . . . . . . . 44.7 t-80 -136.58 -51.13 0.68 Allowed 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 174.758 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 434' ' ' HIS . . . . . 0.543 ' O ' ' HB2' ' A' ' 435' ' ' HIS . 25.6 t60 -179.78 -56.35 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 106.534 -1.654 . . . . 0.0 106.534 169.105 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 435' ' ' HIS . . . . . 0.543 ' HB2' ' O ' ' A' ' 434' ' ' HIS . 4.6 t-160 . . . . . 0 C--O 1.248 0.987 0 CA-C-N 114.18 -1.373 . . . . 0.0 108.665 165.601 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 276' ' ' ASN . . . . . . . . . . . . . 30.3 p-10 . . . . . 0 N--CA 1.479 1.023 0 N-CA-C 111.354 0.131 . . . . 0.0 111.354 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 277' ' ' ILE . . . . . 0.569 HD11 ' HB3' ' A' ' 293' ' ' LYS . 7.0 mt -84.55 40.43 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -169.801 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 278' ' ' PHE . . . . . . . . . . . . . 51.1 p90 -63.92 138.88 58.67 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.203 -0.665 . . . . 0.0 109.203 175.394 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -162.32 97.01 1.17 Allowed Pre-proline 0 C--N 1.33 -0.26 0 CA-C-O 120.726 0.298 . . . . 0.0 111.661 -176.757 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 280' ' ' PRO . . . . . 0.425 ' HD2' ' HB3' ' A' ' 289' ' ' TYR . 89.3 Cg_endo -85.16 162.83 11.49 Favored 'Trans proline' 0 CA--C 1.534 0.515 0 C-N-CA 123.091 2.527 . . . . 0.0 113.471 176.484 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 281' ' ' GLU . . . . . 0.689 ' HB2' ' HE2' ' A' ' 284' ' ' TYR . 31.9 mt-10 76.91 -151.43 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.501 0 CA-C-N 115.221 -0.9 . . . . 0.0 112.717 169.688 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -82.17 -150.92 8.84 Favored Glycine 0 C--N 1.338 0.651 0 N-CA-C 114.791 0.676 . . . . 0.0 114.791 -166.324 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 283' ' ' ASN . . . . . 0.548 ' HA ' ' O ' ' A' ' 286' ' ' TYR . 16.9 p-10 -89.9 83.52 6.16 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.531 0.682 . . . . 0.0 112.594 -170.384 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 284' ' ' TYR . . . . . 0.689 ' HE2' ' HB2' ' A' ' 281' ' ' GLU . 18.3 m-85 -101.47 98.88 9.16 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.649 -0.705 . . . . 0.0 109.28 173.977 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 285' ' ' ARG . . . . . 0.797 ' HB2' ' HD2' ' A' ' 302' ' ' ARG . 5.1 ttp180 65.06 49.48 2.03 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 -168.639 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.557 ' HB3' ' O ' ' A' ' 285' ' ' ARG . 83.6 t80 75.88 -49.33 0.61 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 114.966 -1.015 . . . . 0.0 109.411 -167.377 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 287' ' ' LEU . . . . . 0.422 ' HA ' ' H ' ' A' ' 284' ' ' TYR . 13.7 tp 179.1 123.85 0.05 Allowed 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 124.141 0.977 . . . . 0.0 108.538 170.082 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 288' ' ' THR . . . . . . . . . . . . . 38.3 m -174.03 130.14 0.39 Allowed 'General case' 0 N--CA 1.452 -0.34 0 O-C-N 123.542 0.526 . . . . 0.0 110.016 179.097 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 289' ' ' TYR . . . . . 0.425 ' HB3' ' HD2' ' A' ' 280' ' ' PRO . 2.7 t80 -146.01 116.59 7.6 Favored 'General case' 0 C--N 1.313 -0.992 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 164.233 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 108.42 -151.06 17.06 Favored Glycine 0 N--CA 1.437 -1.269 0 C-N-CA 118.823 -1.656 . . . . 0.0 110.574 -172.239 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 291' ' ' ALA . . . . . 0.678 ' HA ' HD13 ' A' ' 301' ' ' LEU . . . -93.91 136.92 33.7 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-O 121.337 0.589 . . . . 0.0 111.021 -177.956 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 292' ' ' GLU . . . . . 0.595 ' HG3' ' HB3' ' A' ' 300' ' ' ALA . 8.7 pt-20 -109.5 164.53 12.43 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 175.604 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 293' ' ' LYS . . . . . 0.569 ' HB3' HD11 ' A' ' 277' ' ' ILE . 53.6 tptt -116.9 134.15 55.12 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 121.15 0.5 . . . . 0.0 111.197 -178.091 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 294' ' ' LEU . . . . . 0.611 ' HB2' ' HB2' ' A' ' 298' ' ' SER . 61.6 mt -103.85 145.12 30.04 Favored Pre-proline 0 C--N 1.319 -0.735 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.345 176.624 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 295' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -54.5 97.05 0.05 OUTLIER 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 123.15 2.566 . . . . 0.0 112.092 179.136 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . 142.73 -140.56 9.92 Favored Glycine 0 N--CA 1.445 -0.741 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 -175.375 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . -105.22 3.18 40.48 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 120.523 -0.846 . . . . 0.0 112.081 179.352 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 298' ' ' SER . . . . . 0.611 ' HB2' ' HB2' ' A' ' 294' ' ' LEU . 6.1 m -81.45 143.26 32.22 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.273 0.558 . . . . 0.0 111.914 -174.701 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 299' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -122.59 142.35 50.73 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 108.231 -1.026 . . . . 0.0 108.231 172.798 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 300' ' ' ALA . . . . . 0.595 ' HB3' ' HG3' ' A' ' 292' ' ' GLU . . . -132.82 161.87 33.0 Favored 'General case' 0 C--N 1.319 -0.738 0 C-N-CA 120.777 -0.369 . . . . 0.0 111.652 -178.132 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 301' ' ' LEU . . . . . 0.678 HD13 ' HA ' ' A' ' 291' ' ' ALA . 2.5 mm? -121.84 123.33 41.52 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 175.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 302' ' ' ARG . . . . . 0.797 ' HD2' ' HB2' ' A' ' 285' ' ' ARG . 0.0 OUTLIER -128.07 125.0 38.44 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 172.787 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 303' ' ' VAL . . . . . . . . . . . . . 2.2 m -140.56 148.87 21.69 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.917 0 CA-C-N 116.223 -0.444 . . . . 0.0 109.85 175.021 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 304' ' ' GLN . . . . . 0.633 ' HB2' ' HD1' ' A' ' 284' ' ' TYR . 18.7 mm-40 -125.51 116.76 22.3 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 121.123 0.487 . . . . 0.0 110.277 178.801 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 305' ' ' GLY . . . . . 0.415 ' O ' ' HD3' ' A' ' 307' ' ' PRO . . . -176.81 169.27 41.63 Favored Glycine 0 N--CA 1.446 -0.687 0 CA-C-N 115.049 -0.978 . . . . 0.0 110.844 -179.321 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 306' ' ' GLU . . . . . 0.45 ' HB3' ' CA ' ' A' ' 395' ' ' GLY . 10.7 mp0 -114.2 90.67 20.82 Favored Pre-proline 0 C--N 1.323 -0.561 0 CA-C-N 117.063 0.432 . . . . 0.0 110.221 176.991 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 307' ' ' PRO . . . . . 0.415 ' HD3' ' O ' ' A' ' 305' ' ' GLY . 10.2 Cg_endo -90.86 122.58 0.83 Allowed 'Trans proline' 0 N--CA 1.457 -0.618 0 C-N-CA 123.441 2.761 . . . . 0.0 112.848 177.475 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 308' ' ' ALA . . . . . 0.895 ' HB1' HD22 ' A' ' 313' ' ' LEU . . . -58.13 157.23 8.43 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.844 170.621 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 309' ' ' LYS . . . . . 0.498 ' N ' HD23 ' A' ' 313' ' ' LEU . 63.1 mttp -128.43 98.42 5.04 Favored 'General case' 0 C--O 1.222 -0.364 0 C-N-CA 121.022 -0.271 . . . . 0.0 110.425 -176.328 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -48.23 -43.23 25.77 Favored Glycine 0 CA--C 1.519 0.304 0 N-CA-C 114.978 0.751 . . . . 0.0 114.978 -167.784 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -76.45 -9.46 58.67 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 112.846 0.684 . . . . 0.0 112.846 -177.989 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 2.5 tpt -113.93 -37.39 4.51 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.72 0.771 . . . . 0.0 109.654 -177.396 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 313' ' ' LEU . . . . . 0.895 HD22 ' HB1' ' A' ' 308' ' ' ALA . 0.6 OUTLIER -81.39 129.99 34.86 Favored 'General case' 0 N--CA 1.44 -0.938 0 CA-C-N 114.677 -1.147 . . . . 0.0 109.143 178.161 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 314' ' ' ALA . . . . . 0.643 ' HA ' ' CB ' ' A' ' 346' ' ' PHE . . . -159.19 175.57 13.28 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.989 -170.726 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.4 160.77 11.27 Favored Glycine 0 N--CA 1.447 -0.597 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -177.621 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 18.7 p -96.87 125.12 41.08 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 173.258 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -132.08 149.67 52.35 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 113.15 0.796 . . . . 0.0 113.15 -163.417 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 7.7 p -118.95 113.64 42.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 CA-C-N 115.039 -0.982 . . . . 0.0 110.338 176.067 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 319' ' ' TYR . . . . . 0.46 ' CE2' ' HB2' ' A' ' 424' ' ' LYS . 27.1 m-85 -108.04 140.68 40.84 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.583 177.454 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 2.4 p-10 -142.75 143.78 32.37 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.65 174.671 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -166.32 -150.26 6.27 Favored Glycine 0 N--CA 1.443 -0.863 0 C-N-CA 120.931 -0.652 . . . . 0.0 111.874 -178.153 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -129.49 147.81 51.33 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.124 0.488 . . . . 0.0 111.038 -176.541 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 323' ' ' VAL . . . . . 0.581 ' O ' ' HA ' ' A' ' 337' ' ' ARG . 54.6 t -106.14 142.31 19.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.331 -178.876 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 324' ' ' LEU . . . . . . . . . . . . . 17.2 tp -124.87 103.95 8.34 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 110.21 -0.293 . . . . 0.0 110.21 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 325' ' ' HIS . . . . . 0.841 ' CE1' ' HB ' ' A' ' 336' ' ' THR . 7.0 p80 -103.21 117.19 33.97 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.501 0.667 . . . . 0.0 111.429 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 326' ' ' PHE . . . . . 0.605 ' HD1' ' H ' ' A' ' 418' ' ' GLY . 22.9 m-85 -89.71 129.85 36.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 114.705 -1.134 . . . . 0.0 110.351 -173.119 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 327' ' ' HIS . . . . . . . . . . . . . 51.4 p-80 -176.26 172.53 2.29 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.139 -0.482 . . . . 0.0 109.863 -178.244 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 328' ' ' THR . . . . . . . . . . . . . 58.1 m -93.08 100.14 12.61 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 172.392 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 329' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 -81.58 159.56 24.05 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.212 -176.087 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 330' ' ' ASN . . . . . . . . . . . . . 32.9 m-80 -80.82 52.79 1.79 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.578 0.704 . . . . 0.0 109.426 177.806 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 331' ' ' GLY . . . . . . . . . . . . . . . -174.56 -176.41 42.89 Favored Glycine 0 N--CA 1.443 -0.89 0 CA-C-N 114.923 -1.035 . . . . 0.0 110.807 -176.218 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 332' ' ' ARG . . . . . 0.496 ' N ' ' HD2' ' A' ' 333' ' ' PRO . 95.9 mtt180 -77.05 -38.32 1.93 Allowed Pre-proline 0 C--N 1.319 -0.719 0 N-CA-C 112.683 0.623 . . . . 0.0 112.683 179.782 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 333' ' ' PRO . . . . . 0.496 ' HD2' ' N ' ' A' ' 332' ' ' ARG . 59.8 Cg_endo -74.35 86.46 1.32 Allowed 'Trans proline' 0 C--N 1.354 0.837 0 C-N-CA 121.462 1.441 . . . . 0.0 111.911 172.341 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 334' ' ' TYR . . . . . 0.764 ' HB2' ' HD3' ' A' ' 335' ' ' PRO . 78.7 m-85 -62.4 -53.68 55.71 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.304 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 335' ' ' PRO . . . . . 0.764 ' HD3' ' HB2' ' A' ' 334' ' ' TYR . 3.4 Cg_exo -80.39 127.08 6.43 Favored 'Trans proline' 0 N--CA 1.451 -1.012 0 C-N-CA 121.572 1.515 . . . . 0.0 110.427 172.457 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 336' ' ' THR . . . . . 0.841 ' HB ' ' CE1' ' A' ' 325' ' ' HIS . 0.3 OUTLIER -119.68 147.54 44.44 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 -177.141 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 337' ' ' ARG . . . . . 0.581 ' HA ' ' O ' ' A' ' 323' ' ' VAL . 0.0 OUTLIER -102.56 157.7 16.75 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.187 0.517 . . . . 0.0 110.82 -177.105 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -136.12 178.55 18.67 Favored Glycine 0 N--CA 1.443 -0.889 0 CA-C-N 115.392 -0.822 . . . . 0.0 111.178 176.113 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 339' ' ' ARG . . . . . 0.582 ' O ' ' HA ' ' A' ' 355' ' ' ILE . 57.8 mtp180 -104.02 132.89 49.82 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 -179.093 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 340' ' ' PHE . . . . . 0.574 ' HB2' HG23 ' A' ' 323' ' ' VAL . 36.8 t80 -133.9 132.2 40.01 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 121.057 0.456 . . . . 0.0 111.108 -175.848 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 341' ' ' ALA . . . . . . . . . . . . . . . -134.72 168.39 19.11 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 172.263 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -155.22 139.65 16.79 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.095 0.474 . . . . 0.0 111.023 -176.48 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 343' ' ' LYS . . . . . 0.525 ' HB3' ' HB2' ' A' ' 352' ' ' ASP . 24.9 tptp -115.97 97.32 6.02 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 179.222 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 344' ' ' VAL . . . . . 0.698 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.9 OUTLIER -121.05 135.61 60.68 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 CA-C-O 121.526 0.679 . . . . 0.0 111.627 -170.234 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -117.04 101.13 8.23 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-N 114.884 -1.053 . . . . 0.0 108.284 -178.653 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 346' ' ' PHE . . . . . 0.689 ' O ' ' HE3' ' A' ' 349' ' ' LYS . 67.4 m-85 -69.75 -25.96 64.07 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 -173.476 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -64.01 -22.15 66.46 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.533 -0.841 . . . . 0.0 111.917 176.579 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 48.2 t -108.84 -4.24 17.02 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.033 0.444 . . . . 0.0 110.499 178.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 349' ' ' LYS . . . . . 0.689 ' HE3' ' O ' ' A' ' 346' ' ' PHE . 8.2 mmpt? 49.7 50.98 17.36 Favored 'General case' 0 C--O 1.226 -0.176 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.581 -172.187 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 8.3 m -134.08 146.31 50.18 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.104 -178.178 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 351' ' ' VAL . . . . . 0.698 ' HB ' ' HB ' ' A' ' 344' ' ' VAL . 0.1 OUTLIER -149.36 133.92 9.51 Favored 'Isoleucine or valine' 0 C--O 1.236 0.365 0 CA-C-O 121.531 0.681 . . . . 0.0 112.552 -175.617 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 352' ' ' ASP . . . . . 0.646 ' HA ' ' HD3' ' A' ' 369' ' ' LYS . 1.5 m-20 -95.24 155.48 16.72 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 114.676 -1.147 . . . . 0.0 108.961 173.21 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 353' ' ' GLY . . . . . 0.521 ' C ' ' HB3' ' A' ' 367' ' ' LYS . . . -142.38 152.17 23.53 Favored Glycine 0 N--CA 1.44 -1.091 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 172.508 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 354' ' ' ILE . . . . . 0.484 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -146.78 130.12 9.1 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 116.964 0.382 . . . . 0.0 110.087 -179.643 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 355' ' ' ILE . . . . . 0.894 HD11 ' HE2' ' A' ' 367' ' ' LYS . 82.5 mt -126.16 125.99 68.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 CA-C-O 121.064 0.459 . . . . 0.0 111.919 178.32 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 356' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -109.8 120.41 42.39 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.285 -0.871 . . . . 0.0 108.857 174.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 23.8 t -85.71 1.49 49.23 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.267 0.556 . . . . 0.0 110.6 -177.021 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 358' ' ' GLY . . . . . . . . . . . . . . . 129.08 -32.03 3.35 Favored Glycine 0 N--CA 1.444 -0.807 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 -178.497 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 359' ' ' ASP . . . . . 0.577 ' OD2' ' HB2' ' A' ' 362' ' ' HIS . 9.5 t70 -133.44 95.57 3.53 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.485 0.659 . . . . 0.0 110.894 178.753 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 360' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -83.65 -24.43 31.37 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.594 175.734 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 361' ' ' LEU . . . . . 0.467 HD22 ' N ' ' A' ' 361' ' ' LEU . 3.1 mm? -74.45 -35.4 63.33 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 113.052 0.76 . . . . 0.0 113.052 -171.373 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 362' ' ' HIS . . . . . 0.577 ' HB2' ' OD2' ' A' ' 359' ' ' ASP . 98.1 m-70 -107.79 -59.33 1.85 Allowed 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.426 -0.51 . . . . 0.0 111.25 -177.42 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 363' ' ' MET . . . . . . . . . . . . . 26.2 mmt -62.35 -29.47 70.49 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.451 -179.238 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 364' ' ' GLY . . . . . . . . . . . . . . . 67.49 74.5 0.56 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.788 -0.72 . . . . 0.0 111.579 -179.752 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 365' ' ' THR . . . . . . . . . . . . . 3.2 m -101.49 115.05 29.63 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.051 0.453 . . . . 0.0 110.447 -175.664 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 82.5 mt-30 -120.98 178.55 4.68 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.859 179.574 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 367' ' ' LYS . . . . . 0.975 ' HA ' ' HZ3' ' A' ' 381' ' ' TRP . 19.3 tttm -131.03 172.91 11.54 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.096 0.474 . . . . 0.0 110.899 176.165 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 368' ' ' PHE . . . . . 0.826 ' H ' ' HG2' ' A' ' 367' ' ' LYS . 0.1 OUTLIER -73.89 163.16 28.28 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.113 -0.949 . . . . 0.0 111.814 -172.306 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 369' ' ' LYS . . . . . 0.646 ' HD3' ' HA ' ' A' ' 352' ' ' ASP . 0.0 OUTLIER -113.86 134.23 54.93 Favored 'General case' 0 C--N 1.314 -0.957 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 169.171 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 370' ' ' ALA . . . . . 0.672 ' HB2' ' CE2' ' A' ' 368' ' ' PHE . . . -130.2 162.85 27.98 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 113.095 0.776 . . . . 0.0 113.095 -172.579 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -116.73 135.93 53.37 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 114.657 -1.156 . . . . 0.0 108.924 171.401 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 372' ' ' ILE . . . . . 0.546 HG13 HG12 ' A' ' 351' ' ' VAL . 83.0 mt -82.69 115.04 24.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.142 0.496 . . . . 0.0 111.06 -177.004 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -104.92 83.38 1.99 Allowed 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.333 177.891 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 79.67 -118.8 4.82 Favored Glycine 0 N--CA 1.446 -0.678 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.559 -179.664 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 375' ' ' ASN . . . . . 0.484 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 3.2 p-10 -98.81 50.21 0.97 Allowed 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.65 0.738 . . . . 0.0 111.425 -176.147 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 165.08 175.05 35.42 Favored Glycine 0 N--CA 1.445 -0.716 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 -179.155 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 377' ' ' PHE . . . . . 0.553 ' CZ ' HG21 ' A' ' 401' ' ' VAL . 3.7 p90 -140.99 153.16 45.44 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.551 0.691 . . . . 0.0 111.703 177.918 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 378' ' ' LYS . . . . . . . . . . . . . 15.6 ptpt -131.99 138.38 48.24 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 114.498 -1.228 . . . . 0.0 108.484 175.677 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -151.55 -161.76 10.31 Favored Glycine 0 N--CA 1.443 -0.85 0 C-N-CA 120.068 -1.063 . . . . 0.0 112.61 -176.374 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 380' ' ' THR . . . . . 0.435 ' C ' ' HB2' ' A' ' 368' ' ' PHE . 6.5 t -144.57 140.62 28.89 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.811 0.339 . . . . 0.0 110.942 -175.254 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 381' ' ' TRP . . . . . 0.975 ' HZ3' ' HA ' ' A' ' 367' ' ' LYS . 50.4 m95 -56.82 145.43 29.54 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.98 178.439 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 382' ' ' THR . . . . . . . . . . . . . 25.8 p -78.28 -5.77 53.02 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.077 -0.511 . . . . 0.0 112.305 179.261 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 383' ' ' GLU . . . . . 0.61 ' HG3' ' HB3' ' A' ' 381' ' ' TRP . 0.0 OUTLIER -82.02 52.98 2.09 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 121.222 0.534 . . . . 0.0 110.655 178.344 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 384' ' ' ASN . . . . . 0.542 ' HB2' ' O ' ' A' ' 383' ' ' GLU . 10.9 m120 80.21 -39.7 0.18 Allowed 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 114.683 -1.144 . . . . 0.0 111.322 -173.446 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 385' ' ' GLY . . . . . . . . . . . . . . . 115.87 52.46 0.39 Allowed Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.669 -0.777 . . . . 0.0 111.875 179.304 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 386' ' ' GLY . . . . . . . . . . . . . . . -81.48 -19.85 65.45 Favored Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.275 -178.589 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -137.3 147.88 19.48 Favored Glycine 0 N--CA 1.446 -0.638 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.341 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -93.74 154.13 17.95 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 178.617 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 389' ' ' VAL . . . . . 0.532 ' HB ' ' CD2' ' A' ' 368' ' ' PHE . 20.0 t -131.39 139.57 50.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.057 -179.095 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 10.8 m -141.6 141.03 33.46 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.659 0.266 . . . . 0.0 110.791 178.308 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -141.05 152.64 23.34 Favored Glycine 0 C--O 1.236 0.221 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.981 179.458 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 9.7 ptm180 -115.61 144.73 43.48 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 -175.821 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 393' ' ' PHE . . . . . 0.519 ' CZ ' ' HE1' ' A' ' 346' ' ' PHE . 1.2 m-85 -94.55 154.84 17.19 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.429 0.633 . . . . 0.0 111.979 -175.104 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 394' ' ' TYR . . . . . 0.719 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 3.5 m-85 -102.73 -176.78 3.19 Favored 'General case' 0 C--O 1.216 -0.686 0 CA-C-N 114.775 -1.102 . . . . 0.0 110.816 -178.823 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 395' ' ' GLY . . . . . 0.45 ' CA ' ' HB3' ' A' ' 306' ' ' GLU . . . -37.77 161.35 0.01 OUTLIER Glycine 0 C--N 1.335 0.505 0 O-C-N 124.333 1.021 . . . . 0.0 115.099 -175.816 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_exo -11.13 -57.03 0.0 OUTLIER 'Trans proline' 0 C--N 1.347 0.467 1 C-N-CA 127.386 5.391 . . . . 0.0 117.517 -162.393 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 397' ' ' ALA . . . . . 0.63 ' HB3' ' HG3' ' A' ' 399' ' ' GLU . . . -84.96 -11.12 56.22 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 112.678 0.621 . . . . 0.0 112.678 -167.391 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 67.2 22.18 72.48 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.226 -179.142 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 399' ' ' GLU . . . . . 0.63 ' HG3' ' HB3' ' A' ' 397' ' ' ALA . 50.5 mt-10 -63.63 -14.4 51.38 Favored 'General case' 0 CA--C 1.521 -0.154 0 CA-C-O 121.12 0.486 . . . . 0.0 111.148 -177.222 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -121.77 133.48 54.92 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 170.558 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 401' ' ' VAL . . . . . 0.553 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 9.9 p -140.99 135.0 32.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.85 176.147 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -131.25 139.59 49.67 Favored 'General case' 0 C--N 1.315 -0.935 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.771 178.293 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -162.89 156.04 27.61 Favored Glycine 0 N--CA 1.437 -1.272 0 C-N-CA 120.304 -0.95 . . . . 0.0 111.105 -174.149 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 404' ' ' LYS . . . . . 0.987 ' HG2' HG23 ' A' ' 419' ' ' VAL . 17.5 mtmt -123.9 162.73 22.74 Favored 'General case' 0 C--N 1.31 -1.144 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 -174.36 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 405' ' ' TYR . . . . . 0.539 ' CG ' ' HZ2' ' A' ' 381' ' ' TRP . 25.4 p90 -126.13 147.18 49.67 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-O 121.225 0.536 . . . . 0.0 111.466 179.22 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 7.9 m -88.84 103.48 16.03 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.768 176.667 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 407' ' ' TYR . . . . . 0.469 ' HD1' ' H ' ' A' ' 407' ' ' TYR . 3.3 p90 -87.54 138.71 31.24 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.385 0.612 . . . . 0.0 110.659 -178.775 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 408' ' ' ARG . . . . . . . . . . . . . 36.9 mtm180 -57.73 -44.49 99.49 Favored Pre-proline 0 N--CA 1.468 0.445 0 CA-C-N 114.502 -1.226 . . . . 0.0 114.148 -174.916 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 409' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -70.12 68.01 1.92 Allowed 'Trans proline' 0 C--N 1.354 0.825 0 C-N-CA 122.074 1.849 . . . . 0.0 112.137 176.778 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 410' ' ' THR . . . . . . . . . . . . . 3.4 t -67.13 87.72 0.16 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.736 0.779 . . . . 0.0 111.463 -178.182 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 411' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -77.31 -25.48 51.28 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.451 179.412 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 412' ' ' ALA . . . . . . . . . . . . . . . -98.1 -178.02 3.92 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.415 178.128 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 413' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 -61.94 -57.26 12.4 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.424 0.63 . . . . 0.0 111.245 -178.902 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 414' ' ' LYS . . . . . . . . . . . . . 13.8 pttp -118.98 142.17 48.02 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.371 -0.831 . . . . 0.0 111.06 -175.366 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 415' ' ' GLY . . . . . . . . . . . . . . . -73.12 145.11 35.78 Favored Glycine 0 N--CA 1.446 -0.683 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 175.71 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 416' ' ' GLY . . . . . . . . . . . . . . . 157.5 -20.88 0.4 Allowed Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.767 -175.043 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 417' ' ' PHE . . . . . 0.473 ' HB3' ' HB2' ' A' ' 326' ' ' PHE . 87.9 m-85 -71.5 163.45 27.7 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 173.823 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 418' ' ' GLY . . . . . 0.612 ' HA2' ' HA ' ' A' ' 325' ' ' HIS . . . 83.33 76.83 1.13 Allowed Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.024 -1.084 . . . . 0.0 110.933 -169.721 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 419' ' ' VAL . . . . . 0.987 HG23 ' HG2' ' A' ' 404' ' ' LYS . 8.4 p -107.33 166.03 4.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-O 121.28 0.562 . . . . 0.0 110.605 -177.576 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 420' ' ' PHE . . . . . 0.445 ' H ' HG22 ' A' ' 419' ' ' VAL . 41.8 p90 -140.76 157.53 45.29 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.224 -0.898 . . . . 0.0 109.904 177.218 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -142.69 136.06 28.63 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 177.122 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -121.74 138.42 12.27 Favored Glycine 0 N--CA 1.446 -0.668 0 C-N-CA 120.562 -0.828 . . . . 0.0 112.177 -177.726 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -110.78 127.11 55.24 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 178.629 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 424' ' ' LYS . . . . . 0.506 ' HB3' ' HB3' ' A' ' 399' ' ' GLU . 23.2 tptm -66.85 115.28 6.45 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.835 0.35 . . . . 0.0 110.603 176.972 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -98.86 113.24 25.28 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 175.427 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 426' ' ' GLN . . . . . . . . . . . . . 19.3 mp0 -86.39 78.57 9.24 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 179.704 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 427' ' ' ASP . . . . . 0.556 ' HA ' ' HB2' ' A' ' 430' ' ' HIS . 26.1 t70 -103.39 60.26 0.76 Allowed 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.418 0.628 . . . . 0.0 110.43 -177.9 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -70.66 -64.05 0.97 Allowed 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 176.025 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 429' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -128.77 20.72 5.99 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.934 173.663 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 430' ' ' HIS . . . . . 0.556 ' HB2' ' HA ' ' A' ' 427' ' ' ASP . 10.2 m80 -71.74 -173.79 1.04 Allowed 'General case' 0 C--O 1.232 0.162 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.654 -176.013 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 76.5 m80 60.51 52.33 4.69 Favored 'General case' 0 C--O 1.233 0.228 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 -168.39 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 432' ' ' HIS . . . . . . . . . . . . . 62.7 m170 -59.35 131.79 52.04 Favored 'General case' 0 CA--C 1.517 -0.293 0 CA-C-N 114.032 -1.44 . . . . 0.0 111.837 -173.039 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 433' ' ' HIS . . . . . 0.499 ' O ' ' HB2' ' A' ' 434' ' ' HIS . 15.6 t60 -137.08 87.17 2.26 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 176.358 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 434' ' ' HIS . . . . . 0.499 ' HB2' ' O ' ' A' ' 433' ' ' HIS . 71.6 m-70 74.83 -47.79 0.63 Allowed 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 123.712 0.805 . . . . 0.0 109.667 -167.732 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 435' ' ' HIS . . . . . . . . . . . . . 24.1 m80 . . . . . 0 C--O 1.246 0.918 0 CA-C-O 118.484 -0.769 . . . . 0.0 109.274 172.674 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 276' ' ' ASN . . . . . 0.537 ' ND2' ' HA ' ' A' ' 299' ' ' TYR . 96.8 m-20 . . . . . 0 N--CA 1.482 1.141 0 N-CA-C 110.784 -0.08 . . . . 0.0 110.784 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 2.4 mp -110.02 -53.05 5.97 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.306 0 CA-C-O 121.259 0.552 . . . . 0.0 110.976 177.856 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 278' ' ' PHE . . . . . 0.631 ' HE1' ' HE1' ' A' ' 299' ' ' TYR . 31.4 p90 -81.84 13.51 3.21 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.307 178.109 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -149.81 123.92 4.6 Favored Pre-proline 0 C--N 1.326 -0.452 0 CA-C-N 115.234 -0.894 . . . . 0.0 109.416 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 280' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_exo -63.06 162.21 26.97 Favored 'Trans proline' 0 N--CA 1.473 0.279 0 C-N-CA 123.302 2.668 . . . . 0.0 112.299 -179.708 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -59.36 102.93 0.15 Allowed 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.107 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 152.14 -160.06 28.68 Favored Glycine 0 N--CA 1.446 -0.645 0 N-CA-C 111.28 -0.728 . . . . 0.0 111.28 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 283' ' ' ASN . . . . . . . . . . . . . 21.4 p-10 -132.27 84.58 2.17 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.935 0.874 . . . . 0.0 110.497 177.508 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 63.5 m-85 -85.37 113.8 21.95 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.198 -179.718 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 11.5 ptp180 -92.59 -0.06 57.36 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.551 0.691 . . . . 0.0 109.886 176.821 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -98.98 11.81 37.85 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.019 -0.991 . . . . 0.0 108.839 171.194 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 287' ' ' LEU . . . . . 0.815 ' HG ' ' H ' ' A' ' 288' ' ' THR . 16.2 tp -74.23 175.51 7.5 Favored 'General case' 0 N--CA 1.442 -0.868 0 CA-C-N 114.715 -1.13 . . . . 0.0 110.533 -179.085 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 288' ' ' THR . . . . . 0.815 ' H ' ' HG ' ' A' ' 287' ' ' LEU . 26.7 m -89.74 166.1 13.78 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.927 -0.579 . . . . 0.0 109.514 -179.774 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 289' ' ' TYR . . . . . 0.721 ' N ' ' HB2' ' A' ' 304' ' ' GLN . 0.1 OUTLIER -102.12 123.46 46.02 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 -172.11 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . -179.27 152.12 10.82 Favored Glycine 0 N--CA 1.444 -0.8 0 N-CA-C 110.639 -0.985 . . . . 0.0 110.639 -178.453 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 291' ' ' ALA . . . . . 0.413 ' CB ' HD13 ' A' ' 301' ' ' LEU . . . -145.02 113.6 6.71 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 -175.931 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 292' ' ' GLU . . . . . . . . . . . . . 23.7 mt-10 -146.76 110.01 4.78 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.671 168.78 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 293' ' ' LYS . . . . . 0.787 ' HA ' ' HB3' ' A' ' 299' ' ' TYR . 36.9 ttpt -97.94 136.52 38.1 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 -178.962 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 294' ' ' LEU . . . . . 0.618 ' O ' HD13 ' A' ' 294' ' ' LEU . 0.0 OUTLIER -73.62 139.52 77.76 Favored Pre-proline 0 C--N 1.329 -0.323 0 C-N-CA 119.578 -0.849 . . . . 0.0 110.629 -174.784 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 295' ' ' PRO . . . . . 0.468 ' HD3' ' HA ' ' A' ' 294' ' ' LEU . 38.0 Cg_exo -60.57 89.92 0.09 OUTLIER 'Trans proline' 0 C--N 1.349 0.568 0 C-N-CA 123.258 2.638 . . . . 0.0 111.485 178.553 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . 169.17 -26.01 0.11 Allowed Glycine 0 N--CA 1.441 -1.019 0 N-CA-C 110.435 -1.066 . . . . 0.0 110.435 -172.405 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 111.82 -11.01 27.55 Favored Glycine 0 N--CA 1.442 -0.905 0 C-N-CA 120.529 -0.843 . . . . 0.0 113.841 171.159 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 298' ' ' SER . . . . . 0.514 ' O ' HD12 ' A' ' 294' ' ' LEU . 43.9 m -107.04 83.76 1.88 Allowed 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.879 0.847 . . . . 0.0 112.032 -174.509 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 299' ' ' TYR . . . . . 0.787 ' HB3' ' HA ' ' A' ' 293' ' ' LYS . 0.4 OUTLIER -166.97 171.19 11.4 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 114.649 -1.16 . . . . 0.0 109.439 178.81 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 300' ' ' ALA . . . . . 0.468 ' H ' ' HD1' ' A' ' 299' ' ' TYR . . . -158.04 161.48 38.05 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.783 -168.68 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 301' ' ' LEU . . . . . 0.413 HD13 ' CB ' ' A' ' 291' ' ' ALA . 0.2 OUTLIER -129.84 135.53 48.5 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.14 177.199 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 302' ' ' ARG . . . . . 0.682 ' HB3' HD23 ' A' ' 287' ' ' LEU . 3.8 tpp180 -114.43 166.5 11.62 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 -178.107 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 303' ' ' VAL . . . . . . . . . . . . . 35.1 m -106.81 149.32 10.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 CA-C-O 121.414 0.626 . . . . 0.0 112.553 -168.116 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 304' ' ' GLN . . . . . 0.721 ' HB2' ' N ' ' A' ' 289' ' ' TYR . 56.5 tt0 -108.37 150.73 26.97 Favored 'General case' 0 N--CA 1.444 -0.755 0 CA-C-N 114.795 -1.093 . . . . 0.0 108.657 172.699 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 305' ' ' GLY . . . . . 0.749 ' H ' ' HG3' ' A' ' 396' ' ' PRO . . . -95.15 178.01 35.54 Favored Glycine 0 N--CA 1.436 -1.343 0 C-N-CA 120.294 -0.955 . . . . 0.0 111.827 177.623 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 306' ' ' GLU . . . . . 0.728 ' HB2' ' HD2' ' A' ' 307' ' ' PRO . 12.7 pt-20 -83.52 -177.9 1.07 Allowed Pre-proline 0 C--N 1.315 -0.933 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 176.673 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 307' ' ' PRO . . . . . 0.757 ' HA ' ' HA2' ' A' ' 395' ' ' GLY . 98.0 Cg_exo -46.36 136.09 15.34 Favored 'Trans proline' 0 C--N 1.358 1.032 0 C-N-CA 122.097 1.865 . . . . 0.0 111.645 176.168 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 308' ' ' ALA . . . . . 0.713 ' HB1' HD11 ' A' ' 313' ' ' LEU . . . -31.44 106.6 0.04 OUTLIER 'General case' 0 CA--C 1.506 -0.727 0 O-C-N 124.923 1.39 . . . . 0.0 112.844 -165.591 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 309' ' ' LYS . . . . . 0.509 ' HE3' ' OE2' ' A' ' 311' ' ' GLU . 23.4 tptt -69.62 91.76 0.62 Allowed 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 115.222 -0.899 . . . . 0.0 109.97 -173.311 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 310' ' ' GLY . . . . . 0.72 ' HA2' HD12 ' A' ' 313' ' ' LEU . . . -60.6 -30.32 71.84 Favored Glycine 0 C--N 1.331 0.264 0 CA-C-N 115.578 -0.737 . . . . 0.0 114.086 -169.241 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 311' ' ' GLU . . . . . 0.509 ' OE2' ' HE3' ' A' ' 309' ' ' LYS . 4.8 pm0 -72.42 -17.06 61.83 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 120.74 0.305 . . . . 0.0 111.069 179.15 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 66.2 mtm -117.13 -0.18 12.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.797 0.332 . . . . 0.0 110.922 178.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 313' ' ' LEU . . . . . 0.72 HD12 ' HA2' ' A' ' 310' ' ' GLY . 83.8 mt -70.93 134.37 47.17 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 173.34 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -149.66 137.92 20.59 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.331 -173.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.77 171.95 14.49 Favored Glycine 0 N--CA 1.444 -0.799 0 N-CA-C 111.385 -0.686 . . . . 0.0 111.385 179.401 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 42.5 p -102.61 149.4 24.46 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 173.996 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -142.78 148.28 36.92 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 121.16 0.505 . . . . 0.0 112.32 -175.258 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 318' ' ' VAL . . . . . 0.534 ' O ' ' HA ' ' A' ' 424' ' ' LYS . 13.8 t -114.56 104.32 16.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.913 175.329 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 319' ' ' TYR . . . . . 0.508 ' HH ' ' HZ ' ' A' ' 346' ' ' PHE . 60.3 m-85 -97.88 127.33 43.76 Favored 'General case' 0 C--N 1.312 -1.05 0 C-N-CA 120.264 -0.574 . . . . 0.0 110.046 177.168 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 4.1 p-10 -138.31 145.16 40.87 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 178.799 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -172.14 -152.28 8.4 Favored Glycine 0 N--CA 1.44 -1.083 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.856 -177.696 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -114.49 143.74 44.46 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 120.897 0.38 . . . . 0.0 110.779 -174.413 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 323' ' ' VAL . . . . . 0.644 HG23 ' HB2' ' A' ' 340' ' ' PHE . 59.1 t -106.8 116.62 50.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.935 175.258 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 324' ' ' LEU . . . . . 0.658 HD11 ' HB2' ' A' ' 335' ' ' PRO . 24.9 tp -97.53 102.69 14.51 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-O 121.139 0.495 . . . . 0.0 109.889 -179.505 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 325' ' ' HIS . . . . . . . . . . . . . 3.8 p80 -105.03 114.72 29.09 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.344 0.592 . . . . 0.0 109.73 176.691 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 326' ' ' PHE . . . . . 0.735 ' HD1' ' HB2' ' A' ' 417' ' ' PHE . 31.3 m-85 -82.9 114.69 21.37 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.168 -0.924 . . . . 0.0 110.96 -170.167 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 327' ' ' HIS . . . . . . . . . . . . . 76.1 m80 -110.79 105.23 14.01 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 171.05 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 328' ' ' THR . . . . . 0.549 HG22 ' HA ' ' A' ' 332' ' ' ARG . 22.1 p -137.01 96.01 3.22 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.253 0.549 . . . . 0.0 109.65 172.829 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 329' ' ' GLU . . . . . 0.416 ' O ' ' HB3' ' A' ' 330' ' ' ASN . 39.5 mt-10 -108.99 120.39 42.39 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.619 -0.718 . . . . 0.0 109.675 178.34 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 330' ' ' ASN . . . . . 0.416 ' HB3' ' O ' ' A' ' 329' ' ' GLU . 54.2 t30 72.94 -57.92 0.62 Allowed 'General case' 0 N--CA 1.468 0.453 0 O-C-N 123.903 0.752 . . . . 0.0 110.721 -176.049 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 331' ' ' GLY . . . . . 0.446 ' O ' ' HD3' ' A' ' 333' ' ' PRO . . . -124.32 174.72 17.0 Favored Glycine 0 N--CA 1.449 -0.497 0 N-CA-C 111.757 -0.537 . . . . 0.0 111.757 177.695 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 332' ' ' ARG . . . . . 0.549 ' HA ' HG22 ' A' ' 328' ' ' THR . 72.5 mtp180 -108.38 96.86 20.1 Favored Pre-proline 0 C--N 1.325 -0.483 0 N-CA-C 110.247 -0.279 . . . . 0.0 110.247 178.853 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 333' ' ' PRO . . . . . 0.446 ' HD3' ' O ' ' A' ' 331' ' ' GLY . 1.1 Cg_endo -84.07 -79.05 0.0 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 123.045 2.497 . . . . 0.0 113.006 -178.325 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 334' ' ' TYR . . . . . . . . . . . . . 86.1 t80 -161.27 126.23 2.15 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.333 -177.074 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 335' ' ' PRO . . . . . 0.658 ' HB2' HD11 ' A' ' 324' ' ' LEU . 5.2 Cg_exo -80.17 127.89 7.0 Favored 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 122.697 2.265 . . . . 0.0 111.137 174.971 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 336' ' ' THR . . . . . . . . . . . . . 4.8 p -94.88 139.18 31.67 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.088 0.471 . . . . 0.0 111.126 -179.044 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 337' ' ' ARG . . . . . 0.513 ' HA ' ' O ' ' A' ' 323' ' ' VAL . 24.2 mtm180 -103.81 128.67 51.23 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.428 0.632 . . . . 0.0 110.664 178.151 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -95.21 -177.12 37.62 Favored Glycine 0 N--CA 1.439 -1.111 0 CA-C-N 115.222 -0.899 . . . . 0.0 111.613 176.969 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 339' ' ' ARG . . . . . 0.459 ' HB2' ' HB3' ' A' ' 356' ' ' ASP . 56.1 mtp180 -106.09 133.48 50.73 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 -176.133 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 340' ' ' PHE . . . . . 0.644 ' HB2' HG23 ' A' ' 323' ' ' VAL . 26.1 t80 -132.43 139.46 48.03 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-O 120.986 0.422 . . . . 0.0 111.342 -176.226 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 341' ' ' ALA . . . . . . . . . . . . . . . -142.86 165.85 26.24 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.223 -0.899 . . . . 0.0 109.374 174.509 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -157.18 134.09 10.19 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-O 120.875 0.369 . . . . 0.0 110.901 -174.296 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 343' ' ' LYS . . . . . 0.401 ' HB3' ' HB2' ' A' ' 352' ' ' ASP . 4.5 tppp? -108.03 102.8 11.94 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.06 178.799 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 344' ' ' VAL . . . . . 0.659 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.3 OUTLIER -125.83 133.34 69.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 CA-C-O 121.703 0.763 . . . . 0.0 112.553 -172.08 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -102.31 121.9 43.19 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 114.586 -1.188 . . . . 0.0 108.176 172.082 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 346' ' ' PHE . . . . . 0.508 ' HZ ' ' HH ' ' A' ' 319' ' ' TYR . 33.1 m-85 -72.3 -37.92 68.84 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 120.979 -0.288 . . . . 0.0 110.931 -179.108 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -61.0 -30.51 73.65 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.111 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 47.8 t -97.88 -10.02 25.35 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 123.008 -0.113 . . . . 0.0 110.783 -179.666 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 349' ' ' LYS . . . . . 0.481 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 29.0 mtmt 47.35 55.69 7.9 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-O 121.62 0.724 . . . . 0.0 111.266 -176.22 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 29.1 m -147.52 138.94 23.81 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.632 179.483 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 351' ' ' VAL . . . . . 0.659 ' HB ' ' HB ' ' A' ' 344' ' ' VAL . 0.6 OUTLIER -130.1 148.46 33.17 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 CA-C-O 121.288 0.566 . . . . 0.0 111.379 -174.894 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 352' ' ' ASP . . . . . 0.401 ' HB2' ' HB3' ' A' ' 343' ' ' LYS . 6.3 m-20 -100.46 151.78 21.15 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 107.179 -1.415 . . . . 0.0 107.179 165.915 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 353' ' ' GLY . . . . . 0.64 ' HA3' ' CE1' ' A' ' 368' ' ' PHE . . . -142.52 138.17 8.26 Favored Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.483 -0.865 . . . . 0.0 111.541 175.217 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 354' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -121.68 129.74 75.23 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-O 121.185 0.516 . . . . 0.0 109.818 178.669 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 355' ' ' ILE . . . . . 0.765 HG13 ' CZ3' ' A' ' 381' ' ' TRP . 7.0 mm -119.34 98.94 6.88 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.591 -174.23 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 356' ' ' ASP . . . . . 0.459 ' HB3' ' HB2' ' A' ' 339' ' ' ARG . 12.2 t0 -95.54 139.0 32.43 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 176.382 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 24.1 t -91.02 -8.15 49.9 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.365 0.602 . . . . 0.0 109.492 179.095 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 358' ' ' GLY . . . . . 0.411 ' H ' ' CG ' ' A' ' 356' ' ' ASP . . . 106.82 -9.96 40.77 Favored Glycine 0 N--CA 1.444 -0.82 0 N-CA-C 110.075 -1.21 . . . . 0.0 110.075 -173.922 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 359' ' ' ASP . . . . . 0.493 ' HB3' ' HB2' ' A' ' 362' ' ' HIS . 13.6 m-20 -120.92 45.29 2.29 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 114.662 -0.769 . . . . 0.0 110.336 -175.537 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 360' ' ' ASP . . . . . 0.48 ' OD1' ' HB ' ' A' ' 365' ' ' THR . 9.6 t70 -56.19 -35.08 66.85 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 121.131 0.491 . . . . 0.0 110.694 176.773 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 361' ' ' LEU . . . . . . . . . . . . . 93.0 mt -77.9 -0.95 29.45 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.548 -179.314 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 362' ' ' HIS . . . . . 0.493 ' HB2' ' HB3' ' A' ' 359' ' ' ASP . 22.1 m170 -105.05 -89.76 0.41 Allowed 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.642 0.258 . . . . 0.0 110.53 -179.397 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 363' ' ' MET . . . . . . . . . . . . . 3.6 mpp? -79.23 -18.58 52.58 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.227 0.537 . . . . 0.0 110.457 -179.096 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 364' ' ' GLY . . . . . . . . . . . . . . . 104.01 170.75 25.2 Favored Glycine 0 N--CA 1.443 -0.855 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -174.814 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 365' ' ' THR . . . . . 0.48 ' HB ' ' OD1' ' A' ' 360' ' ' ASP . 12.1 t -93.33 154.68 17.84 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 120.922 0.391 . . . . 0.0 110.411 179.23 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 79.4 mt-30 -107.28 162.94 13.44 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 178.091 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 367' ' ' LYS . . . . . 0.443 ' HG3' ' HA ' ' A' ' 382' ' ' THR . 8.7 ptpp? -147.22 168.94 20.42 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.138 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 368' ' ' PHE . . . . . 0.64 ' CE1' ' HA3' ' A' ' 353' ' ' GLY . 31.6 p90 -151.49 156.08 39.86 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 175.164 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 1.7 mptp? -118.94 130.77 55.89 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 175.838 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 370' ' ' ALA . . . . . 0.518 ' HA ' ' HA3' ' A' ' 379' ' ' GLY . . . -135.75 141.47 44.83 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.104 -175.884 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -102.51 136.04 43.05 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.724 176.747 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 372' ' ' ILE . . . . . 0.481 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 74.9 mt -81.18 114.26 21.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 121.545 0.688 . . . . 0.0 110.528 -177.801 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 373' ' ' ASP . . . . . 0.424 ' HB2' ' HE3' ' A' ' 378' ' ' LYS . 36.0 t70 -117.11 80.75 1.53 Allowed 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 114.704 -1.135 . . . . 0.0 109.158 -178.834 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 61.18 119.12 0.01 OUTLIER Glycine 0 CA--C 1.52 0.372 0 CA-C-N 114.968 -1.014 . . . . 0.0 113.408 -175.73 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 375' ' ' ASN . . . . . 0.598 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 3.6 p-10 26.13 48.1 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 124.582 1.153 . . . . 0.0 114.08 179.519 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 162.95 171.45 29.19 Favored Glycine 0 N--CA 1.444 -0.81 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 178.771 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 377' ' ' PHE . . . . . 0.43 ' CD2' HG11 ' A' ' 351' ' ' VAL . 4.0 p90 -138.83 147.94 43.11 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.458 0.647 . . . . 0.0 111.983 -179.245 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 378' ' ' LYS . . . . . 0.424 ' HE3' ' HB2' ' A' ' 373' ' ' ASP . 0.0 OUTLIER -130.59 133.13 45.93 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 114.775 -1.102 . . . . 0.0 109.659 173.468 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 379' ' ' GLY . . . . . 0.518 ' HA3' ' HA ' ' A' ' 370' ' ' ALA . . . -154.85 -158.36 8.67 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.489 -176.472 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -138.17 151.85 48.12 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 120.74 0.305 . . . . 0.0 111.489 -173.835 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 381' ' ' TRP . . . . . 0.765 ' CZ3' HG13 ' A' ' 355' ' ' ILE . 19.3 m95 -56.36 139.19 49.39 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.992 176.668 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 382' ' ' THR . . . . . 0.443 ' HA ' ' HG3' ' A' ' 367' ' ' LYS . 8.0 m 63.86 -78.35 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.244 -176.153 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 383' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -163.29 -32.87 0.04 OUTLIER 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.8 175.295 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 384' ' ' ASN . . . . . . . . . . . . . 27.5 p30 -155.61 19.39 0.4 Allowed 'General case' 0 C--O 1.233 0.222 0 N-CA-C 112.192 0.441 . . . . 0.0 112.192 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 385' ' ' GLY . . . . . . . . . . . . . . . -148.61 125.93 2.17 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.221 -0.99 . . . . 0.0 112.782 -176.559 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 386' ' ' GLY . . . . . . . . . . . . . . . 134.38 -70.48 0.51 Allowed Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.985 -0.626 . . . . 0.0 112.493 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . 174.05 -175.32 46.55 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 121.122 -0.561 . . . . 0.0 111.865 -178.734 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -90.9 137.42 32.38 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.056 0.455 . . . . 0.0 110.992 -177.4 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 29.5 t -128.98 115.37 36.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.58 177.765 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 2.4 p -139.11 137.51 36.22 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.355 0.598 . . . . 0.0 112.477 -175.316 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 391' ' ' GLY . . . . . 0.405 ' CA ' ' HA3' ' A' ' 403' ' ' GLY . . . -147.84 159.33 27.99 Favored Glycine 0 N--CA 1.447 -0.614 0 CA-C-N 115.474 -0.785 . . . . 0.0 111.515 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 392' ' ' ARG . . . . . 0.417 ' HD2' ' N ' ' A' ' 392' ' ' ARG . 8.2 mpt_? -117.01 142.43 46.96 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.05 0.453 . . . . 0.0 111.076 -174.423 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 393' ' ' PHE . . . . . 0.414 ' CD1' ' HB ' ' A' ' 401' ' ' VAL . 21.0 m-85 -82.34 163.09 21.98 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 115.295 -0.866 . . . . 0.0 109.671 176.626 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 394' ' ' TYR . . . . . 0.437 ' HD1' ' N ' ' A' ' 394' ' ' TYR . 1.2 m-85 -100.77 -176.99 3.34 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 176.094 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 395' ' ' GLY . . . . . 0.757 ' HA2' ' HA ' ' A' ' 307' ' ' PRO . . . -52.74 -146.96 0.0 OUTLIER Glycine 0 CA--C 1.527 0.836 0 O-C-N 124.062 0.851 . . . . 0.0 114.755 -176.256 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 396' ' ' PRO . . . . . 0.749 ' HG3' ' H ' ' A' ' 305' ' ' GLY . 19.4 Cg_endo -59.22 -11.49 13.25 Favored 'Trans proline' 0 CA--C 1.536 0.605 0 C-N-CA 121.515 1.477 . . . . 0.0 111.051 179.389 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 397' ' ' ALA . . . . . . . . . . . . . . . -94.82 28.79 2.56 Favored 'General case' 0 N--CA 1.453 -0.316 0 CA-C-N 114.798 -1.092 . . . . 0.0 110.557 175.767 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . -57.78 2.42 0.14 Allowed Glycine 0 C--N 1.338 0.646 0 CA-C-N 115.923 -0.58 . . . . 0.0 113.657 -179.681 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 399' ' ' GLU . . . . . 0.815 ' HG2' ' HD3' ' A' ' 424' ' ' LYS . 35.7 mt-10 -58.73 -9.22 1.63 Allowed 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 123.401 0.68 . . . . 0.0 109.756 166.114 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -115.02 125.68 53.87 Favored 'General case' 0 N--CA 1.447 -0.62 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.437 171.001 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 401' ' ' VAL . . . . . 0.414 ' HB ' ' CD1' ' A' ' 393' ' ' PHE . 9.7 p -135.09 146.57 30.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.725 178.128 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -142.19 135.07 28.58 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.82 0.343 . . . . 0.0 110.896 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 403' ' ' GLY . . . . . 0.405 ' HA3' ' CA ' ' A' ' 391' ' ' GLY . . . -153.14 -177.91 27.18 Favored Glycine 0 N--CA 1.44 -1.089 0 C-N-CA 120.667 -0.777 . . . . 0.0 112.085 -178.368 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 404' ' ' LYS . . . . . 0.844 ' HG2' HG12 ' A' ' 419' ' ' VAL . 70.2 mttt -142.0 163.01 34.04 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 -179.562 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 29.2 p90 -125.35 153.01 43.99 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.218 0.533 . . . . 0.0 111.208 178.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 4.9 p -90.37 116.09 28.06 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.028 177.144 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 407' ' ' TYR . . . . . 0.42 ' O ' ' CB ' ' A' ' 408' ' ' ARG . 28.8 t80 -151.07 152.79 33.94 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 -178.152 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 408' ' ' ARG . . . . . 0.926 ' HB3' ' HD3' ' A' ' 409' ' ' PRO . 40.3 ttt180 106.44 -68.45 0.0 OUTLIER Pre-proline 0 N--CA 1.482 1.148 0 O-C-N 125.122 1.514 . . . . 0.0 110.763 -178.647 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 409' ' ' PRO . . . . . 0.926 ' HD3' ' HB3' ' A' ' 408' ' ' ARG . 6.5 Cg_exo -73.95 126.99 11.05 Favored 'Trans proline' 0 C--N 1.356 0.966 0 C-N-CA 121.789 1.659 . . . . 0.0 111.345 178.134 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 410' ' ' THR . . . . . . . . . . . . . 14.5 m -76.9 -27.28 54.89 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.15 -176.265 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 411' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -127.89 71.53 1.37 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.225 0.536 . . . . 0.0 110.294 -178.658 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 412' ' ' ALA . . . . . 0.567 ' HB3' ' HB2' ' A' ' 409' ' ' PRO . . . -166.13 148.91 7.21 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.119 -179.766 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 413' ' ' GLU . . . . . . . . . . . . . 38.8 mm-40 -110.83 36.36 3.16 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.384 -177.769 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 414' ' ' LYS . . . . . . . . . . . . . 4.9 ttmp? -130.82 128.84 41.48 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.792 0.329 . . . . 0.0 111.121 -177.2 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 415' ' ' GLY . . . . . . . . . . . . . . . -105.47 133.11 11.42 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.716 -0.754 . . . . 0.0 111.668 175.222 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 416' ' ' GLY . . . . . . . . . . . . . . . -110.13 -55.61 0.53 Allowed Glycine 0 N--CA 1.446 -0.692 0 C-N-CA 120.724 -0.751 . . . . 0.0 111.327 179.759 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 417' ' ' PHE . . . . . 0.735 ' HB2' ' HD1' ' A' ' 326' ' ' PHE . 47.8 p90 -98.99 177.99 5.08 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 175.326 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 81.54 71.23 1.3 Allowed Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.53 -0.843 . . . . 0.0 112.278 177.804 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 419' ' ' VAL . . . . . 0.844 HG12 ' HG2' ' A' ' 404' ' ' LYS . 22.9 m -109.72 153.04 11.6 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 178.819 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 420' ' ' PHE . . . . . 0.437 ' HB3' HG22 ' A' ' 323' ' ' VAL . 38.3 p90 -142.4 160.45 40.24 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 121.358 0.599 . . . . 0.0 110.873 179.408 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -139.45 136.11 34.29 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 114.943 -1.026 . . . . 0.0 109.076 177.873 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -118.94 132.44 9.65 Favored Glycine 0 N--CA 1.441 -1.007 0 C-N-CA 120.607 -0.806 . . . . 0.0 111.681 -178.812 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 35.2 mtmt -116.18 124.6 50.69 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 179.181 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 424' ' ' LYS . . . . . 0.815 ' HD3' ' HG2' ' A' ' 399' ' ' GLU . 46.2 tttm -67.48 125.57 26.57 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.69 -177.795 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 26.2 tt0 -86.58 111.79 20.96 Favored 'General case' 0 N--CA 1.444 -0.762 0 CA-C-O 121.416 0.627 . . . . 0.0 111.138 -172.012 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 426' ' ' GLN . . . . . . . . . . . . . 46.0 mt-30 -103.83 -179.11 3.85 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.263 -0.881 . . . . 0.0 108.776 170.597 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 427' ' ' ASP . . . . . 0.423 ' CG ' ' H ' ' A' ' 428' ' ' LEU . 29.2 t70 67.66 -175.08 0.19 Allowed 'General case' 0 CA--C 1.54 0.59 0 O-C-N 123.538 0.524 . . . . 0.0 110.191 -178.198 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 428' ' ' LEU . . . . . 0.423 ' H ' ' CG ' ' A' ' 427' ' ' ASP . 7.1 mp -85.52 -26.48 26.19 Favored 'General case' 0 C--N 1.327 -0.393 0 O-C-N 122.087 -0.383 . . . . 0.0 110.713 178.229 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 429' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -137.79 -103.31 0.19 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.047 0.451 . . . . 0.0 109.91 178.459 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 430' ' ' HIS . . . . . . . . . . . . . 55.8 m-70 -147.0 77.36 1.46 Allowed 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 107.88 -1.156 . . . . 0.0 107.88 175.095 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 9.9 t60 -66.39 -17.25 64.67 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.299 -174.102 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 432' ' ' HIS . . . . . . . . . . . . . 77.0 m-70 -78.09 62.02 2.75 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.267 0.556 . . . . 0.0 109.574 172.004 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 433' ' ' HIS . . . . . . . . . . . . . 9.8 t60 -91.86 -53.27 4.35 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.21 -176.327 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 434' ' ' HIS . . . . . . . . . . . . . 39.4 t-80 -85.82 -12.81 49.89 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.174 0.511 . . . . 0.0 109.986 179.367 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 435' ' ' HIS . . . . . . . . . . . . . 67.9 t60 . . . . . 0 C--O 1.248 0.999 0 CA-C-O 118.298 -0.858 . . . . 0.0 109.93 179.188 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 276' ' ' ASN . . . . . 0.436 ' OD1' ' HE2' ' A' ' 293' ' ' LYS . 15.4 t-20 . . . . . 0 N--CA 1.482 1.162 0 CA-C-O 121.303 0.573 . . . . 0.0 109.867 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 10.9 tp -98.1 -18.59 6.29 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.128 0 CA-C-O 121.558 0.694 . . . . 0.0 110.395 178.574 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 278' ' ' PHE . . . . . . . . . . . . . 7.8 p90 -89.96 44.05 1.18 Allowed 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.353 -178.789 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 279' ' ' ALA . . . . . 0.425 ' HA ' ' HD3' ' A' ' 280' ' ' PRO . . . -75.5 148.84 83.45 Favored Pre-proline 0 C--N 1.326 -0.415 0 CA-C-N 115.202 -0.908 . . . . 0.0 110.245 178.395 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 280' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 279' ' ' ALA . 22.9 Cg_exo -65.01 161.92 34.8 Favored 'Trans proline' 0 N--CA 1.464 -0.229 0 C-N-CA 123.105 2.537 . . . . 0.0 112.846 -178.566 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 281' ' ' GLU . . . . . 0.443 ' HB3' ' HE2' ' A' ' 284' ' ' TYR . 45.0 tt0 -43.35 -57.36 3.07 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.505 -0.771 . . . . 0.0 111.998 -178.541 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -114.08 -94.81 2.07 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.853 -0.689 . . . . 0.0 111.795 178.623 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 283' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -154.73 90.26 1.3 Allowed 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 177.22 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 284' ' ' TYR . . . . . 0.732 ' HD1' ' HE1' ' A' ' 286' ' ' TYR . 98.6 m-85 -101.04 111.3 23.47 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.404 0.621 . . . . 0.0 110.992 -172.527 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 285' ' ' ARG . . . . . 0.477 ' HD3' ' N ' ' A' ' 285' ' ' ARG . 0.0 OUTLIER -120.3 -10.99 9.24 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.574 -0.739 . . . . 0.0 112.001 -173.637 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 286' ' ' TYR . . . . . 0.732 ' HE1' ' HD1' ' A' ' 284' ' ' TYR . 25.9 p90 -58.78 -51.7 68.85 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 121.205 0.526 . . . . 0.0 110.268 178.983 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 287' ' ' LEU . . . . . 0.543 ' HG ' ' CD2' ' A' ' 286' ' ' TYR . 3.9 pp -168.04 131.11 1.57 Allowed 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 172.47 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 288' ' ' THR . . . . . 0.446 HG22 ' N ' ' A' ' 289' ' ' TYR . 22.2 m -155.0 161.82 41.26 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.032 -174.205 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 289' ' ' TYR . . . . . 0.446 ' N ' HG22 ' A' ' 288' ' ' THR . 5.7 t80 -126.18 119.34 27.23 Favored 'General case' 0 N--CA 1.435 -1.212 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 169.095 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 130.47 -155.59 21.19 Favored Glycine 0 N--CA 1.443 -0.854 0 C-N-CA 120.282 -0.961 . . . . 0.0 112.428 -177.725 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 291' ' ' ALA . . . . . 0.401 ' O ' ' HD3' ' A' ' 280' ' ' PRO . . . -100.79 163.69 12.2 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.182 0.515 . . . . 0.0 111.714 -176.357 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 292' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -145.81 157.27 43.93 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 114.959 -1.019 . . . . 0.0 108.281 176.783 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 293' ' ' LYS . . . . . 0.436 ' HE2' ' OD1' ' A' ' 276' ' ' ASN . 18.0 tppt? -112.58 139.46 48.15 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-O 120.927 0.394 . . . . 0.0 110.358 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 294' ' ' LEU . . . . . 0.498 HD22 ' HB2' ' A' ' 300' ' ' ALA . 0.7 OUTLIER -114.84 143.27 29.74 Favored Pre-proline 0 C--N 1.322 -0.621 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.259 176.343 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 295' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 294' ' ' LEU . 87.2 Cg_exo -48.81 102.96 0.05 OUTLIER 'Trans proline' 0 C--N 1.352 0.728 0 C-N-CA 123.742 2.961 . . . . 0.0 112.862 -177.914 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . 143.83 -131.34 4.41 Favored Glycine 0 N--CA 1.443 -0.89 0 CA-C-N 115.37 -0.832 . . . . 0.0 111.096 -177.003 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . -132.26 29.66 3.29 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.319 -179.834 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 298' ' ' SER . . . . . 0.493 ' HB2' HD11 ' A' ' 294' ' ' LEU . 50.8 m -108.34 167.58 9.93 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-N 116.974 0.387 . . . . 0.0 110.571 -178.783 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 299' ' ' TYR . . . . . . . . . . . . . 14.0 m-85 -122.2 137.91 54.66 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 300' ' ' ALA . . . . . 0.498 ' HB2' HD22 ' A' ' 294' ' ' LEU . . . -120.71 153.76 36.51 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 120.733 0.301 . . . . 0.0 110.842 179.007 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 301' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -121.73 141.17 51.44 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 173.452 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 302' ' ' ARG . . . . . 0.741 ' HA ' ' HE ' ' A' ' 302' ' ' ARG . 2.2 mmp_? -120.49 140.58 51.23 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 120.68 -0.408 . . . . 0.0 110.824 -179.029 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 303' ' ' VAL . . . . . . . . . . . . . 23.4 m -120.57 149.05 23.42 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.796 -175.815 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 304' ' ' GLN . . . . . 0.479 ' HB3' ' HB2' ' A' ' 287' ' ' LEU . 3.5 pt20 -125.82 176.09 7.18 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 114.986 -1.006 . . . . 0.0 108.908 173.817 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -91.22 118.14 5.34 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.351 -0.928 . . . . 0.0 112.012 -173.954 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 306' ' ' GLU . . . . . 0.804 ' O ' ' HA2' ' A' ' 395' ' ' GLY . 43.5 tt0 -145.72 128.74 8.21 Favored Pre-proline 0 N--CA 1.447 -0.58 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 -173.873 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_exo -51.97 126.05 18.98 Favored 'Trans proline' 0 CA--C 1.528 0.224 0 C-N-CA 122.235 1.956 . . . . 0.0 111.216 174.177 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 308' ' ' ALA . . . . . 0.689 ' HB2' ' O ' ' A' ' 394' ' ' TYR . . . -48.07 152.51 0.8 Allowed 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 112.968 0.729 . . . . 0.0 112.968 -177.92 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 309' ' ' LYS . . . . . 0.583 ' O ' ' HG ' ' A' ' 313' ' ' LEU . 29.9 mmmt -108.87 107.9 18.48 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.489 177.896 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 310' ' ' GLY . . . . . 0.608 ' HA2' HD12 ' A' ' 313' ' ' LEU . . . -64.91 -34.89 91.09 Favored Glycine 0 CA--C 1.516 0.133 0 C-N-CA 121.355 -0.45 . . . . 0.0 113.705 -172.737 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 2.9 pm0 -71.72 -25.56 62.12 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.234 0.54 . . . . 0.0 110.031 178.692 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 312' ' ' MET . . . . . 0.475 ' HB3' ' HB2' ' A' ' 309' ' ' LYS . 27.6 ttt -87.11 -18.06 31.37 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.461 -179.45 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 313' ' ' LEU . . . . . 0.608 HD12 ' HA2' ' A' ' 310' ' ' GLY . 96.1 mt -66.55 139.96 57.95 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.554 179.167 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -159.62 135.64 8.75 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.011 -176.384 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.5 177.69 15.94 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.918 -0.658 . . . . 0.0 111.592 178.168 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 38.7 p -108.75 142.16 39.7 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 117.303 0.551 . . . . 0.0 110.471 174.845 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -146.68 155.28 42.31 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.258 -179.093 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 318' ' ' VAL . . . . . 0.561 ' HA ' ' O ' ' A' ' 342' ' ' ALA . 2.5 p -132.94 119.71 38.17 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-O 121.285 0.564 . . . . 0.0 110.732 174.504 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 319' ' ' TYR . . . . . 0.477 ' HE1' ' HA ' ' A' ' 399' ' ' GLU . 76.8 m-85 -104.51 128.35 52.42 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.956 -178.671 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 1.9 p-10 -127.75 141.84 51.48 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.142 179.297 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -167.03 -140.98 3.02 Favored Glycine 0 N--CA 1.442 -0.913 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.28 -178.194 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 31.0 mt-10 -118.66 150.38 39.82 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.831 0.348 . . . . 0.0 111.051 -173.577 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 323' ' ' VAL . . . . . 0.626 HG23 ' HB2' ' A' ' 340' ' ' PHE . 56.1 t -109.9 120.95 61.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.925 172.644 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 324' ' ' LEU . . . . . 0.449 ' HB2' HG22 ' A' ' 419' ' ' VAL . 95.7 mt -101.87 104.21 14.94 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.092 -179.624 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 325' ' ' HIS . . . . . 0.742 ' HB3' ' HB ' ' A' ' 336' ' ' THR . 28.1 t-80 -96.21 138.83 33.25 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.187 -0.461 . . . . 0.0 109.814 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 326' ' ' PHE . . . . . 0.558 ' HE2' HG13 ' A' ' 419' ' ' VAL . 10.8 m-85 -126.31 175.05 8.11 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.587 -176.35 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 327' ' ' HIS . . . . . . . . . . . . . 4.9 p-80 -160.81 -176.34 5.47 Favored 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 107.626 -1.25 . . . . 0.0 107.626 179.002 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 328' ' ' THR . . . . . . . . . . . . . 9.2 t -53.95 114.09 1.46 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.545 0.688 . . . . 0.0 109.74 176.24 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 329' ' ' GLU . . . . . 0.459 ' O ' ' HB2' ' A' ' 330' ' ' ASN . 0.0 OUTLIER -95.41 175.18 6.67 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.363 -177.181 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 330' ' ' ASN . . . . . 0.459 ' HB2' ' O ' ' A' ' 329' ' ' GLU . 94.9 m-20 74.25 3.64 4.39 Favored 'General case' 0 N--CA 1.469 0.477 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 -163.825 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 331' ' ' GLY . . . . . . . . . . . . . . . -145.4 96.43 0.18 Allowed Glycine 0 N--CA 1.438 -1.231 0 N-CA-C 109.459 -1.457 . . . . 0.0 109.459 174.544 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 332' ' ' ARG . . . . . 0.404 ' HB3' ' CE1' ' A' ' 334' ' ' TYR . 6.4 mpt_? 65.64 73.51 0.41 Allowed Pre-proline 0 N--CA 1.466 0.356 0 CA-C-O 121.397 0.618 . . . . 0.0 110.081 -171.658 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 333' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -83.92 39.5 0.8 Allowed 'Trans proline' 0 N--CA 1.462 -0.368 0 C-N-CA 123.581 2.854 . . . . 0.0 113.342 -172.458 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 334' ' ' TYR . . . . . 0.404 ' CE1' ' HB3' ' A' ' 332' ' ' ARG . 40.5 p90 -107.15 128.61 25.71 Favored Pre-proline 0 C--N 1.323 -0.553 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 176.189 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 335' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -81.12 129.59 6.92 Favored 'Trans proline' 0 N--CA 1.461 -0.436 0 C-N-CA 122.641 2.228 . . . . 0.0 112.424 179.445 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 336' ' ' THR . . . . . 0.742 ' HB ' ' HB3' ' A' ' 325' ' ' HIS . 0.2 OUTLIER -72.58 140.1 47.86 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 175.825 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 337' ' ' ARG . . . . . 0.483 ' HA ' ' O ' ' A' ' 323' ' ' VAL . 51.2 mtm180 -128.7 112.99 14.81 Favored 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 120.298 -0.561 . . . . 0.0 111.576 -174.689 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -107.57 -177.12 22.49 Favored Glycine 0 N--CA 1.444 -0.83 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.092 176.707 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 339' ' ' ARG . . . . . 0.795 ' HB2' ' HB2' ' A' ' 356' ' ' ASP . 40.0 mtp-105 -104.45 153.46 21.08 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 340' ' ' PHE . . . . . 0.626 ' HB2' HG23 ' A' ' 323' ' ' VAL . 53.0 t80 -143.41 137.52 28.71 Favored 'General case' 0 C--N 1.317 -0.848 0 CA-C-O 121.139 0.495 . . . . 0.0 111.484 -178.51 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 341' ' ' ALA . . . . . 0.401 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -141.05 163.49 32.84 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.228 -0.896 . . . . 0.0 108.889 173.334 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 342' ' ' ALA . . . . . 0.821 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -155.9 118.14 4.09 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 120.871 0.367 . . . . 0.0 110.667 -176.926 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 343' ' ' LYS . . . . . 0.502 ' C ' ' HD3' ' A' ' 343' ' ' LYS . 12.7 tmtt? -94.3 103.35 15.36 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 178.223 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 344' ' ' VAL . . . . . 1.026 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.2 OUTLIER -119.4 132.83 68.1 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.109 0 CA-C-O 121.607 0.718 . . . . 0.0 112.105 -172.716 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -109.16 118.69 37.39 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.885 -1.052 . . . . 0.0 108.247 175.563 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 346' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -79.25 -24.59 42.9 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 111.584 0.216 . . . . 0.0 111.584 -175.509 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -69.52 -38.54 79.25 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.239 -0.981 . . . . 0.0 111.285 179.227 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 3.4 m -92.58 -9.74 40.04 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.002 0.43 . . . . 0.0 110.019 178.096 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 349' ' ' LYS . . . . . 0.621 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 10.1 mtmp? 52.03 58.67 5.19 Favored 'General case' 0 N--CA 1.456 -0.142 0 CA-C-N 115.439 -0.801 . . . . 0.0 110.394 -176.734 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 17.9 m -140.9 145.84 36.67 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.48 -179.211 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 351' ' ' VAL . . . . . 1.026 ' HB ' ' HB ' ' A' ' 344' ' ' VAL . 0.2 OUTLIER -141.83 139.0 31.38 Favored 'Isoleucine or valine' 0 C--O 1.237 0.396 0 CA-C-O 121.299 0.571 . . . . 0.0 111.559 -177.035 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 352' ' ' ASP . . . . . 0.821 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 1.5 m-20 -106.61 118.54 36.93 Favored 'General case' 0 C--O 1.214 -0.798 0 CA-C-N 115.057 -0.974 . . . . 0.0 109.304 179.637 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -110.1 143.24 16.73 Favored Glycine 0 C--N 1.313 -0.715 0 C-N-CA 120.23 -0.986 . . . . 0.0 111.873 -177.076 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 354' ' ' ILE . . . . . 0.536 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -140.29 129.92 27.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 CA-C-O 120.856 0.36 . . . . 0.0 110.362 -177.962 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 355' ' ' ILE . . . . . 0.59 HG23 HG21 ' A' ' 323' ' ' VAL . 3.3 mp -119.34 111.07 31.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.329 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 356' ' ' ASP . . . . . 0.795 ' HB2' ' HB2' ' A' ' 339' ' ' ARG . 7.4 m-20 -69.1 120.74 15.42 Favored 'General case' 0 CA--C 1.512 -0.502 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.454 177.05 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 27.7 t -89.71 -6.32 56.18 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.854 176.906 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 358' ' ' GLY . . . . . . . . . . . . . . . 104.57 -68.1 0.27 Allowed Glycine 0 N--CA 1.448 -0.556 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.732 -179.114 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 359' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -100.32 81.23 2.34 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.381 0.61 . . . . 0.0 110.014 178.891 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 360' ' ' ASP . . . . . 0.422 ' O ' ' HA2' ' A' ' 364' ' ' GLY . 20.1 t70 -61.83 -27.07 68.51 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.762 178.175 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 361' ' ' LEU . . . . . . . . . . . . . 96.3 mt -78.66 -15.39 58.55 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.193 -179.364 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 362' ' ' HIS . . . . . . . . . . . . . 1.5 t-80 -108.14 -79.09 0.58 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.759 -0.2 . . . . 0.0 110.469 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 363' ' ' MET . . . . . . . . . . . . . 90.6 mtp -78.97 -29.87 44.12 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.139 0.495 . . . . 0.0 110.836 -179.261 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 364' ' ' GLY . . . . . 0.422 ' HA2' ' O ' ' A' ' 360' ' ' ASP . . . 96.42 135.2 8.34 Favored Glycine 0 N--CA 1.445 -0.744 0 CA-C-N 115.489 -0.778 . . . . 0.0 112.348 179.136 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 365' ' ' THR . . . . . 0.566 HG23 ' HA ' ' A' ' 356' ' ' ASP . 7.6 m -82.42 119.05 23.69 Favored 'General case' 0 N--CA 1.445 -0.718 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 171.197 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 14.6 mm100 -103.78 145.37 30.19 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.624 0.726 . . . . 0.0 111.076 -166.556 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 44.9 mttp -125.74 147.72 49.29 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 114.599 -1.182 . . . . 0.0 110.394 -170.697 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 368' ' ' PHE . . . . . 0.685 ' CD1' HG21 ' A' ' 389' ' ' VAL . 41.9 p90 -126.39 160.23 31.05 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 177.371 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 369' ' ' LYS . . . . . 0.589 ' HD3' ' HA ' ' A' ' 352' ' ' ASP . 2.0 tppt? -125.96 147.39 49.53 Favored 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 173.442 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 370' ' ' ALA . . . . . 0.435 ' HB1' ' HB2' ' A' ' 377' ' ' PHE . . . -141.58 147.71 38.12 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.83 0.347 . . . . 0.0 111.123 -176.697 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -105.45 127.57 53.07 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.079 177.759 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 372' ' ' ILE . . . . . 0.621 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 84.0 mt -82.8 121.32 35.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-O 121.008 0.433 . . . . 0.0 111.257 -178.905 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -137.91 105.27 5.5 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 170.786 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 92.88 -155.2 22.37 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 110.349 -1.1 . . . . 0.0 110.349 -168.012 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 375' ' ' ASN . . . . . 0.552 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 21.8 p-10 -94.33 42.6 1.1 Allowed 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 117.533 0.666 . . . . 0.0 110.681 178.718 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . -170.37 164.48 37.77 Favored Glycine 0 N--CA 1.441 -1.016 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -178.789 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 377' ' ' PHE . . . . . 0.512 ' CD2' HG11 ' A' ' 351' ' ' VAL . 8.8 p90 -136.91 139.0 41.26 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-O 120.964 0.412 . . . . 0.0 110.939 -179.307 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 378' ' ' LYS . . . . . . . . . . . . . 63.7 mttm -112.72 137.09 51.52 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.293 172.081 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 379' ' ' GLY . . . . . 0.627 ' C ' HG22 ' A' ' 389' ' ' VAL . . . -144.53 -154.73 6.22 Favored Glycine 0 N--CA 1.437 -1.283 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.097 -172.432 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 12.7 t -169.16 154.66 6.09 Favored 'General case' 0 C--N 1.313 -1.016 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 -173.534 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 381' ' ' TRP . . . . . 0.901 ' HD1' ' HA3' ' A' ' 387' ' ' GLY . 38.8 m95 -62.16 154.47 27.14 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.299 0.571 . . . . 0.0 110.87 178.337 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 382' ' ' THR . . . . . . . . . . . . . 12.3 t -62.13 -8.29 5.31 Favored 'General case' 0 CA--C 1.538 0.514 0 CA-C-N 115.386 -0.825 . . . . 0.0 111.407 173.402 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 383' ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -117.59 156.17 28.58 Favored 'General case' 0 C--N 1.333 -0.132 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 174.563 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 384' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -88.01 27.88 1.13 Allowed 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.187 0.439 . . . . 0.0 112.187 -173.08 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 385' ' ' GLY . . . . . . . . . . . . . . . -78.02 41.59 2.0 Allowed Glycine 0 CA--C 1.52 0.404 0 C-N-CA 120.787 -0.721 . . . . 0.0 113.06 -178.108 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 386' ' ' GLY . . . . . 0.473 ' HA3' ' O ' ' A' ' 408' ' ' ARG . . . 57.9 24.06 52.91 Favored Glycine 0 C--N 1.331 0.255 0 C-N-CA 121.802 -0.237 . . . . 0.0 113.015 179.643 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 387' ' ' GLY . . . . . 0.901 ' HA3' ' HD1' ' A' ' 381' ' ' TRP . . . -86.73 93.62 1.89 Allowed Glycine 0 N--CA 1.446 -0.69 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.637 -177.019 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -96.18 128.04 42.74 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 178.994 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 389' ' ' VAL . . . . . 0.685 HG21 ' CD1' ' A' ' 368' ' ' PHE . 3.5 m -117.28 160.48 16.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 C-N-CA 120.87 -0.332 . . . . 0.0 110.714 -176.589 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 390' ' ' SER . . . . . 0.521 ' O ' ' HA3' ' A' ' 403' ' ' GLY . 24.7 t -157.44 158.46 35.87 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.245 178.622 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -170.13 153.15 20.82 Favored Glycine 0 C--N 1.32 -0.329 0 N-CA-C 111.443 -0.663 . . . . 0.0 111.443 178.666 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 4.3 ptm180 -131.92 149.32 52.47 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 117.319 0.56 . . . . 0.0 110.751 -176.706 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -89.88 166.11 13.7 Favored 'General case' 0 CA--C 1.498 -1.037 0 CA-C-O 122.424 1.107 . . . . 0.0 111.786 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 394' ' ' TYR . . . . . 0.689 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 0.5 OUTLIER -101.86 -176.15 3.05 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 112.709 -2.042 . . . . 0.0 108.923 176.949 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 395' ' ' GLY . . . . . 0.804 ' HA2' ' O ' ' A' ' 306' ' ' GLU . . . -36.26 158.38 0.01 OUTLIER Glycine 0 N--CA 1.461 0.304 0 O-C-N 124.71 1.256 . . . . 0.0 115.045 -175.06 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -22.95 -42.42 0.03 OUTLIER 'Trans proline' 0 C--N 1.358 1.032 1 C-N-CA 127.322 5.348 . . . . 0.0 117.178 -161.711 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 397' ' ' ALA . . . . . 0.42 ' N ' ' O ' ' A' ' 395' ' ' GLY . . . -73.04 -19.46 61.18 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 -175.068 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 57.85 25.06 55.54 Favored Glycine 0 C--N 1.34 0.767 0 CA-C-N 116.186 -0.461 . . . . 0.0 112.887 176.165 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 399' ' ' GLU . . . . . 0.477 ' HA ' ' HE1' ' A' ' 319' ' ' TYR . 51.3 mt-10 -71.3 -8.37 53.21 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 122.956 0.502 . . . . 0.0 112.024 -174.03 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 400' ' ' GLU . . . . . 0.451 ' HG2' ' CE1' ' A' ' 394' ' ' TYR . 5.2 tt0 -131.9 144.29 50.75 Favored 'General case' 0 N--CA 1.433 -1.284 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 171.438 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 401' ' ' VAL . . . . . 0.492 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 14.8 p -142.08 136.73 29.9 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.107 0 CA-C-N 115.012 -0.995 . . . . 0.0 109.722 179.019 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -135.7 138.94 43.27 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.122 -178.74 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 403' ' ' GLY . . . . . 0.521 ' HA3' ' O ' ' A' ' 390' ' ' SER . . . -161.06 -161.09 11.25 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 120.747 -0.739 . . . . 0.0 111.646 178.424 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 404' ' ' LYS . . . . . 0.7 ' HG2' HG12 ' A' ' 419' ' ' VAL . 28.4 mtmm -144.45 161.71 38.36 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.557 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 34.9 p90 -120.41 133.21 55.47 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 171.915 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 46.2 m -116.22 103.78 10.86 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 116.508 -0.314 . . . . 0.0 110.549 -178.444 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 407' ' ' TYR . . . . . 0.485 ' HA ' ' HA2' ' A' ' 387' ' ' GLY . 10.4 p90 -82.49 127.18 33.07 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 174.975 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 408' ' ' ARG . . . . . 0.473 ' O ' ' HA3' ' A' ' 386' ' ' GLY . 29.1 ttp180 -138.62 79.23 29.67 Favored Pre-proline 0 C--N 1.319 -0.75 0 CA-C-N 115.804 -0.634 . . . . 0.0 109.912 -177.841 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 409' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -90.29 -7.66 4.19 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 123.059 2.506 . . . . 0.0 112.004 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 410' ' ' THR . . . . . . . . . . . . . 15.0 m -121.28 128.02 51.94 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.954 -179.686 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 411' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -75.54 83.93 2.6 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.335 0.588 . . . . 0.0 110.402 176.211 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 412' ' ' ALA . . . . . . . . . . . . . . . -146.3 -54.34 0.26 Allowed 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.255 -0.884 . . . . 0.0 109.571 178.01 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 413' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -151.17 163.06 39.69 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.581 179.1 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 414' ' ' LYS . . . . . . . . . . . . . 36.3 mtmm -89.82 158.34 17.52 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.879 0.371 . . . . 0.0 110.781 -179.014 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 415' ' ' GLY . . . . . . . . . . . . . . . -75.64 178.82 47.51 Favored Glycine 0 N--CA 1.448 -0.517 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.193 178.317 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 416' ' ' GLY . . . . . . . . . . . . . . . -175.58 -37.18 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.884 -0.674 . . . . 0.0 111.661 -178.406 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 417' ' ' PHE . . . . . 0.506 ' CD1' ' HB2' ' A' ' 326' ' ' PHE . 32.7 m-85 -68.82 159.37 32.56 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 175.76 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 418' ' ' GLY . . . . . 0.448 ' HA2' ' HA ' ' A' ' 325' ' ' HIS . . . 83.82 78.17 1.11 Allowed Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 119.904 -1.141 . . . . 0.0 112.678 -178.262 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 419' ' ' VAL . . . . . 0.7 HG12 ' HG2' ' A' ' 404' ' ' LYS . 13.5 m -105.03 163.29 4.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.832 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 29.9 p90 -143.38 153.71 42.97 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-O 121.406 0.622 . . . . 0.0 111.234 -178.133 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -142.81 136.15 28.5 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.259 -0.882 . . . . 0.0 109.037 176.664 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -124.05 134.71 9.34 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.399 -0.905 . . . . 0.0 112.327 -178.341 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 423' ' ' LYS . . . . . 0.451 ' HE2' ' HB3' ' A' ' 423' ' ' LYS . 44.6 mtpt -104.8 140.18 38.48 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 120.753 0.311 . . . . 0.0 110.198 178.722 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 424' ' ' LYS . . . . . 0.408 ' HB2' ' HE1' ' A' ' 319' ' ' TYR . 26.0 tptp -58.14 116.25 3.43 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.626 -0.716 . . . . 0.0 111.8 179.652 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 425' ' ' GLU . . . . . 0.535 ' HB3' HG13 ' A' ' 318' ' ' VAL . 19.8 tp10 -64.94 112.71 3.42 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 169.009 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 426' ' ' GLN . . . . . . . . . . . . . 3.1 tp-100 -88.16 127.99 35.44 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 121.352 0.596 . . . . 0.0 111.086 -172.802 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 427' ' ' ASP . . . . . . . . . . . . . 9.0 p-10 -107.4 -161.76 0.8 Allowed 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.263 -0.88 . . . . 0.0 109.476 176.601 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 428' ' ' LEU . . . . . 0.586 ' CD1' ' H ' ' A' ' 428' ' ' LEU . 0.0 OUTLIER -72.12 -14.94 61.97 Favored 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 121.086 -0.246 . . . . 0.0 111.162 179.976 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 429' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 66.62 -81.17 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.381 0 C-N-CA 123.298 0.639 . . . . 0.0 111.123 179.503 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 430' ' ' HIS . . . . . . . . . . . . . 96.0 m-70 -141.67 111.76 6.82 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 431' ' ' HIS . . . . . 0.456 ' O ' ' HB2' ' A' ' 432' ' ' HIS . 75.3 t60 -69.37 141.19 54.23 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 179.779 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 432' ' ' HIS . . . . . 0.456 ' HB2' ' O ' ' A' ' 431' ' ' HIS . 43.4 m170 76.08 -75.91 0.06 Allowed 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 123.641 0.776 . . . . 0.0 110.59 -174.429 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 433' ' ' HIS . . . . . . . . . . . . . 48.0 m80 -149.23 167.34 26.27 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 179.172 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 434' ' ' HIS . . . . . . . . . . . . . 5.2 p80 -63.43 -27.06 69.03 Favored 'General case' 0 C--N 1.332 -0.186 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 174.477 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 435' ' ' HIS . . . . . . . . . . . . . 55.4 t-80 . . . . . 0 C--O 1.244 0.777 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.021 176.64 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo . . . . . 0 N--CA 1.444 -1.414 0 N-CA-C 111.575 -0.202 . . . . 0.0 111.575 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 308' ' ' ALA . . . . . 0.675 ' HB2' ' O ' ' A' ' 394' ' ' TYR . . . -59.47 163.54 4.01 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.15 -0.62 . . . . 0.0 109.974 168.828 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 309' ' ' LYS . . . . . 0.537 ' HB3' ' HB2' ' A' ' 312' ' ' MET . 10.8 tptp -123.96 93.45 3.93 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 174.1 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 310' ' ' GLY . . . . . 0.7 ' HA2' HD12 ' A' ' 313' ' ' LEU . . . -57.24 -34.02 66.47 Favored Glycine 0 C--N 1.332 0.315 0 C-N-CA 121.147 -0.549 . . . . 0.0 113.013 -173.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . 0.425 ' HA ' ' HE3' ' A' ' 349' ' ' LYS . 11.2 pt-20 -62.82 -26.9 68.97 Favored 'General case' 0 C--N 1.319 -0.755 0 C-N-CA 122.483 0.313 . . . . 0.0 111.581 174.807 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 312' ' ' MET . . . . . 0.537 ' HB2' ' HB3' ' A' ' 309' ' ' LYS . 90.0 mtp -102.37 -6.37 23.1 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.921 0.391 . . . . 0.0 110.567 -179.77 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 313' ' ' LEU . . . . . 0.7 HD12 ' HA2' ' A' ' 310' ' ' GLY . 92.4 mt -75.26 133.2 41.4 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.729 176.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -143.68 137.09 27.97 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.017 -173.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.53 -159.53 15.28 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 121.001 -0.618 . . . . 0.0 111.665 178.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 12.7 p -123.89 156.17 36.76 Favored 'General case' 0 C--N 1.317 -0.806 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 173.462 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 317' ' ' ALA . . . . . 0.402 ' HB3' HG13 ' A' ' 344' ' ' VAL . . . -146.51 160.41 42.15 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 120.918 0.39 . . . . 0.0 110.694 176.657 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . 0.582 ' HA ' ' O ' ' A' ' 342' ' ' ALA . 8.7 p -138.78 113.75 8.5 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.691 172.849 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . 0.731 ' HE2' HG11 ' A' ' 344' ' ' VAL . 55.4 m-85 -98.08 127.46 44.04 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.331 -177.256 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -115.79 132.4 56.65 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.478 174.459 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . 0.48 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -166.27 -143.17 3.65 Favored Glycine 0 N--CA 1.438 -1.197 0 C-N-CA 120.697 -0.763 . . . . 0.0 111.948 -179.143 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -136.94 164.67 27.78 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 120.927 0.394 . . . . 0.0 111.236 -173.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 323' ' ' VAL . . . . . 0.608 HG23 ' HB2' ' A' ' 340' ' ' PHE . 75.2 t -126.34 116.42 45.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.53 178.792 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 324' ' ' LEU . . . . . 0.426 ' HB2' HG22 ' A' ' 419' ' ' VAL . 93.7 mt -89.4 101.76 14.43 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 175.486 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 325' ' ' HIS . . . . . 0.52 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 1.9 p80 -102.24 114.76 29.19 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.493 0.663 . . . . 0.0 110.066 -179.123 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 326' ' ' PHE . . . . . 0.5 ' HB2' ' HB3' ' A' ' 417' ' ' PHE . 49.0 m-85 . . . . . 0 C--N 1.323 -0.552 0 CA-C-N 114.734 -1.121 . . . . 0.0 110.897 -170.011 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 337' ' ' ARG . . . . . . . . . . . . . 54.6 mtp180 . . . . . 0 N--CA 1.454 -0.23 0 CA-C-O 120.957 0.408 . . . . 0.0 110.707 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -96.82 -176.81 35.22 Favored Glycine 0 N--CA 1.447 -0.591 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 173.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 339' ' ' ARG . . . . . . . . . . . . . 29.0 mtm180 -112.41 163.31 14.58 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 118.055 0.928 . . . . 0.0 110.213 179.393 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 340' ' ' PHE . . . . . 0.608 ' HB2' HG23 ' A' ' 323' ' ' VAL . 30.7 t80 -151.67 140.13 20.55 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.83 0.347 . . . . 0.0 111.137 -179.243 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 341' ' ' ALA . . . . . 0.562 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -137.25 152.55 49.94 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.12 175.364 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . 0.929 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -143.83 118.3 9.71 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.044 0.45 . . . . 0.0 111.513 -178.375 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 343' ' ' LYS . . . . . 0.525 ' HB3' ' HB2' ' A' ' 352' ' ' ASP . 55.7 tptt -96.52 103.61 15.54 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.109 177.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 344' ' ' VAL . . . . . 0.731 HG11 ' HE2' ' A' ' 319' ' ' TYR . 0.7 OUTLIER -122.86 140.33 46.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -170.691 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -114.4 121.31 43.19 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.839 -1.073 . . . . 0.0 108.46 171.164 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 346' ' ' PHE . . . . . . . . . . . . . 51.8 m-85 -76.7 -17.04 59.34 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 111.734 0.272 . . . . 0.0 111.734 -175.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -75.29 -42.12 29.14 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.461 -0.876 . . . . 0.0 111.269 178.568 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 55.9 m -88.37 -10.93 47.7 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-O 120.811 0.339 . . . . 0.0 110.108 177.33 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 349' ' ' LYS . . . . . 0.64 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 48.4 mttm 51.24 58.81 5.12 Favored 'General case' 0 CA--C 1.52 -0.198 0 CA-C-O 121.863 0.84 . . . . 0.0 109.896 -179.723 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 50.7 m -147.77 146.02 29.02 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 114.777 -1.101 . . . . 0.0 109.607 176.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 351' ' ' VAL . . . . . 0.782 HG22 ' HB3' ' A' ' 370' ' ' ALA . 1.3 m -129.69 156.35 41.97 Favored 'Isoleucine or valine' 0 C--O 1.237 0.427 0 CA-C-O 121.181 0.515 . . . . 0.0 110.461 -176.451 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 352' ' ' ASP . . . . . 0.929 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 0.9 OUTLIER -109.48 117.37 33.81 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 170.481 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -114.7 117.08 3.95 Favored Glycine 0 N--CA 1.444 -0.792 0 C-N-CA 120.218 -0.991 . . . . 0.0 112.136 -177.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 354' ' ' ILE . . . . . 0.526 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -117.65 133.14 65.39 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.127 0 CA-C-N 115.321 -0.439 . . . . 0.0 109.916 -176.995 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 355' ' ' ILE . . . . . 0.514 ' HB ' ' HB3' ' A' ' 366' ' ' GLN . 3.4 mp . . . . . 0 C--N 1.32 -0.71 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.797 -178.016 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 366' ' ' GLN . . . . . 0.514 ' HB3' ' HB ' ' A' ' 355' ' ' ILE . 17.5 tp60 . . . . . 0 N--CA 1.45 -0.471 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 37.5 ttpt -156.54 136.98 13.04 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.427 -176.344 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 368' ' ' PHE . . . . . 0.424 ' HB3' ' CE3' ' A' ' 381' ' ' TRP . 46.9 p90 -129.51 156.42 44.17 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.095 0.474 . . . . 0.0 109.978 178.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 4.0 tptp -116.62 131.59 56.91 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 175.149 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 370' ' ' ALA . . . . . 0.782 ' HB3' HG22 ' A' ' 351' ' ' VAL . . . -128.87 140.77 51.53 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 112.193 0.442 . . . . 0.0 112.193 -170.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -101.31 130.83 47.54 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.603 175.311 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 372' ' ' ILE . . . . . 0.64 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 84.2 mt -80.8 105.17 10.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.842 0.829 . . . . 0.0 110.08 -179.24 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -113.63 83.93 1.93 Allowed 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 114.337 -1.301 . . . . 0.0 108.944 -177.16 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 374' ' ' GLY . . . . . 0.56 ' O ' ' HA3' ' A' ' 310' ' ' GLY . . . 101.34 -141.79 15.46 Favored Glycine 0 N--CA 1.444 -0.811 0 CA-C-N 115.159 -0.928 . . . . 0.0 111.117 -174.15 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 375' ' ' ASN . . . . . . . . . . . . . 30.9 p-10 -97.57 59.56 1.52 Allowed 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 122.582 1.182 . . . . 0.0 109.545 179.034 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 162.1 178.43 35.98 Favored Glycine 0 N--CA 1.443 -0.893 0 CA-C-N 113.993 -1.458 . . . . 0.0 109.959 -174.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 377' ' ' PHE . . . . . 0.472 ' CZ ' HG21 ' A' ' 401' ' ' VAL . 4.8 p90 -139.45 150.99 45.86 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 117.655 0.728 . . . . 0.0 112.155 -178.412 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 378' ' ' LYS . . . . . 0.442 ' HD2' ' N ' ' A' ' 378' ' ' LYS . 0.0 OUTLIER -115.06 129.5 56.71 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 172.818 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 379' ' ' GLY . . . . . 0.513 ' HA2' ' HA ' ' A' ' 370' ' ' ALA . . . -126.33 169.3 18.28 Favored Glycine 0 N--CA 1.444 -0.777 0 C-N-CA 119.997 -1.097 . . . . 0.0 113.411 -171.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 11.3 p -131.19 140.17 49.86 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.118 -0.541 . . . . 0.0 109.872 178.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 381' ' ' TRP . . . . . 0.488 ' CZ3' ' HG3' ' A' ' 366' ' ' GLN . 73.7 m95 . . . . . 0 C--N 1.327 -0.401 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.701 179.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.737 0 N-CA-C 112.27 -0.332 . . . . 0.0 112.27 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -99.66 138.94 36.04 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.817 0.342 . . . . 0.0 110.594 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 389' ' ' VAL . . . . . 0.49 HG22 ' HB3' ' A' ' 405' ' ' TYR . 22.1 t -109.53 144.81 17.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 177.641 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 14.7 m -147.44 139.64 24.43 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.52 0.2 . . . . 0.0 110.557 175.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -145.08 150.14 22.31 Favored Glycine 0 C--N 1.32 -0.326 0 N-CA-C 111.692 -0.563 . . . . 0.0 111.692 179.38 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 392' ' ' ARG . . . . . 0.64 ' HD3' ' O ' ' A' ' 393' ' ' PHE . 4.5 tmt_? -118.67 136.55 53.85 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -175.501 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 393' ' ' PHE . . . . . 0.64 ' O ' ' HD3' ' A' ' 392' ' ' ARG . 8.1 m-85 -82.24 159.76 23.13 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.263 -177.693 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 394' ' ' TYR . . . . . 0.675 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 2.4 m-85 -100.81 -174.67 2.68 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.861 -177.164 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 395' ' ' GLY . . . . . . . . . . . . . . . -38.42 170.45 0.01 OUTLIER Glycine 0 C--N 1.335 0.487 0 O-C-N 124.277 0.985 . . . . 0.0 114.985 -177.718 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -51.52 -15.11 2.35 Favored 'Trans proline' 0 N--CA 1.477 0.502 0 C-N-CA 124.384 3.389 . . . . 0.0 115.526 -163.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 397' ' ' ALA . . . . . . . . . . . . . . . -80.22 -20.49 44.54 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 111.735 0.272 . . . . 0.0 111.735 177.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 56.23 18.62 21.46 Favored Glycine 0 C--N 1.34 0.763 0 CA-C-N 116.09 -0.505 . . . . 0.0 114.081 175.046 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 399' ' ' GLU . . . . . 0.908 ' HG3' ' HB3' ' A' ' 424' ' ' LYS . 17.7 tt0 -73.15 -19.15 61.19 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.193 0.52 . . . . 0.0 110.838 -177.751 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -116.7 137.47 52.17 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-O 121.18 0.514 . . . . 0.0 110.362 177.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 401' ' ' VAL . . . . . 0.472 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 9.0 p -139.46 134.55 39.67 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.546 173.423 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -131.14 135.18 47.24 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.172 -179.335 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -151.05 -176.64 24.12 Favored Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.177 -1.011 . . . . 0.0 112.152 -177.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 404' ' ' LYS . . . . . 0.675 ' HG2' HG12 ' A' ' 419' ' ' VAL . 27.0 mttm -147.69 162.47 39.1 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 -179.352 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 405' ' ' TYR . . . . . 0.49 ' HB3' HG22 ' A' ' 389' ' ' VAL . 6.9 p90 . . . . . 0 C--N 1.318 -0.77 0 CA-C-O 121.251 0.548 . . . . 0.0 111.593 175.644 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 417' ' ' PHE . . . . . 0.5 ' HB3' ' HB2' ' A' ' 326' ' ' PHE . 64.1 m-85 . . . . . 0 N--CA 1.447 -0.605 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 418' ' ' GLY . . . . . 0.52 ' HA2' ' HA ' ' A' ' 325' ' ' HIS . . . 82.4 77.32 1.07 Allowed Glycine 0 N--CA 1.442 -0.935 0 C-N-CA 119.78 -1.2 . . . . 0.0 111.447 -175.454 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 419' ' ' VAL . . . . . 0.675 HG12 ' HG2' ' A' ' 404' ' ' LYS . 19.7 m -105.08 146.96 11.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 -178.109 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 420' ' ' PHE . . . . . 0.48 ' HB3' HG22 ' A' ' 323' ' ' VAL . 47.0 p90 -130.29 161.07 32.06 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 121.023 0.44 . . . . 0.0 110.696 -179.299 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 421' ' ' ALA . . . . . 0.48 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -153.92 136.54 15.17 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.025 179.821 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -132.54 141.67 13.06 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.187 -1.006 . . . . 0.0 113.052 -177.336 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 72.3 mmtt -102.46 125.56 49.22 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 175.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 424' ' ' LYS . . . . . 0.908 ' HB3' ' HG3' ' A' ' 399' ' ' GLU . 80.0 tttt -63.16 105.72 0.75 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.272 0.558 . . . . 0.0 110.626 178.16 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 . . . . . 0 C--N 1.321 -0.673 0 CA-C-N 115.53 -0.759 . . . . 0.0 109.984 -179.708 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_exo . . . . . 0 CA--C 1.533 0.441 0 N-CA-C 112.672 0.22 . . . . 0.0 112.672 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 308' ' ' ALA . . . . . 0.626 ' HB2' ' O ' ' A' ' 394' ' ' TYR . . . -47.51 153.88 0.5 Allowed 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 121.137 0.494 . . . . 0.0 111.965 170.091 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 309' ' ' LYS . . . . . 0.677 ' O ' ' HG ' ' A' ' 313' ' ' LEU . 65.9 mmtt -91.76 88.28 6.62 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 178.157 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 310' ' ' GLY . . . . . 0.627 ' HA2' HD12 ' A' ' 313' ' ' LEU . . . -58.31 -40.22 93.73 Favored Glycine 0 C--N 1.333 0.41 0 C-N-CA 121.616 -0.326 . . . . 0.0 113.818 -171.213 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . 0.408 ' HG2' ' HG2' ' A' ' 312' ' ' MET . 0.2 OUTLIER -72.61 -19.97 61.37 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.818 0.342 . . . . 0.0 110.95 -178.4 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 312' ' ' MET . . . . . 0.408 ' HG2' ' HG2' ' A' ' 311' ' ' GLU . 78.3 mmm -108.43 6.48 26.3 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.812 0.339 . . . . 0.0 111.192 -178.687 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 313' ' ' LEU . . . . . 0.677 ' HG ' ' O ' ' A' ' 309' ' ' LYS . 91.9 mt -75.47 133.8 40.99 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 175.224 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -151.61 139.4 19.85 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.773 -172.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.23 161.81 11.63 Favored Glycine 0 N--CA 1.448 -0.556 0 N-CA-C 111.306 -0.718 . . . . 0.0 111.306 178.822 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 21.7 p -97.82 135.01 40.19 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 173.044 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -133.47 151.51 51.79 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.78 -172.166 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -120.75 110.4 28.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.439 -0.8 . . . . 0.0 109.384 175.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . 0.707 ' O ' ' HA ' ' A' ' 341' ' ' ALA . 90.9 m-85 -99.18 127.49 45.16 Favored 'General case' 0 C--N 1.312 -1.04 0 C-N-CA 120.327 -0.549 . . . . 0.0 110.424 178.327 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 48.0 m-80 -120.85 132.74 55.17 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.377 178.834 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . 0.566 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -166.53 -154.18 8.2 Favored Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.54 -179.598 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 3.7 mp0 -116.12 153.95 30.87 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.056 0.455 . . . . 0.0 111.122 -174.168 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 323' ' ' VAL . . . . . 0.559 HG23 ' HB2' ' A' ' 340' ' ' PHE . 72.5 t -112.06 117.44 55.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.355 -0.839 . . . . 0.0 109.208 172.397 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 324' ' ' LEU . . . . . 0.47 ' HB2' HG22 ' A' ' 419' ' ' VAL . 93.7 mt -95.69 104.31 16.22 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.129 0.49 . . . . 0.0 110.298 -177.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 325' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -98.52 113.98 26.21 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 179.512 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 326' ' ' PHE . . . . . 0.515 ' HD2' ' H ' ' A' ' 418' ' ' GLY . 57.9 m-85 . . . . . 0 C--N 1.321 -0.636 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.377 -174.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 337' ' ' ARG . . . . . . . . . . . . . 51.9 mtm180 . . . . . 0 N--CA 1.45 -0.438 0 CA-C-O 120.911 0.386 . . . . 0.0 110.268 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -90.52 -177.13 44.36 Favored Glycine 0 N--CA 1.44 -1.08 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 172.827 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 339' ' ' ARG . . . . . . . . . . . . . 65.1 mtt180 -104.49 154.92 19.28 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 176.237 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 340' ' ' PHE . . . . . 0.559 ' HB2' HG23 ' A' ' 323' ' ' VAL . 27.0 t80 -148.74 139.02 22.42 Favored 'General case' 0 C--N 1.309 -1.16 0 CA-C-O 121.165 0.507 . . . . 0.0 110.494 179.161 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 341' ' ' ALA . . . . . 0.707 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -136.84 164.2 28.87 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 114.967 -1.015 . . . . 0.0 108.908 175.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . 0.849 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -151.76 120.11 6.39 Favored 'General case' 0 C--N 1.314 -0.943 0 N-CA-C 109.654 -0.499 . . . . 0.0 109.654 -179.758 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 13.0 tptm -100.81 98.43 8.95 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.727 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 344' ' ' VAL . . . . . 0.491 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.2 OUTLIER -118.45 136.93 54.05 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 CA-C-N 115.833 -0.621 . . . . 0.0 112.176 -169.576 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 10.4 t0 -107.23 113.0 26.13 Favored 'General case' 0 C--N 1.321 -0.63 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 171.194 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 346' ' ' PHE . . . . . . . . . . . . . 48.4 m-85 -74.77 -27.64 60.42 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 111.701 0.26 . . . . 0.0 111.701 -176.091 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -61.87 -33.36 85.13 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.695 -0.764 . . . . 0.0 111.654 177.198 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 6.8 t -101.59 -4.48 26.57 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-O 120.688 0.28 . . . . 0.0 111.083 178.162 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 349' ' ' LYS . . . . . 0.479 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 10.0 mtmp? 51.28 59.05 4.88 Favored 'General case' 0 N--CA 1.466 0.362 0 C-N-CA 123.148 0.579 . . . . 0.0 111.543 -178.265 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 40.2 m -149.6 140.51 22.83 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.14 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 351' ' ' VAL . . . . . 0.517 HG22 ' HB3' ' A' ' 370' ' ' ALA . 0.8 OUTLIER -129.08 156.43 41.68 Favored 'Isoleucine or valine' 0 C--O 1.236 0.369 0 CA-C-O 121.289 0.566 . . . . 0.0 111.147 -175.665 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 352' ' ' ASP . . . . . 0.849 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 17.9 t70 -111.72 119.19 37.79 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.981 -1.009 . . . . 0.0 108.414 166.493 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -111.31 120.81 5.57 Favored Glycine 0 C--N 1.306 -1.11 0 C-N-CA 120.621 -0.8 . . . . 0.0 111.369 -178.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 354' ' ' ILE . . . . . 0.536 HG12 ' N ' ' A' ' 355' ' ' ILE . 0.2 OUTLIER -121.29 140.9 43.96 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.233 0 CA-C-O 121.084 0.469 . . . . 0.0 110.577 -176.233 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 355' ' ' ILE . . . . . 0.916 ' HB ' ' HB2' ' A' ' 366' ' ' GLN . 3.1 mp . . . . . 0 C--N 1.315 -0.904 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.26 177.614 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 366' ' ' GLN . . . . . 0.916 ' HB2' ' HB ' ' A' ' 355' ' ' ILE . 41.2 mt-30 . . . . . 0 N--CA 1.451 -0.379 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 367' ' ' LYS . . . . . 0.436 ' HD3' ' HE2' ' A' ' 369' ' ' LYS . 26.2 ttmt -148.43 139.8 23.43 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.181 -0.463 . . . . 0.0 109.752 -178.777 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 368' ' ' PHE . . . . . . . . . . . . . 52.3 p90 -139.06 145.12 39.18 Favored 'General case' 0 C--N 1.321 -0.663 0 O-C-N 123.33 0.394 . . . . 0.0 110.365 176.69 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 369' ' ' LYS . . . . . 0.436 ' HE2' ' HD3' ' A' ' 367' ' ' LYS . 3.4 mptp? -106.74 131.94 53.29 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 175.626 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 370' ' ' ALA . . . . . 0.517 ' HB3' HG22 ' A' ' 351' ' ' VAL . . . -135.64 135.89 40.54 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.549 -172.325 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -92.89 133.88 35.65 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.761 176.233 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 372' ' ' ILE . . . . . 0.479 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 87.4 mt -82.17 108.11 14.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 121.191 0.52 . . . . 0.0 110.405 -178.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -109.61 81.18 1.4 Allowed 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.485 -0.78 . . . . 0.0 109.096 178.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 374' ' ' GLY . . . . . 0.623 ' HA2' ' HA3' ' A' ' 310' ' ' GLY . . . 53.79 118.95 0.01 OUTLIER Glycine 0 CA--C 1.524 0.61 0 CA-C-N 114.992 -1.004 . . . . 0.0 114.841 -176.108 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 375' ' ' ASN . . . . . 0.526 ' HB2' ' O ' ' A' ' 308' ' ' ALA . 40.2 t30 40.69 44.28 1.81 Allowed 'General case' 0 N--CA 1.47 0.566 0 CA-C-O 122.053 0.93 . . . . 0.0 112.182 175.506 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 156.66 167.79 18.41 Favored Glycine 0 N--CA 1.442 -0.931 0 C-N-CA 120.302 -0.952 . . . . 0.0 111.608 176.065 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 377' ' ' PHE . . . . . 0.507 ' CD2' HG11 ' A' ' 351' ' ' VAL . 2.3 p90 -133.44 143.8 49.08 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-O 121.34 0.59 . . . . 0.0 111.5 -179.18 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 378' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.67 125.29 47.31 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 114.887 -1.051 . . . . 0.0 108.262 174.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -142.26 -165.3 10.47 Favored Glycine 0 N--CA 1.44 -1.055 0 C-N-CA 120.361 -0.923 . . . . 0.0 112.587 -176.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 95.4 m -142.46 147.05 35.45 Favored 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 -176.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 381' ' ' TRP . . . . . . . . . . . . . 42.0 m95 . . . . . 0 C--N 1.331 -0.214 0 O-C-N 123.633 0.583 . . . . 0.0 111.43 178.9 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.666 0 CA-C-O 120.985 0.214 . . . . 0.0 113.327 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -89.73 159.07 17.25 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 -177.407 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 79.6 t -135.67 135.99 50.75 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 174.166 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 16.9 m -143.11 141.68 31.3 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.8 0.334 . . . . 0.0 110.692 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 391' ' ' GLY . . . . . 0.435 ' HA2' ' CA ' ' A' ' 403' ' ' GLY . . . -145.36 155.9 26.7 Favored Glycine 0 C--N 1.316 -0.581 0 N-CA-C 111.487 -0.645 . . . . 0.0 111.487 -178.515 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 392' ' ' ARG . . . . . 0.526 ' HD3' ' O ' ' A' ' 375' ' ' ASN . 25.0 tpp180 -117.07 135.62 53.59 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.768 0.318 . . . . 0.0 110.24 -175.751 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -85.12 165.23 17.63 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.951 176.317 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 394' ' ' TYR . . . . . 0.626 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 4.8 m-85 -109.58 -177.38 3.26 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.99 -177.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 395' ' ' GLY . . . . . 0.479 ' O ' ' N ' ' A' ' 397' ' ' ALA . . . -37.83 160.72 0.01 OUTLIER Glycine 0 C--N 1.336 0.541 0 O-C-N 124.492 1.12 . . . . 0.0 114.922 -176.625 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_exo -17.25 -40.46 0.0 OUTLIER 'Trans proline' 0 C--N 1.353 0.78 1 C-N-CA 127.773 5.649 . . . . 0.0 118.501 -165.122 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 397' ' ' ALA . . . . . 0.552 ' HB1' ' HG3' ' A' ' 399' ' ' GLU . . . -81.16 -20.24 41.69 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 118.754 0.706 . . . . 0.0 111.633 -171.536 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 60.96 10.63 20.78 Favored Glycine 0 C--N 1.338 0.682 0 C-N-CA 121.409 -0.424 . . . . 0.0 112.725 176.668 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 399' ' ' GLU . . . . . 0.552 ' HG3' ' HB1' ' A' ' 397' ' ' ALA . 30.5 mt-10 -70.19 -8.93 53.82 Favored 'General case' 0 N--CA 1.451 -0.406 0 CA-C-O 121.66 0.743 . . . . 0.0 110.123 -178.378 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 400' ' ' GLU . . . . . 0.408 ' HB2' ' HB2' ' A' ' 394' ' ' TYR . 41.9 mt-10 -117.54 128.36 54.89 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.82 175.16 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 401' ' ' VAL . . . . . 0.46 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 10.1 p -140.87 140.49 32.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.844 0.354 . . . . 0.0 110.517 177.888 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -142.16 131.34 23.38 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.269 178.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 403' ' ' GLY . . . . . 0.435 ' CA ' ' HA2' ' A' ' 391' ' ' GLY . . . -145.02 -169.04 13.2 Favored Glycine 0 N--CA 1.438 -1.18 0 C-N-CA 120.47 -0.872 . . . . 0.0 112.271 -177.153 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 404' ' ' LYS . . . . . 0.775 ' HG2' HG12 ' A' ' 419' ' ' VAL . 37.5 mtpt -148.8 169.11 21.22 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 -178.344 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 5.8 m-85 . . . . . 0 C--N 1.32 -0.712 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 177.287 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 417' ' ' PHE . . . . . 0.478 ' HB2' ' HB2' ' A' ' 326' ' ' PHE . 35.2 p90 . . . . . 0 N--CA 1.453 -0.304 0 CA-C-O 120.973 0.416 . . . . 0.0 111.144 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 418' ' ' GLY . . . . . 0.515 ' H ' ' HD2' ' A' ' 326' ' ' PHE . . . 83.93 76.49 1.16 Allowed Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.3 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 419' ' ' VAL . . . . . 0.775 HG12 ' HG2' ' A' ' 404' ' ' LYS . 16.0 m -115.64 160.06 15.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 110.429 -0.211 . . . . 0.0 110.429 178.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 38.7 p90 -138.41 158.65 43.86 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.068 0.461 . . . . 0.0 110.506 178.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 421' ' ' ALA . . . . . 0.566 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -146.44 136.68 23.7 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.346 176.627 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -130.34 139.97 11.38 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.566 -0.826 . . . . 0.0 111.71 -179.365 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 72.1 mttt -117.66 136.4 53.35 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.173 0.511 . . . . 0.0 110.616 179.476 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 424' ' ' LYS . . . . . 0.513 ' HG2' ' OE2' ' A' ' 399' ' ' GLU . 23.0 tptm -59.0 125.82 25.17 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 114.838 -1.074 . . . . 0.0 113.126 -174.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 . . . . . 0 N--CA 1.446 -0.651 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 166.27 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo . . . . . 0 N--CA 1.461 -0.404 0 CA-C-O 120.653 0.189 . . . . 0.0 112.249 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 308' ' ' ALA . . . . . 0.787 ' O ' ' HB3' ' A' ' 375' ' ' ASN . . . -49.09 160.42 0.21 Allowed 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.148 169.291 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 309' ' ' LYS . . . . . 0.582 ' N ' HD23 ' A' ' 313' ' ' LEU . 79.2 mttt -127.01 91.46 3.34 Favored 'General case' 0 C--O 1.217 -0.611 0 O-C-N 121.798 -0.564 . . . . 0.0 109.817 -176.564 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -56.74 -23.46 44.47 Favored Glycine 0 CA--C 1.52 0.391 0 N-CA-C 114.873 0.709 . . . . 0.0 114.873 -168.298 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -87.65 -12.03 46.7 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 117.44 0.62 . . . . 0.0 111.574 178.392 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 14.8 tpt -115.5 -35.57 4.54 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.767 0.794 . . . . 0.0 109.511 -175.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 313' ' ' LEU . . . . . 0.78 HD22 ' HB1' ' A' ' 308' ' ' ALA . 0.4 OUTLIER -83.39 134.85 34.87 Favored 'General case' 0 N--CA 1.436 -1.169 0 CA-C-N 114.717 -1.128 . . . . 0.0 108.057 176.147 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 314' ' ' ALA . . . . . 0.644 ' HA ' ' CB ' ' A' ' 346' ' ' PHE . . . -161.91 173.18 14.85 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.177 0.513 . . . . 0.0 112.187 -170.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 121.71 168.67 13.43 Favored Glycine 0 N--CA 1.448 -0.531 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.277 -177.412 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 14.0 p -100.24 130.41 46.36 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 117.409 0.604 . . . . 0.0 109.94 174.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 317' ' ' ALA . . . . . 0.404 ' CB ' ' HE3' ' A' ' 424' ' ' LYS . . . -139.62 150.62 45.19 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 112.241 0.46 . . . . 0.0 112.241 -170.688 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 7.5 p -125.68 122.48 62.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.229 175.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . 0.413 ' O ' ' HA ' ' A' ' 341' ' ' ALA . 19.5 m-85 -111.99 146.61 37.55 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.732 -178.464 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 320' ' ' ASN . . . . . 0.632 HD22 ' HG3' ' A' ' 425' ' ' GLU . 43.4 m-80 -129.97 137.29 50.23 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.108 175.665 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . 0.598 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -162.52 -163.02 14.33 Favored Glycine 0 N--CA 1.44 -1.055 0 C-N-CA 120.344 -0.932 . . . . 0.0 112.697 -178.745 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -117.93 146.17 44.16 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.654 0.264 . . . . 0.0 110.33 -175.305 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 323' ' ' VAL . . . . . 0.671 HG23 ' HB2' ' A' ' 340' ' ' PHE . 84.9 t -110.39 117.05 53.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.105 176.084 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 324' ' ' LEU . . . . . 0.436 HD12 ' CE1' ' A' ' 326' ' ' PHE . 0.2 OUTLIER -94.44 103.03 15.01 Favored 'General case' 0 C--N 1.312 -1.038 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 177.796 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 325' ' ' HIS . . . . . 0.437 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 8.3 p-80 -95.88 115.48 27.5 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.14 -179.199 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 326' ' ' PHE . . . . . 0.737 ' HB2' ' HD1' ' A' ' 417' ' ' PHE . 16.5 m-85 . . . . . 0 C--N 1.321 -0.654 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.895 -175.283 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 337' ' ' ARG . . . . . 0.453 ' HA ' ' O ' ' A' ' 323' ' ' VAL . 17.4 ptp180 . . . . . 0 N--CA 1.45 -0.467 0 CA-C-O 121.042 0.448 . . . . 0.0 110.786 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -113.21 -176.69 19.49 Favored Glycine 0 N--CA 1.443 -0.869 0 CA-C-N 115.422 -0.808 . . . . 0.0 111.554 178.226 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 339' ' ' ARG . . . . . . . . . . . . . 73.6 mtt180 -104.91 131.16 52.76 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 120.747 0.308 . . . . 0.0 110.358 -175.085 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 340' ' ' PHE . . . . . 0.671 ' HB2' HG23 ' A' ' 323' ' ' VAL . 55.2 t80 -132.85 137.27 46.65 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-O 121.252 0.548 . . . . 0.0 111.472 -176.346 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 341' ' ' ALA . . . . . 0.413 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -139.48 143.85 37.71 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.137 -0.938 . . . . 0.0 108.999 174.512 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . 0.932 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -136.33 120.04 17.26 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-O 121.039 0.447 . . . . 0.0 110.84 -177.012 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -102.43 102.86 13.21 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.327 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 344' ' ' VAL . . . . . 0.446 ' HA ' ' HA ' ' A' ' 351' ' ' VAL . 0.3 OUTLIER -115.95 124.78 72.67 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 CA-C-O 121.6 0.714 . . . . 0.0 111.83 -172.649 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -97.44 98.59 10.07 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 172.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 346' ' ' PHE . . . . . 0.644 ' CB ' ' HA ' ' A' ' 314' ' ' ALA . 72.7 m-85 -65.27 -26.76 68.23 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.689 0.28 . . . . 0.0 111.259 -176.188 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -65.75 -19.57 67.44 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.831 -0.7 . . . . 0.0 111.843 178.001 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 11.9 t -112.03 -6.67 14.16 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.986 0.422 . . . . 0.0 110.058 177.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 349' ' ' LYS . . . . . 0.59 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 37.5 mtmm 52.61 59.12 4.71 Favored 'General case' 0 C--O 1.227 -0.098 0 CA-C-N 115.064 -0.971 . . . . 0.0 111.159 -176.013 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 68.1 p -149.32 138.35 21.3 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.181 179.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 351' ' ' VAL . . . . . 0.446 ' HA ' ' HA ' ' A' ' 344' ' ' VAL . 0.9 OUTLIER -123.89 151.77 28.95 Favored 'Isoleucine or valine' 0 C--O 1.235 0.334 0 CA-C-O 121.05 0.452 . . . . 0.0 110.789 -178.497 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 352' ' ' ASP . . . . . 0.932 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 21.3 t70 -112.02 118.4 35.33 Favored 'General case' 0 C--O 1.213 -0.857 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.353 173.444 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -119.82 119.01 4.1 Favored Glycine 0 N--CA 1.442 -0.925 0 C-N-CA 120.257 -0.973 . . . . 0.0 112.173 -176.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 354' ' ' ILE . . . . . 0.549 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -114.81 129.64 70.61 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.065 0 CA-C-O 121.038 0.447 . . . . 0.0 110.103 -178.125 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 355' ' ' ILE . . . . . 0.44 HD11 ' HE2' ' A' ' 368' ' ' PHE . 3.7 mp . . . . . 0 C--N 1.323 -0.57 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.159 -177.741 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 . . . . . 0 CA--C 1.522 -0.101 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 19.3 pttp -148.23 151.33 35.29 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.191 0.519 . . . . 0.0 111.631 -179.121 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 368' ' ' PHE . . . . . 0.659 ' CD1' HG21 ' A' ' 389' ' ' VAL . 27.2 p90 -134.99 161.45 35.24 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.195 -0.911 . . . . 0.0 109.189 179.238 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 33.3 mtmm -131.62 150.9 51.99 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-O 121.264 0.554 . . . . 0.0 110.513 173.619 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -141.55 139.84 33.29 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.164 -173.701 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -92.69 130.73 38.23 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 174.223 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 372' ' ' ILE . . . . . 0.67 ' HA ' ' HB3' ' A' ' 377' ' ' PHE . 83.4 mt -79.45 108.17 12.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-O 121.758 0.79 . . . . 0.0 110.585 -176.322 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -110.58 82.38 1.58 Allowed 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 114.647 -1.16 . . . . 0.0 109.495 -178.712 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 59.48 119.29 0.01 OUTLIER Glycine 0 CA--C 1.52 0.402 0 CA-C-N 114.928 -1.033 . . . . 0.0 113.776 -177.146 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 375' ' ' ASN . . . . . 0.787 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 2.2 p-10 28.85 44.6 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 124.734 1.214 . . . . 0.0 114.123 177.238 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 160.59 -178.77 36.47 Favored Glycine 0 N--CA 1.442 -0.906 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 -178.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 377' ' ' PHE . . . . . 0.67 ' HB3' ' HA ' ' A' ' 372' ' ' ILE . 6.3 p90 -153.51 150.66 28.96 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 117.362 0.581 . . . . 0.0 111.783 -178.787 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 378' ' ' LYS . . . . . 0.555 ' HD3' ' H ' ' A' ' 378' ' ' LYS . 0.0 OUTLIER -117.77 140.59 49.47 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 171.102 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 379' ' ' GLY . . . . . 0.54 ' C ' HG22 ' A' ' 389' ' ' VAL . . . -149.06 -155.13 6.59 Favored Glycine 0 N--CA 1.44 -1.062 0 C-N-CA 120.504 -0.855 . . . . 0.0 112.235 -172.852 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 380' ' ' THR . . . . . 0.456 ' HA ' ' HA ' ' A' ' 388' ' ' ASP . 7.0 t -170.99 154.49 4.17 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 -173.52 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 381' ' ' TRP . . . . . 0.672 ' HD1' ' HA3' ' A' ' 387' ' ' GLY . 39.4 m95 . . . . . 0 C--N 1.327 -0.375 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.422 -179.597 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . 0.672 ' HA3' ' HD1' ' A' ' 381' ' ' TRP . . . . . . . . 0 N--CA 1.443 -0.881 0 N-CA-C 111.965 -0.454 . . . . 0.0 111.965 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 388' ' ' ASP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 380' ' ' THR . 43.4 m-20 -107.73 147.33 30.92 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.027 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 389' ' ' VAL . . . . . 0.659 HG21 ' CD1' ' A' ' 368' ' ' PHE . 3.3 m -121.49 167.15 15.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 120.713 0.292 . . . . 0.0 111.589 -171.736 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 33.6 t -161.87 157.61 24.21 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 173.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -157.57 163.57 32.64 Favored Glycine 0 C--N 1.32 -0.308 0 N-CA-C 111.682 -0.567 . . . . 0.0 111.682 179.666 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 25.6 ttt180 -125.71 143.21 51.14 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.791 0.295 . . . . 0.0 110.313 -176.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 393' ' ' PHE . . . . . 0.582 ' CZ ' ' HE1' ' A' ' 346' ' ' PHE . 2.5 m-85 -92.92 157.45 16.34 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.432 0.634 . . . . 0.0 112.261 -175.433 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 394' ' ' TYR . . . . . 0.729 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 1.2 m-85 -102.5 -176.5 3.12 Favored 'General case' 0 C--O 1.22 -0.5 0 CA-C-N 114.816 -1.083 . . . . 0.0 110.372 178.615 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 395' ' ' GLY . . . . . . . . . . . . . . . -36.67 153.64 0.01 OUTLIER Glycine 0 C--N 1.335 0.479 0 O-C-N 124.394 1.059 . . . . 0.0 114.941 -176.879 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_exo -16.15 -50.63 0.02 OUTLIER 'Trans proline' 0 C--N 1.351 0.691 1 C-N-CA 127.453 5.435 . . . . 0.0 117.724 -165.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 397' ' ' ALA . . . . . 0.537 ' HB3' ' HG2' ' A' ' 399' ' ' GLU . . . -75.46 -16.72 60.29 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 112.377 0.51 . . . . 0.0 112.377 -171.504 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 68.49 24.92 75.1 Favored Glycine 0 N--CA 1.447 -0.591 0 N-CA-C 111.769 -0.532 . . . . 0.0 111.769 179.538 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 399' ' ' GLU . . . . . 0.537 ' HG2' ' HB3' ' A' ' 397' ' ' ALA . 10.9 mm-40 -58.86 -16.54 17.86 Favored 'General case' 0 N--CA 1.463 0.208 0 C-N-CA 123.248 0.619 . . . . 0.0 111.557 -175.488 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 400' ' ' GLU . . . . . 0.409 ' HA ' ' O ' ' A' ' 422' ' ' GLY . 35.1 mt-10 -138.53 146.72 42.27 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 172.613 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 401' ' ' VAL . . . . . 0.488 HG21 ' CE2' ' A' ' 377' ' ' PHE . 7.3 p -144.54 133.01 17.92 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.398 177.032 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -124.61 132.22 53.44 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.332 -178.694 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -146.86 -172.14 16.82 Favored Glycine 0 N--CA 1.44 -1.049 0 C-N-CA 120.498 -0.858 . . . . 0.0 112.088 -179.139 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 404' ' ' LYS . . . . . 0.739 ' HG2' HG12 ' A' ' 419' ' ' VAL . 30.1 mtmt -146.51 158.43 43.9 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 179.815 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 405' ' ' TYR . . . . . 0.5 ' HB3' HG12 ' A' ' 389' ' ' VAL . 17.6 p90 . . . . . 0 C--N 1.32 -0.716 0 CA-C-O 121.222 0.534 . . . . 0.0 110.579 176.58 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 417' ' ' PHE . . . . . 0.737 ' HD1' ' HB2' ' A' ' 326' ' ' PHE . 71.5 m-85 . . . . . 0 N--CA 1.452 -0.366 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 418' ' ' GLY . . . . . 0.512 ' H ' ' HD2' ' A' ' 326' ' ' PHE . . . 81.8 76.86 1.06 Allowed Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 120.339 -0.934 . . . . 0.0 112.567 176.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 419' ' ' VAL . . . . . 0.739 HG12 ' HG2' ' A' ' 404' ' ' LYS . 18.9 m -106.43 152.84 7.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 N-CA-C 110.207 -0.294 . . . . 0.0 110.207 179.441 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 420' ' ' PHE . . . . . 0.419 ' HB3' HG22 ' A' ' 323' ' ' VAL . 40.9 p90 -138.03 154.42 49.3 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 120.934 0.397 . . . . 0.0 110.273 -179.438 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 421' ' ' ALA . . . . . 0.598 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -142.24 136.02 29.42 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 177.112 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 422' ' ' GLY . . . . . 0.409 ' O ' ' HA ' ' A' ' 400' ' ' GLU . . . -118.1 135.6 11.76 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 120.67 -0.776 . . . . 0.0 111.974 -179.046 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 63.9 mttm -113.37 133.68 55.03 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.816 0.341 . . . . 0.0 110.359 -179.086 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 424' ' ' LYS . . . . . 0.404 ' HE3' ' CB ' ' A' ' 317' ' ' ALA . 23.6 tptm -60.92 112.05 1.9 Allowed 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.354 -177.736 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 425' ' ' GLU . . . . . 0.632 ' HG3' HD22 ' A' ' 320' ' ' ASN . 8.8 mm-40 . . . . . 0 C--N 1.324 -0.541 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.516 177.433 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 307' ' ' PRO . . . . . 0.568 ' C ' ' HA2' ' A' ' 395' ' ' GLY . 66.6 Cg_endo . . . . . 0 N--CA 1.453 -0.898 0 CA-C-O 120.753 0.23 . . . . 0.0 111.634 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 308' ' ' ALA . . . . . 0.59 ' HB1' HD21 ' A' ' 313' ' ' LEU . . . -61.11 161.1 9.07 Favored 'General case' 0 CA--C 1.515 -0.372 0 CA-C-O 121.372 0.606 . . . . 0.0 112.106 -175.513 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 309' ' ' LYS . . . . . . . . . . . . . 45.1 mttm -104.66 84.61 2.19 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 171.598 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 310' ' ' GLY . . . . . 0.705 ' HA3' ' O ' ' A' ' 374' ' ' GLY . . . -55.51 -34.25 59.81 Favored Glycine 0 CA--C 1.508 -0.35 0 CA-C-N 115.832 -0.622 . . . . 0.0 113.054 -173.623 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -45.6 -37.6 5.74 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 123.663 0.785 . . . . 0.0 112.288 175.629 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 73.2 mtm -131.08 31.75 4.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.718 0.294 . . . . 0.0 111.144 -177.381 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 313' ' ' LEU . . . . . 0.611 HD12 ' HA2' ' A' ' 310' ' ' GLY . 10.3 mt -65.79 -165.45 0.03 OUTLIER 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 112.387 0.514 . . . . 0.0 112.387 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -76.25 -168.98 1.05 Allowed 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -170.429 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . 0.616 ' O ' ' HB2' ' A' ' 346' ' ' PHE . . . -93.11 -122.64 3.3 Favored Glycine 0 C--O 1.223 -0.574 0 CA-C-N 115.019 -0.991 . . . . 0.0 111.469 178.278 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 18.0 p -96.56 131.68 42.94 Favored 'General case' 0 C--N 1.311 -1.074 0 O-C-N 122.28 -0.541 . . . . 0.0 110.912 177.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -142.92 162.2 36.11 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.587 -174.294 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 4.7 p -127.92 114.68 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.642 0 CA-C-O 121.452 0.644 . . . . 0.0 110.489 172.854 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 1.3 m-85 -98.89 155.42 17.4 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 175.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 320' ' ' ASN . . . . . 0.435 ' HA ' ' HA ' ' A' ' 341' ' ' ALA . 8.3 p30 -157.83 156.11 30.88 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 120.855 0.359 . . . . 0.0 110.75 173.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . 0.412 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -176.81 -150.24 8.17 Favored Glycine 0 N--CA 1.443 -0.846 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.145 -178.646 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 23.5 mm-40 -112.98 149.76 32.83 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.779 0.323 . . . . 0.0 110.861 -173.431 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 323' ' ' VAL . . . . . 0.685 HG21 HG23 ' A' ' 355' ' ' ILE . 55.5 t -108.52 118.29 55.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.051 174.091 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 324' ' ' LEU . . . . . . . . . . . . . 92.2 mt -97.61 103.48 15.42 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.896 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 325' ' ' HIS . . . . . . . . . . . . . 26.3 t60 -98.97 112.73 24.76 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 -178.144 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 326' ' ' PHE . . . . . 0.625 ' HB2' ' HB3' ' A' ' 417' ' ' PHE . 30.3 m-85 . . . . . 0 C--N 1.327 -0.409 0 CA-C-N 116.28 -0.418 . . . . 0.0 109.925 -173.78 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 337' ' ' ARG . . . . . . . . . . . . . 18.5 mtp180 . . . . . 0 N--CA 1.444 -0.726 0 CA-C-O 121.289 0.566 . . . . 0.0 111.054 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -98.53 165.37 21.34 Favored Glycine 0 N--CA 1.436 -1.318 0 N-CA-C 110.132 -1.187 . . . . 0.0 110.132 173.734 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 339' ' ' ARG . . . . . 0.524 ' HD2' ' N ' ' A' ' 339' ' ' ARG . 5.6 mpt_? -104.92 157.56 17.13 Favored 'General case' 0 C--N 1.313 -0.992 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 176.651 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 340' ' ' PHE . . . . . 0.75 ' HA ' ' O ' ' A' ' 354' ' ' ILE . 11.1 t80 -154.68 140.56 18.22 Favored 'General case' 0 C--N 1.313 -0.992 0 C-N-CA 120.496 -0.482 . . . . 0.0 111.35 -176.777 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 341' ' ' ALA . . . . . 0.435 ' HA ' ' HA ' ' A' ' 320' ' ' ASN . . . -136.81 165.75 25.2 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 174.351 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . 0.861 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -147.96 118.98 7.66 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-O 121.12 0.486 . . . . 0.0 111.222 -177.32 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 343' ' ' LYS . . . . . 0.531 ' HB3' ' HB2' ' A' ' 352' ' ' ASP . 27.0 tptp -87.28 98.0 11.09 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 174.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 344' ' ' VAL . . . . . 0.488 ' HA ' ' HA ' ' A' ' 351' ' ' VAL . 0.3 OUTLIER -115.95 117.31 55.12 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-O 121.816 0.817 . . . . 0.0 111.802 -172.718 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -95.44 94.11 7.61 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 114.282 -1.327 . . . . 0.0 108.591 175.48 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 346' ' ' PHE . . . . . 0.616 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 44.9 m-85 -65.54 -21.2 66.58 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.965 -174.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -62.28 -33.8 87.21 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.363 176.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 39.0 m -106.78 -6.57 17.67 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.163 0.506 . . . . 0.0 110.15 176.506 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 349' ' ' LYS . . . . . 0.775 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 22.4 mttm 53.79 62.71 2.49 Favored 'General case' 0 C--O 1.22 -0.466 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.89 -177.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 49.8 m -141.01 145.46 35.95 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.207 -0.906 . . . . 0.0 109.207 175.458 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 351' ' ' VAL . . . . . 0.517 HG22 ' HB3' ' A' ' 370' ' ' ALA . 0.9 OUTLIER -129.27 156.47 41.81 Favored 'Isoleucine or valine' 0 C--O 1.235 0.327 0 CA-C-O 120.856 0.36 . . . . 0.0 110.526 -176.999 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 352' ' ' ASP . . . . . 0.861 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 1.8 m-20 -121.13 118.0 28.58 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 170.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 353' ' ' GLY . . . . . 0.403 ' HA2' ' O ' ' A' ' 341' ' ' ALA . . . -111.13 124.02 6.75 Favored Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.11 -1.043 . . . . 0.0 112.435 -175.68 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 354' ' ' ILE . . . . . 0.75 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 1.0 OUTLIER -112.99 129.51 68.52 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-O 120.686 0.279 . . . . 0.0 110.455 -178.063 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 355' ' ' ILE . . . . . 0.685 HG23 HG21 ' A' ' 323' ' ' VAL . 4.3 mm . . . . . 0 C--N 1.323 -0.555 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.022 179.126 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 17.2 mm100 . . . . . 0 N--CA 1.447 -0.591 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -153.63 154.37 34.07 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 176.216 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 368' ' ' PHE . . . . . 0.507 ' HB3' ' CE3' ' A' ' 381' ' ' TRP . 47.2 p90 -136.05 160.21 39.35 Favored 'General case' 0 C--N 1.319 -0.757 0 O-C-N 123.437 0.46 . . . . 0.0 109.836 -176.41 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 369' ' ' LYS . . . . . 0.513 ' HG3' ' O ' ' A' ' 351' ' ' VAL . 26.9 tttp -127.6 132.87 49.74 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 174.119 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 370' ' ' ALA . . . . . 0.517 ' HB3' HG22 ' A' ' 351' ' ' VAL . . . -128.85 148.46 50.89 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.182 -172.065 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -104.41 129.27 52.37 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.947 176.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 372' ' ' ILE . . . . . 0.775 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 93.3 mt -81.86 103.81 9.53 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.638 0 CA-C-O 121.925 0.869 . . . . 0.0 109.747 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 19.1 t0 -107.8 96.99 6.77 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 114.375 -1.284 . . . . 0.0 108.859 178.277 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 374' ' ' GLY . . . . . 0.705 ' O ' ' HA3' ' A' ' 310' ' ' GLY . . . 92.51 -123.32 7.24 Favored Glycine 0 N--CA 1.441 -0.981 0 C-N-CA 120.621 -0.799 . . . . 0.0 111.244 -174.254 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 375' ' ' ASN . . . . . 0.4 HD22 ' HB2' ' A' ' 307' ' ' PRO . 42.3 p-10 -114.15 35.63 4.07 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.925 0.869 . . . . 0.0 110.82 -175.244 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . -177.93 171.59 44.12 Favored Glycine 0 N--CA 1.443 -0.855 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 -176.295 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 377' ' ' PHE . . . . . 0.486 ' HD2' HG12 ' A' ' 372' ' ' ILE . 6.7 p90 -131.57 145.69 51.84 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 117.715 0.757 . . . . 0.0 112.616 -176.129 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 378' ' ' LYS . . . . . 0.461 ' HD2' ' H ' ' A' ' 378' ' ' LYS . 0.0 OUTLIER -119.68 134.33 55.27 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 114.578 -1.192 . . . . 0.0 108.167 171.676 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -150.3 -169.68 16.65 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.062 -1.066 . . . . 0.0 112.986 -175.597 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 15.1 t -147.46 153.68 39.86 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -175.849 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 381' ' ' TRP . . . . . 0.507 ' CE3' ' HB3' ' A' ' 368' ' ' PHE . 61.4 m95 . . . . . 0 C--N 1.33 -0.27 0 CA-C-O 120.985 0.421 . . . . 0.0 110.282 179.672 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.445 -0.75 0 N-CA-C 112.105 -0.398 . . . . 0.0 112.105 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -142.16 134.82 28.29 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 110.204 -0.295 . . . . 0.0 110.204 -178.593 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 38.2 t -112.95 133.87 57.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.347 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 31.7 m -144.61 143.3 30.71 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.076 0.465 . . . . 0.0 111.224 178.229 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -157.4 157.17 27.89 Favored Glycine 0 N--CA 1.445 -0.763 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 178.63 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 11.3 ptp180 -136.02 150.74 49.32 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 117.405 0.602 . . . . 0.0 110.764 -175.3 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 393' ' ' PHE . . . . . 0.481 ' CD1' ' HB ' ' A' ' 401' ' ' VAL . 95.1 m-85 -84.49 167.75 16.09 Favored 'General case' 0 CA--C 1.496 -1.098 0 CA-C-O 122.134 0.969 . . . . 0.0 111.184 -178.084 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 394' ' ' TYR . . . . . 0.569 ' HD1' ' N ' ' A' ' 394' ' ' TYR . 0.6 OUTLIER -97.56 -179.11 4.36 Favored 'General case' 0 N--CA 1.428 -1.562 0 N-CA-C 105.621 -1.992 . . . . 0.0 105.621 173.153 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 395' ' ' GLY . . . . . 0.568 ' HA2' ' C ' ' A' ' 307' ' ' PRO . . . -51.48 -148.16 0.0 OUTLIER Glycine 0 N--CA 1.474 1.168 0 O-C-N 124.497 1.123 . . . . 0.0 115.754 -172.314 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -57.67 -10.86 7.88 Favored 'Trans proline' 0 CA--C 1.539 0.729 0 C-N-CA 121.227 1.285 . . . . 0.0 111.042 176.192 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 397' ' ' ALA . . . . . 0.489 ' C ' ' H ' ' A' ' 399' ' ' GLU . . . -93.97 27.66 2.71 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 114.77 -1.104 . . . . 0.0 110.811 174.127 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . -53.6 8.54 0.01 OUTLIER Glycine 0 N--CA 1.469 0.87 0 C-N-CA 124.069 0.842 . . . . 0.0 114.599 176.079 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 399' ' ' GLU . . . . . 0.489 ' H ' ' C ' ' A' ' 397' ' ' ALA . 3.7 mp0 -59.97 -9.99 3.66 Favored 'General case' 0 C--N 1.323 -0.587 0 C-N-CA 123.929 0.892 . . . . 0.0 110.019 166.676 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 -119.21 125.05 48.24 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-N 115.344 -0.844 . . . . 0.0 109.439 174.15 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 401' ' ' VAL . . . . . 0.481 ' HB ' ' CD1' ' A' ' 393' ' ' PHE . 12.2 p -132.71 141.12 45.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 176.607 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -130.01 137.56 50.33 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-O 120.761 0.315 . . . . 0.0 110.679 178.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -144.88 177.03 23.62 Favored Glycine 0 N--CA 1.439 -1.161 0 C-N-CA 120.458 -0.877 . . . . 0.0 112.143 179.805 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 404' ' ' LYS . . . . . 0.454 ' CG ' HG12 ' A' ' 419' ' ' VAL . 0.0 OUTLIER -141.13 155.7 46.07 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 176.905 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 19.7 p90 . . . . . 0 C--N 1.313 -0.982 0 CA-C-O 120.977 0.417 . . . . 0.0 110.287 176.851 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 417' ' ' PHE . . . . . 0.625 ' HB3' ' HB2' ' A' ' 326' ' ' PHE . 73.8 m-85 . . . . . 0 N--CA 1.452 -0.344 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 82.8 76.99 1.1 Allowed Glycine 0 N--CA 1.449 -0.467 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.374 -177.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 419' ' ' VAL . . . . . 0.454 HG12 ' CG ' ' A' ' 404' ' ' LYS . 19.8 m -106.4 167.36 3.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 -179.34 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 45.9 p90 -148.24 162.69 38.98 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-O 120.796 0.331 . . . . 0.0 110.144 178.077 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 421' ' ' ALA . . . . . 0.412 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -142.85 135.39 27.67 Favored 'General case' 0 C--N 1.316 -0.877 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 177.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -122.95 135.72 10.2 Favored Glycine 0 N--CA 1.441 -1.021 0 C-N-CA 120.749 -0.739 . . . . 0.0 111.451 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 60.3 mttm -118.93 139.8 51.05 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-O 121.041 0.448 . . . . 0.0 110.354 179.442 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 424' ' ' LYS . . . . . . . . . . . . . 5.6 tppp? -60.06 122.41 14.3 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.011 -0.995 . . . . 0.0 111.86 -177.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 . . . . . 0 C--N 1.319 -0.756 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 166.758 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo . . . . . 0 N--CA 1.457 -0.626 0 N-CA-C 109.478 -1.008 . . . . 0.0 109.478 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 308' ' ' ALA . . . . . 0.753 ' HB1' HD11 ' A' ' 313' ' ' LEU . . . -49.45 118.95 3.03 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 121.118 0.485 . . . . 0.0 111.366 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 309' ' ' LYS . . . . . 0.452 ' O ' ' HG ' ' A' ' 313' ' ' LEU . 24.8 mmmt -73.95 81.5 1.68 Allowed 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -177.578 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 310' ' ' GLY . . . . . 0.708 ' HA2' HD12 ' A' ' 313' ' ' LEU . . . -52.56 -40.48 55.06 Favored Glycine 0 C--N 1.333 0.387 0 O-C-N 123.332 0.395 . . . . 0.0 113.145 -174.445 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . 0.552 ' HG3' ' HG3' ' A' ' 312' ' ' MET . 10.1 pt-20 -56.63 -28.26 60.13 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 122.635 0.374 . . . . 0.0 111.923 177.307 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 312' ' ' MET . . . . . 0.552 ' HG3' ' HG3' ' A' ' 311' ' ' GLU . 76.3 mtm -113.83 1.97 14.96 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.687 0.28 . . . . 0.0 111.352 -177.424 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 313' ' ' LEU . . . . . 0.753 HD11 ' HB1' ' A' ' 308' ' ' ALA . 78.8 mt -72.69 131.04 41.87 Favored 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 175.598 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -143.9 143.67 31.38 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.569 -173.042 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 121.66 169.87 13.73 Favored Glycine 0 N--CA 1.445 -0.743 0 C-N-CA 120.981 -0.628 . . . . 0.0 111.843 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 25.4 p -107.32 133.04 52.44 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 175.242 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -142.03 160.26 40.58 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 121.271 0.557 . . . . 0.0 112.076 -172.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 6.1 p -129.13 115.93 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.878 174.512 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . 0.578 ' CZ ' ' HB2' ' A' ' 424' ' ' LYS . 2.0 m-85 -98.07 128.74 44.77 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 179.09 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 4.0 p30 -131.37 144.05 50.94 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 120.868 0.366 . . . . 0.0 110.727 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -173.67 -143.89 4.5 Favored Glycine 0 N--CA 1.443 -0.855 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.007 -179.722 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -119.48 147.81 43.99 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.832 0.349 . . . . 0.0 110.975 -175.163 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 323' ' ' VAL . . . . . 0.717 HG13 ' HB2' ' A' ' 340' ' ' PHE . 4.5 m -106.71 117.04 51.75 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 CA-C-N 115.846 -0.616 . . . . 0.0 109.391 168.027 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 324' ' ' LEU . . . . . 0.544 ' HB2' HG22 ' A' ' 419' ' ' VAL . 97.5 mt -91.63 101.94 14.57 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 177.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 325' ' ' HIS . . . . . 0.489 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 6.2 p80 -102.41 117.67 35.21 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.754 0.788 . . . . 0.0 109.766 -176.333 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 326' ' ' PHE . . . . . 0.782 ' HD2' ' HB3' ' A' ' 417' ' ' PHE . 58.4 m-85 . . . . . 0 C--N 1.322 -0.598 0 CA-C-N 114.649 -1.16 . . . . 0.0 111.22 -168.521 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 337' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.452 -0.365 0 CA-C-O 121.53 0.681 . . . . 0.0 111.487 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 338' ' ' GLY . . . . . 0.412 ' HA3' ' CG2' ' A' ' 323' ' ' VAL . . . -106.46 -175.42 23.29 Favored Glycine 0 N--CA 1.437 -1.251 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 170.032 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 339' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -111.29 131.56 55.06 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 117.222 0.511 . . . . 0.0 109.799 178.109 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 340' ' ' PHE . . . . . 0.717 ' HB2' HG13 ' A' ' 323' ' ' VAL . 10.9 t80 -127.37 133.53 50.02 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.793 -178.182 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 341' ' ' ALA . . . . . 0.471 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -131.9 160.7 34.94 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.613 175.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . 0.889 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -147.83 119.4 7.97 Favored 'General case' 0 N--CA 1.442 -0.844 0 CA-C-O 121.204 0.526 . . . . 0.0 110.446 -177.7 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 343' ' ' LYS . . . . . 0.442 ' HB3' ' HB2' ' A' ' 352' ' ' ASP . 6.3 tmtt? -91.68 98.74 11.82 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 178.363 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 344' ' ' VAL . . . . . 0.617 ' HB ' HG12 ' A' ' 351' ' ' VAL . 0.2 OUTLIER -118.51 128.52 75.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-O 121.794 0.806 . . . . 0.0 112.239 -172.189 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -108.14 110.62 22.32 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 114.489 -1.232 . . . . 0.0 108.419 174.443 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 346' ' ' PHE . . . . . 0.478 ' HZ ' ' OH ' ' A' ' 319' ' ' TYR . 64.8 m-85 -73.16 -18.74 61.24 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.705 0.288 . . . . 0.0 111.732 -176.291 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -62.77 -28.19 71.27 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.475 -0.869 . . . . 0.0 111.249 176.199 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 20.5 t -112.46 -10.12 13.76 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-N 115.897 -0.151 . . . . 0.0 110.974 177.72 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 349' ' ' LYS . . . . . 0.643 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 35.2 mttp 57.23 59.46 3.37 Favored 'General case' 0 C--O 1.224 -0.275 0 CA-C-O 121.58 0.705 . . . . 0.0 110.646 -178.308 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 8.6 t -146.86 152.61 39.01 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.296 177.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 351' ' ' VAL . . . . . 0.728 HG22 ' HB3' ' A' ' 370' ' ' ALA . 1.2 m -134.8 155.25 38.12 Favored 'Isoleucine or valine' 0 C--O 1.236 0.382 0 CA-C-O 121.205 0.526 . . . . 0.0 110.836 -176.786 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 352' ' ' ASP . . . . . 0.889 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 1.2 m-20 -110.7 117.91 34.74 Favored 'General case' 0 C--O 1.215 -0.728 0 CA-C-N 115.244 -0.889 . . . . 0.0 108.692 168.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -110.91 124.43 6.96 Favored Glycine 0 N--CA 1.441 -1.03 0 C-N-CA 120.193 -1.003 . . . . 0.0 111.562 -176.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 354' ' ' ILE . . . . . 0.472 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -122.05 129.73 75.15 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 CA-C-O 121.187 0.518 . . . . 0.0 109.85 -177.058 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 355' ' ' ILE . . . . . 0.617 HG23 HG21 ' A' ' 323' ' ' VAL . 4.2 mp . . . . . 0 C--N 1.32 -0.714 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.858 -178.57 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 43.9 mt-30 . . . . . 0 N--CA 1.457 -0.101 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -138.55 148.61 44.42 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 176.429 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 368' ' ' PHE . . . . . 0.451 ' HB3' ' CE3' ' A' ' 381' ' ' TRP . 34.4 p90 -140.83 149.99 42.72 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.0 0.429 . . . . 0.0 110.465 178.577 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 1.6 mptp? -104.9 138.1 41.66 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 173.473 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 370' ' ' ALA . . . . . 0.728 ' HB3' HG22 ' A' ' 351' ' ' VAL . . . -134.26 147.45 50.66 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.18 0.514 . . . . 0.0 111.574 -177.127 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -105.96 130.47 53.89 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.628 175.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 372' ' ' ILE . . . . . 0.643 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 87.6 mt -81.66 107.38 13.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 121.545 0.688 . . . . 0.0 110.755 -178.04 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 373' ' ' ASP . . . . . 0.494 ' HB2' ' HE2' ' A' ' 378' ' ' LYS . 28.5 t70 -111.46 80.2 1.29 Allowed 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.093 -0.958 . . . . 0.0 109.435 179.417 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 58.87 119.07 0.01 OUTLIER Glycine 0 CA--C 1.521 0.42 0 CA-C-N 114.889 -1.051 . . . . 0.0 113.76 -177.484 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 375' ' ' ASN . . . . . 0.732 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 2.4 p-10 29.86 46.05 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 113.912 1.078 . . . . 0.0 113.912 178.582 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 165.06 172.35 32.41 Favored Glycine 0 N--CA 1.445 -0.766 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 178.032 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 377' ' ' PHE . . . . . 0.464 ' CZ ' HG21 ' A' ' 401' ' ' VAL . 3.4 p90 -147.95 150.54 34.23 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.447 0.641 . . . . 0.0 111.793 179.185 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 378' ' ' LYS . . . . . 0.821 ' HD3' ' H ' ' A' ' 378' ' ' LYS . 0.3 OUTLIER -112.37 130.29 56.01 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 114.638 -1.164 . . . . 0.0 108.383 174.688 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -126.23 156.64 19.83 Favored Glycine 0 N--CA 1.444 -0.821 0 C-N-CA 120.4 -0.905 . . . . 0.0 113.248 -172.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 26.7 p -125.24 137.74 54.1 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.219 -0.491 . . . . 0.0 109.938 178.007 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 381' ' ' TRP . . . . . 0.451 ' CE3' ' HB3' ' A' ' 368' ' ' PHE . 41.2 m95 . . . . . 0 C--N 1.33 -0.242 0 CA-C-O 121.146 0.498 . . . . 0.0 110.943 -178.074 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.447 -0.591 0 N-CA-C 111.647 -0.581 . . . . 0.0 111.647 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 20.6 m-20 -93.41 143.44 26.28 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 120.961 0.41 . . . . 0.0 110.64 -177.168 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 389' ' ' VAL . . . . . 0.412 HG22 ' HB3' ' A' ' 405' ' ' TYR . 23.9 t -112.7 137.09 46.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.782 179.464 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 5.0 p -147.42 138.83 23.87 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.817 0.341 . . . . 0.0 111.459 -179.077 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -156.74 154.11 25.26 Favored Glycine 0 N--CA 1.445 -0.764 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 23.2 mtt180 -119.51 153.15 35.78 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.468 0.652 . . . . 0.0 111.952 -175.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -93.71 159.31 15.26 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 114.649 -1.159 . . . . 0.0 110.045 178.643 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 394' ' ' TYR . . . . . 0.631 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 3.5 m-85 -101.62 -178.45 3.73 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.723 -177.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 395' ' ' GLY . . . . . 0.407 ' O ' ' N ' ' A' ' 397' ' ' ALA . . . -42.52 168.47 0.01 OUTLIER Glycine 0 CA--C 1.524 0.594 0 O-C-N 124.048 0.842 . . . . 0.0 115.159 -175.046 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_exo -19.35 -45.17 0.02 OUTLIER 'Trans proline' 0 C--N 1.356 0.924 1 C-N-CA 127.204 5.269 . . . . 0.0 117.588 -167.23 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 397' ' ' ALA . . . . . 0.407 ' N ' ' O ' ' A' ' 395' ' ' GLY . . . -72.25 -21.26 61.41 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -174.17 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 54.33 19.13 11.33 Favored Glycine 0 C--O 1.219 -0.837 0 CA-C-N 115.918 -0.583 . . . . 0.0 113.777 174.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 399' ' ' GLU . . . . . 0.882 ' HG3' ' HB3' ' A' ' 424' ' ' LYS . 23.0 tt0 -79.7 -10.66 59.82 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.538 0.685 . . . . 0.0 110.161 -174.312 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -118.54 125.7 50.41 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.864 178.458 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 401' ' ' VAL . . . . . 0.464 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 12.9 p -130.36 141.12 47.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.64 178.01 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -145.43 139.01 26.6 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.847 -177.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -167.75 -163.83 22.35 Favored Glycine 0 N--CA 1.444 -0.799 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.1 179.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 404' ' ' LYS . . . . . 0.553 ' HG2' HG12 ' A' ' 419' ' ' VAL . 21.2 mtmt -146.89 158.98 44.06 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 405' ' ' TYR . . . . . 0.412 ' HB3' HG22 ' A' ' 389' ' ' VAL . 19.1 p90 . . . . . 0 C--N 1.318 -0.775 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 170.329 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 417' ' ' PHE . . . . . 0.782 ' HB3' ' HD2' ' A' ' 326' ' ' PHE . 99.0 m-85 . . . . . 0 N--CA 1.435 -1.185 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 418' ' ' GLY . . . . . 0.496 ' H ' ' HD2' ' A' ' 326' ' ' PHE . . . 81.95 77.07 1.06 Allowed Glycine 0 N--CA 1.436 -1.311 0 C-N-CA 118.212 -1.947 . . . . 0.0 110.771 -174.58 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 419' ' ' VAL . . . . . 0.584 HG13 ' HE2' ' A' ' 326' ' ' PHE . 13.0 m -104.73 161.54 4.77 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -175.264 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 420' ' ' PHE . . . . . 0.437 ' HB3' HG12 ' A' ' 323' ' ' VAL . 49.5 p90 -139.27 147.74 42.09 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.109 0.48 . . . . 0.0 110.645 -178.405 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -137.44 134.61 36.04 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 174.254 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -132.0 134.75 7.79 Favored Glycine 0 N--CA 1.437 -1.257 0 C-N-CA 120.321 -0.942 . . . . 0.0 111.625 -177.695 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 17.2 mtpp -109.48 125.61 52.64 Favored 'General case' 0 C--N 1.314 -0.943 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 178.377 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 424' ' ' LYS . . . . . 0.882 ' HB3' ' HG3' ' A' ' 399' ' ' GLU . 8.0 tttm -66.53 117.88 9.35 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.855 -179.284 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 11.2 tp10 . . . . . 0 C--N 1.312 -1.025 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 173.762 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 85.2 Cg_endo . . . . . 0 N--CA 1.452 -0.937 0 CA-C-O 121.045 0.352 . . . . 0.0 111.947 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 308' ' ' ALA . . . . . 0.755 ' HB1' ' CD2' ' A' ' 313' ' ' LEU . . . -61.24 169.26 2.21 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.231 174.027 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 309' ' ' LYS . . . . . 0.7 ' H ' HD23 ' A' ' 313' ' ' LEU . 13.0 mptt -125.42 85.24 2.38 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 174.355 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -57.4 -19.71 34.36 Favored Glycine 0 N--CA 1.462 0.409 0 N-CA-C 114.28 0.472 . . . . 0.0 114.28 -168.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -87.35 -16.27 35.51 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.91 0.386 . . . . 0.0 111.227 179.15 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 47.9 tpp -110.95 -34.38 6.24 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.153 -175.067 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 313' ' ' LEU . . . . . 0.755 ' CD2' ' HB1' ' A' ' 308' ' ' ALA . 1.7 pp -83.45 137.09 34.06 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 175.471 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 314' ' ' ALA . . . . . 0.53 ' HA ' ' HB2' ' A' ' 346' ' ' PHE . . . -145.63 172.57 13.07 Favored 'General case' 0 C--N 1.318 -0.781 0 N-CA-C 112.62 0.6 . . . . 0.0 112.62 -166.049 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.31 176.5 15.77 Favored Glycine 0 N--CA 1.445 -0.758 0 CA-C-N 115.061 -0.972 . . . . 0.0 110.932 -177.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 15.7 p -108.0 134.01 51.5 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 170.619 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -139.45 161.12 38.24 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-O 121.204 0.526 . . . . 0.0 111.785 -172.273 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . 0.713 ' HA ' ' O ' ' A' ' 342' ' ' ALA . 7.7 p -141.22 124.12 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.936 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.51 173.818 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . 0.595 ' CE2' ' HB2' ' A' ' 424' ' ' LYS . 1.9 m-85 -102.18 143.76 31.58 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.605 -178.133 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 47.0 m-80 -127.78 132.6 49.49 Favored 'General case' 0 C--N 1.311 -1.073 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 176.132 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -165.12 -159.33 11.28 Favored Glycine 0 N--CA 1.442 -0.91 0 C-N-CA 120.218 -0.992 . . . . 0.0 112.167 -178.522 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -120.78 156.13 32.53 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 120.969 0.414 . . . . 0.0 110.298 -177.473 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 323' ' ' VAL . . . . . 0.831 HG21 HG12 ' A' ' 355' ' ' ILE . 41.0 t -119.45 118.32 56.94 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.621 -179.24 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 324' ' ' LEU . . . . . . . . . . . . . 96.4 mt -104.3 102.4 12.1 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.317 0.58 . . . . 0.0 110.149 -179.349 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 325' ' ' HIS . . . . . 0.489 ' HB3' ' OH ' ' A' ' 405' ' ' TYR . 6.3 p80 -108.1 132.06 53.97 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.523 176.524 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 326' ' ' PHE . . . . . 0.672 ' HD2' ' HB3' ' A' ' 417' ' ' PHE . 10.3 m-85 . . . . . 0 C--N 1.322 -0.592 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.695 -169.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 337' ' ' ARG . . . . . 0.6 ' HA ' ' O ' ' A' ' 323' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.451 -0.391 0 CA-C-O 121.416 0.627 . . . . 0.0 111.503 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -103.69 -177.97 25.86 Favored Glycine 0 N--CA 1.442 -0.904 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.949 174.355 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 339' ' ' ARG . . . . . 0.442 ' O ' ' HA ' ' A' ' 355' ' ' ILE . 75.4 mtp180 -114.18 127.49 55.92 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 120.952 0.406 . . . . 0.0 109.911 -177.575 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 340' ' ' PHE . . . . . 0.617 ' HB2' HG23 ' A' ' 323' ' ' VAL . 29.6 t80 -126.85 139.91 52.74 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.257 -169.412 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 341' ' ' ALA . . . . . 0.533 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -139.04 155.75 47.71 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 114.587 -1.188 . . . . 0.0 108.844 172.662 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . 0.848 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -143.12 117.82 9.85 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.14 0.495 . . . . 0.0 111.405 -177.368 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 343' ' ' LYS . . . . . 0.677 ' HB3' ' HB3' ' A' ' 352' ' ' ASP . 3.6 tppp? -96.07 98.95 10.76 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 114.851 -1.068 . . . . 0.0 108.943 -179.699 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 344' ' ' VAL . . . . . 0.653 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.6 OUTLIER -123.33 128.33 74.75 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 N-CA-C 113.099 0.777 . . . . 0.0 113.099 -169.56 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 345' ' ' ASP . . . . . 0.445 ' HB2' ' HB3' ' A' ' 348' ' ' SER . 1.8 m-20 -100.41 107.64 19.44 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 174.159 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 346' ' ' PHE . . . . . 0.53 ' HB2' ' HA ' ' A' ' 314' ' ' ALA . 38.0 m-85 -64.79 -36.58 84.77 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.807 0.337 . . . . 0.0 111.204 -176.391 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -68.62 -14.8 67.78 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.406 -178.544 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 348' ' ' SER . . . . . 0.445 ' HB3' ' HB2' ' A' ' 345' ' ' ASP . 44.2 t -109.13 -9.6 15.03 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.292 0.568 . . . . 0.0 110.135 179.219 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 349' ' ' LYS . . . . . 0.441 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 31.8 mtmm 52.44 55.36 9.22 Favored 'General case' 0 N--CA 1.462 0.137 0 CA-C-N 114.966 -1.016 . . . . 0.0 111.326 -176.07 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 8.6 t -146.72 145.69 30.07 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.508 179.518 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 351' ' ' VAL . . . . . 0.653 ' HB ' ' HB ' ' A' ' 344' ' ' VAL . 0.6 OUTLIER -136.46 146.65 28.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.956 0.408 . . . . 0.0 110.432 -177.042 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 352' ' ' ASP . . . . . 0.848 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 36.8 t70 -108.6 117.47 34.26 Favored 'General case' 0 C--O 1.211 -0.929 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 172.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -116.04 114.28 3.06 Favored Glycine 0 C--N 1.302 -1.334 0 C-N-CA 120.242 -0.98 . . . . 0.0 112.031 -176.668 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 354' ' ' ILE . . . . . 0.558 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -113.65 129.08 70.12 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 CA-C-O 120.977 0.418 . . . . 0.0 110.475 -175.495 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 355' ' ' ILE . . . . . 0.831 HG12 HG21 ' A' ' 323' ' ' VAL . 5.1 mp . . . . . 0 C--N 1.325 -0.497 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.95 177.715 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 21.6 mp0 . . . . . 0 N--CA 1.444 -0.731 0 CA-C-O 121.363 0.602 . . . . 0.0 109.934 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 25.4 pttm -114.96 146.99 40.62 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.665 178.54 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 368' ' ' PHE . . . . . 0.414 ' HB3' ' CE3' ' A' ' 381' ' ' TRP . 44.6 p90 -124.68 157.96 34.32 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 178.048 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 8.0 ttpt -126.05 134.96 51.26 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 173.538 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -136.14 144.87 45.28 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.095 -173.583 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -96.92 134.92 39.64 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 175.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 372' ' ' ILE . . . . . 0.441 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 66.8 mt -79.75 105.71 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.619 0 CA-C-O 121.884 0.85 . . . . 0.0 110.739 -177.804 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 373' ' ' ASP . . . . . 0.445 ' HB3' ' HD3' ' A' ' 378' ' ' LYS . 32.1 t70 -108.27 80.69 1.39 Allowed 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 114.492 -1.231 . . . . 0.0 109.19 -178.217 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 62.97 118.83 0.01 OUTLIER Glycine 0 CA--C 1.523 0.541 0 CA-C-N 114.54 -1.209 . . . . 0.0 113.488 -176.705 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 375' ' ' ASN . . . . . 0.705 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 3.1 p-10 28.92 46.67 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 124.363 1.065 . . . . 0.0 113.631 178.211 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 158.71 178.89 33.15 Favored Glycine 0 N--CA 1.442 -0.914 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 179.551 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 377' ' ' PHE . . . . . 0.607 ' CZ ' HG21 ' A' ' 401' ' ' VAL . 4.0 p90 -140.62 150.99 44.27 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 117.797 0.798 . . . . 0.0 112.127 -176.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 378' ' ' LYS . . . . . 0.445 ' HD3' ' HB3' ' A' ' 373' ' ' ASP . 0.0 OUTLIER -125.96 134.77 51.42 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 176.562 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -161.19 -158.6 9.46 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.178 -1.011 . . . . 0.0 112.853 -177.016 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 15.2 t -150.13 166.45 29.76 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.706 0.289 . . . . 0.0 110.383 -177.288 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 381' ' ' TRP . . . . . 0.791 ' HD1' ' HA3' ' A' ' 387' ' ' GLY . 49.5 m95 . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.856 -178.502 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . 0.791 ' HA3' ' HD1' ' A' ' 381' ' ' TRP . . . . . . . . 0 N--CA 1.446 -0.656 0 N-CA-C 112.087 -0.405 . . . . 0.0 112.087 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -82.49 138.86 34.22 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 110.304 -0.258 . . . . 0.0 110.304 178.664 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 44.5 t -132.17 128.56 59.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.493 0.187 . . . . 0.0 110.694 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 18.2 m -133.94 151.34 51.45 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.726 -0.215 . . . . 0.0 110.673 179.245 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 391' ' ' GLY . . . . . 0.552 ' HA2' ' HA3' ' A' ' 403' ' ' GLY . . . -158.59 151.52 22.56 Favored Glycine 0 N--CA 1.454 -0.141 0 C-N-CA 121.227 -0.511 . . . . 0.0 111.859 175.795 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 5.7 mpt_? -120.3 146.87 45.69 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.873 0.368 . . . . 0.0 110.862 -176.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -91.07 158.39 16.69 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.95 -179.814 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 394' ' ' TYR . . . . . 0.66 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 2.9 m-85 -102.18 -177.19 3.33 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.188 -0.915 . . . . 0.0 110.058 177.262 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 395' ' ' GLY . . . . . 0.421 ' O ' ' N ' ' A' ' 397' ' ' ALA . . . -37.98 159.33 0.01 OUTLIER Glycine 0 CA--C 1.525 0.705 0 O-C-N 124.224 0.953 . . . . 0.0 115.169 -175.539 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_exo -18.1 -42.65 0.01 OUTLIER 'Trans proline' 0 C--N 1.352 0.723 1 C-N-CA 127.729 5.62 . . . . 0.0 118.213 -168.136 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 397' ' ' ALA . . . . . 0.421 ' N ' ' O ' ' A' ' 395' ' ' GLY . . . -78.51 -19.44 52.97 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 118.402 0.546 . . . . 0.0 112.457 -173.106 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 62.41 12.1 37.57 Favored Glycine 0 C--O 1.216 -0.977 0 CA-C-O 119.355 -0.691 . . . . 0.0 114.221 176.624 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 399' ' ' GLU . . . . . 0.716 ' HG3' ' HD3' ' A' ' 424' ' ' LYS . 1.1 mp0 -63.54 -10.57 18.7 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 118.189 0.994 . . . . 0.0 111.314 -178.161 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -122.55 128.32 50.6 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 121.041 0.448 . . . . 0.0 110.003 176.107 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 401' ' ' VAL . . . . . 0.607 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 12.2 p -131.89 138.01 53.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.758 175.866 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -141.67 132.01 25.09 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.083 -178.647 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 403' ' ' GLY . . . . . 0.552 ' HA3' ' HA2' ' A' ' 391' ' ' GLY . . . -151.29 -173.76 21.49 Favored Glycine 0 N--CA 1.439 -1.136 0 C-N-CA 120.089 -1.053 . . . . 0.0 112.426 -178.055 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 404' ' ' LYS . . . . . 0.82 ' HG2' HG12 ' A' ' 419' ' ' VAL . 30.3 mtpt -145.73 155.66 43.11 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -179.684 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 405' ' ' TYR . . . . . 0.489 ' OH ' ' HB3' ' A' ' 325' ' ' HIS . 50.7 p90 . . . . . 0 C--N 1.314 -0.974 0 CA-C-O 121.011 0.434 . . . . 0.0 110.525 -179.232 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 417' ' ' PHE . . . . . 0.672 ' HB3' ' HD2' ' A' ' 326' ' ' PHE . 66.1 m-85 . . . . . 0 N--CA 1.456 -0.128 0 N-CA-C 110.472 -0.196 . . . . 0.0 110.472 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 418' ' ' GLY . . . . . 0.455 ' HA2' ' HA ' ' A' ' 325' ' ' HIS . . . 82.31 77.1 1.07 Allowed Glycine 0 C--O 1.224 -0.489 0 C-N-CA 120.746 -0.74 . . . . 0.0 113.125 176.214 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 419' ' ' VAL . . . . . 0.82 HG12 ' HG2' ' A' ' 404' ' ' LYS . 23.8 m -109.71 157.61 10.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 120.903 0.382 . . . . 0.0 110.822 -179.715 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 40.8 p90 -146.4 154.8 42.04 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.952 0.406 . . . . 0.0 110.535 177.58 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -148.83 136.54 20.54 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.48 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -133.18 140.62 11.98 Favored Glycine 0 N--CA 1.445 -0.711 0 C-N-CA 120.196 -1.002 . . . . 0.0 112.582 -177.668 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 25.1 mmmt -101.9 123.83 46.49 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 176.82 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 424' ' ' LYS . . . . . 0.716 ' HD3' ' HG3' ' A' ' 399' ' ' GLU . 72.1 tttt -70.16 117.25 11.48 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 116.55 -0.296 . . . . 0.0 110.572 -179.591 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 . . . . . 0 C--N 1.323 -0.572 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 -179.502 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo . . . . . 0 N--CA 1.462 -0.337 0 N-CA-C 111.315 -0.302 . . . . 0.0 111.315 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 308' ' ' ALA . . . . . 0.703 ' HB2' ' O ' ' A' ' 394' ' ' TYR . . . -54.18 159.54 1.86 Allowed 'General case' 0 N--CA 1.467 0.385 0 CA-C-O 121.48 0.657 . . . . 0.0 112.282 175.804 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 309' ' ' LYS . . . . . 0.649 ' O ' ' HG ' ' A' ' 313' ' ' LEU . 35.0 mtmt -123.55 98.91 6.05 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.357 176.746 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 310' ' ' GLY . . . . . 0.694 ' HA2' HD12 ' A' ' 313' ' ' LEU . . . -60.04 -37.75 93.23 Favored Glycine 0 C--O 1.227 -0.304 0 CA-C-N 116.093 -0.503 . . . . 0.0 114.128 -170.314 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . 0.454 ' H ' ' CD ' ' A' ' 311' ' ' GLU . 1.3 pm0 -72.61 -20.03 61.36 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.86 0.33 . . . . 0.0 110.856 179.115 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 26.0 ttt -91.46 -21.61 20.84 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.143 0.497 . . . . 0.0 109.95 177.302 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 313' ' ' LEU . . . . . 0.694 HD12 ' HA2' ' A' ' 310' ' ' GLY . 96.1 mt -66.19 138.95 58.05 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.332 178.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -156.32 139.2 15.28 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.303 -174.326 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 121.01 167.88 13.39 Favored Glycine 0 N--CA 1.443 -0.845 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.929 177.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 28.5 p -100.05 134.22 43.28 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 174.715 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 317' ' ' ALA . . . . . 0.56 ' HB1' ' HD3' ' A' ' 424' ' ' LYS . . . -138.6 152.57 48.25 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 121.053 0.454 . . . . 0.0 111.731 -174.833 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 7.3 p -121.59 113.24 38.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.441 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.263 177.5 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . 0.598 ' CE2' ' HB2' ' A' ' 424' ' ' LYS . 21.4 m-85 -103.16 132.52 49.36 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.925 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 44.6 m-80 -124.81 139.56 53.73 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.077 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . 0.591 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -169.25 -145.93 4.83 Favored Glycine 0 N--CA 1.441 -1.014 0 C-N-CA 120.577 -0.82 . . . . 0.0 112.397 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -135.04 161.92 33.93 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 120.978 0.418 . . . . 0.0 110.947 -173.66 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 323' ' ' VAL . . . . . 0.649 HG23 ' HB2' ' A' ' 340' ' ' PHE . 68.9 t -121.12 117.89 54.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.163 178.331 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 324' ' ' LEU . . . . . . . . . . . . . 2.0 tt -98.53 103.27 15.2 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 176.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 325' ' ' HIS . . . . . 0.446 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 18.3 t-160 -88.58 113.32 24.03 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 -179.307 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 326' ' ' PHE . . . . . 0.664 ' HE2' HG13 ' A' ' 419' ' ' VAL . 88.4 m-85 . . . . . 0 C--N 1.321 -0.641 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.008 -177.85 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 337' ' ' ARG . . . . . . . . . . . . . 39.1 ttt180 . . . . . 0 N--CA 1.449 -0.524 0 CA-C-O 121.036 0.446 . . . . 0.0 110.346 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -103.26 -177.0 26.41 Favored Glycine 0 N--CA 1.446 -0.695 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 179.037 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 339' ' ' ARG . . . . . . . . . . . . . 66.7 mtp180 -110.28 164.5 12.6 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 178.379 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 340' ' ' PHE . . . . . 0.649 ' HB2' HG23 ' A' ' 323' ' ' VAL . 41.1 t80 -152.43 142.73 22.49 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 121.255 0.55 . . . . 0.0 111.096 -178.275 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 341' ' ' ALA . . . . . . . . . . . . . . . -138.59 156.25 47.63 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.206 -0.906 . . . . 0.0 109.025 174.063 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . 0.884 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -145.94 118.94 8.76 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-O 121.304 0.573 . . . . 0.0 110.173 -179.729 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 343' ' ' LYS . . . . . 0.438 ' HE2' ' HB3' ' A' ' 343' ' ' LYS . 4.8 tmmm? -102.96 103.14 13.23 Favored 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 -179.625 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 344' ' ' VAL . . . . . 0.443 ' HA ' ' HA ' ' A' ' 351' ' ' VAL . 0.2 OUTLIER -117.14 132.77 65.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-O 121.485 0.66 . . . . 0.0 112.639 -169.224 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -102.48 100.08 10.17 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 114.515 -1.22 . . . . 0.0 108.7 172.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 346' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -67.88 -23.19 65.1 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.527 0.204 . . . . 0.0 111.184 -177.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -63.9 -25.27 69.11 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.016 178.315 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 37.9 m -112.58 -4.43 14.15 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.912 0.387 . . . . 0.0 110.567 177.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 349' ' ' LYS . . . . . 0.645 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 31.4 mtmm 55.69 59.3 3.91 Favored 'General case' 0 C--O 1.226 -0.179 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.892 -178.02 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 52.9 p -148.84 141.28 24.24 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.282 -179.326 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 351' ' ' VAL . . . . . 0.51 HG22 ' HB3' ' A' ' 370' ' ' ALA . 1.0 OUTLIER -127.57 151.84 34.9 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 CA-C-O 121.126 0.489 . . . . 0.0 110.986 -176.21 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 352' ' ' ASP . . . . . 0.884 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 19.5 t70 -108.59 119.07 38.44 Favored 'General case' 0 C--O 1.211 -0.954 0 CA-C-N 115.184 -0.917 . . . . 0.0 109.338 171.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -115.33 130.22 9.02 Favored Glycine 0 N--CA 1.441 -1.02 0 C-N-CA 120.473 -0.87 . . . . 0.0 111.658 -178.72 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 354' ' ' ILE . . . . . 0.475 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -131.52 129.62 62.0 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 CA-C-O 120.973 0.416 . . . . 0.0 110.196 -176.973 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 355' ' ' ILE . . . . . 0.605 HG13 HG21 ' A' ' 323' ' ' VAL . 2.3 mp . . . . . 0 C--N 1.318 -0.763 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.416 178.295 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 90.6 mt-30 . . . . . 0 N--CA 1.452 -0.363 0 CA-C-O 121.305 0.574 . . . . 0.0 111.372 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -123.85 144.63 49.62 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.565 179.48 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 368' ' ' PHE . . . . . 0.493 ' HB3' ' CE3' ' A' ' 381' ' ' TRP . 33.2 p90 -140.17 150.74 44.58 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.963 0.411 . . . . 0.0 109.996 175.364 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 369' ' ' LYS . . . . . 0.766 ' HD3' ' HA ' ' A' ' 352' ' ' ASP . 0.0 OUTLIER -123.61 135.19 53.81 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 175.962 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 370' ' ' ALA . . . . . 0.529 ' HB1' ' HB2' ' A' ' 377' ' ' PHE . . . -132.11 152.23 51.35 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.478 -0.783 . . . . 0.0 111.213 -172.287 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -109.06 134.82 51.17 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.656 176.369 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 372' ' ' ILE . . . . . 0.645 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 95.5 mt -82.75 108.91 16.04 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-O 121.171 0.51 . . . . 0.0 110.939 -178.042 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -126.4 84.23 2.25 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-O 121.612 0.72 . . . . 0.0 110.288 178.361 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 79.07 121.22 0.3 Allowed Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.145 -0.934 . . . . 0.0 112.267 -177.188 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 375' ' ' ASN . . . . . 0.524 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 17.7 p30 1.8 60.38 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 125.6 1.56 . . . . 0.0 114.986 -171.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 157.55 -174.28 34.98 Favored Glycine 0 N--CA 1.438 -1.172 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 179.068 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 377' ' ' PHE . . . . . 0.529 ' HB2' ' HB1' ' A' ' 370' ' ' ALA . 1.6 p90 -142.34 148.71 38.39 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.327 0.584 . . . . 0.0 111.625 -179.345 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 378' ' ' LYS . . . . . . . . . . . . . 2.7 tmtm? -123.64 112.63 17.64 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 176.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -135.59 -165.6 10.74 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.428 -0.891 . . . . 0.0 112.627 -175.677 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 15.0 t -144.93 159.67 42.55 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.86 0.362 . . . . 0.0 110.449 -177.516 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 381' ' ' TRP . . . . . 0.493 ' CE3' ' HB3' ' A' ' 368' ' ' PHE . 48.3 m95 . . . . . 0 C--N 1.326 -0.436 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.512 179.95 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.675 0 N-CA-C 112.448 -0.261 . . . . 0.0 112.448 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -94.19 167.54 11.49 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.517 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 22.2 t -128.35 121.18 54.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 175.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 390' ' ' SER . . . . . 0.417 ' O ' ' HA3' ' A' ' 403' ' ' GLY . 39.5 m -117.98 155.61 29.97 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.521 -0.309 . . . . 0.0 110.698 -177.375 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -165.64 144.67 9.42 Favored Glycine 0 N--CA 1.451 -0.349 0 N-CA-C 111.541 -0.623 . . . . 0.0 111.541 177.291 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 13.7 ptp180 -116.09 152.31 33.87 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.044 0.45 . . . . 0.0 110.895 -177.142 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 10.7 m-85 -98.1 157.59 16.05 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.889 0.852 . . . . 0.0 111.81 -175.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 394' ' ' TYR . . . . . 0.703 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 6.2 m-85 -102.94 -171.95 2.03 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 114.119 -1.4 . . . . 0.0 111.247 -175.075 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 395' ' ' GLY . . . . . 0.435 ' O ' ' N ' ' A' ' 397' ' ' ALA . . . -33.15 157.59 0.01 OUTLIER Glycine 0 C--N 1.34 0.792 0 O-C-N 124.576 1.173 . . . . 0.0 114.215 -178.316 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 12.2 Cg_endo -46.37 -17.98 0.41 Allowed 'Trans proline' 0 N--CA 1.482 0.818 1 C-N-CA 125.674 4.249 . . . . 0.0 116.831 -149.843 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 397' ' ' ALA . . . . . 0.435 ' N ' ' O ' ' A' ' 395' ' ' GLY . . . -90.89 -17.9 25.69 Favored 'General case' 0 C--N 1.316 -0.872 0 C-N-CA 120.728 -0.389 . . . . 0.0 111.83 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 72.74 16.35 77.95 Favored Glycine 0 C--N 1.336 0.56 0 C-N-CA 121.178 -0.534 . . . . 0.0 112.544 173.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 399' ' ' GLU . . . . . 0.478 ' HG2' ' CE ' ' A' ' 424' ' ' LYS . 28.5 mt-10 -67.7 -10.78 55.41 Favored 'General case' 0 C--N 1.332 -0.18 0 C-N-CA 122.902 0.481 . . . . 0.0 111.115 -174.766 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -123.31 136.02 54.48 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 173.1 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 401' ' ' VAL . . . . . 0.52 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 14.0 p -140.15 143.1 30.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.137 177.413 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -143.19 138.81 29.98 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.181 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 403' ' ' GLY . . . . . 0.417 ' HA3' ' O ' ' A' ' 390' ' ' SER . . . -157.25 -176.2 29.04 Favored Glycine 0 N--CA 1.441 -0.985 0 C-N-CA 120.379 -0.915 . . . . 0.0 112.185 -178.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 404' ' ' LYS . . . . . 0.841 ' HG2' HG12 ' A' ' 419' ' ' VAL . 52.2 mttt -145.34 158.85 43.75 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 -178.516 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 36.2 p90 . . . . . 0 C--N 1.322 -0.61 0 CA-C-O 121.043 0.449 . . . . 0.0 111.34 179.658 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 417' ' ' PHE . . . . . 0.66 ' HA ' ' HD2' ' A' ' 326' ' ' PHE . 28.3 m-85 . . . . . 0 N--CA 1.447 -0.593 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 418' ' ' GLY . . . . . 0.514 ' H ' ' HD2' ' A' ' 326' ' ' PHE . . . 78.51 76.82 0.9 Allowed Glycine 0 N--CA 1.441 -1.018 0 C-N-CA 120.068 -1.063 . . . . 0.0 111.211 -174.468 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 419' ' ' VAL . . . . . 0.841 HG12 ' HG2' ' A' ' 404' ' ' LYS . 32.3 m -105.47 153.12 7.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-O 120.705 0.288 . . . . 0.0 110.388 -177.791 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 51.9 p90 -135.69 155.01 51.08 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.893 179.104 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 421' ' ' ALA . . . . . 0.591 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -143.72 136.1 26.96 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.089 179.384 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -129.98 133.6 7.5 Favored Glycine 0 N--CA 1.44 -1.044 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.038 -179.048 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 63.0 mttm -111.81 125.72 54.31 Favored 'General case' 0 C--N 1.313 -0.979 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 177.211 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 424' ' ' LYS . . . . . 0.598 ' HB2' ' CE2' ' A' ' 319' ' ' TYR . 27.2 ttpp -70.23 122.3 19.24 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 120.893 0.378 . . . . 0.0 110.101 178.551 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 . . . . . 0 C--N 1.313 -0.989 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 176.685 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 10.2 Cg_endo . . . . . 0 N--CA 1.457 -0.618 0 N-CA-C 112.848 0.288 . . . . 0.0 112.848 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 308' ' ' ALA . . . . . 0.895 ' HB1' HD22 ' A' ' 313' ' ' LEU . . . -58.13 157.23 8.43 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.844 170.621 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 309' ' ' LYS . . . . . 0.498 ' N ' HD23 ' A' ' 313' ' ' LEU . 63.1 mttp -128.43 98.42 5.04 Favored 'General case' 0 C--O 1.222 -0.364 0 C-N-CA 121.022 -0.271 . . . . 0.0 110.425 -176.328 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -48.23 -43.23 25.77 Favored Glycine 0 CA--C 1.519 0.304 0 N-CA-C 114.978 0.751 . . . . 0.0 114.978 -167.784 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -76.45 -9.46 58.67 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 112.846 0.684 . . . . 0.0 112.846 -177.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 2.5 tpt -113.93 -37.39 4.51 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.72 0.771 . . . . 0.0 109.654 -177.396 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 313' ' ' LEU . . . . . 0.895 HD22 ' HB1' ' A' ' 308' ' ' ALA . 0.6 OUTLIER -81.39 129.99 34.86 Favored 'General case' 0 N--CA 1.44 -0.938 0 CA-C-N 114.677 -1.147 . . . . 0.0 109.143 178.161 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 314' ' ' ALA . . . . . 0.643 ' HA ' ' CB ' ' A' ' 346' ' ' PHE . . . -159.19 175.57 13.28 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.989 -170.726 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.4 160.77 11.27 Favored Glycine 0 N--CA 1.447 -0.597 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -177.621 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 18.7 p -96.87 125.12 41.08 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 173.258 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -132.08 149.67 52.35 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 113.15 0.796 . . . . 0.0 113.15 -163.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 7.7 p -118.95 113.64 42.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 CA-C-N 115.039 -0.982 . . . . 0.0 110.338 176.067 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . 0.46 ' CE2' ' HB2' ' A' ' 424' ' ' LYS . 27.1 m-85 -108.04 140.68 40.84 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.583 177.454 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -142.75 143.78 32.37 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.65 174.671 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -166.32 -150.26 6.27 Favored Glycine 0 N--CA 1.443 -0.863 0 C-N-CA 120.931 -0.652 . . . . 0.0 111.874 -178.153 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -129.49 147.81 51.33 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.124 0.488 . . . . 0.0 111.038 -176.541 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 323' ' ' VAL . . . . . 0.581 ' O ' ' HA ' ' A' ' 337' ' ' ARG . 54.6 t -106.14 142.31 19.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.331 -178.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 324' ' ' LEU . . . . . . . . . . . . . 17.2 tp -124.87 103.95 8.34 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 110.21 -0.293 . . . . 0.0 110.21 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 325' ' ' HIS . . . . . 0.612 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 3.2 p-80 -103.21 117.19 33.97 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.501 0.667 . . . . 0.0 111.429 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 326' ' ' PHE . . . . . 0.605 ' HD1' ' H ' ' A' ' 418' ' ' GLY . 22.9 m-85 . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 114.705 -1.134 . . . . 0.0 110.351 -173.119 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 337' ' ' ARG . . . . . 0.581 ' HA ' ' O ' ' A' ' 323' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.45 -0.427 0 CA-C-O 121.187 0.517 . . . . 0.0 110.82 . . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -136.12 178.55 18.67 Favored Glycine 0 N--CA 1.443 -0.889 0 CA-C-N 115.392 -0.822 . . . . 0.0 111.178 176.113 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 339' ' ' ARG . . . . . 0.582 ' O ' ' HA ' ' A' ' 355' ' ' ILE . 57.8 mtp180 -104.02 132.89 49.82 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 -179.093 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 340' ' ' PHE . . . . . 0.574 ' HB2' HG23 ' A' ' 323' ' ' VAL . 36.8 t80 -133.9 132.2 40.01 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 121.057 0.456 . . . . 0.0 111.108 -175.848 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 341' ' ' ALA . . . . . . . . . . . . . . . -134.72 168.39 19.11 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 172.263 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -155.22 139.65 16.79 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.095 0.474 . . . . 0.0 111.023 -176.48 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 343' ' ' LYS . . . . . 0.525 ' HB3' ' HB2' ' A' ' 352' ' ' ASP . 24.9 tptp -115.97 97.32 6.02 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 179.222 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 344' ' ' VAL . . . . . 0.698 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.9 OUTLIER -121.05 135.61 60.68 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 CA-C-O 121.526 0.679 . . . . 0.0 111.627 -170.234 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -117.04 101.13 8.23 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-N 114.884 -1.053 . . . . 0.0 108.284 -178.653 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 346' ' ' PHE . . . . . 0.689 ' O ' ' HE3' ' A' ' 349' ' ' LYS . 67.4 m-85 -69.75 -25.96 64.07 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 -173.476 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -64.01 -22.15 66.46 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.533 -0.841 . . . . 0.0 111.917 176.579 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 48.2 t -108.84 -4.24 17.02 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.033 0.444 . . . . 0.0 110.499 178.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 349' ' ' LYS . . . . . 0.689 ' HE3' ' O ' ' A' ' 346' ' ' PHE . 8.2 mmpt? 49.7 50.98 17.36 Favored 'General case' 0 C--O 1.226 -0.176 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.581 -172.187 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 8.3 m -134.08 146.31 50.18 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.104 -178.178 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 351' ' ' VAL . . . . . 0.698 ' HB ' ' HB ' ' A' ' 344' ' ' VAL . 0.1 OUTLIER -149.36 133.92 9.51 Favored 'Isoleucine or valine' 0 C--O 1.236 0.365 0 CA-C-O 121.531 0.681 . . . . 0.0 112.552 -175.617 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 352' ' ' ASP . . . . . 0.646 ' HA ' ' HD3' ' A' ' 369' ' ' LYS . 1.5 m-20 -95.24 155.48 16.72 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 114.676 -1.147 . . . . 0.0 108.961 173.21 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 353' ' ' GLY . . . . . 0.521 ' C ' ' HB3' ' A' ' 367' ' ' LYS . . . -142.38 152.17 23.53 Favored Glycine 0 N--CA 1.44 -1.091 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 172.508 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 354' ' ' ILE . . . . . 0.484 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -146.78 130.12 9.1 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 116.964 0.382 . . . . 0.0 110.087 -179.643 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 355' ' ' ILE . . . . . 0.894 HD11 ' HE2' ' A' ' 367' ' ' LYS . 82.5 mt . . . . . 0 N--CA 1.449 -0.51 0 CA-C-O 121.064 0.459 . . . . 0.0 111.919 178.32 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 82.5 mt-30 . . . . . 0 N--CA 1.454 -0.255 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 367' ' ' LYS . . . . . 0.975 ' HA ' ' HZ3' ' A' ' 381' ' ' TRP . 19.3 tttm -131.03 172.91 11.54 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.096 0.474 . . . . 0.0 110.899 176.165 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 368' ' ' PHE . . . . . 0.826 ' H ' ' HG2' ' A' ' 367' ' ' LYS . 0.1 OUTLIER -73.89 163.16 28.28 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.113 -0.949 . . . . 0.0 111.814 -172.306 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 369' ' ' LYS . . . . . 0.646 ' HD3' ' HA ' ' A' ' 352' ' ' ASP . 0.0 OUTLIER -113.86 134.23 54.93 Favored 'General case' 0 C--N 1.314 -0.957 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 169.171 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 370' ' ' ALA . . . . . 0.672 ' HB2' ' CE2' ' A' ' 368' ' ' PHE . . . -130.2 162.85 27.98 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 113.095 0.776 . . . . 0.0 113.095 -172.579 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -116.73 135.93 53.37 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 114.657 -1.156 . . . . 0.0 108.924 171.401 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 372' ' ' ILE . . . . . 0.546 HG13 HG12 ' A' ' 351' ' ' VAL . 83.0 mt -82.69 115.04 24.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.142 0.496 . . . . 0.0 111.06 -177.004 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -104.92 83.38 1.99 Allowed 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.333 177.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 79.67 -118.8 4.82 Favored Glycine 0 N--CA 1.446 -0.678 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.559 -179.664 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 375' ' ' ASN . . . . . 0.484 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 3.2 p-10 -98.81 50.21 0.97 Allowed 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.65 0.738 . . . . 0.0 111.425 -176.147 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 165.08 175.05 35.42 Favored Glycine 0 N--CA 1.445 -0.716 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 -179.155 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 377' ' ' PHE . . . . . 0.553 ' CZ ' HG21 ' A' ' 401' ' ' VAL . 3.7 p90 -140.99 153.16 45.44 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.551 0.691 . . . . 0.0 111.703 177.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 378' ' ' LYS . . . . . . . . . . . . . 15.6 ptpt -131.99 138.38 48.24 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 114.498 -1.228 . . . . 0.0 108.484 175.677 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -151.55 -161.76 10.31 Favored Glycine 0 N--CA 1.443 -0.85 0 C-N-CA 120.068 -1.063 . . . . 0.0 112.61 -176.374 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 380' ' ' THR . . . . . 0.435 ' C ' ' HB2' ' A' ' 368' ' ' PHE . 6.5 t -144.57 140.62 28.89 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.811 0.339 . . . . 0.0 110.942 -175.254 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 381' ' ' TRP . . . . . 0.975 ' HZ3' ' HA ' ' A' ' 367' ' ' LYS . 50.4 m95 . . . . . 0 N--CA 1.465 0.323 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.98 178.439 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.446 -0.638 0 N-CA-C 112.341 -0.303 . . . . 0.0 112.341 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -93.74 154.13 17.95 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 178.617 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 389' ' ' VAL . . . . . 0.532 ' HB ' ' CD2' ' A' ' 368' ' ' PHE . 20.0 t -131.39 139.57 50.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.057 -179.095 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 10.8 m -141.6 141.03 33.46 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.659 0.266 . . . . 0.0 110.791 178.308 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -141.05 152.64 23.34 Favored Glycine 0 C--O 1.236 0.221 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.981 179.458 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 9.7 ptm180 -115.61 144.73 43.48 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 -175.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 393' ' ' PHE . . . . . 0.519 ' CZ ' ' HE1' ' A' ' 346' ' ' PHE . 1.2 m-85 -94.55 154.84 17.19 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.429 0.633 . . . . 0.0 111.979 -175.104 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 394' ' ' TYR . . . . . 0.719 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 3.5 m-85 -102.73 -176.78 3.19 Favored 'General case' 0 C--O 1.216 -0.686 0 CA-C-N 114.775 -1.102 . . . . 0.0 110.816 -178.823 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 395' ' ' GLY . . . . . . . . . . . . . . . -37.77 161.35 0.01 OUTLIER Glycine 0 C--N 1.335 0.505 0 O-C-N 124.333 1.021 . . . . 0.0 115.099 -175.816 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_exo -11.13 -57.03 0.0 OUTLIER 'Trans proline' 0 C--N 1.347 0.467 1 C-N-CA 127.386 5.391 . . . . 0.0 117.517 -162.393 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 397' ' ' ALA . . . . . 0.63 ' HB3' ' HG3' ' A' ' 399' ' ' GLU . . . -84.96 -11.12 56.22 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 112.678 0.621 . . . . 0.0 112.678 -167.391 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 67.2 22.18 72.48 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.226 -179.142 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 399' ' ' GLU . . . . . 0.63 ' HG3' ' HB3' ' A' ' 397' ' ' ALA . 50.5 mt-10 -63.63 -14.4 51.38 Favored 'General case' 0 CA--C 1.521 -0.154 0 CA-C-O 121.12 0.486 . . . . 0.0 111.148 -177.222 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -121.77 133.48 54.92 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 170.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 401' ' ' VAL . . . . . 0.553 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 9.9 p -140.99 135.0 32.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.85 176.147 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -131.25 139.59 49.67 Favored 'General case' 0 C--N 1.315 -0.935 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.771 178.293 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -162.89 156.04 27.61 Favored Glycine 0 N--CA 1.437 -1.272 0 C-N-CA 120.304 -0.95 . . . . 0.0 111.105 -174.149 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 404' ' ' LYS . . . . . 0.987 ' HG2' HG23 ' A' ' 419' ' ' VAL . 17.5 mtmt -123.9 162.73 22.74 Favored 'General case' 0 C--N 1.31 -1.144 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 -174.36 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 405' ' ' TYR . . . . . 0.539 ' CG ' ' HZ2' ' A' ' 381' ' ' TRP . 25.4 p90 . . . . . 0 C--N 1.315 -0.918 0 CA-C-O 121.225 0.536 . . . . 0.0 111.466 179.22 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 417' ' ' PHE . . . . . 0.473 ' HB3' ' HB2' ' A' ' 326' ' ' PHE . 87.9 m-85 . . . . . 0 N--CA 1.45 -0.456 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 418' ' ' GLY . . . . . 0.612 ' HA2' ' HA ' ' A' ' 325' ' ' HIS . . . 83.33 76.83 1.13 Allowed Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.024 -1.084 . . . . 0.0 110.933 -169.721 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 419' ' ' VAL . . . . . 0.987 HG23 ' HG2' ' A' ' 404' ' ' LYS . 8.4 p -107.33 166.03 4.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-O 121.28 0.562 . . . . 0.0 110.605 -177.576 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 420' ' ' PHE . . . . . 0.445 ' H ' HG22 ' A' ' 419' ' ' VAL . 41.8 p90 -140.76 157.53 45.29 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.224 -0.898 . . . . 0.0 109.904 177.218 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -142.69 136.06 28.63 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 177.122 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -121.74 138.42 12.27 Favored Glycine 0 N--CA 1.446 -0.668 0 C-N-CA 120.562 -0.828 . . . . 0.0 112.177 -177.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -110.78 127.11 55.24 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 178.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 424' ' ' LYS . . . . . 0.506 ' HB3' ' HB3' ' A' ' 399' ' ' GLU . 23.2 tptm -66.85 115.28 6.45 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.835 0.35 . . . . 0.0 110.603 176.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 . . . . . 0 C--N 1.319 -0.744 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 175.427 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 307' ' ' PRO . . . . . 0.757 ' HA ' ' HA2' ' A' ' 395' ' ' GLY . 98.0 Cg_exo . . . . . 0 C--O 1.235 0.365 0 N-CA-C 111.645 -0.175 . . . . 0.0 111.645 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 308' ' ' ALA . . . . . 0.713 ' HB1' HD11 ' A' ' 313' ' ' LEU . . . -31.44 106.6 0.04 OUTLIER 'General case' 0 CA--C 1.506 -0.727 0 O-C-N 124.923 1.39 . . . . 0.0 112.844 -165.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 309' ' ' LYS . . . . . 0.509 ' HE3' ' OE2' ' A' ' 311' ' ' GLU . 23.4 tptt -69.62 91.76 0.62 Allowed 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 115.222 -0.899 . . . . 0.0 109.97 -173.311 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 310' ' ' GLY . . . . . 0.72 ' HA2' HD12 ' A' ' 313' ' ' LEU . . . -60.6 -30.32 71.84 Favored Glycine 0 C--N 1.331 0.264 0 CA-C-N 115.578 -0.737 . . . . 0.0 114.086 -169.241 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . 0.509 ' OE2' ' HE3' ' A' ' 309' ' ' LYS . 4.8 pm0 -72.42 -17.06 61.83 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 120.74 0.305 . . . . 0.0 111.069 179.15 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 66.2 mtm -117.13 -0.18 12.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.797 0.332 . . . . 0.0 110.922 178.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 313' ' ' LEU . . . . . 0.72 HD12 ' HA2' ' A' ' 310' ' ' GLY . 83.8 mt -70.93 134.37 47.17 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 173.34 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -149.66 137.92 20.59 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.331 -173.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.77 171.95 14.49 Favored Glycine 0 N--CA 1.444 -0.799 0 N-CA-C 111.385 -0.686 . . . . 0.0 111.385 179.401 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 42.5 p -102.61 149.4 24.46 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 173.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -142.78 148.28 36.92 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 121.16 0.505 . . . . 0.0 112.32 -175.258 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . 0.534 ' O ' ' HA ' ' A' ' 424' ' ' LYS . 13.8 t -114.56 104.32 16.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.913 175.329 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . 0.508 ' HH ' ' HZ ' ' A' ' 346' ' ' PHE . 60.3 m-85 -97.88 127.33 43.76 Favored 'General case' 0 C--N 1.312 -1.05 0 C-N-CA 120.264 -0.574 . . . . 0.0 110.046 177.168 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 320' ' ' ASN . . . . . 0.418 ' ND2' ' HB2' ' A' ' 425' ' ' GLU . 7.6 p30 -138.31 145.16 40.87 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 178.799 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -172.14 -152.28 8.4 Favored Glycine 0 N--CA 1.44 -1.083 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.856 -177.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -114.49 143.74 44.46 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 120.897 0.38 . . . . 0.0 110.779 -174.413 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 323' ' ' VAL . . . . . 0.644 HG23 ' HB2' ' A' ' 340' ' ' PHE . 59.1 t -106.8 116.62 50.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.935 175.258 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 324' ' ' LEU . . . . . 0.507 HD13 ' HG2' ' A' ' 337' ' ' ARG . 24.9 tp -97.53 102.69 14.51 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-O 121.139 0.495 . . . . 0.0 109.889 -179.505 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 325' ' ' HIS . . . . . . . . . . . . . 1.3 p-80 -105.03 114.72 29.09 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.344 0.592 . . . . 0.0 109.73 176.691 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 326' ' ' PHE . . . . . 0.735 ' HD1' ' HB2' ' A' ' 417' ' ' PHE . 31.3 m-85 . . . . . 0 C--N 1.322 -0.626 0 CA-C-N 115.168 -0.924 . . . . 0.0 110.96 -170.167 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 337' ' ' ARG . . . . . 0.513 ' HA ' ' O ' ' A' ' 323' ' ' VAL . 24.2 mtm180 . . . . . 0 N--CA 1.45 -0.438 0 CA-C-O 121.428 0.632 . . . . 0.0 110.664 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -95.21 -177.12 37.62 Favored Glycine 0 N--CA 1.439 -1.111 0 CA-C-N 115.222 -0.899 . . . . 0.0 111.613 176.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 339' ' ' ARG . . . . . . . . . . . . . 56.1 mtp180 -106.09 133.48 50.73 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 -176.133 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 340' ' ' PHE . . . . . 0.644 ' HB2' HG23 ' A' ' 323' ' ' VAL . 26.1 t80 -132.43 139.46 48.03 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-O 120.986 0.422 . . . . 0.0 111.342 -176.226 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 341' ' ' ALA . . . . . . . . . . . . . . . -142.86 165.85 26.24 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.223 -0.899 . . . . 0.0 109.374 174.509 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -157.18 134.09 10.19 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-O 120.875 0.369 . . . . 0.0 110.901 -174.296 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 343' ' ' LYS . . . . . 0.401 ' HB3' ' HB2' ' A' ' 352' ' ' ASP . 4.5 tppp? -108.03 102.8 11.94 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.06 178.799 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 344' ' ' VAL . . . . . 0.659 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.3 OUTLIER -125.83 133.34 69.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 CA-C-O 121.703 0.763 . . . . 0.0 112.553 -172.08 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -102.31 121.9 43.19 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 114.586 -1.188 . . . . 0.0 108.176 172.082 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 346' ' ' PHE . . . . . 0.508 ' HZ ' ' HH ' ' A' ' 319' ' ' TYR . 33.1 m-85 -72.3 -37.92 68.84 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 120.979 -0.288 . . . . 0.0 110.931 -179.108 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -61.0 -30.51 73.65 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.111 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 47.8 t -97.88 -10.02 25.35 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 123.008 -0.113 . . . . 0.0 110.783 -179.666 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 349' ' ' LYS . . . . . 0.481 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 29.0 mtmt 47.35 55.69 7.9 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-O 121.62 0.724 . . . . 0.0 111.266 -176.22 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 29.1 m -147.52 138.94 23.81 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.632 179.483 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 351' ' ' VAL . . . . . 0.659 ' HB ' ' HB ' ' A' ' 344' ' ' VAL . 0.6 OUTLIER -130.1 148.46 33.17 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 CA-C-O 121.288 0.566 . . . . 0.0 111.379 -174.894 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 352' ' ' ASP . . . . . 0.401 ' HB2' ' HB3' ' A' ' 343' ' ' LYS . 6.3 m-20 -100.46 151.78 21.15 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 107.179 -1.415 . . . . 0.0 107.179 165.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 353' ' ' GLY . . . . . 0.64 ' HA3' ' CE1' ' A' ' 368' ' ' PHE . . . -142.52 138.17 8.26 Favored Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.483 -0.865 . . . . 0.0 111.541 175.217 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 354' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -121.68 129.74 75.23 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-O 121.185 0.516 . . . . 0.0 109.818 178.669 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 355' ' ' ILE . . . . . 0.765 HG13 ' CZ3' ' A' ' 381' ' ' TRP . 7.0 mm . . . . . 0 C--N 1.32 -0.711 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.591 -174.23 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 79.4 mt-30 . . . . . 0 N--CA 1.448 -0.537 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 8.7 ptpp? -147.22 168.94 20.42 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.138 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 368' ' ' PHE . . . . . 0.64 ' CE1' ' HA3' ' A' ' 353' ' ' GLY . 31.6 p90 -151.49 156.08 39.86 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 175.164 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 1.7 mptp? -118.94 130.77 55.89 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 175.838 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 370' ' ' ALA . . . . . 0.518 ' HA ' ' HA3' ' A' ' 379' ' ' GLY . . . -135.75 141.47 44.83 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.104 -175.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -102.51 136.04 43.05 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.724 176.747 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 372' ' ' ILE . . . . . 0.481 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 74.9 mt -81.18 114.26 21.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 121.545 0.688 . . . . 0.0 110.528 -177.801 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 373' ' ' ASP . . . . . 0.424 ' HB2' ' HE3' ' A' ' 378' ' ' LYS . 36.0 t70 -117.11 80.75 1.53 Allowed 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 114.704 -1.135 . . . . 0.0 109.158 -178.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 61.18 119.12 0.01 OUTLIER Glycine 0 CA--C 1.52 0.372 0 CA-C-N 114.968 -1.014 . . . . 0.0 113.408 -175.73 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 375' ' ' ASN . . . . . 0.598 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 3.6 p-10 26.13 48.1 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 124.582 1.153 . . . . 0.0 114.08 179.519 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 162.95 171.45 29.19 Favored Glycine 0 N--CA 1.444 -0.81 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 178.771 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 377' ' ' PHE . . . . . 0.43 ' CD2' HG11 ' A' ' 351' ' ' VAL . 4.0 p90 -138.83 147.94 43.11 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.458 0.647 . . . . 0.0 111.983 -179.245 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 378' ' ' LYS . . . . . 0.424 ' HE3' ' HB2' ' A' ' 373' ' ' ASP . 0.0 OUTLIER -130.59 133.13 45.93 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 114.775 -1.102 . . . . 0.0 109.659 173.468 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 379' ' ' GLY . . . . . 0.518 ' HA3' ' HA ' ' A' ' 370' ' ' ALA . . . -154.85 -158.36 8.67 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.489 -176.472 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -138.17 151.85 48.12 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 120.74 0.305 . . . . 0.0 111.489 -173.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 381' ' ' TRP . . . . . 0.765 ' CZ3' HG13 ' A' ' 355' ' ' ILE . 19.3 m95 . . . . . 0 C--O 1.233 0.211 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.992 176.668 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.449 -0.496 0 N-CA-C 111.865 -0.494 . . . . 0.0 111.865 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -90.9 137.42 32.38 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.056 0.455 . . . . 0.0 110.992 -177.4 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 29.5 t -128.98 115.37 36.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.58 177.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 2.4 p -139.11 137.51 36.22 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.355 0.598 . . . . 0.0 112.477 -175.316 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 391' ' ' GLY . . . . . 0.405 ' CA ' ' HA3' ' A' ' 403' ' ' GLY . . . -147.84 159.33 27.99 Favored Glycine 0 N--CA 1.447 -0.614 0 CA-C-N 115.474 -0.785 . . . . 0.0 111.515 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 392' ' ' ARG . . . . . 0.417 ' N ' ' HD2' ' A' ' 392' ' ' ARG . 8.2 mpt_? -117.01 142.43 46.96 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.05 0.453 . . . . 0.0 111.076 -174.423 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 393' ' ' PHE . . . . . 0.414 ' CD1' ' HB ' ' A' ' 401' ' ' VAL . 21.0 m-85 -82.34 163.09 21.98 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 115.295 -0.866 . . . . 0.0 109.671 176.626 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 394' ' ' TYR . . . . . 0.437 ' HD1' ' N ' ' A' ' 394' ' ' TYR . 1.2 m-85 -100.77 -176.99 3.34 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 176.094 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 395' ' ' GLY . . . . . 0.757 ' HA2' ' HA ' ' A' ' 307' ' ' PRO . . . -52.74 -146.96 0.0 OUTLIER Glycine 0 CA--C 1.527 0.836 0 O-C-N 124.062 0.851 . . . . 0.0 114.755 -176.256 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 396' ' ' PRO . . . . . 0.404 ' HD2' ' HA3' ' A' ' 395' ' ' GLY . 19.4 Cg_endo -59.22 -11.49 13.25 Favored 'Trans proline' 0 CA--C 1.536 0.605 0 C-N-CA 121.515 1.477 . . . . 0.0 111.051 179.389 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 397' ' ' ALA . . . . . . . . . . . . . . . -94.82 28.79 2.56 Favored 'General case' 0 N--CA 1.453 -0.316 0 CA-C-N 114.798 -1.092 . . . . 0.0 110.557 175.767 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . -57.78 2.42 0.14 Allowed Glycine 0 C--N 1.338 0.646 0 CA-C-N 115.923 -0.58 . . . . 0.0 113.657 -179.681 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 399' ' ' GLU . . . . . 0.815 ' HG2' ' HD3' ' A' ' 424' ' ' LYS . 35.7 mt-10 -58.73 -9.22 1.63 Allowed 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 123.401 0.68 . . . . 0.0 109.756 166.114 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -115.02 125.68 53.87 Favored 'General case' 0 N--CA 1.447 -0.62 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.437 171.001 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 401' ' ' VAL . . . . . 0.414 ' HB ' ' CD1' ' A' ' 393' ' ' PHE . 9.7 p -135.09 146.57 30.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.725 178.128 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -142.19 135.07 28.58 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.82 0.343 . . . . 0.0 110.896 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 403' ' ' GLY . . . . . 0.405 ' HA3' ' CA ' ' A' ' 391' ' ' GLY . . . -153.14 -177.91 27.18 Favored Glycine 0 N--CA 1.44 -1.089 0 C-N-CA 120.667 -0.777 . . . . 0.0 112.085 -178.368 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 404' ' ' LYS . . . . . 0.844 ' HG2' HG12 ' A' ' 419' ' ' VAL . 70.2 mttt -142.0 163.01 34.04 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 -179.562 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 29.2 p90 . . . . . 0 C--N 1.32 -0.711 0 CA-C-O 121.218 0.533 . . . . 0.0 111.208 178.988 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 417' ' ' PHE . . . . . 0.735 ' HB2' ' HD1' ' A' ' 326' ' ' PHE . 47.8 p90 . . . . . 0 N--CA 1.449 -0.513 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 81.54 71.23 1.3 Allowed Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.53 -0.843 . . . . 0.0 112.278 177.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 419' ' ' VAL . . . . . 0.844 HG12 ' HG2' ' A' ' 404' ' ' LYS . 22.9 m -109.72 153.04 11.6 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 178.819 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 420' ' ' PHE . . . . . 0.437 ' HB3' HG22 ' A' ' 323' ' ' VAL . 38.3 p90 -142.4 160.45 40.24 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 121.358 0.599 . . . . 0.0 110.873 179.408 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -139.45 136.11 34.29 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 114.943 -1.026 . . . . 0.0 109.076 177.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -118.94 132.44 9.65 Favored Glycine 0 N--CA 1.441 -1.007 0 C-N-CA 120.607 -0.806 . . . . 0.0 111.681 -178.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 35.2 mtmt -116.18 124.6 50.69 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 179.181 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 424' ' ' LYS . . . . . 0.815 ' HD3' ' HG2' ' A' ' 399' ' ' GLU . 46.2 tttm -67.48 125.57 26.57 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.69 -177.795 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 425' ' ' GLU . . . . . 0.418 ' HB2' ' ND2' ' A' ' 320' ' ' ASN . 26.2 tt0 . . . . . 0 N--CA 1.444 -0.762 0 CA-C-O 121.416 0.627 . . . . 0.0 111.138 -172.012 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_exo . . . . . 0 CA--C 1.528 0.224 0 N-CA-C 111.216 -0.34 . . . . 0.0 111.216 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 308' ' ' ALA . . . . . 0.689 ' HB2' ' O ' ' A' ' 394' ' ' TYR . . . -48.07 152.51 0.8 Allowed 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 112.968 0.729 . . . . 0.0 112.968 -177.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 309' ' ' LYS . . . . . 0.583 ' O ' ' HG ' ' A' ' 313' ' ' LEU . 29.9 mmmt -108.87 107.9 18.48 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.489 177.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 310' ' ' GLY . . . . . 0.608 ' HA2' HD12 ' A' ' 313' ' ' LEU . . . -64.91 -34.89 91.09 Favored Glycine 0 CA--C 1.516 0.133 0 C-N-CA 121.355 -0.45 . . . . 0.0 113.705 -172.737 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 2.9 pm0 -71.72 -25.56 62.12 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.234 0.54 . . . . 0.0 110.031 178.692 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 312' ' ' MET . . . . . 0.475 ' HB3' ' HB2' ' A' ' 309' ' ' LYS . 27.6 ttt -87.11 -18.06 31.37 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.461 -179.45 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 313' ' ' LEU . . . . . 0.608 HD12 ' HA2' ' A' ' 310' ' ' GLY . 96.1 mt -66.55 139.96 57.95 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.554 179.167 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -159.62 135.64 8.75 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.011 -176.384 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.5 177.69 15.94 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.918 -0.658 . . . . 0.0 111.592 178.168 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 38.7 p -108.75 142.16 39.7 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 117.303 0.551 . . . . 0.0 110.471 174.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -146.68 155.28 42.31 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.258 -179.093 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 318' ' ' VAL . . . . . 0.561 ' HA ' ' O ' ' A' ' 342' ' ' ALA . 2.5 p -132.94 119.71 38.17 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-O 121.285 0.564 . . . . 0.0 110.732 174.504 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 319' ' ' TYR . . . . . 0.477 ' HE1' ' HA ' ' A' ' 399' ' ' GLU . 76.8 m-85 -104.51 128.35 52.42 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.956 -178.671 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 4.5 p30 -127.75 141.84 51.48 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.142 179.297 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -167.03 -140.98 3.02 Favored Glycine 0 N--CA 1.442 -0.913 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.28 -178.194 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 31.0 mt-10 -118.66 150.38 39.82 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.831 0.348 . . . . 0.0 111.051 -173.577 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 323' ' ' VAL . . . . . 0.626 HG23 ' HB2' ' A' ' 340' ' ' PHE . 56.1 t -109.9 120.95 61.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.925 172.644 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 324' ' ' LEU . . . . . 0.449 ' HB2' HG22 ' A' ' 419' ' ' VAL . 95.7 mt -101.87 104.21 14.94 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.092 -179.624 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 325' ' ' HIS . . . . . 0.448 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 28.1 t-80 -96.21 138.83 33.25 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.187 -0.461 . . . . 0.0 109.814 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 326' ' ' PHE . . . . . 0.558 ' HE2' HG13 ' A' ' 419' ' ' VAL . 10.8 m-85 . . . . . 0 C--N 1.321 -0.67 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.587 -176.35 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 337' ' ' ARG . . . . . 0.483 ' HA ' ' O ' ' A' ' 323' ' ' VAL . 51.2 mtm180 . . . . . 0 CA--C 1.516 -0.338 0 CA-C-O 121.254 0.549 . . . . 0.0 111.576 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -107.57 -177.12 22.49 Favored Glycine 0 N--CA 1.444 -0.83 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.092 176.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 339' ' ' ARG . . . . . 0.503 ' O ' ' HA ' ' A' ' 355' ' ' ILE . 40.0 mtp-105 -104.45 153.46 21.08 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 340' ' ' PHE . . . . . 0.626 ' HB2' HG23 ' A' ' 323' ' ' VAL . 53.0 t80 -143.41 137.52 28.71 Favored 'General case' 0 C--N 1.317 -0.848 0 CA-C-O 121.139 0.495 . . . . 0.0 111.484 -178.51 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 341' ' ' ALA . . . . . 0.401 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -141.05 163.49 32.84 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.228 -0.896 . . . . 0.0 108.889 173.334 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 342' ' ' ALA . . . . . 0.821 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -155.9 118.14 4.09 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 120.871 0.367 . . . . 0.0 110.667 -176.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 343' ' ' LYS . . . . . 0.502 ' C ' ' HD3' ' A' ' 343' ' ' LYS . 12.7 tmtt? -94.3 103.35 15.36 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 178.223 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 344' ' ' VAL . . . . . 1.026 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.2 OUTLIER -119.4 132.83 68.1 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.109 0 CA-C-O 121.607 0.718 . . . . 0.0 112.105 -172.716 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -109.16 118.69 37.39 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.885 -1.052 . . . . 0.0 108.247 175.563 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 346' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -79.25 -24.59 42.9 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 111.584 0.216 . . . . 0.0 111.584 -175.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -69.52 -38.54 79.25 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.239 -0.981 . . . . 0.0 111.285 179.227 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 3.4 m -92.58 -9.74 40.04 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.002 0.43 . . . . 0.0 110.019 178.096 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 349' ' ' LYS . . . . . 0.621 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 10.1 mtmp? 52.03 58.67 5.19 Favored 'General case' 0 N--CA 1.456 -0.142 0 CA-C-N 115.439 -0.801 . . . . 0.0 110.394 -176.734 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 17.9 m -140.9 145.84 36.67 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.48 -179.211 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 351' ' ' VAL . . . . . 1.026 ' HB ' ' HB ' ' A' ' 344' ' ' VAL . 0.2 OUTLIER -141.83 139.0 31.38 Favored 'Isoleucine or valine' 0 C--O 1.237 0.396 0 CA-C-O 121.299 0.571 . . . . 0.0 111.559 -177.035 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 352' ' ' ASP . . . . . 0.821 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 1.5 m-20 -106.61 118.54 36.93 Favored 'General case' 0 C--O 1.214 -0.798 0 CA-C-N 115.057 -0.974 . . . . 0.0 109.304 179.637 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -110.1 143.24 16.73 Favored Glycine 0 C--N 1.313 -0.715 0 C-N-CA 120.23 -0.986 . . . . 0.0 111.873 -177.076 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 354' ' ' ILE . . . . . 0.536 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -140.29 129.92 27.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 CA-C-O 120.856 0.36 . . . . 0.0 110.362 -177.962 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 355' ' ' ILE . . . . . 0.59 HG23 HG21 ' A' ' 323' ' ' VAL . 3.3 mp . . . . . 0 C--N 1.326 -0.419 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.329 179.811 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 14.6 mm100 . . . . . 0 N--CA 1.447 -0.577 0 CA-C-O 121.624 0.726 . . . . 0.0 111.076 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 44.9 mttp -125.74 147.72 49.29 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 114.599 -1.182 . . . . 0.0 110.394 -170.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 368' ' ' PHE . . . . . 0.685 ' CD1' HG21 ' A' ' 389' ' ' VAL . 41.9 p90 -126.39 160.23 31.05 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 177.371 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 369' ' ' LYS . . . . . 0.589 ' HD3' ' HA ' ' A' ' 352' ' ' ASP . 2.0 tppt? -125.96 147.39 49.53 Favored 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 173.442 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 370' ' ' ALA . . . . . 0.435 ' HB1' ' HB2' ' A' ' 377' ' ' PHE . . . -141.58 147.71 38.12 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.83 0.347 . . . . 0.0 111.123 -176.697 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -105.45 127.57 53.07 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.079 177.759 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 372' ' ' ILE . . . . . 0.621 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 84.0 mt -82.8 121.32 35.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-O 121.008 0.433 . . . . 0.0 111.257 -178.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -137.91 105.27 5.5 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 170.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 92.88 -155.2 22.37 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 110.349 -1.1 . . . . 0.0 110.349 -168.012 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 375' ' ' ASN . . . . . 0.552 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 21.8 p-10 -94.33 42.6 1.1 Allowed 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 117.533 0.666 . . . . 0.0 110.681 178.718 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . -170.37 164.48 37.77 Favored Glycine 0 N--CA 1.441 -1.016 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -178.789 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 377' ' ' PHE . . . . . 0.512 ' CD2' HG11 ' A' ' 351' ' ' VAL . 8.8 p90 -136.91 139.0 41.26 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-O 120.964 0.412 . . . . 0.0 110.939 -179.307 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 378' ' ' LYS . . . . . . . . . . . . . 63.7 mttm -112.72 137.09 51.52 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.293 172.081 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 379' ' ' GLY . . . . . 0.627 ' C ' HG22 ' A' ' 389' ' ' VAL . . . -144.53 -154.73 6.22 Favored Glycine 0 N--CA 1.437 -1.283 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.097 -172.432 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 12.7 t -169.16 154.66 6.09 Favored 'General case' 0 C--N 1.313 -1.016 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 -173.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 381' ' ' TRP . . . . . 0.901 ' HD1' ' HA3' ' A' ' 387' ' ' GLY . 38.8 m95 . . . . . 0 C--N 1.327 -0.373 0 CA-C-O 121.299 0.571 . . . . 0.0 110.87 178.337 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 387' ' ' GLY . . . . . 0.901 ' HA3' ' HD1' ' A' ' 381' ' ' TRP . . . . . . . . 0 N--CA 1.446 -0.69 0 N-CA-C 112.637 -0.185 . . . . 0.0 112.637 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -96.18 128.04 42.74 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 178.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 389' ' ' VAL . . . . . 0.685 HG21 ' CD1' ' A' ' 368' ' ' PHE . 3.5 m -117.28 160.48 16.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 C-N-CA 120.87 -0.332 . . . . 0.0 110.714 -176.589 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 390' ' ' SER . . . . . 0.521 ' O ' ' HA3' ' A' ' 403' ' ' GLY . 24.7 t -157.44 158.46 35.87 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.245 178.622 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -170.13 153.15 20.82 Favored Glycine 0 C--N 1.32 -0.329 0 N-CA-C 111.443 -0.663 . . . . 0.0 111.443 178.666 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 4.3 ptm180 -131.92 149.32 52.47 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 117.319 0.56 . . . . 0.0 110.751 -176.706 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -89.88 166.11 13.7 Favored 'General case' 0 CA--C 1.498 -1.037 0 CA-C-O 122.424 1.107 . . . . 0.0 111.786 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 394' ' ' TYR . . . . . 0.689 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 0.5 OUTLIER -101.86 -176.15 3.05 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 112.709 -2.042 . . . . 0.0 108.923 176.949 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 395' ' ' GLY . . . . . 0.42 ' O ' ' N ' ' A' ' 397' ' ' ALA . . . -36.26 158.38 0.01 OUTLIER Glycine 0 N--CA 1.461 0.304 0 O-C-N 124.71 1.256 . . . . 0.0 115.045 -175.06 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -22.95 -42.42 0.03 OUTLIER 'Trans proline' 0 C--N 1.358 1.032 1 C-N-CA 127.322 5.348 . . . . 0.0 117.178 -161.711 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 397' ' ' ALA . . . . . 0.42 ' N ' ' O ' ' A' ' 395' ' ' GLY . . . -73.04 -19.46 61.18 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 -175.068 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 57.85 25.06 55.54 Favored Glycine 0 C--N 1.34 0.767 0 CA-C-N 116.186 -0.461 . . . . 0.0 112.887 176.165 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 399' ' ' GLU . . . . . 0.477 ' HA ' ' HE1' ' A' ' 319' ' ' TYR . 51.3 mt-10 -71.3 -8.37 53.21 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 122.956 0.502 . . . . 0.0 112.024 -174.03 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 400' ' ' GLU . . . . . 0.451 ' HG2' ' CE1' ' A' ' 394' ' ' TYR . 5.2 tt0 -131.9 144.29 50.75 Favored 'General case' 0 N--CA 1.433 -1.284 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 171.438 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 401' ' ' VAL . . . . . 0.492 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 14.8 p -142.08 136.73 29.9 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.107 0 CA-C-N 115.012 -0.995 . . . . 0.0 109.722 179.019 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -135.7 138.94 43.27 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.122 -178.74 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 403' ' ' GLY . . . . . 0.521 ' HA3' ' O ' ' A' ' 390' ' ' SER . . . -161.06 -161.09 11.25 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 120.747 -0.739 . . . . 0.0 111.646 178.424 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 404' ' ' LYS . . . . . 0.7 ' HG2' HG12 ' A' ' 419' ' ' VAL . 28.4 mtmm -144.45 161.71 38.36 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.557 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 34.9 p90 . . . . . 0 C--N 1.318 -0.776 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 171.915 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 417' ' ' PHE . . . . . 0.506 ' CD1' ' HB2' ' A' ' 326' ' ' PHE . 32.7 m-85 . . . . . 0 N--CA 1.454 -0.243 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 418' ' ' GLY . . . . . 0.448 ' HA2' ' HA ' ' A' ' 325' ' ' HIS . . . 83.82 78.17 1.11 Allowed Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 119.904 -1.141 . . . . 0.0 112.678 -178.262 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 419' ' ' VAL . . . . . 0.7 HG12 ' HG2' ' A' ' 404' ' ' LYS . 13.5 m -105.03 163.29 4.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.832 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 29.9 p90 -143.38 153.71 42.97 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-O 121.406 0.622 . . . . 0.0 111.234 -178.133 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -142.81 136.15 28.5 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.259 -0.882 . . . . 0.0 109.037 176.664 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -124.05 134.71 9.34 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.399 -0.905 . . . . 0.0 112.327 -178.341 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 423' ' ' LYS . . . . . 0.451 ' HE2' ' HB3' ' A' ' 423' ' ' LYS . 44.6 mtpt -104.8 140.18 38.48 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 120.753 0.311 . . . . 0.0 110.198 178.722 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 424' ' ' LYS . . . . . 0.408 ' HB2' ' HE1' ' A' ' 319' ' ' TYR . 26.0 tptp -58.14 116.25 3.43 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.626 -0.716 . . . . 0.0 111.8 179.652 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 425' ' ' GLU . . . . . 0.535 ' HB3' HG13 ' A' ' 318' ' ' VAL . 19.8 tp10 . . . . . 0 C--N 1.325 -0.473 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 169.009 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 276' ' ' ASN . . . . . 0.513 ' HA ' ' OE2' ' A' ' 292' ' ' GLU . 17.2 p30 . . . . . 0 N--CA 1.483 1.189 0 CA-C-O 121.348 0.594 . . . . 0.0 110.013 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 15.6 tt -81.67 15.27 0.42 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.426 0 CA-C-N 115.563 -0.744 . . . . 0.0 111.313 -171.798 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 278' ' ' PHE . . . . . . . . . . . . . 25.1 p90 -79.03 -21.52 46.76 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.451 176.091 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 279' ' ' ALA . . . . . 0.622 ' HB1' ' HA ' ' A' ' 283' ' ' ASN . . . -144.43 64.08 11.68 Favored Pre-proline 0 C--N 1.33 -0.241 0 CA-C-N 116.13 -0.487 . . . . 0.0 111.199 178.435 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 280' ' ' PRO . . . . . 0.47 ' O ' ' HB2' ' A' ' 281' ' ' GLU . 4.5 Cg_endo -84.23 144.9 10.71 Favored 'Trans proline' 0 N--CA 1.455 -0.768 0 C-N-CA 123.08 2.52 . . . . 0.0 111.403 179.462 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . 0.47 ' HB2' ' O ' ' A' ' 280' ' ' PRO . 1.6 mp0 70.83 -64.01 0.39 Allowed 'General case' 0 N--CA 1.469 0.52 0 O-C-N 123.61 0.569 . . . . 0.0 110.774 -178.301 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -107.77 93.35 0.81 Allowed Glycine 0 N--CA 1.446 -0.665 0 CA-C-N 115.78 -0.645 . . . . 0.0 111.873 177.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 283' ' ' ASN . . . . . 0.622 ' HA ' ' HB1' ' A' ' 279' ' ' ALA . 2.6 p-10 -71.42 108.03 4.64 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-O 121.49 0.662 . . . . 0.0 110.161 178.228 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 70.9 m-85 -72.99 99.31 2.69 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.686 -0.688 . . . . 0.0 110.995 -175.554 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 3.3 ptp180 -92.93 2.32 56.84 Favored 'General case' 0 C--N 1.321 -0.651 0 CA-C-N 115.824 -0.626 . . . . 0.0 109.714 177.146 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 4.9 m-85 -79.06 -42.48 26.32 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 115.347 -0.842 . . . . 0.0 108.738 177.574 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . 0.521 HD11 ' HB3' ' A' ' 306' ' ' GLU . 21.5 tp -166.25 128.94 1.95 Allowed 'General case' 0 N--CA 1.442 -0.831 0 CA-C-N 115.072 -0.967 . . . . 0.0 109.544 175.914 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 288' ' ' THR . . . . . 0.589 ' H ' ' HB2' ' A' ' 304' ' ' GLN . 6.0 m -172.37 143.66 1.45 Allowed 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 123.354 0.661 . . . . 0.0 109.473 179.084 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 289' ' ' TYR . . . . . . . . . . . . . 46.6 t80 -136.42 128.26 29.21 Favored 'General case' 0 N--CA 1.443 -0.808 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 171.849 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 144.43 158.4 7.6 Favored Glycine 0 C--N 1.312 -0.785 0 N-CA-C 111.355 -0.698 . . . . 0.0 111.355 -177.011 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 291' ' ' ALA . . . . . 0.433 ' HB1' ' OH ' ' A' ' 299' ' ' TYR . . . -156.17 130.15 8.57 Favored 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 116.866 0.333 . . . . 0.0 111.284 -177.646 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 292' ' ' GLU . . . . . 0.513 ' OE2' ' HA ' ' A' ' 276' ' ' ASN . 44.7 mt-10 -137.1 119.43 15.72 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.231 -0.44 . . . . 0.0 109.999 175.916 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 293' ' ' LYS . . . . . . . . . . . . . 5.2 tppp? -88.02 139.49 30.45 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.495 -0.321 . . . . 0.0 110.612 -179.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 294' ' ' LEU . . . . . 0.461 ' HB2' ' O ' ' A' ' 298' ' ' SER . 6.5 mp -82.25 115.7 59.28 Favored Pre-proline 0 C--N 1.327 -0.375 0 N-CA-C 109.18 -0.674 . . . . 0.0 109.18 173.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 295' ' ' PRO . . . . . 0.413 ' HD3' ' HA ' ' A' ' 294' ' ' LEU . 21.7 Cg_exo -65.27 100.39 0.38 Allowed 'Trans proline' 0 C--O 1.236 0.387 0 C-N-CA 122.576 2.184 . . . . 0.0 111.096 179.088 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . 80.69 48.28 6.3 Favored Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 120.679 -0.772 . . . . 0.0 111.433 -174.27 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . -166.43 -140.94 3.01 Favored Glycine 0 N--CA 1.443 -0.888 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.8 -178.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 298' ' ' SER . . . . . 0.461 ' O ' ' HB2' ' A' ' 294' ' ' LEU . 8.3 t -94.42 -175.45 3.64 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.078 0.466 . . . . 0.0 110.901 -175.509 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 299' ' ' TYR . . . . . 0.433 ' OH ' ' HB1' ' A' ' 291' ' ' ALA . 1.3 t80 -139.32 135.78 34.14 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.529 -0.545 . . . . 0.0 109.529 176.09 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 300' ' ' ALA . . . . . 0.486 ' HB3' ' ND2' ' A' ' 276' ' ' ASN . . . -144.19 110.51 5.5 Favored 'General case' 0 C--N 1.32 -0.702 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.178 179.477 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 301' ' ' LEU . . . . . . . . . . . . . 2.6 pt? -142.15 162.68 34.86 Favored 'General case' 0 C--N 1.319 -0.723 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.427 178.066 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 302' ' ' ARG . . . . . 0.571 ' NE ' ' HA ' ' A' ' 302' ' ' ARG . 2.3 mmp_? -136.78 131.8 33.86 Favored 'General case' 0 C--N 1.32 -0.681 0 N-CA-C 109.718 -0.475 . . . . 0.0 109.718 174.378 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 303' ' ' VAL . . . . . . . . . . . . . 3.4 p -113.43 96.44 4.67 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.59 0 CA-C-O 122.073 0.939 . . . . 0.0 110.487 178.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 304' ' ' GLN . . . . . 0.589 ' HB2' ' H ' ' A' ' 288' ' ' THR . 5.1 mp0 -121.94 151.86 40.29 Favored 'General case' 0 C--N 1.32 -0.691 0 CA-C-N 114.855 -1.066 . . . . 0.0 109.814 177.47 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -102.94 119.44 6.43 Favored Glycine 0 N--CA 1.444 -0.814 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.692 -177.641 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 306' ' ' GLU . . . . . 0.521 ' HB3' HD11 ' A' ' 287' ' ' LEU . 6.0 pt-20 -116.35 84.31 14.27 Favored Pre-proline 0 C--N 1.324 -0.539 0 CA-C-O 121.598 0.713 . . . . 0.0 109.845 173.678 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 45.6 Cg_endo -91.0 122.41 0.78 Allowed 'Trans proline' 0 N--CA 1.444 -1.414 0 C-N-CA 122.591 2.194 . . . . 0.0 111.575 175.009 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . 0.675 ' HB2' ' O ' ' A' ' 394' ' ' TYR . . . -59.47 163.54 4.01 Favored 'General case' 0 C--N 1.326 -0.437 0 C-N-CA 120.15 -0.62 . . . . 0.0 109.974 168.828 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 309' ' ' LYS . . . . . 0.537 ' HB3' ' HB2' ' A' ' 312' ' ' MET . 10.8 tptp -123.96 93.45 3.93 Favored 'General case' 0 C--N 1.313 -0.988 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 174.1 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 310' ' ' GLY . . . . . 0.7 ' HA2' HD12 ' A' ' 313' ' ' LEU . . . -57.24 -34.02 66.47 Favored Glycine 0 C--N 1.332 0.315 0 C-N-CA 121.147 -0.549 . . . . 0.0 113.013 -173.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . 0.425 ' HA ' ' HE3' ' A' ' 349' ' ' LYS . 11.2 pt-20 -62.82 -26.9 68.97 Favored 'General case' 0 C--N 1.319 -0.755 0 C-N-CA 122.483 0.313 . . . . 0.0 111.581 174.807 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 312' ' ' MET . . . . . 0.537 ' HB2' ' HB3' ' A' ' 309' ' ' LYS . 90.0 mtp -102.37 -6.37 23.1 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-O 120.921 0.391 . . . . 0.0 110.567 -179.77 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 313' ' ' LEU . . . . . 0.7 HD12 ' HA2' ' A' ' 310' ' ' GLY . 92.4 mt -75.26 133.2 41.4 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.061 -0.518 . . . . 0.0 109.729 176.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -143.68 137.09 27.97 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.017 -173.822 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.53 -159.53 15.28 Favored Glycine 0 N--CA 1.448 -0.551 0 C-N-CA 121.001 -0.618 . . . . 0.0 111.665 178.994 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 12.7 p -123.89 156.17 36.76 Favored 'General case' 0 C--N 1.317 -0.806 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 173.462 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 317' ' ' ALA . . . . . 0.402 ' HB3' HG13 ' A' ' 344' ' ' VAL . . . -146.51 160.41 42.15 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 120.918 0.39 . . . . 0.0 110.694 176.657 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . 0.582 ' HA ' ' O ' ' A' ' 342' ' ' ALA . 8.7 p -138.78 113.75 8.5 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.843 0 CA-C-N 115.839 -0.619 . . . . 0.0 109.691 172.849 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . 0.731 ' HE2' HG11 ' A' ' 344' ' ' VAL . 55.4 m-85 -98.08 127.46 44.04 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 116.355 -0.384 . . . . 0.0 110.331 -177.256 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 93.2 m-20 -115.79 132.4 56.65 Favored 'General case' 0 C--N 1.316 -0.875 0 CA-C-N 115.721 -0.672 . . . . 0.0 109.478 174.459 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . 0.48 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -166.27 -143.17 3.65 Favored Glycine 0 N--CA 1.438 -1.197 0 C-N-CA 120.697 -0.763 . . . . 0.0 111.948 -179.143 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 12.0 pt-20 -136.94 164.67 27.78 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-O 120.927 0.394 . . . . 0.0 111.236 -173.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 323' ' ' VAL . . . . . 0.608 HG23 ' HB2' ' A' ' 340' ' ' PHE . 75.2 t -126.34 116.42 45.41 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.645 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.53 178.792 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 324' ' ' LEU . . . . . 0.426 ' HB2' HG22 ' A' ' 419' ' ' VAL . 93.7 mt -89.4 101.76 14.43 Favored 'General case' 0 C--N 1.315 -0.907 0 N-CA-C 108.938 -0.764 . . . . 0.0 108.938 175.486 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 325' ' ' HIS . . . . . 0.52 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 1.9 p80 -102.24 114.76 29.19 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.493 0.663 . . . . 0.0 110.066 -179.123 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 326' ' ' PHE . . . . . 0.5 ' HB2' ' HB3' ' A' ' 417' ' ' PHE . 49.0 m-85 -88.16 124.33 33.7 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-N 114.734 -1.121 . . . . 0.0 110.897 -170.011 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 327' ' ' HIS . . . . . . . . . . . . . 31.2 p-80 -150.31 106.57 3.47 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.063 -0.717 . . . . 0.0 109.063 176.636 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 328' ' ' THR . . . . . . . . . . . . . 30.2 m -146.49 97.38 2.92 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.195 0.521 . . . . 0.0 110.937 179.113 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 329' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -106.41 115.4 30.14 Favored 'General case' 0 C--N 1.32 -0.678 0 N-CA-C 107.351 -1.352 . . . . 0.0 107.351 169.157 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 330' ' ' ASN . . . . . . . . . . . . . 22.7 p-10 30.96 54.72 0.2 Allowed 'General case' 0 N--CA 1.477 0.876 0 O-C-N 124.333 1.021 . . . . 0.0 111.139 -167.873 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 331' ' ' GLY . . . . . . . . . . . . . . . -101.73 138.34 13.83 Favored Glycine 0 N--CA 1.444 -0.785 0 CA-C-N 115.01 -0.995 . . . . 0.0 113.332 -170.725 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 332' ' ' ARG . . . . . 0.571 ' N ' ' HD2' ' A' ' 333' ' ' PRO . 67.5 mtp180 -84.68 -42.84 0.7 Allowed Pre-proline 0 C--N 1.322 -0.6 0 CA-C-N 115.385 -0.407 . . . . 0.0 111.828 177.956 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 333' ' ' PRO . . . . . 0.571 ' HD2' ' N ' ' A' ' 332' ' ' ARG . 45.7 Cg_endo -68.74 -173.93 0.65 Allowed 'Trans proline' 0 C--N 1.36 1.132 0 C-N-CA 122.11 1.873 . . . . 0.0 112.674 175.472 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 334' ' ' TYR . . . . . 0.692 ' HB2' ' HD2' ' A' ' 335' ' ' PRO . 36.1 p90 -122.59 168.81 10.96 Favored Pre-proline 0 C--N 1.323 -0.574 0 CA-C-N 115.686 -0.688 . . . . 0.0 109.815 -178.609 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 335' ' ' PRO . . . . . 0.692 ' HD2' ' HB2' ' A' ' 334' ' ' TYR . 6.1 Cg_endo -48.55 144.41 14.09 Favored 'Trans proline' 0 C--N 1.353 0.77 0 C-N-CA 123.15 2.566 . . . . 0.0 113.038 179.165 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 336' ' ' THR . . . . . 0.408 ' HB ' ' NE2' ' A' ' 325' ' ' HIS . 1.6 m -94.34 151.97 19.0 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.579 -177.923 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 337' ' ' ARG . . . . . . . . . . . . . 54.6 mtp180 -102.48 112.63 25.44 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 120.957 0.408 . . . . 0.0 110.707 -178.756 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -96.82 -176.81 35.22 Favored Glycine 0 N--CA 1.447 -0.591 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 173.951 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 339' ' ' ARG . . . . . 0.591 ' HB2' ' HB2' ' A' ' 356' ' ' ASP . 29.0 mtm180 -112.41 163.31 14.58 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-N 118.055 0.928 . . . . 0.0 110.213 179.393 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 340' ' ' PHE . . . . . 0.608 ' HB2' HG23 ' A' ' 323' ' ' VAL . 30.7 t80 -151.67 140.13 20.55 Favored 'General case' 0 C--N 1.322 -0.629 0 CA-C-O 120.83 0.347 . . . . 0.0 111.137 -179.243 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 341' ' ' ALA . . . . . 0.562 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -137.25 152.55 49.94 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.522 -0.763 . . . . 0.0 109.12 175.364 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . 0.929 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -143.83 118.3 9.71 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.044 0.45 . . . . 0.0 111.513 -178.375 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . 0.525 ' HB3' ' HB2' ' A' ' 352' ' ' ASP . 55.7 tptt -96.52 103.61 15.54 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.109 177.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 344' ' ' VAL . . . . . 0.731 HG11 ' HE2' ' A' ' 319' ' ' TYR . 0.7 OUTLIER -122.86 140.33 46.95 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 N-CA-C 112.874 0.694 . . . . 0.0 112.874 -170.691 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 12.6 t70 -114.4 121.31 43.19 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 114.839 -1.073 . . . . 0.0 108.46 171.164 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 346' ' ' PHE . . . . . . . . . . . . . 51.8 m-85 -76.7 -17.04 59.34 Favored 'General case' 0 C--N 1.326 -0.449 0 N-CA-C 111.734 0.272 . . . . 0.0 111.734 -175.301 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -75.29 -42.12 29.14 Favored Glycine 0 N--CA 1.447 -0.63 0 C-N-CA 120.461 -0.876 . . . . 0.0 111.269 178.568 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 55.9 m -88.37 -10.93 47.7 Favored 'General case' 0 N--CA 1.449 -0.499 0 CA-C-O 120.811 0.339 . . . . 0.0 110.108 177.33 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 349' ' ' LYS . . . . . 0.64 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 48.4 mttm 51.24 58.81 5.12 Favored 'General case' 0 CA--C 1.52 -0.198 0 CA-C-O 121.863 0.84 . . . . 0.0 109.896 -179.723 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 50.7 m -147.77 146.02 29.02 Favored 'General case' 0 C--N 1.321 -0.631 0 CA-C-N 114.777 -1.101 . . . . 0.0 109.607 176.958 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 351' ' ' VAL . . . . . 0.782 HG22 ' HB3' ' A' ' 370' ' ' ALA . 1.3 m -129.69 156.35 41.97 Favored 'Isoleucine or valine' 0 C--O 1.237 0.427 0 CA-C-O 121.181 0.515 . . . . 0.0 110.461 -176.451 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 352' ' ' ASP . . . . . 0.929 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 0.9 OUTLIER -109.48 117.37 33.81 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 108.775 -0.824 . . . . 0.0 108.775 170.481 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -114.7 117.08 3.95 Favored Glycine 0 N--CA 1.444 -0.792 0 C-N-CA 120.218 -0.991 . . . . 0.0 112.136 -177.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 354' ' ' ILE . . . . . 0.526 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -117.65 133.14 65.39 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.127 0 CA-C-N 115.321 -0.439 . . . . 0.0 109.916 -176.995 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 355' ' ' ILE . . . . . 0.514 ' HB ' ' HB3' ' A' ' 366' ' ' GLN . 3.4 mp -116.14 113.2 42.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.71 0 CA-C-N 115.854 -0.612 . . . . 0.0 109.797 -178.016 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 356' ' ' ASP . . . . . 0.591 ' HB2' ' HB2' ' A' ' 339' ' ' ARG . 20.4 m-20 -68.43 100.72 1.12 Allowed 'General case' 0 C--O 1.238 0.5 0 N-CA-C 109.103 -0.703 . . . . 0.0 109.103 175.34 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 15.9 t -70.83 -32.4 69.44 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.472 -0.786 . . . . 0.0 110.064 -177.781 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 358' ' ' GLY . . . . . . . . . . . . . . . 124.43 -41.64 1.69 Allowed Glycine 0 N--CA 1.448 -0.514 0 N-CA-C 111.107 -0.797 . . . . 0.0 111.107 -178.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 359' ' ' ASP . . . . . 0.48 ' OD2' ' HB3' ' A' ' 362' ' ' HIS . 20.8 t70 -133.39 68.31 1.5 Allowed 'General case' 0 C--N 1.321 -0.665 0 CA-C-O 122.153 0.978 . . . . 0.0 108.843 174.381 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 360' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -78.02 -20.8 51.78 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 114.921 -1.036 . . . . 0.0 111.303 -174.505 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 361' ' ' LEU . . . . . . . . . . . . . 93.8 mt -83.86 -11.13 57.41 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 116.459 -0.337 . . . . 0.0 111.373 -176.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 362' ' ' HIS . . . . . 0.48 ' HB3' ' OD2' ' A' ' 359' ' ' ASP . 47.2 t60 -129.77 -66.16 0.81 Allowed 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.712 -0.222 . . . . 0.0 111.408 179.018 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 363' ' ' MET . . . . . . . . . . . . . 15.1 tpt -55.55 -48.92 73.96 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-O 120.769 0.319 . . . . 0.0 110.789 179.867 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 364' ' ' GLY . . . . . . . . . . . . . . . 153.43 135.29 2.12 Favored Glycine 0 N--CA 1.447 -0.572 0 C-N-CA 120.394 -0.908 . . . . 0.0 112.31 176.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 365' ' ' THR . . . . . . . . . . . . . 5.9 m -78.81 132.54 36.91 Favored 'General case' 0 C--N 1.323 -0.585 0 N-CA-C 109.892 -0.41 . . . . 0.0 109.892 178.973 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 366' ' ' GLN . . . . . 0.514 ' HB3' ' HB ' ' A' ' 355' ' ' ILE . 17.5 tp60 -106.18 117.63 34.52 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 109.632 -0.507 . . . . 0.0 109.632 -179.734 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 37.5 ttpt -156.54 136.98 13.04 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.427 -176.344 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 368' ' ' PHE . . . . . 0.424 ' HB3' ' CE3' ' A' ' 381' ' ' TRP . 46.9 p90 -129.51 156.42 44.17 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-O 121.095 0.474 . . . . 0.0 109.978 178.876 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 4.0 tptp -116.62 131.59 56.91 Favored 'General case' 0 C--N 1.313 -0.981 0 N-CA-C 108.33 -0.989 . . . . 0.0 108.33 175.149 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . 0.782 ' HB3' HG22 ' A' ' 351' ' ' VAL . . . -128.87 140.77 51.53 Favored 'General case' 0 C--N 1.317 -0.814 0 N-CA-C 112.193 0.442 . . . . 0.0 112.193 -170.994 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -101.31 130.83 47.54 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 115.54 -0.755 . . . . 0.0 109.603 175.311 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 372' ' ' ILE . . . . . 0.64 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 84.2 mt -80.8 105.17 10.31 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.661 0 CA-C-O 121.842 0.829 . . . . 0.0 110.08 -179.24 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 35.0 t70 -113.63 83.93 1.93 Allowed 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 114.337 -1.301 . . . . 0.0 108.944 -177.16 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 374' ' ' GLY . . . . . 0.56 ' O ' ' HA3' ' A' ' 310' ' ' GLY . . . 101.34 -141.79 15.46 Favored Glycine 0 N--CA 1.444 -0.811 0 CA-C-N 115.159 -0.928 . . . . 0.0 111.117 -174.15 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 375' ' ' ASN . . . . . . . . . . . . . 30.9 p-10 -97.57 59.56 1.52 Allowed 'General case' 0 C--N 1.318 -0.781 0 CA-C-O 122.582 1.182 . . . . 0.0 109.545 179.034 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 162.1 178.43 35.98 Favored Glycine 0 N--CA 1.443 -0.893 0 CA-C-N 113.993 -1.458 . . . . 0.0 109.959 -174.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 377' ' ' PHE . . . . . 0.472 ' CZ ' HG21 ' A' ' 401' ' ' VAL . 4.8 p90 -139.45 150.99 45.86 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 117.655 0.728 . . . . 0.0 112.155 -178.412 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 378' ' ' LYS . . . . . 0.442 ' HD2' ' N ' ' A' ' 378' ' ' LYS . 0.0 OUTLIER -115.06 129.5 56.71 Favored 'General case' 0 C--N 1.319 -0.749 0 N-CA-C 107.703 -1.221 . . . . 0.0 107.703 172.818 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 379' ' ' GLY . . . . . 0.513 ' HA2' ' HA ' ' A' ' 370' ' ' ALA . . . -126.33 169.3 18.28 Favored Glycine 0 N--CA 1.444 -0.777 0 C-N-CA 119.997 -1.097 . . . . 0.0 113.411 -171.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 11.3 p -131.19 140.17 49.86 Favored 'General case' 0 C--N 1.321 -0.659 0 CA-C-N 115.118 -0.541 . . . . 0.0 109.872 178.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 381' ' ' TRP . . . . . 0.516 ' CB ' ' HA3' ' A' ' 385' ' ' GLY . 73.7 m95 -66.18 139.62 58.13 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-N 116.25 -0.432 . . . . 0.0 110.701 179.496 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 382' ' ' THR . . . . . . . . . . . . . 13.8 t -66.28 112.87 4.2 Favored 'General case' 0 CA--C 1.536 0.405 0 CA-C-O 121.4 0.619 . . . . 0.0 111.696 -173.99 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 383' ' ' GLU . . . . . . . . . . . . . 20.1 mm-40 62.14 -88.56 0.03 OUTLIER 'General case' 0 C--O 1.234 0.288 0 CA-C-N 115.063 -0.971 . . . . 0.0 112.498 177.125 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 384' ' ' ASN . . . . . . . . . . . . . 44.4 t-20 -91.52 74.48 5.96 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-O 121.072 0.463 . . . . 0.0 110.509 -174.126 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 385' ' ' GLY . . . . . 0.516 ' HA3' ' CB ' ' A' ' 381' ' ' TRP . . . -154.56 89.18 0.12 Allowed Glycine 0 N--CA 1.444 -0.803 0 C-N-CA 120.648 -0.787 . . . . 0.0 112.18 178.072 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 386' ' ' GLY . . . . . . . . . . . . . . . -75.33 72.42 1.68 Allowed Glycine 0 CA--C 1.519 0.303 0 C-N-CA 120.922 -0.656 . . . . 0.0 112.464 178.665 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -164.03 148.8 15.29 Favored Glycine 0 N--CA 1.445 -0.737 0 C-N-CA 121.092 -0.575 . . . . 0.0 112.27 179.304 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 6.4 m-20 -99.66 138.94 36.04 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.817 0.342 . . . . 0.0 110.594 179.64 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 389' ' ' VAL . . . . . 0.49 HG22 ' HB3' ' A' ' 405' ' ' TYR . 22.1 t -109.53 144.81 17.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.515 0 N-CA-C 109.691 -0.485 . . . . 0.0 109.691 177.641 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 14.7 m -147.44 139.64 24.43 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 120.52 0.2 . . . . 0.0 110.557 175.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -145.08 150.14 22.31 Favored Glycine 0 C--N 1.32 -0.326 0 N-CA-C 111.692 -0.563 . . . . 0.0 111.692 179.38 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 392' ' ' ARG . . . . . 0.64 ' HD3' ' O ' ' A' ' 393' ' ' PHE . 4.5 tmt_? -118.67 136.55 53.85 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.749 -0.463 . . . . 0.0 109.749 -175.501 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 393' ' ' PHE . . . . . 0.64 ' O ' ' HD3' ' A' ' 392' ' ' ARG . 8.1 m-85 -82.24 159.76 23.13 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.263 -177.693 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 394' ' ' TYR . . . . . 0.675 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 2.4 m-85 -100.81 -174.67 2.68 Favored 'General case' 0 C--N 1.317 -0.841 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.861 -177.164 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 395' ' ' GLY . . . . . 0.454 ' CA ' ' HB2' ' A' ' 306' ' ' GLU . . . -38.42 170.45 0.01 OUTLIER Glycine 0 C--N 1.335 0.487 0 O-C-N 124.277 0.985 . . . . 0.0 114.985 -177.718 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_endo -51.52 -15.11 2.35 Favored 'Trans proline' 0 N--CA 1.477 0.502 0 C-N-CA 124.384 3.389 . . . . 0.0 115.526 -163.853 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 397' ' ' ALA . . . . . . . . . . . . . . . -80.22 -20.49 44.54 Favored 'General case' 0 C--N 1.324 -0.517 0 N-CA-C 111.735 0.272 . . . . 0.0 111.735 177.299 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 56.23 18.62 21.46 Favored Glycine 0 C--N 1.34 0.763 0 CA-C-N 116.09 -0.505 . . . . 0.0 114.081 175.046 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 399' ' ' GLU . . . . . 0.908 ' HG3' ' HB3' ' A' ' 424' ' ' LYS . 17.7 tt0 -73.15 -19.15 61.19 Favored 'General case' 0 C--N 1.327 -0.394 0 CA-C-O 121.193 0.52 . . . . 0.0 110.838 -177.751 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -116.7 137.47 52.17 Favored 'General case' 0 C--N 1.314 -0.966 0 CA-C-O 121.18 0.514 . . . . 0.0 110.362 177.974 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 401' ' ' VAL . . . . . 0.472 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 9.0 p -139.46 134.55 39.67 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.871 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.546 173.423 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -131.14 135.18 47.24 Favored 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.172 -179.335 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -151.05 -176.64 24.12 Favored Glycine 0 N--CA 1.438 -1.203 0 C-N-CA 120.177 -1.011 . . . . 0.0 112.152 -177.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 404' ' ' LYS . . . . . 0.675 ' HG2' HG12 ' A' ' 419' ' ' VAL . 27.0 mttm -147.69 162.47 39.1 Favored 'General case' 0 C--N 1.316 -0.859 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 -179.352 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 405' ' ' TYR . . . . . 0.49 ' HB3' HG22 ' A' ' 389' ' ' VAL . 6.9 p90 -124.36 151.22 44.64 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-O 121.251 0.548 . . . . 0.0 111.593 175.644 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . 0.482 ' OG ' ' HA3' ' A' ' 415' ' ' GLY . 28.1 t -129.08 112.89 14.47 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.279 -176.679 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 97.3 m-85 -87.47 140.57 29.39 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.416 -0.356 . . . . 0.0 110.84 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 408' ' ' ARG . . . . . 0.478 ' N ' ' HD3' ' A' ' 409' ' ' PRO . 36.1 mmt180 -136.18 58.21 21.14 Favored Pre-proline 0 C--N 1.327 -0.406 0 CA-C-N 116.028 -0.533 . . . . 0.0 110.531 174.775 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 409' ' ' PRO . . . . . 0.478 ' HD3' ' N ' ' A' ' 408' ' ' ARG . 10.2 Cg_endo -90.19 -59.05 0.02 OUTLIER 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 122.865 2.376 . . . . 0.0 113.116 -176.266 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 410' ' ' THR . . . . . 0.475 ' HB ' ' H ' ' A' ' 411' ' ' ASP . 11.0 p -87.56 -151.24 0.18 Allowed 'General case' 0 C--N 1.324 -0.519 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.5 -175.369 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 411' ' ' ASP . . . . . 0.475 ' H ' ' HB ' ' A' ' 410' ' ' THR . 17.9 t70 -61.38 91.3 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.22 0 CA-C-N 116.275 -0.42 . . . . 0.0 110.757 177.219 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 412' ' ' ALA . . . . . . . . . . . . . . . 61.74 -78.82 0.03 OUTLIER 'General case' 0 N--CA 1.463 0.18 0 O-C-N 123.83 0.706 . . . . 0.0 111.202 -176.944 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 413' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 71.04 132.88 0.04 OUTLIER 'General case' 0 C--N 1.333 -0.146 0 C-N-CA 123.576 0.751 . . . . 0.0 110.76 179.946 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 414' ' ' LYS . . . . . . . . . . . . . 52.2 mtpt -80.78 123.13 27.97 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-N 115.883 -0.599 . . . . 0.0 111.042 -175.57 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 415' ' ' GLY . . . . . 0.482 ' HA3' ' OG ' ' A' ' 406' ' ' SER . . . -102.84 178.32 25.88 Favored Glycine 0 N--CA 1.443 -0.874 0 N-CA-C 111.213 -0.755 . . . . 0.0 111.213 175.702 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 416' ' ' GLY . . . . . . . . . . . . . . . 106.2 -25.75 22.53 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.554 -0.832 . . . . 0.0 111.234 -179.53 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 417' ' ' PHE . . . . . 0.5 ' HB3' ' HB2' ' A' ' 326' ' ' PHE . 64.1 m-85 -77.17 158.72 30.21 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 109.028 -0.73 . . . . 0.0 109.028 174.4 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 418' ' ' GLY . . . . . 0.52 ' HA2' ' HA ' ' A' ' 325' ' ' HIS . . . 82.4 77.32 1.07 Allowed Glycine 0 N--CA 1.442 -0.935 0 C-N-CA 119.78 -1.2 . . . . 0.0 111.447 -175.454 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 419' ' ' VAL . . . . . 0.675 HG12 ' HG2' ' A' ' 404' ' ' LYS . 19.7 m -105.08 146.96 11.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.654 0 N-CA-C 109.616 -0.513 . . . . 0.0 109.616 -178.109 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 420' ' ' PHE . . . . . 0.48 ' HB3' HG22 ' A' ' 323' ' ' VAL . 47.0 p90 -130.29 161.07 32.06 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-O 121.023 0.44 . . . . 0.0 110.696 -179.299 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 421' ' ' ALA . . . . . 0.48 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -153.92 136.54 15.17 Favored 'General case' 0 C--N 1.317 -0.829 0 CA-C-N 115.348 -0.842 . . . . 0.0 109.025 179.821 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -132.54 141.67 13.06 Favored Glycine 0 N--CA 1.446 -0.669 0 C-N-CA 120.187 -1.006 . . . . 0.0 113.052 -177.336 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 72.3 mmtt -102.46 125.56 49.22 Favored 'General case' 0 C--N 1.326 -0.424 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 175.722 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 424' ' ' LYS . . . . . 0.908 ' HB3' ' HG3' ' A' ' 399' ' ' GLU . 80.0 tttt -63.16 105.72 0.75 Allowed 'General case' 0 C--N 1.323 -0.567 0 CA-C-O 121.272 0.558 . . . . 0.0 110.626 178.16 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 10.1 tp10 -76.57 113.56 14.33 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.53 -0.759 . . . . 0.0 109.984 -179.708 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 426' ' ' GLN . . . . . . . . . . . . . 48.0 mt-30 -103.47 109.11 20.63 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 115.403 -0.817 . . . . 0.0 109.55 177.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 427' ' ' ASP . . . . . . . . . . . . . 7.3 p-10 -64.65 -13.73 55.2 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 116.328 -0.397 . . . . 0.0 111.091 -176.725 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . 0.709 ' HG ' ' HB2' ' A' ' 431' ' ' HIS . 29.7 tp -76.27 -13.24 60.17 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.854 179.339 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 429' ' ' GLU . . . . . . . . . . . . . 69.6 mm-40 59.52 39.68 21.37 Favored 'General case' 0 N--CA 1.466 0.361 0 CA-C-N 115.55 -0.75 . . . . 0.0 111.744 178.548 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 430' ' ' HIS . . . . . . . . . . . . . 49.8 m80 73.5 -51.46 0.7 Allowed 'General case' 0 N--CA 1.475 0.789 0 C-N-CA 123.283 0.633 . . . . 0.0 110.818 179.991 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . 0.709 ' HB2' ' HG ' ' A' ' 428' ' ' LEU . 25.9 t-80 60.15 77.81 0.3 Allowed 'General case' 0 C--N 1.329 -0.297 0 C-N-CA 123.402 0.681 . . . . 0.0 112.073 170.551 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 432' ' ' HIS . . . . . . . . . . . . . 36.0 m80 -134.27 -78.71 0.46 Allowed 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.409 -0.36 . . . . 0.0 110.214 174.004 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 433' ' ' HIS . . . . . . . . . . . . . 12.7 t-80 -176.86 -36.42 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.633 -0.258 . . . . 0.0 111.008 -178.674 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 434' ' ' HIS . . . . . . . . . . . . . 24.2 p80 -150.22 -179.82 7.5 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-O 120.825 0.345 . . . . 0.0 110.934 -178.556 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 435' ' ' HIS . . . . . . . . . . . . . 17.9 p80 . . . . . 0 C--O 1.243 0.757 0 CA-C-N 115.604 -0.726 . . . . 0.0 109.206 172.539 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 276' ' ' ASN . . . . . 0.453 ' CG ' HD11 ' A' ' 301' ' ' LEU . 0.9 OUTLIER . . . . . 0 N--CA 1.483 1.218 0 N-CA-C 111.542 0.201 . . . . 0.0 111.542 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.43 HG22 ' O ' ' A' ' 277' ' ' ILE . 25.7 mm -98.03 4.9 9.62 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.35 0 CA-C-O 121.54 0.686 . . . . 0.0 110.889 -174.655 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 278' ' ' PHE . . . . . . . . . . . . . 48.5 p90 -95.16 4.51 53.54 Favored 'General case' 0 C--N 1.323 -0.585 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.52 -176.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 279' ' ' ALA . . . . . 0.936 ' HB2' ' HB3' ' A' ' 301' ' ' LEU . . . -101.05 132.54 21.86 Favored Pre-proline 0 C--N 1.324 -0.51 0 CA-C-O 120.881 0.372 . . . . 0.0 111.954 -174.061 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 280' ' ' PRO . . . . . 0.511 ' HD2' ' O ' ' A' ' 302' ' ' ARG . 33.1 Cg_exo -58.47 147.06 87.98 Favored 'Trans proline' 0 N--CA 1.463 -0.299 0 C-N-CA 122.642 2.228 . . . . 0.0 110.509 168.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 27.1 tt0 -66.5 -19.7 65.85 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 116.012 -0.54 . . . . 0.0 112.245 -171.724 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -76.9 111.35 3.25 Favored Glycine 0 N--CA 1.45 -0.401 0 C-N-CA 120.673 -0.775 . . . . 0.0 111.907 178.538 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 283' ' ' ASN . . . . . . . . . . . . . 40.5 m-80 -79.09 82.91 5.21 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-O 121.198 0.523 . . . . 0.0 110.685 -177.917 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 77.5 m-85 -96.11 146.12 24.92 Favored 'General case' 0 C--N 1.324 -0.543 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.9 178.135 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . 0.514 ' HA ' ' CE2' ' A' ' 289' ' ' TYR . 0.0 OUTLIER -140.5 44.17 1.86 Allowed 'General case' 0 CA--C 1.534 0.363 0 CA-C-O 121.396 0.617 . . . . 0.0 111.517 -175.189 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 76.6 m-85 -120.22 -34.87 3.57 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.302 0.572 . . . . 0.0 110.902 179.807 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . . . . . . . . . 7.2 mp -93.74 -178.48 4.7 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 115.216 -0.902 . . . . 0.0 110.573 -176.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 288' ' ' THR . . . . . . . . . . . . . 25.0 m -77.71 139.14 39.38 Favored 'General case' 0 N--CA 1.448 -0.573 0 N-CA-C 108.375 -0.972 . . . . 0.0 108.375 175.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 289' ' ' TYR . . . . . 1.025 ' HB3' ' HA ' ' A' ' 302' ' ' ARG . 42.6 m-85 -140.95 178.22 7.51 Favored 'General case' 0 C--N 1.327 -0.404 0 O-C-N 123.605 0.566 . . . . 0.0 110.185 -175.015 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.727 ' O ' ' HB2' ' A' ' 301' ' ' LEU . . . -136.85 134.1 6.9 Favored Glycine 0 CA--C 1.495 -1.217 0 N-CA-C 107.459 -2.256 . . . . 0.0 107.459 175.161 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 291' ' ' ALA . . . . . 0.637 ' HB2' ' O ' ' A' ' 301' ' ' LEU . . . -155.49 131.95 10.35 Favored 'General case' 0 C--N 1.31 -1.123 0 CA-C-N 117.748 0.774 . . . . 0.0 111.025 -162.599 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 292' ' ' GLU . . . . . 0.586 ' H ' ' CD2' ' A' ' 301' ' ' LEU . 4.0 pm0 -123.76 109.65 13.94 Favored 'General case' 0 C--N 1.325 -0.491 0 N-CA-C 108.703 -0.851 . . . . 0.0 108.703 162.234 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 293' ' ' LYS . . . . . 0.71 ' HB2' ' HB2' ' A' ' 300' ' ' ALA . 63.7 tttp -95.41 127.82 41.76 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.495 -0.775 . . . . 0.0 111.335 -173.7 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 294' ' ' LEU . . . . . 0.653 HD23 ' HB2' ' A' ' 298' ' ' SER . 3.9 mm? -110.11 141.76 24.5 Favored Pre-proline 0 C--N 1.318 -0.786 0 CA-C-N 115.319 -0.855 . . . . 0.0 109.133 174.408 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 295' ' ' PRO . . . . . 0.432 ' HD3' ' HA ' ' A' ' 294' ' ' LEU . 7.3 Cg_exo -74.3 41.14 0.65 Allowed 'Trans proline' 0 CA--C 1.53 0.277 0 C-N-CA 123.27 2.647 . . . . 0.0 112.658 -178.284 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . 156.43 91.98 0.09 OUTLIER Glycine 0 N--CA 1.444 -0.77 0 C-N-CA 121.12 -0.562 . . . . 0.0 112.184 -178.34 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 116.41 -95.41 0.68 Allowed Glycine 0 N--CA 1.449 -0.492 0 C-N-CA 121.012 -0.613 . . . . 0.0 111.827 178.321 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 298' ' ' SER . . . . . 0.653 ' HB2' HD23 ' A' ' 294' ' ' LEU . 15.5 m -64.23 137.94 58.19 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-O 121.017 0.437 . . . . 0.0 110.316 178.959 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 299' ' ' TYR . . . . . . . . . . . . . 19.3 p90 -113.13 175.04 5.61 Favored 'General case' 0 C--N 1.316 -0.879 0 CA-C-N 116.077 -0.511 . . . . 0.0 111.26 -172.359 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 300' ' ' ALA . . . . . 0.71 ' HB2' ' HB2' ' A' ' 293' ' ' LYS . . . -80.52 113.72 18.9 Favored 'General case' 0 C--N 1.321 -0.644 0 CA-C-N 115.87 -0.604 . . . . 0.0 109.938 179.25 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 301' ' ' LEU . . . . . 0.936 ' HB3' ' HB2' ' A' ' 279' ' ' ALA . 0.3 OUTLIER -80.19 166.77 21.1 Favored 'General case' 0 C--N 1.324 -0.535 0 CA-C-O 122.014 0.912 . . . . 0.0 112.157 -172.548 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 302' ' ' ARG . . . . . 1.025 ' HA ' ' HB3' ' A' ' 289' ' ' TYR . 14.9 mmt180 -137.71 122.74 19.06 Favored 'General case' 0 C--N 1.31 -1.121 0 CA-C-N 114.456 -1.247 . . . . 0.0 108.275 -178.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 303' ' ' VAL . . . . . 0.663 ' O ' ' HA ' ' A' ' 289' ' ' TYR . 9.2 p -145.12 138.92 22.19 Favored 'Isoleucine or valine' 0 C--O 1.223 -0.329 0 N-CA-C 112.18 0.437 . . . . 0.0 112.18 -178.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 304' ' ' GLN . . . . . . . . . . . . . 50.6 mt-30 -90.12 162.12 15.45 Favored 'General case' 0 C--N 1.319 -0.736 0 N-CA-C 109.555 -0.535 . . . . 0.0 109.555 172.813 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -94.42 115.23 4.99 Favored Glycine 0 N--CA 1.444 -0.814 0 C-N-CA 120.379 -0.915 . . . . 0.0 112.088 -175.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 306' ' ' GLU . . . . . 0.518 ' O ' ' HA2' ' A' ' 395' ' ' GLY . 7.3 pt-20 -116.48 173.03 3.3 Favored Pre-proline 0 C--N 1.323 -0.587 0 N-CA-C 108.986 -0.746 . . . . 0.0 108.986 178.829 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . 0.441 ' HD2' ' HB2' ' A' ' 306' ' ' GLU . 52.8 Cg_exo -56.52 124.51 16.43 Favored 'Trans proline' 0 CA--C 1.533 0.441 0 C-N-CA 122.008 1.805 . . . . 0.0 112.672 174.339 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . 0.626 ' HB2' ' O ' ' A' ' 394' ' ' TYR . . . -47.51 153.88 0.5 Allowed 'General case' 0 N--CA 1.467 0.377 0 CA-C-O 121.137 0.494 . . . . 0.0 111.965 170.091 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 309' ' ' LYS . . . . . 0.677 ' O ' ' HG ' ' A' ' 313' ' ' LEU . 65.9 mmtt -91.76 88.28 6.62 Favored 'General case' 0 C--N 1.321 -0.67 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 178.157 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 310' ' ' GLY . . . . . 0.627 ' HA2' HD12 ' A' ' 313' ' ' LEU . . . -58.31 -40.22 93.73 Favored Glycine 0 C--N 1.333 0.41 0 C-N-CA 121.616 -0.326 . . . . 0.0 113.818 -171.213 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . 0.408 ' HG2' ' HG2' ' A' ' 312' ' ' MET . 0.2 OUTLIER -72.61 -19.97 61.37 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 120.818 0.342 . . . . 0.0 110.95 -178.4 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 312' ' ' MET . . . . . 0.408 ' HG2' ' HG2' ' A' ' 311' ' ' GLU . 78.3 mmm -108.43 6.48 26.3 Favored 'General case' 0 C--N 1.326 -0.432 0 CA-C-O 120.812 0.339 . . . . 0.0 111.192 -178.687 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 313' ' ' LEU . . . . . 0.677 ' HG ' ' O ' ' A' ' 309' ' ' LYS . 91.9 mt -75.47 133.8 40.99 Favored 'General case' 0 C--N 1.325 -0.487 0 N-CA-C 109.241 -0.651 . . . . 0.0 109.241 175.224 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -151.61 139.4 19.85 Favored 'General case' 0 C--N 1.319 -0.749 0 CA-C-N 116.064 -0.516 . . . . 0.0 111.773 -172.939 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.23 161.81 11.63 Favored Glycine 0 N--CA 1.448 -0.556 0 N-CA-C 111.306 -0.718 . . . . 0.0 111.306 178.822 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 21.7 p -97.82 135.01 40.19 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 109.308 -0.627 . . . . 0.0 109.308 173.044 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -133.47 151.51 51.79 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.78 -172.166 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -120.75 110.4 28.26 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.533 0 CA-C-N 115.439 -0.8 . . . . 0.0 109.384 175.956 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . 0.707 ' O ' ' HA ' ' A' ' 341' ' ' ALA . 90.9 m-85 -99.18 127.49 45.16 Favored 'General case' 0 C--N 1.312 -1.04 0 C-N-CA 120.327 -0.549 . . . . 0.0 110.424 178.327 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 48.0 m-80 -120.85 132.74 55.17 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.697 -0.683 . . . . 0.0 109.377 178.834 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . 0.566 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -166.53 -154.18 8.2 Favored Glycine 0 N--CA 1.444 -0.822 0 C-N-CA 120.493 -0.861 . . . . 0.0 112.54 -179.598 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 3.7 mp0 -116.12 153.95 30.87 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-O 121.056 0.455 . . . . 0.0 111.122 -174.168 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 323' ' ' VAL . . . . . 0.559 HG23 ' HB2' ' A' ' 340' ' ' PHE . 72.5 t -112.06 117.44 55.19 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.682 0 CA-C-N 115.355 -0.839 . . . . 0.0 109.208 172.397 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 324' ' ' LEU . . . . . 0.47 ' HB2' HG22 ' A' ' 419' ' ' VAL . 93.7 mt -95.69 104.31 16.22 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-O 121.129 0.49 . . . . 0.0 110.298 -177.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 325' ' ' HIS . . . . . . . . . . . . . 9.8 t-80 -98.52 113.98 26.21 Favored 'General case' 0 C--N 1.322 -0.613 0 N-CA-C 109.26 -0.644 . . . . 0.0 109.26 179.512 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 326' ' ' PHE . . . . . 0.515 ' HD2' ' H ' ' A' ' 418' ' ' GLY . 57.9 m-85 -89.29 150.08 22.76 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.377 -174.954 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 327' ' ' HIS . . . . . . . . . . . . . 1.8 p-80 -157.92 115.64 3.02 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.885 -0.598 . . . . 0.0 110.886 -179.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 328' ' ' THR . . . . . . . . . . . . . 6.5 p -89.31 99.57 12.54 Favored 'General case' 0 N--CA 1.445 -0.724 0 N-CA-C 109.422 -0.584 . . . . 0.0 109.422 173.214 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 329' ' ' GLU . . . . . 0.512 ' HG3' ' HD3' ' A' ' 332' ' ' ARG . 63.9 mm-40 -104.6 173.38 6.33 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.043 -177.097 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 330' ' ' ASN . . . . . . . . . . . . . 89.8 m-20 -60.77 -58.45 8.38 Favored 'General case' 0 C--N 1.325 -0.495 0 N-CA-C 109.835 -0.432 . . . . 0.0 109.835 177.086 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 331' ' ' GLY . . . . . . . . . . . . . . . -143.68 89.39 0.17 Allowed Glycine 0 N--CA 1.446 -0.637 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 174.064 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 332' ' ' ARG . . . . . 0.512 ' HD3' ' HG3' ' A' ' 329' ' ' GLU . 77.7 ttt180 -177.74 78.06 0.23 Allowed Pre-proline 0 C--N 1.325 -0.492 0 N-CA-C 109.283 -0.636 . . . . 0.0 109.283 -173.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 333' ' ' PRO . . . . . . . . . . . . . 84.3 Cg_endo -83.73 -179.47 4.16 Favored 'Trans proline' 0 N--CA 1.46 -0.452 0 C-N-CA 122.946 2.431 . . . . 0.0 113.031 -175.548 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 334' ' ' TYR . . . . . 0.449 ' HA ' ' HD3' ' A' ' 335' ' ' PRO . 79.2 m-85 73.5 116.51 0.03 OUTLIER Pre-proline 0 C--O 1.235 0.293 0 CA-C-N 115.094 -0.957 . . . . 0.0 112.076 176.812 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 335' ' ' PRO . . . . . 0.449 ' HD3' ' HA ' ' A' ' 334' ' ' TYR . 13.8 Cg_exo -68.87 128.82 17.45 Favored 'Trans proline' 0 N--CA 1.461 -0.44 0 C-N-CA 122.817 2.345 . . . . 0.0 111.056 175.229 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 336' ' ' THR . . . . . . . . . . . . . 23.2 p -70.89 139.22 50.71 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 116.418 -0.355 . . . . 0.0 110.332 -178.158 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 337' ' ' ARG . . . . . . . . . . . . . 51.9 mtm180 -101.42 112.31 24.8 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-O 120.911 0.386 . . . . 0.0 110.268 -177.721 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -90.52 -177.13 44.36 Favored Glycine 0 N--CA 1.44 -1.08 0 N-CA-C 110.327 -1.109 . . . . 0.0 110.327 172.827 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 339' ' ' ARG . . . . . 0.886 ' HB2' ' HB3' ' A' ' 356' ' ' ASP . 65.1 mtt180 -104.49 154.92 19.28 Favored 'General case' 0 C--N 1.314 -0.966 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 176.237 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 340' ' ' PHE . . . . . 0.559 ' HB2' HG23 ' A' ' 323' ' ' VAL . 27.0 t80 -148.74 139.02 22.42 Favored 'General case' 0 C--N 1.309 -1.16 0 CA-C-O 121.165 0.507 . . . . 0.0 110.494 179.161 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 341' ' ' ALA . . . . . 0.707 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -136.84 164.2 28.87 Favored 'General case' 0 C--N 1.316 -0.863 0 CA-C-N 114.967 -1.015 . . . . 0.0 108.908 175.809 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . 0.849 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -151.76 120.11 6.39 Favored 'General case' 0 C--N 1.314 -0.943 0 N-CA-C 109.654 -0.499 . . . . 0.0 109.654 -179.758 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 13.0 tptm -100.81 98.43 8.95 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 108.392 -0.966 . . . . 0.0 108.392 179.727 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 344' ' ' VAL . . . . . 0.491 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.2 OUTLIER -118.45 136.93 54.05 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.828 0 CA-C-N 115.833 -0.621 . . . . 0.0 112.176 -169.576 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 10.4 t0 -107.23 113.0 26.13 Favored 'General case' 0 C--N 1.321 -0.63 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 171.194 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 346' ' ' PHE . . . . . . . . . . . . . 48.4 m-85 -74.77 -27.64 60.42 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 111.701 0.26 . . . . 0.0 111.701 -176.091 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -61.87 -33.36 85.13 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.695 -0.764 . . . . 0.0 111.654 177.198 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 6.8 t -101.59 -4.48 26.57 Favored 'General case' 0 CA--C 1.534 0.365 0 CA-C-O 120.688 0.28 . . . . 0.0 111.083 178.162 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 349' ' ' LYS . . . . . 0.479 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 10.0 mtmp? 51.28 59.05 4.88 Favored 'General case' 0 N--CA 1.466 0.362 0 C-N-CA 123.148 0.579 . . . . 0.0 111.543 -178.265 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 40.2 m -149.6 140.51 22.83 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.846 -0.616 . . . . 0.0 110.14 -179.869 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 351' ' ' VAL . . . . . 0.517 HG22 ' HB3' ' A' ' 370' ' ' ALA . 0.8 OUTLIER -129.08 156.43 41.68 Favored 'Isoleucine or valine' 0 C--O 1.236 0.369 0 CA-C-O 121.289 0.566 . . . . 0.0 111.147 -175.665 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 352' ' ' ASP . . . . . 0.849 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 17.9 t70 -111.72 119.19 37.79 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 114.981 -1.009 . . . . 0.0 108.414 166.493 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -111.31 120.81 5.57 Favored Glycine 0 C--N 1.306 -1.11 0 C-N-CA 120.621 -0.8 . . . . 0.0 111.369 -178.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 354' ' ' ILE . . . . . 0.536 HG12 ' N ' ' A' ' 355' ' ' ILE . 0.2 OUTLIER -121.29 140.9 43.96 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.233 0 CA-C-O 121.084 0.469 . . . . 0.0 110.577 -176.233 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 355' ' ' ILE . . . . . 0.916 ' HB ' ' HB2' ' A' ' 366' ' ' GLN . 3.1 mp -114.2 98.27 6.74 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.904 0 CA-C-N 115.667 -0.697 . . . . 0.0 109.26 177.614 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 356' ' ' ASP . . . . . 0.886 ' HB3' ' HB2' ' A' ' 339' ' ' ARG . 18.5 t70 -78.68 92.3 4.75 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 115.061 -0.972 . . . . 0.0 108.908 178.217 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 81.2 p -70.56 -29.37 65.8 Favored 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.783 -0.644 . . . . 0.0 111.392 -174.057 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 358' ' ' GLY . . . . . . . . . . . . . . . 94.87 -5.56 69.22 Favored Glycine 0 N--CA 1.444 -0.785 0 N-CA-C 110.657 -0.977 . . . . 0.0 110.657 -174.365 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 359' ' ' ASP . . . . . 0.416 ' OD2' ' HB2' ' A' ' 362' ' ' HIS . 25.9 t70 -129.18 26.89 5.42 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 122.106 0.955 . . . . 0.0 108.459 176.754 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 360' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -61.12 -28.78 69.34 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 114.58 -1.191 . . . . 0.0 111.121 -176.816 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 361' ' ' LEU . . . . . 0.468 ' N ' HD22 ' A' ' 361' ' ' LEU . 3.2 mm? -73.76 -27.0 60.94 Favored 'General case' 0 N--CA 1.447 -0.605 0 CA-C-N 115.965 -0.562 . . . . 0.0 111.643 179.623 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 362' ' ' HIS . . . . . 0.416 ' HB2' ' OD2' ' A' ' 359' ' ' ASP . 72.4 m-70 -100.7 -73.35 0.64 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-O 120.711 0.291 . . . . 0.0 110.654 -175.641 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 363' ' ' MET . . . . . . . . . . . . . 53.9 ttp -66.25 -47.61 73.16 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.612 -179.584 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 364' ' ' GLY . . . . . . . . . . . . . . . 139.68 160.48 8.36 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.978 -0.63 . . . . 0.0 111.738 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 365' ' ' THR . . . . . . . . . . . . . 8.9 t -92.82 152.64 19.32 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 110.139 -0.319 . . . . 0.0 110.139 179.265 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 366' ' ' GLN . . . . . 0.916 ' HB2' ' HB ' ' A' ' 355' ' ' ILE . 41.2 mt-30 -114.65 130.83 56.85 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 110.09 -0.337 . . . . 0.0 110.09 179.069 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 367' ' ' LYS . . . . . 0.816 ' HB3' ' HG2' ' A' ' 383' ' ' GLU . 26.2 ttmt -148.43 139.8 23.43 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-N 116.181 -0.463 . . . . 0.0 109.752 -178.777 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 368' ' ' PHE . . . . . . . . . . . . . 52.3 p90 -139.06 145.12 39.18 Favored 'General case' 0 C--N 1.321 -0.663 0 O-C-N 123.33 0.394 . . . . 0.0 110.365 176.69 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 369' ' ' LYS . . . . . 0.436 ' HE2' ' HD3' ' A' ' 367' ' ' LYS . 3.4 mptp? -106.74 131.94 53.29 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.244 -0.65 . . . . 0.0 109.244 175.626 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . 0.517 ' HB3' HG22 ' A' ' 351' ' ' VAL . . . -135.64 135.89 40.54 Favored 'General case' 0 C--N 1.32 -0.699 0 CA-C-N 115.745 -0.661 . . . . 0.0 111.549 -172.325 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -92.89 133.88 35.65 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 115.918 -0.583 . . . . 0.0 109.761 176.233 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 372' ' ' ILE . . . . . 0.479 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 87.4 mt -82.17 108.11 14.83 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 121.191 0.52 . . . . 0.0 110.405 -178.961 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 28.5 t70 -109.61 81.18 1.4 Allowed 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.485 -0.78 . . . . 0.0 109.096 178.955 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 374' ' ' GLY . . . . . 0.623 ' HA2' ' HA3' ' A' ' 310' ' ' GLY . . . 53.79 118.95 0.01 OUTLIER Glycine 0 CA--C 1.524 0.61 0 CA-C-N 114.992 -1.004 . . . . 0.0 114.841 -176.108 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 375' ' ' ASN . . . . . 0.526 ' HB2' ' O ' ' A' ' 308' ' ' ALA . 40.2 t30 40.69 44.28 1.81 Allowed 'General case' 0 N--CA 1.47 0.566 0 CA-C-O 122.053 0.93 . . . . 0.0 112.182 175.506 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 156.66 167.79 18.41 Favored Glycine 0 N--CA 1.442 -0.931 0 C-N-CA 120.302 -0.952 . . . . 0.0 111.608 176.065 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 377' ' ' PHE . . . . . 0.507 ' CD2' HG11 ' A' ' 351' ' ' VAL . 2.3 p90 -133.44 143.8 49.08 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-O 121.34 0.59 . . . . 0.0 111.5 -179.18 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 378' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.67 125.29 47.31 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-N 114.887 -1.051 . . . . 0.0 108.262 174.983 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -142.26 -165.3 10.47 Favored Glycine 0 N--CA 1.44 -1.055 0 C-N-CA 120.361 -0.923 . . . . 0.0 112.587 -176.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 95.4 m -142.46 147.05 35.45 Favored 'General case' 0 N--CA 1.439 -1.02 0 N-CA-C 109.978 -0.378 . . . . 0.0 109.978 -176.719 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 381' ' ' TRP . . . . . 0.633 ' HB3' ' HB3' ' A' ' 384' ' ' ASN . 42.0 m95 -56.25 117.37 3.72 Favored 'General case' 0 C--N 1.331 -0.214 0 O-C-N 123.633 0.583 . . . . 0.0 111.43 178.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 382' ' ' THR . . . . . . . . . . . . . 71.0 m -83.49 -58.18 2.93 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-N 115.682 -0.69 . . . . 0.0 110.803 -176.742 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 383' ' ' GLU . . . . . 0.816 ' HG2' ' HB3' ' A' ' 367' ' ' LYS . 57.9 mm-40 -85.82 53.99 2.97 Favored 'General case' 0 C--N 1.329 -0.3 0 N-CA-C 109.98 -0.378 . . . . 0.0 109.98 179.694 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 384' ' ' ASN . . . . . 0.633 ' HB3' ' HB3' ' A' ' 381' ' ' TRP . 4.6 t30 -175.7 -45.04 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 116.124 -0.489 . . . . 0.0 110.113 -176.587 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 385' ' ' GLY . . . . . . . . . . . . . . . 60.24 55.74 28.46 Favored Glycine 0 C--N 1.331 0.29 0 C-N-CA 120.636 -0.792 . . . . 0.0 111.417 -176.387 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 386' ' ' GLY . . . . . . . . . . . . . . . -118.01 -96.73 1.83 Allowed Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.608 -0.806 . . . . 0.0 113.153 -173.787 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . 0.437 ' H ' ' HD1' ' A' ' 381' ' ' TRP . . . -107.37 -170.86 22.12 Favored Glycine 0 N--CA 1.446 -0.666 0 C-N-CA 120.539 -0.839 . . . . 0.0 113.327 -174.322 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 388' ' ' ASP . . . . . 0.565 ' HB2' ' HB3' ' A' ' 406' ' ' SER . 6.6 m-20 -89.73 159.07 17.25 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 -177.407 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 79.6 t -135.67 135.99 50.75 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 109.531 -0.544 . . . . 0.0 109.531 174.166 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 16.9 m -143.11 141.68 31.3 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 120.8 0.334 . . . . 0.0 110.692 -179.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 391' ' ' GLY . . . . . 0.435 ' HA2' ' CA ' ' A' ' 403' ' ' GLY . . . -145.36 155.9 26.7 Favored Glycine 0 C--N 1.316 -0.581 0 N-CA-C 111.487 -0.645 . . . . 0.0 111.487 -178.515 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 392' ' ' ARG . . . . . 0.526 ' HD3' ' O ' ' A' ' 375' ' ' ASN . 25.0 tpp180 -117.07 135.62 53.59 Favored 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 120.768 0.318 . . . . 0.0 110.24 -175.751 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -85.12 165.23 17.63 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.759 -0.655 . . . . 0.0 109.951 176.317 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 394' ' ' TYR . . . . . 0.626 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 4.8 m-85 -109.58 -177.38 3.26 Favored 'General case' 0 C--N 1.315 -0.933 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.99 -177.947 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 395' ' ' GLY . . . . . 0.518 ' HA2' ' O ' ' A' ' 306' ' ' GLU . . . -37.83 160.72 0.01 OUTLIER Glycine 0 C--N 1.336 0.541 0 O-C-N 124.492 1.12 . . . . 0.0 114.922 -176.625 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_exo -17.25 -40.46 0.0 OUTLIER 'Trans proline' 0 C--N 1.353 0.78 1 C-N-CA 127.773 5.649 . . . . 0.0 118.501 -165.122 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 397' ' ' ALA . . . . . 0.552 ' HB1' ' HG3' ' A' ' 399' ' ' GLU . . . -81.16 -20.24 41.69 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-N 118.754 0.706 . . . . 0.0 111.633 -171.536 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 60.96 10.63 20.78 Favored Glycine 0 C--N 1.338 0.682 0 C-N-CA 121.409 -0.424 . . . . 0.0 112.725 176.668 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 399' ' ' GLU . . . . . 0.552 ' HG3' ' HB1' ' A' ' 397' ' ' ALA . 30.5 mt-10 -70.19 -8.93 53.82 Favored 'General case' 0 N--CA 1.451 -0.406 0 CA-C-O 121.66 0.743 . . . . 0.0 110.123 -178.378 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 400' ' ' GLU . . . . . 0.408 ' HB2' ' HB2' ' A' ' 394' ' ' TYR . 41.9 mt-10 -117.54 128.36 54.89 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 114.808 -1.087 . . . . 0.0 109.82 175.16 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 401' ' ' VAL . . . . . 0.46 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 10.1 p -140.87 140.49 32.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-O 120.844 0.354 . . . . 0.0 110.517 177.888 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -142.16 131.34 23.38 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 116.382 -0.372 . . . . 0.0 110.269 178.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 403' ' ' GLY . . . . . 0.435 ' CA ' ' HA2' ' A' ' 391' ' ' GLY . . . -145.02 -169.04 13.2 Favored Glycine 0 N--CA 1.438 -1.18 0 C-N-CA 120.47 -0.872 . . . . 0.0 112.271 -177.153 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 404' ' ' LYS . . . . . 0.775 ' HG2' HG12 ' A' ' 419' ' ' VAL . 37.5 mtpt -148.8 169.11 21.22 Favored 'General case' 0 C--N 1.32 -0.676 0 N-CA-C 108.515 -0.92 . . . . 0.0 108.515 -178.344 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 5.8 m-85 -113.54 134.75 54.52 Favored 'General case' 0 C--N 1.32 -0.712 0 N-CA-C 109.446 -0.576 . . . . 0.0 109.446 177.287 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . 0.565 ' HB3' ' HB2' ' A' ' 388' ' ' ASP . 47.5 t -95.04 103.65 15.5 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 109.474 -0.565 . . . . 0.0 109.474 -179.915 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 86.6 m-85 -82.95 105.96 14.38 Favored 'General case' 0 C--N 1.322 -0.618 0 CA-C-O 121.281 0.563 . . . . 0.0 110.329 -179.62 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 408' ' ' ARG . . . . . 0.57 ' HB2' ' HD3' ' A' ' 409' ' ' PRO . 98.3 mtt180 -62.21 -47.63 89.59 Favored Pre-proline 0 CA--C 1.536 0.408 0 CA-C-N 115.07 -0.968 . . . . 0.0 111.938 -179.782 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 409' ' ' PRO . . . . . 0.57 ' HD3' ' HB2' ' A' ' 408' ' ' ARG . 12.4 Cg_exo -71.83 56.73 2.43 Favored 'Trans proline' 0 C--N 1.358 1.068 0 C-N-CA 122.312 2.008 . . . . 0.0 112.848 178.09 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 410' ' ' THR . . . . . . . . . . . . . 2.0 p -109.21 -58.09 2.08 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 116.005 -0.543 . . . . 0.0 109.585 173.627 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 411' ' ' ASP . . . . . . . . . . . . . 37.1 t70 -172.14 -67.22 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.226 -0.897 . . . . 0.0 109.371 175.649 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 412' ' ' ALA . . . . . . . . . . . . . . . -161.24 -48.47 0.04 OUTLIER 'General case' 0 C--N 1.327 -0.41 0 CA-C-N 115.877 -0.601 . . . . 0.0 109.668 176.459 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 413' ' ' GLU . . . . . . . . . . . . . 6.0 tp10 -77.62 82.89 4.02 Favored 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 108.913 -0.773 . . . . 0.0 108.913 173.928 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 414' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -85.46 123.02 30.43 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-O 121.368 0.604 . . . . 0.0 111.777 -175.547 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 415' ' ' GLY . . . . . . . . . . . . . . . 147.1 133.36 2.4 Favored Glycine 0 N--CA 1.447 -0.574 0 CA-C-N 115.41 -0.814 . . . . 0.0 111.423 177.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 416' ' ' GLY . . . . . . . . . . . . . . . 164.96 -105.56 0.25 Allowed Glycine 0 N--CA 1.447 -0.613 0 C-N-CA 120.289 -0.958 . . . . 0.0 112.481 178.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 417' ' ' PHE . . . . . 0.478 ' HB2' ' HB2' ' A' ' 326' ' ' PHE . 35.2 p90 -68.49 167.08 15.59 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-O 120.973 0.416 . . . . 0.0 111.144 -178.304 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 418' ' ' GLY . . . . . 0.515 ' H ' ' HD2' ' A' ' 326' ' ' PHE . . . 83.93 76.49 1.16 Allowed Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.851 -0.69 . . . . 0.0 112.3 179.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 419' ' ' VAL . . . . . 0.775 HG12 ' HG2' ' A' ' 404' ' ' LYS . 16.0 m -115.64 160.06 15.21 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.474 0 N-CA-C 110.429 -0.211 . . . . 0.0 110.429 178.992 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 38.7 p90 -138.41 158.65 43.86 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-O 121.068 0.461 . . . . 0.0 110.506 178.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 421' ' ' ALA . . . . . 0.566 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -146.44 136.68 23.7 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-N 115.61 -0.723 . . . . 0.0 109.346 176.627 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -130.34 139.97 11.38 Favored Glycine 0 N--CA 1.446 -0.698 0 C-N-CA 120.566 -0.826 . . . . 0.0 111.71 -179.365 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 72.1 mttt -117.66 136.4 53.35 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 121.173 0.511 . . . . 0.0 110.616 179.476 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 424' ' ' LYS . . . . . 0.513 ' HG2' ' OE2' ' A' ' 399' ' ' GLU . 23.0 tptm -59.0 125.82 25.17 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 114.838 -1.074 . . . . 0.0 113.126 -174.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -88.29 118.06 27.63 Favored 'General case' 0 N--CA 1.446 -0.651 0 N-CA-C 108.363 -0.977 . . . . 0.0 108.363 166.27 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 426' ' ' GLN . . . . . . . . . . . . . 26.4 mp0 -67.03 144.43 56.17 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-O 121.213 0.53 . . . . 0.0 110.85 -177.096 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 427' ' ' ASP . . . . . . . . . . . . . 10.0 p-10 -84.54 26.48 0.79 Allowed 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 115.631 -0.713 . . . . 0.0 110.884 -177.273 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 62.1 tp -65.09 -52.8 53.4 Favored 'General case' 0 C--N 1.325 -0.475 0 CA-C-N 115.933 -0.576 . . . . 0.0 110.965 -178.548 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 429' ' ' GLU . . . . . . . . . . . . . 39.0 tt0 54.4 63.04 2.3 Favored 'General case' 0 C--O 1.236 0.368 0 CA-C-O 121.664 0.745 . . . . 0.0 109.954 -178.25 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 430' ' ' HIS . . . . . . . . . . . . . 72.8 t60 -70.11 -49.59 49.26 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.426 -178.07 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 32.0 t-80 -175.84 -52.74 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.441 0 N-CA-C 108.864 -0.791 . . . . 0.0 108.864 177.699 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 432' ' ' HIS . . . . . . . . . . . . . 51.6 t60 -68.34 139.7 55.88 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.227 -0.897 . . . . 0.0 109.481 173.517 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 433' ' ' HIS . . . . . . . . . . . . . 6.0 t-160 64.1 69.36 0.53 Allowed 'General case' 0 N--CA 1.463 0.194 0 O-C-N 123.707 0.629 . . . . 0.0 109.82 179.605 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 434' ' ' HIS . . . . . . . . . . . . . 1.6 t-80 -75.56 -12.63 60.26 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.362 -0.835 . . . . 0.0 110.601 -175.937 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 435' ' ' HIS . . . . . . . . . . . . . 5.8 t60 . . . . . 0 C--O 1.247 0.943 0 CA-C-O 118.644 -0.693 . . . . 0.0 109.655 -179.889 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 276' ' ' ASN . . . . . . . . . . . . . 7.6 t30 . . . . . 0 N--CA 1.479 0.976 0 CA-C-O 120.404 0.145 . . . . 0.0 111.055 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.407 HG22 ' HB2' ' A' ' 293' ' ' LYS . 38.1 pt -80.03 38.36 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.434 0 N-CA-C 113.674 0.991 . . . . 0.0 113.674 -172.379 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 278' ' ' PHE . . . . . 0.455 ' HE1' ' HA3' ' A' ' 290' ' ' GLY . 10.4 p90 -80.77 -11.63 59.58 Favored 'General case' 0 C--N 1.327 -0.396 0 O-C-N 122.198 -0.314 . . . . 0.0 111.821 -178.503 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 279' ' ' ALA . . . . . 0.629 ' HB2' ' HA ' ' A' ' 304' ' ' GLN . . . -126.95 78.22 74.19 Favored Pre-proline 0 C--N 1.328 -0.35 0 CA-C-O 120.902 0.382 . . . . 0.0 110.151 176.335 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 280' ' ' PRO . . . . . . . . . . . . . 89.7 Cg_endo -83.97 120.62 2.67 Favored 'Trans proline' 0 N--CA 1.457 -0.628 0 C-N-CA 122.629 2.219 . . . . 0.0 113.635 -175.551 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 5.3 mm-40 72.76 161.92 0.25 Allowed 'General case' 0 N--CA 1.469 0.507 0 CA-C-O 121.635 0.731 . . . . 0.0 112.91 174.093 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 87.07 99.12 0.84 Allowed Glycine 0 N--CA 1.444 -0.786 0 CA-C-N 115.031 -0.986 . . . . 0.0 112.329 179.563 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 283' ' ' ASN . . . . . . . . . . . . . 62.1 t30 -79.33 83.5 5.35 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-O 120.942 0.401 . . . . 0.0 110.29 178.28 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . 0.983 ' HB2' HG21 ' A' ' 303' ' ' VAL . 55.6 m-85 -101.08 146.79 26.99 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.538 -0.541 . . . . 0.0 109.538 175.866 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 38.2 ttp180 -132.67 18.76 4.26 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-O 121.347 0.594 . . . . 0.0 110.521 -173.732 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 77.8 m-85 -137.13 35.92 2.55 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.656 0.741 . . . . 0.0 110.013 -177.085 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . 0.47 ' HB2' ' HB ' ' A' ' 303' ' ' VAL . 36.7 mt -134.77 -179.59 5.7 Favored 'General case' 0 C--N 1.318 -0.764 0 CA-C-N 114.624 -1.171 . . . . 0.0 110.668 -177.021 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 288' ' ' THR . . . . . . . . . . . . . 2.8 m -70.86 149.57 46.66 Favored 'General case' 0 C--O 1.218 -0.587 0 N-CA-C 107.357 -1.349 . . . . 0.0 107.357 178.158 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 289' ' ' TYR . . . . . 0.61 ' HA ' ' HA ' ' A' ' 303' ' ' VAL . 2.0 m-85 -102.29 150.22 23.53 Favored 'General case' 0 C--N 1.318 -0.799 0 CA-C-O 121.878 0.847 . . . . 0.0 112.927 -169.59 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.455 ' HA3' ' HE1' ' A' ' 278' ' ' PHE . . . -156.93 -153.22 6.57 Favored Glycine 0 N--CA 1.44 -1.038 0 CA-C-N 113.852 -1.522 . . . . 0.0 110.436 -173.983 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 291' ' ' ALA . . . . . . . . . . . . . . . -121.65 154.08 37.29 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.267 0.556 . . . . 0.0 112.322 -176.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 292' ' ' GLU . . . . . . . . . . . . . 5.9 tp10 -133.64 158.2 43.82 Favored 'General case' 0 C--N 1.326 -0.452 0 N-CA-C 107.56 -1.274 . . . . 0.0 107.56 173.45 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 293' ' ' LYS . . . . . 0.407 ' HB2' HG22 ' A' ' 277' ' ' ILE . 28.1 tptp -103.58 135.75 44.59 Favored 'General case' 0 C--N 1.322 -0.621 0 CA-C-O 121.129 0.49 . . . . 0.0 111.451 -176.682 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 294' ' ' LEU . . . . . . . . . . . . . 69.7 mt -104.17 135.51 19.33 Favored Pre-proline 0 C--N 1.32 -0.69 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.204 173.607 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 295' ' ' PRO . . . . . . . . . . . . . 50.3 Cg_exo -54.25 106.14 0.16 Allowed 'Trans proline' 0 C--O 1.234 0.312 0 C-N-CA 122.943 2.429 . . . . 0.0 112.267 -179.329 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . 129.65 -139.39 10.92 Favored Glycine 0 N--CA 1.444 -0.783 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 -177.671 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . -108.42 38.23 3.43 Favored Glycine 0 N--CA 1.447 -0.568 0 C-N-CA 120.875 -0.679 . . . . 0.0 112.527 -179.334 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 298' ' ' SER . . . . . . . . . . . . . 20.1 m -127.49 151.01 49.4 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-O 121.14 0.495 . . . . 0.0 111.447 179.868 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 299' ' ' TYR . . . . . . . . . . . . . 76.8 m-85 -117.95 154.2 32.33 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.601 -0.727 . . . . 0.0 109.458 174.982 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 300' ' ' ALA . . . . . . . . . . . . . . . -122.4 149.44 43.81 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 109.821 -0.437 . . . . 0.0 109.821 179.667 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 301' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -110.55 115.3 29.37 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 121.358 0.599 . . . . 0.0 110.171 178.853 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 302' ' ' ARG . . . . . 0.631 ' HG3' ' H ' ' A' ' 303' ' ' VAL . 16.4 tpp180 -146.94 -178.89 6.44 Favored 'General case' 0 C--N 1.317 -0.819 0 N-CA-C 108.116 -1.068 . . . . 0.0 108.116 179.86 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 303' ' ' VAL . . . . . 0.983 HG21 ' HB2' ' A' ' 284' ' ' TYR . 33.6 m -70.05 142.58 15.67 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.897 0 CA-C-O 121.709 0.766 . . . . 0.0 112.397 -171.419 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 304' ' ' GLN . . . . . 0.629 ' HA ' ' HB2' ' A' ' 279' ' ' ALA . 0.7 OUTLIER -91.43 120.8 32.58 Favored 'General case' 0 N--CA 1.444 -0.745 0 CA-C-N 114.543 -1.208 . . . . 0.0 108.16 172.82 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -94.95 144.73 17.36 Favored Glycine 0 N--CA 1.44 -1.046 0 C-N-CA 120.121 -1.038 . . . . 0.0 113.146 -172.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 306' ' ' GLU . . . . . 0.639 ' O ' ' HA2' ' A' ' 395' ' ' GLY . 5.4 mm-40 -114.73 86.3 12.76 Favored Pre-proline 0 C--N 1.32 -0.682 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 173.541 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo -60.98 122.87 11.86 Favored 'Trans proline' 0 N--CA 1.461 -0.404 0 C-N-CA 122.458 2.105 . . . . 0.0 112.249 -174.784 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . 0.787 ' O ' ' HB3' ' A' ' 375' ' ' ASN . . . -49.09 160.42 0.21 Allowed 'General case' 0 CA--C 1.535 0.385 0 CA-C-N 115.834 -0.621 . . . . 0.0 111.148 169.291 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 309' ' ' LYS . . . . . 0.582 ' N ' HD23 ' A' ' 313' ' ' LEU . 79.2 mttt -127.01 91.46 3.34 Favored 'General case' 0 C--O 1.217 -0.611 0 O-C-N 121.798 -0.564 . . . . 0.0 109.817 -176.564 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -56.74 -23.46 44.47 Favored Glycine 0 CA--C 1.52 0.391 0 N-CA-C 114.873 0.709 . . . . 0.0 114.873 -168.298 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 7.1 pt-20 -87.65 -12.03 46.7 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-N 117.44 0.62 . . . . 0.0 111.574 178.392 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 14.8 tpt -115.5 -35.57 4.54 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.767 0.794 . . . . 0.0 109.511 -175.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 313' ' ' LEU . . . . . 0.78 HD22 ' HB1' ' A' ' 308' ' ' ALA . 0.4 OUTLIER -83.39 134.85 34.87 Favored 'General case' 0 N--CA 1.436 -1.169 0 CA-C-N 114.717 -1.128 . . . . 0.0 108.057 176.147 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 314' ' ' ALA . . . . . 0.644 ' HA ' ' CB ' ' A' ' 346' ' ' PHE . . . -161.91 173.18 14.85 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-O 121.177 0.513 . . . . 0.0 112.187 -170.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 121.71 168.67 13.43 Favored Glycine 0 N--CA 1.448 -0.531 0 CA-C-N 115.349 -0.841 . . . . 0.0 111.277 -177.412 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 14.0 p -100.24 130.41 46.36 Favored 'General case' 0 C--N 1.318 -0.793 0 CA-C-N 117.409 0.604 . . . . 0.0 109.94 174.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 317' ' ' ALA . . . . . 0.404 ' CB ' ' HE3' ' A' ' 424' ' ' LYS . . . -139.62 150.62 45.19 Favored 'General case' 0 C--N 1.317 -0.845 0 N-CA-C 112.241 0.46 . . . . 0.0 112.241 -170.688 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 7.5 p -125.68 122.48 62.38 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.389 0 CA-C-N 115.731 -0.668 . . . . 0.0 110.229 175.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . 0.413 ' O ' ' HA ' ' A' ' 341' ' ' ALA . 19.5 m-85 -111.99 146.61 37.55 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.965 -0.561 . . . . 0.0 110.732 -178.464 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 320' ' ' ASN . . . . . 0.632 HD22 ' HG3' ' A' ' 425' ' ' GLU . 43.4 m-80 -129.97 137.29 50.23 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 115.634 -0.712 . . . . 0.0 109.108 175.665 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . 0.598 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -162.52 -163.02 14.33 Favored Glycine 0 N--CA 1.44 -1.055 0 C-N-CA 120.344 -0.932 . . . . 0.0 112.697 -178.745 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 37.2 mt-10 -117.93 146.17 44.16 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-O 120.654 0.264 . . . . 0.0 110.33 -175.305 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 323' ' ' VAL . . . . . 0.671 HG23 ' HB2' ' A' ' 340' ' ' PHE . 84.9 t -110.39 117.05 53.93 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.476 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.105 176.084 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 324' ' ' LEU . . . . . 0.436 HD12 ' CE1' ' A' ' 326' ' ' PHE . 0.2 OUTLIER -94.44 103.03 15.01 Favored 'General case' 0 C--N 1.312 -1.038 0 N-CA-C 108.548 -0.908 . . . . 0.0 108.548 177.796 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 325' ' ' HIS . . . . . 0.437 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 8.3 p-80 -95.88 115.48 27.5 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 115.894 -0.593 . . . . 0.0 110.14 -179.199 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 326' ' ' PHE . . . . . 0.737 ' HB2' ' HD1' ' A' ' 417' ' ' PHE . 16.5 m-85 -95.5 158.51 15.42 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-N 115.599 -0.728 . . . . 0.0 109.895 -175.283 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 327' ' ' HIS . . . . . 0.689 ' HB2' ' HG3' ' A' ' 329' ' ' GLU . 19.0 m80 -135.67 159.67 40.92 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 107.861 -1.163 . . . . 0.0 107.861 174.129 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 328' ' ' THR . . . . . . . . . . . . . 11.0 m -82.68 93.69 7.42 Favored 'General case' 0 N--CA 1.442 -0.828 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 170.099 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 329' ' ' GLU . . . . . 0.689 ' HG3' ' HB2' ' A' ' 327' ' ' HIS . 43.9 mt-10 -110.2 174.36 5.9 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-N 115.232 -0.894 . . . . 0.0 111.548 -173.549 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 330' ' ' ASN . . . . . . . . . . . . . 28.2 p30 -72.93 -10.75 60.14 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.409 -0.814 . . . . 0.0 111.954 -177.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 331' ' ' GLY . . . . . . . . . . . . . . . -144.9 160.54 28.02 Favored Glycine 0 N--CA 1.445 -0.706 0 C-N-CA 120.953 -0.641 . . . . 0.0 111.604 178.967 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 332' ' ' ARG . . . . . 0.543 ' HA ' ' HD3' ' A' ' 332' ' ' ARG . 11.1 mmt180 -92.03 -11.61 0.17 Allowed Pre-proline 0 C--N 1.325 -0.491 0 N-CA-C 114.393 1.257 . . . . 0.0 114.393 178.88 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 333' ' ' PRO . . . . . 0.464 ' CD ' ' N ' ' A' ' 332' ' ' ARG . 39.0 Cg_exo -66.31 -151.13 0.02 OUTLIER 'Trans proline' 0 C--N 1.357 1.001 0 CA-C-N 120.819 1.328 . . . . 0.0 111.027 160.025 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 334' ' ' TYR . . . . . 0.611 ' N ' ' HD3' ' A' ' 335' ' ' PRO . 98.0 m-85 59.99 49.13 2.1 Favored Pre-proline 0 CA--C 1.537 0.479 0 N-CA-C 112.625 0.602 . . . . 0.0 112.625 178.995 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 335' ' ' PRO . . . . . 0.611 ' HD3' ' N ' ' A' ' 334' ' ' TYR . 6.1 Cg_endo -87.06 127.53 2.57 Favored 'Trans proline' 0 N--CA 1.452 -0.939 0 C-N-CA 121.833 1.688 . . . . 0.0 111.439 179.597 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 336' ' ' THR . . . . . . . . . . . . . 1.1 p -118.96 139.1 52.23 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-O 121.113 0.482 . . . . 0.0 111.388 179.475 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 337' ' ' ARG . . . . . 0.453 ' HA ' ' O ' ' A' ' 323' ' ' VAL . 17.4 ptp180 -119.25 142.92 47.61 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.816 -0.629 . . . . 0.0 110.786 -175.241 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -113.21 -176.69 19.49 Favored Glycine 0 N--CA 1.443 -0.869 0 CA-C-N 115.422 -0.808 . . . . 0.0 111.554 178.226 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 339' ' ' ARG . . . . . 0.426 ' HB2' ' HB3' ' A' ' 356' ' ' ASP . 73.6 mtt180 -104.91 131.16 52.76 Favored 'General case' 0 C--N 1.319 -0.729 0 CA-C-O 120.747 0.308 . . . . 0.0 110.358 -175.085 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 340' ' ' PHE . . . . . 0.671 ' HB2' HG23 ' A' ' 323' ' ' VAL . 55.2 t80 -132.85 137.27 46.65 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-O 121.252 0.548 . . . . 0.0 111.472 -176.346 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 341' ' ' ALA . . . . . 0.413 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -139.48 143.85 37.71 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-N 115.137 -0.938 . . . . 0.0 108.999 174.512 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . 0.932 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -136.33 120.04 17.26 Favored 'General case' 0 N--CA 1.444 -0.767 0 CA-C-O 121.039 0.447 . . . . 0.0 110.84 -177.012 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -102.43 102.86 13.21 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.067 -1.086 . . . . 0.0 108.067 178.327 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 344' ' ' VAL . . . . . 0.446 ' HA ' ' HA ' ' A' ' 351' ' ' VAL . 0.3 OUTLIER -115.95 124.78 72.67 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.972 0 CA-C-O 121.6 0.714 . . . . 0.0 111.83 -172.649 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 3.9 m-20 -97.44 98.59 10.07 Favored 'General case' 0 C--N 1.318 -0.767 0 N-CA-C 108.006 -1.109 . . . . 0.0 108.006 172.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 346' ' ' PHE . . . . . 0.644 ' CB ' ' HA ' ' A' ' 314' ' ' ALA . 72.7 m-85 -65.27 -26.76 68.23 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.689 0.28 . . . . 0.0 111.259 -176.188 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -65.75 -19.57 67.44 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.831 -0.7 . . . . 0.0 111.843 178.001 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 11.9 t -112.03 -6.67 14.16 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-O 120.986 0.422 . . . . 0.0 110.058 177.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 349' ' ' LYS . . . . . 0.59 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 37.5 mtmm 52.61 59.12 4.71 Favored 'General case' 0 C--O 1.227 -0.098 0 CA-C-N 115.064 -0.971 . . . . 0.0 111.159 -176.013 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 68.1 p -149.32 138.35 21.3 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.628 -0.715 . . . . 0.0 110.181 179.809 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 351' ' ' VAL . . . . . 0.446 ' HA ' ' HA ' ' A' ' 344' ' ' VAL . 0.9 OUTLIER -123.89 151.77 28.95 Favored 'Isoleucine or valine' 0 C--O 1.235 0.334 0 CA-C-O 121.05 0.452 . . . . 0.0 110.789 -178.497 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 352' ' ' ASP . . . . . 0.932 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 21.3 t70 -112.02 118.4 35.33 Favored 'General case' 0 C--O 1.213 -0.857 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.353 173.444 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -119.82 119.01 4.1 Favored Glycine 0 N--CA 1.442 -0.925 0 C-N-CA 120.257 -0.973 . . . . 0.0 112.173 -176.781 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 354' ' ' ILE . . . . . 0.677 HD11 HG23 ' A' ' 365' ' ' THR . 0.0 OUTLIER -114.81 129.64 70.61 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.065 0 CA-C-O 121.038 0.447 . . . . 0.0 110.103 -178.125 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 355' ' ' ILE . . . . . 0.44 HD11 ' HE2' ' A' ' 368' ' ' PHE . 3.7 mp -120.7 113.87 41.57 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.57 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.159 -177.741 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 356' ' ' ASP . . . . . 0.426 ' HB3' ' HB2' ' A' ' 339' ' ' ARG . 10.2 t70 -102.79 141.78 35.02 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.861 -0.609 . . . . 0.0 110.429 176.024 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 23.2 t -110.88 8.72 22.32 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.237 -0.438 . . . . 0.0 110.384 178.309 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 358' ' ' GLY . . . . . 0.418 ' H ' ' CG ' ' A' ' 356' ' ' ASP . . . 113.83 24.43 4.61 Favored Glycine 0 N--CA 1.448 -0.505 0 C-N-CA 120.95 -0.643 . . . . 0.0 112.976 177.32 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 359' ' ' ASP . . . . . 0.404 ' HB3' ' N ' ' A' ' 364' ' ' GLY . 14.0 t70 -153.0 104.54 2.84 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-O 121.069 0.461 . . . . 0.0 110.726 178.9 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 360' ' ' ASP . . . . . . . . . . . . . 30.7 t70 -83.56 -9.38 58.97 Favored 'General case' 0 C--N 1.315 -0.903 0 CA-C-O 121.062 0.458 . . . . 0.0 111.09 -179.157 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 361' ' ' LEU . . . . . . . . . . . . . 90.5 mt -71.39 -35.6 71.1 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.809 -174.681 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 362' ' ' HIS . . . . . . . . . . . . . 55.7 t-80 -178.65 -43.72 0.01 OUTLIER 'General case' 0 N--CA 1.466 0.337 0 N-CA-C 111.818 0.303 . . . . 0.0 111.818 178.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 363' ' ' MET . . . . . . . . . . . . . 15.7 tpt -78.42 -37.94 42.63 Favored 'General case' 0 C--N 1.323 -0.568 0 N-CA-C 112.516 0.561 . . . . 0.0 112.516 -167.472 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 364' ' ' GLY . . . . . 0.404 ' N ' ' HB3' ' A' ' 359' ' ' ASP . . . -88.79 -42.28 5.75 Favored Glycine 0 N--CA 1.447 -0.609 0 C-N-CA 119.962 -1.114 . . . . 0.0 113.134 -170.291 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 365' ' ' THR . . . . . 0.677 HG23 HD11 ' A' ' 354' ' ' ILE . 89.7 m -84.4 98.97 10.35 Favored 'General case' 0 C--N 1.319 -0.724 0 CA-C-O 121.267 0.556 . . . . 0.0 112.496 -175.039 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 1.1 mp0 -109.53 165.43 11.67 Favored 'General case' 0 C--N 1.324 -0.522 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 168.702 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 19.3 pttp -148.23 151.33 35.29 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.191 0.519 . . . . 0.0 111.631 -179.121 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 368' ' ' PHE . . . . . 0.659 ' CD1' HG21 ' A' ' 389' ' ' VAL . 27.2 p90 -134.99 161.45 35.24 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.195 -0.911 . . . . 0.0 109.189 179.238 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 33.3 mtmm -131.62 150.9 51.99 Favored 'General case' 0 C--N 1.316 -0.851 0 CA-C-O 121.264 0.554 . . . . 0.0 110.513 173.619 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -141.55 139.84 33.29 Favored 'General case' 0 C--N 1.318 -0.778 0 CA-C-N 115.243 -0.889 . . . . 0.0 111.164 -173.701 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -92.69 130.73 38.23 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 109.25 -0.648 . . . . 0.0 109.25 174.223 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 372' ' ' ILE . . . . . 0.67 ' HA ' ' HB3' ' A' ' 377' ' ' PHE . 83.4 mt -79.45 108.17 12.69 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.573 0 CA-C-O 121.758 0.79 . . . . 0.0 110.585 -176.322 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -110.58 82.38 1.58 Allowed 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 114.647 -1.16 . . . . 0.0 109.495 -178.712 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 59.48 119.29 0.01 OUTLIER Glycine 0 CA--C 1.52 0.402 0 CA-C-N 114.928 -1.033 . . . . 0.0 113.776 -177.146 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 375' ' ' ASN . . . . . 0.787 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 2.2 p-10 28.85 44.6 0.01 OUTLIER 'General case' 0 N--CA 1.477 0.887 0 C-N-CA 124.734 1.214 . . . . 0.0 114.123 177.238 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 160.59 -178.77 36.47 Favored Glycine 0 N--CA 1.442 -0.906 0 N-CA-C 110.176 -1.17 . . . . 0.0 110.176 -178.693 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 377' ' ' PHE . . . . . 0.67 ' HB3' ' HA ' ' A' ' 372' ' ' ILE . 6.3 p90 -153.51 150.66 28.96 Favored 'General case' 0 C--N 1.318 -0.761 0 CA-C-N 117.362 0.581 . . . . 0.0 111.783 -178.787 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 378' ' ' LYS . . . . . 0.555 ' HD3' ' H ' ' A' ' 378' ' ' LYS . 0.0 OUTLIER -117.77 140.59 49.47 Favored 'General case' 0 C--N 1.319 -0.758 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 171.102 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 379' ' ' GLY . . . . . 0.54 ' C ' HG22 ' A' ' 389' ' ' VAL . . . -149.06 -155.13 6.59 Favored Glycine 0 N--CA 1.44 -1.062 0 C-N-CA 120.504 -0.855 . . . . 0.0 112.235 -172.852 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 380' ' ' THR . . . . . 0.456 ' HA ' ' HA ' ' A' ' 388' ' ' ASP . 7.0 t -170.99 154.49 4.17 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 -173.52 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 381' ' ' TRP . . . . . 0.672 ' HD1' ' HA3' ' A' ' 387' ' ' GLY . 39.4 m95 -65.78 132.66 49.26 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.905 -0.589 . . . . 0.0 111.422 -179.597 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 382' ' ' THR . . . . . . . . . . . . . 19.4 m -87.29 -23.12 24.77 Favored 'General case' 0 C--N 1.325 -0.487 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.846 176.782 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 383' ' ' GLU . . . . . . . . . . . . . 28.4 mm-40 -100.34 -19.43 16.31 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.828 -0.624 . . . . 0.0 111.633 -175.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 384' ' ' ASN . . . . . . . . . . . . . 14.9 m120 -114.09 166.27 11.79 Favored 'General case' 0 C--N 1.323 -0.546 0 CA-C-O 120.907 0.384 . . . . 0.0 110.719 -174.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 385' ' ' GLY . . . . . . . . . . . . . . . -126.28 75.35 0.41 Allowed Glycine 0 N--CA 1.445 -0.721 0 N-CA-C 111.549 -0.62 . . . . 0.0 111.549 177.9 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 386' ' ' GLY . . . . . . . . . . . . . . . 147.72 40.32 0.04 OUTLIER Glycine 0 N--CA 1.449 -0.484 0 C-N-CA 120.668 -0.777 . . . . 0.0 111.95 -177.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . 0.672 ' HA3' ' HD1' ' A' ' 381' ' ' TRP . . . -154.03 114.38 0.62 Allowed Glycine 0 N--CA 1.443 -0.881 0 C-N-CA 121.108 -0.568 . . . . 0.0 111.965 178.562 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 388' ' ' ASP . . . . . 0.456 ' HA ' ' HA ' ' A' ' 380' ' ' THR . 43.4 m-20 -107.73 147.33 30.92 Favored 'General case' 0 C--N 1.324 -0.542 0 N-CA-C 109.858 -0.423 . . . . 0.0 109.858 179.027 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 389' ' ' VAL . . . . . 0.659 HG21 ' CD1' ' A' ' 368' ' ' PHE . 3.3 m -121.49 167.15 15.28 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 120.713 0.292 . . . . 0.0 111.589 -171.736 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 33.6 t -161.87 157.61 24.21 Favored 'General case' 0 C--N 1.327 -0.399 0 N-CA-C 109.335 -0.617 . . . . 0.0 109.335 173.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -157.57 163.57 32.64 Favored Glycine 0 C--N 1.32 -0.308 0 N-CA-C 111.682 -0.567 . . . . 0.0 111.682 179.666 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 25.6 ttt180 -125.71 143.21 51.14 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 116.791 0.295 . . . . 0.0 110.313 -176.775 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 393' ' ' PHE . . . . . 0.582 ' CZ ' ' HE1' ' A' ' 346' ' ' PHE . 2.5 m-85 -92.92 157.45 16.34 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.432 0.634 . . . . 0.0 112.261 -175.433 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 394' ' ' TYR . . . . . 0.729 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 1.2 m-85 -102.5 -176.5 3.12 Favored 'General case' 0 C--O 1.22 -0.5 0 CA-C-N 114.816 -1.083 . . . . 0.0 110.372 178.615 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 395' ' ' GLY . . . . . 0.639 ' HA2' ' O ' ' A' ' 306' ' ' GLU . . . -36.67 153.64 0.01 OUTLIER Glycine 0 C--N 1.335 0.479 0 O-C-N 124.394 1.059 . . . . 0.0 114.941 -176.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_exo -16.15 -50.63 0.02 OUTLIER 'Trans proline' 0 C--N 1.351 0.691 1 C-N-CA 127.453 5.435 . . . . 0.0 117.724 -165.911 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 397' ' ' ALA . . . . . 0.537 ' HB3' ' HG2' ' A' ' 399' ' ' GLU . . . -75.46 -16.72 60.29 Favored 'General case' 0 C--N 1.325 -0.472 0 N-CA-C 112.377 0.51 . . . . 0.0 112.377 -171.504 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 68.49 24.92 75.1 Favored Glycine 0 N--CA 1.447 -0.591 0 N-CA-C 111.769 -0.532 . . . . 0.0 111.769 179.538 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 399' ' ' GLU . . . . . 0.537 ' HG2' ' HB3' ' A' ' 397' ' ' ALA . 10.9 mm-40 -58.86 -16.54 17.86 Favored 'General case' 0 N--CA 1.463 0.208 0 C-N-CA 123.248 0.619 . . . . 0.0 111.557 -175.488 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 400' ' ' GLU . . . . . 0.409 ' HA ' ' O ' ' A' ' 422' ' ' GLY . 35.1 mt-10 -138.53 146.72 42.27 Favored 'General case' 0 N--CA 1.443 -0.791 0 N-CA-C 109.729 -0.471 . . . . 0.0 109.729 172.613 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 401' ' ' VAL . . . . . 0.488 HG21 ' CE2' ' A' ' 377' ' ' PHE . 7.3 p -144.54 133.01 17.92 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 CA-C-N 115.339 -0.846 . . . . 0.0 109.398 177.032 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -124.61 132.22 53.44 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 116.393 -0.367 . . . . 0.0 110.332 -178.694 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -146.86 -172.14 16.82 Favored Glycine 0 N--CA 1.44 -1.049 0 C-N-CA 120.498 -0.858 . . . . 0.0 112.088 -179.139 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 404' ' ' LYS . . . . . 0.739 ' HG2' HG12 ' A' ' 419' ' ' VAL . 30.1 mtmt -146.51 158.43 43.9 Favored 'General case' 0 C--N 1.319 -0.719 0 N-CA-C 108.399 -0.963 . . . . 0.0 108.399 179.815 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 405' ' ' TYR . . . . . 0.5 ' HB3' HG12 ' A' ' 389' ' ' VAL . 17.6 p90 -119.83 134.25 55.3 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-O 121.222 0.534 . . . . 0.0 110.579 176.58 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . 0.505 ' O ' ' HA2' ' A' ' 387' ' ' GLY . 41.9 t -94.56 104.52 16.47 Favored 'General case' 0 C--N 1.32 -0.678 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.399 -177.388 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 48.7 p90 -120.11 140.04 51.66 Favored 'General case' 0 C--N 1.322 -0.617 0 N-CA-C 109.249 -0.649 . . . . 0.0 109.249 175.472 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 408' ' ' ARG . . . . . 0.602 ' HD3' ' O ' ' A' ' 408' ' ' ARG . 0.0 OUTLIER -101.58 111.53 64.0 Favored Pre-proline 0 C--N 1.32 -0.711 0 CA-C-O 121.392 0.615 . . . . 0.0 111.262 179.079 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 409' ' ' PRO . . . . . . . . . . . . . 11.2 Cg_exo -72.08 -34.26 8.5 Favored 'Trans proline' 0 N--CA 1.463 -0.318 0 C-N-CA 122.763 2.309 . . . . 0.0 110.585 172.889 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 410' ' ' THR . . . . . . . . . . . . . 27.9 m -150.27 -46.71 0.13 Allowed 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.412 176.093 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 411' ' ' ASP . . . . . . . . . . . . . 3.7 p30 -142.72 -174.09 4.06 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.654 -0.703 . . . . 0.0 110.602 -179.546 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 412' ' ' ALA . . . . . . . . . . . . . . . 70.48 106.16 0.06 Allowed 'General case' 0 N--CA 1.465 0.316 0 O-C-N 124.156 0.91 . . . . 0.0 111.703 -179.112 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 413' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -103.12 38.49 1.75 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.896 0.855 . . . . 0.0 109.01 177.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 414' ' ' LYS . . . . . . . . . . . . . 56.6 mtpt -124.58 158.89 31.92 Favored 'General case' 0 C--N 1.324 -0.534 0 CA-C-N 115.018 -0.992 . . . . 0.0 109.554 -176.932 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 415' ' ' GLY . . . . . . . . . . . . . . . -86.27 131.99 10.86 Favored Glycine 0 N--CA 1.447 -0.622 0 C-N-CA 120.265 -0.969 . . . . 0.0 111.987 -178.115 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 416' ' ' GLY . . . . . . . . . . . . . . . -163.13 -59.1 0.02 OUTLIER Glycine 0 N--CA 1.447 -0.597 0 C-N-CA 120.663 -0.78 . . . . 0.0 112.15 -178.082 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 417' ' ' PHE . . . . . 0.737 ' HD1' ' HB2' ' A' ' 326' ' ' PHE . 71.5 m-85 -87.64 145.92 25.96 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 178.591 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 418' ' ' GLY . . . . . 0.512 ' H ' ' HD2' ' A' ' 326' ' ' PHE . . . 81.8 76.86 1.06 Allowed Glycine 0 N--CA 1.445 -0.72 0 C-N-CA 120.339 -0.934 . . . . 0.0 112.567 176.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 419' ' ' VAL . . . . . 0.739 HG12 ' HG2' ' A' ' 404' ' ' LYS . 18.9 m -106.43 152.84 7.91 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.587 0 N-CA-C 110.207 -0.294 . . . . 0.0 110.207 179.441 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 420' ' ' PHE . . . . . 0.419 ' HB3' HG22 ' A' ' 323' ' ' VAL . 40.9 p90 -138.03 154.42 49.3 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-O 120.934 0.397 . . . . 0.0 110.273 -179.438 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 421' ' ' ALA . . . . . 0.598 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -142.24 136.02 29.42 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 109.178 -0.675 . . . . 0.0 109.178 177.112 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 422' ' ' GLY . . . . . 0.409 ' O ' ' HA ' ' A' ' 400' ' ' GLU . . . -118.1 135.6 11.76 Favored Glycine 0 N--CA 1.444 -0.812 0 C-N-CA 120.67 -0.776 . . . . 0.0 111.974 -179.046 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 63.9 mttm -113.37 133.68 55.03 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-O 120.816 0.341 . . . . 0.0 110.359 -179.086 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 424' ' ' LYS . . . . . 0.404 ' HE3' ' CB ' ' A' ' 317' ' ' ALA . 23.6 tptm -60.92 112.05 1.9 Allowed 'General case' 0 C--N 1.322 -0.59 0 CA-C-N 115.701 -0.681 . . . . 0.0 111.354 -177.736 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 425' ' ' GLU . . . . . 0.632 ' HG3' HD22 ' A' ' 320' ' ' ASN . 8.8 mm-40 -101.99 113.53 26.85 Favored 'General case' 0 C--N 1.324 -0.541 0 CA-C-N 115.869 -0.605 . . . . 0.0 109.516 177.433 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 426' ' ' GLN . . . . . 0.475 ' HB3' ' HG ' ' A' ' 428' ' ' LEU . 27.0 mp0 -75.75 143.75 41.84 Favored 'General case' 0 C--N 1.318 -0.768 0 CA-C-N 116.011 -0.54 . . . . 0.0 110.38 -179.259 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 427' ' ' ASP . . . . . . . . . . . . . 19.3 t70 -69.71 -12.74 61.87 Favored 'General case' 0 N--CA 1.466 0.334 0 CA-C-N 115.648 -0.705 . . . . 0.0 110.968 -175.367 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . 0.475 ' HG ' ' HB3' ' A' ' 426' ' ' GLN . 3.5 pp -69.9 -3.17 14.72 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-N 115.628 -0.715 . . . . 0.0 112.425 -177.576 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 429' ' ' GLU . . . . . 0.699 ' OE2' ' HA ' ' A' ' 431' ' ' HIS . 0.2 OUTLIER -66.28 145.53 55.64 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.939 0.4 . . . . 0.0 110.951 -178.523 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 430' ' ' HIS . . . . . . . . . . . . . 40.5 t60 -63.61 95.68 0.11 Allowed 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 107.721 -1.214 . . . . 0.0 107.721 167.338 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . 0.699 ' HA ' ' OE2' ' A' ' 429' ' ' GLU . 1.4 t60 -41.51 101.69 0.02 OUTLIER 'General case' 0 N--CA 1.464 0.248 0 O-C-N 124.447 1.092 . . . . 0.0 112.587 -164.092 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 432' ' ' HIS . . . . . . . . . . . . . 68.0 m80 -85.04 -34.66 22.25 Favored 'General case' 0 C--N 1.325 -0.488 0 CA-C-N 114.947 -1.024 . . . . 0.0 110.32 -176.525 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 433' ' ' HIS . . . . . . . . . . . . . 44.9 m-70 -93.98 106.21 18.2 Favored 'General case' 0 C--N 1.326 -0.454 0 N-CA-C 108.909 -0.775 . . . . 0.0 108.909 177.51 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 434' ' ' HIS . . . . . . . . . . . . . 14.9 p80 -61.55 115.1 3.65 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.276 0.56 . . . . 0.0 109.819 179.841 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 435' ' ' HIS . . . . . . . . . . . . . 44.7 t-80 . . . . . 0 C--O 1.25 1.132 0 CA-C-O 118.405 -0.807 . . . . 0.0 109.077 -175.939 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 276' ' ' ASN . . . . . . . . . . . . . 2.0 m-20 . . . . . 0 N--CA 1.485 1.309 0 CA-C-O 120.666 0.269 . . . . 0.0 110.488 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 13.0 mt -88.99 37.23 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.442 0 CA-C-O 121.807 0.813 . . . . 0.0 110.827 -176.39 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 278' ' ' PHE . . . . . . . . . . . . . 36.4 m-85 -89.57 72.96 7.81 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.487 0.661 . . . . 0.0 109.531 176.756 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 279' ' ' ALA . . . . . 0.417 ' HA ' ' HD3' ' A' ' 280' ' ' PRO . . . -75.85 145.32 77.78 Favored Pre-proline 0 C--N 1.325 -0.476 0 CA-C-N 115.19 -0.913 . . . . 0.0 111.537 -174.749 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 280' ' ' PRO . . . . . 0.417 ' HD3' ' HA ' ' A' ' 279' ' ' ALA . 36.2 Cg_exo -61.72 125.36 16.48 Favored 'Trans proline' 0 C--O 1.235 0.36 0 C-N-CA 122.99 2.46 . . . . 0.0 111.829 176.583 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . 0.445 ' HG2' ' O ' ' A' ' 281' ' ' GLU . 22.5 tt0 66.08 15.9 10.25 Favored 'General case' 0 N--CA 1.467 0.424 0 CA-C-O 121.857 0.837 . . . . 0.0 110.606 -178.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -148.14 31.45 1.3 Allowed Glycine 0 N--CA 1.445 -0.704 0 CA-C-N 115.603 -0.726 . . . . 0.0 111.616 179.348 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 283' ' ' ASN . . . . . . . . . . . . . 28.6 p30 -80.37 147.19 31.15 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.038 0.446 . . . . 0.0 110.044 179.179 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . 0.455 ' O ' ' HD2' ' A' ' 302' ' ' ARG . 20.2 m-85 -101.08 103.89 15.0 Favored 'General case' 0 C--N 1.32 -0.688 0 CA-C-N 116.057 -0.52 . . . . 0.0 110.736 -176.812 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . 0.62 ' HD3' ' O ' ' A' ' 285' ' ' ARG . 3.4 tmt_? -123.61 -6.05 8.1 Favored 'General case' 0 C--N 1.324 -0.527 0 N-CA-C 108.694 -0.854 . . . . 0.0 108.694 177.084 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 45.4 t80 -50.51 -56.78 10.08 Favored 'General case' 0 CA--C 1.521 -0.139 0 CA-C-N 115.179 -0.919 . . . . 0.0 109.361 177.356 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . . . . . . . . . 28.9 tp -152.82 127.57 9.5 Favored 'General case' 0 N--CA 1.442 -0.844 0 N-CA-C 108.284 -1.006 . . . . 0.0 108.284 170.33 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 288' ' ' THR . . . . . 0.546 ' O ' ' HG3' ' A' ' 304' ' ' GLN . 33.6 m -165.57 160.2 17.39 Favored 'General case' 0 N--CA 1.446 -0.645 0 N-CA-C 108.897 -0.779 . . . . 0.0 108.897 -174.285 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 289' ' ' TYR . . . . . 0.748 ' O ' ' HB3' ' A' ' 301' ' ' LEU . 0.0 OUTLIER -125.61 -175.94 3.47 Favored 'General case' 0 C--N 1.32 -0.699 0 N-CA-C 109.914 -0.402 . . . . 0.0 109.914 177.411 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.469 ' CA ' HG22 ' A' ' 303' ' ' VAL . . . -73.16 177.43 42.65 Favored Glycine 0 N--CA 1.447 -0.595 0 C-N-CA 120.095 -1.05 . . . . 0.0 113.637 -166.275 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 291' ' ' ALA . . . . . 1.004 ' HA ' ' H ' ' A' ' 301' ' ' LEU . . . -93.45 114.32 26.69 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.588 -0.306 . . . . 0.0 111.279 -163.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 292' ' ' GLU . . . . . . . . . . . . . 42.6 mt-10 -125.37 109.19 12.46 Favored 'General case' 0 C--N 1.321 -0.672 0 N-CA-C 109.018 -0.734 . . . . 0.0 109.018 169.066 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 293' ' ' LYS . . . . . . . . . . . . . 38.4 ttpt -95.42 109.05 21.29 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-O 121.217 0.532 . . . . 0.0 111.363 -171.934 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 294' ' ' LEU . . . . . 0.597 HD23 ' HB2' ' A' ' 298' ' ' SER . 3.9 mm? -110.09 158.42 35.16 Favored Pre-proline 0 C--N 1.321 -0.648 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.353 175.318 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 295' ' ' PRO . . . . . . . . . . . . . 74.4 Cg_exo -51.11 -55.69 3.79 Favored 'Trans proline' 0 C--O 1.237 0.44 0 C-N-CA 122.322 2.014 . . . . 0.0 112.194 178.073 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . -135.19 150.1 20.11 Favored Glycine 0 N--CA 1.449 -0.471 0 C-N-CA 120.801 -0.714 . . . . 0.0 112.029 179.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 91.69 -72.91 1.65 Allowed Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.866 -0.683 . . . . 0.0 111.95 178.701 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 298' ' ' SER . . . . . 0.597 ' HB2' HD23 ' A' ' 294' ' ' LEU . 6.3 m -94.83 142.86 26.97 Favored 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 109.843 -0.428 . . . . 0.0 109.843 179.719 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 299' ' ' TYR . . . . . . . . . . . . . 19.1 p90 -140.54 178.11 7.55 Favored 'General case' 0 C--N 1.323 -0.555 0 N-CA-C 110.152 -0.314 . . . . 0.0 110.152 -176.144 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 300' ' ' ALA . . . . . . . . . . . . . . . -77.78 126.25 30.58 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-O 121.345 0.593 . . . . 0.0 111.142 -173.903 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 301' ' ' LEU . . . . . 1.004 ' H ' ' HA ' ' A' ' 291' ' ' ALA . 7.4 mp -121.54 168.91 11.2 Favored 'General case' 0 CA--C 1.538 0.487 0 CA-C-N 114.616 -1.174 . . . . 0.0 111.767 -174.013 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 302' ' ' ARG . . . . . 0.455 ' HD2' ' O ' ' A' ' 284' ' ' TYR . 8.7 ptp180 -114.77 131.05 56.92 Favored 'General case' 0 C--N 1.318 -0.788 0 O-C-N 121.88 -0.513 . . . . 0.0 111.914 -174.469 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 303' ' ' VAL . . . . . 0.469 HG22 ' CA ' ' A' ' 290' ' ' GLY . 16.4 t -76.79 107.0 7.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.14 -179.339 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 304' ' ' GLN . . . . . 0.546 ' HG3' ' O ' ' A' ' 288' ' ' THR . 4.6 pp0? -91.53 175.32 6.95 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 168.501 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -92.06 106.32 3.38 Favored Glycine 0 N--CA 1.444 -0.818 0 C-N-CA 119.53 -1.319 . . . . 0.0 112.223 -173.43 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 306' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -84.88 135.63 39.75 Favored Pre-proline 0 C--N 1.325 -0.481 0 N-CA-C 109.494 -0.558 . . . . 0.0 109.494 -178.109 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . 0.568 ' C ' ' HA2' ' A' ' 395' ' ' GLY . 66.6 Cg_endo -89.33 167.21 5.32 Favored 'Trans proline' 0 N--CA 1.453 -0.898 0 C-N-CA 122.832 2.354 . . . . 0.0 111.634 173.046 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . 0.59 ' HB1' HD21 ' A' ' 313' ' ' LEU . . . -61.11 161.1 9.07 Favored 'General case' 0 CA--C 1.515 -0.372 0 CA-C-O 121.372 0.606 . . . . 0.0 112.106 -175.513 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 309' ' ' LYS . . . . . . . . . . . . . 45.1 mttm -104.66 84.61 2.19 Favored 'General case' 0 C--N 1.319 -0.729 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 171.598 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 310' ' ' GLY . . . . . 0.705 ' HA3' ' O ' ' A' ' 374' ' ' GLY . . . -55.51 -34.25 59.81 Favored Glycine 0 CA--C 1.508 -0.35 0 CA-C-N 115.832 -0.622 . . . . 0.0 113.054 -173.623 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 5.7 pt-20 -45.6 -37.6 5.74 Favored 'General case' 0 C--N 1.319 -0.718 0 C-N-CA 123.663 0.785 . . . . 0.0 112.288 175.629 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 73.2 mtm -131.08 31.75 4.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.718 0.294 . . . . 0.0 111.144 -177.381 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 313' ' ' LEU . . . . . 0.611 HD12 ' HA2' ' A' ' 310' ' ' GLY . 10.3 mt -65.79 -165.45 0.03 OUTLIER 'General case' 0 CA--C 1.541 0.61 0 N-CA-C 112.387 0.514 . . . . 0.0 112.387 179.728 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -76.25 -168.98 1.05 Allowed 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 113.306 0.854 . . . . 0.0 113.306 -170.429 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . 0.616 ' O ' ' HB2' ' A' ' 346' ' ' PHE . . . -93.11 -122.64 3.3 Favored Glycine 0 C--O 1.223 -0.574 0 CA-C-N 115.019 -0.991 . . . . 0.0 111.469 178.278 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 18.0 p -96.56 131.68 42.94 Favored 'General case' 0 C--N 1.311 -1.074 0 O-C-N 122.28 -0.541 . . . . 0.0 110.912 177.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -142.92 162.2 36.11 Favored 'General case' 0 C--N 1.323 -0.558 0 CA-C-N 115.948 -0.569 . . . . 0.0 111.587 -174.294 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 4.7 p -127.92 114.68 36.11 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.642 0 CA-C-O 121.452 0.644 . . . . 0.0 110.489 172.854 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . . . . . . . . . 1.3 m-85 -98.89 155.42 17.4 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 108.937 -0.764 . . . . 0.0 108.937 175.925 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 320' ' ' ASN . . . . . 0.435 ' HA ' ' HA ' ' A' ' 341' ' ' ALA . 8.3 p30 -157.83 156.11 30.88 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 120.855 0.359 . . . . 0.0 110.75 173.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . 0.412 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -176.81 -150.24 8.17 Favored Glycine 0 N--CA 1.443 -0.846 0 CA-C-N 115.877 -0.601 . . . . 0.0 112.145 -178.646 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 23.5 mm-40 -112.98 149.76 32.83 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 120.779 0.323 . . . . 0.0 110.861 -173.431 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 323' ' ' VAL . . . . . 0.685 HG21 HG23 ' A' ' 355' ' ' ILE . 55.5 t -108.52 118.29 55.79 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.896 -0.593 . . . . 0.0 110.051 174.091 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 324' ' ' LEU . . . . . . . . . . . . . 92.2 mt -97.61 103.48 15.42 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-N 115.951 -0.568 . . . . 0.0 109.896 179.986 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 325' ' ' HIS . . . . . . . . . . . . . 26.3 t60 -98.97 112.73 24.76 Favored 'General case' 0 C--N 1.323 -0.569 0 N-CA-C 109.692 -0.484 . . . . 0.0 109.692 -178.144 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 326' ' ' PHE . . . . . 0.625 ' HB2' ' HB3' ' A' ' 417' ' ' PHE . 30.3 m-85 -92.2 142.81 27.07 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.28 -0.418 . . . . 0.0 109.925 -173.78 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 327' ' ' HIS . . . . . . . . . . . . . 47.3 p-80 -176.2 118.38 0.14 Allowed 'General case' 0 C--N 1.327 -0.384 0 O-C-N 123.475 0.484 . . . . 0.0 110.538 178.913 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 328' ' ' THR . . . . . . . . . . . . . 5.1 t -84.77 101.75 12.49 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.932 0.872 . . . . 0.0 109.144 174.591 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 329' ' ' GLU . . . . . 0.483 ' H ' ' HG3' ' A' ' 333' ' ' PRO . 42.8 tt0 -105.33 94.14 5.06 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.619 -175.642 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 330' ' ' ASN . . . . . . . . . . . . . 54.4 t30 56.68 42.33 27.08 Favored 'General case' 0 CA--C 1.528 0.102 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.009 177.355 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 331' ' ' GLY . . . . . 0.661 ' O ' ' HD3' ' A' ' 333' ' ' PRO . . . 134.68 -175.49 20.49 Favored Glycine 0 N--CA 1.444 -0.79 0 C-N-CA 120.379 -0.915 . . . . 0.0 111.578 -175.791 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 332' ' ' ARG . . . . . . . . . . . . . 8.5 mpt_? -91.74 100.31 3.25 Favored Pre-proline 0 C--N 1.327 -0.405 0 CA-C-O 120.646 0.26 . . . . 0.0 110.49 175.1 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 333' ' ' PRO . . . . . 0.661 ' HD3' ' O ' ' A' ' 331' ' ' GLY . 85.1 Cg_endo -98.06 177.36 0.44 Allowed 'Trans proline' 0 N--CA 1.449 -1.139 0 C-N-CA 123.339 2.693 . . . . 0.0 111.767 178.512 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 334' ' ' TYR . . . . . 0.453 ' OH ' ' HD2' ' A' ' 337' ' ' ARG . 60.6 t80 -88.49 120.73 70.4 Favored Pre-proline 0 C--N 1.322 -0.611 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 174.857 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 335' ' ' PRO . . . . . 0.432 ' HD2' ' HA ' ' A' ' 334' ' ' TYR . 8.8 Cg_endo -50.85 128.95 26.02 Favored 'Trans proline' 0 N--CA 1.462 -0.351 0 C-N-CA 122.776 2.317 . . . . 0.0 111.527 179.256 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 336' ' ' THR . . . . . . . . . . . . . 6.1 p -67.98 137.98 55.55 Favored 'General case' 0 N--CA 1.448 -0.555 0 CA-C-O 121.03 0.443 . . . . 0.0 110.294 -176.471 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 337' ' ' ARG . . . . . 0.453 ' HD2' ' OH ' ' A' ' 334' ' ' TYR . 18.5 mtp180 -105.31 113.44 27.02 Favored 'General case' 0 N--CA 1.444 -0.726 0 CA-C-N 115.775 -0.648 . . . . 0.0 111.054 -173.887 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -98.53 165.37 21.34 Favored Glycine 0 N--CA 1.436 -1.318 0 N-CA-C 110.132 -1.187 . . . . 0.0 110.132 173.734 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 339' ' ' ARG . . . . . 0.856 ' HB2' ' HB2' ' A' ' 356' ' ' ASP . 5.6 mpt_? -104.92 157.56 17.13 Favored 'General case' 0 C--N 1.313 -0.992 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 176.651 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 340' ' ' PHE . . . . . 0.75 ' HA ' ' O ' ' A' ' 354' ' ' ILE . 11.1 t80 -154.68 140.56 18.22 Favored 'General case' 0 C--N 1.313 -0.992 0 C-N-CA 120.496 -0.482 . . . . 0.0 111.35 -176.777 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 341' ' ' ALA . . . . . 0.435 ' HA ' ' HA ' ' A' ' 320' ' ' ASN . . . -136.81 165.75 25.2 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 108.829 -0.804 . . . . 0.0 108.829 174.351 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . 0.861 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -147.96 118.98 7.66 Favored 'General case' 0 N--CA 1.443 -0.788 0 CA-C-O 121.12 0.486 . . . . 0.0 111.222 -177.32 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . 0.531 ' HB3' ' HB2' ' A' ' 352' ' ' ASP . 27.0 tptp -87.28 98.0 11.09 Favored 'General case' 0 C--N 1.319 -0.739 0 N-CA-C 108.214 -1.032 . . . . 0.0 108.214 174.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 344' ' ' VAL . . . . . 0.488 ' HA ' ' HA ' ' A' ' 351' ' ' VAL . 0.3 OUTLIER -115.95 117.31 55.12 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 CA-C-O 121.816 0.817 . . . . 0.0 111.802 -172.718 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -95.44 94.11 7.61 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-N 114.282 -1.327 . . . . 0.0 108.591 175.48 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 346' ' ' PHE . . . . . 0.616 ' HB2' ' O ' ' A' ' 315' ' ' GLY . 44.9 m-85 -65.54 -21.2 66.58 Favored 'General case' 0 C--N 1.327 -0.413 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.965 -174.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -62.28 -33.8 87.21 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.363 176.529 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 39.0 m -106.78 -6.57 17.67 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.163 0.506 . . . . 0.0 110.15 176.506 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 349' ' ' LYS . . . . . 0.775 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 22.4 mttm 53.79 62.71 2.49 Favored 'General case' 0 C--O 1.22 -0.466 0 CA-C-N 115.313 -0.858 . . . . 0.0 109.89 -177.908 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 49.8 m -141.01 145.46 35.95 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.207 -0.906 . . . . 0.0 109.207 175.458 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 351' ' ' VAL . . . . . 0.517 HG22 ' HB3' ' A' ' 370' ' ' ALA . 0.9 OUTLIER -129.27 156.47 41.81 Favored 'Isoleucine or valine' 0 C--O 1.235 0.327 0 CA-C-O 120.856 0.36 . . . . 0.0 110.526 -176.999 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 352' ' ' ASP . . . . . 0.861 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 1.8 m-20 -121.13 118.0 28.58 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.623 -0.88 . . . . 0.0 108.623 170.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 353' ' ' GLY . . . . . 0.403 ' HA2' ' O ' ' A' ' 341' ' ' ALA . . . -111.13 124.02 6.75 Favored Glycine 0 N--CA 1.446 -0.657 0 C-N-CA 120.11 -1.043 . . . . 0.0 112.435 -175.68 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 354' ' ' ILE . . . . . 0.75 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 1.0 OUTLIER -112.99 129.51 68.52 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.809 0 CA-C-O 120.686 0.279 . . . . 0.0 110.455 -178.063 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 355' ' ' ILE . . . . . 0.685 HG23 HG21 ' A' ' 323' ' ' VAL . 4.3 mm -107.29 97.63 5.9 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.555 0 CA-C-N 115.871 -0.604 . . . . 0.0 110.022 179.126 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 356' ' ' ASP . . . . . 0.856 ' HB2' ' HB2' ' A' ' 339' ' ' ARG . 16.8 m-20 -75.24 93.22 2.81 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 116.27 -0.423 . . . . 0.0 109.966 175.992 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 15.6 m -71.52 -13.86 61.93 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.941 178.677 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 358' ' ' GLY . . . . . . . . . . . . . . . 144.4 -35.16 1.57 Allowed Glycine 0 N--CA 1.446 -0.681 0 C-N-CA 120.757 -0.735 . . . . 0.0 111.81 -179.894 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 359' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -141.02 99.24 3.55 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-O 121.061 0.457 . . . . 0.0 110.492 178.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 360' ' ' ASP . . . . . 0.649 ' HA ' ' OG1' ' A' ' 365' ' ' THR . 31.8 t70 -83.42 -7.56 59.54 Favored 'General case' 0 C--N 1.321 -0.663 0 CA-C-N 115.703 -0.681 . . . . 0.0 110.361 175.807 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 361' ' ' LEU . . . . . 0.461 ' N ' HD22 ' A' ' 361' ' ' LEU . 2.9 mm? -73.06 -36.09 66.82 Favored 'General case' 0 N--CA 1.447 -0.607 0 CA-C-N 115.665 -0.698 . . . . 0.0 112.578 -170.665 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 362' ' ' HIS . . . . . . . . . . . . . 23.2 t-80 -167.79 -14.95 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.245 0 N-CA-C 112.8 0.667 . . . . 0.0 112.8 178.511 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 363' ' ' MET . . . . . . . . . . . . . 54.7 ttp -59.65 -32.18 70.21 Favored 'General case' 0 N--CA 1.465 0.324 0 CA-C-O 120.79 0.328 . . . . 0.0 111.672 -176.484 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 364' ' ' GLY . . . . . . . . . . . . . . . 114.18 72.44 0.56 Allowed Glycine 0 N--CA 1.449 -0.458 0 C-N-CA 120.662 -0.78 . . . . 0.0 111.777 179.416 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 365' ' ' THR . . . . . 0.649 ' OG1' ' HA ' ' A' ' 360' ' ' ASP . 0.0 OUTLIER -78.35 158.05 28.91 Favored 'General case' 0 N--CA 1.435 -1.194 0 CA-C-O 120.886 0.374 . . . . 0.0 111.277 -177.65 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 17.2 mm100 -107.85 141.8 38.88 Favored 'General case' 0 C--N 1.32 -0.674 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 177.672 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -153.63 154.37 34.07 Favored 'General case' 0 C--N 1.318 -0.798 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 176.216 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 368' ' ' PHE . . . . . 0.507 ' HB3' ' CE3' ' A' ' 381' ' ' TRP . 47.2 p90 -136.05 160.21 39.35 Favored 'General case' 0 C--N 1.319 -0.757 0 O-C-N 123.437 0.46 . . . . 0.0 109.836 -176.41 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 369' ' ' LYS . . . . . 0.513 ' HG3' ' O ' ' A' ' 351' ' ' VAL . 26.9 tttp -127.6 132.87 49.74 Favored 'General case' 0 C--N 1.315 -0.92 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 174.119 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . 0.517 ' HB3' HG22 ' A' ' 351' ' ' VAL . . . -128.85 148.46 50.89 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.182 -172.065 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -104.41 129.27 52.37 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-N 115.788 -0.642 . . . . 0.0 109.947 176.964 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 372' ' ' ILE . . . . . 0.775 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 93.3 mt -81.86 103.81 9.53 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.638 0 CA-C-O 121.925 0.869 . . . . 0.0 109.747 -179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 19.1 t0 -107.8 96.99 6.77 Favored 'General case' 0 C--N 1.303 -1.429 0 CA-C-N 114.375 -1.284 . . . . 0.0 108.859 178.277 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 374' ' ' GLY . . . . . 0.705 ' O ' ' HA3' ' A' ' 310' ' ' GLY . . . 92.51 -123.32 7.24 Favored Glycine 0 N--CA 1.441 -0.981 0 C-N-CA 120.621 -0.799 . . . . 0.0 111.244 -174.254 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 375' ' ' ASN . . . . . 0.4 HD22 ' HB2' ' A' ' 307' ' ' PRO . 42.3 p-10 -114.15 35.63 4.07 Favored 'General case' 0 C--N 1.32 -0.69 0 CA-C-O 121.925 0.869 . . . . 0.0 110.82 -175.244 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . -177.93 171.59 44.12 Favored Glycine 0 N--CA 1.443 -0.855 0 N-CA-C 109.776 -1.33 . . . . 0.0 109.776 -176.295 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 377' ' ' PHE . . . . . 0.486 ' HD2' HG12 ' A' ' 372' ' ' ILE . 6.7 p90 -131.57 145.69 51.84 Favored 'General case' 0 C--N 1.318 -0.794 0 CA-C-N 117.715 0.757 . . . . 0.0 112.616 -176.129 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 378' ' ' LYS . . . . . 0.461 ' HD2' ' H ' ' A' ' 378' ' ' LYS . 0.0 OUTLIER -119.68 134.33 55.27 Favored 'General case' 0 C--N 1.321 -0.657 0 CA-C-N 114.578 -1.192 . . . . 0.0 108.167 171.676 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -150.3 -169.68 16.65 Favored Glycine 0 N--CA 1.445 -0.715 0 C-N-CA 120.062 -1.066 . . . . 0.0 112.986 -175.597 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 15.1 t -147.46 153.68 39.86 Favored 'General case' 0 C--N 1.32 -0.703 0 N-CA-C 109.719 -0.475 . . . . 0.0 109.719 -175.849 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 381' ' ' TRP . . . . . 0.507 ' CE3' ' HB3' ' A' ' 368' ' ' PHE . 61.4 m95 -59.65 130.29 46.09 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-O 120.985 0.421 . . . . 0.0 110.282 179.672 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 382' ' ' THR . . . . . . . . . . . . . 37.5 m -61.3 -35.77 78.26 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.154 -0.93 . . . . 0.0 112.944 -169.099 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 383' ' ' GLU . . . . . 0.501 ' OE1' ' HB3' ' A' ' 381' ' ' TRP . 0.0 OUTLIER -87.51 -49.2 7.35 Favored 'General case' 0 C--N 1.325 -0.491 0 C-N-CA 120.545 -0.462 . . . . 0.0 110.708 -179.548 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 384' ' ' ASN . . . . . . . . . . . . . 40.0 t-20 -166.93 -72.68 0.03 OUTLIER 'General case' 0 C--N 1.326 -0.444 0 N-CA-C 110.107 -0.331 . . . . 0.0 110.107 175.882 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 385' ' ' GLY . . . . . 0.441 ' HA3' ' HB2' ' A' ' 381' ' ' TRP . . . 78.75 -65.46 3.48 Favored Glycine 0 N--CA 1.45 -0.42 0 CA-C-N 116.076 -0.511 . . . . 0.0 112.856 178.557 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 386' ' ' GLY . . . . . . . . . . . . . . . 86.36 27.76 29.47 Favored Glycine 0 N--CA 1.448 -0.541 0 C-N-CA 120.931 -0.652 . . . . 0.0 111.738 -177.03 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -145.61 -157.95 7.49 Favored Glycine 0 N--CA 1.445 -0.75 0 C-N-CA 121.006 -0.616 . . . . 0.0 112.105 -178.069 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 19.0 t70 -142.16 134.82 28.29 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 110.204 -0.295 . . . . 0.0 110.204 -178.593 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 38.2 t -112.95 133.87 57.41 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.379 0 CA-C-N 116.549 -0.296 . . . . 0.0 110.347 179.948 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 31.7 m -144.61 143.3 30.71 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.076 0.465 . . . . 0.0 111.224 178.229 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -157.4 157.17 27.89 Favored Glycine 0 N--CA 1.445 -0.763 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 178.63 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 11.3 ptp180 -136.02 150.74 49.32 Favored 'General case' 0 C--N 1.319 -0.75 0 CA-C-N 117.405 0.602 . . . . 0.0 110.764 -175.3 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 393' ' ' PHE . . . . . 0.481 ' CD1' ' HB ' ' A' ' 401' ' ' VAL . 95.1 m-85 -84.49 167.75 16.09 Favored 'General case' 0 CA--C 1.496 -1.098 0 CA-C-O 122.134 0.969 . . . . 0.0 111.184 -178.084 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 394' ' ' TYR . . . . . 0.569 ' HD1' ' N ' ' A' ' 394' ' ' TYR . 0.6 OUTLIER -97.56 -179.11 4.36 Favored 'General case' 0 N--CA 1.428 -1.562 0 N-CA-C 105.621 -1.992 . . . . 0.0 105.621 173.153 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 395' ' ' GLY . . . . . 0.568 ' HA2' ' C ' ' A' ' 307' ' ' PRO . . . -51.48 -148.16 0.0 OUTLIER Glycine 0 N--CA 1.474 1.168 0 O-C-N 124.497 1.123 . . . . 0.0 115.754 -172.314 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -57.67 -10.86 7.88 Favored 'Trans proline' 0 CA--C 1.539 0.729 0 C-N-CA 121.227 1.285 . . . . 0.0 111.042 176.192 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 397' ' ' ALA . . . . . 0.489 ' C ' ' H ' ' A' ' 399' ' ' GLU . . . -93.97 27.66 2.71 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 114.77 -1.104 . . . . 0.0 110.811 174.127 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . -53.6 8.54 0.01 OUTLIER Glycine 0 N--CA 1.469 0.87 0 C-N-CA 124.069 0.842 . . . . 0.0 114.599 176.079 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 399' ' ' GLU . . . . . 0.489 ' H ' ' C ' ' A' ' 397' ' ' ALA . 3.7 mp0 -59.97 -9.99 3.66 Favored 'General case' 0 C--N 1.323 -0.587 0 C-N-CA 123.929 0.892 . . . . 0.0 110.019 166.676 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 -119.21 125.05 48.24 Favored 'General case' 0 N--CA 1.446 -0.653 0 CA-C-N 115.344 -0.844 . . . . 0.0 109.439 174.15 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 401' ' ' VAL . . . . . 0.481 ' HB ' ' CD1' ' A' ' 393' ' ' PHE . 12.2 p -132.71 141.12 45.87 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.732 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 176.607 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -130.01 137.56 50.33 Favored 'General case' 0 C--N 1.318 -0.786 0 CA-C-O 120.761 0.315 . . . . 0.0 110.679 178.902 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -144.88 177.03 23.62 Favored Glycine 0 N--CA 1.439 -1.161 0 C-N-CA 120.458 -0.877 . . . . 0.0 112.143 179.805 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 404' ' ' LYS . . . . . 0.454 ' CG ' HG12 ' A' ' 419' ' ' VAL . 0.0 OUTLIER -141.13 155.7 46.07 Favored 'General case' 0 C--N 1.318 -0.764 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 176.905 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 19.7 p90 -119.42 133.58 55.64 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-O 120.977 0.417 . . . . 0.0 110.287 176.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 49.1 m -92.29 103.84 16.25 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.51 -0.552 . . . . 0.0 109.51 177.359 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 37.5 p90 -66.38 149.67 50.05 Favored 'General case' 0 C--N 1.324 -0.518 0 CA-C-N 115.588 -0.733 . . . . 0.0 109.976 177.27 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 408' ' ' ARG . . . . . 0.425 ' HA ' ' HD3' ' A' ' 409' ' ' PRO . 37.6 ttt180 -59.78 117.45 23.19 Favored Pre-proline 0 C--N 1.327 -0.372 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.517 -179.649 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 409' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 408' ' ' ARG . 18.1 Cg_exo -66.31 84.64 0.27 Allowed 'Trans proline' 0 N--CA 1.464 -0.225 0 C-N-CA 123.059 2.506 . . . . 0.0 112.128 -178.7 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 410' ' ' THR . . . . . . . . . . . . . 9.8 m -91.71 99.84 12.66 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.865 179.003 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 411' ' ' ASP . . . . . . . . . . . . . 26.4 t70 73.7 -36.62 0.35 Allowed 'General case' 0 N--CA 1.471 0.612 0 C-N-CA 123.831 0.852 . . . . 0.0 110.95 -176.195 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 412' ' ' ALA . . . . . . . . . . . . . . . -59.17 139.13 57.23 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 116.332 -0.395 . . . . 0.0 110.488 175.031 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 413' ' ' GLU . . . . . 0.629 ' HG2' ' HG2' ' A' ' 414' ' ' LYS . 0.5 OUTLIER -80.25 -23.85 40.54 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.754 -0.657 . . . . 0.0 112.202 -172.035 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 414' ' ' LYS . . . . . 0.629 ' HG2' ' HG2' ' A' ' 413' ' ' GLU . 21.9 pttp -156.25 166.46 33.37 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 120.985 0.421 . . . . 0.0 111.089 -178.044 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 415' ' ' GLY . . . . . . . . . . . . . . . -139.74 179.36 18.92 Favored Glycine 0 N--CA 1.448 -0.506 0 CA-C-N 115.402 -0.817 . . . . 0.0 111.205 -179.411 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 416' ' ' GLY . . . . . . . . . . . . . . . 142.62 -10.54 2.41 Favored Glycine 0 N--CA 1.45 -0.41 0 C-N-CA 120.269 -0.967 . . . . 0.0 112.388 -178.213 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 417' ' ' PHE . . . . . 0.625 ' HB3' ' HB2' ' A' ' 326' ' ' PHE . 73.8 m-85 -81.81 170.16 16.03 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 109.741 -0.466 . . . . 0.0 109.741 175.427 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 82.8 76.99 1.1 Allowed Glycine 0 N--CA 1.449 -0.467 0 C-N-CA 120.296 -0.954 . . . . 0.0 112.374 -177.938 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 419' ' ' VAL . . . . . 0.454 HG12 ' CG ' ' A' ' 404' ' ' LYS . 19.8 m -106.4 167.36 3.33 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 N-CA-C 110.348 -0.241 . . . . 0.0 110.348 -179.34 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 45.9 p90 -148.24 162.69 38.98 Favored 'General case' 0 N--CA 1.448 -0.541 0 CA-C-O 120.796 0.331 . . . . 0.0 110.144 178.077 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 421' ' ' ALA . . . . . 0.412 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -142.85 135.39 27.67 Favored 'General case' 0 C--N 1.316 -0.877 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 177.994 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -122.95 135.72 10.2 Favored Glycine 0 N--CA 1.441 -1.021 0 C-N-CA 120.749 -0.739 . . . . 0.0 111.451 179.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 60.3 mttm -118.93 139.8 51.05 Favored 'General case' 0 C--N 1.315 -0.896 0 CA-C-O 121.041 0.448 . . . . 0.0 110.354 179.442 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 424' ' ' LYS . . . . . . . . . . . . . 5.6 tppp? -60.06 122.41 14.3 Favored 'General case' 0 C--N 1.322 -0.611 0 CA-C-N 115.011 -0.995 . . . . 0.0 111.86 -177.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 35.8 tt0 -103.18 112.92 26.02 Favored 'General case' 0 C--N 1.319 -0.756 0 N-CA-C 107.431 -1.322 . . . . 0.0 107.431 166.758 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 426' ' ' GLN . . . . . 0.731 ' HB2' HD23 ' A' ' 428' ' ' LEU . 10.6 pt20 -109.59 130.69 55.49 Favored 'General case' 0 C--N 1.315 -0.898 0 CA-C-O 121.659 0.742 . . . . 0.0 111.286 -171.742 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 427' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -84.87 9.52 14.1 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.16 -0.927 . . . . 0.0 110.317 -175.94 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . 0.731 HD23 ' HB2' ' A' ' 426' ' ' GLN . 3.6 mm? -67.73 -16.06 63.94 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.408 -0.814 . . . . 0.0 110.831 179.585 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 429' ' ' GLU . . . . . . . . . . . . . 18.9 tt0 -61.92 -32.2 72.57 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 121.552 0.691 . . . . 0.0 110.062 174.086 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 430' ' ' HIS . . . . . . . . . . . . . 36.4 m80 -94.67 145.09 25.08 Favored 'General case' 0 C--N 1.323 -0.587 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.569 -176.394 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 76.2 t60 -149.19 119.1 7.1 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 121.069 0.461 . . . . 0.0 111.164 178.662 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 432' ' ' HIS . . . . . . . . . . . . . 39.1 m-70 -131.46 165.86 22.6 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.921 -0.77 . . . . 0.0 108.921 175.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 433' ' ' HIS . . . . . . . . . . . . . 3.1 t-160 -162.34 -35.7 0.04 OUTLIER 'General case' 0 C--N 1.328 -0.368 0 CA-C-O 120.905 0.383 . . . . 0.0 110.874 176.958 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 434' ' ' HIS . . . . . . . . . . . . . 26.6 t-80 -85.85 -39.89 16.55 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 175.094 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 435' ' ' HIS . . . . . . . . . . . . . 72.5 t60 . . . . . 0 C--O 1.25 1.102 0 CA-C-O 117.725 -1.131 . . . . 0.0 108.764 174.018 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 276' ' ' ASN . . . . . 0.435 ' CG ' ' HD2' ' A' ' 299' ' ' TYR . 56.2 t30 . . . . . 0 N--CA 1.48 1.059 0 CA-C-O 121.178 0.514 . . . . 0.0 110.681 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 10.5 tp -99.6 -16.27 7.16 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-O 121.306 0.574 . . . . 0.0 110.49 178.151 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 278' ' ' PHE . . . . . 0.44 ' HE2' ' N ' ' A' ' 301' ' ' LEU . 28.3 p90 38.5 31.92 0.05 OUTLIER 'General case' 0 N--CA 1.472 0.674 0 C-N-CA 125.244 1.418 . . . . 0.0 114.168 178.12 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -168.5 149.1 4.34 Favored Pre-proline 0 N--CA 1.452 -0.329 0 CA-C-N 116.679 -0.237 . . . . 0.0 110.652 -178.214 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 280' ' ' PRO . . . . . . . . . . . . . 23.0 Cg_exo -65.46 128.42 20.21 Favored 'Trans proline' 0 N--CA 1.458 -0.601 0 C-N-CA 122.481 2.121 . . . . 0.0 110.519 171.551 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . 0.44 ' HA ' HD11 ' A' ' 287' ' ' LEU . 43.3 mt-10 -62.85 92.24 0.05 OUTLIER 'General case' 0 C--N 1.327 -0.399 0 CA-C-O 121.696 0.76 . . . . 0.0 111.756 -176.935 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 156.53 32.41 0.02 OUTLIER Glycine 0 N--CA 1.444 -0.789 0 CA-C-N 114.668 -1.151 . . . . 0.0 110.402 -178.609 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 283' ' ' ASN . . . . . 0.535 ' H ' HD13 ' A' ' 287' ' ' LEU . 15.2 t-20 -133.43 147.62 51.73 Favored 'General case' 0 C--N 1.324 -0.533 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 -179.194 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . 0.43 ' C ' ' H ' ' A' ' 286' ' ' TYR . 2.3 m-85 -100.21 145.16 28.38 Favored 'General case' 0 C--N 1.316 -0.86 0 C-N-CA 120.554 -0.458 . . . . 0.0 111.114 -173.588 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 17.9 mmm180 73.38 -27.48 0.19 Allowed 'General case' 0 N--CA 1.47 0.546 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.206 -172.186 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.43 ' H ' ' C ' ' A' ' 284' ' ' TYR . 35.8 m-85 -80.62 -22.66 40.38 Favored 'General case' 0 N--CA 1.444 -0.745 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 163.606 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . 0.623 HD23 ' HA ' ' A' ' 304' ' ' GLN . 5.8 mp -116.85 129.03 55.82 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-N 115.668 -0.696 . . . . 0.0 109.613 165.866 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 288' ' ' THR . . . . . 0.548 ' N ' ' HG3' ' A' ' 304' ' ' GLN . 9.1 m -168.51 171.73 8.74 Favored 'General case' 0 C--N 1.32 -0.677 0 N-CA-C 105.97 -1.863 . . . . 0.0 105.97 -178.276 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 289' ' ' TYR . . . . . 0.414 ' N ' HG22 ' A' ' 288' ' ' THR . 12.2 m-85 -108.55 117.19 33.53 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 119.167 0.894 . . . . 0.0 109.671 167.737 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 122.43 136.18 4.83 Favored Glycine 0 C--N 1.334 0.446 0 C-N-CA 120.553 -0.832 . . . . 0.0 111.292 -178.188 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 291' ' ' ALA . . . . . 0.791 ' HB1' ' HA ' ' A' ' 301' ' ' LEU . . . -165.71 164.85 18.93 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 112.076 0.399 . . . . 0.0 112.076 -172.171 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 292' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -127.28 114.48 17.68 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.416 173.485 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 293' ' ' LYS . . . . . 0.452 ' HE3' ' HB3' ' A' ' 299' ' ' TYR . 88.5 tttt -75.82 126.86 31.81 Favored 'General case' 0 C--N 1.323 -0.581 0 N-CA-C 108.886 -0.783 . . . . 0.0 108.886 175.748 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 294' ' ' LEU . . . . . 0.601 HD22 ' HB2' ' A' ' 298' ' ' SER . 7.2 mp -65.72 124.18 86.75 Favored Pre-proline 0 C--N 1.322 -0.594 0 CA-C-O 120.743 0.306 . . . . 0.0 110.573 -175.045 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 295' ' ' PRO . . . . . 0.507 ' HD3' ' HA ' ' A' ' 294' ' ' LEU . 17.0 Cg_exo -67.68 81.33 0.45 Allowed 'Trans proline' 0 C--O 1.235 0.357 0 C-N-CA 123.229 2.619 . . . . 0.0 112.164 -178.608 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . 165.51 -109.76 0.38 Allowed Glycine 0 N--CA 1.443 -0.868 0 CA-C-N 115.572 -0.74 . . . . 0.0 111.948 178.963 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . -97.94 -41.3 3.34 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.908 -0.663 . . . . 0.0 113.324 -176.335 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 298' ' ' SER . . . . . 0.601 ' HB2' HD22 ' A' ' 294' ' ' LEU . 69.3 m -80.08 152.29 29.42 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 121.477 0.656 . . . . 0.0 111.663 -174.592 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 299' ' ' TYR . . . . . 0.452 ' HB3' ' HE3' ' A' ' 293' ' ' LYS . 13.8 p90 -134.89 135.38 41.58 Favored 'General case' 0 C--N 1.32 -0.704 0 CA-C-N 115.23 -0.896 . . . . 0.0 108.893 178.587 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 300' ' ' ALA . . . . . 0.422 ' N ' HD21 ' A' ' 276' ' ' ASN . . . -157.37 119.84 3.88 Favored 'General case' 0 C--N 1.331 -0.225 0 C-N-CA 120.985 -0.286 . . . . 0.0 111.76 -176.44 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 301' ' ' LEU . . . . . 0.791 ' HA ' ' HB1' ' A' ' 291' ' ' ALA . 1.8 pp -143.33 155.77 44.53 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-O 121.133 0.492 . . . . 0.0 111.209 171.017 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 302' ' ' ARG . . . . . 0.607 ' H ' ' HB2' ' A' ' 291' ' ' ALA . 80.9 mtm180 -108.87 134.59 51.35 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.787 -0.642 . . . . 0.0 109.717 -178.556 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 303' ' ' VAL . . . . . 0.43 HG23 HD12 ' A' ' 301' ' ' LEU . 95.7 t -132.95 124.18 49.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.368 0 CA-C-N 116.379 -0.373 . . . . 0.0 110.296 175.938 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 304' ' ' GLN . . . . . 0.623 ' HA ' HD23 ' A' ' 287' ' ' LEU . 10.8 mt-30 -90.5 141.78 28.41 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.28 176.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -97.34 105.66 3.21 Favored Glycine 0 N--CA 1.446 -0.651 0 N-CA-C 110.457 -1.057 . . . . 0.0 110.457 173.068 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 306' ' ' GLU . . . . . . . . . . . . . 34.9 mm-40 -103.57 134.73 19.59 Favored Pre-proline 0 C--N 1.321 -0.631 0 CA-C-O 120.849 0.357 . . . . 0.0 111.683 -173.524 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 73.2 Cg_endo -78.57 160.98 28.28 Favored 'Trans proline' 0 N--CA 1.457 -0.626 0 C-N-CA 122.24 1.96 . . . . 0.0 109.478 164.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . 0.753 ' HB1' HD11 ' A' ' 313' ' ' LEU . . . -49.45 118.95 3.03 Favored 'General case' 0 N--CA 1.465 0.297 0 CA-C-O 121.118 0.485 . . . . 0.0 111.366 -179.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 309' ' ' LYS . . . . . 0.452 ' O ' ' HG ' ' A' ' 313' ' ' LEU . 24.8 mmmt -73.95 81.5 1.68 Allowed 'General case' 0 C--N 1.317 -0.815 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 -177.578 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 310' ' ' GLY . . . . . 0.708 ' HA2' HD12 ' A' ' 313' ' ' LEU . . . -52.56 -40.48 55.06 Favored Glycine 0 C--N 1.333 0.387 0 O-C-N 123.332 0.395 . . . . 0.0 113.145 -174.445 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . 0.552 ' HG3' ' HG3' ' A' ' 312' ' ' MET . 10.1 pt-20 -56.63 -28.26 60.13 Favored 'General case' 0 C--N 1.322 -0.611 0 C-N-CA 122.635 0.374 . . . . 0.0 111.923 177.307 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 312' ' ' MET . . . . . 0.552 ' HG3' ' HG3' ' A' ' 311' ' ' GLU . 76.3 mtm -113.83 1.97 14.96 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.687 0.28 . . . . 0.0 111.352 -177.424 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 313' ' ' LEU . . . . . 0.753 HD11 ' HB1' ' A' ' 308' ' ' ALA . 78.8 mt -72.69 131.04 41.87 Favored 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 175.598 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -143.9 143.67 31.38 Favored 'General case' 0 C--N 1.312 -1.031 0 CA-C-N 115.831 -0.622 . . . . 0.0 111.569 -173.042 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 121.66 169.87 13.73 Favored Glycine 0 N--CA 1.445 -0.743 0 C-N-CA 120.981 -0.628 . . . . 0.0 111.843 178.706 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 25.4 p -107.32 133.04 52.44 Favored 'General case' 0 C--N 1.318 -0.774 0 N-CA-C 110.014 -0.365 . . . . 0.0 110.014 175.242 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -142.03 160.26 40.58 Favored 'General case' 0 C--N 1.317 -0.823 0 CA-C-O 121.271 0.557 . . . . 0.0 112.076 -172.912 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 6.1 p -129.13 115.93 38.1 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.64 0 CA-C-N 115.393 -0.821 . . . . 0.0 109.878 174.512 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . 0.578 ' CZ ' ' HB2' ' A' ' 424' ' ' LYS . 2.0 m-85 -98.07 128.74 44.77 Favored 'General case' 0 C--N 1.319 -0.74 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 179.09 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 4.0 p30 -131.37 144.05 50.94 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-O 120.868 0.366 . . . . 0.0 110.727 179.898 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -173.67 -143.89 4.5 Favored Glycine 0 N--CA 1.443 -0.855 0 C-N-CA 120.986 -0.626 . . . . 0.0 112.007 -179.722 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 46.8 mt-10 -119.48 147.81 43.99 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 120.832 0.349 . . . . 0.0 110.975 -175.163 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 323' ' ' VAL . . . . . 0.717 HG13 ' HB2' ' A' ' 340' ' ' PHE . 4.5 m -106.71 117.04 51.75 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.977 0 CA-C-N 115.846 -0.616 . . . . 0.0 109.391 168.027 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 324' ' ' LEU . . . . . 0.544 ' HB2' HG22 ' A' ' 419' ' ' VAL . 97.5 mt -91.63 101.94 14.57 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 108.652 -0.87 . . . . 0.0 108.652 177.895 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 325' ' ' HIS . . . . . 0.489 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 6.2 p80 -102.41 117.67 35.21 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.754 0.788 . . . . 0.0 109.766 -176.333 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 326' ' ' PHE . . . . . 0.782 ' HD2' ' HB3' ' A' ' 417' ' ' PHE . 58.4 m-85 -94.27 173.68 7.52 Favored 'General case' 0 C--N 1.322 -0.598 0 CA-C-N 114.649 -1.16 . . . . 0.0 111.22 -168.521 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 327' ' ' HIS . . . . . . . . . . . . . 8.2 p-80 -173.73 148.63 1.5 Allowed 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.275 -0.875 . . . . 0.0 109.112 -174.428 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 328' ' ' THR . . . . . . . . . . . . . 15.8 p -64.73 122.25 16.43 Favored 'General case' 0 C--N 1.327 -0.378 0 O-C-N 123.263 0.352 . . . . 0.0 110.128 177.233 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 329' ' ' GLU . . . . . . . . . . . . . 11.4 pt-20 -63.48 128.15 34.53 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 121.266 0.555 . . . . 0.0 111.637 -174.539 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 330' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -96.34 -32.57 12.32 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.449 -0.796 . . . . 0.0 109.219 173.469 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 331' ' ' GLY . . . . . . . . . . . . . . . -173.29 117.32 0.64 Allowed Glycine 0 N--CA 1.442 -0.901 0 CA-C-N 115.21 -0.905 . . . . 0.0 111.341 178.947 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 332' ' ' ARG . . . . . 0.412 ' NH2' ' HB2' ' A' ' 334' ' ' TYR . 0.2 OUTLIER 68.49 88.55 0.1 Allowed Pre-proline 0 C--N 1.33 -0.282 0 C-N-CA 122.888 0.475 . . . . 0.0 109.986 -179.026 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 333' ' ' PRO . . . . . . . . . . . . . 26.2 Cg_endo -60.94 110.39 0.84 Allowed 'Trans proline' 0 C--N 1.343 0.243 0 C-N-CA 123.016 2.477 . . . . 0.0 112.809 -176.142 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 334' ' ' TYR . . . . . 0.412 ' HB2' ' NH2' ' A' ' 332' ' ' ARG . 86.8 t80 -132.83 113.51 13.87 Favored Pre-proline 0 C--N 1.322 -0.618 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.767 177.038 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 335' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_exo -70.22 126.83 13.44 Favored 'Trans proline' 0 N--CA 1.456 -0.686 0 C-N-CA 122.126 1.884 . . . . 0.0 109.978 171.254 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 336' ' ' THR . . . . . . . . . . . . . 1.3 m -97.96 148.33 23.58 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 109.867 -0.42 . . . . 0.0 109.867 -176.683 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 337' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -112.97 135.03 54.19 Favored 'General case' 0 C--N 1.321 -0.654 0 CA-C-O 121.53 0.681 . . . . 0.0 111.487 -176.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 338' ' ' GLY . . . . . 0.412 ' HA3' ' CG2' ' A' ' 323' ' ' VAL . . . -106.46 -175.42 23.29 Favored Glycine 0 N--CA 1.437 -1.251 0 N-CA-C 110.006 -1.238 . . . . 0.0 110.006 170.032 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 339' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -111.29 131.56 55.06 Favored 'General case' 0 C--N 1.317 -0.813 0 CA-C-N 117.222 0.511 . . . . 0.0 109.799 178.109 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 340' ' ' PHE . . . . . 0.717 ' HB2' HG13 ' A' ' 323' ' ' VAL . 10.9 t80 -127.37 133.53 50.02 Favored 'General case' 0 C--N 1.314 -0.968 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.793 -178.182 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 341' ' ' ALA . . . . . 0.471 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -131.9 160.7 34.94 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.613 175.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . 0.889 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -147.83 119.4 7.97 Favored 'General case' 0 N--CA 1.442 -0.844 0 CA-C-O 121.204 0.526 . . . . 0.0 110.446 -177.7 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . 0.442 ' HB3' ' HB2' ' A' ' 352' ' ' ASP . 6.3 tmtt? -91.68 98.74 11.82 Favored 'General case' 0 C--N 1.318 -0.783 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 178.363 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 344' ' ' VAL . . . . . 0.617 ' HB ' HG12 ' A' ' 351' ' ' VAL . 0.2 OUTLIER -118.51 128.52 75.45 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-O 121.794 0.806 . . . . 0.0 112.239 -172.189 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -108.14 110.62 22.32 Favored 'General case' 0 C--N 1.321 -0.656 0 CA-C-N 114.489 -1.232 . . . . 0.0 108.419 174.443 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 346' ' ' PHE . . . . . 0.478 ' HZ ' ' OH ' ' A' ' 319' ' ' TYR . 64.8 m-85 -73.16 -18.74 61.24 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 120.705 0.288 . . . . 0.0 111.732 -176.291 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -62.77 -28.19 71.27 Favored Glycine 0 N--CA 1.447 -0.582 0 C-N-CA 120.475 -0.869 . . . . 0.0 111.249 176.199 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 20.5 t -112.46 -10.12 13.76 Favored 'General case' 0 N--CA 1.45 -0.469 0 CA-C-N 115.897 -0.151 . . . . 0.0 110.974 177.72 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 349' ' ' LYS . . . . . 0.643 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 35.2 mttp 57.23 59.46 3.37 Favored 'General case' 0 C--O 1.224 -0.275 0 CA-C-O 121.58 0.705 . . . . 0.0 110.646 -178.308 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 8.6 t -146.86 152.61 39.01 Favored 'General case' 0 C--N 1.324 -0.527 0 CA-C-N 115.518 -0.765 . . . . 0.0 109.296 177.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 351' ' ' VAL . . . . . 0.728 HG22 ' HB3' ' A' ' 370' ' ' ALA . 1.2 m -134.8 155.25 38.12 Favored 'Isoleucine or valine' 0 C--O 1.236 0.382 0 CA-C-O 121.205 0.526 . . . . 0.0 110.836 -176.786 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 352' ' ' ASP . . . . . 0.889 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 1.2 m-20 -110.7 117.91 34.74 Favored 'General case' 0 C--O 1.215 -0.728 0 CA-C-N 115.244 -0.889 . . . . 0.0 108.692 168.925 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -110.91 124.43 6.96 Favored Glycine 0 N--CA 1.441 -1.03 0 C-N-CA 120.193 -1.003 . . . . 0.0 111.562 -176.954 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 354' ' ' ILE . . . . . 0.472 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -122.05 129.73 75.15 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.1 0 CA-C-O 121.187 0.518 . . . . 0.0 109.85 -177.058 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 355' ' ' ILE . . . . . 0.617 HG23 HG21 ' A' ' 323' ' ' VAL . 4.2 mp -122.34 108.7 22.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.714 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.858 -178.57 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 356' ' ' ASP . . . . . 0.466 ' HA ' ' O ' ' A' ' 364' ' ' GLY . 0.0 OUTLIER -121.24 134.42 55.18 Favored 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.455 -0.572 . . . . 0.0 109.455 175.142 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 23.8 m -105.61 9.8 33.18 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 116.098 -0.501 . . . . 0.0 110.524 -179.123 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 358' ' ' GLY . . . . . . . . . . . . . . . 85.1 11.87 75.12 Favored Glycine 0 N--CA 1.448 -0.532 0 C-N-CA 120.745 -0.741 . . . . 0.0 111.728 -176.408 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 359' ' ' ASP . . . . . 0.822 ' HB2' ' HA3' ' A' ' 364' ' ' GLY . 52.6 m-20 -116.7 52.46 0.94 Allowed 'General case' 0 C--N 1.325 -0.477 0 CA-C-O 121.211 0.529 . . . . 0.0 109.607 179.207 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 360' ' ' ASP . . . . . 0.644 ' HA ' ' OG1' ' A' ' 365' ' ' THR . 2.2 m-20 -62.1 -19.51 63.06 Favored 'General case' 0 N--CA 1.465 0.303 0 CA-C-N 115.107 -0.951 . . . . 0.0 112.342 -175.403 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 361' ' ' LEU . . . . . . . . . . . . . 89.6 mt -82.54 8.21 12.38 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.598 -0.274 . . . . 0.0 111.516 -178.81 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 362' ' ' HIS . . . . . 0.463 ' HB3' ' H ' ' A' ' 363' ' ' MET . 0.1 OUTLIER -160.59 -128.97 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 120.974 -0.29 . . . . 0.0 111.115 176.732 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 363' ' ' MET . . . . . 0.463 ' H ' ' HB3' ' A' ' 362' ' ' HIS . 0.0 OUTLIER -78.48 -4.19 47.27 Favored 'General case' 0 C--N 1.328 -0.345 0 N-CA-C 112.346 0.499 . . . . 0.0 112.346 -173.5 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 364' ' ' GLY . . . . . 0.822 ' HA3' ' HB2' ' A' ' 359' ' ' ASP . . . -75.47 4.21 43.69 Favored Glycine 0 N--CA 1.449 -0.479 0 C-N-CA 121.008 -0.615 . . . . 0.0 113.544 -172.693 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 365' ' ' THR . . . . . 0.644 ' OG1' ' HA ' ' A' ' 360' ' ' ASP . 32.5 m -129.17 119.04 23.4 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 116.999 0.399 . . . . 0.0 110.949 178.363 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 43.9 mt-30 -140.05 149.01 42.62 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 115.998 -0.546 . . . . 0.0 109.907 177.927 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -138.55 148.61 44.42 Favored 'General case' 0 C--N 1.326 -0.423 0 N-CA-C 110.234 -0.284 . . . . 0.0 110.234 176.429 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 368' ' ' PHE . . . . . 0.451 ' HB3' ' CE3' ' A' ' 381' ' ' TRP . 34.4 p90 -140.83 149.99 42.72 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-O 121.0 0.429 . . . . 0.0 110.465 178.577 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 1.6 mptp? -104.9 138.1 41.66 Favored 'General case' 0 C--N 1.319 -0.751 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 173.473 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . 0.728 ' HB3' HG22 ' A' ' 351' ' ' VAL . . . -134.26 147.45 50.66 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-O 121.18 0.514 . . . . 0.0 111.574 -177.127 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -105.96 130.47 53.89 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.561 -0.745 . . . . 0.0 109.628 175.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 372' ' ' ILE . . . . . 0.643 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 87.6 mt -81.66 107.38 13.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 121.545 0.688 . . . . 0.0 110.755 -178.04 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . 0.494 ' HB2' ' HE2' ' A' ' 378' ' ' LYS . 28.5 t70 -111.46 80.2 1.29 Allowed 'General case' 0 C--N 1.318 -0.763 0 CA-C-N 115.093 -0.958 . . . . 0.0 109.435 179.417 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 58.87 119.07 0.01 OUTLIER Glycine 0 CA--C 1.521 0.42 0 CA-C-N 114.889 -1.051 . . . . 0.0 113.76 -177.484 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 375' ' ' ASN . . . . . 0.732 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 2.4 p-10 29.86 46.05 0.02 OUTLIER 'General case' 0 N--CA 1.476 0.871 0 N-CA-C 113.912 1.078 . . . . 0.0 113.912 178.582 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 165.06 172.35 32.41 Favored Glycine 0 N--CA 1.445 -0.766 0 N-CA-C 111.099 -0.8 . . . . 0.0 111.099 178.032 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 377' ' ' PHE . . . . . 0.464 ' CZ ' HG21 ' A' ' 401' ' ' VAL . 3.4 p90 -147.95 150.54 34.23 Favored 'General case' 0 C--N 1.32 -0.683 0 CA-C-O 121.447 0.641 . . . . 0.0 111.793 179.185 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 378' ' ' LYS . . . . . 0.821 ' HD3' ' H ' ' A' ' 378' ' ' LYS . 0.3 OUTLIER -112.37 130.29 56.01 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 114.638 -1.164 . . . . 0.0 108.383 174.688 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -126.23 156.64 19.83 Favored Glycine 0 N--CA 1.444 -0.821 0 C-N-CA 120.4 -0.905 . . . . 0.0 113.248 -172.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 26.7 p -125.24 137.74 54.1 Favored 'General case' 0 C--N 1.321 -0.668 0 CA-C-N 115.219 -0.491 . . . . 0.0 109.938 178.007 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 381' ' ' TRP . . . . . 0.451 ' CE3' ' HB3' ' A' ' 368' ' ' PHE . 41.2 m95 -60.61 121.01 11.11 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-O 121.146 0.498 . . . . 0.0 110.943 -178.074 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 382' ' ' THR . . . . . . . . . . . . . 4.2 m -104.34 55.11 0.72 Allowed 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.815 -0.629 . . . . 0.0 111.35 -171.447 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 383' ' ' GLU . . . . . . . . . . . . . 28.5 tt0 -177.61 -56.79 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.765 174.468 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 384' ' ' ASN . . . . . . . . . . . . . 4.0 p-10 -153.46 148.93 27.2 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 109.295 -0.631 . . . . 0.0 109.295 178.334 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 385' ' ' GLY . . . . . . . . . . . . . . . 109.91 135.1 7.04 Favored Glycine 0 N--CA 1.447 -0.594 0 C-N-CA 120.64 -0.79 . . . . 0.0 112.318 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 386' ' ' GLY . . . . . . . . . . . . . . . -113.38 41.27 2.25 Favored Glycine 0 N--CA 1.447 -0.589 0 C-N-CA 120.995 -0.621 . . . . 0.0 112.055 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -112.21 153.33 17.45 Favored Glycine 0 N--CA 1.447 -0.591 0 C-N-CA 120.965 -0.636 . . . . 0.0 111.647 179.545 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 20.6 m-20 -93.41 143.44 26.28 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-O 120.961 0.41 . . . . 0.0 110.64 -177.168 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 389' ' ' VAL . . . . . 0.412 HG22 ' HB3' ' A' ' 405' ' ' TYR . 23.9 t -112.7 137.09 46.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.613 0 CA-C-N 115.891 -0.595 . . . . 0.0 109.782 179.464 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 5.0 p -147.42 138.83 23.87 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.817 0.341 . . . . 0.0 111.459 -179.077 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -156.74 154.11 25.26 Favored Glycine 0 N--CA 1.445 -0.764 0 N-CA-C 111.247 -0.741 . . . . 0.0 111.247 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 23.2 mtt180 -119.51 153.15 35.78 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-O 121.468 0.652 . . . . 0.0 111.952 -175.945 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 26.6 m-85 -93.71 159.31 15.26 Favored 'General case' 0 C--N 1.319 -0.735 0 CA-C-N 114.649 -1.159 . . . . 0.0 110.045 178.643 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 394' ' ' TYR . . . . . 0.631 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 3.5 m-85 -101.62 -178.45 3.73 Favored 'General case' 0 C--N 1.317 -0.818 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.723 -177.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 395' ' ' GLY . . . . . 0.407 ' O ' ' N ' ' A' ' 397' ' ' ALA . . . -42.52 168.47 0.01 OUTLIER Glycine 0 CA--C 1.524 0.594 0 O-C-N 124.048 0.842 . . . . 0.0 115.159 -175.046 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_exo -19.35 -45.17 0.02 OUTLIER 'Trans proline' 0 C--N 1.356 0.924 1 C-N-CA 127.204 5.269 . . . . 0.0 117.588 -167.23 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 397' ' ' ALA . . . . . 0.407 ' N ' ' O ' ' A' ' 395' ' ' GLY . . . -72.25 -21.26 61.41 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -174.17 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 54.33 19.13 11.33 Favored Glycine 0 C--O 1.219 -0.837 0 CA-C-N 115.918 -0.583 . . . . 0.0 113.777 174.437 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 399' ' ' GLU . . . . . 0.882 ' HG3' ' HB3' ' A' ' 424' ' ' LYS . 23.0 tt0 -79.7 -10.66 59.82 Favored 'General case' 0 C--N 1.324 -0.516 0 CA-C-O 121.538 0.685 . . . . 0.0 110.161 -174.312 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 44.6 mt-10 -118.54 125.7 50.41 Favored 'General case' 0 C--N 1.315 -0.934 0 CA-C-N 116.011 -0.54 . . . . 0.0 109.864 178.458 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 401' ' ' VAL . . . . . 0.464 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 12.9 p -130.36 141.12 47.12 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.718 0 CA-C-N 115.931 -0.577 . . . . 0.0 109.64 178.01 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -145.43 139.01 26.6 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-N 116.419 -0.355 . . . . 0.0 110.847 -177.678 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -167.75 -163.83 22.35 Favored Glycine 0 N--CA 1.444 -0.799 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.1 179.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 404' ' ' LYS . . . . . 0.553 ' HG2' HG12 ' A' ' 419' ' ' VAL . 21.2 mtmt -146.89 158.98 44.06 Favored 'General case' 0 C--N 1.325 -0.499 0 N-CA-C 109.259 -0.645 . . . . 0.0 109.259 -178.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 405' ' ' TYR . . . . . 0.412 ' HB3' HG22 ' A' ' 389' ' ' VAL . 19.1 p90 -114.74 134.75 54.85 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.107 -0.701 . . . . 0.0 109.107 170.329 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . 0.407 ' OG ' ' HA2' ' A' ' 416' ' ' GLY . 40.0 m -149.06 125.61 11.0 Favored 'General case' 0 C--N 1.32 -0.709 0 CA-C-O 121.021 0.439 . . . . 0.0 111.724 -174.569 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 27.3 p90 -93.13 106.62 18.56 Favored 'General case' 0 N--CA 1.448 -0.531 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 166.89 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 408' ' ' ARG . . . . . . . . . . . . . 14.2 ptm180 -136.03 72.19 61.16 Favored Pre-proline 0 C--N 1.322 -0.603 0 N-CA-C 112.757 0.651 . . . . 0.0 112.757 -172.65 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 409' ' ' PRO . . . . . . . . . . . . . 27.1 Cg_exo -63.52 -44.06 15.45 Favored 'Trans proline' 0 C--N 1.347 0.49 0 C-N-CA 122.267 1.978 . . . . 0.0 109.67 169.64 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 410' ' ' THR . . . . . 0.549 ' HB ' ' HD3' ' A' ' 414' ' ' LYS . 2.4 m -94.86 129.85 41.68 Favored 'General case' 0 N--CA 1.445 -0.684 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 168.199 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 411' ' ' ASP . . . . . . . . . . . . . 10.2 m-20 -84.01 30.6 0.51 Allowed 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 120.954 0.407 . . . . 0.0 111.101 -178.18 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 412' ' ' ALA . . . . . . . . . . . . . . . -154.66 138.74 16.45 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.914 -0.585 . . . . 0.0 110.117 178.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 413' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 50.01 23.56 1.14 Allowed 'General case' 0 N--CA 1.479 0.983 0 C-N-CA 124.535 1.134 . . . . 0.0 112.581 178.203 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 414' ' ' LYS . . . . . 0.549 ' HD3' ' HB ' ' A' ' 410' ' ' THR . 12.2 mptt -106.42 -171.56 1.92 Allowed 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 109.142 -0.688 . . . . 0.0 109.142 176.148 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 415' ' ' GLY . . . . . . . . . . . . . . . -67.94 131.11 28.08 Favored Glycine 0 N--CA 1.444 -0.803 0 C-N-CA 119.625 -1.274 . . . . 0.0 111.165 -179.797 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 416' ' ' GLY . . . . . 0.407 ' HA2' ' OG ' ' A' ' 406' ' ' SER . . . -165.86 21.68 0.12 Allowed Glycine 0 N--CA 1.446 -0.64 0 N-CA-C 111.34 -0.704 . . . . 0.0 111.34 -177.0 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 417' ' ' PHE . . . . . 0.782 ' HB3' ' HD2' ' A' ' 326' ' ' PHE . 99.0 m-85 -126.65 -176.24 3.63 Favored 'General case' 0 N--CA 1.435 -1.185 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 -179.545 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 418' ' ' GLY . . . . . 0.496 ' H ' ' HD2' ' A' ' 326' ' ' PHE . . . 81.95 77.07 1.06 Allowed Glycine 0 N--CA 1.436 -1.311 0 C-N-CA 118.212 -1.947 . . . . 0.0 110.771 -174.58 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 419' ' ' VAL . . . . . 0.584 HG13 ' HE2' ' A' ' 326' ' ' PHE . 13.0 m -104.73 161.54 4.77 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 N-CA-C 109.899 -0.408 . . . . 0.0 109.899 -175.264 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 420' ' ' PHE . . . . . 0.437 ' HB3' HG12 ' A' ' 323' ' ' VAL . 49.5 p90 -139.27 147.74 42.09 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-O 121.109 0.48 . . . . 0.0 110.645 -178.405 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -137.44 134.61 36.04 Favored 'General case' 0 C--N 1.314 -0.973 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 174.254 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -132.0 134.75 7.79 Favored Glycine 0 N--CA 1.437 -1.257 0 C-N-CA 120.321 -0.942 . . . . 0.0 111.625 -177.695 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 17.2 mtpp -109.48 125.61 52.64 Favored 'General case' 0 C--N 1.314 -0.943 0 N-CA-C 109.396 -0.594 . . . . 0.0 109.396 178.377 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 424' ' ' LYS . . . . . 0.882 ' HB3' ' HG3' ' A' ' 399' ' ' GLU . 8.0 tttm -66.53 117.88 9.35 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-N 115.734 -0.666 . . . . 0.0 110.855 -179.284 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 11.2 tp10 -100.46 113.27 25.91 Favored 'General case' 0 C--N 1.312 -1.025 0 N-CA-C 108.626 -0.879 . . . . 0.0 108.626 173.762 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 426' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 -73.9 80.5 1.65 Allowed 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.574 0.702 . . . . 0.0 109.642 175.603 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 427' ' ' ASP . . . . . . . . . . . . . 51.8 t0 -62.06 124.69 21.49 Favored 'General case' 0 C--N 1.326 -0.427 0 CA-C-N 114.563 -1.199 . . . . 0.0 110.949 -177.02 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . 0.472 ' O ' ' HB3' ' A' ' 429' ' ' GLU . 52.8 tp -67.55 -39.96 84.97 Favored 'General case' 0 C--N 1.32 -0.708 0 CA-C-N 114.794 -1.094 . . . . 0.0 109.688 176.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 429' ' ' GLU . . . . . 0.472 ' HB3' ' O ' ' A' ' 428' ' ' LEU . 2.4 pp20? 167.83 -25.57 0.0 OUTLIER 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 114.556 -1.202 . . . . 0.0 108.037 178.387 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 430' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER 66.45 -70.51 0.1 Allowed 'General case' 0 N--CA 1.465 0.29 0 CA-C-N 114.858 -1.064 . . . . 0.0 111.986 175.94 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 30.6 t-80 -165.03 72.34 0.19 Allowed 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.004 0.431 . . . . 0.0 110.695 -179.571 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 432' ' ' HIS . . . . . . . . . . . . . 81.2 m-70 -106.95 -4.44 19.09 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.018 0.437 . . . . 0.0 110.13 173.057 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 433' ' ' HIS . . . . . . . . . . . . . 44.6 m-70 -97.11 96.48 8.48 Favored 'General case' 0 C--N 1.326 -0.452 0 CA-C-N 115.994 -0.548 . . . . 0.0 110.872 178.483 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 434' ' ' HIS . . . . . . . . . . . . . 4.6 t-80 -110.65 -23.79 10.88 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 108.537 -0.912 . . . . 0.0 108.537 172.637 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 435' ' ' HIS . . . . . . . . . . . . . 5.1 p-80 . . . . . 0 C--O 1.246 0.882 0 CA-C-N 114.692 -1.14 . . . . 0.0 109.271 173.497 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 276' ' ' ASN . . . . . . . . . . . . . 27.5 p-10 . . . . . 0 N--CA 1.483 1.179 0 CA-C-O 120.399 0.142 . . . . 0.0 111.153 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 70.3 mt -95.7 -74.43 0.45 Allowed 'Isoleucine or valine' 0 CA--C 1.517 -0.304 0 CA-C-O 121.218 0.532 . . . . 0.0 111.463 -177.744 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 278' ' ' PHE . . . . . . . . . . . . . 58.2 m-85 -63.52 -31.95 73.26 Favored 'General case' 0 C--N 1.314 -0.943 0 CA-C-N 115.061 -0.972 . . . . 0.0 111.117 -178.486 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -136.16 87.52 23.21 Favored Pre-proline 0 C--N 1.323 -0.557 0 CA-C-N 115.985 -0.552 . . . . 0.0 110.721 179.165 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 280' ' ' PRO . . . . . 0.498 ' O ' ' HB2' ' A' ' 281' ' ' GLU . 1.0 OUTLIER -84.04 117.77 2.27 Favored 'Trans proline' 0 N--CA 1.454 -0.805 0 C-N-CA 122.672 2.248 . . . . 0.0 111.286 174.584 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . 0.498 ' HB2' ' O ' ' A' ' 280' ' ' PRO . 26.1 tt0 170.51 -43.86 0.01 OUTLIER 'General case' 0 N--CA 1.465 0.284 0 O-C-N 123.662 0.601 . . . . 0.0 110.219 -179.57 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -176.71 -148.91 7.35 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.803 -0.713 . . . . 0.0 112.146 -179.538 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 283' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -102.36 84.38 2.45 Favored 'General case' 0 C--N 1.322 -0.606 0 CA-C-O 120.872 0.368 . . . . 0.0 111.289 -177.488 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 82.4 m-85 -92.0 120.06 32.3 Favored 'General case' 0 C--N 1.324 -0.535 0 N-CA-C 109.844 -0.428 . . . . 0.0 109.844 176.082 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . 0.472 ' HA ' ' NE ' ' A' ' 302' ' ' ARG . 17.8 ptp180 -133.16 -13.06 2.78 Favored 'General case' 0 C--N 1.324 -0.523 0 CA-C-N 115.913 -0.585 . . . . 0.0 111.914 -172.894 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.424 ' HB3' HD22 ' A' ' 287' ' ' LEU . 42.5 m-85 -74.77 -68.49 0.54 Allowed 'General case' 0 C--N 1.324 -0.51 0 C-N-CA 120.565 -0.454 . . . . 0.0 110.111 176.569 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . 0.502 HD13 ' HG3' ' A' ' 304' ' ' GLN . 3.5 mm? -115.58 127.21 55.07 Favored 'General case' 0 C--N 1.325 -0.485 0 C-N-CA 120.814 -0.355 . . . . 0.0 110.93 177.392 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 288' ' ' THR . . . . . 0.733 ' HB ' ' CB ' ' A' ' 302' ' ' ARG . 59.8 m -170.17 152.96 4.36 Favored 'General case' 0 C--N 1.327 -0.376 0 N-CA-C 107.163 -1.421 . . . . 0.0 107.163 176.434 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 289' ' ' TYR . . . . . . . . . . . . . 84.3 m-85 -138.17 122.46 18.2 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 109.79 -0.448 . . . . 0.0 109.79 176.568 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . 0.415 ' O ' ' HA ' ' A' ' 301' ' ' LEU . . . 158.08 168.39 20.31 Favored Glycine 0 N--CA 1.444 -0.781 0 C-N-CA 119.015 -1.564 . . . . 0.0 112.524 170.704 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 291' ' ' ALA . . . . . 0.576 ' HA ' HD13 ' A' ' 301' ' ' LEU . . . -143.84 111.09 5.82 Favored 'General case' 0 N--CA 1.445 -0.724 0 CA-C-O 120.996 0.427 . . . . 0.0 111.717 178.041 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 292' ' ' GLU . . . . . 0.432 ' O ' ' HB3' ' A' ' 300' ' ' ALA . 29.1 tt0 -163.8 121.05 1.77 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.292 -0.867 . . . . 0.0 108.977 169.161 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 293' ' ' LYS . . . . . 0.401 ' HB3' ' HE2' ' A' ' 293' ' ' LYS . 31.1 ttpt -118.14 125.32 50.01 Favored 'General case' 0 C--N 1.307 -1.26 0 CA-C-N 115.857 -0.611 . . . . 0.0 110.225 -177.136 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 294' ' ' LEU . . . . . 0.776 ' HB3' ' HB3' ' A' ' 298' ' ' SER . 6.1 tt -86.87 118.97 70.87 Favored Pre-proline 0 N--CA 1.442 -0.854 0 N-CA-C 109.493 -0.558 . . . . 0.0 109.493 -179.148 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 295' ' ' PRO . . . . . . . . . . . . . 20.9 Cg_exo -65.9 97.59 0.34 Allowed 'Trans proline' 0 N--CA 1.464 -0.235 0 C-N-CA 122.803 2.336 . . . . 0.0 111.387 179.155 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . 157.25 15.41 0.04 OUTLIER Glycine 0 N--CA 1.445 -0.7 0 CA-C-N 115.681 -0.69 . . . . 0.0 112.356 -177.119 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 115.9 -24.66 10.0 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.572 -0.823 . . . . 0.0 113.383 177.786 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 298' ' ' SER . . . . . 0.776 ' HB3' ' HB3' ' A' ' 294' ' ' LEU . 8.7 t -82.89 167.87 17.61 Favored 'General case' 0 C--N 1.327 -0.404 0 CA-C-N 117.063 0.431 . . . . 0.0 110.901 -174.544 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 299' ' ' TYR . . . . . . . . . . . . . 1.3 p90 -159.56 142.97 14.42 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.252 -173.769 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 300' ' ' ALA . . . . . 0.631 ' O ' HD13 ' A' ' 301' ' ' LEU . . . -152.07 90.14 1.5 Allowed 'General case' 0 C--N 1.323 -0.57 0 C-N-CA 120.441 -0.504 . . . . 0.0 111.185 171.677 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 301' ' ' LEU . . . . . 0.631 HD13 ' O ' ' A' ' 300' ' ' ALA . 0.5 OUTLIER -139.59 150.1 44.61 Favored 'General case' 0 CA--C 1.512 -0.489 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 172.28 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 302' ' ' ARG . . . . . 0.733 ' CB ' ' HB ' ' A' ' 288' ' ' THR . 15.1 tpp180 -164.99 127.74 2.24 Favored 'General case' 0 C--N 1.317 -0.832 0 N-CA-C 108.58 -0.896 . . . . 0.0 108.58 168.298 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 303' ' ' VAL . . . . . . . . . . . . . 17.5 m -111.88 122.38 66.1 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.644 0 CA-C-O 121.108 0.48 . . . . 0.0 110.992 -179.641 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 304' ' ' GLN . . . . . 0.502 ' HG3' HD13 ' A' ' 287' ' ' LEU . 75.6 mm-40 -138.26 160.34 39.71 Favored 'General case' 0 C--N 1.319 -0.742 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.294 177.702 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . 0.626 ' O ' ' HD3' ' A' ' 307' ' ' PRO . . . -94.15 -171.37 38.36 Favored Glycine 0 N--CA 1.444 -0.816 0 N-CA-C 110.547 -1.021 . . . . 0.0 110.547 175.54 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 306' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -88.48 106.02 11.37 Favored Pre-proline 0 C--N 1.323 -0.581 0 CA-C-N 117.268 0.534 . . . . 0.0 110.381 -179.842 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . 0.626 ' HD3' ' O ' ' A' ' 305' ' ' GLY . 85.2 Cg_endo -89.27 149.33 5.46 Favored 'Trans proline' 0 N--CA 1.452 -0.937 0 C-N-CA 122.848 2.365 . . . . 0.0 111.947 178.283 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . 0.755 ' HB1' ' CD2' ' A' ' 313' ' ' LEU . . . -61.24 169.26 2.21 Favored 'General case' 0 C--N 1.323 -0.564 0 CA-C-N 115.888 -0.596 . . . . 0.0 111.231 174.027 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 309' ' ' LYS . . . . . 0.7 ' H ' HD23 ' A' ' 313' ' ' LEU . 13.0 mptt -125.42 85.24 2.38 Favored 'General case' 0 C--N 1.322 -0.587 0 N-CA-C 107.72 -1.215 . . . . 0.0 107.72 174.355 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -57.4 -19.71 34.36 Favored Glycine 0 N--CA 1.462 0.409 0 N-CA-C 114.28 0.472 . . . . 0.0 114.28 -168.83 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 9.8 pt-20 -87.35 -16.27 35.51 Favored 'General case' 0 C--N 1.323 -0.577 0 CA-C-O 120.91 0.386 . . . . 0.0 111.227 179.15 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 47.9 tpp -110.95 -34.38 6.24 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.153 -175.067 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 313' ' ' LEU . . . . . 0.755 ' CD2' ' HB1' ' A' ' 308' ' ' ALA . 1.7 pp -83.45 137.09 34.06 Favored 'General case' 0 C--N 1.328 -0.357 0 N-CA-C 108.458 -0.942 . . . . 0.0 108.458 175.471 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 314' ' ' ALA . . . . . 0.53 ' HA ' ' HB2' ' A' ' 346' ' ' PHE . . . -145.63 172.57 13.07 Favored 'General case' 0 C--N 1.318 -0.781 0 N-CA-C 112.62 0.6 . . . . 0.0 112.62 -166.049 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.31 176.5 15.77 Favored Glycine 0 N--CA 1.445 -0.758 0 CA-C-N 115.061 -0.972 . . . . 0.0 110.932 -177.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 15.7 p -108.0 134.01 51.5 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 109.344 -0.613 . . . . 0.0 109.344 170.619 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -139.45 161.12 38.24 Favored 'General case' 0 C--N 1.317 -0.82 0 CA-C-O 121.204 0.526 . . . . 0.0 111.785 -172.273 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . 0.713 ' HA ' ' O ' ' A' ' 342' ' ' ALA . 7.7 p -141.22 124.12 15.45 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.936 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.51 173.818 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . 0.595 ' CE2' ' HB2' ' A' ' 424' ' ' LYS . 1.9 m-85 -102.18 143.76 31.58 Favored 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.533 -0.758 . . . . 0.0 109.605 -178.133 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 47.0 m-80 -127.78 132.6 49.49 Favored 'General case' 0 C--N 1.311 -1.073 0 N-CA-C 108.801 -0.814 . . . . 0.0 108.801 176.132 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -165.12 -159.33 11.28 Favored Glycine 0 N--CA 1.442 -0.91 0 C-N-CA 120.218 -0.992 . . . . 0.0 112.167 -178.522 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 44.0 mt-10 -120.78 156.13 32.53 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-O 120.969 0.414 . . . . 0.0 110.298 -177.473 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 323' ' ' VAL . . . . . 0.831 HG21 HG12 ' A' ' 355' ' ' ILE . 41.0 t -119.45 118.32 56.94 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.677 0 CA-C-N 115.812 -0.631 . . . . 0.0 110.621 -179.24 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 324' ' ' LEU . . . . . . . . . . . . . 96.4 mt -104.3 102.4 12.1 Favored 'General case' 0 C--N 1.319 -0.759 0 CA-C-O 121.317 0.58 . . . . 0.0 110.149 -179.349 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 325' ' ' HIS . . . . . 0.489 ' HB3' ' OH ' ' A' ' 405' ' ' TYR . 6.3 p80 -108.1 132.06 53.97 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.992 -0.549 . . . . 0.0 109.523 176.524 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 326' ' ' PHE . . . . . 0.672 ' HD2' ' HB3' ' A' ' 417' ' ' PHE . 10.3 m-85 -106.52 150.15 26.41 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-N 115.455 -0.793 . . . . 0.0 110.695 -169.395 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 327' ' ' HIS . . . . . . . . . . . . . 10.9 p-80 -166.37 150.94 7.79 Favored 'General case' 0 C--N 1.325 -0.483 0 CA-C-N 115.628 -0.715 . . . . 0.0 109.119 175.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 328' ' ' THR . . . . . . . . . . . . . 9.5 p -84.52 100.69 11.54 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 121.222 0.534 . . . . 0.0 111.772 -174.601 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 329' ' ' GLU . . . . . 0.526 ' HG3' ' CE2' ' A' ' 334' ' ' TYR . 6.5 mm-40 -88.75 93.45 9.58 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.579 -0.737 . . . . 0.0 110.033 177.664 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 330' ' ' ASN . . . . . . . . . . . . . 7.4 t30 67.65 -66.49 0.21 Allowed 'General case' 0 N--CA 1.467 0.405 0 C-N-CA 123.279 0.632 . . . . 0.0 110.886 -175.734 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 331' ' ' GLY . . . . . 0.599 ' O ' ' HB2' ' A' ' 332' ' ' ARG . . . -177.69 88.32 0.07 OUTLIER Glycine 0 N--CA 1.446 -0.683 0 N-CA-C 110.702 -0.959 . . . . 0.0 110.702 176.751 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 332' ' ' ARG . . . . . 0.599 ' HB2' ' O ' ' A' ' 331' ' ' GLY . 0.0 OUTLIER 156.61 90.97 0.0 OUTLIER Pre-proline 0 N--CA 1.465 0.286 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 -175.248 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 333' ' ' PRO . . . . . . . . . . . . . 8.2 Cg_exo -72.08 70.54 2.99 Favored 'Trans proline' 0 C--O 1.234 0.295 0 C-N-CA 122.783 2.322 . . . . 0.0 112.676 -177.457 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 334' ' ' TYR . . . . . 0.526 ' CE2' ' HG3' ' A' ' 329' ' ' GLU . 51.3 p90 -77.53 135.15 65.12 Favored Pre-proline 0 N--CA 1.453 -0.282 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 175.232 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 335' ' ' PRO . . . . . 0.414 ' HD3' ' HA ' ' A' ' 334' ' ' TYR . 2.8 Cg_endo -79.64 125.65 6.28 Favored 'Trans proline' 0 N--CA 1.447 -1.25 0 C-N-CA 122.138 1.892 . . . . 0.0 112.232 -176.265 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 336' ' ' THR . . . . . . . . . . . . . 4.9 p -87.01 138.82 31.17 Favored 'General case' 0 C--N 1.316 -0.85 0 CA-C-N 115.542 -0.754 . . . . 0.0 109.132 172.635 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 337' ' ' ARG . . . . . 0.6 ' HA ' ' O ' ' A' ' 323' ' ' VAL . 0.0 OUTLIER -115.7 124.22 50.28 Favored 'General case' 0 C--N 1.318 -0.796 0 CA-C-O 121.416 0.627 . . . . 0.0 111.503 -172.428 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -103.69 -177.97 25.86 Favored Glycine 0 N--CA 1.442 -0.904 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.949 174.355 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 339' ' ' ARG . . . . . 0.442 ' O ' ' HA ' ' A' ' 355' ' ' ILE . 75.4 mtp180 -114.18 127.49 55.92 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 120.952 0.406 . . . . 0.0 109.911 -177.575 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 340' ' ' PHE . . . . . 0.617 ' HB2' HG23 ' A' ' 323' ' ' VAL . 29.6 t80 -126.85 139.91 52.74 Favored 'General case' 0 C--N 1.32 -0.716 0 CA-C-N 115.641 -0.709 . . . . 0.0 112.257 -169.412 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 341' ' ' ALA . . . . . 0.533 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -139.04 155.75 47.71 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 114.587 -1.188 . . . . 0.0 108.844 172.662 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . 0.848 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -143.12 117.82 9.85 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.14 0.495 . . . . 0.0 111.405 -177.368 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . 0.677 ' HB3' ' HB3' ' A' ' 352' ' ' ASP . 3.6 tppp? -96.07 98.95 10.76 Favored 'General case' 0 C--N 1.32 -0.692 0 CA-C-N 114.851 -1.068 . . . . 0.0 108.943 -179.699 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 344' ' ' VAL . . . . . 0.653 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.6 OUTLIER -123.33 128.33 74.75 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.85 0 N-CA-C 113.099 0.777 . . . . 0.0 113.099 -169.56 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 345' ' ' ASP . . . . . 0.445 ' HB2' ' HB3' ' A' ' 348' ' ' SER . 1.8 m-20 -100.41 107.64 19.44 Favored 'General case' 0 C--N 1.325 -0.462 0 N-CA-C 108.161 -1.051 . . . . 0.0 108.161 174.159 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 346' ' ' PHE . . . . . 0.53 ' HB2' ' HA ' ' A' ' 314' ' ' ALA . 38.0 m-85 -64.79 -36.58 84.77 Favored 'General case' 0 C--N 1.327 -0.396 0 CA-C-O 120.807 0.337 . . . . 0.0 111.204 -176.391 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -68.62 -14.8 67.78 Favored Glycine 0 N--CA 1.45 -0.396 0 C-N-CA 120.893 -0.67 . . . . 0.0 112.406 -178.544 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 348' ' ' SER . . . . . 0.445 ' HB3' ' HB2' ' A' ' 345' ' ' ASP . 44.2 t -109.13 -9.6 15.03 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-O 121.292 0.568 . . . . 0.0 110.135 179.219 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 349' ' ' LYS . . . . . 0.441 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 31.8 mtmm 52.44 55.36 9.22 Favored 'General case' 0 N--CA 1.462 0.137 0 CA-C-N 114.966 -1.016 . . . . 0.0 111.326 -176.07 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 8.6 t -146.72 145.69 30.07 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.508 179.518 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 351' ' ' VAL . . . . . 0.653 ' HB ' ' HB ' ' A' ' 344' ' ' VAL . 0.6 OUTLIER -136.46 146.65 28.51 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.452 0 CA-C-O 120.956 0.408 . . . . 0.0 110.432 -177.042 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 352' ' ' ASP . . . . . 0.848 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 36.8 t70 -108.6 117.47 34.26 Favored 'General case' 0 C--O 1.211 -0.929 0 N-CA-C 108.74 -0.837 . . . . 0.0 108.74 172.927 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -116.04 114.28 3.06 Favored Glycine 0 C--N 1.302 -1.334 0 C-N-CA 120.242 -0.98 . . . . 0.0 112.031 -176.668 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 354' ' ' ILE . . . . . 0.558 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -113.65 129.08 70.12 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.259 0 CA-C-O 120.977 0.418 . . . . 0.0 110.475 -175.495 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 355' ' ' ILE . . . . . 0.831 HG12 HG21 ' A' ' 323' ' ' VAL . 5.1 mp -127.5 111.78 26.06 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-N 115.826 -0.625 . . . . 0.0 109.95 177.715 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 356' ' ' ASP . . . . . . . . . . . . . 1.7 p-10 -103.25 142.64 33.83 Favored 'General case' 0 C--N 1.323 -0.583 0 C-N-CA 120.164 -0.614 . . . . 0.0 109.688 175.028 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 20.2 m -92.67 10.22 31.54 Favored 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.786 -0.643 . . . . 0.0 111.236 -175.784 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 358' ' ' GLY . . . . . . . . . . . . . . . 78.08 -0.09 74.54 Favored Glycine 0 N--CA 1.453 -0.211 0 N-CA-C 111.381 -0.688 . . . . 0.0 111.381 -174.176 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 359' ' ' ASP . . . . . . . . . . . . . 11.4 t70 -148.39 100.98 3.2 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.07 -0.565 . . . . 0.0 109.667 -179.303 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 360' ' ' ASP . . . . . 0.424 ' O ' ' HA2' ' A' ' 364' ' ' GLY . 32.8 t70 -83.26 -23.91 32.5 Favored 'General case' 0 C--N 1.321 -0.645 0 CA-C-O 121.051 0.453 . . . . 0.0 111.493 -178.083 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 361' ' ' LEU . . . . . 0.48 HD22 ' H ' ' A' ' 361' ' ' LEU . 2.2 mm? -76.78 -34.88 57.96 Favored 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 112.543 0.571 . . . . 0.0 112.543 -170.785 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 362' ' ' HIS . . . . . . . . . . . . . 42.5 m80 -111.42 -57.16 2.29 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.942 0.401 . . . . 0.0 110.666 -175.121 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 363' ' ' MET . . . . . 0.518 ' HA ' ' CE ' ' A' ' 363' ' ' MET . 9.8 mmt -77.39 -53.33 7.79 Favored 'General case' 0 C--N 1.325 -0.468 0 N-CA-C 109.447 -0.575 . . . . 0.0 109.447 177.256 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 364' ' ' GLY . . . . . 0.424 ' HA2' ' O ' ' A' ' 360' ' ' ASP . . . 110.98 170.33 19.26 Favored Glycine 0 N--CA 1.441 -1.032 0 CA-C-N 115.331 -0.85 . . . . 0.0 112.55 175.87 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 365' ' ' THR . . . . . . . . . . . . . 31.7 m -107.16 112.76 25.8 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 108.55 -0.907 . . . . 0.0 108.55 170.595 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 21.6 mp0 -105.43 117.56 34.33 Favored 'General case' 0 C--N 1.316 -0.861 0 CA-C-O 121.363 0.602 . . . . 0.0 109.934 -173.512 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 25.4 pttm -114.96 146.99 40.62 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.695 -0.684 . . . . 0.0 109.665 178.54 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 368' ' ' PHE . . . . . 0.488 ' HA ' ' H ' ' A' ' 382' ' ' THR . 44.6 p90 -124.68 157.96 34.32 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 109.403 -0.592 . . . . 0.0 109.403 178.048 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 8.0 ttpt -126.05 134.96 51.26 Favored 'General case' 0 C--N 1.314 -0.964 0 N-CA-C 108.77 -0.826 . . . . 0.0 108.77 173.538 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . . . . . . . . . . . -136.14 144.87 45.28 Favored 'General case' 0 C--N 1.318 -0.766 0 CA-C-N 115.864 -0.607 . . . . 0.0 111.095 -173.583 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -96.92 134.92 39.64 Favored 'General case' 0 N--CA 1.447 -0.616 0 N-CA-C 109.171 -0.677 . . . . 0.0 109.171 175.847 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 372' ' ' ILE . . . . . 0.441 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 66.8 mt -79.75 105.71 9.69 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.619 0 CA-C-O 121.884 0.85 . . . . 0.0 110.739 -177.804 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . 0.445 ' HB3' ' HD3' ' A' ' 378' ' ' LYS . 32.1 t70 -108.27 80.69 1.39 Allowed 'General case' 0 C--N 1.321 -0.652 0 CA-C-N 114.492 -1.231 . . . . 0.0 109.19 -178.217 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 62.97 118.83 0.01 OUTLIER Glycine 0 CA--C 1.523 0.541 0 CA-C-N 114.54 -1.209 . . . . 0.0 113.488 -176.705 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 375' ' ' ASN . . . . . 0.705 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 3.1 p-10 28.92 46.67 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.021 0 C-N-CA 124.363 1.065 . . . . 0.0 113.631 178.211 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 158.71 178.89 33.15 Favored Glycine 0 N--CA 1.442 -0.914 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 179.551 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 377' ' ' PHE . . . . . 0.607 ' CZ ' HG21 ' A' ' 401' ' ' VAL . 4.0 p90 -140.62 150.99 44.27 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-N 117.797 0.798 . . . . 0.0 112.127 -176.981 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 378' ' ' LYS . . . . . 0.445 ' HD3' ' HB3' ' A' ' 373' ' ' ASP . 0.0 OUTLIER -125.96 134.77 51.42 Favored 'General case' 0 C--N 1.32 -0.684 0 N-CA-C 107.833 -1.173 . . . . 0.0 107.833 176.562 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -161.19 -158.6 9.46 Favored Glycine 0 N--CA 1.448 -0.565 0 C-N-CA 120.178 -1.011 . . . . 0.0 112.853 -177.016 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 15.2 t -150.13 166.45 29.76 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 120.706 0.289 . . . . 0.0 110.383 -177.288 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 381' ' ' TRP . . . . . 0.791 ' HD1' ' HA3' ' A' ' 387' ' ' GLY . 49.5 m95 -67.62 121.11 15.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.959 -0.564 . . . . 0.0 111.856 -178.502 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 382' ' ' THR . . . . . 0.488 ' H ' ' HA ' ' A' ' 368' ' ' PHE . 22.7 m 60.73 -85.88 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 114.774 -1.103 . . . . 0.0 112.533 179.46 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 383' ' ' GLU . . . . . . . . . . . . . 39.2 tt0 -133.01 -48.85 0.86 Allowed 'General case' 0 C--N 1.319 -0.728 0 N-CA-C 108.988 -0.745 . . . . 0.0 108.988 -176.249 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 384' ' ' ASN . . . . . . . . . . . . . 44.9 t-20 -163.17 72.09 0.29 Allowed 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.185 -0.916 . . . . 0.0 108.864 172.254 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 385' ' ' GLY . . . . . . . . . . . . . . . -88.3 2.63 85.23 Favored Glycine 0 N--CA 1.451 -0.315 0 CA-C-N 115.624 -0.716 . . . . 0.0 112.34 -179.146 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 386' ' ' GLY . . . . . . . . . . . . . . . 86.49 -14.94 53.55 Favored Glycine 0 N--CA 1.453 -0.175 0 C-N-CA 120.947 -0.644 . . . . 0.0 112.667 179.554 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . 0.791 ' HA3' ' HD1' ' A' ' 381' ' ' TRP . . . -88.17 126.61 8.17 Favored Glycine 0 N--CA 1.446 -0.656 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.087 -179.486 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -82.49 138.86 34.22 Favored 'General case' 0 C--N 1.323 -0.566 0 N-CA-C 110.304 -0.258 . . . . 0.0 110.304 178.664 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 44.5 t -132.17 128.56 59.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.366 0 CA-C-O 120.493 0.187 . . . . 0.0 110.694 -179.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 18.2 m -133.94 151.34 51.45 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 116.726 -0.215 . . . . 0.0 110.673 179.245 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 391' ' ' GLY . . . . . 0.552 ' HA2' ' HA3' ' A' ' 403' ' ' GLY . . . -158.59 151.52 22.56 Favored Glycine 0 N--CA 1.454 -0.141 0 C-N-CA 121.227 -0.511 . . . . 0.0 111.859 175.795 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 5.7 mpt_? -120.3 146.87 45.69 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-O 120.873 0.368 . . . . 0.0 110.862 -176.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 0.4 OUTLIER -91.07 158.39 16.69 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.95 -179.814 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 394' ' ' TYR . . . . . 0.66 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 2.9 m-85 -102.18 -177.19 3.33 Favored 'General case' 0 C--N 1.318 -0.775 0 CA-C-N 115.188 -0.915 . . . . 0.0 110.058 177.262 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 395' ' ' GLY . . . . . 0.421 ' O ' ' N ' ' A' ' 397' ' ' ALA . . . -37.98 159.33 0.01 OUTLIER Glycine 0 CA--C 1.525 0.705 0 O-C-N 124.224 0.953 . . . . 0.0 115.169 -175.539 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_exo -18.1 -42.65 0.01 OUTLIER 'Trans proline' 0 C--N 1.352 0.723 1 C-N-CA 127.729 5.62 . . . . 0.0 118.213 -168.136 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 397' ' ' ALA . . . . . 0.421 ' N ' ' O ' ' A' ' 395' ' ' GLY . . . -78.51 -19.44 52.97 Favored 'General case' 0 C--N 1.326 -0.441 0 CA-C-N 118.402 0.546 . . . . 0.0 112.457 -173.106 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 62.41 12.1 37.57 Favored Glycine 0 C--O 1.216 -0.977 0 CA-C-O 119.355 -0.691 . . . . 0.0 114.221 176.624 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 399' ' ' GLU . . . . . 0.716 ' HG3' ' HD3' ' A' ' 424' ' ' LYS . 1.1 mp0 -63.54 -10.57 18.7 Favored 'General case' 0 N--CA 1.467 0.401 0 CA-C-N 118.189 0.994 . . . . 0.0 111.314 -178.161 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 48.2 mt-10 -122.55 128.32 50.6 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 121.041 0.448 . . . . 0.0 110.003 176.107 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 401' ' ' VAL . . . . . 0.607 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 12.2 p -131.89 138.01 53.65 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.799 0 CA-C-N 115.693 -0.685 . . . . 0.0 109.758 175.866 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -141.67 132.01 25.09 Favored 'General case' 0 C--N 1.319 -0.757 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.083 -178.647 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 403' ' ' GLY . . . . . 0.552 ' HA3' ' HA2' ' A' ' 391' ' ' GLY . . . -151.29 -173.76 21.49 Favored Glycine 0 N--CA 1.439 -1.136 0 C-N-CA 120.089 -1.053 . . . . 0.0 112.426 -178.055 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 404' ' ' LYS . . . . . 0.82 ' HG2' HG12 ' A' ' 419' ' ' VAL . 30.3 mtpt -145.73 155.66 43.11 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -179.684 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 405' ' ' TYR . . . . . 0.489 ' OH ' ' HB3' ' A' ' 325' ' ' HIS . 50.7 p90 -131.43 147.42 52.55 Favored 'General case' 0 C--N 1.314 -0.974 0 CA-C-O 121.011 0.434 . . . . 0.0 110.525 -179.232 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 28.3 m -84.3 103.31 13.37 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-N 116.123 -0.49 . . . . 0.0 110.14 -178.422 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . . . . . . . . . 31.8 t80 -81.45 106.87 13.75 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 178.318 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 408' ' ' ARG . . . . . 0.458 ' HA ' ' HD2' ' A' ' 409' ' ' PRO . 22.9 mmm180 67.81 118.11 0.03 OUTLIER Pre-proline 0 N--CA 1.464 0.247 0 O-C-N 124.174 0.921 . . . . 0.0 110.69 -174.424 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 409' ' ' PRO . . . . . 0.458 ' HD2' ' HA ' ' A' ' 408' ' ' ARG . 11.6 Cg_endo -54.1 112.94 1.12 Allowed 'Trans proline' 0 C--O 1.236 0.383 0 C-N-CA 123.264 2.643 . . . . 0.0 112.9 -177.653 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 410' ' ' THR . . . . . . . . . . . . . 2.6 m -62.1 129.23 39.85 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.571 -0.741 . . . . 0.0 110.25 177.317 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 411' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -76.63 67.08 2.7 Favored 'General case' 0 N--CA 1.467 0.399 0 CA-C-O 121.483 0.659 . . . . 0.0 111.06 -177.27 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 412' ' ' ALA . . . . . . . . . . . . . . . 178.87 -69.99 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.496 0 CA-C-N 114.895 -1.048 . . . . 0.0 108.214 178.076 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 413' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -151.88 119.47 6.07 Favored 'General case' 0 C--N 1.322 -0.625 0 N-CA-C 107.925 -1.139 . . . . 0.0 107.925 171.063 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 414' ' ' LYS . . . . . 0.463 ' HD2' ' H ' ' A' ' 414' ' ' LYS . 0.0 OUTLIER -70.39 134.17 47.6 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.072 0.463 . . . . 0.0 111.808 -169.739 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 415' ' ' GLY . . . . . . . . . . . . . . . 146.84 133.83 2.49 Favored Glycine 0 N--CA 1.45 -0.392 0 CA-C-N 115.539 -0.755 . . . . 0.0 111.601 176.415 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 416' ' ' GLY . . . . . . . . . . . . . . . -177.76 -101.66 0.15 Allowed Glycine 0 N--CA 1.45 -0.422 0 C-N-CA 120.04 -1.076 . . . . 0.0 112.78 178.473 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 417' ' ' PHE . . . . . 0.672 ' HB3' ' HD2' ' A' ' 326' ' ' PHE . 66.1 m-85 -84.36 -175.4 5.77 Favored 'General case' 0 C--N 1.325 -0.463 0 C-N-CA 122.254 0.222 . . . . 0.0 110.472 -177.346 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 418' ' ' GLY . . . . . 0.455 ' HA2' ' HA ' ' A' ' 325' ' ' HIS . . . 82.31 77.1 1.07 Allowed Glycine 0 C--O 1.224 -0.489 0 C-N-CA 120.746 -0.74 . . . . 0.0 113.125 176.214 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 419' ' ' VAL . . . . . 0.82 HG12 ' HG2' ' A' ' 404' ' ' LYS . 23.8 m -109.71 157.61 10.11 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.521 0 CA-C-O 120.903 0.382 . . . . 0.0 110.822 -179.715 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 40.8 p90 -146.4 154.8 42.04 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 120.952 0.406 . . . . 0.0 110.535 177.58 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -148.83 136.54 20.54 Favored 'General case' 0 C--N 1.32 -0.689 0 CA-C-N 115.746 -0.661 . . . . 0.0 109.48 -179.869 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -133.18 140.62 11.98 Favored Glycine 0 N--CA 1.445 -0.711 0 C-N-CA 120.196 -1.002 . . . . 0.0 112.582 -177.668 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 25.1 mmmt -101.9 123.83 46.49 Favored 'General case' 0 C--N 1.323 -0.56 0 N-CA-C 109.395 -0.594 . . . . 0.0 109.395 176.82 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 424' ' ' LYS . . . . . 0.716 ' HD3' ' HG3' ' A' ' 399' ' ' GLU . 72.1 tttt -70.16 117.25 11.48 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-N 116.55 -0.296 . . . . 0.0 110.572 -179.591 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 32.4 tt0 -73.9 114.12 11.84 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 -179.502 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 426' ' ' GLN . . . . . . . . . . . . . 5.7 tp-100 -86.78 144.34 27.1 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.39 -175.092 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 427' ' ' ASP . . . . . . . . . . . . . 4.6 t0 -79.34 92.82 5.21 Favored 'General case' 0 C--N 1.325 -0.464 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 177.193 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . 0.597 ' HB2' ' OE2' ' A' ' 429' ' ' GLU . 70.1 mt -84.7 -65.69 0.98 Allowed 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 115.997 -0.547 . . . . 0.0 110.939 -173.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 429' ' ' GLU . . . . . 0.597 ' OE2' ' HB2' ' A' ' 428' ' ' LEU . 1.8 mp0 -68.49 157.44 35.92 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 178.345 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 430' ' ' HIS . . . . . 0.434 ' HB3' ' O ' ' A' ' 429' ' ' GLU . 8.9 t60 73.4 -51.33 0.7 Allowed 'General case' 0 N--CA 1.472 0.642 0 O-C-N 123.484 0.49 . . . . 0.0 112.152 174.28 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 23.2 t-80 -75.74 -4.29 39.64 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 116.316 -0.402 . . . . 0.0 111.911 -171.978 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 432' ' ' HIS . . . . . . . . . . . . . 20.7 m170 -109.05 -53.84 2.6 Favored 'General case' 0 C--N 1.326 -0.446 0 C-N-CA 120.719 -0.392 . . . . 0.0 111.951 -179.403 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 433' ' ' HIS . . . . . . . . . . . . . 91.0 m-70 -120.14 142.0 49.34 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.24 0.543 . . . . 0.0 111.721 -176.878 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 434' ' ' HIS . . . . . . . . . . . . . 56.9 t-80 -150.27 110.45 4.16 Favored 'General case' 0 C--N 1.321 -0.661 0 CA-C-N 115.536 -0.756 . . . . 0.0 109.819 175.453 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 435' ' ' HIS . . . . . . . . . . . . . 9.5 m170 . . . . . 0 C--O 1.246 0.886 0 CA-C-O 118.38 -0.819 . . . . 0.0 110.086 177.74 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 276' ' ' ASN . . . . . 0.543 HD22 ' HE1' ' A' ' 278' ' ' PHE . 15.8 m120 . . . . . 0 N--CA 1.482 1.125 0 CA-C-O 121.183 0.516 . . . . 0.0 110.425 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 17.3 mt -83.9 42.6 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.45 0 CA-C-N 115.529 -0.759 . . . . 0.0 110.699 -177.711 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 278' ' ' PHE . . . . . 0.543 ' HE1' HD22 ' A' ' 276' ' ' ASN . 79.3 m-85 -35.66 121.9 0.63 Allowed 'General case' 0 N--CA 1.471 0.589 0 CA-C-N 115.235 -0.893 . . . . 0.0 113.108 -177.715 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -68.95 111.09 7.34 Favored Pre-proline 0 C--N 1.329 -0.318 0 CA-C-N 115.26 -0.882 . . . . 0.0 109.989 177.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 280' ' ' PRO . . . . . . . . . . . . . 68.5 Cg_endo -82.37 120.2 3.2 Favored 'Trans proline' 0 N--CA 1.458 -0.599 0 C-N-CA 122.593 2.195 . . . . 0.0 113.447 -173.208 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 37.0 tt0 173.56 -52.56 0.01 OUTLIER 'General case' 0 C--O 1.235 0.333 0 CA-C-N 115.007 -0.997 . . . . 0.0 108.404 176.281 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -164.08 160.21 33.11 Favored Glycine 0 N--CA 1.445 -0.734 0 CA-C-N 114.618 -1.173 . . . . 0.0 110.336 176.477 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 283' ' ' ASN . . . . . . . . . . . . . 3.6 p30 -82.49 83.39 7.56 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 121.748 0.785 . . . . 0.0 110.202 178.899 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . 0.609 ' HB2' HD21 ' A' ' 287' ' ' LEU . 65.1 m-85 -89.97 144.13 26.19 Favored 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 115.409 -0.814 . . . . 0.0 109.445 179.463 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . 0.428 ' HG3' ' CE2' ' A' ' 289' ' ' TYR . 28.8 ttt180 -130.48 21.29 5.16 Favored 'General case' 0 C--N 1.318 -0.798 0 CA-C-O 121.754 0.788 . . . . 0.0 110.521 -174.247 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 69.5 t80 -111.05 -2.71 15.79 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-O 122.439 1.114 . . . . 0.0 108.903 178.482 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . 0.609 HD21 ' HB2' ' A' ' 284' ' ' TYR . 1.2 pp -101.3 -178.35 3.71 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 113.747 -1.569 . . . . 0.0 109.696 178.91 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 288' ' ' THR . . . . . 0.712 ' HB ' ' HA ' ' A' ' 304' ' ' GLN . 4.3 m -69.06 157.54 36.62 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 109.518 -0.549 . . . . 0.0 109.518 -175.022 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 289' ' ' TYR . . . . . 0.834 ' HA ' ' H ' ' A' ' 303' ' ' VAL . 1.9 m-30 -137.79 164.11 29.71 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-O 121.42 0.628 . . . . 0.0 112.512 -175.357 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 158.05 131.74 1.33 Allowed Glycine 0 N--CA 1.449 -0.45 0 CA-C-N 114.679 -1.146 . . . . 0.0 111.418 169.939 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 291' ' ' ALA . . . . . 0.984 ' HB3' ' HA ' ' A' ' 301' ' ' LEU . . . -169.07 166.27 11.0 Favored 'General case' 0 C--O 1.235 0.29 0 CA-C-N 116.64 0.22 . . . . 0.0 110.886 176.35 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 292' ' ' GLU . . . . . . . . . . . . . 57.7 mm-40 -110.18 109.0 19.34 Favored 'General case' 0 C--N 1.326 -0.453 0 N-CA-C 108.462 -0.94 . . . . 0.0 108.462 177.273 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 293' ' ' LYS . . . . . 0.472 ' HB2' ' HA ' ' A' ' 300' ' ' ALA . 59.8 tttm -81.29 112.61 18.76 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.38 0.609 . . . . 0.0 112.023 -171.953 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 294' ' ' LEU . . . . . 0.64 HD13 ' HB2' ' A' ' 298' ' ' SER . 10.6 mp -122.02 161.7 41.13 Favored Pre-proline 0 C--N 1.32 -0.709 0 CA-C-N 114.963 -1.017 . . . . 0.0 108.477 171.671 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 295' ' ' PRO . . . . . . . . . . . . . 8.9 Cg_exo -73.15 -8.44 22.06 Favored 'Trans proline' 0 C--N 1.344 0.319 0 C-N-CA 122.551 2.167 . . . . 0.0 111.752 176.453 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . -165.15 141.49 7.08 Favored Glycine 0 N--CA 1.45 -0.413 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.779 178.149 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 89.81 -76.21 1.73 Allowed Glycine 0 N--CA 1.452 -0.245 0 C-N-CA 120.79 -0.719 . . . . 0.0 111.883 -179.49 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 298' ' ' SER . . . . . 0.64 ' HB2' HD13 ' A' ' 294' ' ' LEU . 35.1 m -89.74 148.94 22.96 Favored 'General case' 0 C--N 1.323 -0.58 0 N-CA-C 109.453 -0.573 . . . . 0.0 109.453 176.0 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 299' ' ' TYR . . . . . 0.406 ' H ' ' ND2' ' A' ' 276' ' ' ASN . 57.2 m-85 -122.43 177.21 5.5 Favored 'General case' 0 C--N 1.326 -0.443 0 CA-C-O 120.935 0.398 . . . . 0.0 111.972 -172.593 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 300' ' ' ALA . . . . . 0.515 ' O ' ' HZ ' ' A' ' 278' ' ' PHE . . . -75.9 163.41 27.23 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-N 115.673 -0.694 . . . . 0.0 110.339 -175.143 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 301' ' ' LEU . . . . . 0.984 ' HA ' ' HB3' ' A' ' 291' ' ' ALA . 1.2 pt? -78.26 113.4 16.2 Favored 'General case' 0 C--N 1.319 -0.73 0 N-CA-C 113.717 1.006 . . . . 0.0 113.717 -161.04 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 302' ' ' ARG . . . . . 0.699 ' HG3' ' CE1' ' A' ' 289' ' ' TYR . 18.6 ttp180 -164.12 113.49 1.21 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 114.734 -1.121 . . . . 0.0 108.793 162.133 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 303' ' ' VAL . . . . . 0.834 ' H ' ' HA ' ' A' ' 289' ' ' TYR . 11.6 p -153.91 126.36 1.06 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.61 0 N-CA-C 111.944 0.349 . . . . 0.0 111.944 167.527 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 304' ' ' GLN . . . . . 0.712 ' HA ' ' HB ' ' A' ' 288' ' ' THR . 6.5 pt20 -88.3 135.97 33.2 Favored 'General case' 0 C--N 1.318 -0.765 0 CA-C-O 121.246 0.545 . . . . 0.0 111.283 -177.419 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . 0.516 ' H ' ' HB ' ' A' ' 288' ' ' THR . . . -174.41 107.12 0.24 Allowed Glycine 0 N--CA 1.446 -0.682 0 CA-C-N 115.374 -0.83 . . . . 0.0 111.51 177.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 306' ' ' GLU . . . . . 0.957 ' HB3' ' HD3' ' A' ' 396' ' ' PRO . 34.6 tt0 -146.33 136.72 12.19 Favored Pre-proline 0 C--N 1.324 -0.517 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 -176.873 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 64.1 Cg_endo -75.05 129.97 12.79 Favored 'Trans proline' 0 N--CA 1.462 -0.337 0 C-N-CA 121.997 1.798 . . . . 0.0 111.315 175.408 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . 0.703 ' HB2' ' O ' ' A' ' 394' ' ' TYR . . . -54.18 159.54 1.86 Allowed 'General case' 0 N--CA 1.467 0.385 0 CA-C-O 121.48 0.657 . . . . 0.0 112.282 175.804 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 309' ' ' LYS . . . . . 0.649 ' O ' ' HG ' ' A' ' 313' ' ' LEU . 35.0 mtmt -123.55 98.91 6.05 Favored 'General case' 0 C--N 1.322 -0.617 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.357 176.746 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 310' ' ' GLY . . . . . 0.694 ' HA2' HD12 ' A' ' 313' ' ' LEU . . . -60.04 -37.75 93.23 Favored Glycine 0 C--O 1.227 -0.304 0 CA-C-N 116.093 -0.503 . . . . 0.0 114.128 -170.314 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . 0.454 ' H ' ' CD ' ' A' ' 311' ' ' GLU . 1.3 pm0 -72.61 -20.03 61.36 Favored 'General case' 0 C--N 1.324 -0.507 0 CA-C-N 116.86 0.33 . . . . 0.0 110.856 179.115 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 26.0 ttt -91.46 -21.61 20.84 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-O 121.143 0.497 . . . . 0.0 109.95 177.302 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 313' ' ' LEU . . . . . 0.694 HD12 ' HA2' ' A' ' 310' ' ' GLY . 96.1 mt -66.19 138.95 58.05 Favored 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.332 178.998 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -156.32 139.2 15.28 Favored 'General case' 0 C--N 1.318 -0.801 0 CA-C-N 115.518 -0.765 . . . . 0.0 111.303 -174.326 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 121.01 167.88 13.39 Favored Glycine 0 N--CA 1.443 -0.845 0 CA-C-N 115.84 -0.618 . . . . 0.0 111.929 177.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 28.5 p -100.05 134.22 43.28 Favored 'General case' 0 C--N 1.317 -0.811 0 N-CA-C 109.769 -0.456 . . . . 0.0 109.769 174.715 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 317' ' ' ALA . . . . . 0.56 ' HB1' ' HD3' ' A' ' 424' ' ' LYS . . . -138.6 152.57 48.25 Favored 'General case' 0 C--N 1.316 -0.871 0 CA-C-O 121.053 0.454 . . . . 0.0 111.731 -174.833 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 7.3 p -121.59 113.24 38.49 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.441 0 CA-C-N 115.551 -0.75 . . . . 0.0 110.263 177.5 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . 0.598 ' CE2' ' HB2' ' A' ' 424' ' ' LYS . 21.4 m-85 -103.16 132.52 49.36 Favored 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.842 -0.617 . . . . 0.0 109.925 -179.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 44.6 m-80 -124.81 139.56 53.73 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.02 -0.536 . . . . 0.0 110.077 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . 0.591 ' HA3' ' O ' ' A' ' 421' ' ' ALA . . . -169.25 -145.93 4.83 Favored Glycine 0 N--CA 1.441 -1.014 0 C-N-CA 120.577 -0.82 . . . . 0.0 112.397 179.898 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 10.2 pt-20 -135.04 161.92 33.93 Favored 'General case' 0 C--N 1.32 -0.698 0 CA-C-O 120.978 0.418 . . . . 0.0 110.947 -173.66 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 323' ' ' VAL . . . . . 0.649 HG23 ' HB2' ' A' ' 340' ' ' PHE . 68.9 t -121.12 117.89 54.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.56 0 CA-C-N 115.526 -0.761 . . . . 0.0 110.163 178.331 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 324' ' ' LEU . . . . . . . . . . . . . 2.0 tt -98.53 103.27 15.2 Favored 'General case' 0 C--N 1.315 -0.924 0 N-CA-C 108.557 -0.905 . . . . 0.0 108.557 176.631 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 325' ' ' HIS . . . . . 0.446 ' HA ' ' HA2' ' A' ' 418' ' ' GLY . 18.3 t-160 -88.58 113.32 24.03 Favored 'General case' 0 C--N 1.321 -0.634 0 N-CA-C 109.351 -0.611 . . . . 0.0 109.351 -179.307 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 326' ' ' PHE . . . . . 0.664 ' HE2' HG13 ' A' ' 419' ' ' VAL . 88.4 m-85 -82.15 162.24 22.52 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 116.087 -0.506 . . . . 0.0 110.008 -177.85 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 327' ' ' HIS . . . . . . . . . . . . . 32.3 p-80 -175.74 -174.0 0.65 Allowed 'General case' 0 C--N 1.316 -0.864 0 CA-C-N 115.375 -0.83 . . . . 0.0 108.769 -173.786 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 328' ' ' THR . . . . . . . . . . . . . 17.9 p -47.47 159.93 0.13 Allowed 'General case' 0 C--O 1.236 0.369 0 O-C-N 123.706 0.629 . . . . 0.0 112.035 179.337 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 329' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -57.54 161.78 3.34 Favored 'General case' 0 C--O 1.237 0.425 0 CA-C-N 115.577 -0.738 . . . . 0.0 112.622 -171.691 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 330' ' ' ASN . . . . . 0.523 ' OD1' ' HA ' ' A' ' 334' ' ' TYR . 11.4 t30 -76.95 85.95 3.49 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.11 -0.95 . . . . 0.0 111.298 -172.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 331' ' ' GLY . . . . . 0.472 ' O ' ' HD3' ' A' ' 333' ' ' PRO . . . -150.23 93.72 0.15 Allowed Glycine 0 N--CA 1.443 -0.87 0 N-CA-C 111.063 -0.815 . . . . 0.0 111.063 174.09 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 332' ' ' ARG . . . . . 0.722 ' HB3' ' HD3' ' A' ' 333' ' ' PRO . 48.3 ttt180 104.45 -66.19 0.0 OUTLIER Pre-proline 0 N--CA 1.482 1.162 0 C-N-CA 125.295 1.438 . . . . 0.0 112.81 -178.935 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 333' ' ' PRO . . . . . 0.722 ' HD3' ' HB3' ' A' ' 332' ' ' ARG . 4.4 Cg_exo -75.81 -23.88 12.1 Favored 'Trans proline' 0 C--N 1.358 1.034 0 C-N-CA 121.822 1.681 . . . . 0.0 113.412 -175.547 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 334' ' ' TYR . . . . . 0.792 ' HB3' ' HD2' ' A' ' 335' ' ' PRO . 62.7 m-85 66.5 174.81 0.07 OUTLIER Pre-proline 0 CA--C 1.538 0.496 0 O-C-N 123.478 0.486 . . . . 0.0 110.484 -177.841 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 335' ' ' PRO . . . . . 0.792 ' HD2' ' HB3' ' A' ' 334' ' ' TYR . 68.4 Cg_endo -75.23 151.14 38.15 Favored 'Trans proline' 0 C--N 1.35 0.642 0 C-N-CA 121.976 1.784 . . . . 0.0 111.674 177.531 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 336' ' ' THR . . . . . 0.518 HG21 ' CE1' ' A' ' 362' ' ' HIS . 25.5 p -112.8 138.32 49.8 Favored 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 120.269 -0.572 . . . . 0.0 111.012 179.414 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 337' ' ' ARG . . . . . . . . . . . . . 39.1 ttt180 -131.85 112.84 12.81 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 115.583 -0.735 . . . . 0.0 110.346 -174.849 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 338' ' ' GLY . . . . . 0.855 ' HA2' ' HA3' ' A' ' 358' ' ' GLY . . . -103.26 -177.0 26.41 Favored Glycine 0 N--CA 1.446 -0.695 0 N-CA-C 111.198 -0.761 . . . . 0.0 111.198 179.037 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 339' ' ' ARG . . . . . 0.992 ' HB2' ' HB3' ' A' ' 356' ' ' ASP . 66.7 mtp180 -110.28 164.5 12.6 Favored 'General case' 0 C--N 1.32 -0.706 0 N-CA-C 109.463 -0.569 . . . . 0.0 109.463 178.379 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 340' ' ' PHE . . . . . 0.649 ' HB2' HG23 ' A' ' 323' ' ' VAL . 41.1 t80 -152.43 142.73 22.49 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 121.255 0.55 . . . . 0.0 111.096 -178.275 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 341' ' ' ALA . . . . . . . . . . . . . . . -138.59 156.25 47.63 Favored 'General case' 0 C--N 1.319 -0.732 0 CA-C-N 115.206 -0.906 . . . . 0.0 109.025 174.063 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . 0.884 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -145.94 118.94 8.76 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-O 121.304 0.573 . . . . 0.0 110.173 -179.729 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . 0.438 ' HE2' ' HB3' ' A' ' 343' ' ' LYS . 4.8 tmmm? -102.96 103.14 13.23 Favored 'General case' 0 C--N 1.318 -0.766 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 -179.625 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 344' ' ' VAL . . . . . 0.443 ' HA ' ' HA ' ' A' ' 351' ' ' VAL . 0.2 OUTLIER -117.14 132.77 65.93 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.778 0 CA-C-O 121.485 0.66 . . . . 0.0 112.639 -169.224 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -102.48 100.08 10.17 Favored 'General case' 0 C--N 1.323 -0.582 0 CA-C-N 114.515 -1.22 . . . . 0.0 108.7 172.541 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 346' ' ' PHE . . . . . . . . . . . . . 74.5 m-85 -67.88 -23.19 65.1 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 120.527 0.204 . . . . 0.0 111.184 -177.875 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -63.9 -25.27 69.11 Favored Glycine 0 N--CA 1.449 -0.483 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.016 178.315 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 37.9 m -112.58 -4.43 14.15 Favored 'General case' 0 C--N 1.326 -0.428 0 CA-C-O 120.912 0.387 . . . . 0.0 110.567 177.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 349' ' ' LYS . . . . . 0.645 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 31.4 mtmm 55.69 59.3 3.91 Favored 'General case' 0 C--O 1.226 -0.179 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.892 -178.02 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 52.9 p -148.84 141.28 24.24 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 115.744 -0.662 . . . . 0.0 110.282 -179.326 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 351' ' ' VAL . . . . . 0.51 HG22 ' HB3' ' A' ' 370' ' ' ALA . 1.0 OUTLIER -127.57 151.84 34.9 Favored 'Isoleucine or valine' 0 C--O 1.235 0.335 0 CA-C-O 121.126 0.489 . . . . 0.0 110.986 -176.21 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 352' ' ' ASP . . . . . 0.884 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 19.5 t70 -108.59 119.07 38.44 Favored 'General case' 0 C--O 1.211 -0.954 0 CA-C-N 115.184 -0.917 . . . . 0.0 109.338 171.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -115.33 130.22 9.02 Favored Glycine 0 N--CA 1.441 -1.02 0 C-N-CA 120.473 -0.87 . . . . 0.0 111.658 -178.72 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 354' ' ' ILE . . . . . 0.475 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -131.52 129.62 62.0 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.957 0 CA-C-O 120.973 0.416 . . . . 0.0 110.196 -176.973 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 355' ' ' ILE . . . . . 0.605 HG13 HG21 ' A' ' 323' ' ' VAL . 2.3 mp -101.6 111.36 31.04 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.763 0 CA-C-N 115.909 -0.587 . . . . 0.0 109.416 178.295 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 356' ' ' ASP . . . . . 0.992 ' HB3' ' HB2' ' A' ' 339' ' ' ARG . 9.1 t70 -74.4 154.39 38.83 Favored 'General case' 0 C--N 1.324 -0.538 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.481 -175.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 3.6 m -52.99 12.09 0.0 OUTLIER 'General case' 0 N--CA 1.479 0.994 0 N-CA-C 117.177 2.288 . . . . 0.0 117.177 -163.407 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 358' ' ' GLY . . . . . 0.855 ' HA3' ' HA2' ' A' ' 338' ' ' GLY . . . -52.65 -44.0 59.82 Favored Glycine 0 CA--C 1.525 0.657 0 CA-C-N 118.767 0.712 . . . . 0.0 113.007 177.647 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 359' ' ' ASP . . . . . 0.589 ' OD2' ' HB2' ' A' ' 362' ' ' HIS . 20.9 t70 -110.93 35.46 3.51 Favored 'General case' 0 N--CA 1.465 0.283 0 CA-C-O 121.757 0.789 . . . . 0.0 109.691 178.984 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 360' ' ' ASP . . . . . 0.697 ' HA ' ' HA2' ' A' ' 364' ' ' GLY . 18.5 t70 -65.44 -25.17 67.4 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.913 -0.585 . . . . 0.0 110.953 -178.031 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 361' ' ' LEU . . . . . . . . . . . . . 92.0 mt -76.45 -5.66 48.37 Favored 'General case' 0 C--N 1.326 -0.414 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.663 -178.149 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 362' ' ' HIS . . . . . 0.589 ' HB2' ' OD2' ' A' ' 359' ' ' ASP . 34.8 m80 -125.5 -74.35 0.61 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-O 120.765 0.317 . . . . 0.0 110.568 178.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 363' ' ' MET . . . . . . . . . . . . . 21.7 mmt -78.76 -39.72 35.27 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.041 0.448 . . . . 0.0 110.663 178.018 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 364' ' ' GLY . . . . . 0.697 ' HA2' ' HA ' ' A' ' 360' ' ' ASP . . . 101.45 -169.58 20.59 Favored Glycine 0 N--CA 1.448 -0.562 0 CA-C-N 115.648 -0.705 . . . . 0.0 111.492 -178.588 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 365' ' ' THR . . . . . . . . . . . . . 23.1 m -83.96 98.43 9.8 Favored 'General case' 0 C--N 1.321 -0.664 0 N-CA-C 108.967 -0.753 . . . . 0.0 108.967 173.419 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 90.6 mt-30 -106.38 145.51 31.62 Favored 'General case' 0 C--N 1.323 -0.559 0 CA-C-O 121.305 0.574 . . . . 0.0 111.372 -172.808 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 87.4 mttt -123.85 144.63 49.62 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.565 179.48 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 368' ' ' PHE . . . . . 0.493 ' HB3' ' CE3' ' A' ' 381' ' ' TRP . 33.2 p90 -140.17 150.74 44.58 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.963 0.411 . . . . 0.0 109.996 175.364 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 369' ' ' LYS . . . . . 0.766 ' HD3' ' HA ' ' A' ' 352' ' ' ASP . 0.0 OUTLIER -123.61 135.19 53.81 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 175.962 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . 0.529 ' HB1' ' HB2' ' A' ' 377' ' ' PHE . . . -132.11 152.23 51.35 Favored 'General case' 0 C--N 1.317 -0.811 0 CA-C-N 115.478 -0.783 . . . . 0.0 111.213 -172.287 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -109.06 134.82 51.17 Favored 'General case' 0 C--N 1.321 -0.674 0 CA-C-N 115.848 -0.615 . . . . 0.0 109.656 176.369 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 372' ' ' ILE . . . . . 0.645 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 95.5 mt -82.75 108.91 16.04 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.759 0 CA-C-O 121.171 0.51 . . . . 0.0 110.939 -178.042 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 2.3 p-10 -126.4 84.23 2.25 Favored 'General case' 0 N--CA 1.445 -0.721 0 CA-C-O 121.612 0.72 . . . . 0.0 110.288 178.361 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 79.07 121.22 0.3 Allowed Glycine 0 N--CA 1.45 -0.377 0 CA-C-N 115.145 -0.934 . . . . 0.0 112.267 -177.188 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 375' ' ' ASN . . . . . 0.524 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 17.7 p30 1.8 60.38 0.0 OUTLIER 'General case' 0 N--CA 1.485 1.284 0 C-N-CA 125.6 1.56 . . . . 0.0 114.986 -171.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 157.55 -174.28 34.98 Favored Glycine 0 N--CA 1.438 -1.172 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 179.068 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 377' ' ' PHE . . . . . 0.529 ' HB2' ' HB1' ' A' ' 370' ' ' ALA . 1.6 p90 -142.34 148.71 38.39 Favored 'General case' 0 C--N 1.313 -1.018 0 CA-C-O 121.327 0.584 . . . . 0.0 111.625 -179.345 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 378' ' ' LYS . . . . . . . . . . . . . 2.7 tmtm? -123.64 112.63 17.64 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 176.733 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -135.59 -165.6 10.74 Favored Glycine 0 N--CA 1.45 -0.419 0 C-N-CA 120.428 -0.891 . . . . 0.0 112.627 -175.677 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 15.0 t -144.93 159.67 42.55 Favored 'General case' 0 C--N 1.321 -0.666 0 CA-C-O 120.86 0.362 . . . . 0.0 110.449 -177.516 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 381' ' ' TRP . . . . . 0.493 ' CE3' ' HB3' ' A' ' 368' ' ' PHE . 48.3 m95 -64.23 126.49 27.92 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.724 -0.671 . . . . 0.0 111.512 179.95 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 382' ' ' THR . . . . . . . . . . . . . 9.4 m -83.18 65.36 8.19 Favored 'General case' 0 C--N 1.323 -0.562 0 N-CA-C 109.183 -0.673 . . . . 0.0 109.183 177.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 383' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -157.04 -75.84 0.09 Allowed 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.426 -0.806 . . . . 0.0 109.638 -176.19 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 384' ' ' ASN . . . . . . . . . . . . . 25.3 t-20 -113.2 -61.38 1.75 Allowed 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.125 -176.395 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 385' ' ' GLY . . . . . . . . . . . . . . . 134.67 -156.87 22.69 Favored Glycine 0 N--CA 1.448 -0.535 0 N-CA-C 111.388 -0.685 . . . . 0.0 111.388 -179.249 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 386' ' ' GLY . . . . . . . . . . . . . . . 72.16 -82.99 0.53 Allowed Glycine 0 N--CA 1.452 -0.264 0 C-N-CA 121.298 -0.477 . . . . 0.0 112.463 179.148 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -63.47 128.73 39.02 Favored Glycine 0 N--CA 1.446 -0.675 0 C-N-CA 121.18 -0.533 . . . . 0.0 112.448 -179.132 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -94.19 167.54 11.49 Favored 'General case' 0 C--N 1.321 -0.642 0 N-CA-C 109.889 -0.412 . . . . 0.0 109.889 179.517 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 22.2 t -128.35 121.18 54.91 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.814 0 N-CA-C 109.543 -0.54 . . . . 0.0 109.543 175.996 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 390' ' ' SER . . . . . 0.417 ' O ' ' HA3' ' A' ' 403' ' ' GLY . 39.5 m -117.98 155.61 29.97 Favored 'General case' 0 C--N 1.321 -0.635 0 CA-C-N 116.521 -0.309 . . . . 0.0 110.698 -177.375 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -165.64 144.67 9.42 Favored Glycine 0 N--CA 1.451 -0.349 0 N-CA-C 111.541 -0.623 . . . . 0.0 111.541 177.291 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 13.7 ptp180 -116.09 152.31 33.87 Favored 'General case' 0 C--N 1.326 -0.418 0 CA-C-O 121.044 0.45 . . . . 0.0 110.895 -177.142 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 10.7 m-85 -98.1 157.59 16.05 Favored 'General case' 0 C--N 1.325 -0.472 0 CA-C-O 121.889 0.852 . . . . 0.0 111.81 -175.857 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 394' ' ' TYR . . . . . 0.703 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 6.2 m-85 -102.94 -171.95 2.03 Favored 'General case' 0 C--N 1.319 -0.753 0 CA-C-N 114.119 -1.4 . . . . 0.0 111.247 -175.075 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 395' ' ' GLY . . . . . 0.806 ' HA2' ' O ' ' A' ' 306' ' ' GLU . . . -33.15 157.59 0.01 OUTLIER Glycine 0 C--N 1.34 0.792 0 O-C-N 124.576 1.173 . . . . 0.0 114.215 -178.316 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 396' ' ' PRO . . . . . 0.957 ' HD3' ' HB3' ' A' ' 306' ' ' GLU . 12.2 Cg_endo -46.37 -17.98 0.41 Allowed 'Trans proline' 0 N--CA 1.482 0.818 1 C-N-CA 125.674 4.249 . . . . 0.0 116.831 -149.843 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 397' ' ' ALA . . . . . 0.435 ' N ' ' O ' ' A' ' 395' ' ' GLY . . . -90.89 -17.9 25.69 Favored 'General case' 0 C--N 1.316 -0.872 0 C-N-CA 120.728 -0.389 . . . . 0.0 111.83 -179.655 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 72.74 16.35 77.95 Favored Glycine 0 C--N 1.336 0.56 0 C-N-CA 121.178 -0.534 . . . . 0.0 112.544 173.811 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 399' ' ' GLU . . . . . 0.478 ' HG2' ' CE ' ' A' ' 424' ' ' LYS . 28.5 mt-10 -67.7 -10.78 55.41 Favored 'General case' 0 C--N 1.332 -0.18 0 C-N-CA 122.902 0.481 . . . . 0.0 111.115 -174.766 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -123.31 136.02 54.48 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 109.166 -0.679 . . . . 0.0 109.166 173.1 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 401' ' ' VAL . . . . . 0.52 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 14.0 p -140.15 143.1 30.37 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-N 116.33 -0.396 . . . . 0.0 110.137 177.413 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -143.19 138.81 29.98 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-N 116.383 -0.372 . . . . 0.0 110.181 179.879 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 403' ' ' GLY . . . . . 0.417 ' HA3' ' O ' ' A' ' 390' ' ' SER . . . -157.25 -176.2 29.04 Favored Glycine 0 N--CA 1.441 -0.985 0 C-N-CA 120.379 -0.915 . . . . 0.0 112.185 -178.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 404' ' ' LYS . . . . . 0.841 ' HG2' HG12 ' A' ' 419' ' ' VAL . 52.2 mttt -145.34 158.85 43.75 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 108.79 -0.819 . . . . 0.0 108.79 -178.516 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 36.2 p90 -119.72 161.56 20.52 Favored 'General case' 0 C--N 1.322 -0.61 0 CA-C-O 121.043 0.449 . . . . 0.0 111.34 179.658 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 19.2 t -83.9 111.34 19.15 Favored 'General case' 0 N--CA 1.45 -0.442 0 CA-C-N 115.815 -0.63 . . . . 0.0 109.673 178.837 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . 0.595 ' HE2' ' H ' ' A' ' 411' ' ' ASP . 19.7 p90 -60.31 135.09 57.63 Favored 'General case' 0 C--N 1.323 -0.575 0 CA-C-N 114.918 -1.037 . . . . 0.0 111.929 -178.072 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 408' ' ' ARG . . . . . 0.558 ' HB2' ' HD3' ' A' ' 409' ' ' PRO . 57.1 mtp180 -42.56 -54.14 8.58 Favored Pre-proline 0 N--CA 1.471 0.612 0 N-CA-C 114.222 1.193 . . . . 0.0 114.222 -173.415 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 409' ' ' PRO . . . . . 0.558 ' HD3' ' HB2' ' A' ' 408' ' ' ARG . 55.1 Cg_exo -53.96 -36.07 82.62 Favored 'Trans proline' 0 C--N 1.358 1.053 0 C-N-CA 122.379 2.052 . . . . 0.0 113.084 -177.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 410' ' ' THR . . . . . . . . . . . . . 4.9 m 49.38 64.2 1.84 Allowed 'General case' 0 C--O 1.236 0.35 0 CA-C-O 121.225 0.536 . . . . 0.0 110.88 -178.031 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 411' ' ' ASP . . . . . 0.595 ' H ' ' HE2' ' A' ' 407' ' ' TYR . 15.2 m-20 -72.74 -49.74 29.02 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.924 -0.58 . . . . 0.0 110.365 -179.49 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 412' ' ' ALA . . . . . . . . . . . . . . . -121.19 152.77 38.41 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.577 -0.738 . . . . 0.0 109.956 178.132 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 413' ' ' GLU . . . . . . . . . . . . . 26.0 tt0 -76.39 64.35 2.11 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.752 -177.494 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 414' ' ' LYS . . . . . . . . . . . . . 45.1 mtmt -143.42 127.45 17.44 Favored 'General case' 0 C--N 1.326 -0.419 0 CA-C-N 116.009 -0.541 . . . . 0.0 110.446 179.06 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 415' ' ' GLY . . . . . . . . . . . . . . . -90.11 132.17 11.13 Favored Glycine 0 N--CA 1.441 -1.003 0 N-CA-C 109.493 -1.443 . . . . 0.0 109.493 167.748 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 416' ' ' GLY . . . . . 0.583 ' HA2' ' HD3' ' A' ' 404' ' ' LYS . . . 177.76 -40.57 0.09 OUTLIER Glycine 0 N--CA 1.446 -0.663 0 C-N-CA 119.647 -1.263 . . . . 0.0 113.048 -174.68 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 417' ' ' PHE . . . . . 0.66 ' HA ' ' HD2' ' A' ' 326' ' ' PHE . 28.3 m-85 -80.31 141.39 35.52 Favored 'General case' 0 C--N 1.321 -0.639 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 178.418 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 418' ' ' GLY . . . . . 0.514 ' H ' ' HD2' ' A' ' 326' ' ' PHE . . . 78.51 76.82 0.9 Allowed Glycine 0 N--CA 1.441 -1.018 0 C-N-CA 120.068 -1.063 . . . . 0.0 111.211 -174.468 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 419' ' ' VAL . . . . . 0.841 HG12 ' HG2' ' A' ' 404' ' ' LYS . 32.3 m -105.47 153.12 7.1 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.705 0 CA-C-O 120.705 0.288 . . . . 0.0 110.388 -177.791 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 51.9 p90 -135.69 155.01 51.08 Favored 'General case' 0 C--N 1.317 -0.834 0 CA-C-N 116.15 -0.477 . . . . 0.0 109.893 179.104 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 421' ' ' ALA . . . . . 0.591 ' O ' ' HA3' ' A' ' 321' ' ' GLY . . . -143.72 136.1 26.96 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.605 -0.725 . . . . 0.0 109.089 179.384 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -129.98 133.6 7.5 Favored Glycine 0 N--CA 1.44 -1.044 0 C-N-CA 120.638 -0.792 . . . . 0.0 112.038 -179.048 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 63.0 mttm -111.81 125.72 54.31 Favored 'General case' 0 C--N 1.313 -0.979 0 N-CA-C 109.497 -0.557 . . . . 0.0 109.497 177.211 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 424' ' ' LYS . . . . . 0.598 ' HB2' ' CE2' ' A' ' 319' ' ' TYR . 27.2 ttpp -70.23 122.3 19.24 Favored 'General case' 0 C--N 1.322 -0.599 0 CA-C-O 120.893 0.378 . . . . 0.0 110.101 178.551 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 8.2 tp10 -97.28 126.31 42.41 Favored 'General case' 0 C--N 1.313 -0.989 0 N-CA-C 109.013 -0.736 . . . . 0.0 109.013 176.685 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 426' ' ' GLN . . . . . . . . . . . . . 64.2 mt-30 -81.71 80.25 8.08 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.862 -0.608 . . . . 0.0 109.517 -178.228 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 427' ' ' ASP . . . . . . . . . . . . . 12.3 t70 76.43 136.4 0.06 Allowed 'General case' 0 N--CA 1.466 0.339 0 CA-C-N 114.16 -1.382 . . . . 0.0 110.585 -177.191 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 96.0 mt -63.92 -30.92 71.96 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.353 -0.84 . . . . 0.0 111.415 -177.28 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 429' ' ' GLU . . . . . . . . . . . . . 42.6 mm-40 -92.67 63.96 4.07 Favored 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.496 0.665 . . . . 0.0 109.516 175.536 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 430' ' ' HIS . . . . . . . . . . . . . 36.1 t60 -82.87 70.27 9.83 Favored 'General case' 0 C--N 1.32 -0.682 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.81 -173.351 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 73.4 m-70 -100.05 39.39 1.34 Allowed 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 179.076 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 432' ' ' HIS . . . . . . . . . . . . . 46.8 t-80 -53.19 -37.59 62.08 Favored 'General case' 0 CA--C 1.529 0.141 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.789 -178.003 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 433' ' ' HIS . . . . . . . . . . . . . 44.7 t-80 -136.58 -51.13 0.68 Allowed 'General case' 0 C--N 1.321 -0.653 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 174.758 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 434' ' ' HIS . . . . . 0.543 ' O ' ' HB2' ' A' ' 435' ' ' HIS . 25.6 t60 -179.78 -56.35 0.01 OUTLIER 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 106.534 -1.654 . . . . 0.0 106.534 169.105 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 435' ' ' HIS . . . . . 0.543 ' HB2' ' O ' ' A' ' 434' ' ' HIS . 4.6 t-160 . . . . . 0 C--O 1.248 0.987 0 CA-C-N 114.18 -1.373 . . . . 0.0 108.665 165.601 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 276' ' ' ASN . . . . . . . . . . . . . 30.3 p-10 . . . . . 0 N--CA 1.479 1.023 0 N-CA-C 111.354 0.131 . . . . 0.0 111.354 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . 0.569 HD11 ' HB3' ' A' ' 293' ' ' LYS . 7.0 mt -84.55 40.43 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 N-CA-C 112.409 0.522 . . . . 0.0 112.409 -169.801 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 278' ' ' PHE . . . . . . . . . . . . . 51.1 p90 -63.92 138.88 58.67 Favored 'General case' 0 C--N 1.325 -0.485 0 N-CA-C 109.203 -0.665 . . . . 0.0 109.203 175.394 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -162.32 97.01 1.17 Allowed Pre-proline 0 C--N 1.33 -0.26 0 CA-C-O 120.726 0.298 . . . . 0.0 111.661 -176.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 280' ' ' PRO . . . . . 0.425 ' HD2' ' HB3' ' A' ' 289' ' ' TYR . 89.3 Cg_endo -85.16 162.83 11.49 Favored 'Trans proline' 0 CA--C 1.534 0.515 0 C-N-CA 123.091 2.527 . . . . 0.0 113.471 176.484 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . 0.689 ' HB2' ' HE2' ' A' ' 284' ' ' TYR . 31.9 mt-10 76.91 -151.43 0.03 OUTLIER 'General case' 0 N--CA 1.469 0.501 0 CA-C-N 115.221 -0.9 . . . . 0.0 112.717 169.688 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -82.17 -150.92 8.84 Favored Glycine 0 C--N 1.338 0.651 0 N-CA-C 114.791 0.676 . . . . 0.0 114.791 -166.324 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 283' ' ' ASN . . . . . 0.548 ' HA ' ' O ' ' A' ' 286' ' ' TYR . 16.9 p-10 -89.9 83.52 6.16 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 121.531 0.682 . . . . 0.0 112.594 -170.384 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . 0.689 ' HE2' ' HB2' ' A' ' 281' ' ' GLU . 18.3 m-85 -101.47 98.88 9.16 Favored 'General case' 0 C--N 1.322 -0.614 0 CA-C-N 115.649 -0.705 . . . . 0.0 109.28 173.977 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . 0.797 ' HB2' ' HD2' ' A' ' 302' ' ' ARG . 5.1 ttp180 65.06 49.48 2.03 Favored 'General case' 0 C--N 1.328 -0.356 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 -168.639 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.557 ' HB3' ' O ' ' A' ' 285' ' ' ARG . 83.6 t80 75.88 -49.33 0.61 Allowed 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 114.966 -1.015 . . . . 0.0 109.411 -167.377 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . 0.422 ' HA ' ' H ' ' A' ' 284' ' ' TYR . 13.7 tp 179.1 123.85 0.05 Allowed 'General case' 0 C--N 1.327 -0.38 0 C-N-CA 124.141 0.977 . . . . 0.0 108.538 170.082 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 288' ' ' THR . . . . . . . . . . . . . 38.3 m -174.03 130.14 0.39 Allowed 'General case' 0 N--CA 1.452 -0.34 0 O-C-N 123.542 0.526 . . . . 0.0 110.016 179.097 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 289' ' ' TYR . . . . . 0.425 ' HB3' ' HD2' ' A' ' 280' ' ' PRO . 2.7 t80 -146.01 116.59 7.6 Favored 'General case' 0 C--N 1.313 -0.992 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 164.233 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 108.42 -151.06 17.06 Favored Glycine 0 N--CA 1.437 -1.269 0 C-N-CA 118.823 -1.656 . . . . 0.0 110.574 -172.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 291' ' ' ALA . . . . . 0.678 ' HA ' HD13 ' A' ' 301' ' ' LEU . . . -93.91 136.92 33.7 Favored 'General case' 0 C--N 1.317 -0.815 0 CA-C-O 121.337 0.589 . . . . 0.0 111.021 -177.956 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 292' ' ' GLU . . . . . 0.595 ' HG3' ' HB3' ' A' ' 300' ' ' ALA . 8.7 pt-20 -109.5 164.53 12.43 Favored 'General case' 0 C--N 1.316 -0.88 0 N-CA-C 108.941 -0.763 . . . . 0.0 108.941 175.604 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 293' ' ' LYS . . . . . 0.569 ' HB3' HD11 ' A' ' 277' ' ' ILE . 53.6 tptt -116.9 134.15 55.12 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 121.15 0.5 . . . . 0.0 111.197 -178.091 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 294' ' ' LEU . . . . . 0.611 ' HB2' ' HB2' ' A' ' 298' ' ' SER . 61.6 mt -103.85 145.12 30.04 Favored Pre-proline 0 C--N 1.319 -0.735 0 CA-C-N 115.281 -0.872 . . . . 0.0 109.345 176.624 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 295' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_exo -54.5 97.05 0.05 OUTLIER 'Trans proline' 0 C--N 1.345 0.367 0 C-N-CA 123.15 2.566 . . . . 0.0 112.092 179.136 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . 142.73 -140.56 9.92 Favored Glycine 0 N--CA 1.445 -0.741 0 N-CA-C 110.583 -1.007 . . . . 0.0 110.583 -175.375 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . -105.22 3.18 40.48 Favored Glycine 0 N--CA 1.447 -0.583 0 C-N-CA 120.523 -0.846 . . . . 0.0 112.081 179.352 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 298' ' ' SER . . . . . 0.611 ' HB2' ' HB2' ' A' ' 294' ' ' LEU . 6.1 m -81.45 143.26 32.22 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-O 121.273 0.558 . . . . 0.0 111.914 -174.701 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 299' ' ' TYR . . . . . . . . . . . . . 59.8 m-85 -122.59 142.35 50.73 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 108.231 -1.026 . . . . 0.0 108.231 172.798 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 300' ' ' ALA . . . . . 0.595 ' HB3' ' HG3' ' A' ' 292' ' ' GLU . . . -132.82 161.87 33.0 Favored 'General case' 0 C--N 1.319 -0.738 0 C-N-CA 120.777 -0.369 . . . . 0.0 111.652 -178.132 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 301' ' ' LEU . . . . . 0.678 HD13 ' HA ' ' A' ' 291' ' ' ALA . 2.5 mm? -121.84 123.33 41.52 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.971 -0.381 . . . . 0.0 109.971 175.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 302' ' ' ARG . . . . . 0.797 ' HD2' ' HB2' ' A' ' 285' ' ' ARG . 0.0 OUTLIER -128.07 125.0 38.44 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 109.072 -0.714 . . . . 0.0 109.072 172.787 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 303' ' ' VAL . . . . . . . . . . . . . 2.2 m -140.56 148.87 21.69 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.917 0 CA-C-N 116.223 -0.444 . . . . 0.0 109.85 175.021 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 304' ' ' GLN . . . . . 0.633 ' HB2' ' HD1' ' A' ' 284' ' ' TYR . 18.7 mm-40 -125.51 116.76 22.3 Favored 'General case' 0 C--N 1.316 -0.883 0 CA-C-O 121.123 0.487 . . . . 0.0 110.277 178.801 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . 0.415 ' O ' ' HD3' ' A' ' 307' ' ' PRO . . . -176.81 169.27 41.63 Favored Glycine 0 N--CA 1.446 -0.687 0 CA-C-N 115.049 -0.978 . . . . 0.0 110.844 -179.321 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 306' ' ' GLU . . . . . 0.45 ' HB3' ' CA ' ' A' ' 395' ' ' GLY . 10.7 mp0 -114.2 90.67 20.82 Favored Pre-proline 0 C--N 1.323 -0.561 0 CA-C-N 117.063 0.432 . . . . 0.0 110.221 176.991 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . 0.415 ' HD3' ' O ' ' A' ' 305' ' ' GLY . 10.2 Cg_endo -90.86 122.58 0.83 Allowed 'Trans proline' 0 N--CA 1.457 -0.618 0 C-N-CA 123.441 2.761 . . . . 0.0 112.848 177.475 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . 0.895 ' HB1' HD22 ' A' ' 313' ' ' LEU . . . -58.13 157.23 8.43 Favored 'General case' 0 CA--C 1.53 0.201 0 CA-C-N 116.324 -0.398 . . . . 0.0 110.844 170.621 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 309' ' ' LYS . . . . . 0.498 ' N ' HD23 ' A' ' 313' ' ' LEU . 63.1 mttp -128.43 98.42 5.04 Favored 'General case' 0 C--O 1.222 -0.364 0 C-N-CA 121.022 -0.271 . . . . 0.0 110.425 -176.328 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 310' ' ' GLY . . . . . . . . . . . . . . . -48.23 -43.23 25.77 Favored Glycine 0 CA--C 1.519 0.304 0 N-CA-C 114.978 0.751 . . . . 0.0 114.978 -167.784 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 4.7 pt-20 -76.45 -9.46 58.67 Favored 'General case' 0 C--N 1.32 -0.679 0 N-CA-C 112.846 0.684 . . . . 0.0 112.846 -177.989 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 2.5 tpt -113.93 -37.39 4.51 Favored 'General case' 0 C--N 1.324 -0.54 0 CA-C-O 121.72 0.771 . . . . 0.0 109.654 -177.396 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 313' ' ' LEU . . . . . 0.895 HD22 ' HB1' ' A' ' 308' ' ' ALA . 0.6 OUTLIER -81.39 129.99 34.86 Favored 'General case' 0 N--CA 1.44 -0.938 0 CA-C-N 114.677 -1.147 . . . . 0.0 109.143 178.161 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 314' ' ' ALA . . . . . 0.643 ' HA ' ' CB ' ' A' ' 346' ' ' PHE . . . -159.19 175.57 13.28 Favored 'General case' 0 C--N 1.318 -0.77 0 CA-C-N 115.942 -0.572 . . . . 0.0 111.989 -170.726 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.4 160.77 11.27 Favored Glycine 0 N--CA 1.447 -0.597 0 N-CA-C 110.98 -0.848 . . . . 0.0 110.98 -177.621 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 18.7 p -96.87 125.12 41.08 Favored 'General case' 0 C--N 1.32 -0.698 0 N-CA-C 108.979 -0.749 . . . . 0.0 108.979 173.258 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -132.08 149.67 52.35 Favored 'General case' 0 C--N 1.314 -0.974 0 N-CA-C 113.15 0.796 . . . . 0.0 113.15 -163.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . . . . . . . . . 7.7 p -118.95 113.64 42.2 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.49 0 CA-C-N 115.039 -0.982 . . . . 0.0 110.338 176.067 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . 0.46 ' CE2' ' HB2' ' A' ' 424' ' ' LYS . 27.1 m-85 -108.04 140.68 40.84 Favored 'General case' 0 C--N 1.322 -0.615 0 CA-C-N 116.081 -0.508 . . . . 0.0 110.583 177.454 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 7.0 p30 -142.75 143.78 32.37 Favored 'General case' 0 C--N 1.314 -0.939 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.65 174.671 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -166.32 -150.26 6.27 Favored Glycine 0 N--CA 1.443 -0.863 0 C-N-CA 120.931 -0.652 . . . . 0.0 111.874 -178.153 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -129.49 147.81 51.33 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-O 121.124 0.488 . . . . 0.0 111.038 -176.541 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 323' ' ' VAL . . . . . 0.581 ' O ' ' HA ' ' A' ' 337' ' ' ARG . 54.6 t -106.14 142.31 19.41 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.568 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.331 -178.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 324' ' ' LEU . . . . . . . . . . . . . 17.2 tp -124.87 103.95 8.34 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 110.21 -0.293 . . . . 0.0 110.21 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 325' ' ' HIS . . . . . 0.646 ' NE2' ' HB ' ' A' ' 336' ' ' THR . 3.2 p-80 -103.21 117.19 33.97 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-O 121.501 0.667 . . . . 0.0 111.429 -179.945 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 326' ' ' PHE . . . . . 0.605 ' HD1' ' H ' ' A' ' 418' ' ' GLY . 22.9 m-85 -89.71 129.85 36.07 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 114.705 -1.134 . . . . 0.0 110.351 -173.119 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 327' ' ' HIS . . . . . . . . . . . . . 51.4 p-80 -176.26 172.53 2.29 Favored 'General case' 0 C--N 1.326 -0.444 0 CA-C-N 116.139 -0.482 . . . . 0.0 109.863 -178.244 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 328' ' ' THR . . . . . . . . . . . . . 58.1 m -93.08 100.14 12.61 Favored 'General case' 0 C--N 1.321 -0.648 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 172.392 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 329' ' ' GLU . . . . . . . . . . . . . 9.8 tp10 -81.58 159.56 24.05 Favored 'General case' 0 C--N 1.322 -0.593 0 CA-C-N 115.627 -0.715 . . . . 0.0 110.212 -176.087 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 330' ' ' ASN . . . . . . . . . . . . . 32.9 m-80 -80.82 52.79 1.79 Allowed 'General case' 0 C--N 1.326 -0.414 0 CA-C-O 121.578 0.704 . . . . 0.0 109.426 177.806 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 331' ' ' GLY . . . . . . . . . . . . . . . -174.56 -176.41 42.89 Favored Glycine 0 N--CA 1.443 -0.89 0 CA-C-N 114.923 -1.035 . . . . 0.0 110.807 -176.218 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 332' ' ' ARG . . . . . 0.496 ' N ' ' HD2' ' A' ' 333' ' ' PRO . 95.9 mtt180 -77.05 -38.32 1.93 Allowed Pre-proline 0 C--N 1.319 -0.719 0 N-CA-C 112.683 0.623 . . . . 0.0 112.683 179.782 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 333' ' ' PRO . . . . . 0.496 ' HD2' ' N ' ' A' ' 332' ' ' ARG . 59.8 Cg_endo -74.35 86.46 1.32 Allowed 'Trans proline' 0 C--N 1.354 0.837 0 C-N-CA 121.462 1.441 . . . . 0.0 111.911 172.341 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 334' ' ' TYR . . . . . 0.764 ' HB2' ' HD3' ' A' ' 335' ' ' PRO . 78.7 m-85 -62.4 -53.68 55.71 Favored Pre-proline 0 C--N 1.329 -0.3 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.304 179.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 335' ' ' PRO . . . . . 0.764 ' HD3' ' HB2' ' A' ' 334' ' ' TYR . 3.4 Cg_exo -80.39 127.08 6.43 Favored 'Trans proline' 0 N--CA 1.451 -1.012 0 C-N-CA 121.572 1.515 . . . . 0.0 110.427 172.457 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 336' ' ' THR . . . . . 0.646 ' HB ' ' NE2' ' A' ' 325' ' ' HIS . 0.3 OUTLIER -119.68 147.54 44.44 Favored 'General case' 0 C--N 1.316 -0.87 0 N-CA-C 110.095 -0.335 . . . . 0.0 110.095 -177.141 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 337' ' ' ARG . . . . . 0.581 ' HA ' ' O ' ' A' ' 323' ' ' VAL . 0.0 OUTLIER -102.56 157.7 16.75 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-O 121.187 0.517 . . . . 0.0 110.82 -177.105 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -136.12 178.55 18.67 Favored Glycine 0 N--CA 1.443 -0.889 0 CA-C-N 115.392 -0.822 . . . . 0.0 111.178 176.113 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 339' ' ' ARG . . . . . 0.582 ' O ' ' HA ' ' A' ' 355' ' ' ILE . 57.8 mtp180 -104.02 132.89 49.82 Favored 'General case' 0 C--N 1.318 -0.796 0 N-CA-C 109.606 -0.516 . . . . 0.0 109.606 -179.093 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 340' ' ' PHE . . . . . 0.574 ' HB2' HG23 ' A' ' 323' ' ' VAL . 36.8 t80 -133.9 132.2 40.01 Favored 'General case' 0 C--N 1.314 -0.947 0 CA-C-O 121.057 0.456 . . . . 0.0 111.108 -175.848 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 341' ' ' ALA . . . . . . . . . . . . . . . -134.72 168.39 19.11 Favored 'General case' 0 C--N 1.318 -0.785 0 N-CA-C 108.715 -0.846 . . . . 0.0 108.715 172.263 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -155.22 139.65 16.79 Favored 'General case' 0 C--N 1.319 -0.727 0 CA-C-O 121.095 0.474 . . . . 0.0 111.023 -176.48 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . 0.525 ' HB3' ' HB2' ' A' ' 352' ' ' ASP . 24.9 tptp -115.97 97.32 6.02 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 179.222 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 344' ' ' VAL . . . . . 0.698 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.9 OUTLIER -121.05 135.61 60.68 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.924 0 CA-C-O 121.526 0.679 . . . . 0.0 111.627 -170.234 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 15.8 m-20 -117.04 101.13 8.23 Favored 'General case' 0 N--CA 1.445 -0.687 0 CA-C-N 114.884 -1.053 . . . . 0.0 108.284 -178.653 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 346' ' ' PHE . . . . . 0.689 ' O ' ' HE3' ' A' ' 349' ' ' LYS . 67.4 m-85 -69.75 -25.96 64.07 Favored 'General case' 0 C--N 1.324 -0.538 0 N-CA-C 111.892 0.33 . . . . 0.0 111.892 -173.476 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -64.01 -22.15 66.46 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.533 -0.841 . . . . 0.0 111.917 176.579 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 48.2 t -108.84 -4.24 17.02 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-O 121.033 0.444 . . . . 0.0 110.499 178.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 349' ' ' LYS . . . . . 0.689 ' HE3' ' O ' ' A' ' 346' ' ' PHE . 8.2 mmpt? 49.7 50.98 17.36 Favored 'General case' 0 C--O 1.226 -0.176 0 CA-C-N 115.467 -0.788 . . . . 0.0 110.581 -172.187 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 8.3 m -134.08 146.31 50.18 Favored 'General case' 0 C--N 1.325 -0.464 0 CA-C-N 115.444 -0.798 . . . . 0.0 109.104 -178.178 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 351' ' ' VAL . . . . . 0.698 ' HB ' ' HB ' ' A' ' 344' ' ' VAL . 0.1 OUTLIER -149.36 133.92 9.51 Favored 'Isoleucine or valine' 0 C--O 1.236 0.365 0 CA-C-O 121.531 0.681 . . . . 0.0 112.552 -175.617 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 352' ' ' ASP . . . . . 0.646 ' HA ' ' HD3' ' A' ' 369' ' ' LYS . 1.5 m-20 -95.24 155.48 16.72 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 114.676 -1.147 . . . . 0.0 108.961 173.21 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 353' ' ' GLY . . . . . 0.521 ' C ' ' HB3' ' A' ' 367' ' ' LYS . . . -142.38 152.17 23.53 Favored Glycine 0 N--CA 1.44 -1.091 0 N-CA-C 110.77 -0.932 . . . . 0.0 110.77 172.508 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 354' ' ' ILE . . . . . 0.484 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -146.78 130.12 9.1 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.784 0 CA-C-N 116.964 0.382 . . . . 0.0 110.087 -179.643 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 355' ' ' ILE . . . . . 0.894 HD11 ' HE2' ' A' ' 367' ' ' LYS . 82.5 mt -126.16 125.99 68.75 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.51 0 CA-C-O 121.064 0.459 . . . . 0.0 111.919 178.32 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 356' ' ' ASP . . . . . . . . . . . . . 56.2 t0 -109.8 120.41 42.39 Favored 'General case' 0 C--N 1.321 -0.636 0 CA-C-N 115.285 -0.871 . . . . 0.0 108.857 174.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 23.8 t -85.71 1.49 49.23 Favored 'General case' 0 C--N 1.323 -0.545 0 CA-C-O 121.267 0.556 . . . . 0.0 110.6 -177.021 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 358' ' ' GLY . . . . . . . . . . . . . . . 129.08 -32.03 3.35 Favored Glycine 0 N--CA 1.444 -0.807 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 -178.497 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 359' ' ' ASP . . . . . 0.577 ' OD2' ' HB2' ' A' ' 362' ' ' HIS . 9.5 t70 -133.44 95.57 3.53 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.485 0.659 . . . . 0.0 110.894 178.753 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 360' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -83.65 -24.43 31.37 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.594 175.734 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 361' ' ' LEU . . . . . 0.467 ' N ' HD22 ' A' ' 361' ' ' LEU . 3.1 mm? -74.45 -35.4 63.33 Favored 'General case' 0 C--N 1.327 -0.402 0 N-CA-C 113.052 0.76 . . . . 0.0 113.052 -171.373 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 362' ' ' HIS . . . . . 0.577 ' HB2' ' OD2' ' A' ' 359' ' ' ASP . 98.1 m-70 -107.79 -59.33 1.85 Allowed 'General case' 0 C--N 1.328 -0.333 0 C-N-CA 120.426 -0.51 . . . . 0.0 111.25 -177.42 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 363' ' ' MET . . . . . . . . . . . . . 26.2 mmt -62.35 -29.47 70.49 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 116.494 -0.321 . . . . 0.0 111.451 -179.238 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 364' ' ' GLY . . . . . . . . . . . . . . . 67.49 74.5 0.56 Allowed Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.788 -0.72 . . . . 0.0 111.579 -179.752 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 365' ' ' THR . . . . . . . . . . . . . 3.2 m -101.49 115.05 29.63 Favored 'General case' 0 C--N 1.322 -0.62 0 CA-C-O 121.051 0.453 . . . . 0.0 110.447 -175.664 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 82.5 mt-30 -120.98 178.55 4.68 Favored 'General case' 0 C--N 1.322 -0.623 0 CA-C-N 115.833 -0.621 . . . . 0.0 109.859 179.574 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 367' ' ' LYS . . . . . 0.975 ' HA ' ' HZ3' ' A' ' 381' ' ' TRP . 19.3 tttm -131.03 172.91 11.54 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.096 0.474 . . . . 0.0 110.899 176.165 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 368' ' ' PHE . . . . . 0.826 ' H ' ' HG2' ' A' ' 367' ' ' LYS . 0.1 OUTLIER -73.89 163.16 28.28 Favored 'General case' 0 C--N 1.317 -0.807 0 CA-C-N 115.113 -0.949 . . . . 0.0 111.814 -172.306 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 369' ' ' LYS . . . . . 0.646 ' HD3' ' HA ' ' A' ' 352' ' ' ASP . 0.0 OUTLIER -113.86 134.23 54.93 Favored 'General case' 0 C--N 1.314 -0.957 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 169.171 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . 0.672 ' HB2' ' CE2' ' A' ' 368' ' ' PHE . . . -130.2 162.85 27.98 Favored 'General case' 0 C--N 1.327 -0.375 0 N-CA-C 113.095 0.776 . . . . 0.0 113.095 -172.579 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -116.73 135.93 53.37 Favored 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 114.657 -1.156 . . . . 0.0 108.924 171.401 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 372' ' ' ILE . . . . . 0.546 HG13 HG12 ' A' ' 351' ' ' VAL . 83.0 mt -82.69 115.04 24.52 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.636 0 CA-C-O 121.142 0.496 . . . . 0.0 111.06 -177.004 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -104.92 83.38 1.99 Allowed 'General case' 0 C--N 1.322 -0.61 0 CA-C-N 115.581 -0.736 . . . . 0.0 109.333 177.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 79.67 -118.8 4.82 Favored Glycine 0 N--CA 1.446 -0.678 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.559 -179.664 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 375' ' ' ASN . . . . . 0.484 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 3.2 p-10 -98.81 50.21 0.97 Allowed 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.65 0.738 . . . . 0.0 111.425 -176.147 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 165.08 175.05 35.42 Favored Glycine 0 N--CA 1.445 -0.716 0 N-CA-C 110.673 -0.971 . . . . 0.0 110.673 -179.155 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 377' ' ' PHE . . . . . 0.553 ' CZ ' HG21 ' A' ' 401' ' ' VAL . 3.7 p90 -140.99 153.16 45.44 Favored 'General case' 0 C--N 1.32 -0.685 0 CA-C-O 121.551 0.691 . . . . 0.0 111.703 177.918 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 378' ' ' LYS . . . . . . . . . . . . . 15.6 ptpt -131.99 138.38 48.24 Favored 'General case' 0 C--N 1.316 -0.858 0 CA-C-N 114.498 -1.228 . . . . 0.0 108.484 175.677 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 379' ' ' GLY . . . . . . . . . . . . . . . -151.55 -161.76 10.31 Favored Glycine 0 N--CA 1.443 -0.85 0 C-N-CA 120.068 -1.063 . . . . 0.0 112.61 -176.374 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 380' ' ' THR . . . . . 0.435 ' C ' ' HB2' ' A' ' 368' ' ' PHE . 6.5 t -144.57 140.62 28.89 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.811 0.339 . . . . 0.0 110.942 -175.254 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 381' ' ' TRP . . . . . 0.975 ' HZ3' ' HA ' ' A' ' 367' ' ' LYS . 50.4 m95 -56.82 145.43 29.54 Favored 'General case' 0 N--CA 1.465 0.323 0 CA-C-N 115.595 -0.73 . . . . 0.0 110.98 178.439 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 382' ' ' THR . . . . . . . . . . . . . 25.8 p -78.28 -5.77 53.02 Favored 'General case' 0 C--N 1.326 -0.447 0 CA-C-N 116.077 -0.511 . . . . 0.0 112.305 179.261 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 383' ' ' GLU . . . . . 0.61 ' HG3' ' HB3' ' A' ' 381' ' ' TRP . 0.0 OUTLIER -82.02 52.98 2.09 Favored 'General case' 0 N--CA 1.464 0.236 0 CA-C-O 121.222 0.534 . . . . 0.0 110.655 178.344 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 384' ' ' ASN . . . . . 0.542 ' HB2' ' O ' ' A' ' 383' ' ' GLU . 10.9 m120 80.21 -39.7 0.18 Allowed 'General case' 0 N--CA 1.467 0.398 0 CA-C-N 114.683 -1.144 . . . . 0.0 111.322 -173.446 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 385' ' ' GLY . . . . . . . . . . . . . . . 115.87 52.46 0.39 Allowed Glycine 0 N--CA 1.446 -0.662 0 C-N-CA 120.669 -0.777 . . . . 0.0 111.875 179.304 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 386' ' ' GLY . . . . . . . . . . . . . . . -81.48 -19.85 65.45 Favored Glycine 0 N--CA 1.446 -0.66 0 C-N-CA 121.065 -0.588 . . . . 0.0 112.275 -178.589 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . -137.3 147.88 19.48 Favored Glycine 0 N--CA 1.446 -0.638 0 C-N-CA 120.872 -0.68 . . . . 0.0 112.341 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 3.4 p-10 -93.74 154.13 17.95 Favored 'General case' 0 C--N 1.326 -0.438 0 N-CA-C 110.074 -0.343 . . . . 0.0 110.074 178.617 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 389' ' ' VAL . . . . . 0.532 ' HB ' ' CD2' ' A' ' 368' ' ' PHE . 20.0 t -131.39 139.57 50.49 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.399 0 CA-C-N 116.347 -0.388 . . . . 0.0 110.057 -179.095 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 10.8 m -141.6 141.03 33.46 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 120.659 0.266 . . . . 0.0 110.791 178.308 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -141.05 152.64 23.34 Favored Glycine 0 C--O 1.236 0.221 0 CA-C-N 116.035 -0.53 . . . . 0.0 111.981 179.458 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 9.7 ptm180 -115.61 144.73 43.48 Favored 'General case' 0 C--N 1.326 -0.434 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 -175.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 393' ' ' PHE . . . . . 0.519 ' CZ ' ' HE1' ' A' ' 346' ' ' PHE . 1.2 m-85 -94.55 154.84 17.19 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-O 121.429 0.633 . . . . 0.0 111.979 -175.104 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 394' ' ' TYR . . . . . 0.719 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 3.5 m-85 -102.73 -176.78 3.19 Favored 'General case' 0 C--O 1.216 -0.686 0 CA-C-N 114.775 -1.102 . . . . 0.0 110.816 -178.823 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 395' ' ' GLY . . . . . 0.45 ' CA ' ' HB3' ' A' ' 306' ' ' GLU . . . -37.77 161.35 0.01 OUTLIER Glycine 0 C--N 1.335 0.505 0 O-C-N 124.333 1.021 . . . . 0.0 115.099 -175.816 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_exo -11.13 -57.03 0.0 OUTLIER 'Trans proline' 0 C--N 1.347 0.467 1 C-N-CA 127.386 5.391 . . . . 0.0 117.517 -162.393 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 397' ' ' ALA . . . . . 0.63 ' HB3' ' HG3' ' A' ' 399' ' ' GLU . . . -84.96 -11.12 56.22 Favored 'General case' 0 C--N 1.324 -0.519 0 N-CA-C 112.678 0.621 . . . . 0.0 112.678 -167.391 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 67.2 22.18 72.48 Favored Glycine 0 N--CA 1.446 -0.65 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.226 -179.142 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 399' ' ' GLU . . . . . 0.63 ' HG3' ' HB3' ' A' ' 397' ' ' ALA . 50.5 mt-10 -63.63 -14.4 51.38 Favored 'General case' 0 CA--C 1.521 -0.154 0 CA-C-O 121.12 0.486 . . . . 0.0 111.148 -177.222 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 42.9 mt-10 -121.77 133.48 54.92 Favored 'General case' 0 C--N 1.316 -0.86 0 N-CA-C 108.732 -0.84 . . . . 0.0 108.732 170.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 401' ' ' VAL . . . . . 0.553 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 9.9 p -140.99 135.0 32.64 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.953 0 CA-C-N 116.025 -0.534 . . . . 0.0 109.85 176.147 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -131.25 139.59 49.67 Favored 'General case' 0 C--N 1.315 -0.935 0 CA-C-N 115.901 -0.59 . . . . 0.0 109.771 178.293 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 403' ' ' GLY . . . . . . . . . . . . . . . -162.89 156.04 27.61 Favored Glycine 0 N--CA 1.437 -1.272 0 C-N-CA 120.304 -0.95 . . . . 0.0 111.105 -174.149 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 404' ' ' LYS . . . . . 0.987 ' HG2' HG23 ' A' ' 419' ' ' VAL . 17.5 mtmt -123.9 162.73 22.74 Favored 'General case' 0 C--N 1.31 -1.144 0 N-CA-C 109.598 -0.519 . . . . 0.0 109.598 -174.36 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 405' ' ' TYR . . . . . 0.539 ' CG ' ' HZ2' ' A' ' 381' ' ' TRP . 25.4 p90 -126.13 147.18 49.67 Favored 'General case' 0 C--N 1.315 -0.918 0 CA-C-O 121.225 0.536 . . . . 0.0 111.466 179.22 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 7.9 m -88.84 103.48 16.03 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-N 115.853 -0.612 . . . . 0.0 109.768 176.667 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . 0.469 ' H ' ' HD1' ' A' ' 407' ' ' TYR . 3.3 p90 -87.54 138.71 31.24 Favored 'General case' 0 C--N 1.322 -0.604 0 CA-C-O 121.385 0.612 . . . . 0.0 110.659 -178.775 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 408' ' ' ARG . . . . . . . . . . . . . 36.9 mtm180 -57.73 -44.49 99.49 Favored Pre-proline 0 N--CA 1.468 0.445 0 CA-C-N 114.502 -1.226 . . . . 0.0 114.148 -174.916 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 409' ' ' PRO . . . . . . . . . . . . . 15.6 Cg_exo -70.12 68.01 1.92 Allowed 'Trans proline' 0 C--N 1.354 0.825 0 C-N-CA 122.074 1.849 . . . . 0.0 112.137 176.778 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 410' ' ' THR . . . . . . . . . . . . . 3.4 t -67.13 87.72 0.16 Allowed 'General case' 0 C--N 1.328 -0.335 0 CA-C-O 121.736 0.779 . . . . 0.0 111.463 -178.182 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 411' ' ' ASP . . . . . . . . . . . . . 38.6 t70 -77.31 -25.48 51.28 Favored 'General case' 0 C--N 1.324 -0.508 0 CA-C-N 115.615 -0.721 . . . . 0.0 110.451 179.412 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 412' ' ' ALA . . . . . . . . . . . . . . . -98.1 -178.02 3.92 Favored 'General case' 0 C--N 1.326 -0.416 0 CA-C-N 115.868 -0.605 . . . . 0.0 110.415 178.128 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 413' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 -61.94 -57.26 12.4 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-O 121.424 0.63 . . . . 0.0 111.245 -178.902 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 414' ' ' LYS . . . . . . . . . . . . . 13.8 pttp -118.98 142.17 48.02 Favored 'General case' 0 C--N 1.321 -0.667 0 CA-C-N 115.371 -0.831 . . . . 0.0 111.06 -175.366 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 415' ' ' GLY . . . . . . . . . . . . . . . -73.12 145.11 35.78 Favored Glycine 0 N--CA 1.446 -0.683 0 N-CA-C 111.261 -0.736 . . . . 0.0 111.261 175.71 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 416' ' ' GLY . . . . . . . . . . . . . . . 157.5 -20.88 0.4 Allowed Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.771 -0.728 . . . . 0.0 111.767 -175.043 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 417' ' ' PHE . . . . . 0.473 ' HB3' ' HB2' ' A' ' 326' ' ' PHE . 87.9 m-85 -71.5 163.45 27.7 Favored 'General case' 0 N--CA 1.45 -0.456 0 N-CA-C 109.489 -0.56 . . . . 0.0 109.489 173.823 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 418' ' ' GLY . . . . . 0.612 ' HA2' ' HA ' ' A' ' 325' ' ' HIS . . . 83.33 76.83 1.13 Allowed Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 120.024 -1.084 . . . . 0.0 110.933 -169.721 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 419' ' ' VAL . . . . . 0.987 HG23 ' HG2' ' A' ' 404' ' ' LYS . 8.4 p -107.33 166.03 4.16 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.703 0 CA-C-O 121.28 0.562 . . . . 0.0 110.605 -177.576 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 420' ' ' PHE . . . . . 0.445 ' H ' HG22 ' A' ' 419' ' ' VAL . 41.8 p90 -140.76 157.53 45.29 Favored 'General case' 0 C--N 1.312 -1.024 0 CA-C-N 115.224 -0.898 . . . . 0.0 109.904 177.218 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -142.69 136.06 28.63 Favored 'General case' 0 C--N 1.317 -0.81 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 177.122 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -121.74 138.42 12.27 Favored Glycine 0 N--CA 1.446 -0.668 0 C-N-CA 120.562 -0.828 . . . . 0.0 112.177 -177.726 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -110.78 127.11 55.24 Favored 'General case' 0 C--N 1.324 -0.543 0 N-CA-C 110.112 -0.329 . . . . 0.0 110.112 178.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 424' ' ' LYS . . . . . 0.506 ' HB3' ' HB3' ' A' ' 399' ' ' GLU . 23.2 tptm -66.85 115.28 6.45 Favored 'General case' 0 C--N 1.323 -0.578 0 CA-C-O 120.835 0.35 . . . . 0.0 110.603 176.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 425' ' ' GLU . . . . . . . . . . . . . 35.0 tt0 -98.86 113.24 25.28 Favored 'General case' 0 C--N 1.319 -0.744 0 N-CA-C 108.956 -0.757 . . . . 0.0 108.956 175.427 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 426' ' ' GLN . . . . . . . . . . . . . 19.3 mp0 -86.39 78.57 9.24 Favored 'General case' 0 C--N 1.322 -0.609 0 N-CA-C 109.353 -0.61 . . . . 0.0 109.353 179.704 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 427' ' ' ASP . . . . . 0.556 ' HA ' ' HB2' ' A' ' 430' ' ' HIS . 26.1 t70 -103.39 60.26 0.76 Allowed 'General case' 0 C--N 1.322 -0.628 0 CA-C-O 121.418 0.628 . . . . 0.0 110.43 -177.9 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -70.66 -64.05 0.97 Allowed 'General case' 0 C--N 1.327 -0.406 0 N-CA-C 109.121 -0.696 . . . . 0.0 109.121 176.025 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 429' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -128.77 20.72 5.99 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.934 173.663 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 430' ' ' HIS . . . . . 0.556 ' HB2' ' HA ' ' A' ' 427' ' ' ASP . 6.2 m-70 -71.74 -173.79 1.04 Allowed 'General case' 0 C--O 1.232 0.162 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.654 -176.013 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 76.5 m80 60.51 52.33 4.69 Favored 'General case' 0 C--O 1.233 0.228 0 N-CA-C 107.768 -1.197 . . . . 0.0 107.768 -168.39 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 432' ' ' HIS . . . . . . . . . . . . . 62.7 m170 -59.35 131.79 52.04 Favored 'General case' 0 CA--C 1.517 -0.293 0 CA-C-N 114.032 -1.44 . . . . 0.0 111.837 -173.039 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 433' ' ' HIS . . . . . 0.499 ' O ' ' HB2' ' A' ' 434' ' ' HIS . 15.6 t60 -137.08 87.17 2.26 Favored 'General case' 0 C--N 1.318 -0.769 0 N-CA-C 108.004 -1.11 . . . . 0.0 108.004 176.358 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 434' ' ' HIS . . . . . 0.499 ' HB2' ' O ' ' A' ' 433' ' ' HIS . 71.6 m-70 74.83 -47.79 0.63 Allowed 'General case' 0 N--CA 1.473 0.707 0 C-N-CA 123.712 0.805 . . . . 0.0 109.667 -167.732 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 435' ' ' HIS . . . . . . . . . . . . . 24.1 m80 . . . . . 0 C--O 1.246 0.918 0 CA-C-O 118.484 -0.769 . . . . 0.0 109.274 172.674 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 276' ' ' ASN . . . . . 0.537 ' ND2' ' HA ' ' A' ' 299' ' ' TYR . 96.8 m-20 . . . . . 0 N--CA 1.482 1.141 0 N-CA-C 110.784 -0.08 . . . . 0.0 110.784 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 2.4 mp -110.02 -53.05 5.97 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.306 0 CA-C-O 121.259 0.552 . . . . 0.0 110.976 177.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 278' ' ' PHE . . . . . 0.631 ' HE1' ' HE1' ' A' ' 299' ' ' TYR . 31.4 p90 -81.84 13.51 3.21 Favored 'General case' 0 C--N 1.315 -0.924 0 CA-C-N 115.591 -0.731 . . . . 0.0 110.307 178.109 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 279' ' ' ALA . . . . . . . . . . . . . . . -149.81 123.92 4.6 Favored Pre-proline 0 C--N 1.326 -0.452 0 CA-C-N 115.234 -0.894 . . . . 0.0 109.416 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 280' ' ' PRO . . . . . . . . . . . . . 27.2 Cg_exo -63.06 162.21 26.97 Favored 'Trans proline' 0 N--CA 1.473 0.279 0 C-N-CA 123.302 2.668 . . . . 0.0 112.299 -179.708 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . . . . . . . . . 37.9 tt0 -59.36 102.93 0.15 Allowed 'General case' 0 C--O 1.236 0.354 0 CA-C-N 115.852 -0.613 . . . . 0.0 111.107 179.834 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . 152.14 -160.06 28.68 Favored Glycine 0 N--CA 1.446 -0.645 0 N-CA-C 111.28 -0.728 . . . . 0.0 111.28 -179.816 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 283' ' ' ASN . . . . . . . . . . . . . 21.4 p-10 -132.27 84.58 2.17 Favored 'General case' 0 C--N 1.321 -0.673 0 CA-C-O 121.935 0.874 . . . . 0.0 110.497 177.508 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . . . . . . . . . 63.5 m-85 -85.37 113.8 21.95 Favored 'General case' 0 C--N 1.321 -0.653 0 CA-C-N 115.198 -0.91 . . . . 0.0 110.198 -179.718 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . . . . . . . . . 11.5 ptp180 -92.59 -0.06 57.36 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-O 121.551 0.691 . . . . 0.0 109.886 176.821 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . . . . . . . . . 94.2 m-85 -98.98 11.81 37.85 Favored 'General case' 0 C--N 1.325 -0.47 0 CA-C-N 115.019 -0.991 . . . . 0.0 108.839 171.194 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . 0.815 ' HG ' ' H ' ' A' ' 288' ' ' THR . 16.2 tp -74.23 175.51 7.5 Favored 'General case' 0 N--CA 1.442 -0.868 0 CA-C-N 114.715 -1.13 . . . . 0.0 110.533 -179.085 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 288' ' ' THR . . . . . 0.815 ' H ' ' HG ' ' A' ' 287' ' ' LEU . 26.7 m -89.74 166.1 13.78 Favored 'General case' 0 C--N 1.317 -0.812 0 CA-C-N 115.927 -0.579 . . . . 0.0 109.514 -179.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 289' ' ' TYR . . . . . 0.721 ' N ' ' HB2' ' A' ' 304' ' ' GLN . 0.1 OUTLIER -102.12 123.46 46.02 Favored 'General case' 0 N--CA 1.448 -0.559 0 N-CA-C 109.884 -0.413 . . . . 0.0 109.884 -172.11 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . -179.27 152.12 10.82 Favored Glycine 0 N--CA 1.444 -0.8 0 N-CA-C 110.639 -0.985 . . . . 0.0 110.639 -178.453 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 291' ' ' ALA . . . . . 0.413 ' CB ' HD13 ' A' ' 301' ' ' LEU . . . -145.02 113.6 6.71 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 112.666 0.617 . . . . 0.0 112.666 -175.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 292' ' ' GLU . . . . . . . . . . . . . 23.7 mt-10 -146.76 110.01 4.78 Favored 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 115.712 -0.676 . . . . 0.0 109.671 168.78 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 293' ' ' LYS . . . . . 0.787 ' HA ' ' HB3' ' A' ' 299' ' ' TYR . 36.9 ttpt -97.94 136.52 38.1 Favored 'General case' 0 C--N 1.321 -0.657 0 N-CA-C 108.919 -0.771 . . . . 0.0 108.919 -178.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 294' ' ' LEU . . . . . 0.618 HD13 ' O ' ' A' ' 294' ' ' LEU . 0.0 OUTLIER -73.62 139.52 77.76 Favored Pre-proline 0 C--N 1.329 -0.323 0 C-N-CA 119.578 -0.849 . . . . 0.0 110.629 -174.784 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 295' ' ' PRO . . . . . 0.468 ' HD3' ' HA ' ' A' ' 294' ' ' LEU . 38.0 Cg_exo -60.57 89.92 0.09 OUTLIER 'Trans proline' 0 C--N 1.349 0.568 0 C-N-CA 123.258 2.638 . . . . 0.0 111.485 178.553 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . 169.17 -26.01 0.11 Allowed Glycine 0 N--CA 1.441 -1.019 0 N-CA-C 110.435 -1.066 . . . . 0.0 110.435 -172.405 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . 111.82 -11.01 27.55 Favored Glycine 0 N--CA 1.442 -0.905 0 C-N-CA 120.529 -0.843 . . . . 0.0 113.841 171.159 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 298' ' ' SER . . . . . 0.514 ' O ' HD12 ' A' ' 294' ' ' LEU . 43.9 m -107.04 83.76 1.88 Allowed 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.879 0.847 . . . . 0.0 112.032 -174.509 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 299' ' ' TYR . . . . . 0.787 ' HB3' ' HA ' ' A' ' 293' ' ' LYS . 0.4 OUTLIER -166.97 171.19 11.4 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 114.649 -1.16 . . . . 0.0 109.439 178.81 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 300' ' ' ALA . . . . . 0.468 ' H ' ' HD1' ' A' ' 299' ' ' TYR . . . -158.04 161.48 38.05 Favored 'General case' 0 C--N 1.315 -0.917 0 CA-C-N 115.836 -0.62 . . . . 0.0 109.783 -168.68 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 301' ' ' LEU . . . . . 0.413 HD13 ' CB ' ' A' ' 291' ' ' ALA . 0.2 OUTLIER -129.84 135.53 48.5 Favored 'General case' 0 C--N 1.316 -0.881 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.14 177.199 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 302' ' ' ARG . . . . . 0.682 ' HB3' HD23 ' A' ' 287' ' ' LEU . 3.8 tpp180 -114.43 166.5 11.62 Favored 'General case' 0 C--N 1.317 -0.816 0 N-CA-C 109.452 -0.573 . . . . 0.0 109.452 -178.107 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 303' ' ' VAL . . . . . . . . . . . . . 35.1 m -106.81 149.32 10.34 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 CA-C-O 121.414 0.626 . . . . 0.0 112.553 -168.116 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 304' ' ' GLN . . . . . 0.721 ' HB2' ' N ' ' A' ' 289' ' ' TYR . 8.3 tt0 -108.37 150.73 26.97 Favored 'General case' 0 N--CA 1.444 -0.755 0 CA-C-N 114.795 -1.093 . . . . 0.0 108.657 172.699 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . 0.749 ' H ' ' HG3' ' A' ' 396' ' ' PRO . . . -95.15 178.01 35.54 Favored Glycine 0 N--CA 1.436 -1.343 0 C-N-CA 120.294 -0.955 . . . . 0.0 111.827 177.623 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 306' ' ' GLU . . . . . 0.728 ' HB2' ' HD2' ' A' ' 307' ' ' PRO . 12.7 pt-20 -83.52 -177.9 1.07 Allowed Pre-proline 0 C--N 1.315 -0.933 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 176.673 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . 0.757 ' HA ' ' HA2' ' A' ' 395' ' ' GLY . 98.0 Cg_exo -46.36 136.09 15.34 Favored 'Trans proline' 0 C--N 1.358 1.032 0 C-N-CA 122.097 1.865 . . . . 0.0 111.645 176.168 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . 0.713 ' HB1' HD11 ' A' ' 313' ' ' LEU . . . -31.44 106.6 0.04 OUTLIER 'General case' 0 CA--C 1.506 -0.727 0 O-C-N 124.923 1.39 . . . . 0.0 112.844 -165.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 309' ' ' LYS . . . . . 0.509 ' HE3' ' OE2' ' A' ' 311' ' ' GLU . 23.4 tptt -69.62 91.76 0.62 Allowed 'General case' 0 C--N 1.316 -0.854 0 CA-C-N 115.222 -0.899 . . . . 0.0 109.97 -173.311 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 310' ' ' GLY . . . . . 0.72 ' HA2' HD12 ' A' ' 313' ' ' LEU . . . -60.6 -30.32 71.84 Favored Glycine 0 C--N 1.331 0.264 0 CA-C-N 115.578 -0.737 . . . . 0.0 114.086 -169.241 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . 0.509 ' OE2' ' HE3' ' A' ' 309' ' ' LYS . 4.8 pm0 -72.42 -17.06 61.83 Favored 'General case' 0 C--N 1.319 -0.74 0 CA-C-O 120.74 0.305 . . . . 0.0 111.069 179.15 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 312' ' ' MET . . . . . . . . . . . . . 66.2 mtm -117.13 -0.18 12.17 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 120.797 0.332 . . . . 0.0 110.922 178.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 313' ' ' LEU . . . . . 0.72 HD12 ' HA2' ' A' ' 310' ' ' GLY . 83.8 mt -70.93 134.37 47.17 Favored 'General case' 0 C--N 1.328 -0.327 0 N-CA-C 109.077 -0.712 . . . . 0.0 109.077 173.34 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -149.66 137.92 20.59 Favored 'General case' 0 C--N 1.315 -0.928 0 CA-C-N 115.927 -0.579 . . . . 0.0 111.331 -173.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.77 171.95 14.49 Favored Glycine 0 N--CA 1.444 -0.799 0 N-CA-C 111.385 -0.686 . . . . 0.0 111.385 179.401 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 42.5 p -102.61 149.4 24.46 Favored 'General case' 0 C--N 1.316 -0.874 0 N-CA-C 109.788 -0.449 . . . . 0.0 109.788 173.996 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -142.78 148.28 36.92 Favored 'General case' 0 C--N 1.314 -0.969 0 CA-C-O 121.16 0.505 . . . . 0.0 112.32 -175.258 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . 0.534 ' O ' ' HA ' ' A' ' 424' ' ' LYS . 13.8 t -114.56 104.32 16.74 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.556 0 CA-C-N 115.291 -0.868 . . . . 0.0 109.913 175.329 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . 0.508 ' HH ' ' HZ ' ' A' ' 346' ' ' PHE . 60.3 m-85 -97.88 127.33 43.76 Favored 'General case' 0 C--N 1.312 -1.05 0 C-N-CA 120.264 -0.574 . . . . 0.0 110.046 177.168 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 320' ' ' ASN . . . . . 0.418 ' ND2' ' HB2' ' A' ' 425' ' ' GLU . 7.6 p30 -138.31 145.16 40.87 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 109.578 -0.527 . . . . 0.0 109.578 178.799 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -172.14 -152.28 8.4 Favored Glycine 0 N--CA 1.44 -1.083 0 C-N-CA 120.735 -0.745 . . . . 0.0 111.856 -177.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 2.8 mp0 -114.49 143.74 44.46 Favored 'General case' 0 C--N 1.32 -0.695 0 CA-C-O 120.897 0.38 . . . . 0.0 110.779 -174.413 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 323' ' ' VAL . . . . . 0.644 HG23 ' HB2' ' A' ' 340' ' ' PHE . 59.1 t -106.8 116.62 50.93 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.507 0 CA-C-N 115.941 -0.572 . . . . 0.0 109.935 175.258 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 324' ' ' LEU . . . . . 0.658 HD11 ' HB2' ' A' ' 335' ' ' PRO . 24.9 tp -97.53 102.69 14.51 Favored 'General case' 0 C--N 1.311 -1.101 0 CA-C-O 121.139 0.495 . . . . 0.0 109.889 -179.505 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 325' ' ' HIS . . . . . . . . . . . . . 1.3 p-80 -105.03 114.72 29.09 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-O 121.344 0.592 . . . . 0.0 109.73 176.691 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 326' ' ' PHE . . . . . 0.735 ' HD1' ' HB2' ' A' ' 417' ' ' PHE . 31.3 m-85 -82.9 114.69 21.37 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.168 -0.924 . . . . 0.0 110.96 -170.167 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 327' ' ' HIS . . . . . . . . . . . . . 76.1 m80 -110.79 105.23 14.01 Favored 'General case' 0 C--N 1.324 -0.505 0 N-CA-C 110.085 -0.339 . . . . 0.0 110.085 171.05 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 328' ' ' THR . . . . . 0.549 HG22 ' HA ' ' A' ' 332' ' ' ARG . 22.1 p -137.01 96.01 3.22 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.253 0.549 . . . . 0.0 109.65 172.829 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 329' ' ' GLU . . . . . 0.416 ' O ' ' HB3' ' A' ' 330' ' ' ASN . 39.5 mt-10 -108.99 120.39 42.39 Favored 'General case' 0 C--N 1.318 -0.8 0 CA-C-N 115.619 -0.718 . . . . 0.0 109.675 178.34 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 330' ' ' ASN . . . . . 0.416 ' HB3' ' O ' ' A' ' 329' ' ' GLU . 54.2 t30 72.94 -57.92 0.62 Allowed 'General case' 0 N--CA 1.468 0.453 0 O-C-N 123.903 0.752 . . . . 0.0 110.721 -176.049 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 331' ' ' GLY . . . . . 0.446 ' O ' ' HD3' ' A' ' 333' ' ' PRO . . . -124.32 174.72 17.0 Favored Glycine 0 N--CA 1.449 -0.497 0 N-CA-C 111.757 -0.537 . . . . 0.0 111.757 177.695 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 332' ' ' ARG . . . . . 0.549 ' HA ' HG22 ' A' ' 328' ' ' THR . 72.5 mtp180 -108.38 96.86 20.1 Favored Pre-proline 0 C--N 1.325 -0.483 0 N-CA-C 110.247 -0.279 . . . . 0.0 110.247 178.853 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 333' ' ' PRO . . . . . 0.446 ' HD3' ' O ' ' A' ' 331' ' ' GLY . 1.1 Cg_endo -84.07 -79.05 0.0 OUTLIER 'Trans proline' 0 N--CA 1.456 -0.687 0 C-N-CA 123.045 2.497 . . . . 0.0 113.006 -178.325 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 334' ' ' TYR . . . . . . . . . . . . . 86.1 t80 -161.27 126.23 2.15 Favored Pre-proline 0 C--N 1.329 -0.317 0 CA-C-N 116.403 -0.362 . . . . 0.0 110.333 -177.074 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 335' ' ' PRO . . . . . 0.658 ' HB2' HD11 ' A' ' 324' ' ' LEU . 5.2 Cg_exo -80.17 127.89 7.0 Favored 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 122.697 2.265 . . . . 0.0 111.137 174.971 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 336' ' ' THR . . . . . . . . . . . . . 4.8 p -94.88 139.18 31.67 Favored 'General case' 0 C--N 1.322 -0.592 0 CA-C-O 121.088 0.471 . . . . 0.0 111.126 -179.044 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 337' ' ' ARG . . . . . 0.513 ' HA ' ' O ' ' A' ' 323' ' ' VAL . 24.2 mtm180 -103.81 128.67 51.23 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.428 0.632 . . . . 0.0 110.664 178.151 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -95.21 -177.12 37.62 Favored Glycine 0 N--CA 1.439 -1.111 0 CA-C-N 115.222 -0.899 . . . . 0.0 111.613 176.969 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 339' ' ' ARG . . . . . 0.459 ' HB2' ' HB3' ' A' ' 356' ' ' ASP . 56.1 mtp180 -106.09 133.48 50.73 Favored 'General case' 0 C--N 1.315 -0.901 0 N-CA-C 110.081 -0.34 . . . . 0.0 110.081 -176.133 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 340' ' ' PHE . . . . . 0.644 ' HB2' HG23 ' A' ' 323' ' ' VAL . 26.1 t80 -132.43 139.46 48.03 Favored 'General case' 0 C--N 1.316 -0.877 0 CA-C-O 120.986 0.422 . . . . 0.0 111.342 -176.226 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 341' ' ' ALA . . . . . . . . . . . . . . . -142.86 165.85 26.24 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.223 -0.899 . . . . 0.0 109.374 174.509 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . . . . . . . . . . . -157.18 134.09 10.19 Favored 'General case' 0 N--CA 1.448 -0.548 0 CA-C-O 120.875 0.369 . . . . 0.0 110.901 -174.296 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . 0.401 ' HB3' ' HB2' ' A' ' 352' ' ' ASP . 4.5 tppp? -108.03 102.8 11.94 Favored 'General case' 0 C--N 1.322 -0.624 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.06 178.799 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 344' ' ' VAL . . . . . 0.659 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.3 OUTLIER -125.83 133.34 69.28 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.734 0 CA-C-O 121.703 0.763 . . . . 0.0 112.553 -172.08 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 4.2 m-20 -102.31 121.9 43.19 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 114.586 -1.188 . . . . 0.0 108.176 172.082 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 346' ' ' PHE . . . . . 0.508 ' HZ ' ' HH ' ' A' ' 319' ' ' TYR . 33.1 m-85 -72.3 -37.92 68.84 Favored 'General case' 0 C--N 1.325 -0.482 0 C-N-CA 120.979 -0.288 . . . . 0.0 110.931 -179.108 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -61.0 -30.51 73.65 Favored Glycine 0 N--CA 1.451 -0.333 0 C-N-CA 120.818 -0.706 . . . . 0.0 112.111 -179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 47.8 t -97.88 -10.02 25.35 Favored 'General case' 0 C--N 1.325 -0.457 0 O-C-N 123.008 -0.113 . . . . 0.0 110.783 -179.666 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 349' ' ' LYS . . . . . 0.481 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 29.0 mtmt 47.35 55.69 7.9 Favored 'General case' 0 CA--C 1.53 0.194 0 CA-C-O 121.62 0.724 . . . . 0.0 111.266 -176.22 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 29.1 m -147.52 138.94 23.81 Favored 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.332 -0.849 . . . . 0.0 109.632 179.483 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 351' ' ' VAL . . . . . 0.659 ' HB ' ' HB ' ' A' ' 344' ' ' VAL . 0.6 OUTLIER -130.1 148.46 33.17 Favored 'Isoleucine or valine' 0 C--O 1.236 0.38 0 CA-C-O 121.288 0.566 . . . . 0.0 111.379 -174.894 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 352' ' ' ASP . . . . . 0.401 ' HB2' ' HB3' ' A' ' 343' ' ' LYS . 6.3 m-20 -100.46 151.78 21.15 Favored 'General case' 0 C--N 1.319 -0.724 0 N-CA-C 107.179 -1.415 . . . . 0.0 107.179 165.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 353' ' ' GLY . . . . . 0.64 ' HA3' ' CE1' ' A' ' 368' ' ' PHE . . . -142.52 138.17 8.26 Favored Glycine 0 N--CA 1.442 -0.956 0 C-N-CA 120.483 -0.865 . . . . 0.0 111.541 175.217 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 354' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -121.68 129.74 75.23 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.749 0 CA-C-O 121.185 0.516 . . . . 0.0 109.818 178.669 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 355' ' ' ILE . . . . . 0.765 HG13 ' CZ3' ' A' ' 381' ' ' TRP . 7.0 mm -119.34 98.94 6.88 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.711 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.591 -174.23 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 356' ' ' ASP . . . . . 0.459 ' HB3' ' HB2' ' A' ' 339' ' ' ARG . 12.2 t0 -95.54 139.0 32.43 Favored 'General case' 0 C--N 1.317 -0.833 0 N-CA-C 109.561 -0.533 . . . . 0.0 109.561 176.382 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 24.1 t -91.02 -8.15 49.9 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-O 121.365 0.602 . . . . 0.0 109.492 179.095 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 358' ' ' GLY . . . . . 0.411 ' H ' ' CG ' ' A' ' 356' ' ' ASP . . . 106.82 -9.96 40.77 Favored Glycine 0 N--CA 1.444 -0.82 0 N-CA-C 110.075 -1.21 . . . . 0.0 110.075 -173.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 359' ' ' ASP . . . . . 0.493 ' HB3' ' HB2' ' A' ' 362' ' ' HIS . 13.6 m-20 -120.92 45.29 2.29 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-N 114.662 -0.769 . . . . 0.0 110.336 -175.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 360' ' ' ASP . . . . . 0.48 ' OD1' ' HB ' ' A' ' 365' ' ' THR . 9.6 t70 -56.19 -35.08 66.85 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-O 121.131 0.491 . . . . 0.0 110.694 176.773 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 361' ' ' LEU . . . . . . . . . . . . . 93.0 mt -77.9 -0.95 29.45 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 116.039 -0.528 . . . . 0.0 111.548 -179.314 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 362' ' ' HIS . . . . . 0.493 ' HB2' ' HB3' ' A' ' 359' ' ' ASP . 22.1 m170 -105.05 -89.76 0.41 Allowed 'General case' 0 C--N 1.327 -0.397 0 CA-C-O 120.642 0.258 . . . . 0.0 110.53 -179.397 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 363' ' ' MET . . . . . . . . . . . . . 3.6 mpp? -79.23 -18.58 52.58 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-O 121.227 0.537 . . . . 0.0 110.457 -179.096 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 364' ' ' GLY . . . . . . . . . . . . . . . 104.01 170.75 25.2 Favored Glycine 0 N--CA 1.443 -0.855 0 N-CA-C 110.928 -0.869 . . . . 0.0 110.928 -174.814 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 365' ' ' THR . . . . . 0.48 ' HB ' ' OD1' ' A' ' 360' ' ' ASP . 12.1 t -93.33 154.68 17.84 Favored 'General case' 0 C--N 1.318 -0.785 0 CA-C-O 120.922 0.391 . . . . 0.0 110.411 179.23 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 79.4 mt-30 -107.28 162.94 13.44 Favored 'General case' 0 C--N 1.32 -0.717 0 N-CA-C 109.49 -0.559 . . . . 0.0 109.49 178.091 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 367' ' ' LYS . . . . . 0.443 ' HG3' ' HA ' ' A' ' 382' ' ' THR . 8.7 ptpp? -147.22 168.94 20.42 Favored 'General case' 0 C--N 1.316 -0.852 0 N-CA-C 109.666 -0.494 . . . . 0.0 109.666 179.138 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 368' ' ' PHE . . . . . 0.64 ' CE1' ' HA3' ' A' ' 353' ' ' GLY . 31.6 p90 -151.49 156.08 39.86 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 109.862 -0.421 . . . . 0.0 109.862 175.164 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 369' ' ' LYS . . . . . . . . . . . . . 1.7 mptp? -118.94 130.77 55.89 Favored 'General case' 0 C--N 1.319 -0.759 0 N-CA-C 109.487 -0.56 . . . . 0.0 109.487 175.838 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . 0.518 ' HA ' ' HA3' ' A' ' 379' ' ' GLY . . . -135.75 141.47 44.83 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.244 -0.434 . . . . 0.0 111.104 -175.884 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -102.51 136.04 43.05 Favored 'General case' 0 C--N 1.319 -0.733 0 CA-C-N 115.96 -0.564 . . . . 0.0 109.724 176.747 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 372' ' ' ILE . . . . . 0.481 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 74.9 mt -81.18 114.26 21.87 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.605 0 CA-C-O 121.545 0.688 . . . . 0.0 110.528 -177.801 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . 0.424 ' HB2' ' HE3' ' A' ' 378' ' ' LYS . 36.0 t70 -117.11 80.75 1.53 Allowed 'General case' 0 C--N 1.322 -0.627 0 CA-C-N 114.704 -1.135 . . . . 0.0 109.158 -178.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 61.18 119.12 0.01 OUTLIER Glycine 0 CA--C 1.52 0.372 0 CA-C-N 114.968 -1.014 . . . . 0.0 113.408 -175.73 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 375' ' ' ASN . . . . . 0.598 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 3.6 p-10 26.13 48.1 0.01 OUTLIER 'General case' 0 N--CA 1.476 0.85 0 C-N-CA 124.582 1.153 . . . . 0.0 114.08 179.519 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . 162.95 171.45 29.19 Favored Glycine 0 N--CA 1.444 -0.81 0 N-CA-C 110.921 -0.872 . . . . 0.0 110.921 178.771 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 377' ' ' PHE . . . . . 0.43 ' CD2' HG11 ' A' ' 351' ' ' VAL . 4.0 p90 -138.83 147.94 43.11 Favored 'General case' 0 C--N 1.319 -0.738 0 CA-C-O 121.458 0.647 . . . . 0.0 111.983 -179.245 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 378' ' ' LYS . . . . . 0.424 ' HE3' ' HB2' ' A' ' 373' ' ' ASP . 0.0 OUTLIER -130.59 133.13 45.93 Favored 'General case' 0 C--N 1.319 -0.72 0 CA-C-N 114.775 -1.102 . . . . 0.0 109.659 173.468 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 379' ' ' GLY . . . . . 0.518 ' HA3' ' HA ' ' A' ' 370' ' ' ALA . . . -154.85 -158.36 8.67 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 120.794 -0.717 . . . . 0.0 112.489 -176.472 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 1.0 OUTLIER -138.17 151.85 48.12 Favored 'General case' 0 C--N 1.317 -0.837 0 CA-C-O 120.74 0.305 . . . . 0.0 111.489 -173.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 381' ' ' TRP . . . . . 0.765 ' CZ3' HG13 ' A' ' 355' ' ' ILE . 19.3 m95 -56.36 139.19 49.39 Favored 'General case' 0 C--O 1.233 0.211 0 CA-C-N 115.724 -0.671 . . . . 0.0 110.992 176.668 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 382' ' ' THR . . . . . 0.443 ' HA ' ' HG3' ' A' ' 367' ' ' LYS . 8.0 m 63.86 -78.35 0.03 OUTLIER 'General case' 0 C--N 1.333 -0.151 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.244 -176.153 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 383' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -163.29 -32.87 0.04 OUTLIER 'General case' 0 C--N 1.322 -0.621 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.8 175.295 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 384' ' ' ASN . . . . . . . . . . . . . 27.5 p30 -155.61 19.39 0.4 Allowed 'General case' 0 C--O 1.233 0.222 0 N-CA-C 112.192 0.441 . . . . 0.0 112.192 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 385' ' ' GLY . . . . . . . . . . . . . . . -148.61 125.93 2.17 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.221 -0.99 . . . . 0.0 112.782 -176.559 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 386' ' ' GLY . . . . . . . . . . . . . . . 134.38 -70.48 0.51 Allowed Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.985 -0.626 . . . . 0.0 112.493 -179.782 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . . . . . . . . . . . 174.05 -175.32 46.55 Favored Glycine 0 N--CA 1.449 -0.496 0 C-N-CA 121.122 -0.561 . . . . 0.0 111.865 -178.734 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -90.9 137.42 32.38 Favored 'General case' 0 C--N 1.323 -0.566 0 CA-C-O 121.056 0.455 . . . . 0.0 110.992 -177.4 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 389' ' ' VAL . . . . . . . . . . . . . 29.5 t -128.98 115.37 36.27 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.595 0 CA-C-N 115.794 -0.639 . . . . 0.0 109.58 177.765 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 390' ' ' SER . . . . . . . . . . . . . 2.4 p -139.11 137.51 36.22 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 121.355 0.598 . . . . 0.0 112.477 -175.316 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 391' ' ' GLY . . . . . 0.405 ' CA ' ' HA3' ' A' ' 403' ' ' GLY . . . -147.84 159.33 27.99 Favored Glycine 0 N--CA 1.447 -0.614 0 CA-C-N 115.474 -0.785 . . . . 0.0 111.515 179.856 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 392' ' ' ARG . . . . . 0.417 ' N ' ' HD2' ' A' ' 392' ' ' ARG . 8.2 mpt_? -117.01 142.43 46.96 Favored 'General case' 0 C--N 1.326 -0.445 0 CA-C-O 121.05 0.453 . . . . 0.0 111.076 -174.423 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 393' ' ' PHE . . . . . 0.414 ' CD1' ' HB ' ' A' ' 401' ' ' VAL . 21.0 m-85 -82.34 163.09 21.98 Favored 'General case' 0 N--CA 1.447 -0.614 0 CA-C-N 115.295 -0.866 . . . . 0.0 109.671 176.626 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 394' ' ' TYR . . . . . 0.437 ' HD1' ' N ' ' A' ' 394' ' ' TYR . 1.2 m-85 -100.77 -176.99 3.34 Favored 'General case' 0 C--N 1.314 -0.956 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 176.094 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 395' ' ' GLY . . . . . 0.757 ' HA2' ' HA ' ' A' ' 307' ' ' PRO . . . -52.74 -146.96 0.0 OUTLIER Glycine 0 CA--C 1.527 0.836 0 O-C-N 124.062 0.851 . . . . 0.0 114.755 -176.256 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 396' ' ' PRO . . . . . 0.749 ' HG3' ' H ' ' A' ' 305' ' ' GLY . 19.4 Cg_endo -59.22 -11.49 13.25 Favored 'Trans proline' 0 CA--C 1.536 0.605 0 C-N-CA 121.515 1.477 . . . . 0.0 111.051 179.389 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 397' ' ' ALA . . . . . . . . . . . . . . . -94.82 28.79 2.56 Favored 'General case' 0 N--CA 1.453 -0.316 0 CA-C-N 114.798 -1.092 . . . . 0.0 110.557 175.767 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . -57.78 2.42 0.14 Allowed Glycine 0 C--N 1.338 0.646 0 CA-C-N 115.923 -0.58 . . . . 0.0 113.657 -179.681 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 399' ' ' GLU . . . . . 0.815 ' HG2' ' HD3' ' A' ' 424' ' ' LYS . 35.7 mt-10 -58.73 -9.22 1.63 Allowed 'General case' 0 N--CA 1.45 -0.446 0 C-N-CA 123.401 0.68 . . . . 0.0 109.756 166.114 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 400' ' ' GLU . . . . . . . . . . . . . 43.4 mt-10 -115.02 125.68 53.87 Favored 'General case' 0 N--CA 1.447 -0.62 0 CA-C-N 115.189 -0.914 . . . . 0.0 109.437 171.001 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 401' ' ' VAL . . . . . 0.414 ' HB ' ' CD1' ' A' ' 393' ' ' PHE . 9.7 p -135.09 146.57 30.17 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.496 0 CA-C-N 115.851 -0.613 . . . . 0.0 109.725 178.128 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -142.19 135.07 28.58 Favored 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 120.82 0.343 . . . . 0.0 110.896 179.705 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 403' ' ' GLY . . . . . 0.405 ' HA3' ' CA ' ' A' ' 391' ' ' GLY . . . -153.14 -177.91 27.18 Favored Glycine 0 N--CA 1.44 -1.089 0 C-N-CA 120.667 -0.777 . . . . 0.0 112.085 -178.368 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 404' ' ' LYS . . . . . 0.844 ' HG2' HG12 ' A' ' 419' ' ' VAL . 70.2 mttt -142.0 163.01 34.04 Favored 'General case' 0 C--N 1.317 -0.808 0 N-CA-C 108.793 -0.817 . . . . 0.0 108.793 -179.562 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 29.2 p90 -125.35 153.01 43.99 Favored 'General case' 0 C--N 1.32 -0.711 0 CA-C-O 121.218 0.533 . . . . 0.0 111.208 178.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 4.9 p -90.37 116.09 28.06 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-N 115.788 -0.642 . . . . 0.0 110.028 177.144 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . 0.42 ' O ' ' CB ' ' A' ' 408' ' ' ARG . 28.8 t80 -151.07 152.79 33.94 Favored 'General case' 0 C--N 1.32 -0.702 0 N-CA-C 108.604 -0.887 . . . . 0.0 108.604 -178.152 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 408' ' ' ARG . . . . . 0.926 ' HB3' ' HD3' ' A' ' 409' ' ' PRO . 40.3 ttt180 106.44 -68.45 0.0 OUTLIER Pre-proline 0 N--CA 1.482 1.148 0 O-C-N 125.122 1.514 . . . . 0.0 110.763 -178.647 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 409' ' ' PRO . . . . . 0.926 ' HD3' ' HB3' ' A' ' 408' ' ' ARG . 6.5 Cg_exo -73.95 126.99 11.05 Favored 'Trans proline' 0 C--N 1.356 0.966 0 C-N-CA 121.789 1.659 . . . . 0.0 111.345 178.134 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 410' ' ' THR . . . . . . . . . . . . . 14.5 m -76.9 -27.28 54.89 Favored 'General case' 0 C--N 1.323 -0.549 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.15 -176.265 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 411' ' ' ASP . . . . . . . . . . . . . 27.5 t70 -127.89 71.53 1.37 Allowed 'General case' 0 C--N 1.327 -0.387 0 CA-C-O 121.225 0.536 . . . . 0.0 110.294 -178.658 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 412' ' ' ALA . . . . . 0.567 ' HB3' ' HB2' ' A' ' 409' ' ' PRO . . . -166.13 148.91 7.21 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.119 -179.766 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 413' ' ' GLU . . . . . . . . . . . . . 38.8 mm-40 -110.83 36.36 3.16 Favored 'General case' 0 C--N 1.325 -0.457 0 CA-C-N 116.286 -0.415 . . . . 0.0 110.384 -177.769 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 414' ' ' LYS . . . . . . . . . . . . . 4.9 ttmp? -130.82 128.84 41.48 Favored 'General case' 0 C--N 1.325 -0.46 0 CA-C-O 120.792 0.329 . . . . 0.0 111.121 -177.2 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 415' ' ' GLY . . . . . . . . . . . . . . . -105.47 133.11 11.42 Favored Glycine 0 N--CA 1.447 -0.623 0 C-N-CA 120.716 -0.754 . . . . 0.0 111.668 175.222 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 416' ' ' GLY . . . . . . . . . . . . . . . -110.13 -55.61 0.53 Allowed Glycine 0 N--CA 1.446 -0.692 0 C-N-CA 120.724 -0.751 . . . . 0.0 111.327 179.759 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 417' ' ' PHE . . . . . 0.735 ' HB2' ' HD1' ' A' ' 326' ' ' PHE . 47.8 p90 -98.99 177.99 5.08 Favored 'General case' 0 C--N 1.322 -0.614 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 175.326 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 418' ' ' GLY . . . . . . . . . . . . . . . 81.54 71.23 1.3 Allowed Glycine 0 N--CA 1.447 -0.588 0 C-N-CA 120.53 -0.843 . . . . 0.0 112.278 177.804 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 419' ' ' VAL . . . . . 0.844 HG12 ' HG2' ' A' ' 404' ' ' LYS . 22.9 m -109.72 153.04 11.6 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.708 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 178.819 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 420' ' ' PHE . . . . . 0.437 ' HB3' HG22 ' A' ' 323' ' ' VAL . 38.3 p90 -142.4 160.45 40.24 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-O 121.358 0.599 . . . . 0.0 110.873 179.408 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -139.45 136.11 34.29 Favored 'General case' 0 C--N 1.314 -0.948 0 CA-C-N 114.943 -1.026 . . . . 0.0 109.076 177.873 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -118.94 132.44 9.65 Favored Glycine 0 N--CA 1.441 -1.007 0 C-N-CA 120.607 -0.806 . . . . 0.0 111.681 -178.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 423' ' ' LYS . . . . . . . . . . . . . 35.2 mtmt -116.18 124.6 50.69 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 109.663 -0.495 . . . . 0.0 109.663 179.181 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 424' ' ' LYS . . . . . 0.815 ' HD3' ' HG2' ' A' ' 399' ' ' GLU . 46.2 tttm -67.48 125.57 26.57 Favored 'General case' 0 C--N 1.321 -0.63 0 CA-C-N 116.1 -0.5 . . . . 0.0 110.69 -177.795 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 425' ' ' GLU . . . . . 0.418 ' HB2' ' ND2' ' A' ' 320' ' ' ASN . 26.2 tt0 -86.58 111.79 20.96 Favored 'General case' 0 N--CA 1.444 -0.762 0 CA-C-O 121.416 0.627 . . . . 0.0 111.138 -172.012 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 426' ' ' GLN . . . . . . . . . . . . . 46.0 mt-30 -103.83 -179.11 3.85 Favored 'General case' 0 C--N 1.32 -0.71 0 CA-C-N 115.263 -0.881 . . . . 0.0 108.776 170.597 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 427' ' ' ASP . . . . . 0.423 ' CG ' ' H ' ' A' ' 428' ' ' LEU . 29.2 t70 67.66 -175.08 0.19 Allowed 'General case' 0 CA--C 1.54 0.59 0 O-C-N 123.538 0.524 . . . . 0.0 110.191 -178.198 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . 0.423 ' H ' ' CG ' ' A' ' 427' ' ' ASP . 7.1 mp -85.52 -26.48 26.19 Favored 'General case' 0 C--N 1.327 -0.393 0 O-C-N 122.087 -0.383 . . . . 0.0 110.713 178.229 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 429' ' ' GLU . . . . . . . . . . . . . 29.5 tt0 -137.79 -103.31 0.19 Allowed 'General case' 0 C--N 1.326 -0.436 0 CA-C-O 121.047 0.451 . . . . 0.0 109.91 178.459 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 430' ' ' HIS . . . . . . . . . . . . . 55.8 m-70 -147.0 77.36 1.46 Allowed 'General case' 0 C--N 1.322 -0.606 0 N-CA-C 107.88 -1.156 . . . . 0.0 107.88 175.095 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . . . . . . . . . 9.9 t60 -66.39 -17.25 64.67 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.299 -174.102 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 432' ' ' HIS . . . . . . . . . . . . . 77.0 m-70 -78.09 62.02 2.75 Favored 'General case' 0 C--N 1.326 -0.454 0 CA-C-O 121.267 0.556 . . . . 0.0 109.574 172.004 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 433' ' ' HIS . . . . . . . . . . . . . 9.8 t60 -91.86 -53.27 4.35 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.21 -176.327 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 434' ' ' HIS . . . . . . . . . . . . . 39.4 t-80 -85.82 -12.81 49.89 Favored 'General case' 0 C--N 1.326 -0.434 0 CA-C-O 121.174 0.511 . . . . 0.0 109.986 179.367 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 435' ' ' HIS . . . . . . . . . . . . . 67.9 t60 . . . . . 0 C--O 1.248 0.999 0 CA-C-O 118.298 -0.858 . . . . 0.0 109.93 179.188 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 276' ' ' ASN . . . . . 0.436 ' OD1' ' HE2' ' A' ' 293' ' ' LYS . 15.4 t-20 . . . . . 0 N--CA 1.482 1.162 0 CA-C-O 121.303 0.573 . . . . 0.0 109.867 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 277' ' ' ILE . . . . . . . . . . . . . 10.9 tp -98.1 -18.59 6.29 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.128 0 CA-C-O 121.558 0.694 . . . . 0.0 110.395 178.574 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 278' ' ' PHE . . . . . . . . . . . . . 7.8 p90 -89.96 44.05 1.18 Allowed 'General case' 0 C--N 1.315 -0.919 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.353 -178.789 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 279' ' ' ALA . . . . . 0.425 ' HA ' ' HD3' ' A' ' 280' ' ' PRO . . . -75.5 148.84 83.45 Favored Pre-proline 0 C--N 1.326 -0.415 0 CA-C-N 115.202 -0.908 . . . . 0.0 110.245 178.395 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 280' ' ' PRO . . . . . 0.425 ' HD3' ' HA ' ' A' ' 279' ' ' ALA . 22.9 Cg_exo -65.01 161.92 34.8 Favored 'Trans proline' 0 N--CA 1.464 -0.229 0 C-N-CA 123.105 2.537 . . . . 0.0 112.846 -178.566 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 281' ' ' GLU . . . . . 0.443 ' HB3' ' HE2' ' A' ' 284' ' ' TYR . 45.0 tt0 -43.35 -57.36 3.07 Favored 'General case' 0 N--CA 1.466 0.327 0 CA-C-N 115.505 -0.771 . . . . 0.0 111.998 -178.541 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 282' ' ' GLY . . . . . . . . . . . . . . . -114.08 -94.81 2.07 Favored Glycine 0 N--CA 1.449 -0.468 0 C-N-CA 120.853 -0.689 . . . . 0.0 111.795 178.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 283' ' ' ASN . . . . . . . . . . . . . 25.8 t-20 -154.73 90.26 1.3 Allowed 'General case' 0 C--N 1.324 -0.508 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 177.22 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 284' ' ' TYR . . . . . 0.732 ' HD1' ' HE1' ' A' ' 286' ' ' TYR . 98.6 m-85 -101.04 111.3 23.47 Favored 'General case' 0 C--N 1.322 -0.591 0 CA-C-O 121.404 0.621 . . . . 0.0 110.992 -172.527 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 285' ' ' ARG . . . . . 0.477 ' HD3' ' N ' ' A' ' 285' ' ' ARG . 0.0 OUTLIER -120.3 -10.99 9.24 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.574 -0.739 . . . . 0.0 112.001 -173.637 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 286' ' ' TYR . . . . . 0.732 ' HE1' ' HD1' ' A' ' 284' ' ' TYR . 25.9 p90 -58.78 -51.7 68.85 Favored 'General case' 0 N--CA 1.463 0.212 0 CA-C-O 121.205 0.526 . . . . 0.0 110.268 178.983 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 287' ' ' LEU . . . . . 0.543 ' HG ' ' CD2' ' A' ' 286' ' ' TYR . 3.9 pp -168.04 131.11 1.57 Allowed 'General case' 0 C--N 1.321 -0.647 0 N-CA-C 108.624 -0.88 . . . . 0.0 108.624 172.47 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 288' ' ' THR . . . . . 0.446 HG22 ' N ' ' A' ' 289' ' ' TYR . 22.2 m -155.0 161.82 41.26 Favored 'General case' 0 C--N 1.313 -1.009 0 CA-C-N 115.587 -0.733 . . . . 0.0 109.032 -174.205 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 289' ' ' TYR . . . . . 0.446 ' N ' HG22 ' A' ' 288' ' ' THR . 5.7 t80 -126.18 119.34 27.23 Favored 'General case' 0 N--CA 1.435 -1.212 0 N-CA-C 108.686 -0.857 . . . . 0.0 108.686 169.095 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 290' ' ' GLY . . . . . . . . . . . . . . . 130.47 -155.59 21.19 Favored Glycine 0 N--CA 1.443 -0.854 0 C-N-CA 120.282 -0.961 . . . . 0.0 112.428 -177.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 291' ' ' ALA . . . . . 0.401 ' O ' ' HD3' ' A' ' 280' ' ' PRO . . . -100.79 163.69 12.2 Favored 'General case' 0 C--N 1.322 -0.625 0 CA-C-O 121.182 0.515 . . . . 0.0 111.714 -176.357 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 292' ' ' GLU . . . . . . . . . . . . . 9.7 tp10 -145.81 157.27 43.93 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 114.959 -1.019 . . . . 0.0 108.281 176.783 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 293' ' ' LYS . . . . . 0.436 ' HE2' ' OD1' ' A' ' 276' ' ' ASN . 18.0 tppt? -112.58 139.46 48.15 Favored 'General case' 0 C--N 1.316 -0.87 0 CA-C-O 120.927 0.394 . . . . 0.0 110.358 -179.938 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 294' ' ' LEU . . . . . 0.498 HD22 ' HB2' ' A' ' 300' ' ' ALA . 0.7 OUTLIER -114.84 143.27 29.74 Favored Pre-proline 0 C--N 1.322 -0.621 0 CA-C-N 116.353 -0.385 . . . . 0.0 110.259 176.343 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 295' ' ' PRO . . . . . 0.4 ' HD3' ' HA ' ' A' ' 294' ' ' LEU . 87.2 Cg_exo -48.81 102.96 0.05 OUTLIER 'Trans proline' 0 C--N 1.352 0.728 0 C-N-CA 123.742 2.961 . . . . 0.0 112.862 -177.914 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 296' ' ' GLY . . . . . . . . . . . . . . . 143.83 -131.34 4.41 Favored Glycine 0 N--CA 1.443 -0.89 0 CA-C-N 115.37 -0.832 . . . . 0.0 111.096 -177.003 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 297' ' ' GLY . . . . . . . . . . . . . . . -132.26 29.66 3.29 Favored Glycine 0 N--CA 1.449 -0.434 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.319 -179.834 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 298' ' ' SER . . . . . 0.493 ' HB2' HD11 ' A' ' 294' ' ' LEU . 50.8 m -108.34 167.58 9.93 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-N 116.974 0.387 . . . . 0.0 110.571 -178.783 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 299' ' ' TYR . . . . . . . . . . . . . 14.0 m-85 -122.2 137.91 54.66 Favored 'General case' 0 C--N 1.326 -0.44 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 179.829 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 300' ' ' ALA . . . . . 0.498 ' HB2' HD22 ' A' ' 294' ' ' LEU . . . -120.71 153.76 36.51 Favored 'General case' 0 C--N 1.32 -0.703 0 CA-C-O 120.733 0.301 . . . . 0.0 110.842 179.007 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 301' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -121.73 141.17 51.44 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 108.348 -0.982 . . . . 0.0 108.348 173.452 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 302' ' ' ARG . . . . . 0.741 ' HE ' ' HA ' ' A' ' 302' ' ' ARG . 2.2 mmp_? -120.49 140.58 51.23 Favored 'General case' 0 C--N 1.319 -0.726 0 C-N-CA 120.68 -0.408 . . . . 0.0 110.824 -179.029 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 303' ' ' VAL . . . . . . . . . . . . . 23.4 m -120.57 149.05 23.42 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.594 0 CA-C-N 115.574 -0.739 . . . . 0.0 111.796 -175.815 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 304' ' ' GLN . . . . . 0.479 ' HB3' ' HB2' ' A' ' 287' ' ' LEU . 3.5 pt20 -125.82 176.09 7.18 Favored 'General case' 0 C--N 1.32 -0.687 0 CA-C-N 114.986 -1.006 . . . . 0.0 108.908 173.817 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 305' ' ' GLY . . . . . . . . . . . . . . . -91.22 118.14 5.34 Favored Glycine 0 N--CA 1.45 -0.43 0 C-N-CA 120.351 -0.928 . . . . 0.0 112.012 -173.954 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 306' ' ' GLU . . . . . 0.804 ' O ' ' HA2' ' A' ' 395' ' ' GLY . 43.5 tt0 -145.72 128.74 8.21 Favored Pre-proline 0 N--CA 1.447 -0.58 0 N-CA-C 109.138 -0.69 . . . . 0.0 109.138 -173.873 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 307' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_exo -51.97 126.05 18.98 Favored 'Trans proline' 0 CA--C 1.528 0.224 0 C-N-CA 122.235 1.956 . . . . 0.0 111.216 174.177 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 308' ' ' ALA . . . . . 0.689 ' HB2' ' O ' ' A' ' 394' ' ' TYR . . . -48.07 152.51 0.8 Allowed 'General case' 0 N--CA 1.472 0.671 0 N-CA-C 112.968 0.729 . . . . 0.0 112.968 -177.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 309' ' ' LYS . . . . . 0.583 ' O ' ' HG ' ' A' ' 313' ' ' LEU . 29.9 mmmt -108.87 107.9 18.48 Favored 'General case' 0 C--N 1.326 -0.433 0 CA-C-N 115.861 -0.609 . . . . 0.0 109.489 177.896 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 310' ' ' GLY . . . . . 0.608 ' HA2' HD12 ' A' ' 313' ' ' LEU . . . -64.91 -34.89 91.09 Favored Glycine 0 CA--C 1.516 0.133 0 C-N-CA 121.355 -0.45 . . . . 0.0 113.705 -172.737 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 311' ' ' GLU . . . . . . . . . . . . . 2.9 pm0 -71.72 -25.56 62.12 Favored 'General case' 0 C--N 1.323 -0.556 0 CA-C-O 121.234 0.54 . . . . 0.0 110.031 178.692 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 312' ' ' MET . . . . . 0.475 ' HB3' ' HB2' ' A' ' 309' ' ' LYS . 27.6 ttt -87.11 -18.06 31.37 Favored 'General case' 0 C--N 1.326 -0.413 0 CA-C-N 115.723 -0.671 . . . . 0.0 110.461 -179.45 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 313' ' ' LEU . . . . . 0.608 HD12 ' HA2' ' A' ' 310' ' ' GLY . 96.1 mt -66.55 139.96 57.95 Favored 'General case' 0 C--N 1.326 -0.426 0 CA-C-N 116.114 -0.493 . . . . 0.0 110.554 179.167 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 314' ' ' ALA . . . . . . . . . . . . . . . -159.62 135.64 8.75 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-N 115.699 -0.682 . . . . 0.0 111.011 -176.384 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 315' ' ' GLY . . . . . . . . . . . . . . . 120.5 177.69 15.94 Favored Glycine 0 N--CA 1.45 -0.417 0 C-N-CA 120.918 -0.658 . . . . 0.0 111.592 178.168 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 316' ' ' THR . . . . . . . . . . . . . 38.7 p -108.75 142.16 39.7 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 117.303 0.551 . . . . 0.0 110.471 174.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 317' ' ' ALA . . . . . . . . . . . . . . . -146.68 155.28 42.31 Favored 'General case' 0 C--N 1.316 -0.868 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.258 -179.093 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 318' ' ' VAL . . . . . 0.561 ' HA ' ' O ' ' A' ' 342' ' ' ALA . 2.5 p -132.94 119.71 38.17 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.81 0 CA-C-O 121.285 0.564 . . . . 0.0 110.732 174.504 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 319' ' ' TYR . . . . . 0.477 ' HE1' ' HA ' ' A' ' 399' ' ' GLU . 76.8 m-85 -104.51 128.35 52.42 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.956 -178.671 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 320' ' ' ASN . . . . . . . . . . . . . 4.5 p30 -127.75 141.84 51.48 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-N 115.941 -0.572 . . . . 0.0 110.142 179.297 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 321' ' ' GLY . . . . . . . . . . . . . . . -167.03 -140.98 3.02 Favored Glycine 0 N--CA 1.442 -0.913 0 C-N-CA 120.87 -0.681 . . . . 0.0 112.28 -178.194 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 322' ' ' GLU . . . . . . . . . . . . . 31.0 mt-10 -118.66 150.38 39.82 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.831 0.348 . . . . 0.0 111.051 -173.577 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 323' ' ' VAL . . . . . 0.626 HG23 ' HB2' ' A' ' 340' ' ' PHE . 56.1 t -109.9 120.95 61.98 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.505 0 CA-C-N 115.898 -0.592 . . . . 0.0 109.925 172.644 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 324' ' ' LEU . . . . . 0.449 ' HB2' HG22 ' A' ' 419' ' ' VAL . 95.7 mt -101.87 104.21 14.94 Favored 'General case' 0 C--N 1.321 -0.649 0 CA-C-N 116.392 -0.367 . . . . 0.0 110.092 -179.624 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 325' ' ' HIS . . . . . 0.742 ' HB3' ' HB ' ' A' ' 336' ' ' THR . 28.1 t-80 -96.21 138.83 33.25 Favored 'General case' 0 C--N 1.322 -0.6 0 CA-C-N 116.187 -0.461 . . . . 0.0 109.814 -179.815 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 326' ' ' PHE . . . . . 0.558 ' HE2' HG13 ' A' ' 419' ' ' VAL . 10.8 m-85 -126.31 175.05 8.11 Favored 'General case' 0 C--N 1.321 -0.67 0 CA-C-N 115.939 -0.573 . . . . 0.0 109.587 -176.35 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 327' ' ' HIS . . . . . . . . . . . . . 4.9 p-80 -160.81 -176.34 5.47 Favored 'General case' 0 C--N 1.313 -0.995 0 N-CA-C 107.626 -1.25 . . . . 0.0 107.626 179.002 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 328' ' ' THR . . . . . . . . . . . . . 9.2 t -53.95 114.09 1.46 Allowed 'General case' 0 C--N 1.327 -0.406 0 CA-C-O 121.545 0.688 . . . . 0.0 109.74 176.24 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 329' ' ' GLU . . . . . 0.459 ' O ' ' HB2' ' A' ' 330' ' ' ASN . 0.0 OUTLIER -95.41 175.18 6.67 Favored 'General case' 0 C--N 1.324 -0.501 0 CA-C-N 116.037 -0.528 . . . . 0.0 111.363 -177.181 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 330' ' ' ASN . . . . . 0.459 ' HB2' ' O ' ' A' ' 329' ' ' GLU . 94.9 m-20 74.25 3.64 4.39 Favored 'General case' 0 N--CA 1.469 0.477 0 N-CA-C 108.37 -0.974 . . . . 0.0 108.37 -163.825 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 331' ' ' GLY . . . . . . . . . . . . . . . -145.4 96.43 0.18 Allowed Glycine 0 N--CA 1.438 -1.231 0 N-CA-C 109.459 -1.457 . . . . 0.0 109.459 174.544 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 332' ' ' ARG . . . . . 0.404 ' HB3' ' CE1' ' A' ' 334' ' ' TYR . 6.4 mpt_? 65.64 73.51 0.41 Allowed Pre-proline 0 N--CA 1.466 0.356 0 CA-C-O 121.397 0.618 . . . . 0.0 110.081 -171.658 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 333' ' ' PRO . . . . . . . . . . . . . 1.2 Cg_endo -83.92 39.5 0.8 Allowed 'Trans proline' 0 N--CA 1.462 -0.368 0 C-N-CA 123.581 2.854 . . . . 0.0 113.342 -172.458 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 334' ' ' TYR . . . . . 0.404 ' CE1' ' HB3' ' A' ' 332' ' ' ARG . 40.5 p90 -107.15 128.61 25.71 Favored Pre-proline 0 C--N 1.323 -0.553 0 N-CA-C 109.739 -0.467 . . . . 0.0 109.739 176.189 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 335' ' ' PRO . . . . . . . . . . . . . 88.6 Cg_endo -81.12 129.59 6.92 Favored 'Trans proline' 0 N--CA 1.461 -0.436 0 C-N-CA 122.641 2.228 . . . . 0.0 112.424 179.445 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 336' ' ' THR . . . . . 0.742 ' HB ' ' HB3' ' A' ' 325' ' ' HIS . 0.2 OUTLIER -72.58 140.1 47.86 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 108.935 -0.765 . . . . 0.0 108.935 175.825 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 337' ' ' ARG . . . . . 0.483 ' HA ' ' O ' ' A' ' 323' ' ' VAL . 51.2 mtm180 -128.7 112.99 14.81 Favored 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 120.298 -0.561 . . . . 0.0 111.576 -174.689 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 338' ' ' GLY . . . . . . . . . . . . . . . -107.57 -177.12 22.49 Favored Glycine 0 N--CA 1.444 -0.83 0 CA-C-N 115.297 -0.865 . . . . 0.0 111.092 176.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 339' ' ' ARG . . . . . 0.795 ' HB2' ' HB2' ' A' ' 356' ' ' ASP . 40.0 mtp-105 -104.45 153.46 21.08 Favored 'General case' 0 C--N 1.32 -0.7 0 N-CA-C 109.399 -0.593 . . . . 0.0 109.399 179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 340' ' ' PHE . . . . . 0.626 ' HB2' HG23 ' A' ' 323' ' ' VAL . 53.0 t80 -143.41 137.52 28.71 Favored 'General case' 0 C--N 1.317 -0.848 0 CA-C-O 121.139 0.495 . . . . 0.0 111.484 -178.51 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 341' ' ' ALA . . . . . 0.401 ' HA ' ' O ' ' A' ' 319' ' ' TYR . . . -141.05 163.49 32.84 Favored 'General case' 0 C--N 1.322 -0.626 0 CA-C-N 115.228 -0.896 . . . . 0.0 108.889 173.334 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 342' ' ' ALA . . . . . 0.821 ' HA ' ' O ' ' A' ' 352' ' ' ASP . . . -155.9 118.14 4.09 Favored 'General case' 0 C--N 1.32 -0.705 0 CA-C-O 120.871 0.367 . . . . 0.0 110.667 -176.926 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 343' ' ' LYS . . . . . 0.502 ' C ' ' HD3' ' A' ' 343' ' ' LYS . 12.7 tmtt? -94.3 103.35 15.36 Favored 'General case' 0 C--N 1.318 -0.787 0 N-CA-C 107.825 -1.176 . . . . 0.0 107.825 178.223 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 344' ' ' VAL . . . . . 1.026 ' HB ' ' HB ' ' A' ' 351' ' ' VAL . 0.2 OUTLIER -119.4 132.83 68.1 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.109 0 CA-C-O 121.607 0.718 . . . . 0.0 112.105 -172.716 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 345' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -109.16 118.69 37.39 Favored 'General case' 0 C--N 1.319 -0.731 0 CA-C-N 114.885 -1.052 . . . . 0.0 108.247 175.563 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 346' ' ' PHE . . . . . . . . . . . . . 70.4 m-85 -79.25 -24.59 42.9 Favored 'General case' 0 C--N 1.321 -0.663 0 N-CA-C 111.584 0.216 . . . . 0.0 111.584 -175.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 347' ' ' GLY . . . . . . . . . . . . . . . -69.52 -38.54 79.25 Favored Glycine 0 N--CA 1.448 -0.519 0 C-N-CA 120.239 -0.981 . . . . 0.0 111.285 179.227 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 348' ' ' SER . . . . . . . . . . . . . 3.4 m -92.58 -9.74 40.04 Favored 'General case' 0 C--N 1.321 -0.648 0 CA-C-O 121.002 0.43 . . . . 0.0 110.019 178.096 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 349' ' ' LYS . . . . . 0.621 ' HB3' ' HB ' ' A' ' 372' ' ' ILE . 10.1 mtmp? 52.03 58.67 5.19 Favored 'General case' 0 N--CA 1.456 -0.142 0 CA-C-N 115.439 -0.801 . . . . 0.0 110.394 -176.734 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 350' ' ' SER . . . . . . . . . . . . . 17.9 m -140.9 145.84 36.67 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 115.162 -0.926 . . . . 0.0 109.48 -179.211 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 351' ' ' VAL . . . . . 1.026 ' HB ' ' HB ' ' A' ' 344' ' ' VAL . 0.2 OUTLIER -141.83 139.0 31.38 Favored 'Isoleucine or valine' 0 C--O 1.237 0.396 0 CA-C-O 121.299 0.571 . . . . 0.0 111.559 -177.035 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 352' ' ' ASP . . . . . 0.821 ' O ' ' HA ' ' A' ' 342' ' ' ALA . 1.5 m-20 -106.61 118.54 36.93 Favored 'General case' 0 C--O 1.214 -0.798 0 CA-C-N 115.057 -0.974 . . . . 0.0 109.304 179.637 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 353' ' ' GLY . . . . . . . . . . . . . . . -110.1 143.24 16.73 Favored Glycine 0 C--N 1.313 -0.715 0 C-N-CA 120.23 -0.986 . . . . 0.0 111.873 -177.076 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 354' ' ' ILE . . . . . 0.536 ' O ' ' HA ' ' A' ' 340' ' ' PHE . 0.0 OUTLIER -140.29 129.92 27.83 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.78 0 CA-C-O 120.856 0.36 . . . . 0.0 110.362 -177.962 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 355' ' ' ILE . . . . . 0.59 HG23 HG21 ' A' ' 323' ' ' VAL . 3.3 mp -119.34 111.07 31.64 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.419 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.329 179.811 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 356' ' ' ASP . . . . . 0.795 ' HB2' ' HB2' ' A' ' 339' ' ' ARG . 7.4 m-20 -69.1 120.74 15.42 Favored 'General case' 0 CA--C 1.512 -0.502 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.454 177.05 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 357' ' ' SER . . . . . . . . . . . . . 27.7 t -89.71 -6.32 56.18 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.899 -0.591 . . . . 0.0 109.854 176.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 358' ' ' GLY . . . . . . . . . . . . . . . 104.57 -68.1 0.27 Allowed Glycine 0 N--CA 1.448 -0.556 0 CA-C-N 115.769 -0.65 . . . . 0.0 111.732 -179.114 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 359' ' ' ASP . . . . . . . . . . . . . 4.8 m-20 -100.32 81.23 2.34 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.381 0.61 . . . . 0.0 110.014 178.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 360' ' ' ASP . . . . . 0.422 ' O ' ' HA2' ' A' ' 364' ' ' GLY . 20.1 t70 -61.83 -27.07 68.51 Favored 'General case' 0 C--N 1.324 -0.537 0 CA-C-N 115.191 -0.913 . . . . 0.0 110.762 178.175 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 361' ' ' LEU . . . . . . . . . . . . . 96.3 mt -78.66 -15.39 58.55 Favored 'General case' 0 C--N 1.323 -0.579 0 CA-C-N 115.739 -0.664 . . . . 0.0 111.193 -179.364 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 362' ' ' HIS . . . . . . . . . . . . . 4.5 t-160 -108.14 -79.09 0.58 Allowed 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.759 -0.2 . . . . 0.0 110.469 -179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 363' ' ' MET . . . . . . . . . . . . . 90.6 mtp -78.97 -29.87 44.12 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-O 121.139 0.495 . . . . 0.0 110.836 -179.261 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 364' ' ' GLY . . . . . 0.422 ' HA2' ' O ' ' A' ' 360' ' ' ASP . . . 96.42 135.2 8.34 Favored Glycine 0 N--CA 1.445 -0.744 0 CA-C-N 115.489 -0.778 . . . . 0.0 112.348 179.136 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 365' ' ' THR . . . . . 0.566 HG23 ' HA ' ' A' ' 356' ' ' ASP . 7.6 m -82.42 119.05 23.69 Favored 'General case' 0 N--CA 1.445 -0.718 0 N-CA-C 108.218 -1.03 . . . . 0.0 108.218 171.197 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 366' ' ' GLN . . . . . . . . . . . . . 14.6 mm100 -103.78 145.37 30.19 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-O 121.624 0.726 . . . . 0.0 111.076 -166.556 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 367' ' ' LYS . . . . . . . . . . . . . 44.9 mttp -125.74 147.72 49.29 Favored 'General case' 0 C--N 1.317 -0.839 0 CA-C-N 114.599 -1.182 . . . . 0.0 110.394 -170.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 368' ' ' PHE . . . . . 0.685 ' CD1' HG21 ' A' ' 389' ' ' VAL . 41.9 p90 -126.39 160.23 31.05 Favored 'General case' 0 C--N 1.32 -0.715 0 N-CA-C 109.146 -0.687 . . . . 0.0 109.146 177.371 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 369' ' ' LYS . . . . . 0.589 ' HD3' ' HA ' ' A' ' 352' ' ' ASP . 2.0 tppt? -125.96 147.39 49.53 Favored 'General case' 0 C--N 1.311 -1.101 0 N-CA-C 109.473 -0.566 . . . . 0.0 109.473 173.442 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 370' ' ' ALA . . . . . 0.435 ' HB1' ' HB2' ' A' ' 377' ' ' PHE . . . -141.58 147.71 38.12 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-O 120.83 0.347 . . . . 0.0 111.123 -176.697 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 371' ' ' ALA . . . . . . . . . . . . . . . -105.45 127.57 53.07 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.079 177.759 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 372' ' ' ILE . . . . . 0.621 ' HB ' ' HB3' ' A' ' 349' ' ' LYS . 84.0 mt -82.8 121.32 35.71 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.535 0 CA-C-O 121.008 0.433 . . . . 0.0 111.257 -178.905 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 373' ' ' ASP . . . . . . . . . . . . . 38.2 t70 -137.91 105.27 5.5 Favored 'General case' 0 C--N 1.32 -0.692 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 170.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 374' ' ' GLY . . . . . . . . . . . . . . . 92.88 -155.2 22.37 Favored Glycine 0 N--CA 1.445 -0.745 0 N-CA-C 110.349 -1.1 . . . . 0.0 110.349 -168.012 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 375' ' ' ASN . . . . . 0.552 ' HB3' ' O ' ' A' ' 308' ' ' ALA . 21.8 p-10 -94.33 42.6 1.1 Allowed 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 117.533 0.666 . . . . 0.0 110.681 178.718 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 376' ' ' GLY . . . . . . . . . . . . . . . -170.37 164.48 37.77 Favored Glycine 0 N--CA 1.441 -1.016 0 N-CA-C 111.048 -0.821 . . . . 0.0 111.048 -178.789 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 377' ' ' PHE . . . . . 0.512 ' CD2' HG11 ' A' ' 351' ' ' VAL . 8.8 p90 -136.91 139.0 41.26 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-O 120.964 0.412 . . . . 0.0 110.939 -179.307 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 378' ' ' LYS . . . . . . . . . . . . . 63.7 mttm -112.72 137.09 51.52 Favored 'General case' 0 C--N 1.317 -0.835 0 CA-C-N 115.692 -0.685 . . . . 0.0 109.293 172.081 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 379' ' ' GLY . . . . . 0.627 ' C ' HG22 ' A' ' 389' ' ' VAL . . . -144.53 -154.73 6.22 Favored Glycine 0 N--CA 1.437 -1.283 0 C-N-CA 120.781 -0.723 . . . . 0.0 112.097 -172.432 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 380' ' ' THR . . . . . . . . . . . . . 12.7 t -169.16 154.66 6.09 Favored 'General case' 0 C--N 1.313 -1.016 0 N-CA-C 109.384 -0.598 . . . . 0.0 109.384 -173.534 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 381' ' ' TRP . . . . . 0.901 ' HD1' ' HA3' ' A' ' 387' ' ' GLY . 38.8 m95 -62.16 154.47 27.14 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-O 121.299 0.571 . . . . 0.0 110.87 178.337 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 382' ' ' THR . . . . . . . . . . . . . 12.3 t -62.13 -8.29 5.31 Favored 'General case' 0 CA--C 1.538 0.514 0 CA-C-N 115.386 -0.825 . . . . 0.0 111.407 173.402 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 383' ' ' GLU . . . . . . . . . . . . . 35.9 mt-10 -117.59 156.17 28.58 Favored 'General case' 0 C--N 1.333 -0.132 0 N-CA-C 109.984 -0.376 . . . . 0.0 109.984 174.563 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 384' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -88.01 27.88 1.13 Allowed 'General case' 0 C--N 1.328 -0.33 0 N-CA-C 112.187 0.439 . . . . 0.0 112.187 -173.08 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 385' ' ' GLY . . . . . . . . . . . . . . . -78.02 41.59 2.0 Allowed Glycine 0 CA--C 1.52 0.404 0 C-N-CA 120.787 -0.721 . . . . 0.0 113.06 -178.108 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 386' ' ' GLY . . . . . 0.473 ' HA3' ' O ' ' A' ' 408' ' ' ARG . . . 57.9 24.06 52.91 Favored Glycine 0 C--N 1.331 0.255 0 C-N-CA 121.802 -0.237 . . . . 0.0 113.015 179.643 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 387' ' ' GLY . . . . . 0.901 ' HA3' ' HD1' ' A' ' 381' ' ' TRP . . . -86.73 93.62 1.89 Allowed Glycine 0 N--CA 1.446 -0.69 0 C-N-CA 120.722 -0.751 . . . . 0.0 112.637 -177.019 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 388' ' ' ASP . . . . . . . . . . . . . 18.8 t70 -96.18 128.04 42.74 Favored 'General case' 0 C--N 1.322 -0.621 0 N-CA-C 109.572 -0.529 . . . . 0.0 109.572 178.994 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 389' ' ' VAL . . . . . 0.685 HG21 ' CD1' ' A' ' 368' ' ' PHE . 3.5 m -117.28 160.48 16.73 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.532 0 C-N-CA 120.87 -0.332 . . . . 0.0 110.714 -176.589 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 390' ' ' SER . . . . . 0.521 ' O ' ' HA3' ' A' ' 403' ' ' GLY . 24.7 t -157.44 158.46 35.87 Favored 'General case' 0 C--N 1.324 -0.524 0 CA-C-N 116.532 -0.304 . . . . 0.0 110.245 178.622 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 391' ' ' GLY . . . . . . . . . . . . . . . -170.13 153.15 20.82 Favored Glycine 0 C--N 1.32 -0.329 0 N-CA-C 111.443 -0.663 . . . . 0.0 111.443 178.666 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 392' ' ' ARG . . . . . . . . . . . . . 4.3 ptm180 -131.92 149.32 52.47 Favored 'General case' 0 C--O 1.235 0.316 0 CA-C-N 117.319 0.56 . . . . 0.0 110.751 -176.706 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 393' ' ' PHE . . . . . . . . . . . . . 88.0 m-85 -89.88 166.11 13.7 Favored 'General case' 0 CA--C 1.498 -1.037 0 CA-C-O 122.424 1.107 . . . . 0.0 111.786 -179.674 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 394' ' ' TYR . . . . . 0.689 ' O ' ' HB2' ' A' ' 308' ' ' ALA . 0.5 OUTLIER -101.86 -176.15 3.05 Favored 'General case' 0 C--N 1.305 -1.347 0 CA-C-N 112.709 -2.042 . . . . 0.0 108.923 176.949 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 395' ' ' GLY . . . . . 0.804 ' HA2' ' O ' ' A' ' 306' ' ' GLU . . . -36.26 158.38 0.01 OUTLIER Glycine 0 N--CA 1.461 0.304 0 O-C-N 124.71 1.256 . . . . 0.0 115.045 -175.06 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 396' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -22.95 -42.42 0.03 OUTLIER 'Trans proline' 0 C--N 1.358 1.032 1 C-N-CA 127.322 5.348 . . . . 0.0 117.178 -161.711 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 397' ' ' ALA . . . . . 0.42 ' N ' ' O ' ' A' ' 395' ' ' GLY . . . -73.04 -19.46 61.18 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 -175.068 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 398' ' ' GLY . . . . . . . . . . . . . . . 57.85 25.06 55.54 Favored Glycine 0 C--N 1.34 0.767 0 CA-C-N 116.186 -0.461 . . . . 0.0 112.887 176.165 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 399' ' ' GLU . . . . . 0.477 ' HA ' ' HE1' ' A' ' 319' ' ' TYR . 51.3 mt-10 -71.3 -8.37 53.21 Favored 'General case' 0 C--N 1.329 -0.292 0 C-N-CA 122.956 0.502 . . . . 0.0 112.024 -174.03 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 400' ' ' GLU . . . . . 0.451 ' HG2' ' CE1' ' A' ' 394' ' ' TYR . 5.2 tt0 -131.9 144.29 50.75 Favored 'General case' 0 N--CA 1.433 -1.284 0 N-CA-C 109.274 -0.639 . . . . 0.0 109.274 171.438 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 401' ' ' VAL . . . . . 0.492 HG21 ' CZ ' ' A' ' 377' ' ' PHE . 14.8 p -142.08 136.73 29.9 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.107 0 CA-C-N 115.012 -0.995 . . . . 0.0 109.722 179.019 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 402' ' ' ALA . . . . . . . . . . . . . . . -135.7 138.94 43.27 Favored 'General case' 0 C--N 1.318 -0.782 0 CA-C-N 116.423 -0.353 . . . . 0.0 111.122 -178.74 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 403' ' ' GLY . . . . . 0.521 ' HA3' ' O ' ' A' ' 390' ' ' SER . . . -161.06 -161.09 11.25 Favored Glycine 0 N--CA 1.442 -0.953 0 C-N-CA 120.747 -0.739 . . . . 0.0 111.646 178.424 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 404' ' ' LYS . . . . . 0.7 ' HG2' HG12 ' A' ' 419' ' ' VAL . 28.4 mtmm -144.45 161.71 38.36 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.336 -0.616 . . . . 0.0 109.336 -179.557 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 405' ' ' TYR . . . . . . . . . . . . . 34.9 p90 -120.41 133.21 55.47 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.218 -0.66 . . . . 0.0 109.218 171.915 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 406' ' ' SER . . . . . . . . . . . . . 46.2 m -116.22 103.78 10.86 Favored 'General case' 0 C--N 1.317 -0.847 0 CA-C-N 116.508 -0.314 . . . . 0.0 110.549 -178.444 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 407' ' ' TYR . . . . . 0.485 ' HA ' ' HA2' ' A' ' 387' ' ' GLY . 10.4 p90 -82.49 127.18 33.07 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 174.975 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 408' ' ' ARG . . . . . 0.473 ' O ' ' HA3' ' A' ' 386' ' ' GLY . 29.1 ttp180 -138.62 79.23 29.67 Favored Pre-proline 0 C--N 1.319 -0.75 0 CA-C-N 115.804 -0.634 . . . . 0.0 109.912 -177.841 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 409' ' ' PRO . . . . . . . . . . . . . 56.0 Cg_endo -90.29 -7.66 4.19 Favored 'Trans proline' 0 N--CA 1.452 -0.949 0 C-N-CA 123.059 2.506 . . . . 0.0 112.004 179.791 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 410' ' ' THR . . . . . . . . . . . . . 15.0 m -121.28 128.02 51.94 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.954 -179.686 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 411' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -75.54 83.93 2.6 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.335 0.588 . . . . 0.0 110.402 176.211 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 412' ' ' ALA . . . . . . . . . . . . . . . -146.3 -54.34 0.26 Allowed 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 115.255 -0.884 . . . . 0.0 109.571 178.01 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 413' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -151.17 163.06 39.69 Favored 'General case' 0 C--N 1.321 -0.643 0 CA-C-N 115.729 -0.669 . . . . 0.0 109.581 179.1 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 414' ' ' LYS . . . . . . . . . . . . . 36.3 mtmm -89.82 158.34 17.52 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 120.879 0.371 . . . . 0.0 110.781 -179.014 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 415' ' ' GLY . . . . . . . . . . . . . . . -75.64 178.82 47.51 Favored Glycine 0 N--CA 1.448 -0.517 0 CA-C-N 115.706 -0.679 . . . . 0.0 112.193 178.317 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 416' ' ' GLY . . . . . . . . . . . . . . . -175.58 -37.18 0.05 OUTLIER Glycine 0 N--CA 1.45 -0.414 0 C-N-CA 120.884 -0.674 . . . . 0.0 111.661 -178.406 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 417' ' ' PHE . . . . . 0.506 ' CD1' ' HB2' ' A' ' 326' ' ' PHE . 32.7 m-85 -68.82 159.37 32.56 Favored 'General case' 0 C--N 1.326 -0.414 0 N-CA-C 109.89 -0.411 . . . . 0.0 109.89 175.76 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 418' ' ' GLY . . . . . 0.448 ' HA2' ' HA ' ' A' ' 325' ' ' HIS . . . 83.82 78.17 1.11 Allowed Glycine 0 N--CA 1.448 -0.529 0 C-N-CA 119.904 -1.141 . . . . 0.0 112.678 -178.262 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 419' ' ' VAL . . . . . 0.7 HG12 ' HG2' ' A' ' 404' ' ' LYS . 13.5 m -105.03 163.29 4.34 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.554 0 N-CA-C 109.793 -0.447 . . . . 0.0 109.793 -179.832 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 420' ' ' PHE . . . . . . . . . . . . . 29.9 p90 -143.38 153.71 42.97 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-O 121.406 0.622 . . . . 0.0 111.234 -178.133 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 421' ' ' ALA . . . . . . . . . . . . . . . -142.81 136.15 28.5 Favored 'General case' 0 C--N 1.317 -0.833 0 CA-C-N 115.259 -0.882 . . . . 0.0 109.037 176.664 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 422' ' ' GLY . . . . . . . . . . . . . . . -124.05 134.71 9.34 Favored Glycine 0 N--CA 1.443 -0.849 0 C-N-CA 120.399 -0.905 . . . . 0.0 112.327 -178.341 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 423' ' ' LYS . . . . . 0.451 ' HE2' ' HB3' ' A' ' 423' ' ' LYS . 44.6 mtpt -104.8 140.18 38.48 Favored 'General case' 0 C--N 1.318 -0.774 0 CA-C-O 120.753 0.311 . . . . 0.0 110.198 178.722 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 424' ' ' LYS . . . . . 0.408 ' HB2' ' HE1' ' A' ' 319' ' ' TYR . 26.0 tptp -58.14 116.25 3.43 Favored 'General case' 0 C--N 1.322 -0.605 0 CA-C-N 115.626 -0.716 . . . . 0.0 111.8 179.652 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 425' ' ' GLU . . . . . 0.535 ' HB3' HG13 ' A' ' 318' ' ' VAL . 19.8 tp10 -64.94 112.71 3.42 Favored 'General case' 0 C--N 1.325 -0.473 0 N-CA-C 107.655 -1.239 . . . . 0.0 107.655 169.009 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 426' ' ' GLN . . . . . . . . . . . . . 3.1 tp-100 -88.16 127.99 35.44 Favored 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 121.352 0.596 . . . . 0.0 111.086 -172.802 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 427' ' ' ASP . . . . . . . . . . . . . 9.0 p-10 -107.4 -161.76 0.8 Allowed 'General case' 0 C--N 1.32 -0.701 0 CA-C-N 115.263 -0.88 . . . . 0.0 109.476 176.601 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 428' ' ' LEU . . . . . 0.586 ' H ' ' CD1' ' A' ' 428' ' ' LEU . 0.0 OUTLIER -72.12 -14.94 61.97 Favored 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 121.086 -0.246 . . . . 0.0 111.162 179.976 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 429' ' ' GLU . . . . . . . . . . . . . 47.3 mt-10 66.62 -81.17 0.03 OUTLIER 'General case' 0 N--CA 1.467 0.381 0 C-N-CA 123.298 0.639 . . . . 0.0 111.123 179.503 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 430' ' ' HIS . . . . . . . . . . . . . 96.0 m-70 -141.67 111.76 6.82 Favored 'General case' 0 C--N 1.321 -0.659 0 N-CA-C 109.393 -0.595 . . . . 0.0 109.393 179.952 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 431' ' ' HIS . . . . . 0.456 ' O ' ' HB2' ' A' ' 432' ' ' HIS . 75.3 t60 -69.37 141.19 54.23 Favored 'General case' 0 C--N 1.326 -0.442 0 N-CA-C 109.548 -0.538 . . . . 0.0 109.548 179.779 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 432' ' ' HIS . . . . . 0.456 ' HB2' ' O ' ' A' ' 431' ' ' HIS . 43.4 m170 76.08 -75.91 0.06 Allowed 'General case' 0 N--CA 1.469 0.482 0 C-N-CA 123.641 0.776 . . . . 0.0 110.59 -174.429 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 433' ' ' HIS . . . . . . . . . . . . . 48.0 m80 -149.23 167.34 26.27 Favored 'General case' 0 C--N 1.325 -0.493 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 179.172 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 434' ' ' HIS . . . . . . . . . . . . . 5.2 p80 -63.43 -27.06 69.03 Favored 'General case' 0 C--N 1.332 -0.186 0 N-CA-C 109.363 -0.606 . . . . 0.0 109.363 174.477 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 435' ' ' HIS . . . . . . . . . . . . . 55.4 t-80 . . . . . 0 C--O 1.244 0.777 0 CA-C-N 115.158 -0.928 . . . . 0.0 109.021 176.64 . . . . . . . . 0 0 . 1 stop_ save_